PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Xing, J; Wriggers, W; Jefferson, GM; Stein, R; Cheung, HC; Rosenfeld, SS				Xing, J; Wriggers, W; Jefferson, GM; Stein, R; Cheung, HC; Rosenfeld, SS			Kinesin has three nucleotide-dependent conformations - Implications for strain-dependent release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; KINETIC MECHANISM; ATP HYDROLYSIS; PURIFICATION; FLUORESCENCE; EXPRESSION; SKELETAL; COMPLEX; ENERGY	Although crystallographic information is available on several nucleotide-induced states in myosin, little is known about the corresponding structural changes in kinesin, since a crystallographic model is only available for the kinesin:ADP complex. This makes it difficult to characterize at a molecular level the structural changes that occur in this motor through the course of its ATPase cycle. In this study, we report on the production of a series of single tryptophan mutants of a monomeric human kinesin motor domain, which demonstrate nucleotide-dependent changes in microtubule affinity that are similar to wild type, We have used these mutations to measure intramolecular distances in both strong and weak binding states, using florescence resonance energy transfer. This work provides direct evidence that movement of the switch II loop and helix are essential to mediate communication between the catalytic and microtubule binding sites, evidence that is supported as well by molecular modeling. Kinetic studies of fluorescent nucleotide binding to these mutants are consistent with these distance changes, and demonstrate as well that binding of ADP produces two structural transitions, neither of which are identical to that produced by the binding of ATP. This study provides a basis for understanding current structural models of the kinesin mechanochemical cycle.	Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Grad Program Cell & Mol Biol, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Rosenfeld, SS (corresponding author), Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.	srosenfeld@email.neuro.uab.edu		Wriggers, Willy/0000-0001-5326-3152	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER; NCRR NIH HHS [RR10404] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR VERSION 3 SYST; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Pastor R., 1994, MOL DYNAMICS LIQUID, P85, DOI 10.1007/978-94-011-1168-3_5; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; Straume M, 1991, TOPICS FLUORESCENCE, P177, DOI DOI 10.1007/B112907; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1	36	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35413	35423		10.1074/jbc.M004232200	http://dx.doi.org/10.1074/jbc.M004232200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10852922	hybrid, Green Submitted			2022-12-27	WOS:000165422800078
J	Antil-Delbeke, S; Gaillard, C; Tamiya, T; Corringer, PJ; Changeux, JP; Servent, D; Menez, A				Antil-Delbeke, S; Gaillard, C; Tamiya, T; Corringer, PJ; Changeux, JP; Servent, D; Menez, A			Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-PROTEIN INTERACTIONS; DOUBLE MUTANT CYCLES; NICOTINIC RECEPTOR; ALPHA-NEUROTOXIN; K+ CHANNEL; 3-DIMENSIONAL STRUCTURE; CURAREMIMETIC TOXINS; PROTON NMR; IDENTIFICATION	Long chain curarimimetic toxins from snake venom bind with high affinities to both muscular type nicotinic acetylcholine receptors (AChRs) (K-d in the pM range) and neuronal alpha 7-AChRs (K-d in the nM range). To understand the molecular basis of this dual function, we submitted alpha-cobratoxin (alpha-Cbtx), a typical long chain curarimimetic toxin, to an extensive mutational analysis. By exploring 36 toxin mutants, we found that Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65 are involved in binding to both neuronal and Torpedo (Antil, S., Servent, D., and Menez, A. (1999) J. Biol. Chem. 274, 34851-34858) AChRs and that some of them (Trp-25, Asp-27, and Arg-33) have similar binding energy contributions for the two receptors. In contrast, Ala-28, Lys-35, and Cys-26-Cys-30 selectively bind to the alpha 7-AChR, whereas Lys-23 and Lys-49 bind solely to the Torpedo AChR. Therefore, alpha-Cbtx binds to two AChR subtypes using both common and specific residues. Double mutant cycle analyses suggested that Arg-33 in alpha-Cbtx is close to Tyr-187 and Pro-193 in the alpha 7 receptor. Since Arg-33 of another curarimimetic toxin is close to the homologous alpha Tyr-190 of the muscular receptor (Ackermann, E. J., Ang, E. T. H., Kanter, J. R., Tsigelny, I., and Taylor, P. (1998) J. Biol Chem. 273, 10958-10964), toxin binding probably occurs in homologous regions of neuronal and muscular AChRs. However, no coupling was seen between alpha-Cbtx Arg-33 and alpha 7 receptor Trp-54, Leu-118, and Asp-163, in contrast to what was observed in a homologous situation involving another toxin and a muscular receptor (Osaka, H., Malany, S., Molles, B. E., Sine, S. M., and Taylor, P. (2000) J. Biol Chem. 275, 5478-5484). Therefore, although occurring in homologous regions, the detailed modes of toxin binding to alpha 7 and muscular receptors are likely to be different, These data offer a molecular basis for the design of toxins with predetermined specificities for various members of the AChR family.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Inst Pasteur, Mol Neurobiol Lab, F-75724 Paris 15, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Servent, D (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Fruchart Gaillard, Carole/GWV-2801-2022	Fruchart Gaillard, Carole/0000-0002-3149-4774; Servent, Denis/0000-0002-0774-1691				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; Alessandri-Haber N, 1999, J BIOL CHEM, V274, P35653, DOI 10.1074/jbc.274.50.35653; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BETZEL C, 1991, J BIOL CHEM, V266, P21530; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; ENDO T, 1991, SNAKE TOXINS; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; MENEZ A, 1997, GUIDEBOOK PROTEIN TO, P194; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Otzen DE, 1999, PROTEIN ENG, V12, P41, DOI 10.1093/protein/12.1.41; PILLET L, 1993, J BIOL CHEM, V268, P909; PRASAD L, 1993, J BIOL CHEM, V268, P10705; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, J PHYSIOLOGY-PARIS, V92, P107, DOI 10.1016/S0928-4257(98)80146-0; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WEBER M, 1974, MOL PHARMACOL, V10, P15; Wuster W, 1996, TOXICON, V34, P399, DOI 10.1016/0041-0101(95)00139-5; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	35	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29594	29601		10.1074/jbc.M909746199	http://dx.doi.org/10.1074/jbc.M909746199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10852927	hybrid			2022-12-27	WOS:000089439800056
J	Chernousov, MA; Rothblum, K; Tyler, WA; Stahl, RC; Carey, DJ				Chernousov, MA; Rothblum, K; Tyler, WA; Stahl, RC; Carey, DJ			Schwann cells synthesize type V collagen that contains a novel alpha 4 chain - Molecular cloning, biochemical characterization, and high affinity heparin binding of alpha 4(V) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-SYNDECAN; EXPRESSION; ORGANIZATION; DOMAIN	Previously, we reported the isolation of a heparan sulfate-binding collagenous protein, p200, that is expressed by Schwann cells in developing peripheral nerves ((1996) J, Biol, Chem, 271, 13844-13853; (1999) J. Neurosci. Res. 56, 284-294), Here, we report the cloning of p200 cDNA from a Schwann cell cDNA library. The deduced amino acid sequence identifies p200 as a novel member of the collagen type V gene family. This polypeptide, which me have named alpha 4 type V (alpha 4(V)) collagen, contains an uninterrupted GIS-X-X collagen domain of 1011 amino acids that shows 82% sequence identity to human alpha 3(V) collagen and 71% identity to rat alpha 1(V) collagen. alpha 4(V) is secreted by Schwann cells as a collagen heterotrimer that also contains alpha 1(V) chains. alpha 4(V)-containing collagen molecules synthesized by Schmann cells retain their amino-terminal non-collagenous domains. alpha 4(V) mRNA was detected by reverse transcriptase-linked polymerase chain reaction amplification in neonatal and adult brain and neonatal peripheral nerve. alpha 4(V) mRNA and protein were not detected in most other tissues, including the placenta and heart, which are known to contain alpha 3(V). This pattern of alpha 4(V) expression contrasted with that of alpha 1(V) mRNA and protein, which were ubiquitously expressed. The isolated alpha 4(V) chain demonstrated an unusually high affinity for heparin, The restricted expression and unusual properties of alpha 4(V)-containing collagen type V molecules suggest a unique and important role for these molecules in peripheral nerve development.	Geisinger Clin, Sigfried & Janet Weis Ctr Res, Danville, PA 17822 USA		Carey, DJ (corresponding author), Geisinger Clin, Sigfried & Janet Weis Ctr Res, 100 Acad Ave, Danville, PA 17822 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; Asundi VK, 1997, EXP CELL RES, V230, P145, DOI 10.1006/excr.1996.3400; BUNGE MB, 1980, J CELL BIOL, V84, P184, DOI 10.1083/jcb.84.1.184; CARERI G, 1992, NANOBIOLOGY, V1, P117; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Chernousov MA, 1999, J NEUROSCI RES, V56, P284, DOI 10.1002/(SICI)1097-4547(19990501)56:3<284::AID-JNR8>3.3.CO;2-H; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; Chernousov MA, 1998, J CELL SCI, V111, P2763; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; LEE SB, 1995, BIOCHEM J, V310, P15, DOI 10.1042/bj3100015; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701	22	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28208	28215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10852920				2022-12-27	WOS:000089197100090
J	Dong, JF; Schade, AJ; Romo, GM; Andrews, RK; Gao, S; McIntire, LV; Lopez, JA				Dong, JF; Schade, AJ; Romo, GM; Andrews, RK; Gao, S; McIntire, LV; Lopez, JA			Novel gain-of-function mutations of platelet glycoprotein Ib alpha by valine mutagenesis in the Cys(209)-Cys(24)8 disulfide loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; IX-V COMPLEX; VONWILLEBRAND-FACTOR BINDING; MOLECULAR MECHANISMS; ENDOTHELIAL-CELLS; P-SELECTIN; DISEASE; EXPRESSION; IDENTIFICATION; SUBSTITUTION	Platelet-type von Willebrand disease is a bleeding disorder resulting from gain-of-function mutations of glycoprotein (GP) Ib alpha that increase its affinity for von Willebrand factor (vWf). The two known naturally occurring mutations, G233V and M239V, both enrich the valine content of an already valine-rich region within the Cys(209)-Cys(248) disulfide loop. We tested the effect of converting other non-valine residues in this region to valine. Of 10 mutants expressed in CHO cells as components of GP nb-M complexes, four displayed a gain-of-function phenotype (G233V, D235V, K237V, and M239V) based on I-125-vWf binding and adhesion to immobilized vWf. The remainder displayed loss-of-function phenotypes. The gain-of-function mutants bound vWf spontaneously and had a heightened response to low concentrations of ristocetin or botrocetin, whereas the loss-of-function mutants bound vWf more poorly than wild-type GP Ib alpha. No distinct gain- or loss-of-function conformations were identified with conformation-sensitive antibodies. Compared with cells expressing wild-type GP Ib alpha, cells expressing the gain of-function mutants rolled significantly more slowly over immobilized vWf under flow than wild-type cells and were able to adhere to vWf coated at lower densities. In aggregate, these data indicate that the region of GP Ib alpha bounded by Asn(226) and Ala(244) regulates the affinity for vWf.	Baylor Coll Med, Thrombosis Res Sect, Dept Internal Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Rice Univ, Cox Lab Bioengn, Houston, TX 77030 USA; Baker Med Res Inst, Melbourne, Vic, Australia	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rice University; Baker Heart and Diabetes Institute	Lopez, JA (corresponding author), Baylor Coll Med, Thrombosis Res Sect, Dept Internal Med, BCM 286 N1319,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R29HL046416] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463, HL46416, HL18673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; CRUZ MA, 1992, J BIOL CHEM, V267, P1303; DONG J, 1996, BLOOD, V88, P51; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1998, J BIOL CHEM, V273, P31449, DOI 10.1074/jbc.273.47.31449; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KRONER PA, 1992, BLOOD, V79, P2048; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; Kunishima S, 1997, BLOOD COAGUL FIBRIN, V8, P311, DOI 10.1097/00001721-199707000-00009; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Lopez J A, 1997, Curr Opin Hematol, V4, P323; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MILLER JL, 1991, P NATL ACAD SCI USA, V88, P4761, DOI 10.1073/pnas.88.11.4761; MILLER JL, 1982, BLOOD, V60, P790; MILLER JL, 1990, BRIT J HAEMATOL, V74, P313, DOI 10.1111/j.1365-2141.1990.tb02589.x; Miller JL, 1996, THROMB HAEMOSTASIS, V75, P865; Moriki T, 1997, BLOOD, V90, P698, DOI 10.1182/blood.V90.2.698.698_698_705; MURATA M, 1993, J CLIN INVEST, V91, P2133, DOI 10.1172/JCI116438; MURATA M, 1991, J BIOL CHEM, V266, P15474; PINCUS MR, 1991, BIOCHIM BIOPHYS ACTA, V1097, P133, DOI 10.1016/0925-4439(91)90097-S; PINCUS MR, 1994, J PROTEIN CHEM, V13, P629, DOI 10.1007/BF01890461; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; RUAN C, 1981, BRIT J HAEMATOL, V49, P511, DOI 10.1111/j.1365-2141.1981.tb07259.x; RUSSELL SD, 1993, BLOOD, V81, P1787; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777; TAKAHASHI H, 1985, AM J HEMATOL, V18, P179, DOI 10.1002/ajh.2830180209; TAKAHASHI H, 1995, BLOOD, V85, P727, DOI 10.1182/blood.V85.3.727.bloodjournal853727; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WEISS HJ, 1982, NEW ENGL J MED, V306, P326, DOI 10.1056/NEJM198202113060603	42	51	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27663	27670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837490				2022-12-27	WOS:000089197100020
J	Belaaouaj, AA; Li, AG; Wun, TC; Welgus, HG; Shapiro, SD				Belaaouaj, AA; Li, AG; Wun, TC; Welgus, HG; Shapiro, SD			Matrix metalloproteinases cleave tissue factor pathway inhibitor - Effects on coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; DEPENDENT BLOOD-COAGULATION; SKIN FIBROBLAST COLLAGENASE; SUBSTRATE-SPECIFICITY; MACROPHAGE ELASTASE; UNSTABLE ANGINA; FACTOR XA; EXPRESSION; IDENTIFICATION; LOCALIZATION	The capacity of inflammatory cell-derived matrix metalloproteinases (MMPs) to cleave tissue factor pathway inhibitor (TFPI) and alter its activity was investigated. MMP-7 (matrilysin) rapidly cleaved TFPI to a major 35-kDa product. In contrast, MMP-1 (collagenase-1), MMP-9 (gelatinase B), and MMP-12 (macrophage elastase) cleaved TFPI into several fragments including the 35-kDa band. However, rates of cleavage were most rapid for MMP-7 and MMP-9. NH2-terminal amino acid sequencing revealed that MMP-12 cleaved TFPI at Lys(20)-Leu(21)(close to Kunitz I domain and producing a 35-kDa band), Arg(83)-Ile(84) (between Kunitz I and II domains), and Ser(174)-Thr(175) (between Kunitz II and III domains). MMP-7 and MMP-9 cleaved TFPI at Lys20-Leu21 with additional COOH-terminal processing. These MMPs did not cleave tissue factor (TF), factor VII, and factor Xa. Proteolytic cleavage by MMP-1, MMP-7, MMP-9, and MMP-12 resulted in considerable loss of TFPI activity. These observations indicate specific cleavage of TFPI by MMPs, which broadens their substrate profile. Go-localization of MMPs, TF, and TFPI in atherosclerotic tissues suggests that release of MMPs from inflammatory cell leukocytes may effect TF-mediated coagulation.	Washington Univ, Sch Med, Div Pulm & Crit Care Med, Barnes Jewish Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Monsanto Corp Res, St Louis, MO 63198 USA	Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Monsanto	Belaaouaj, AA (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care Med, Barnes Jewish Hosp, 216 S Kingshighway, St Louis, MO 63110 USA.		Bentaher, Abderrazzaq/M-4424-2017; A, Bentaher/F-6531-2018	A, Bentaher/0000-0001-6001-5456				BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BELAAOUAJ A, 1993, THROMB RES, V69, P547, DOI 10.1016/0049-3848(93)90059-W; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Brophy C M, 1991, Ann Vasc Surg, V5, P229, DOI 10.1007/BF02329378; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; Drew AF, 1997, LAB INVEST, V77, P291; GALLIS ZS, 1994, J CLIN INVEST, V94, P2493; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HAUST M D, 1960, Heart Bull, V9, P90; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIGUCHI DA, 1992, BLOOD, V79, P1712; KETTNER C, 1981, BIOCHEM J, V195, P369, DOI 10.1042/bj1950369; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Li A, 1998, THROMB HAEMOSTASIS, V80, P423, DOI 10.1055/s-0037-1615224; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; PARKS WC, 1998, MATRIX METALLOPROTEI; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; SIRES UI, 1993, J BIOL CHEM, V268, P2069; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WUN TC, 1992, THROMB HAEMOSTASIS, V68, P54	44	96	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27123	27128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859319				2022-12-27	WOS:000089144800062
J	Miconnet, I; Servis, C; Cerottini, JC; Romero, P; Levy, F				Miconnet, I; Servis, C; Cerottini, JC; Romero, P; Levy, F			Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A*0201-restricted peptide tumor antigen MAGE-3(271-279)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC T-LYMPHOCYTES; HUMAN GENE MAGE-3; 20S PROTEASOME; BETA-SUBUNITS; CELL-PROTEINS; YEAST; DEGRADATION; GENERATION; MELANOMA; SEQUENCE	The proteasome plays a crucial role in the proteolytic processing of antigens presented to T cells in the context of major histocompatibility complex class I molecules. However, the rules governing the specificity of cleavage sites are still largely unknown. We have previously shown that a cytolytic T lymphocyte-defined antigenic peptide derived from the MAGE-3 tumor-associated antigen (MAGE-3(271-279) FLWGPRALV in one-letter code) is not presented at the surface of melanoma cell lines expressing the MAGE-3 protein. By using purified proteasome and MAGE-3(271-279) peptides extended at the C terminus by 6 amino acids, we identified predominant cleavages after residues 278 and 280 but no detectable cleavage after residue Val(279), the C terminus of the antigenic peptide. In the present study, we have investigated the influence of Pro(275), Leu(278), and Glu(280) On the proteasomal digestion of MAGE-3(271-285) substituted at these positions. We show that positions 278 and 280 are major proteasomal cleavage sites because they tolerate most amino acid substitutions. In contrast, the peptide bond after Val(279) is a minor cleavage site, influenced by both distal and proximal amino acid residues.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne	Levy, F (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, Ch Des Boveresses 155, CH-1066 Epalinges, Switzerland.							Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Herman J, 1996, IMMUNOGENETICS, V43, P377, DOI 10.1007/s002510050078; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; NOPPEN C, 2000, IN PRESS INT J CANC; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; SHASTRI N, 1995, J IMMUNOL, V155, P4339; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Theobald M, 1998, J EXP MED, V188, P1017, DOI 10.1084/jem.188.6.1017; Valmori D, 1999, J EXP MED, V189, P895, DOI 10.1084/jem.189.6.895; Valmori D, 1997, CANCER RES, V57, P735; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; YellenShaw AJ, 1997, J IMMUNOL, V158, P1727	30	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26892	26897						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859301				2022-12-27	WOS:000089144800032
J	George, SR; Fan, T; Xie, ZD; Tse, R; Tam, V; Varghese, G; O'Dowd, BF				George, SR; Fan, T; Xie, ZD; Tse, R; Tam, V; Varghese, G; O'Dowd, BF			Oligomerization of mu- and delta-opioid receptors - Generation of novel functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; AGONISTS; BRAIN; DESENSITIZATION; PHOSPHORYLATION; PALMITOYLATION; HETERODIMERS; MODULATION; EXPRESSION; DIMERS	The existence of dimers and oligomers for many G protein-coupled receptors has been described by us and others. Since many G protein-coupled receptor subtypes are highly homologous to each other, we examined whether closely related receptors may interact with each other directly and thus have the potential to create novel signaling units. Using mu- and delta-opioid receptors, we show that each receptor expressed individually was pharmacologically distinct and could be visualized following electrophoresis as monomers, homodimers, homotetramers, and higher molecular mass oligomers. When mu- and delta-opioid receptors were coexpressed, the highly selective synthetic agonists for each had reduced potency and altered rank order, whereas endomorphin-1 and Leu-enkephalin had enhanced affinity, suggesting the formation of a novel binding pocket. No heterodimers were visualized in the membranes coexpressing mu- and delta-receptors by the methods available. However, heterooligomers were identified by the ability to co-immunoprecipitate mu-receptors with delta-receptors and vice versa using differentially epitope-tagged receptors, In contrast to the individually expressed mu- and delta-receptors, the coexpressed receptors showed insensitivity to pertussis toxin and continued signal transduction, likely due to interaction with a different subtype of G protein. In this study, we provide, for the first time, evidence for the direct interaction of mu- and delta-opioid receptors to form oligomers, with the generation of novel pharmacology and G protein coupling properties.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		George, Susan R/P-9669-2018; George, Susan/W-7494-2019	Tam, Vincent/0000-0001-8732-0530				Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; ELLIOTT J, 1995, BRIT J PHARMACOL, V114, P1064, DOI 10.1111/j.1476-5381.1995.tb13314.x; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Matthes HWD, 1998, J NEUROSCI, V18, P7285; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; [No title captured]	23	475	498	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26128	26135		10.1074/jbc.M000345200	http://dx.doi.org/10.1074/jbc.M000345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10842167	hybrid			2022-12-27	WOS:000088999700035
J	Huang, XP; Kagami, N; Inoue, H; Kojima, M; Kimura, T; Makabe, O; Suzuki, K; Takahashi, K				Huang, XP; Kagami, N; Inoue, H; Kojima, M; Kimura, T; Makabe, O; Suzuki, K; Takahashi, K			Identification of a glutamic acid and an aspartic acid residue essential for catalytic activity of aspergillopepsin II, a non-pepsin type acid proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	8th International Conference on Aspartic Proteinases	SEP 07-12, 1999	FUNCHAL, PORTUGAL				INSENSITIVE CARBOXYL PROTEINASE; SITE-DIRECTED MUTAGENESIS; SCYTALIDIUM-LIGNICOLUM; PROTEASE-B; NUCLEOTIDE-SEQUENCE; PEPSTATIN; NIGER; GENE; PURIFICATION; EXPRESSION	Aspergillopepsin II from Aspergillus niger var. mac rosporus is a non-pepsin type or pepstatin-insensitive acid proteinase. To identify the catalytic residues of the enzyme, all acidic residues that are conserved in the homologous proteinases of family A4 were replaced with Asn, Gin, or Ala using site-directed mutagenesis. The wild-type and mutant pro-enzymes were heterologously expressed in Escherichia coli and refolded in vitro. The wild-type pro-enzyme was shown to be processed into a two-chain active enzyme under acidic conditions. Most of the recombinant mutant pro-enzymes showed significant activity under acidic conditions because of autocatalytic activation except for the D123N, D123A, E219Q, and E219A mutants. The D123A, E219Q, and E219A mutants showed neither enzymatic activity nor autoprocessing activity under acidic conditions. The circular dichroism spectra of the mutant pro- and mature enzymes were essentially the same as those of the wildtype pro- and mature enzyme, respectively, indicating that the mutant pro-enzymes were correctly folded. In addition, two single and one double mutant pro-enzyme, D123E, E219D, and D123E/E219D, did not show enzymatic activity under acidic conditions. Taken together, Glu-219 and Asp-123 are deduced to be the catalytic residues of aspergillopepsin II.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1138654, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2220002, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo University of Pharmacy & Life Sciences; University of Tokyo; Meiji Holdings Co., Ltd.; University of Tokyo	Takahashi, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	kenjitak@ls.toyaku.ac.jp						ANSON ML, 1939, J GEN PHYSIOL, V22, P77; AOYAGI T, 1971, J ANTIBIOT, V24, P687, DOI 10.7164/antibiotics.24.687; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BROEKHUIJSEN MP, 1993, J BIOTECHNOL, V31, P135, DOI 10.1016/0168-1656(93)90156-H; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Dunn BM, 1991, STRUCTURE FUNCTION A; FUSEK M, 1990, J BIOL CHEM, V265, P1496; INOUE H, 1991, J BIOL CHEM, V266, P19484; Inoue H, 1996, EUR J BIOCHEM, V237, P719, DOI 10.1111/j.1432-1033.1996.0719p.x; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; James MNG, 1998, ASPARTIC PROTEINASES; Jara P, 1996, MOL GEN GENET, V250, P97, DOI 10.1007/BF02191829; JOHNSON JE, 1998, HDB PROTEOLYTIC ENZY, P963; Kakimori T, 1996, BIOSCI BIOTECH BIOCH, V60, P1210; KOAZE Y, 1964, AGR BIOL CHEM TOKYO, V28, P216, DOI 10.1080/00021369.1964.10858233; Kojima M, 2000, BIOCHEMISTRY-US, V39, P1364, DOI 10.1021/bi991584o; KOSTKA V, 1985, ASPARTIC PROTEINASES; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XL, 1990, J BIOL CHEM, V265, P1490; LIN XL, 1991, STRUCTURE FUNCTION A, P1; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; ODA K, 1994, J BIOL CHEM, V269, P26518; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; Oyama H, 1999, J BIOL CHEM, V274, P27815, DOI 10.1074/jbc.274.39.27815; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI K, 1991, J BIOL CHEM, V266, P19480; TAKAHASHI K, 1995, METHOD ENZYMOL, V248, P146; Takahashi K, 1997, BIOSCI BIOTECH BIOCH, V61, P381, DOI 10.1271/bbb.61.381; TAKAHASHI K, 1994, ASPARTIC PROTEINASES; TANG J, 1971, J BIOL CHEM, V246, P4510; TANG J, 1998, HDB PROTEOLYTIC ENZY, P802; Tang J, 1977, ACID PROTEASES STRUC; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P1305, DOI 10.1080/00021369.1989.10869464	39	18	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26607	26614		10.1074/jbc.M910243199	http://dx.doi.org/10.1074/jbc.M910243199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	348RF	10854444	hybrid			2022-12-27	WOS:000088999700099
J	Wittpoth, C; Scholich, K; Bilyeu, JD; Patel, TB				Wittpoth, C; Scholich, K; Bilyeu, JD; Patel, TB			Adenylyl cyclase regulates signal onset via the inhibitory GTP-binding protein, G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; ACTIVATING PROTEINS; BETA-GAMMA; IDENTIFICATION; RECEPTOR; DESENSITIZATION; PHOSPHORYLATION; MYRISTOYLATION; STIMULATION; DIVERSITY	Adenylyl cyclase, the enzyme that converts ATP to cAMP, is regulated by its stimulatory and inhibitory GTP-binding proteins, G(s), and G(i), respectively. Recently, we demonstrated that besides catalyzing the synthesis of cAMP, type V adenylyl cyclase (ACV) can act as a GTPase activating protein for G alpha(s) and also enhance the ability of activated receptors to stimulate GTP-GDP exchange on heterotrimeric G(s), (Scholich, K., Mullenix, J. B., Wittpoth, C., Poppleton, H. M., Pierre, S. C., Lindorfer, M. A., Garrison, J. C., and Patel, T. B. (1999) Science 283, 1328-1331). This latter action of ACV would facilitate the rapid onset of signaling via G(s). Because the C1 region of ACV interacts with the inhibitory GTP-binding protein G alpha(i), we investigated whether the receptor-mediated activation of heterotrimeric G(i) was also regulated by ACV and its subdomains. Our data show that ACV and its C1 domain increased the ability of a muscarinic receptor mimetic peptide (MIII-4) to enhance activation of heterotrimeric G(i) such that the amount of peptide required to stimulate G(i) in steady state GTPase activity assays was 3-4 orders of magnitude less than without the C1 domain. Additionally, the MIII-4-mediated binding of guanosine 5'-(gamma-thio)triphosphate (GTP gamma S) to G(i) was also markedly increased in the presence of ACV or its C1 domain. In contrast, the C2 domain of ACV was not able to alter either the GTPase activity or the GTP gamma S binding to G(i) in the presence of MIII-4. Furthermore, in adenylyl cyclase assays employing 549 cyc(-) cell membranes, the C1 (but not the C2) domain of ACV enhanced the ability of peptide MIII-4 as well as endogenous somatostatin receptors to activate endogenous G(i) and to inhibit adenylyl cyclase activity. These data demonstrate that adenylyl cyclase and its C1 domain facilitate receptor-mediated activation of G(i).	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 115 Crowe Bldg,874 Union Ave, Memphis, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUVE A, 1990, J BACTERIOL, V172, P2614; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KATADA T, 1984, J BIOL CHEM, V259, P3586; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; SCHOLICH K, 1997, P NATL ACAD SCI USA, V94, P2916; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551	25	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25915	25919		10.1074/jbc.M001687200	http://dx.doi.org/10.1074/jbc.M001687200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852906	hybrid			2022-12-27	WOS:000088999700006
J	Chandel, NS; McClintock, DS; Feliciano, CE; Wood, TM; Melendez, JA; Rodriguez, AM; Schumacker, PT				Chandel, NS; McClintock, DS; Feliciano, CE; Wood, TM; Melendez, JA; Rodriguez, AM; Schumacker, PT			Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - A mechanism of O-2 sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; CYTOCHROME-C-OXIDASE; DNA-BINDING ACTIVITY; HYDROGEN-PEROXIDE; FACTOR-I; PARACOCCUS-DENITRIFICANS; CELLULAR RESPIRATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	During hypoxia, hypoxia-inducible factor-1 alpha (HIF-1 alpha) is required for induction of a variety of genes including erythropoietin and vascular endothelial growth factor. Hypoxia increases mitochondrial reactive oxygen species (ROS) generation at Complex III, which causes accumulation of HIF-1 alpha protein responsible for initiating expression of a luciferase reporter construct under the control of a hypoxic response element. This response is lost in cells depleted of mitochondrial DNA (rho degrees cells). Overexpression of catalase abolishes hypoxic response element-luciferase expression during hypoxia. Exogenous H2O2 stabilizes HIF-1 alpha protein during normoxia and activates luciferase expression in wild-type and rho degrees cells. Isolated mitochondria increase ROS generation during hypoxia, as does the bacterium Paracoccus denitrificans. These findings reveal that mitochondria-derived ROS are both required and sufficient to initiate HIF-1 alpha stabilization during hypoxia.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC6026, Chicago, IL 60637 USA.			Melendez, Juan/0000-0001-8021-3097; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; BASS DA, 1983, J IMMUNOL, V130, P1910; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Hohler B, 1999, FEBS LETT, V457, P53, DOI 10.1016/S0014-5793(99)00999-0; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nakamura K, 1997, J NEUROCHEM, V69, P1850; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wood JG, 1999, J APPL PHYSIOL, V87, P1734, DOI 10.1152/jappl.1999.87.5.1734; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	48	1453	1493	3	109	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25130	25138		10.1074/jbc.M001914200	http://dx.doi.org/10.1074/jbc.M001914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833514	hybrid			2022-12-27	WOS:000088849400014
J	Valentinis, B; Navarro, M; Zanocco-Marani, T; Edmonds, P; McCormick, J; Morrione, A; Sacchi, A; Romano, G; Reiss, K; Baserga, R				Valentinis, B; Navarro, M; Zanocco-Marani, T; Edmonds, P; McCormick, J; Morrione, A; Sacchi, A; Romano, G; Reiss, K; Baserga, R			Insulin receptor substrate-1, p70(S6K), and cell size in transformation and differentiation of hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; P70 S6 KINASE; MULTIPLE SIGNALING PATHWAYS; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; PHOSPHORYLATION SITES; OKADAIC ACID; APOPTOSIS; ACTIVATION	After an initial burst of cell proliferation, the type 1 insulin-like growth factor receptor (IGF-IR) induces granulocytic differentiation of 32D IGF-IR cells, an interleukin-3-dependent murine hemopoietic cell line devoid of insulin receptor substrate-1 (IRS-1). The combined expression of the IGF-IR and IRS-1 (32D IGF-IR/IRS-1 cells) inhibits IGF-I-mediated differentiation, and causes malignant transformation of 32D cells. Because of the role of IRS-1 in changing the fate of 32D IGF-IR cells from differentiation land subsequent cell death) to malignant transformation, we have looked for differences in IGF-IR signaling between 32D IGF-IR and 32D IGF-IR/IRS-1 cells. In this report, we have focused on p70(S6K), which is activated by the IRS-l pathway. We find that the ectopic expression of IRS-1 and the inhibition of differentiation correlated with a sustained activation of p70(S6K), and an increase in cell size. Phosphorylation in vivo of threonine 389 and, to a lesser extent, of threonine 421/serine 424 of p70S6K seemed to be a requirement for inhibition of differentiation. A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells. We have also found that the expression of myeloperoxidase mRNA (a marker of differentiation, which sharply increases in 32D IGF-IR cells), does not increase in 32D IGF-IRI/IRS-1 cells, suggesting that the expression of IRS-1 in 32D IGF-IR cells causes the extinction of the differentiation program initiated by the IGF-IR, while leaving intact its proliferation program.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Inst Regina Elena Studio & Cura Tumori, Ctr Ric Sperimentale, Lab Oncogenesi Mol, I-00158 Rome, Italy	Jefferson University; Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Zanocco Marani, Tommaso/D-5801-2015	Zanocco Marani, Tommaso/0000-0002-9911-7078	NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78890] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BASERGA R, 1995, BIOL CELL REPROD; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; KRUGER A, 1991, ONCOGENE, V6, P245; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; METCALF D, 1985, BLOOD, V65, P357; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Rose DW, 1998, ONCOGENE, V17, P889, DOI 10.1038/sj.onc.1201997; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Soon L, 1999, MOL CELL BIOL, V19, P3816; SURMACZ E, 1987, MOL CELL BIOL, V7, P657, DOI 10.1128/MCB.7.2.657; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926	57	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25451	25459		10.1074/jbc.M002271200	http://dx.doi.org/10.1074/jbc.M002271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10846175	Green Published, hybrid			2022-12-27	WOS:000088849400054
J	Shi, ZD; Xu, WZ; Loechel, F; Wewer, UM; Murphy, LJ				Shi, ZD; Xu, WZ; Loechel, F; Wewer, UM; Murphy, LJ			ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-3; BREAST-CANCER CELLS; PROTEASE ACTIVITY; MELTRIN-ALPHA; FACTOR-I; PROTEOLYSIS; CIRCULATION; INDUCTION; CULTURE	Insulin-like growth factor-binding protein (IGFBP)-3 binds the insulin-like growth factors with high affinity and modulates their actions. Proteolytic cleavage of IGFBP-3 may. regulate insulin-like growth factor bioavailability IGFBP-3 is extensively degraded in serum during pregnancy; however, as yet the pregnancy-specific protease, or proteases, have not been identified. We utilized a yeast two-hybrid assay and a human placental cDNA library to investigate IGFBP-3-interacting proteins. A disintegrin and metalloprotease-12 (ADAM 12), a member of a family of metalloprotease disintegrins that is highly expressed in placental tissue, was identified as interacting with IGFBP-3, This interaction involved the cysteine-rich domain of ADAM 12. Unlike other members of this family of disintegrin metalloproteases that are membrane proteins, ADAM 12 exists as an alternatively spliced soluble secreted protein. To verify the interaction between ADAM 12 and IGFBP-3, an expression construct containing an ADAM 12-S c-DNA was transfected into COS-l cells. Go-precipitation was observed when conditioned medium was analyzed by immunoprecipitation with an antibody against either ADAM 12 or IGFBP-3 followed by Western blotting with anti-IGFBP-3 or anti-ADAM 12, Although minimal proteolysis of IGFBP-3 was observed in conditioned medium from control cells, this was increased similar to 4-fold in conditioned medium from ADAM 12-S-transfected cells. Recombinant ADAM 12-S partially purified from conditioned medium on a heparin-Sepharose column also proteolyzed IGFBP-3. The degradation pattern was similar to that seen with pregnancy serum, and the presence of ADAM 12-S in serum during pregnancy was confirmed. The data suggest that ADAM 12-S has IGFBP-3 protease activity, and it may contribute to the IGFBP-3 protease activity present in pregnancy serum.	Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada; Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark	University of Manitoba; University of Manitoba; University of Copenhagen	Murphy, LJ (corresponding author), Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada.							Alpan RS, 1996, CANCER RES, V56, P4358; Bang P, 1997, ENDOCRINOLOGY, V138, P3912, DOI 10.1210/en.138.9.3912; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P2282, DOI 10.1210/jc.80.8.2282; DAVIES SC, 1991, J ENDOCRINOL, V130, P469, DOI 10.1677/joe.0.1300469; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Globus RK, 1998, J CELL SCI, V111, P1385; GRIMES RW, 1994, ENDOCRINOLOGY, V134, P337, DOI 10.1210/en.134.1.337; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Irwin JC, 2000, ENDOCRINOLOGY, V141, P666, DOI 10.1210/en.141.2.666; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; OH Y, 1993, J BIOL CHEM, V268, P26045; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Sakai K, 1997, ENDOCR J, V44, P409, DOI 10.1507/endocrj.44.409; Salahifar H, 1997, ENDOCRINOLOGY, V138, P1683, DOI 10.1210/en.138.4.1683; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Xu S, 1997, J CLIN ENDOCR METAB, V82, P1863, DOI 10.1210/jc.82.6.1863; ZAPF J, 1989, P NATL ACAD SCI USA, V86, P3813, DOI 10.1073/pnas.86.10.3813	23	159	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18574	18580		10.1074/jbc.M002172200	http://dx.doi.org/10.1074/jbc.M002172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849447	hybrid			2022-12-27	WOS:000087659400090
J	Gaulin, JF; Fiset, A; Fortier, S; Faure, RL				Gaulin, JF; Fiset, A; Fortier, S; Faure, RL			Characterization of Cdk2-cyclin E complexes in plasma membrane and endosomes of liver parenchyma - Insulin-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; VESICLE FUSION INVITRO; CYCLIN-E; CELL-CYCLE; TYROSINE KINASE; S-PHASE; MULTIVESICULAR BODY; ENDOCYTIC VESICLES; GOLGI-APPARATUS; COATED PITS	Rat liver parenchyma Golgi/endosomes fractions harbor a tyrosine-phosphorylated 34-kDa protein. Screening of Golgi, endosomes (ENs), plasmalemma (PM), and cytosolic (Cyt) fractions revealed the presence of the mitotic kinase Cdk2 in ENs, PM and Cyt. The fluid phase endocytic marker horseradish peroxidase gained access to the endosomal Cdk2, confirming its localization, Cdk2 was shown to be associated to cyclin E and was active in ENs and PM fractions. The administration of a single dose of insulin (1.5 mu g/100 g, body weight) induced a time-dependent activation of the insulin receptor kinase in these structures. Insulin receptor-kinase activation was followed by the inhibition of immunoprecipitated Cdk2-cyclin E kinase activity in PM and the progressive disappearance of cyclin E. In marked contrast, no such effect was observed in ENs. The injection of a phosphotyrosyl phosphatase inhibitor (bpV-(phen)) increased the levels of cyclin E in ENs and PM. A massive recruitment of p27(hip1) was observed in the Cdk2-cyclin E complexes isolated from PM and Cyt but not from ENs. In vitro, Cdk2-cyclin E complexes have the capacity to inhibit the formation of hybrid structures containing horseradish peroxidase and radioiodinated epidermal growth factor. Therefore, in the PM and ENs of adult rat liver, an active and regulated pool of the mitotic kinase Cdk2-cyclin E and some yet to be defined effecters are present. Cdk2 may contribute to the modulation of transport events and/or maintenance of the topology of endocytic elements.	Univ Laval, CHUL, Ctr Rech, Lab Biol Cellulaire,Unite Rech Pediat, Quebec City, PQ G1V 4G2, Canada	Laval University	Faure, RL (corresponding author), CHU Laval, Ctr Rech, Unite Rech Pediat, Lab 9800, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Robert.Faure@crchul.ulaval.ca						AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Brule S, 2000, BIOL REPROD, V62, P642, DOI 10.1095/biolreprod62.3.642; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Contreres JO, 1998, J BIOL CHEM, V273, P22007, DOI 10.1074/jbc.273.34.22007; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FAURE R, 1992, J BIOL CHEM, V267, P11215; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; FAURE R, 1999, BIOL REPROD, V1, P132; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schmid JA, 1998, EUR J CELL BIOL, V77, P166, DOI 10.1016/S0171-9335(98)80104-0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; WOODMAN PG, 1989, METHOD CELL BIOL, V31, P197; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	73	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16658	16665		10.1074/jbc.275.22.16658	http://dx.doi.org/10.1074/jbc.275.22.16658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828061	hybrid			2022-12-27	WOS:000087392200038
J	Brembeck, FH; Rustgi, AK				Brembeck, FH; Rustgi, AK			The tissue-dependent keratin 19 gene transcription is regulated by GKLF/KLF4 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; AMINO-ACID-SEQUENCE; CARCINOMA CELL-LINE; INTERMEDIATE FILAMENTS; EPITHELIAL-CELLS; NUCLEAR PROTEINS; EXPRESSION; DIFFERENTIATION; GROWTH; IDENTIFICATION	Keratins play critical roles in cellular differentiation and cytoskeletal organization, Keratin 19 (K19) is unique because it has been implicated as a marker of stem cells in some tissues, such as the hair follicle in the skin. It is also associated with malignant transformation in esophageal and pancreatic cancers. Here, we show that the K19 promoter is active in a subset of gastrointestinal cancer cells derived from esophageal and pancreas but inactive in other contexts. This activity was mapped to a short region containing an overlapping binding site for gut-enriched Kruppel-like factor (GKLF/KLF4) and Sp1. GKLF has a higher binding affinity and is the predominant binding factor in cells with low Sp-1 protein levels. Pancreatic acinar cells normally do not express K19, but overexpression of GKLF and Spl in these cells leads to aberrant expression, similar to what is observed in pancreatic cancer. These results demonstrate the functional interaction of ubiquitous and tissue-restricted transcription factors in determining tissue- and neoplasm-specific patterns of gene expression.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 600A CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BARTEK J, 1986, HISTOCHEM J, V18, P565, DOI 10.1007/BF01675198; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; Bouwens L, 1998, J PATHOL, V184, P234; Brembeck FH, 1998, BRIT J CANCER, V78, P1288, DOI 10.1038/bjc.1998.673; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Ceratto N, 1997, CYTOGENET CELL GENET, V77, P169, DOI 10.1159/000134566; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; FILION M, 1994, GENOMICS, V24, P303, DOI 10.1006/geno.1994.1620; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON BW, 1980, DIFFERENTIATION, V17, P161, DOI 10.1111/j.1432-0436.1980.tb01093.x; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LUSSIER M, 1989, GENE, V85, P435, DOI 10.1016/0378-1119(89)90437-X; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Michel M, 1996, J CELL SCI, V109, P1017; Milisavljevic V, 1996, DNA CELL BIOL, V15, P65, DOI 10.1089/dna.1996.15.65; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; Opitz OG, 2000, CANCER RES, V60, P2825; PENDLETON JW, 1991, GENOMICS, V9, P369, DOI 10.1016/0888-7543(91)90267-I; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Prochasson P, 1999, EXP CELL RES, V248, P243, DOI 10.1006/excr.1999.4402; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; SCHRODER FH, 1989, PROSTATE, P17; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WU RL, 1994, J BIOL CHEM, V269, P28450; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	51	105	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28230	28239						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859317				2022-12-27	WOS:000089197100093
J	Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ				Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ			Sequestration of the active site by interdomain shifting - Crystallographic and spectroscopic evidence for distinct conformations of L-3-hydroxyacyl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; FATTY-ACID OXIDATION; ENOYL-COA HYDRATASE; LARGE ALPHA-SUBUNIT; MALATE-DEHYDROGENASE; MULTIENZYME COMPLEX; BIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; BOVINE LIVER; MECHANISM	L-3-Hydroxyacyl-CoA dehydrogenase reversibly catalyzes the conversion of L-3-hydroxyacyl-CoA to 3-ketoacyl-CoA concomitant with the reduction of NAD(+) to NADH as part of the beta-oxidation spiral. In this report, crystal structures have been solved for the apoenzyme, binary complexes of the enzyme with reduced cofactor or 3-hydroxybutyryl-CoA substrate, and an abortive ternary complex of the enzyme with NAD(+) and acetoacetyl-CoA The models illustrate positioning of cofactor and substrate within the active site of the enzyme. Comparison of these structures with the previous model of the enzyme-NAD(+) complex reveals that although significant shifting of the NAD(+)-binding domain relative to the C-terminal domain occurs in the ternary and substrate-bound complexes, there are few differences between the apoenzyme and cofactor-bound complexes. Analysis of these models clarifies the role of key amino acids implicated in catalysis and highlights additional critical residues. Furthermore, a novel charge transfer complex has been identified in the course of abortive ternary complex formation, and its characterization provides additional insight into aspects of the catalytic mechanism of L-3-hydroxyacyl-CoA dehydrogenase.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Banaszak, LJ (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDDK NIH HHS [1F32-DK09759] Funding Source: Medline; NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; AUER HE, 1980, J BIOL CHEM, V255, P8157; Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; BIRKTOFT JJ, 1987, P NATL ACAD SCI USA, V84, P8262, DOI 10.1073/pnas.84.23.8262; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cunningham MA, 1997, BIOCHEMISTRY-US, V36, P4800, DOI 10.1021/bi962734n; de Launoit Y, 1999, J MOL ENDOCRINOL, V22, P227, DOI 10.1677/jme.0.0220227; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; ENGEL PC, 1971, BIOCHEM J, V125, P889, DOI 10.1042/bj1250889; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; HARTMANN D, 1991, BIOCHEMISTRY-US, V30, P2782, DOI 10.1021/bi00225a007; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; He XY, 1997, BIOCHEMISTRY-US, V36, P261, DOI 10.1021/bi961841e; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HOEFLER G, 1994, GENOMICS, V19, P60, DOI 10.1006/geno.1994.1013; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P437; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; NOYES BE, 1973, J BIOL CHEM, V248, P3052; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Roe C. R., 1995, METABOLIC MOL BASES, P1501; SAHA SK, 1994, J BIOL CHEM, V269, P29592; Saha SK, 1999, BBA-PROTEIN STRUCT M, V1431, P261, DOI 10.1016/S0167-4838(99)00040-0; Slifkin M. A., 1971, CHARGE TRANSFER INTE; STERN JR, 1956, J BIOL CHEM, V221, P33; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; YANG SY, 1994, COMP BIOCHEM PHYS B, V109, P557, DOI 10.1016/0305-0491(94)90117-1	33	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27186	27196						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840044				2022-12-27	WOS:000089144800070
J	Taylor, SC; Green, KN; Carpenter, E; Peers, C				Taylor, SC; Green, KN; Carpenter, E; Peers, C			Protein kinase C evokes quantal catecholamine release from PC12 cells via activation of L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMITTER RELEASE; CALCIUM-CHANNEL; PHORBOL ESTERS; N-TYPE; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; CHROMAFFIN CELLS; PHOSPHORYLATION; ENHANCEMENT; EXOCYTOSIS	Application of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to PC12 cells under resting conditions evoked quantal catecholamine secretion, as detected amperometrically, This effect was not mimicked by 4 alpha-phorbol-12,13-didecanoate, another phorbol ester, which is inactive with respect to protein kinase C activation, and was prevented by the protein kinase C inhibitor bisindolylmaleimide, TPA also caused a rise of [Ca2+](i) in Fura-2-loaded PC12 cells, and again this was not mimicked by 4 alpha-phorbol-12,13-didecanoate and could be blocked by bisindolylmaleimide, TPA-evoked secretion was entirely dependent on extracellular Ca2+ and was fully abolished by nifedipine, as were TPA-induced rises of [Ca2+](i). Resting membrane potential, monitored using perforated patch recordings, was unaffected by TPA. However, a small (6-8 mV) hyperpolarizing shift in the voltage dependence of Ca2+ channel currents (determined using whole-cell patch clamp recordings) was induced by TPA, and this could be fully prevented by nifedipine. In contrast to results with depolarizing stimuli, which evoke exocytosis because of Ca2+ influx through N-type channels in these cells, the present results indicate that protein kinase C activation leads directly to quantal catecholamine secretion in the absence of depolarizing stimuli via a selective shift in the activation of L-type Ca2+ channels.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk		Peers, Chris/0000-0002-8354-346X				AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; Billiard J, 1997, P NATL ACAD SCI USA, V94, P12192, DOI 10.1073/pnas.94.22.12192; Boudier JA, 1996, EUR J NEUROSCI, V8, P545, DOI 10.1111/j.1460-9568.1996.tb01239.x; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chow Robert H., 1995, P245; Cousin MA, 1999, EUR J NEUROSCI, V11, P101, DOI 10.1046/j.1460-9568.1999.00412.x; Dickens G, 1997, J NEUROSCI RES, V47, P271, DOI 10.1002/(SICI)1097-4547(19970201)47:3<271::AID-JNR5>3.0.CO;2-F; DOERNER D, 1990, J NEUROSCI, V10, P1699; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELL JW, 1994, J BIOL CHEM, V269, P7390; Hille B, 1999, J PHYSIOL-LONDON, V520, P23, DOI 10.1111/j.1469-7793.1999.00023.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; Jia M, 1999, J NEUROPHYSIOL, V82, P2847, DOI 10.1152/jn.1999.82.6.2847; Liu HY, 1996, J NEUROSCI, V16, P7557; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; TAKASHIMA A, 1985, BIOCHIM BIOPHYS ACTA, V847, P101, DOI 10.1016/0167-4889(85)90159-4; TAKASHIMA A, 1987, BIOCHIM BIOPHYS ACTA, V930, P264, DOI 10.1016/0167-4889(87)90039-5; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; TAYLOR SC, 1999, J PHYSIOL-LONDON, V519, P756; TISCHLER AS, 1983, J NEUROCHEM, V40, P364, DOI 10.1111/j.1471-4159.1983.tb11291.x; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yawo H, 1999, J PHYSIOL-LONDON, V515, P169, DOI 10.1111/j.1469-7793.1999.169ad.x; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26786	26791						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852919				2022-12-27	WOS:000089144800018
J	Kim, S; Jung, Y; Kim, D; Koh, H; Chung, J				Kim, S; Jung, Y; Kim, D; Koh, H; Chung, J			Extracellular zinc activates p70 S6 kinase through the phosphatidylinositol 3-kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAMMALIAN PROTEIN; EPITHELIAL-CELLS; P70(S6K); INSULIN; AKT; MECHANISM; STRESS; TARGET; PHOSPHORYLATION	We have studied a possible role of extracellular zinc ion in the activation of p70S6k, which plays an important role in the progression of cells from the G(1) to S phase of the cell cycle, Treatment of Swiss 3T3 cells with zinc sulfate led to the activation and phosphorylation of p70S6k in a dose-dependent manner, The activation of p70S6k by zinc treatment was biphasic, the early phase being at 30 min followed by the late phase at 120 min. The zinc-induced activation of p70S6k was partially inhibited by down-regulation of phorbol 12-myristate 13-acetate-responsive protein kinase C (PKC) by chronic treatment with phorbol 12-myristate 13-acetate, but this was not significant. Moreover, Go6976, a specific calcium-dependent PKC inhibitor, did not significantly inhibit the activation of p70S6k by zinc. These results demonstrate that the zinc-induced activation of p70S6k is not related to PKC, Also, extracellular calcium was not involved in the activation of p70S6k by zinc. Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity, In addition, Akt, the upstream component of p70S6k, was activated by zinc in a biphasic manner, as was p70S6k, Moreover, dominant interfering alleles of Akt and PDK1 blocked the zinc-induced activation of p70S6k, whereas the lipid kinase activity of PI3K was potently activated by zinc, Taken together, our data suggest that zinc activates p70S6k through the PI3K signaling pathway.	Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Sci Biol, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Grammer TC, 1996, CANCER SURV, V27, P271; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Huang JS, 1999, EUR J BIOCHEM, V266, P943, DOI 10.1046/j.1432-1327.1999.00932.x; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kiss Z, 1997, FEBS LETT, V415, P71, DOI 10.1016/S0014-5793(97)01095-8; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MAY JM, 1982, J BIOL CHEM, V257, P4362; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924	44	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25979	25984		10.1074/jbc.M001975200	http://dx.doi.org/10.1074/jbc.M001975200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851233	hybrid			2022-12-27	WOS:000088999700015
J	Mao, Y; Desai, SD; Liu, LF				Mao, Y; Desai, SD; Liu, LF			SUMO-1 conjugation to human DNA topoisomerase II isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; ENZYME; RANGAP1; YEAST; DEGRADATION; ALPHA; GENE	Topoisomerase I-mediated DNA damage induced by camptothecin has been shown to induce rapid small ubiquitin-related modifier (SUMO)-1 conjugation to topoisomerase I. In the current study, we show that topoisomerase II-mediated DNA damage induced by teniposide (VM-26) results in the formation of high molecular weight conjugates of both topoisomerase II alpha and II beta isozymes in HeLa cells. Immunological characterization of these conjugates suggests that both topoisomerase II alpha and II beta isozymes are conjugated to SUMO-1, The involvement of SUMO-1/UBC9 in the modification of topoisomerase II isozymes is also supported by the demonstration of physical interaction between topoisomerase II and SUMO-1/UBC9. Surprisingly, ICRF-193, which does not induce topoisomerase II-mediated DNA damage but traps topoisomerase II into a circular clamp conformation, is also shown to induce similar SUMO-1 conjugation to topoisomerase II isozymes. In addition, we show that both oxidative and heat shock stresses, which can cause protein damage, rapidly increase nuclear SUMO-1 conjugates. These studies raise the question on whether SUMO-1 conjugation to topoisomerases is an indirect result of a DNA damage response or a direct result because of protein conformational changes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA 39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Boddy MN, 1996, ONCOGENE, V13, P971; Chen A, 1998, BIOCHEM MOL BIOL INT, V46, P1161; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Danks M K, 1989, Cancer Commun, V1, P101; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu LF, 1996, ANN NY ACAD SCI, V803, P44, DOI 10.1111/j.1749-6632.1996.tb26375.x; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 1999, J VIROL, V73, P5137; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Tyrrell R M, 1996, EXS, V77, P255; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WASSERMAN RA, 1993, CANCER RES, V53, P3591	46	124	127	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26066	26073		10.1074/jbc.M001831200	http://dx.doi.org/10.1074/jbc.M001831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862613	hybrid			2022-12-27	WOS:000088999700026
J	Peracchia, C; Sotkis, A; Wang, XG; Peracchia, LL; Persechini, A				Peracchia, C; Sotkis, A; Wang, XG; Peracchia, LL; Persechini, A			Calmodulin directly gates gap junction channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAYFISH SEPTATE AXONS; GATING SENSITIVITY; COMMUNICATING JUNCTIONS; INTRACELLULAR CALCIUM; BINDING SITES; CONDUCTANCE; PH; PERMEABILITY; PROTEINS; CX32	Cytosolic changes control gap junction channel gating via poorly understood mechanisms. In the past two decades calmodulin participation in gating has been suggested, but compelling evidence for it has been lacking. Here we show that calnodulin indeed is associated with gap junctions and plays a direct role in chemical gating. Expression of a calmodulin mutant with the N-terminal EF hand pair replaced by a copy of the C-terminal pair dramatically increases the chemical gating sensitivity of gap junction channels composed of connexin 32 and decreases their sensitivity to transjunctional voltage. The increased chemical gating sensitivity, most likely because of the higher overall Ca2+ binding affinity of this mutant as compared with native calnodulin, and the decreased voltage sensitivity are only observed when the mutant is expressed before connexin 32, This indicates that the mutant, and by extension native calmodulin, must interact with connexin 32 before gap junctions are formed. Immunofluorescence data suggest further that this interaction leads to incorporation of native or mutant calmodulin into the connexon as an integral regulatory subunit.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Peracchia, C (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	camillo_peracchia@urmc.rochester.edu		Peracchia, Camillo/0000-0001-7405-1271	NIGMS NIH HHS [GM20113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bukauskas FF, 1997, BIOPHYS J, V72, P2137, DOI 10.1016/S0006-3495(97)78856-8; Cotrina ML, 1998, J NEUROSCI, V18, P2520; CROW JM, 1994, INVEST OPHTH VIS SCI, V35, P3332; Dermietzel, 1996, GAP JUNCTIONS NERVOU, P135; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; HERTZBERG EL, 1981, COLD SPRING HARB SYM, V46, P639; Lan L, 1998, BIOCHEM J, V330, P1149, DOI 10.1042/bj3301149; LAZRAK A, 1993, BIOPHYS J, V65, P2002, DOI 10.1016/S0006-3495(93)81242-6; LAZRAK A, 1994, BIOPHYS J, V67, P1052, DOI 10.1016/S0006-3495(94)80570-3; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; MEARS D, 1995, J MEMBRANE BIOL, V146, P163; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; PERACCHIA C, 1984, J MEMBRANE BIOL, V81, P49, DOI 10.1007/BF01868809; Peracchia C, 1999, AM J PHYSIOL-CELL PH, V276, pC1361, DOI 10.1152/ajpcell.1999.276.6.C1361; PERACCHIA C, 1987, PFLUG ARCH EUR J PHY, V408, P379, DOI 10.1007/BF00581132; Peracchia C, 2000, CURR TOP MEMBR, V49, P271; PERACCHIA C, 1981, J CELL BIOL, V91, pA124; PERACCHIA C, 1983, PFLUG ARCH EUR J PHY, V399, P152, DOI 10.1007/BF00663912; Peracchia C, 1996, PFLUG ARCH EUR J PHY, V431, P379, DOI 10.1007/BF02207275; PERACCHIA C, 1990, J MEMBRANE BIOL, V117, P79, DOI 10.1007/BF01871567; PERACCHIA C, 1990, J MEMBRANE BIOL, V113, P75, DOI 10.1007/BF01869608; PERACCHIA C, 1988, MODERN CELL BIOL, V7, P267; PERACCHIA C, 2000, CURRENT TOPICS MEMBR, V49; PERACCHIA C, 1994, HDB MEMBRANE CHANNEL, P361; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; SAIMI Y, 1994, HDB MEMBRANE CHANNEL, P435; Skerrett IM, 2000, BIOPHYS J, V78, p22A; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Torok K, 1997, BIOCHEM J, V326, P479; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; TURIN L, 1977, NATURE, V270, P56, DOI 10.1038/270056a0; VANELDIK LJ, 1985, BIOCHEM BIOPH RES CO, V126, P825, DOI 10.1016/0006-291X(85)90259-1; Wang XG, 1997, BIOPHYS J, V73, P798, DOI 10.1016/S0006-3495(97)78112-8; WANG XG, 1998, AM J PHYSIOL, V44, pC1384; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	44	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26220	26224		10.1074/jbc.M004007200	http://dx.doi.org/10.1074/jbc.M004007200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852921	hybrid			2022-12-27	WOS:000088999700047
J	Vickers, MF; Yao, SYM; Baldwin, SA; Young, JD; Cass, CE				Vickers, MF; Yao, SYM; Baldwin, SA; Young, JD; Cass, CE			Nucleoside transporter proteins of Saccharomyces cerevisiae - Demonstration of a transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA BEWO CELLS; XENOPUS-LAEVIS OOCYTES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VESICLES; PURINE; RECONSTITUTION; ADENOSINE; SYSTEM; EI	FUI1 and function unknown now 26 (FUN26) are proteins of uncertain function with sequence similarities to members of the uracil/allantoin permease and equilibrative nucleoside transporter families of transporter proteins, respectively, [H-3]Uridine influx was eliminated by disruption of the gene encoding FUI1 (fui1) and restored by expression of FUI1 cDNA, whereas influx in transport-competent and full-negative yeast were unaffected, respectively, by disruption of the FUN26 gene or overexpression of FUN26 cDNA, FUI1 transported uridine with high affinity (K-m, 22 +/- 3 mu M) and was unaffected or inhibited only partially by high concentrations (1 mM) Of a variety of ribo- and deoxyribonucleosides or nucleobases. When FUN26 cDNA was expressed in oocytes of Xenopus laevis, inward fluxes of [H-3]uridine, [H-3]adenosine, and [H-3]cytidine were stimulated, and uridine influx was independent of pH and not inhibited by dilazep, dipyridamole, or nitrobenzylmercaptopurine ribonucleoside. Fractionation of yeast membranes containing immunotagged recombinant FUN26 (shown to be functional in oocytes) demonstrated that the protein was primarily in intracellular membranes. These results indicated that FUI1 has high selectivity for uracil-containing ribonucleosides and imports uridine across cell-surface membranes, whereas FUN26 has broad nucleoside selectivity and most likely functions to transport nucleosides across intracellular membranes.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Mol Biol Membranes Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Transport Res Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 1Z2, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.							AUSUBEL F, 1997, CURRENT PROTOCOLS MO, V3; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BARTON AB, 1994, J BACTERIOL, V176, P1872, DOI 10.1128/jb.176.7.1872-1880.1994; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Booth JW, 1997, J BIOL CHEM, V272, P20408, DOI 10.1074/jbc.272.33.20408; BOUMAH CE, 1992, BIOCHEM J, V288, P987, DOI 10.1042/bj2880987; Camins A, 1996, LIFE SCI, V58, P753, DOI 10.1016/0024-3205(95)02353-4; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1999, MEMBRANE TRANSPORTER, V12, P313; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HARLEY ER, 1982, CANCER RES, V42, P1289; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; MATILE P, 1969, BIOCHEM J, V111, pP26, DOI 10.1042/bj1110026P; NAGY M, 1979, BIOCHIM BIOPHYS ACTA, V558, P221, DOI 10.1016/0005-2736(79)90062-2; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; PISONI RL, 1989, J BIOL CHEM, V264, P4850; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1984, J BIOL CHEM, V259, P1505; SATO T, 1984, J BIOL CHEM, V259, P1509; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Wagner R, 1998, FEMS MICROBIOL LETT, V159, P69, DOI 10.1111/j.1574-6968.1998.tb12843.x; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	47	62	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25931	25938		10.1074/jbc.M000239200	http://dx.doi.org/10.1074/jbc.M000239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827169	hybrid			2022-12-27	WOS:000088999700009
J	Kadowaki, T; Tsukuba, T; Bertenshaw, GP; Bond, JS				Kadowaki, T; Tsukuba, T; Bertenshaw, GP; Bond, JS			N-linked oligosaccharides on the meprin A metalloprotease are important for secretion and enzymatic activity, but not for apical targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-SUBUNIT; CHROMOSOMAL LOCALIZATION; ENDOPLASMIC-RETICULUM; ASTACIN FAMILY; MDCK CELLS; EXPRESSION; GLYCOSYLATION; DOMAIN; ASSOCIATION	The alpha and beta subunits of meprins, mammalian zinc metalloendopeptidases, are extensively glycosylated; similar to 25% of the total molecular mass of the subunits is carbohydrate. The aim of this study was to investigate the roles of the N-linked oligosaccharides on the secreted form of mouse meprin A. Recombinant meprin cu and mutants in which one of the 10 potential Asn glycosylation sites was mutated to Can were all secreted and sorted exclusively into the apical medium of polarized Madin-Darby canine kidney cells, indicating that no specific N-linked oligosaccharide acts as a determinant for apical targeting of meprin rw. Several of the mutant proteins had decreased enzymatic activity using a bradykinin analog as substrate, and deglycosylation of the wildtype protein resulted in loss of 75-100% activity. Some of the mutants were also more sensitive to heat inactivation. In studies with agents that inhibit glycosylation processes in vivo, tunicamycin markedly decreased secretion of meprin, whereas castanospermine and swainsonine had little effect on secretion, sorting, or enzymatic properties of meprin, When all the potential glycosylation sites on a truncated form of meprin cy (alpha-(1-445)) were mutated, the protein was not secreted into the medium, but was retained within the cells even after 10 h. These results indicate that there is no one specific glycosylation site or type of oligosaccharide thigh mannose- or complex-type) that determines apical sorting, but that core N-linked carbohydrates are required for optimal enzymatic activity and for secretion of meprin alpha.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.		Tsukuba, Takayuki/I-9542-2018	Tsukuba, Takayuki/0000-0003-3322-1339; Bertenshaw, Greg/0000-0003-4903-3412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R01DK019691, R56DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; JOHNSON GD, 1999, HDB PROTEOLYTIC ENZY, P1222; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lottaz D, 1999, CANCER RES, V59, P1127; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	33	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25577	25584		10.1074/jbc.M003521200	http://dx.doi.org/10.1074/jbc.M003521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837482	hybrid			2022-12-27	WOS:000088849400071
J	Onley, DJ; Knight, CG; Tuckwell, DS; Barnes, MJ; Farndale, RW				Onley, DJ; Knight, CG; Tuckwell, DS; Barnes, MJ; Farndale, RW			Micromolar Ca2+ concentrations are essential for Mg2+-dependent binding of collagen by the integrin alpha(2)beta(1) in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BETA-PROPELLER DOMAIN; I-DOMAIN; CRYSTAL-STRUCTURE; A-DOMAIN; DEPENDENT ADHESION; PLASMA-MEMBRANES; DIVALENT-CATIONS; GLYCOPROTEIN-IA; ALPHA-SUBUNITS	Integrin receptor alpha(2)beta(1) requires micromolar Ca2+ to bind to collagen and to the peptide GPC(GPP)(5)GFO-GER(GPP)(5)GPC (denoted GFOGER-GPP, where O represents hydroxyproline), which contains the minimum recognition sequence for the collagen-binding alpha(2) I-domain (Knight, C, G,, Morton, L, F,, Peachey, A. R,, Tuckwell, D. S,, Farndale, R, W,, and Barnes, M. J, (2000) J, Biol. Chem. 275, 35-40), Platelet adhesion to these ligands is completely dependent on alpha(2)beta(1) in the presence of 2 mM Mg2+. However, we show here that this interaction was abolished in the presence of 25 mu M EGTA. Adhesion of Glanzmann's thrombasthenic platelets, which lack the fibrinogen receptor alpha(IIb)beta(3), was also inhibited by micromolar EGTA. Mg2+-dependent adhesion of platelets was restored by the addition of 10 mu M Ca2+, but millimolar Ca2+ was inhibitory. Binding of isolated alpha(2)beta(1) to GFOGER-GPP was 70% inhibited by 50 mu M EGTA but, as with intact platelets, was fully restored by the addition of micromolar Ca2+. 2 mM Ca2+ did not inhibit binding of isolated alpha(2)beta(1) to collagen or to GFOGER-GPP, Binding of recombinant Lu, I-domain was not inhibited by EGTA, nor did millimolar Ca2+ inhibit binding. Our data suggest that high affinity Ca2+ binding to alpha(2)beta(1), outside the I-domain, is essential for adhesion to collagen, This is the first demonstration of a Ca2+ requirement in alpha(2)beta(1) function.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Cambridge; University of Manchester	Onley, DJ (corresponding author), Univ Cambridge, Dept Biochem, Bldg 0, Cambridge CB2 1QW, England.							BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; COLLER BS, 1989, BLOOD, V74, P182; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; HARGREAVES PG, 1994, THROMB HAEMOSTASIS, V72, P634; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Kehrel B, 1998, BLOOD, V91, P491; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Messent AJ, 1998, J CELL SCI, V111, P1127; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SHATTIL SJ, 1986, BLOOD, V68, P1224; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Verkleij MW, 1998, BLOOD, V91, P3808	38	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24560	24564		10.1074/jbc.M004111200	http://dx.doi.org/10.1074/jbc.M004111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827198	hybrid			2022-12-27	WOS:000088683300045
J	Biederbick, A; Kosan, C; Kunz, J; Elsasser, HP				Biederbick, A; Kosan, C; Kunz, J; Elsasser, HP			First apyrase splice variants have different enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; BRAIN ECTO-APYRASE; E-TYPE ATPASES; ENDOPLASMIC-RETICULUM; ATP-DIPHOSPHOHYDROLASE; TOXOPLASMA-GONDII; DIPHOSPHATASE; CLONING; GLYCOSYLATION; LOCALIZATION	LALP70 is a novel lysosomal membrane protein belonging to the apyrase protein family. The apyrase protein family comprises enzymes capable of cleaving nucleotidetri- and diphosphates in a calcium- or magnesium-dependent manner, not being altered by P-type, F-type, or V-type NTPase inhibitors. In this study we have cloned and sequenced the human LALP70 gene to deter mine the genomic structure. The gene is organized in 11 introns and 12 exons covering a genomic region of approximately 16 kilobase pairs. By fluorescence in, situ hybridization analysis, the hLALP70 gene was mapped to the human chromosome 8p21.1-p21.3. We further show that there is at least one alternatively spliced variant, hLALP70v, which can be generated via an alternative splice side at the 3'-end of exon 7, leading to a protein variant differing in 8 amino acids (VSFASSQQ). This is the first splice variant that has been described in the apyrase protein family. Reverse transcriptase polymerase chain reaction analysis showed an ubiquitous expression of both variants, with different relative mRNA expression levels in different tissues. Comparison of the enzymatic properties of the splice variants revealed a broader substrate specificity for hLALP70v with CTP, UDP, CDP, GTP, and GDP as preferred substrates, while hLALP70 utilized UTP and TTP preferentially. Furthermore, enzyme activity of hLALP70v was equally dependent on Ca2+ and Mg2+, being saturated already at 1 mM concentration. In contrast, hLALP70 enzymatic activity were unsaturated up to 10 mM Ca2+, while Mg2+ showed a saturation at already 1 mhz concentration with 2-3-fold lower enzymatic activity as observed with Ca2+. Our data suggest that the presence or absence of the 8-amino acid motif VSFASSQQ provoke differences in substrate specificity and divalent cation dependence of hLALP70/hLALP70v.	Univ Marburg, Inst Klin Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Marburg, Inst Allgemeine Humangenet, Zentrum Humangenet, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Elsasser, HP (corresponding author), Univ Marburg, Inst Klin Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.		Kosan, Christian/C-1213-2017	Kosan, Christian/0000-0002-8387-3653				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Biederbick A, 1999, J CELL SCI, V112, P2473; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nakaar V, 1998, MOL BIOCHEM PARASIT, V97, P209, DOI 10.1016/S0166-6851(98)00153-4; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PLESNER L, 1995, INT REV CYTOL, V158, P141; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Smith TM, 1999, BIOCHEMISTRY-US, V38, P5849, DOI 10.1021/bi990171k; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; VANSTAPEL F, 1988, J CLIN INVEST, V82, P1113, DOI 10.1172/JCI113668; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392	23	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19018	19024		10.1074/jbc.M001245200	http://dx.doi.org/10.1074/jbc.M001245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858452	hybrid			2022-12-27	WOS:000087815900054
J	Ginisty, H; Serin, G; Ghisolfi-Nieto, L; Roger, B; Libante, V; Amalric, F; Bouvet, P				Ginisty, H; Serin, G; Ghisolfi-Nieto, L; Roger, B; Libante, V; Amalric, F; Bouvet, P			Interaction of nucleolin with an evolutionarily conserved pre-ribosomal RNA sequence is required for the assembly of the primary processing complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL TRANSCRIBED SPACER; PRERIBOSOMAL RNA; NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SECONDARY STRUCTURE; BINDING DOMAINS; MOUSE; CLEAVAGE; SITE; U3	The first processing event of the precursor ribosomal RNA (pre-rRNA) takes place within the 5' external transcribed spacer. This primary processing requires conserved cia-acting RNA sequence downstream from the cleavage site and several nucleic acids (small nucleolar RNAs) and proteins trans-acting factors including nucleolin, a major nucleolar protein, The specific interaction of nucleolin with the pre-rRNA is required for processing in vitro. Xenopus laevis and hamster nucleolin interact with the same pre-rRNA site and stimulate the processing activity of a mouse cell extract. A highly conserved 11-nucleotide sequence located 5-6 nucleotides after the processing site is required for the interaction of nucleolin and processing. In vitro selection experiments with nucleolin have identified an RNA sequence that contains the UCGA motif present in the 11-nucleotide conserved sequence, The interaction of nucleolin with pre-rRNA is required for the formation of an active processing complex. Our findings demonstrate that nucleolin is a key factor for the assembly and maturation of pre-ribosomal ribonucleoparticles.	CNRS, UMR 5089, Lab Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bouvet, P (corresponding author), CNRS, UMR 5089, Lab Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	bouvet@ipbs.fr	Nieto, Laurence/AAJ-5703-2021; , Bouvet/AAC-8779-2020	Nieto, Laurence/0000-0002-1006-0168; Libante, Virginie/0000-0001-9728-8343; Bouvet, Philippe/0000-0003-4524-2233				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BACH R, 1981, NUCLEIC ACIDS RES, V9, P1559, DOI 10.1093/nar/9.7.1559; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BLUM B, 1986, NUCLEIC ACIDS RES, V14, P3153, DOI 10.1093/nar/14.8.3153; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; DELCASSOTREMOUSAYGUE D, 1988, EUR J BIOCHEM, V172, P767, DOI 10.1111/j.1432-1033.1988.tb13956.x; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Enright CA, 1996, RNA, V2, P1094; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Hadjiolov A.A., 1985, CELL BIOL MONOGRAPHS, V12; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MICHOT B, 1982, NUCLEIC ACIDS RES, V10, P5273, DOI 10.1093/nar/10.17.5273; MICHOT B, 1991, EUR J BIOCHEM, V195, P601, DOI 10.1111/j.1432-1033.1991.tb15743.x; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; SAVINO R, 1991, BIOCHIMIE, V73, P805, DOI 10.1016/0300-9084(91)90060-E; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; SHUMARD CM, 1988, J BIOL CHEM, V263, P19346; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; URANO Y, 1980, NUCLEIC ACIDS RES, V8, P6043, DOI 10.1093/nar/8.24.6043	39	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18845	18850		10.1074/jbc.M002350200	http://dx.doi.org/10.1074/jbc.M002350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858445	hybrid			2022-12-27	WOS:000087815900033
J	Abdelouahed, M; Ludlow, A; Brunner, G; Lawler, J				Abdelouahed, M; Ludlow, A; Brunner, G; Lawler, J			Accelerated Publication - Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT TGF-BETA; MICE; CELLS; INFLAMMATION; TGF-BETA-1; MECHANISM; DISEASE; PROTEIN; DEFECTS; PALATE	Thrombospondin-1 (TSP-1) has been shown to bind and activate transforming growth factor-beta 1 (TGF-beta 1). This observation raises the possibility that TSP-1 helps to sequester TGF-beta 1 in platelet alpha granules and activates TGF-beta 1 once both proteins are secreted. Herein, we evaluated the level of active and latent TGF-beta 1 in the plasma and in the supernatant of thrombin-treated platelets from TSP-1 null and wild-type mice on two genetic backgrounds (C57BL/6 and 129Sv). The plasminogen activator inhibitor-1/luciferase bioassay and an immunological assay were used to determine active and latent TGF-beta 1, No significant differences were observed in the levels of active and latent TGF-beta 1 in the supernatant of thrombin-treated platelets from TSP-1 null and wildtype mice. Active and latent TGF-beta 1 were significantly increased in the plasma and platelets of C57BL/6 mice as compared with 129Sv mice. In addition, there was an increase of plasma level of latent TGF-beta 1 in TSP-1 null mice as compared with wild-type mice on the C57BL/6 background but not on the 129Sv background. No active TGF-beta 1 was observed in the plasma of either TSP-1 null and wild-type mice. These data indicate that TSP-I does not function as a chaperon for TGF-beta 1 during platelet production and does not activate significant quantities of secreted TGF-beta 1 despite a vast excess in the number of TSP-1 molecules as compared with TGF-beta 1 molecules. Because platelet releasates from TSP-1 null mice contain active TGF-beta 1, we suggest that other important mechanisms of physiological activation of TGF-beta 1 probably exist in platelets.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Munster, Fachklin Hornheide, Dept Canc Res, D-48157 Munster, Germany; Univ Manchester, Sch Biol Sci, Div Cells Immunol & Dev, Manchester M13 9PT, Lancs, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Munster; University of Manchester	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Res N,Rm 270C,99 Brookline Ave, Boston, MA 02215 USA.	lawler@mbcrr.harvard.edu	Lawler, Jack/AAJ-1379-2020		NHLBI NIH HHS [HL28749] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BOIVIN GP, 1995, AM J PATHOL, V146, P276; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1986, BLOOD, V67, P1197; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587	31	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17933	17936		10.1074/jbc.275.24.17933	http://dx.doi.org/10.1074/jbc.275.24.17933			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849431	hybrid			2022-12-27	WOS:000087659400005
J	Kim, H; Lee, TH; Park, ES; Suh, JM; Park, SJ; Chung, HK; Kwon, OY; Kim, YK; Ro, HK; Shong, M				Kim, H; Lee, TH; Park, ES; Suh, JM; Park, SJ; Chung, HK; Kwon, OY; Kim, YK; Ro, HK; Shong, M			Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; FAS-MEDIATED APOPTOSIS; I GENE-EXPRESSION; NF-KAPPA-B; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; STIMULATING HORMONE; PROTEIN IODINATION; FOLLICULAR CELLS; THYROTROPIN	Peroxiredoxins (Prxs) play an important role in regulating cellular differentiation and proliferation in several types of mammalian cells. One mechanism for this action involves modulation of hydrogen peroxide (H2O2)-mediated cellular responses. This report examines the expression of Prx I and Prx II: in thyroid cells and their roles in eliminating H2O2 produced in response to thyrotropin (TSH), Prx I and Prx II are constitutively expressed in FRTL-5 thyroid cells. Prx I expression, but not Prx II expression, is stimulated by exposure to TSH and H2O2. In addition, methimazole induces a high level of Prx I mRNA and protein in these cells, Overexpression of Prx I and Prx II enhances the elimination of H2O2 produced by TSH in FRTL-5 cells. Treatment with 500 mu M H2O2 causes apoptosis in FRTL-5 cells as evidenced big standard assays of apoptosis the. terminal deoxynucleotidyl transferase deoxyuridine triphosphate-biotin nick end labeling, BAX expression, and poly(ADP-ribose) polymerase cleavage. Overexpression of Prx I and Prx II reduces the amount of H2O2-induced apoptosis measured by these assays. These results suggest that Prx I and Prx LI are involved in the removal of H2O2 in thyroid cells and can protect these cells from undergoing apoptosis. These proteins are likely to be involved in the normal physiological response to TSH-induced production of H2O2 in thyroid cells.	Chungnam Natl Univ, Dept Internal Med, Taejon 301721, South Korea; Chungnam Natl Univ, Dept Anat, Taejon 301721, South Korea; Korea Res Inst Biosci & Biotechnol, Yusong Gu, Taejon 305600, South Korea	Chungnam National University; Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Shong, M (corresponding author), Chungnam Natl Univ, Dept Internal Med, 640 Daesadong Chungku, Taejon 301721, South Korea.	minhos@hanbat.chungnam.ac.kr	/H-7803-2012; Lee, Tae-Hoon/AAR-3708-2021	Lee, Tae-Hoon/0000-0003-0105-1750; shong, minho/0000-0002-0247-7115; Kwon, O-Yu/0000-0002-4236-6276				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; BALAZS C, 1986, CLIN ENDOCRINOL, V25, P7, DOI 10.1111/j.1365-2265.1986.tb03590.x; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carvalho DP, 1996, ENDOCRINOLOGY, V137, P1007, DOI 10.1210/en.137.3.1007; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHO BY, 1992, CLIN ENDOCRINOL, V36, P585, DOI 10.1111/j.1365-2265.1992.tb02269.x; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; Ekholm R, 1997, ENDOCRINOLOGY, V138, P2871, DOI 10.1210/en.138.7.2871; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Feldkamp J, 1999, HORM METAB RES, V31, P355, DOI 10.1055/s-2007-978753; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P737, DOI 10.1210/jc.74.4.737; IMAMURA M, 1986, ACTA ENDOCRINOL-COP, V112, P210, DOI 10.1530/acta.0.1120210; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; KINGSTON RE, 1993, CURRENT PROTOCOL MOL, V1; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KOHN LD, 1986, Patent No. 4609622; KUMURA T, 1997, AM J PHYSIOL, V273, pE639; Lee TH, 1999, GENE, V234, P337, DOI 10.1016/S0378-1119(99)00190-0; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; Lim MJ, 1998, GENE, V216, P197, DOI 10.1016/S0378-1119(98)00290-X; Lyu MS, 1999, MAMM GENOME, V10, P1017, DOI 10.1007/s003359901150; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Montani V, 1998, ENDOCRINOLOGY, V139, P290, DOI 10.1210/en.139.1.290; Mozes E, 1998, J CLIN IMMUNOL, V18, P106, DOI 10.1023/A:1023242732212; NAKAMURA Y, 1991, BIOCHEMISTRY-US, V30, P4880, DOI 10.1021/bi00234a007; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nishida S, 1997, FEBS LETT, V416, P69, DOI 10.1016/S0014-5793(97)01171-X; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; Park ES, 1999, THYROID, V9, P601, DOI 10.1089/thy.1999.9.601; RASPE E, 1995, ENDOCRINOLOGY, V136, P965, DOI 10.1210/en.136.3.965; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Riou C, 1999, ENDOCRINOLOGY, V140, P1990, DOI 10.1210/en.140.5.1990; Riou C, 1998, J ENDOCRINOL, V156, P315, DOI 10.1677/joe.0.1560315; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; Taniguchi S, 1998, MOL ENDOCRINOL, V12, P19, DOI 10.1210/mend.12.1.0052; Villette S, 1998, FEBS LETT, V438, P81, DOI 10.1016/S0014-5793(98)01280-0; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	57	194	209	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18266	18270		10.1074/jbc.275.24.18266	http://dx.doi.org/10.1074/jbc.275.24.18266			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849441	hybrid			2022-12-27	WOS:000087659400049
J	Feng, X; Becker, KP; Stribling, SD; Peters, KG; Hannun, YA				Feng, X; Becker, KP; Stribling, SD; Peters, KG; Hannun, YA			Regulation of receptor-mediated protein kinase C membrane trafficking by autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PLASMA-MEMBRANE; IN-VIVO; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-D; LIVING CELLS; BETA-II; ACTIVATION; DOMAIN; PHOSPHORYLATION	Signal transduction via protein kinase C (PRC) is closely regulated by its subcellular localization. In response to activation of cell-surface receptors, PKC is directed to the plasma membrane by two membrane-targeting domains, namely the C1 and C2 regions. This is followed by the return of the enzyme to the cytoplasm, a process shown recently to require PHC autophosphorylation (Feng, X., and Hannun, Y. A. (1998) J. Biol. Chem. 273, 26870-26874). In the present study, we examined mechanisms of translocation and reverse translocation and the role of autophosphorylation in these processes. By visualizing the trafficking of wild-type as well as mutant PKC beta II in live cells, we demonstrated that in response to cell-surface receptor activation, the function of the C1 region is required but not sufficient for recruitment of the enzyme to the plasma membrane. The C2 region is also critical in anchoring the enzyme to the plasma membrane. Furthermore, the inability of a kinase-deficient PKC to undergo reverse translocation was restored by the addition of intracellular calcium chelators, suggesting a role for the C2 region in the persistent phase of translocation, On the other hand, the inability of a C2 deletion mutant (C1 region intact) to translocate in response to agonist was reversed in mutants lacking kinase activity or by mutation of the Ser(660) autophosphorylation site to alanine, suggesting that autophosphorylation of this site is required for opposing the action of the C2 region Therefore, the membrane-targeting function of the C1 region is facilitated by the C2 region and appears to be opposed by autophosphorylation. Taken together, these findings provide novel evidence of the functional regulation of reversible PRC membrane localization by autophosphorylation, and they show that the dynamic translocation of PKC in response to agonists is tightly regulated in a collaborative fashion by the C1 and C2 regions in balance with the effects of autophosphorylation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Medical University of South Carolina; Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Blobe GC, 1996, CANCER SURV, V27, P213; BORNER C, 1989, J BIOL CHEM, V264, P13902; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LUO JH, 1993, J BIOL CHEM, V268, P23580; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pepio AM, 1998, J BIOL CHEM, V273, P19040, DOI 10.1074/jbc.273.30.19040; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	42	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17024	17034		10.1074/jbc.275.22.17024	http://dx.doi.org/10.1074/jbc.275.22.17024			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828076	hybrid			2022-12-27	WOS:000087392200088
J	Fu, X; Inouye, M; Shinde, U				Fu, X; Inouye, M; Shinde, U			Folding pathway mediated by an intramolecular chaperone - The inhibitory and chaperone functions of the subtilisin propeptide are not obligatorily linked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-SEQUENCE; CARBOXYPEPTIDASE-Y; CRYSTAL-STRUCTURE; COMPLEX; BPN'; REQUIREMENT; CATALYSIS; PROTEINS; REGION	The subtilisin propeptide functions as an intramolecular chaperone (IMC) that facilitates correct folding of the catalytic domain while acting like a competitive inhibitor of proteolytic activity. Upon completion of folding, subtilisin initiates IMC degradation to complete precursor maturation. Existing data suggest that the chaperone and inhibitory functions of the subtilisin IMC domain are interdependent during folding. Based on x-ray structure of the IMC-subtilisin complex, we introduce a point mutation (E112A) to disrupt three hydrogen bonds that stabilize the interface between the protease and its IMC domain. This mutation within subtilisin does not alter the folding kinetics but dramatically slows down autoprocessing of the IMC domain. Inhibition of E112A-subtilisin activity by the IMC added in trans is 35-fold weaker than wild-type subtilisin. Although the IMC domain displays substantial loss of inhibitory function, its ability to chaperone E112A-subtilisin folding remains intact. Our results show that (i) the chaperone activity of the IMC domain is not obligatorily linked with its ability to bind with and inhibit active subtilisin; (ii) degradation and not autoprocessing of the IMC domain is the rate-limiting step in precursor maturation; and (iii) the Glu(112) residue within the IMC-subtilisin interface is not crucial for initiating folding but is important in maintaining the IMC structure capable of binding subtilisin.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Shinde, U (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056419] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-56419-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN P, 1995, INTRAMOLECULAR CHAPE; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hu ZX, 1996, J BIOL CHEM, V271, P3375; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; KWON ST, 1988, EUR J BIOCHEM, V73, P1; LEE YC, 1991, AGR BIOL CHEM TOKYO, V55, P3027, DOI 10.1080/00021369.1991.10857921; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1994, J BIOCHEM, V115, P629, DOI 10.1093/oxfordjournals.jbchem.a124386; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SHINDE U, 1997, MOL CHAPERONES PROTE, P467; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P362; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; SUTER U, 1992, J NEUROSCI, V12, P306; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WONG SL, 1986, J BIOL CHEM, V261, P176; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	38	69	90	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16871	16878		10.1074/jbc.275.22.16871	http://dx.doi.org/10.1074/jbc.275.22.16871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828069	hybrid			2022-12-27	WOS:000087392200067
J	Sandberg, M; Hassett, C; Adman, ET; Meijer, J; Omiecinski, CJ				Sandberg, M; Hassett, C; Adman, ET; Meijer, J; Omiecinski, CJ			Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXYGENASE-DERIVED EICOSANOIDS; AMINO-ACID SUBSTITUTIONS; CATALYTIC MECHANISM; ARACHIDONIC-ACID; CYTOCHROME-P-450 METABOLISM; HUMAN-LYMPHOCYTES; DIMER INTERFACE; HUMAN-LIVER; RAT-LIVER; EXPRESSION	Human soluble epoxide hydrolase (sEH), an enzyme directing the functional disposition of a variety of endogenous and xenobiotic-derived chemical epoxides, was characterized at the genomic level for interindividual variation capable of impacting function. RNA was isolated from 25 human liver samples and used to generate full-length copies of soluble epoxide hydrolase cDNA. The resulting cDNAs were polymerase chain reaction amplified, sequenced, and eight variant loci were identified. The coding region contained five silent single nucleotide polymorphisms (SNPs) and two variant loci resulting in altered protein sequence. An amino acid substitution was identified at residue 287 in exon 8, where the more common arginine was replaced by glutamine. A second variant locus was identified in exon 13 where an arginine residue was inserted following serine 402 resulting in the sequence, arginine 403-404, instead of the more common, arginine 403. This amino acid insertion was confirmed by analyzing genomic DNA from individuals harboring the polymorphic allele. Slot blot hybridization analyses of the liver samples indicated that sEH mRNA steady-state expression varied approximately 10-fold. Transient transfection experiments with CHO and COS-7 cells were used to demonstrate that the two new alleles possess catalytic activity using trans-stilbene oxide as a model substrate. Although the activity of the glutamine 287 variant was similar to the sEH wild type allele, proteins containing the arginine insertion exhibited strikingly lower activity. Allelic forms of human sEH, with markedly different enzymatic profiles, may have important physiological implications with respect to the disposition of epoxides formed from the oxidation of fatty acids, such as arachidonic acid-derived intermediates, as well in the regulation of toxicity due to xenobiotic epoxide exposures.	Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98105 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA; Swedish Univ Agr Sci, Uppsala Genet Ctr, Dept Plant Biol, SE-75007 Uppsala, Sweden	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swedish University of Agricultural Sciences	Omiecinski, CJ (corresponding author), Univ Washington, Dept Environm Hlth, 4225 Roosevelt Way NE, Seattle, WA 98105 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004978, P30ES007033] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES07033, ES04978] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonarakis SE, 1998, HUM MUTAT, V11, P1; ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; FAHLSTADIUS P, 1988, LIPIDS, V23, P1015; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; Gandolfi A.J., 1997, COMPREHENSIVE TOXICO, P283; GILL SS, 1983, ANAL BIOCHEM, V131, P273, DOI 10.1016/0003-2697(83)90166-5; Gonzalez FJ, 1997, REPROD TOXICOL, V11, P397, DOI 10.1016/S0890-6238(96)00154-2; GRANT DF, 1993, J BIOL CHEM, V268, P17628; Hartsfield JK, 1998, CYTOGENET CELL GENET, V83, P44, DOI 10.1159/000015164; Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KOSAKA K, 1994, MOL CELL BIOCHEM, V139, P141, DOI 10.1007/BF01081737; KRAMER A, 1991, BIOCHEM PHARMACOL, V42, P2147, DOI 10.1016/0006-2952(91)90350-E; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001; LARSSON C, 1995, HUM GENET, V95, P356; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MEIJER J, 1985, EUR J BIOCHEM, V148, P421, DOI 10.1111/j.1432-1033.1985.tb08856.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERTES I, 1985, CARCINOGENESIS, V6, P219, DOI 10.1093/carcin/6.2.219; Misawa E, 1998, EUR J BIOCHEM, V253, P173, DOI 10.1046/j.1432-1327.1998.2530173.x; Moghaddam MF, 1997, NAT MED, V3, P562, DOI 10.1038/nm0597-562; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; Mueller MJ, 1998, J BIOL CHEM, V273, P11570, DOI 10.1074/jbc.273.19.11570; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; NORRIS KK, 1989, J CLIN INVEST, V84, P1749, DOI 10.1172/JCI114358; PACEASCIAK CR, 1989, J BIOL CHEM, V264, P9310; Parkinson A., 1996, BASIC SCI POISONS, P113; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; Prasanna V, 1999, PROTEINS, V34, P356; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Sandberg M, 1996, BIOCHEM BIOPH RES CO, V221, P333, DOI 10.1006/bbrc.1996.0596; Scopes DA, 1998, EUR J BIOCHEM, V251, P382, DOI 10.1046/j.1432-1327.1998.2510382.x; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; VanRollins M, 1996, J BIOL CHEM, V271, P14001, DOI 10.1074/jbc.271.24.14001; WATABE T, 1981, J BIOL CHEM, V256, P2900; Weintraub NL, 1999, AM J PHYSIOL-HEART C, V277, pH2098, DOI 10.1152/ajpheart.1999.277.5.H2098; WRENSCH MR, 1989, CANCER RES, V49, P2168; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059	52	68	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28873	28881		10.1074/jbc.M001153200	http://dx.doi.org/10.1074/jbc.M001153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862610	hybrid			2022-12-27	WOS:000089330700071
J	Zhou, YL; Lei, YP; Snead, ML				Zhou, YL; Lei, YP; Snead, ML			Functional antagonism between Msx2 and CCAAT/enhancer-binding protein alpha in regulating the mouse amelogenin gene expression is mediated by protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTICALLY ACTIVATE TRANSCRIPTION; FACTOR C/EBP-ALPHA; NF-KAPPA-B; HOMEOBOX GENE; TOOTH DEVELOPMENT; ADIPOCYTE DIFFERENTIATION; RECIPROCAL REGULATION; NEGATIVE INHIBITOR; CELL-PROLIFERATION; IMPERFECTA AIH1	Ameloblast-specific amelogenin gene expression is spatiotemporally regulated during tooth development. In a previous study, the CCAAT/enhancer-binding protein alpha (C/EBP alpha) was identified as a transcriptional activator of the mouse amelogenin gene in a cell type-specific manner. Here, Msx2 is shown to repress the promoter activity of amelogenin-promoter reporter constructs independent of its intrinsic DNA binding activity. In transient cotransfection assays, Msx2 and C/EBP alpha antagonize each other in regulating the expression of the mouse amelogenin gene. Electrophoresis mobility shift assays demonstrate that Msx2 interferes with the binding of C/EBP alpha to its cognate site in the mouse amelogenin minimal promoter, although Msx2 itself does not bind to the same promoter fragment. Protein-protein interaction between Msx2 and C/EBP alpha is identified with co-immunoprecipitation analyses. Functional antagonism between Msx2 and C/EBP alpha is also observed on the stably transfected a,a-kilobase mouse amelogenin promoter in ameloblast-like LS8 cells, Furthermore, the carboxyl-terminal residues 183-267 of Msx2 are required for protein-protein interaction, whereas the amino-terminal residues 2-97 of Msx2 play a less critical role. Among three family members tested (C/EBP alpha, -beta, and -gamma), Msx2 preferentially interacts with C/EBP alpha. Taken together, these data indicate that protein-protein interaction rather than competition for overlapping binding sites results in the functional antagonism between Msx2 and C/EBP alpha in regulating the mouse amelogenin gene expression.	Univ So Calif, CCMB, Los Angeles, CA 90033 USA	University of Southern California	Snead, ML (corresponding author), Univ So Calif, CCMB, CSA142,2250 Alcazar St, Los Angeles, CA 90033 USA.				NIDCR NIH HHS [DE06988] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALDRED MJ, 1992, HUM GENET, V90, P413; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; CHEN EH, 1994, DEV DYNAM, V199, P189, DOI 10.1002/aja.1001990304; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COUWENHOVEN RI, 1993, J CRAN GENET DEV BIO, V13, P259; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DAlessio M, 1996, MECH DEVELOP, V58, P217, DOI 10.1016/S0925-4773(96)00583-7; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Dhamija S, 1999, J BIOL CHEM, V274, P20738, DOI 10.1074/jbc.274.29.20738; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; Diekwisch TGH, 1997, J HISTOCHEM CYTOCHEM, V45, P859, DOI 10.1177/002215549704500610; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAGERSTROMFERMER M, 1995, GENOMICS, V26, P159, DOI 10.1016/0888-7543(95)80097-6; LANE MD, 1996, INT J OBESITY, V20, P91; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1991, DEVELOPMENT, V113, P601; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; METZGER S, 1993, J BIOL CHEM, V268, P16831; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mina M, 1996, CONNECT TISSUE RES, V35, P79, DOI 10.3109/03008209609029177; MINA M, 1995, DEV DYNAM, V202, P195, DOI 10.1002/aja.1002020211; Mink S, 1996, MOL CELL BIOL, V16, P1316; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; *QIAG INC, 1997, QIAEXPR, P38; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Shimeld SM, 1996, MECH DEVELOP, V55, P201, DOI 10.1016/0925-4773(96)00505-9; SNEAD ML, 1988, DEVELOPMENT, V104, P77; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; SNEAD ML, 1984, DEV BIOL, V104, P255, DOI 10.1016/0012-1606(84)90053-8; SNEAD ML, 1987, MOL APPROACHES DEV B, P641; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stocum DL, 1997, SCIENCE, V276, P15, DOI 10.1126/science.276.5309.15; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; WU KJ, 1994, J BIOL CHEM, V269, P1177; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZeichnerDavid M, 1997, INT J DEV BIOL, V41, P27; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273	77	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29066	29075		10.1074/jbc.M002031200	http://dx.doi.org/10.1074/jbc.M002031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10859305	hybrid			2022-12-27	WOS:000089330700094
J	Inoue, H; Tanabe, T; Umesono, K				Inoue, H; Tanabe, T; Umesono, K			Feedback control of cyclooxygenase-2 expression through PPAR gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; ACTIVATED RECEPTOR-GAMMA; FACTOR-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; NUCLEAR FACTOR; FACTOR-ALPHA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT	Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostaglandins (PG), plays a key role in inflammation, tumorigenesis, development, and circulatory homeostasis. The POD, metabolite 15-deoxy-Delta(12,14) PGJ(2) (15d-PGJ(2)) was identified as a potent natural ligand for the peroxisome proliferator-activated receptor-gamma (PPAR gamma), PPAR gamma expressed in macrophages has been postulated as a negative regulator of inflammation and a positive regulator of differentiation into foam cell associated with atherogenesis. Here, we show that 15d-PGJ(2) suppresses the Lipopolysaccharide (LPS)-induced expression of COX-2 in the macrophage-like differentiated U937 cells but not in vascular endothelial cells. PPAR gamma mRNA abundantly expressed in the U937 cells, not in the endothelial cells, is down-regulated by LPS, In contrast, LPS up-regulates mRNA for the glucocorticoid receptor which ligand anti-inflammatory steroid dexamethasone (DEX) strongly suppresses the LPS-induced expression of COX-2, although both 15d-PGJ(2) and DEX suppressed COX-2 promoter activity by interfering with the NF-kappa B signaling pathway, Transfection of a PPAR gamma expression vector into the endothelial cells acquires this suppressive regulation of COX-2 gene by 15d-PGJ(2) but not by DM. A selective COX-2 inhibitor, NS-398, inhibits production of PGD(2) in the U937 cells. Taking these findings together, we propose that expression of COX-2 is regulated by a negative feedback loop mediated through PPAR gamma, which makes possible a dynamic production of PC, especially in macrophages, and may be attributed to various expression patterns and physiological functions of COX-2.	Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Osaka 5658565, Japan; Kyoto Univ, Inst Virus Res, Dept Mol Biol & Genet, Sakyo Ku, Kyoto 068397, Japan	National Cerebral & Cardiovascular Center - Japan; Kyoto University	Inoue, H (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.							BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; Callejas NA, 1999, J PHARMACOL EXP THER, V288, P1235; Chinery R, 1999, CANCER RES, V59, P2739; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Greene M. E., 1995, Gene Expression, V4, P281; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Inoue H, 1999, BIOCHEM BIOPH RES CO, V254, P292, DOI 10.1006/bbrc.1998.9939; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kuwamoto S, 1997, FEBS LETT, V409, P242, DOI 10.1016/S0014-5793(97)00516-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; Ma HW, 1998, J BIOL CHEM, V273, P30131, DOI 10.1074/jbc.273.46.30131; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sundvold H, 1997, BIOCHEM BIOPH RES CO, V239, P857, DOI 10.1006/bbrc.1997.7564; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; URADE Y, 1989, J IMMUNOL, V143, P2982; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; ZAKAR T, 1995, ENDOCRINOLOGY, V136, P1610, DOI 10.1210/en.136.4.1610	48	259	271	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28028	28032						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10827178				2022-12-27	WOS:000089197100067
J	Jokiranta, TS; Hellwage, J; Koistinen, V; Zipfel, PF; Meri, S				Jokiranta, TS; Hellwage, J; Koistinen, V; Zipfel, PF; Meri, S			Each of the three binding sites on complement factor H interacts with a distinct site on C3b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULONEPHRITIS TYPE-II; SURFACE-PLASMON RESONANCE; ALTERNATIVE PATHWAY; HEPARIN-BINDING; PROTEIN BETA-1H; SIALIC-ACID; FACTOR-B; MONOCLONAL-ANTIBODIES; REGULATORY DOMAINS; TRYPTIC FRAGMENT	Factor H (fH) restricts activation of the alternative pathway of complement at the level of C3, both in the fluid phase and on self-structures, but allows the activation to proceed on foreign structures. To study the interactions between fH and C3b we used surface plasmon resonance analysis (Biacore(R)) and eight recombinantly expressed fH constructs containing fragments of the 20 short consensus repeat domains (SCRs) of fH. We analyzed the binding of these constructs to C3b and its cleavage products C3c and C3d. Three binding sites for C3b were found on fH. Site 1 was localized to the five amino-terminal SCRs (SCR1-5), and its reciprocal binding site on C3b was found to be lost upon the cleavage of C3b to C3c and C3d, Site 2 on fH was localized by exclusion probably within or near SCRs 12-14 (fragment SCR8-20 bound to C3b, C3c, and C3d; SCR8-11 did not bind to C3b at all; and SCR15-20 bound only to the C3d part of C3b). Site 3 on fH for C3b was localized to the carboxyl-terminal SCRs 19-20, and its reciprocal binding site was mapped to the C3d part of C3b. In conclusion, we confirmed and mapped three binding sites on fH for C3b and demonstrated that the three binding sites on fH interact with distinct sites on C3b. Multiple reciprocal interactions between C3b and fH can provide a basis for the different reactivity of the alternative pathway with different target structures.	Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst & HD Diagnost, Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, D-20359 Hamburg, Germany; Hans Knoell Inst Naturstoff Forsch, D-07708 Jena, Germany	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Bernhard Nocht Institut fur Tropenmedizin	Jokiranta, TS (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst & HD Diagnost, Haartmaninkatu 3, Helsinki, Finland.	sakari.jokiranta@helsinki.fi	Jokiranta, T. Sakari/F-1906-2011					ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ALSENZ J, 1990, CURR TOP MICROBIOL, V153, P235; Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; CULLEN DC, 1987, BIOSENSORS, V3, P211; EGGERTSEN G, 1985, MOL IMMUNOL, V22, P833, DOI 10.1016/0161-5890(85)90067-7; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FEARON DT, 1975, J IMMUNOL, V115, P1357; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; GORDON DL, 1995, J IMMUNOL, V155, P348; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; HONG K, 1982, J IMMUNOL, V129, P647; HORSTMANN RD, 1985, J IMMUNOL, V134, P1101; JANSEN JH, 1993, AM J PATHOL, V143, P1356; Jokiranta TS, 1996, FEBS LETT, V393, P297; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lambris JD, 1996, J IMMUNOL, V156, P4821; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; Pathak SS, 1997, IMMUNOL TODAY, V18, P464, DOI 10.1016/S0167-5699(97)01124-9; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180; SCHREIBER RD, 1978, P NATL ACAD SCI USA, V75, P3948, DOI 10.1073/pnas.75.8.3948; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	54	174	183	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27657	27662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837479				2022-12-27	WOS:000089197100019
J	Forsee, WT; Cartee, RT; Yother, J				Forsee, WT; Cartee, RT; Yother, J			Biosynthesis of type 3 capsular polysaccharide in Streptococcus pneumoniae - Enzymatic chain release by an abortive translocation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASES; ARCHITECTURE; EQUISIMILIS; PYOGENES	The type 3 polysaccharide synthase from Streptococcus pneumoniae catalyzes sugar transfer from UDP-Glc and UDP-glucuronic acid (GlcUA) to a polymer with the repeating disaccharide unit of [3)-beta-D-GlcUA-(1-->4)-beta-D-Glc-(1-->]. Evidence is presented that release of the polysaccharide chains from S, pneumoniae membranes is time-, temperature, and pH-dependent and saturable with respect to specific catalytic metabolites. In these studies, the membrane-bound synthase was shown to catalyze a rapid release of enzyme-bound polysaccharide when either UDP-Glc or UDP-GlcUA alone was present in the reaction. Only a slow release of polysaccharide occurred when both UDP sugars were present or when both UDP sugars were absent. Chain size was not a specific determinant in polymer release. The release reaction was saturable with increasing concentrations of UDP-Glc or UDP-GlcUA, with respective apparent K-m, values of 880 and 0.004 mu M, The apparent V-max was 48-fold greater with UDP-Glc compared with UDP-GlcUA. The UDP-Glc-actuated reaction was inhibited by UDP-GlcUA with an approximate K-i of 2 mu m, and UDP-GlcUA-actuated release was inhibited by UDP-Glc with an approximate K-i of 5 mu m. In conjunction with kinetic data regarding the polymerization reaction, these data indicate that UDP-Glc and UDP-GlcUA bind to the same synthase sites in both the biosynthetic reaction and the chain release reaction and that polymer release is catalyzed when one binding site is filled and the concentration of the conjugate UDP-precursor is insufficient to fill the other binding site. The approximate energy of activation values of the biosynthetic and release reactions indicate that release of the polysaccharide occurs by an abortive translocation process. These results are the first to demonstrate a specific enzymatic mechanism for the termination and release of a polysaccharide.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama, Dept Microbiol, BBRB 661-12,845 19th St S, Birmingham, AL 35294 USA.				NHLBI NIH HHS [T32HL07553] Funding Source: Medline; NIGMS NIH HHS [GM53017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Hardy GG, 2000, J BACTERIOL, V182, P1854, DOI 10.1128/JB.182.7.1854-1863.2000; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; Reeves RE, 1941, J BIOL CHEM, V139, P511; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SMITH EEB, 1960, J BIOL CHEM, V235, P1876; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Sunthankar P, 1998, ANAL BIOCHEM, V258, P195, DOI 10.1006/abio.1998.2600; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; TORRIANI A, 1962, J BIOL CHEM, V237, P3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; ZWEIG G, 1967, PAPER CHROMATOGRAPHY	22	29	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25972	25978		10.1074/jbc.M002613200	http://dx.doi.org/10.1074/jbc.M002613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854426	hybrid			2022-12-27	WOS:000088999700014
J	Keilhack, H; Hellman, U; van Hengel, J; van Roy, F; Godovac-Zimmermann, J; Bohmer, FD				Keilhack, H; Hellman, U; van Hengel, J; van Roy, F; Godovac-Zimmermann, J; Bohmer, FD			The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates p120 catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-ADHESION MOLECULE; TUMOR-SUPPRESSOR GENE; E-CADHERIN; BETA-CATENIN; INHIBITORY RECEPTOR; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; ALPHA-CATENIN; EGF RECEPTOR	A prominent tyrosine-phosphorylated protein of similar to 100 kDa (designated pp100) in epidermal growth factor (EGF)-stimulated A431 cells was found to be a main interaction partner of the protein-tyrosine phosphatase SHP-1 in pull-down experiments with a glutathione S-transferase-SHP-1 fusion protein. Binding was largely mediated by the N-terminal SH2 domain of SHP-1 and apparently direct and independent from the previously described association of SHP-1 with the activated EGF receptor. pp100 was partially purified and identified by mass spectrometric analysis of tryptic fragments, partial amino acid sequencing, and use of authentic antibodies as the 3A isoform of the Armadillo repeat protein superfamily member p120 catenin (p120(ctn)). Different p120(ctn) isoforms expressed in human embryonal kidney 293 cells, exhibited differential binding to SHP-1 that correlated partly with the extent of EGF-dependent p120(ctn) tyrosine phosphorylation. Despite strong phosphorylation, p120(ctn) isoforms 3B and 3AB bound, however, less readily to SHP-1. SHP-1 associated transiently with p120(ctn) in EGF-stimulated A431 cells stably transfected with a tetracycline-responsive SHP-1 expression construct, and p120(ctn) exhibited elevated phosphorylation upon a tetracycline-mediated decrease in the SHP-1 level. Functions of p120(ctn), which are regulated by tyrosine phosphorylation, may be modulated by the described SHP-1-p120(ctn) interaction.	Univ Jena Klinikum, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Ludwig Inst Canc Res, Uppsala Branch, SE-75124 Uppsala, Sweden; State Univ Ghent VIB, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Inst Mol Biotechnol, D-07745 Jena, Germany	Friedrich Schiller University of Jena; Ludwig Institute for Cancer Research; Flanders Institute for Biotechnology (VIB); Ghent University	Bohmer, FD (corresponding author), Univ Jena Klinikum, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Zimmermann, Jasminka Godovac/E-6863-2010; van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Adachi M, 1996, CELL, V85, P15; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DOWNING JR, 1991, ONCOGENE, V6, P607; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hellman U, 1997, SPRING LAB MAN, P97; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KIM L, 1995, MOL CELL BIOL, V15, P4553; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Mo YY, 1996, CANCER RES, V56, P2633; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Perez-Villar JJ, 1999, MOL CELL BIOL, V19, P2903; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; Takayama T, 1998, BRIT J CANCER, V77, P605, DOI 10.1038/bjc.1998.97; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Thiery JP, 1996, J CELL BIOCHEM, V61, P489; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Ulyanova T, 1997, IMMUNOL RES, V16, P101, DOI 10.1007/BF02786326; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	67	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26376	26384		10.1074/jbc.M001315200	http://dx.doi.org/10.1074/jbc.M001315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835420	hybrid			2022-12-27	WOS:000088999700068
J	Escoubas, P; De Weille, JR; Lecoq, A; Diochot, S; Waldmann, R; Champigny, G; Moinier, D; Menez, A; Lazdunski, M				Escoubas, P; De Weille, JR; Lecoq, A; Diochot, S; Waldmann, R; Champigny, G; Moinier, D; Menez, A; Lazdunski, M			Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; ROOT GANGLION NEURONS; SENSORY NEURONS; ION CHANNELS; CAENORHABDITIS-ELEGANS; CATION CHANNEL; POTASSIUM CHANNELS; MOLECULAR-CLONING; CALCIUM-CHANNEL	Acid sensing is associated with nociception, taste transduction, and perception of extracellular pH fluctuations in the brain. Acid sensing is carried out by the simplest class of ligand-gated channels, the family of H+-gated Na+ channels. These channels have recently been cloned and belong to the acid-sensitive ion channel (ASIC) family. Toxins from animal venoms have been essential for studies of voltage-sensitive and ligand-gated ion channels. This paper describes a novel 40-amino acid toxin from tarantula venom, which potently blocks (IC50 = 0.9 nM) a particular subclass of ASIC channels that are highly expressed in both central nervous system neurons and sensory neurons from dorsal root ganglia. This channel type has properties identical to those described for the homomultimeric assembly of ASIC1a. Homomultimeric assemblies of other members of the ASIC family and heteromultimeric assemblies of ASIC1a with other ASIC subunits are insensitive to the toxin. The new toxin is the first high affinity and highly selective pharmacological agent for this novel class of ionic channels. It will be important for future studies of their physiological and physio-pathological roles.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Paris 06, F-75006 Paris, France; CEA Saclay, Dept Ingn Prot, F-91130 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Diochot, Sylvie/ABG-5495-2020; Waldmann, Rainer/Q-2108-2016; de Weille, Jan R/F-8103-2014	Waldmann, Rainer/0000-0002-4599-2926; de Weille, Jan R/0000-0002-0505-3166				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 1999, CIRC RES, V84, P921; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen XJ, 1997, INVEST OPHTH VIS SCI, V38, P1944; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; Diochot S, 1999, BRIT J PHARMACOL, V126, P251, DOI 10.1038/sj.bjp.0702283; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LAMPE RA, 1993, MOL PHARMACOL, V44, P451; Lauritzen I, 1997, BRAIN RES, V753, P8, DOI 10.1016/S0006-8993(96)01491-6; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; NARASIMHAN L, 1994, NAT STRUCT BIOL, V1, P850, DOI 10.1038/nsb1294-850; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Pan HL, 1999, J PHYSIOL-LONDON, V518, P857, DOI 10.1111/j.1469-7793.1999.0857p.x; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	38	372	386	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25116	25121		10.1074/jbc.M003643200	http://dx.doi.org/10.1074/jbc.M003643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829030	hybrid			2022-12-27	WOS:000088849400012
J	Kaftan, EJ; Xu, T; Abercrombie, RF; Hille, B				Kaftan, EJ; Xu, T; Abercrombie, RF; Hille, B			Mitochondria shape hormonally induced cytoplasmic calcium oscillations and modulate exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYMPATHETIC NEURONS; PITUITARY GONADOTROPES; FREE CA2+; MECHANISMS; PARTICIPATION; ACCUMULATION; HOMEOSTASIS; INDICATORS; CLEARANCE	Pituitary gonadotropes transduce hormonal input into cytoplasmic calcium ([Ca2+](cyt)) oscillations that drive rhythmic exocytosis of gonadotropins, Using Calcium Green-1 and rhod-2 as optical measures of cytoplasmic and mitochondrial free Ca2+, we show that mitochondria sequester Ca2+ and tune the frequency of [Ca2+](cyt) oscillations in rat gonadotropes. Mitochondria accumulated Ca2+ rapidly and in phase with elevations of [Ca2+](cyt) after GnRH stimulation or membrane depolarization. Inhibiting mitochondrial Ca2+ uptake by the protonophore CCCP reduced the frequency of GnRH-induced [Ca2+](cyt) oscillations or, occasionally, stopped them. Much of the Ca2+ that entered mitochondria is bound by intramitochondrial Ca2+ buffering systems. The mitochondrial Ca2+ binding ratio may be dynamic because [Ca2+](mit), appeared to reach a plateau as mitochondrial Ca2+ accumulation continued. Entry of Ca2+ into mitochondria was associated with a small drop in the mitochondrial membrane potential. Ca2+ was extruded from mitochondria more slowly than it entered, and much of this efflux could be blocked by CGP-37157, a selective inhibitor of mitochondrial Na+-Ca2+ exchange. Plasma membrane capacitance changes in response to depolarizing voltage trains were increased when CCCP was added, showing that mitochondria lower the local [Ca2+](cyt) near sites that trigger exocytosis. Thus, we demonstrate a central role for mitochondria in a significant physiological response.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Emory Univ, Dept Physiol, Atlanta, GA 30322 USA	University of Washington; University of Washington Seattle; Emory University	Kaftan, EJ (corresponding author), Univ Washington, Dept Physiol & Biophys, G-424 Hlth Sci Bldg, Seattle, WA 98195 USA.		Xu, Tao/G-5474-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017803, R01AR017803] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17803] Funding Source: Medline; NICHD NIH HHS [U54 HD12629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABERCROMBIE RF, 1986, AM J PHYSIOL, V250, pC391, DOI 10.1152/ajpcell.1986.250.3.C391; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; COX DA, 1993, TRENDS PHARMACOL SCI, V14, P408, DOI 10.1016/0165-6147(93)90063-P; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FRIEL DD, 1994, J NEUROSCI, V14, P4007; Gillis Kevin D., 1995, P155; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KAFTAN EJ, 1997, J GEN PHYSIOL, V110, P6529; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; LI YX, 1994, P NATL ACAD SCI USA, V91, P58, DOI 10.1073/pnas.91.1.58; MINTA A, 1989, J BIOL CHEM, V264, P8171; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Peng TI, 1998, MOL PHARMACOL, V53, P974; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; PENNISTON JT, 1973, BIOCHEMISTRY-US, V12, P650, DOI 10.1021/bi00728a013; Pivovarova NB, 1999, J NEUROSCI, V19, P6372; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; Tse A, 1994, METHODS NEUROSCIENCE, P85; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; [No title captured]	42	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25465	25470		10.1074/jbc.M000903200	http://dx.doi.org/10.1074/jbc.M000903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835418	hybrid			2022-12-27	WOS:000088849400056
J	Okumoto, K; Abe, I; Fujiki, Y				Okumoto, K; Abe, I; Fujiki, Y			Molecular anatomy of the peroxin Pex12p - Ring finger domain is essential for Pex12p function and interacts with the peroxisome-targeting signal type 1-receptor Pex5p and a ring peroxin, Pex10p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANTS; INTEGRAL MEMBRANE-PROTEIN; ZELLWEGER-SYNDROME; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; CDNA CLONING; BIOGENESIS DISORDERS; MUTATION ANALYSIS; REVERSE 2-HYBRID; AMINO-TERMINUS	The three peroxin genes, PEX12, PEX2, and PEX10, encode peroxisomal integral membrane proteins with RING finger at the C-terminal part and are responsible for human peroxisome biogenesis disorders. Mutation analysis in PEX12 of Chinese hamster ovary cell mutants revealed a homozygous nonsense mutation at residue Trp263Ter in ZP104 cells and a pair of heterozygous nonsense mutations, Trp170Ter and Trp114Ter, in ZP109. This result and domain mapping of Pex12p showed that RING finger is essential for peroxisome-restoring activity of Pex12p but not necessary for targeting to peroxisomes. The N-terminal region of Pex12p, including amino acid residues at positions 17-76, was required for localization to peroxisomes, while the sequence 17-76 was not sufficient for peroxisomal targeting. Peroxins interacting with RING finger of Pex2p, Pex10p, and Pex12p were investigated by yeast two-hybrid as well as in vitro binding assays. The RING finger of Pex12p bound to Pex10p and the PTS1-receptor Pex5p. Pex10p also interacted with Pex2p and Pex5p in vitro. Moreover, Pex12p was co-immunoprecipitated with Pex10p from CHO-K1 cells, where Pex5p was not associated with the Pex12p-Pex10p complex. This observation suggested that Pex5p does not bind to, or only transiently interacts with, Pex10p and Pex12p when Pex10p and Pex12p are in the oligomeric complex in peroxisome membranes. Hence, the RING finger peroxins are most likely to be involved in Pex5p-mediated matrix protein import into peroxisomes.	Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.							Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Harano T, 1999, J BIOCHEM-TOKYO, V125, P1168, DOI 10.1093/oxfordjournals.jbchem.a022400; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V230, P402, DOI 10.1006/bbrc.1996.5971; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Will GK, 1999, MOL CELL BIOL, V19, P2265	50	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25700	25710		10.1074/jbc.M003303200	http://dx.doi.org/10.1074/jbc.M003303200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837480	hybrid			2022-12-27	WOS:000088849400085
J	Paz, Y; Elazar, Z; Fass, D				Paz, Y; Elazar, Z; Fass, D			Structure of GATE-16, membrane transport modulator and mammalian ortholog of autophagocytosis factor Aut7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; COMPLEX; INSIGHTS; MUTANTS; VACUOLE; MODELS; YEAST; NSF	The GATE-16 protein participates in intra-Golgi transport and can associate with the N-ethylmaleimide-sensitive fusion protein and with Golgi SNAREs, The yeast ortholog of GATE-16 is the autophagocytosis factor Aut7p, GATE-16 is also closely related to the GABA receptor-associated protein (GABARAP), which has been proposed to cluster neurotransmitter receptors by mediating interaction with the cytoskeleton, and to the light chain-3 subunit of the neuronal microtubule-associated protein complex. Here, we present the crystal structure of GATE-16 refined to 1.8 Angstrom resolution. GATE-16 contains a ubiquitin fold decorated by two additional N-terminal helices, Proteins with strong structural similarity but no detectable sequence homology to GATE-16 include Ras effectors that mediate diverse downstream functions, but each interacts with Ras by forming pseudo-continuous beta-sheets, The GATE-16 surface suggests that it binds its targets in a similar manner. Moreover, a second potential protein-protein interaction site on GATE-16 may explain the adapter activity observed for members of the GATE-16 family.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Fass, D (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	csfass@wis.weizmann.ac.il						Babor SM, 1999, P NATL ACAD SCI USA, V96, P14759, DOI 10.1073/pnas.96.26.14759; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DOERING D, 1992, THESIS MIT CAMBRIDGE; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LEGESSEMILLER A, 2000, IN PRESS J BIOL CHEM; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MANN SS, 1994, J BIOL CHEM, V269, P11492; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	44	131	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25445	25450		10.1074/jbc.C000307200	http://dx.doi.org/10.1074/jbc.C000307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10856287	hybrid			2022-12-27	WOS:000088849400053
J	Hew, Y; Lau, C; Grzelczak, Z; Keeley, FW				Hew, Y; Lau, C; Grzelczak, Z; Keeley, FW			Identification of a GA-rich sequence as a protein-binding site in the 3 '-untranslated region of chicken elastin mRNA with a potential role in the developmental regulation of elastin mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AORTIC ORGAN; TROPOELASTIN; ELEMENTS; GENE; CULTURES; ACID	Synthesis of aortic elastin peaks in the perinatal period and then is strongly down-regulated with postnatal development and growth. Decreased stability of elastin mRNA contributes to this developmental decrease in chick aortic elastin production. We have previously shown that destabilization of elastin mRNA is correlated with decreased binding of cytosolic protein(s) to a large, GC-rich region of secondary structure in the 3'-untranslated region (3'-UTR) of elastin mRNk In this study, using gel migration shift assays, deletion constructs, and antisense competition assays, we identify a major protein-binding site in the 3'-UTR of elastin as a GA-rich sequence (UGGGGGGAGGGAGGGAGGGA), which we have designated the G3A motif. This motif is present in the 3'-UTR of elastin from several species, Binding proteins are present in both nuclear and cytoplasmic extracts, and their abundance is associated with tissues producing elastin and correlated with circumstances in which elastin mRNA is stable. These results suggest that the conserved GA-rich sequence of the elastin 3'-UTR is an important element in the regulation of stability of the elastin mRNA.	Hosp Sick Children, Res Inst, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Keeley, FW (corresponding author), Hosp Sick Children, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	fwk@sickkids.on.ca						Ausubel FM, 1988, MOL REPROD DEV; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON DJ, 1990, CONNECT TISSUE RES, V24, P277, DOI 10.3109/03008209009152155; JOHNSON DJ, 1995, CIRC RES, V77, P1107, DOI 10.1161/01.RES.77.6.1107; KEELEY FW, 1990, ARCH BIOCHEM BIOPHYS, V282, P226, DOI 10.1016/0003-9861(90)90109-C; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEFEVRE M, 1980, BIOCHIM BIOPHYS ACTA, V630, P519, DOI 10.1016/0304-4165(80)90006-9; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; PIERCE RA, 1992, GENOMICS, V12, P651, DOI 10.1016/0888-7543(92)90289-5; QIAN ZW, 1994, NUCLEIC ACIDS RES, V22, P2334, DOI 10.1093/nar/22.12.2334; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zhang MC, 1999, J BIOL CHEM, V274, P981, DOI 10.1074/jbc.274.2.981	29	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24857	24864		10.1074/jbc.M002776200	http://dx.doi.org/10.1074/jbc.M002776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829024	hybrid			2022-12-27	WOS:000088683300083
J	Chen, ZM; Guo, K; Toh, SY; Zhou, ZH; Li, P				Chen, ZM; Guo, K; Toh, SY; Zhou, ZH; Li, P			Mitochondria localization and dimerization are required for CIDE-B to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; PROTEIN; TRANSLOCATION; INHIBITOR; HOMOLOGY; DOMAINS; FAMILY; DFF45; BAX	Cell death-inducing DFF45-like effector (CIDE)-B is a member of the novel family of apoptosis-inducing factors that share homology with the N-terminal region of DFF, the DNA fragmentation factor. The molecular mechanism of CIDE-B-induced apoptosis is unclear. We have shown here that CIDE-B protein is localized in mitochondria and forms homodimers and heterodimers with other family members. Serial deletion analyses suggest that the mitochondria localization signal and dimerization interface are overlapped and localized to the 30 amino acid residues at the C-terminal region of CIDE-B. Mitochondria localization and dimerization are both required for CIDE-B-induced apoptosis. Our study has thus revealed a mechanism for CIDE-B-induced apoptosis by localization to mitochondria and the formation of a high affinity homo- or heterodimeric complex.	Inst Cell & Mol Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Li, P (corresponding author), Inst Cell & Mol Biol, Lab Apoptosis Regulat, 30 Med Dr, Singapore 117609, Singapore.			Toh, Shen Yon/0000-0002-6421-0862				Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Inohara N, 1999, CELL DEATH DIFFER, V6, P823, DOI 10.1038/sj.cdd.4400570; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415	18	67	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22619	22622		10.1074/jbc.C000207200	http://dx.doi.org/10.1074/jbc.C000207200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837461	hybrid			2022-12-27	WOS:000088419400004
J	Que, NLS; Lin, SH; Cotter, RJ; Raetz, CRH				Que, NLS; Lin, SH; Cotter, RJ; Raetz, CRH			Purification and mass spectrometry of six lipid A species from the bacterial endosymbiont Rhizobium etli - Demonstration of a conserved distal unit and a variable proximal portion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MSBB GENE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LIPOPOLYSACCHARIDE BIOSYNTHESIS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; ENDOTOXIN BIOSYNTHESIS; MULTICOPY SUPPRESSOR; A BIOSYNTHESIS; LEGUMINOSARUM; MUTANT	Lipid A of Rhizobium etli CE3 differs dramatically from that of other Gram-negative bacteria. Key features include the presence of an unusual C28 acyl chain, a galacturonic acid moiety at position 4', and an acylated aminogluconate unit in place of the proximal glucosamine. In addition, R. etli lipid A is reported to lack phosphate and acyloxyacyl residues. Most of these remarkable structural claims are consistent with our recent enzymatic studies. However, the proposed R. etli lipid A structure is inconsistent with the ability of the precursor (3-deoxy-D-manno-octulosonic acid)(2)-4'-P-32-lipid IVA to accept a C28 chain in vitro (Brozek, K. A., Carlson, R. W., and Raetz, C. R. H. (1996) J. Biol. Chern. 271., 32126-32136). To re-evaluate the structure, CE3 lipid A was isolated by new chromatographic procedures. CE3 Lipid A is now resolved into six related components. Aminogluconate is present in D-1, D-2, and E, whereas B and C contain the typical glucosamine disaccharide seen in lipid A of most other bacteria. All the components possess a peculiar acyloxyacyl moiety at position 2', which includes the ester-linked C28 chain. As judged by mass spectrometry, the distal glucosamine units of A through E are the same, but the proximal units are variable. As described in the accompanying article (Que, N. L. S., Ribeiro, A. A., and Raetz, C. R. H. (2000) J. Biol Chem. 275, XXXX-XXXX), the discovery of component B suggests a plausible enzymatic pathway for the biosynthesis of the aminogluconate residue found in species D-l, D-2, and E of R. etli Lipid A. We suggest that the unusual Lipid A species of R. etli might be essential during symbiosis with leguminous host plants.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54882, R37-GM-51796, R37 GM051796, R37 GM051796-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; Bertello LE, 1997, LIPIDS, V32, P907, DOI 10.1007/s11745-997-0117-x; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLEMENTZ T, 1995, FASEB J, V9, pA1311; CLOVER RH, 1989, J BACTERIOL, V171, P3961, DOI 10.1128/jb.171.7.3961-3967.1989; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Downie J. Allan, 1994, Trends in Microbiology, V2, P318, DOI 10.1016/0966-842X(94)90448-0; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Gonzalez JE, 1996, GENE, V179, P141, DOI 10.1016/S0378-1119(96)00322-8; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; MORRISON DC, 1999, ENDOTOXIN HLTH DIS; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; Pueppke SG, 1996, CRIT REV BIOTECHNOL, V16, P1, DOI 10.3109/07388559609146599; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que NLS, 1998, FASEB J, V12, pA1284; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1984, FED PROC, V43, P1567; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Schultze M, 1998, ANNU REV GENET, V32, P33, DOI 10.1146/annurev.genet.32.1.33; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; YORK WS, 1986, METHOD ENZYMOL, V118, P3; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	73	107	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28006	28016						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856303				2022-12-27	WOS:000089197100065
J	Ye, JP; Kohli, LL; Stone, MJ				Ye, JP; Kohli, LL; Stone, MJ			Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HIGH-AFFINITY BINDING; HUMAN INTERLEUKIN-8 RECEPTOR; AMINO-TERMINAL DOMAIN; MOLECULAR-CLONING; ALLERGIC INFLAMMATION; EXTRACELLULAR DOMAIN; COUPLED RECEPTORS; MCP-1 RECEPTOR; RESIDUES	The CC chemokine eotaxin plays a predominant role in eosinophil trafficking in vivo by specifically activating the chemokine receptor CCR3. We have screened a series of synthetic peptides corresponding to extracellular regions of CCR3 for their ability to bind eotaxin, A peptide corresponding to the N terminus of CCR3 (CCR3-(1-35)) bound to eotaxin with a dissociation constant of 80 +/- 38 mu M. However, linear or cyclic peptides derived from the first and third extracellular loops of CCR3 did not bind to eotaxin. Linear and cyclic peptides derived from the second extracellular loop precipitated upon addition of eotaxin, H-1-N-15 correlation NMR spectroscopy indicated that an extended groove in the eotaxin surface, whose edges are defined by the N-loop, 3(10)-helical turn, and beta(2)-beta(3) hairpin, is the most likely binding surface for CCR3-(1-35). NMR assignments for CCR3-(1-35) were obtained using two-dimensional and three-dimensional homonuclear NMR experiments, N-15-Filtered TOCSY spectra indicated that the central region of CCR3-(1-35), surrounding the DDYY sequence, is involved in the interaction with eotaxin, This was supported by the observation that a truncated N-terminal peptide (CCR3-(8-23)) binds to eotaxin with a dissociation constant of 136 +/- 23 mu M, only slightly weaker than the full-length N terminal peptide. Taken together with previous studies, these results suggest that interactions between the N-loop/beta(3), regions of chemokines and the N-terminal regions of their receptors may be a conserved feature of chemokine-receptor complexes across the CC, CXC, and C chemokine subfamilies. However, the low affinity of the interactions observed in these studies suggests the existence of additional binding regions in both the chemokines and the receptors.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Stone, MJ (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	mastone@indiana.edu	Stone, Martin/C-2492-2012	Stone, Martin/0000-0002-6468-4427	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055055, R29GM055055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Baggiolini M, 1996, J CLIN INVEST, V97, P587, DOI 10.1172/JCI118451; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; CIESLAR C, 1990, J MAGN RESON, V89, P184, DOI 10.1016/0022-2364(90)90174-8; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE KK, 1991, HPLC PEPTIDES PROTEI, P389; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MAYER KL, 2000, IN PRESS BIOCHEMISTR; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OSCHKINAT H, 1988, NATURE, V332, P374, DOI 10.1038/332374a0; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Stone MJ, 2000, CHEMOKINES IN ALLERGIC DISEASE, P67; VUISTER GW, 1988, J MAGN RESON, V80, P176, DOI 10.1016/0022-2364(88)90072-8; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	59	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27250	27257						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859315				2022-12-27	WOS:000089144800078
J	Biederer, CH; Ries, SJ; Moser, M; Florio, M; Israel, MA; McCormick, F; Buettner, R				Biederer, CH; Ries, SJ; Moser, M; Florio, M; Israel, MA; McCormick, F; Buettner, R			The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; MOLECULAR-CLONING; E-BOX; PROTEINS; ACTIVATION; FAMILY; MYOD; DIFFERENTIATION; MEMBRANE; IDENTIFICATION	Caveolin-3 protein is the only member of the caveolin family that shows a unique muscle-specific expression pattern, and loss of its functional activity causes muscular dystrophy. Caveolin-3 mRNA levels are dramatically increased during the formation of myotubes in the C2C12 cell line. In this study, we characterized the human caveolin-3 5'-flanking region. Promoter analyses demonstrate that the proximal E box element serves as a myogenin binding site and is both necessary and sufficient to control caveolin-3 gene transcription. Transient transfection assays indicated that overexpression of myogenin activates caveolin-3 reporter gene expression, whereas Id2 overexpression inhibited caveolin-3 promoter activation by myogenin. A mutant Id2 protein lacking the HLH domain was not capable of suppressing myogenin-mediated activation. Determination of caveolin-3 transcript distribution patterns in vivo revealed that mRNA was first detectable at day 10 of gestation in the developing somites and heart. Caveolin-3 protein in myoblasts and myotubes was expressed in both the plasma membrane and vesicular structures. During skeletal myogenesis the level of Id2, an inhibitor of differentiation, decreases, allowing the induced basic helix-loop-helix transcription factor myogenin to form transcriptionally active heterodimers that bind to the caveolin-3 promoter and thereby mediate its transcription.	Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, Preuss Lab Mol Neurooncol, Brain Tumor Res Ctr, San Francisco, CA 94143 USA	RWTH Aachen University; RWTH Aachen University Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Buettner, R (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.							Biederer C, 1998, BBA-MOL BASIS DIS, V1406, P5, DOI 10.1016/S0925-4439(97)00095-1; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAKEDA S, 1995, J BIOL CHEM, V270, P15664, DOI 10.1074/jbc.270.26.15664; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	31	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26245	26251		10.1074/jbc.M001430200	http://dx.doi.org/10.1074/jbc.M001430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835421	hybrid			2022-12-27	WOS:000088999700051
J	Friesen, MJ; Dreyfuss, G				Friesen, MJ; Dreyfuss, G			Specific sequences of the Sm and Sm-like (Lsm) proteins mediate their interaction with the spinal muscular atrophy disease gene product (SMN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON GENE; WERDNIG-HOFFMANN DISEASE; RNA-BINDING PROTEINS; SMALL NUCLEAR-RNA; SNRNP PROTEINS; IN-VITRO; NUCLEOCYTOPLASMIC TRANSPORT; MOLECULAR ANALYSIS; U6 SNRNA; M3G CAP	The spinal muscular atrophy disease gene product (SMN) is crucial for small nuclear ribonuclear protein (snRNP) biogenesis in the cytoplasm and plays a role in pre-mRNA splicing in the nucleus. SMN oligomers interact avidly with the snRNP core proteins SmB, -D1, and -D3. We have delineated the specific sequences in the Sm proteins that mediate their interaction with SMN. We show that unique carboxyl-terminal arginine- and glycine-rich domains comprising the last 29 amino acids of SmD1 and the last 32 amino acids of SmD3 are necessary and sufficient for SMN binding. Interestingly, SMN also interacts with at least two of the U6-associated Sm-like (Lsm) proteins, Lsm4 and Lsm6. Furthermore, the carboxyl-terminal arginine- and glycine-rich domain of Lsm4 directly interacts with SMN. This suggests that SMN also functions in the assembly of the U6 snRNP in the nucleus and in the assembly of other Lsm-containing complexes. These findings demonstrate that arginine- and glycine-rich domains are necessary and sufficient for SMN interaction, and they expand further the range of targets of the SMN protein.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BOELENS WC, 1995, RNA, V1, P273; BOFFA LC, 1977, BIOCHEM BIOPH RES CO, V74, P969, DOI 10.1016/0006-291X(77)91613-8; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CHANG JG, 1995, AM J HUM GENET, V57, P1503; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; COBBEN JM, 1995, AM J HUM GENET, V57, P805; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen ET, 1996, HUM GENET, V98, P122, DOI 10.1007/s004390050172; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257	60	117	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26370	26375		10.1074/jbc.M003299200	http://dx.doi.org/10.1074/jbc.M003299200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851237	hybrid			2022-12-27	WOS:000088999700067
J	Ohmori, S; Sakai, N; Shirai, Y; Yamamoto, H; Miyamoto, E; Shimizu, N; Saito, N				Ohmori, S; Sakai, N; Shirai, Y; Yamamoto, H; Miyamoto, E; Shimizu, N; Saito, N			Importance of protein kinase C targeting for the phosphorylation of its substrate, myristoylated alanine-rich C-kinase substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GAMMA-MUTANT MICE; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; PHORBOL ESTER; CELLULAR SUBSTRATE; MAJOR SUBSTRATE; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; 87-KDA PROTEIN	We visualized the translocation of myristoylated alanine-rich protein kinase C substrate (MARCKS) in living Chinese hamster ovary-K1 cells using MARCKS tagged to green fluorescent protein (MARCKS-GFP). MARCKS-GFP was rapidly translocated from the plasma membrane to the cytoplasm after the treatment with phorbol ester, which translocates protein kinase C (PKC) to the plasma membrane. In contrast, PKC activation by hydrogen peroxide, which was not accompanied by PKC translocation, did not alter the intracellular localization of MARCKS-GFP. Non-myristoylated mutant of MARCKS-GFP was distributed throughout the cytoplasm, including the nucleoplasm, and was not translocated by phorbol ester or by hydrogen peroxide. Phosphorylation of wild-type MARCKS-GFP was observed in cells treated with phorbol ester but not with hydrogen peroxide, whereas non-myristoylated mutant of MARCKS-GFP was phosphorylated in cells treated with hydrogen peroxide but not with phorbol ester. Phosphorylation of both MARCKS-GFPs reduced the amount of F-actin. These findings revealed that PKC targeting to the plasma membrane is required for the phosphorylation of membrane-associated MARCKS and that a mutant MARCKS existing in the cytoplasm can be phosphorylated by PKC activated in the cytoplasm without translocation but not by PHC targeted to the membrane.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan	Kobe University; Kumamoto University; Keio University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.		Shirai, Yasuhito/O-3255-2018					ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Huang XP, 1997, J CELL SCI, V110, P1625; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Seki K, 1996, ARCH BIOCHEM BIOPHYS, V326, P193, DOI 10.1006/abbi.1996.0065; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wang YC, 1999, BIOCHEM MOL BIOL INT, V47, P673; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; Yamamoto H, 1998, ARCH BIOCHEM BIOPHYS, V359, P151, DOI 10.1006/abbi.1998.0920	57	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26449	26457		10.1074/jbc.M003588200	http://dx.doi.org/10.1074/jbc.M003588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840037	hybrid			2022-12-27	WOS:000088999700079
J	Trepakova, ES; Csutora, P; Hunton, DL; Marchase, RB; Cohen, RA; Bolotina, VM				Trepakova, ES; Csutora, P; Hunton, DL; Marchase, RB; Cohen, RA; Bolotina, VM			Calcium influx factor directly activates store-operated cation channels in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+; XENOPUS OOCYTES; DIFFUSIBLE MESSENGER; HUMAN PLATELETS; HTRP3 CHANNELS; ENTRY; RECEPTOR; RELEASE; TRP; RETICULUM	Recently, we described a novel 3-pS Ca2+-conducting channel that is activated by BAPTA and thapsigargin-induced passive depletion of intracellular Ca2+ stores and likely to be a native store-operated channel in vascular smooth muscle cells (SMC). Neither Ca2+ nor inositol 1,4,5-trisphosphate or other second messengers tested activated this channel in membrane patches excised from resting SMC. Here we report that these 3-pS channels are activated in inside-out membrane patches from SMC immediately upon application of Ca2+ influx factor (CIF) extracted from mutant yeast, which has been previously shown to activate Ca2+ influx in Xenopus oocytes and Ca2+ release-activated Ca2+ current in Jurkat cells. In bioassay experiments depletion of Ca2+ stores in permeabilized human platelets resulted in the release of endogenous factor, which activated 3-pS channels in isolated inside-out membrane patches excised from SMC and exposed to permeabilized platelets. The same 3-pS channels in excised membrane patches were also activated by acid extracts of CIF derived from human platelets with depleted Ca2+ stores, which also stimulated Ca2+ influx upon injection into Xenopus oocytes, Specific high pressure liquid chromatography fractions of platelet extracts were found to have CIF activity when injected into oocytes and activate 3-pS channels in excised membrane patches. These data show for the first time that CIF produced by mammalian cells and yeast with depleted Ca2+ stores directly activates native 3-pS cation channels, which in intact SMC are activated by Ca2+ store depletion.	Boston Univ, Sch Med, Vasc Biol Unit, Dept Med, Boston, MA 02118 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Boston University; University of Alabama System; University of Alabama Birmingham	Bolotina, VM (corresponding author), Boston Univ, Sch Med, Vasc Biol Unit, Dept Med, 650 Albany St,X-704, Boston, MA 02118 USA.			Bolotina, Victoria/0000-0001-5862-181X; /0000-0002-1070-6408	NHLBI NIH HHS [HL55993, HL07224, HL54150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150, P50HL055993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Friel DD, 1996, CELL, V85, P617, DOI 10.1016/S0092-8674(00)81021-1; Hirakawa Y, 1999, AM J PHYSIOL-HEART C, V277, pH1732, DOI 10.1152/ajpheart.1999.277.5.H1732; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Oliver AE, 1999, BBA-BIOMEMBRANES, V1416, P349, DOI 10.1016/S0005-2736(98)00239-9; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	27	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26158	26163		10.1074/jbc.M004666200	http://dx.doi.org/10.1074/jbc.M004666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851243	hybrid			2022-12-27	WOS:000088999700039
J	Clish, CB; Levy, BD; Chiang, N; Tai, HH; Serhan, CN				Clish, CB; Levy, BD; Chiang, N; Tai, HH; Serhan, CN			Oxidoreductases in lipoxin A(4) metabolic inactivation - A novel role for 15-oxoprostaglandin 13-reductase/leukotriene B-4 12-hydroxydehydrogenase in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE B-4; STABLE ANALOGS; CDNA CLONING; IDENTIFICATION; PURIFICATION; EXPRESSION; CONVERSION; RECEPTOR; ENZYMES; CELLS	The lipoxins (LX) are autacoids that act within a local inflammatory milieu to dampen neutrophil recruitment and promote resolution. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and 15-oxoprostaglandin 13-reductase, also termed leukotriene B-4 12-hydroxydehydrogenase (PGR/LTB4DH), are two enzymatic activities appreciated for their roles in the metabolism of prostaglandins and LTB4. Here, we determined whether these oxidoreductases also catalyze the conversion of lipoxin A(4) (LXA(4)) and assessed the activities of these LXA(4) metabolites. 15-Oxo-LXA(4) was generated by incubating LXA(4) with 15-PGDH and NAD(+) for studies of its further conversion. PGR/LTB4DH catalyzed the NADH-dependent reduction of 15-oxo-LXA(4) to yield 13,14-dihydro-15-loxo-LXA(4). With NADH as a cofactor, 15-PGDH acted as a 15-carbonyl reductase and catalyzed the conversion of 13,14-dihydro-15-oxo-LXA(4) to 13,14-dihydro-LXA(4). Human polymorphonuclear leukocytes (PMN) exposed to native LXA(4), 15-oxo-LXA(4), or 13,14-dihydro-LXA(4) did not produce superoxide anions. At concentrations where LXA(4) and a metabolically stable LXA(4) analog potently inhibited leukotriene B-4-induced superoxide anion generation, the further metabolites were devoid of activity. Neither 15-oxo-LXA(4) nor 13,14-dihydro-LXA(4) effectively competed with H-3-labeled LXA(4) for specific binding to recombinant LXA(4) receptor (ALXR). In addition, introducing recombinant PGR/LTB4DH into a murine exudative model of inflammation increased PMN number by similar to 2-fold, suggesting that this enzyme participates in the regulation of PMN trafficking. These results establish the structures of LXA(4) further metabolites and indicate that conversion of LXA(4) to oxo- and dihydro- products represents a mode of LXA(4) inactivation in inflammation. Moreover, they suggest that these eicosanoid oxidoreductases have multifaceted roles controlling the levels of specific eicosanoids involved in the regulation of inflammation.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Kentucky	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.		Clish, Clary/AAB-7124-2019; Chiang, Nan/ABA-4924-2021; Clish, Clary B/ABB-9374-2021	Chiang, Nan/0000-0003-1963-1585; Clish, Clary B/0000-0001-8259-9245	NHLBI NIH HHS [HL-46296, K08-HL03788] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296, K08HL003788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; ENSOR CM, 1991, PROSTAGLANDINS LEUKO, P39; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; LEVY BD, 1999, HDB METHODS SIGNAL T, P83; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MURPHY RC, 1989, PROSTAGLANDINS CLIN, P1; Okita RT, 1996, CRIT REV BIOCHEM MOL, V31, P101, DOI 10.3109/10409239609106581; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SERHAN CN, 1999, INFLAMMATION BASIC P, P373; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SIN YM, 1986, ANN RHEUM DIS, V45, P873, DOI 10.1136/ard.45.10.873; Sinzinger H, 1998, PROSTAG OTH LIPID M, V55, P265, DOI 10.1016/S0090-6980(98)00025-2; Sobal G, 1998, PROSTAG OTH LIPID M, V55, P67, DOI 10.1016/S0090-6980(98)00005-7; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Tong M, 2000, BBA-MOL CELL RES, V1497, P61, DOI 10.1016/S0167-4889(00)00039-2; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	154	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25372	25380		10.1074/jbc.M002863200	http://dx.doi.org/10.1074/jbc.M002863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837478	hybrid, Green Published			2022-12-27	WOS:000088849400045
J	Royo, J; Gomez, E; Hueros, G				Royo, J; Gomez, E; Hueros, G			A maize homologue of the bacterial CMP-3-deoxy-D-manno-2-octulosonate (KDO) synthetases - Similar pathways operate in plants and bacteria for the activation of KDO prior to its incorporation into outer cellular envelopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RHAMNOGALACTURONAN-II; TRANSPOSABLE ELEMENT; MOLECULAR-STRUCTURE; ACID SYNTHETASE; CODON USAGE; POLYSACCHARIDE; WALL; CMP; CYTIDYLYLTRANSFERASE	The eight-carbon acid sugar 3-deoxy-D-manno-2-octulosonate (KDO) is an essential component of Gram-negative bacterial cell walls and capsular polysaccharides. KDO is incorporated into these polymers as CMP-KDO, which is produced in an unusual activation step catalyzed by the enzyme CMP-KDO synthetase. CMP-KDO synthetase activity has traditionally been considered exclusive to Gram-negative bacteria. CMP-KDO synthetase inhibitors attract great interest owing to their potential as selective bactericides. The sugar KDO is also a component of the rhamnogalacturonan II pectin fraction of the primary cell walls of most higher plants and of the cell wall polysaccharides of some green algae. However, the metabolic pathway leading to its incorporation into the plant cell mall is unknown. This paper describes the isolation and characterization of a maize gene, which codes for a protein very similar in sequence and activity to prokaryotic CMP-KDO synthetases. Remarkably, the maize gene can complement a CMP-KDO synthetase (kdsB) Salmonella typhimurium mutant defective in cell wall synthesis, ZmCKS activity is novel in eukaryotes, The evolutionary origin of ZmCKS is discussed in relation to the high degree of conservation between the plant and bacterial genes and its atypical codon usage in maize.	Univ Alcala de Henares, Dept Biol Celular & Genet, ES-28871 Alcala De Henares, Spain	Universidad de Alcala	Hueros, G (corresponding author), Univ Alcala de Henares, Dept Biol Celular & Genet, ES-28871 Alcala De Henares, Spain.	gregorio.hueros@alcala.es	Gomez, Elisa E/A-8122-2013; Hueros, Gregorio/L-3513-2017; Royo, Joaquin/L-4855-2015	Hueros, Gregorio/0000-0003-1172-5405; Royo, Joaquin/0000-0002-8245-5791				ALBERSHEIM P, 1994, BIOCHEM SOC T, V22, P374, DOI 10.1042/bst0220374; BECKER B, 1995, CARBOHYD RES, V267, P313, DOI 10.1016/0008-6215(94)00300-5; Becker B, 1998, J PHYCOL, V34, P779, DOI 10.1046/j.1529-8817.1998.340779.x; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; Clark JB, 1997, P NATL ACAD SCI USA, V94, P11428, DOI 10.1073/pnas.94.21.11428; Cosgrove DJ, 1997, ANNU REV CELL DEV BI, V13, P171, DOI 10.1146/annurev.cellbio.13.1.171; DELMER DP, 1988, BIOCH PLANTS, V14, P373; Delwiche CF, 1996, MOL BIOL EVOL, V13, P873, DOI 10.1093/oxfordjournals.molbev.a025647; Edashige Y, 1998, PHYTOCHEMISTRY, V49, P681, DOI 10.1016/S0031-9422(98)00238-6; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; Feingold D. S., 1990, METHODS PLANT BIOCH, V2, P39; FINKE A, 1989, J BACTERIOL, V171, P3074, DOI 10.1128/jb.171.6.3074-3079.1989; Fowler JE, 1997, ANNU REV CELL DEV BI, V13, P697, DOI 10.1146/annurev.cellbio.13.1.697; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HUEROS G, 1995, PLANT CELL, V7, P747, DOI 10.1105/tpc.7.6.747; Jelakovic S, 1996, FEBS LETT, V391, P157, DOI 10.1016/0014-5793(96)00724-7; John M, 1997, TRENDS PLANT SCI, V2, P111, DOI 10.1016/S1360-1385(97)01005-4; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; LENTER M, 1990, CARBOHYD RES, V197, P197, DOI 10.1016/0008-6215(90)84142-H; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P292, DOI 10.1093/nar/27.1.292; Nimtz M, 1997, EUR J BIOCHEM, V250, P608, DOI 10.1111/j.1432-1033.1997.0608a.x; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; ONeill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI [DOI 10.1016/B978-0-12-461012-5.50018-5, 10.1016/b978-0-12-461012-5.50018-5]; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAY PH, 1982, METHOD ENZYMOL, V83, P535; RICK PD, 1982, J BACTERIOL, V150, P456, DOI 10.1128/JB.150.2.456-464.1982; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROSENOW C, 1995, FEMS MICROBIOL LETT, V125, P159, DOI 10.1016/0378-1097(94)00492-A; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHARP PM, 1994, CURR OPIN GENET DEV, V4, P851, DOI 10.1016/0959-437X(94)90070-1; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shin KS, 1997, CARBOHYD RES, V300, P239, DOI 10.1016/S0008-6215(97)00055-4; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	42	36	38	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24993	24999		10.1074/jbc.M905750199	http://dx.doi.org/10.1074/jbc.M905750199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829033	hybrid			2022-12-27	WOS:000088683300101
J	Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Senior, AE				Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Senior, AE			Conserved Walker A Ser residues in the catalytic sites of P-glycoprotein are critical for catalysis and involved primarily at the transition state step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; NUCLEOTIDE-BINDING DOMAINS; STIMULATED ATPASE ACTIVITY; DRUG-BINDING; ABC TRANSPORTER; INHIBITION; MDR1; IDENTIFICATION; MODULATION; F1-ATPASE	P-glycoprotein mutants S430A/T and S1073A/T, affecting conserved Walker A Ser residues, were characterized to elucidate molecular roles of the Ser and functioning of the two P-glycoprotein catalytic sites, Results showed the Ser-OH is critical for MgATPase activity and formation of the normal transition state, although not for initial MgATP binding. Mutation to Ala in either catalytic site abolished MgATPase and transition state formation in both sites, whereas Thr mutants had similar MgATPase to wild-type. Trapping of 1 mol of MgADP/mol of P-glycoprotein by vanadate, shown here with pure protein, yielded full inhibition of ATPase, Thus, congruent with previous work, both sites must be intact and must interact for catalysis, Equivalent mutations (Ala or Thr) in the two catalytic sites had identical effects on a wide range of activities, emphasizing that the two catalytic sites function symmetrically. The role of the Ser-OH is to coordinate Mg2+ in MgATP, but only at the stage of the transition state are its effects tangible. Initial substrate binding is apparently to an "open" catalytic site conformation, where the Ser-OH is dispensable. This changes to a "closed" conformation required to attain the transition state, in which the Ser-OH is a critical ligand, Formation of the latter conformation requires both sites; both sites may provide direct ligands to the transition state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1999, EUR J BIOCHEM, V264, P800, DOI 10.1046/j.1432-1327.1999.00702.x; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JOHN J, 1993, J BIOL CHEM, V268, P923; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7750; Muller M, 1996, J BIOL CHEM, V271, P1877; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Sankaran B, 1997, FEBS LETT, V417, P119, DOI 10.1016/S0014-5793(97)01268-4; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	48	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25031	25038		10.1074/jbc.M003962200	http://dx.doi.org/10.1074/jbc.M003962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831598	hybrid			2022-12-27	WOS:000088683300106
J	Duriez, PJ; Wong, F; Dorovini-Zis, K; Shahidi, R; Karsan, A				Duriez, PJ; Wong, F; Dorovini-Zis, K; Shahidi, R; Karsan, A			A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; FACTOR-MEDIATED CYTOTOXICITY; BCL-2 FAMILY MEMBER; INDUCED CELL-DEATH; SIGNALING COMPLEX; CYTOCHROME-C; INTERLEUKIN-1-CONVERTING ENZYME; CD95 FAS/APO-1; PROTEIN	Tumor necrosis factor (TNF) does not cause endothelial apoptosis unless the expression of cytoprotective genes is blocked. We have previously demonstrated that one of the TNF-inducible cytoprotective genes is the Bcl-2 family member, Al. Al is induced by the action of the transcription factor, NF kappa B, in response to inflammatory mediators. In this report we demonstrate that, as with other cell types, inhibition of NF kappa B initiates microvascular endothelial apoptosis in response to TNF. Al is able to inhibit this apoptosis over 24 h, We demonstrate that Al is localized to and functions at the mitochondria. Whereas Al is able to inhibit mitochondrial depolarization, loss of cytochrome c, cleavage of caspase 9, BID, and poly(ADP-ribose) polymerase, it does not block caspase 8 or caspase 3 cleavage. In contrast, Al is not able to prevent endothelial apoptosis by TNF over 72 h, when NF kappa B signaling is blocked. On the other hand, the caspase inhibitor, benzyloxycarbonyl-VAD-formylmethyl ketone, completely blocks TNF-induced endothelial apoptosis over 72 h. Our findings indicate that Al is able to maintain temporary survival of endothelial cells in response to TNF by maintaining mitochondrial viability and function. However, a mitochondria-independent caspase pathway eventually results in endothelial death despite mitochondrial protection by A1.	St Pauls Hosp, UBC McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia	Karsan, A (corresponding author), St Pauls Hosp, UBC McDonald Res Labs, Rm B292,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	akarsan@mrl.ubc.ca	Karsan, Aly/K-2067-2015	Shahidi, Reza/0000-0001-9452-2595; Duriez, Patrick/0000-0003-1814-2552				ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Han ZY, 1999, MOL CELL BIOL, V19, P1381; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HENNET T, 1993, CANCER RES, V53, P1456; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Karsan A, 1998, TRENDS CARDIOVAS MED, V8, P19, DOI 10.1016/S1050-1738(97)00126-6; Karsan A, 1997, AM J PATHOL, V151, P1775; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PALEOLOG EM, 1994, BLOOD, V84, P2578; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slowik MR, 1997, LAB INVEST, V77, P257; Smith DJ, 1997, J IMMUNOL, V158, P163; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; SUZUKI H, 1991, INT REV EXP PATHOL, V32, P95; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Watanabe N, 1998, CYTOKINE, V10, P645, DOI 10.1006/cyto.1998.0341; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	63	85	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18099	18107		10.1074/jbc.M908925199	http://dx.doi.org/10.1074/jbc.M908925199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849436	hybrid			2022-12-27	WOS:000087659400028
J	Ricciardi, A; le Du, MH; Khayati, M; Dajas, F; Boulain, JC; Menez, A; Ducancel, F				Ricciardi, A; le Du, MH; Khayati, M; Dajas, F; Boulain, JC; Menez, A; Ducancel, F			Do structural deviations between toxins adopting the same fold reflect functional differences?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; MAMBA SNAKE-VENOM; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; DENDROASPIS-ANGUSTICEPS; ACETYLCHOLINE-RECEPTOR; CURAREMIMETIC TOXIN	Three-finger proteins form a structurally related family of compounds that exhibit a great variety of biological properties. To address the question of the prediction of functional. areas on their surfaces, we tentatively conferred the acetylcholinesterase inhibitory activity of fasciculins on a short-chain curaremimetic toxin. For this purpose, we assimilated the three-dimensional structure of fasciculin 2 with the one of toxin a. This comparison revealed that the tips of the first and second loops, together with the C terminus residue, deviated most. A first recombinant fasciculin/toxin a chimera was designed by transferring loop 1 in its entirety together with the tip of loop 2 of fasciculin 2 into the toxin a scaffold. A second chimera (rChII) was obtained by adding the point Asn-61 --> Tyr substitution. Comparison of functional and structural properties of both chimeras show that rChII can accommodate the imposed modifications and displays nearly all the acetylcholinesterase-blocking activities of fasciculins. The three-dimensional structure of rChII demonstrates that rChII adopts a typical three-fingered fold with structural features of both parent toxins. Taken together, these results emphasize the great structural flexibility and functional adaptability of that fold and confirm that structural deviations between fasciculins and short-chain neurotoxins do indeed reflect functional diversity.	Clemente Estable, Inst Invest Biol, Montevideo 11600, Uruguay; CE Saclay, Commissariat Energie Atom, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Instituto de Investigaciones Biologicas Clemente Estable Uruguay; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Ricciardi, A (corresponding author), Clemente Estable, Inst Invest Biol, Montevideo 11600, Uruguay.							ALBRAND JP, 1995, BIOCHEMISTRY-US, V34, P5923, DOI 10.1021/bi00017a022; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BouhaoualaZahar B, 1996, EUR J BIOCHEM, V238, P653, DOI 10.1111/j.1432-1033.1996.0653w.x; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BROWN LR, 1992, J MOL BIOL, V227, P1118, DOI 10.1016/0022-2836(92)90525-O; CERVENANSKY C, 1991, SNAKE TOXINS, P302; Chang C.C., 1979, SNAKE VENOMS, P309; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; Drakopoulou E, 1996, J BIOL CHEM, V271, P11979, DOI 10.1074/jbc.271.20.11979; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F., 1991, P385; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; DURAN R, 1994, BBA-GEN SUBJECTS, V1201, P381, DOI 10.1016/0304-4165(94)90066-3; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Endo T., 1991, P165; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P3872, DOI 10.1021/bi00179a011; Guenneugues M, 1997, BIOCHEMISTRY-US, V36, P16097, DOI 10.1021/bi971293k; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HODGSON D, 1993, EUR J BIOCHEM, V212, P441, DOI 10.1111/j.1432-1033.1993.tb17680.x; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Le Du MH, 2000, J MOL BIOL, V296, P1017; LeDu MH, 1996, ACTA CRYSTALLOGR D, V52, P87, DOI 10.1107/S0907444995007517; LEDU MH, 1992, J BIOL CHEM, V267, P22122; Lobeck K, 1998, INFECT IMMUN, V66, P418, DOI 10.1128/IAI.66.2.418-423.1998; Masson P, 1996, EUR J BIOCHEM, V235, P36, DOI 10.1111/j.1432-1033.1996.00036.x; MENEZ A, 1993, POUR SCI, V190, P34; MENEZ A, 1992, ADV DRUG DISCOVERY, P83; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; PILLET L, 1993, J BIOL CHEM, V268, P909; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; Ruoppolo M, 1998, BIOCHEMISTRY-US, V37, P16060, DOI 10.1021/bi981492j; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SEGALAS I, 1995, BIOCHEMISTRY-US, V34, P1248, DOI 10.1021/bi00004a019; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, TOXICOL LETT, V103, P199, DOI 10.1016/S0378-4274(98)00307-5; STRYDOM DJ, 1979, SNAKE VENOMS HDB EXP, V52, P159; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Vita C, 1997, CURR OPIN BIOTECH, V8, P429, DOI 10.1016/S0958-1669(97)80064-X; Vozza LA, 1996, BIO-TECHNOL, V14, P77, DOI 10.1038/nbt0196-77; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011; ZINNJUSTIN S, 1994, PROTEIN ENG, V7, P917, DOI 10.1093/protein/7.7.917	58	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18302	18310		10.1074/jbc.275.24.18302	http://dx.doi.org/10.1074/jbc.275.24.18302			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849442	hybrid			2022-12-27	WOS:000087659400055
J	Gunnewijk, MGW; Poolman, B				Gunnewijk, MGW; Poolman, B			HPr(His similar to P)-mediated phosphorylation differently affects counterflow and proton motive force-driven uptake via the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; ATP-DEPENDENT PHOSPHORYLATION; PHOSPHOCARRIER PROTEIN; ESCHERICHIA-COLI; CATABOLITE REPRESSION; LACTOBACILLUS-BREVIS; SERYL RESIDUE; HPR; PHOSPHOENOLPYRUVATE; RECONSTITUTION	The lactose transport protein (LacS) of Streptococcus thermophilus has a G-terminal hydrophilic domain that is homologous to IIA protein and protein domains of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS). The IIA domain of LacS is phosphorylated on His-552 by the general energy coupling proteins of the PTS, which are Enzyme I and HPr. To study the effect of phosphorylation on transport, the LacS protein was purified and incorporated into liposomes with the IIA domain facing outwards. This allowed the phosphorylation of the membrane-reconstituted protein by purified HPr(His similar toP) of S. thermophilus. Phosphorylation of LacS increased the V-max of counterflow transport, whereas the V-max of the proton motive force (Deltap)-driven lactose uptake was not affected. In line with a range of kinetic studies, we propose that phosphorylation affects the rate constants for the reorientation of the ternary complex (LacS with bound lactose plus proton), which is rate-determining for counterflow but not for Deltap-driven transport.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012					DASHPER SG, 1994, BIOCHEM BIOPH RES CO, V199, P1297, DOI 10.1006/bbrc.1994.1372; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Galinier A, 1998, P NATL ACAD SCI USA, V95, P1823, DOI 10.1073/pnas.95.4.1823; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gunnewijk MGW, 2000, J BIOL CHEM, V275, P34073, DOI 10.1074/jbc.M003512200; Gunnewijk MGW, 1999, J BACTERIOL, V181, P632, DOI 10.1128/JB.181.2.632-641.1999; Hoischen C, 1996, J BACTERIOL, V178, P6082, DOI 10.1128/jb.178.20.6082-6086.1996; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; NELSON SO, 1983, EMBO J, V2, P715, DOI 10.1002/j.1460-2075.1983.tb01490.x; OSUMI T, 1982, P NATL ACAD SCI-BIOL, V79, P1457, DOI 10.1073/pnas.79.5.1457; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; Sambrook J., 2002, MOL CLONING LAB MANU; VADEBONCOEUR C, 1991, BIOCHIMIE, V73, P1427, DOI 10.1016/0300-9084(91)90174-Y; VADEBONCOEUR C, 1995, RES MICROBIOL, V146, P525, DOI 10.1016/0923-2508(96)80558-4; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; YE JJ, 1994, P NATL ACAD SCI USA, V91, P3102, DOI 10.1073/pnas.91.8.3102; YE JJ, 1994, J BACTERIOL, V176, P3484, DOI 10.1128/JB.176.12.3484-3492.1994	25	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34080	34085		10.1074/jbc.M003513200	http://dx.doi.org/10.1074/jbc.M003513200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10842178	Green Published, hybrid			2022-12-27	WOS:000165095300014
J	Herget, T; Esdar, C; Oehrlein, SA; Heinrich, M; Schutze, S; Maelicke, A; van Echten-Deckert, G				Herget, T; Esdar, C; Oehrlein, SA; Heinrich, M; Schutze, S; Maelicke, A; van Echten-Deckert, G			Production of ceramides causes apoptosis during early neural differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RETINOIC ACID; SPHINGOLIPID BIOSYNTHESIS; SPHINGOMYELIN PATHWAY; GENE-PRODUCT; CHICK-EMBRYO; SPINAL-CORD; DNA-DAMAGE; IN-VITRO; GROWTH	To investigate signal transduction pathways leading to apoptosis during the early phase of neurogenesis, we employed PCC7-Mz1 cells, which cease to proliferate and begin to differentiate into a stable pattern of neurons, astroglial cells, and fibroblasts upon incubation with retinoic acid (RA). As part of lineage determination, a sizable fraction of RA-treated cultures die by apoptosis. Applying natural long-chain C-16-ceramides as well as membrane-permeable C-2/C-6-ceramide analogs caused apoptosis, whereas the biologically nonactive C-2-dihydroceramide did not. Treating PCC7-Mz1 stem cells with a neutral sphingomyelinase or with the ceramidase inhibitor N-oleoylethanolamine elevated the endogenous ceramide levels and concomitantly induced apoptosis. Addition of RA caused an increase in ceramide levels within 3-5 h, which reached a maximum (up to 3.5-fold of control) between days 1 and 3 of differentiation. Differentiated PCC7-Mz1 cells did not respond with ceramide formation and apoptosis to RA treatment. The acidic sphingomyelinase contributed only weakly and the neutral Mg2+-dependent and Mg2+-independent sphingomyelinases not at all to the RA-mediated production of ceramides. However, ceramide increase was sensitive to the ceramide synthase inhibitor fumonisin B-1, suggesting a crucial role for the de novo synthesis pathway. Enzymatic assays revealed that ceramide synthase activity remained unaltered, whereas serine palmitoyltransferase (SPT), a key enzyme in ceramide synthesis, was activated similar to 2.5-fold by RA treatment. Activation of SPT seemed to be mediated via a post-translational mechanism because levels of the mRNAs coding for the two SPT subunits were unaffected. Expression of marker proteins shows that ceramide regulates apoptosis, rather than differentiation, during early neural differentiation.	Univ Mainz, Mol Neurobiol Lab, D-55099 Mainz, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Johannes Gutenberg University of Mainz; University of Kiel; University of Bonn	Herget, T (corresponding author), Axxima Pharmaceut AG, Klopferspitz 19, D-82152 Martinsried, Germany.		Schütze, Stefan/C-8596-2011					Berger C, 1997, EUR J CELL BIOL, V74, P230; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; BUREK MJ, 1998, CELL DEATH DIS NERVO; CARR VM, 1993, EXP NEUROL, V124, P308, DOI 10.1006/exnr.1993.1201; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Esdar C, 1999, EUR J NEUROSCI, V11, P503, DOI 10.1046/j.1460-9568.1999.00455.x; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Gallinat S, 1999, FEBS LETT, V443, P75, DOI 10.1016/S0014-5793(98)01675-5; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Herget T, 1998, J NEUROCHEM, V70, P47; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Jostock R, 1998, EUR J CELL BIOL, V76, P63, DOI 10.1016/S0171-9335(98)80018-6; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LANG E, 1989, J CELL BIOL, V109, P2481, DOI 10.1083/jcb.109.5.2481; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NELSON PE, 1993, ANNU REV PHYTOPATHOL, V31, P233, DOI 10.1146/annurev.py.31.090193.001313; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Oehrlein SA, 1998, EUR J CELL BIOL, V77, P323, DOI 10.1016/S0171-9335(98)80091-5; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P435; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUTZE S, 1995, CYTOKINES PRACTICAL, P93; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Yaginuma H, 1996, J NEUROSCI, V16, P3685; ZAKERI Z, 1988, CELLS DIE, P97; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	54	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30344	30354		10.1074/jbc.M000714200	http://dx.doi.org/10.1074/jbc.M000714200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862608	hybrid			2022-12-27	WOS:000089577900059
J	Oka, T; Futai, M				Oka, T; Futai, M			Requirement of V-ATPase for ovulation and embryogenesis in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; MOLECULAR-CLONING; GENE; CELL; EXPRESSION; OOCYTE; ACIDIFICATION; PROTEOLIPIDS; MUTATIONS; SUBUNIT	Immunofluorescence analysis indicated that VHA-11, the C subunit of Caenorhabditis elegans V-ATPase, was localized in dot-like structures around the nuclei of early embryonic cells and was also detected in embryonic intestinal cells after comma stage. Vital staining with acridine orange showed that the intestinal cells had acidic compartments generated by V-ATPase, consistent with the intracellular localization of VHA-11. RNA interference could efficiently silence vha-ll gene expression: introduction of vha-ll double strand RNA led to embryonic lethality. Worms injected with the vha-11 double strand RNA produced embryos that became lethal. The development of embryos was arrested at various stages. However, their numbers gradually decreased, and the worms eventually became sterile due to the failure of ovulation. Similar results were obtained for RNA interference of the V-ATPase proteolipid genes. These results suggest that V-ATPases, and thus inside-acidic organelles, are required for ovulation and embryogenesis.	Osaka Univ, Japan Sci & TEchnol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan	Japan Science & Technology Agency (JST); Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & TEchnol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Brown D, 2000, J EXP BIOL, V203, P137; CLOKEY GV, 1986, MECH AGEING DEV, V35, P79, DOI 10.1016/0047-6374(86)90068-0; FAGOTTO F, 1994, J CELL BIOL, V125, P1047, DOI 10.1083/jcb.125.5.1047; FINBOW ME, 1994, J CELL SCI, V107, P1817; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forgac M, 2000, J EXP BIOL, V203, P71; Futai M, 2000, J EXP BIOL, V203, P107; Graham LA, 2000, J EXP BIOL, V203, P61; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; Iwasaki K, 1996, J CELL BIOL, V134, P699, DOI 10.1083/jcb.134.3.699; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; MELLMAN I, 1992, J EXP BIOL, V172, P39; Moriyama Y, 2000, J EXP BIOL, V203, P117; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; SCHEDL T, 1997, C ELEGANS, V2, P241; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TOYAMA R, 1991, YEAST, V7, P989, DOI 10.1002/yea.320070911; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WHITE J, 1998, NEMATODE CAENORHABDI, P81; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	33	56	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29556	29561		10.1074/jbc.M002756200	http://dx.doi.org/10.1074/jbc.M002756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10846178	hybrid			2022-12-27	WOS:000089439800051
J	Swaminathan, CP; Gupta, A; Surolia, N; Surolia, A				Swaminathan, CP; Gupta, A; Surolia, N; Surolia, A			Plasticity in the primary binding site of galactose/N-acetylgalactosamine-specific lectins - Implication of the C-H center dot center dot center dot O hydrogen bond at the specificity-determining C-4 locus of the saccharide in 4-methoxygalactose recognition by jacalin and winged bean (basic) agglutinin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSOPHOCARPUS-TETRAGONOLOBUS; CRYSTALLOGRAPHIC EVIDENCE; CARBOHYDRATE-RECOGNITION; PROTEINS; DYNAMICS; DESIGN; H...O; DNA	It is currently believed that an unsubstituted axial hydroxyl at the specificity-determining C-4 locus of galactose is indispensable for recognition by galactose/N-acetylgalactosamine-specific lectins. Titration calorimetry demonstrates that 4-methoxygalactose retains binding allegiance to the Moraceae lectin jacalin and the Leguminosae lectin, winged bean (basic) agglutinin (WBA I). The binding reactions were driven by dominant favorable enthalpic contributions and exhibited significant enthalpy-entropy compensation. Proton NMR titration of C-methoxygalactose with jacalin and WBA I resulted in broadening of the sugar resonances without any change in chemical shift. The alpha-and beta-anomers of 4-methoxygalactose were found to be in slow exchange with free and lectin-bound states. Both the anomers experience magnetically equivalent environments at the respective binding sites. The binding constants derived from the dependence of NMR line widths on 4-methoxygalactose concentration agreed well with those obtained from titration calorimetry. The results unequivocally demonstrate that the loci corresponding to the axially oriented C-4 hydroxyl group of galactose within the primary binding site of these lectins exhibit plasticity. These analyses suggest, for the first time, the existence of C-H ... O-type hydrogen-bond(s) in protein-carbohydrate interactions in general and between the C-4 locus of galactose derivative and the lectins jacalin and WBA I in particular.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009					Bella J, 1996, J MOL BIOL, V264, P734, DOI 10.1006/jmbi.1996.0673; Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; CASU B, 1968, TETRAHEDRON, V24, P803, DOI 10.1016/0040-4020(68)88030-5; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cooper A, 1999, CURR OPIN CHEM BIOL, V3, P557, DOI 10.1016/S1367-5931(99)00008-3; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; DESIRAJU GR, 1993, ACTA CRYSTALLOGR B, V49, P880, DOI 10.1107/S0108768193001703; Desiraju GR, 1996, ACCOUNTS CHEM RES, V29, P441, DOI 10.1021/ar950135n; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Engh RA, 1996, STRUCTURE, V4, P1353, DOI 10.1016/S0969-2126(96)00142-6; Ghosh A, 1999, J MOL BIOL, V294, P1149, DOI 10.1006/jmbi.1999.3323; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KHAN MI, 1986, J BIOL CHEM, V261, P3013; Kuduva SS, 1999, J AM CHEM SOC, V121, P1936, DOI 10.1021/ja981967u; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Mandel-Gutfreund Y, 1998, J MOL BIOL, V277, P1129, DOI 10.1006/jmbi.1998.1660; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; RATHBONE EB, 1971, CARBOHYD RES, V20, P357, DOI 10.1016/S0008-6215(00)81390-7; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; SRINIVAS VR, 1998, CARBOHYDR LETT, V3, P129; Steiner T, 1998, CHEM COMMUN, P891, DOI 10.1039/a708099i; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Swaminathan CP, 1997, BIOCHEMISTRY-US, V36, P13428, DOI 10.1021/bi970550i; SWIFT TJ, 1962, J CHEM PHYS, V37, P307, DOI 10.1063/1.1701321; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28483	28487		10.1074/jbc.M004685200	http://dx.doi.org/10.1074/jbc.M004685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10837488	hybrid			2022-12-27	WOS:000089330700020
J	Hoare, SRJ; Clark, JA; Usdin, TB				Hoare, SRJ; Clark, JA; Usdin, TB			Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor - N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; TRANSMEMBRANE RESIDUES; EXTRACELLULAR LOOP; CHIMERIC RECEPTORS; AMINO-TERMINUS; AGONIST; LIGAND; ACTIVATION; CALCITONIN; EXPRESSION	Tuberoinfundibular peptide of 39 residues (TIP39) and the parathyroid hormone-a (PTH2) receptor form part of an extended family of related signaling molecules that includes the PTH1 receptor, which responds to PTH and PTH-related protein. TIP39 does not appreciably activate the PTH1 receptor, but in this study it is shown to bind the receptor with moderate affinity (59 nM), In this study, we investigated the molecular determinants of both ligand and receptor for the PTH2 receptor selectivity of TIP39 and quantitatively evaluated the role of molecular elements in the binding of TIP39 to the PTH2 and PTH1 receptors, A chimeric receptor composed of the N-terminal extracellular domain of the PTH1 receptor and the remainder (juxtamembrane domain) of the PTH2 receptor (P2-NP1) was fully activated by TIP39 (E-max = 98% of the rPTH-(1-34), E-max, EC50 = 2.0 nnr). This receptor chimera bound TIP39 with an equivalent affinity to the wild-type PTH2 receptor (2.3 and 2.0 nM, respectively). The reciprocal chimeric receptor (P1-NP2) was not activated by TIP39 and bound the ligand with an affinity equivalent to that of the PTH1 receptor. Thus, the juxtamembrane receptor domain specifies the signaling and binding selectivity of TIP39 for the PTH2 receptor over the PTH1 receptor. Removing six N-terminal residues of TIP39 eliminated activation of the PTH2 receptor and reduced binding affinity 70-fold. In contrast, this truncation increased affinity for the PTH1 receptor 10-fold, reversing the PTH2/PTH1 receptor binding selectivity and resulting in a high affinity interaction of TIP-(7-39) with the PTH1 receptor (6 mM), These findings can be explained by a strong interaction between the N-terminal region of TIP39 and the juxtamembrane domain of the PTH2 receptor, with the corresponding domain of the PTH1 receptor acting as a selectivity barrier against high affinity binding of TIP39, As a result, TIP-(7-39) is a highly potent, selective antagonist for the PTH1 receptor.	NIMH, Cell Biol Unit, Genet Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Usdin, TB (corresponding author), NIH, Rm 3D06,Bldg 36,36 Convent Dr MSC4094, Bethesda, MD 20892 USA.		Clark, Janet/P-4896-2018; Hoare, Sam/J-9018-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002685, Z01MH002685] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; DELEAN A, 1979, MOL PHARMACOL, V15, P60; ENGLAND RD, 1983, BIOCHEMISTRY-US, V22, P1722, DOI 10.1021/bi00276a031; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hoare SRJ, 1999, ENDOCRINOLOGY, V140, P4419, DOI 10.1210/en.140.10.4419; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; Hoare SRJ, 1999, J PHARMACOL TOXICOL, V41, P83, DOI 10.1016/S1056-8719(99)00024-6; Hoare SRJ, 2000, J BONE MINER RES, V15, P605, DOI 10.1359/jbmr.2000.15.3.605; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KUKREJA SC, 1994, ENDOCRINOLOGY, V134, P2184, DOI 10.1210/en.134.5.2184; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARTIN TJ, 1995, WILLIAMS TXB ENDOCRI, P967; Piserchio A, 2000, J BIOL CHEM, V275, P27284; POTTS JT, 1995, WILLIAMS TXB ENDOCRI, P920; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Rosen HN, 1997, CALCIFIED TISSUE INT, V61, P455, DOI 10.1007/s002239900367; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724; Usdin TB, 1999, ENDOCRINOLOGY, V140, P3363, DOI 10.1210/en.140.7.3363; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455	41	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27274	27283						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854439				2022-12-27	WOS:000089144800081
J	Huang, HK; Joazeiro, CAP; Bonfoco, E; Kamada, S; Leverson, JD; Hunter, T				Huang, HK; Joazeiro, CAP; Bonfoco, E; Kamada, S; Leverson, JD; Hunter, T			The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIAP; SYSTEM; DOMAIN; MOTIF	The inhibitor of apoptosis, cIAP2, contains a putative Ring finger motif at the C terminus. Using in vitro ubiquitination assays, we found that the Ring finger of cIAP2 alone possesses intrinsic ubiquitin ligase activity and promotes substrate-independent ubiquitination. It also promotes ubiquitination of caspases 3 and 7 but not caspase-1. The Ring fingers of c-Cbl and Apc11 failed to promote caspase-7 ubiquitination, suggesting that the Ring finger of cIAP2 itself is involved in substrate recognition.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu			NATIONAL CANCER INSTITUTE [R01CA082683, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA82683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DEVERAUX QL, 1998, EMBO J, V17, P2215, DOI DOI 10.1093/EMBOJ/17.8.2215; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Ravi R, 2000, GENE DEV, V14, P34; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	37	289	295	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26661	26664						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862606				2022-12-27	WOS:000089144800001
J	Takeuchi, T; Harris, JL; Huang, W; Yan, KW; Coughlin, SR; Craik, CS				Takeuchi, T; Harris, JL; Huang, W; Yan, KW; Coughlin, SR; Craik, CS			Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; MOLECULAR-CLONING; THROMBIN RECEPTOR; COMBINATORIAL APPROACH; PHAGE DISPLAY; GRANZYME-B; PRO-UPA; SPECIFICITIES; TRYPSIN	Membrane-type serine protease 1 (MT-SP1) was recently cloned, and we now report its biochemical characterization. MT-SP1 is predicted to be a type II trans membrane protein with an extracellular protease domain. This localization was experimentally verified using immunofluorescent microscopy and a cell-surface biotinylation technique. The substrate specificity of MT-SP1 was determined using a positional scanning-synthetic combinatorial library and substrate phage techniques. The preferred cleavage sequences were found to be (P4-(Arg/Lys)P3-(X)P2-(Ser)P1-(Arg)P1'-(Ala)) and (P4-(X)P3-(Arg/Lys)P2-(Ser)P1(Arg)P1'(Ala)), where X is a non-basic amino acid, Protease-activated receptor 2 (PAR2) and single chain urokinase-type plasminogen activator are proteins that are localized to the extracellular surface and contain the preferred MT-SP1 cleavage sequence. The ability of MT-SP1 to activate PARs was assessed by exposing PAR-expressing Xenopus oocytes to the soluble MT-SP1 protease domain. The latter triggered calcium signaling in PAR2-expressing oocytes at 10 nM but failed to trigger calcium signaling in oocytes expressing PAR1, PAR3, or PAR4 at 100 nM. Single-chain urokinase-type plasminogen activator was activated using catalytic amounts of MT-SP1 (1 nM), but plasminogen was not cleaved under similar conditions. The membrane localization of MT-SP1 and its affinity for these key extracellular substrates suggests a role of the proteolytic activity in regulatory events.	Univ Calif San Francisco, Dept Pharmaceut Chem & Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; San Francisco State Univ, Ctr Biomed Lab Sci, San Francisco, CA 94132 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California State University System; San Francisco State University	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem & Biochem & Biophys, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [F32CA071097, P01CA072006] Funding Source: NIH RePORTER; NCI NIH HHS [CA71097, CA72006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Backes BJ, 1999, J ORG CHEM, V64, P2322, DOI 10.1021/jo981990y; Bohm SK, 1996, BIOCHEM J, V314, P1009; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCGRATH ME, 1994, EMBO J, V13, P1503; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POLONIGIACOBINO A, 1997, GENOMICS, V44, P309; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schuberth HJ, 1996, J IMMUNOL METHODS, V189, P89, DOI 10.1016/0022-1759(95)00238-3; SHI YE, 1993, CANCER RES, V53, P1409; STACK MS, 1994, J BIOL CHEM, V269, P9416; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Unal A, 1997, J VIROL, V71, P7030, DOI 10.1128/JVI.71.9.7030-7038.1997; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; YOSHIDA E, 1994, CANCER RES, V54, P3300; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618	52	369	413	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26333	26342		10.1074/jbc.M002941200	http://dx.doi.org/10.1074/jbc.M002941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10831593	hybrid			2022-12-27	WOS:000088999700063
J	Tchurikov, NA; Chistyakova, LG; Zavilgelsky, GB; Manukhov, IV; Chernov, BK; Golova, YB				Tchurikov, NA; Chistyakova, LG; Zavilgelsky, GB; Manukhov, IV; Chernov, BK; Golova, YB			Gene-specific silencing by expression of parallel complementary RNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INTERFERENCE; DEGRADATION; COLI; DNA; COSUPPRESSION; MUTAGENESIS; DROSOPHILA; TRANSGENES; SEQUENCES	Gene-specific silencing refers to a phenomenon in which expression of an individual gene can be specifically repressed by different mechanisms on the levels of transcription, RNA splicing, transport, degradation in nuclei or cytoplasm, or blocking of translation. In different species gene-specific silencing was observed by expression or injections of antiparallel double-stranded RNA formed by a fragment of mRNA and antisense RNA. Here we show a potent and specific gene silencing in bacteria by expression of RNA, that is complementary in a parallel orientation to Escherichia coli ion mRNA Moreover, the expression of parallel RNA is more effective at producing interference than expression of antisense RNA corresponding to the same mRNA region. Both effects of interference mediated either by parallel RNA or antiparallel RNA gradually decrease up to the 40th generation. Together with in vitro nuclease protection studies these results indicate that a parallel RNA duplex might be formed in vivo and both types of duplexes, antiparallel or parallel, can induce gene specific silencing by similar mechanisms.	Russian Acad Sci, Dept Genome Org, Moscow 117984, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Grp Genes Chem Synth, Moscow 117984, Russia; State Sci Ctr Russian Federat GNIIGENETICA, Lab Bacterial Genet, Moscow 113545, Russia	Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Tchurikov, NA (corresponding author), Russian Acad Sci, Dept Genome Org, Vavilov Str 32, Moscow 117984, Russia.	tchur@imb.ac.ru	Zavilgelsky, Gennadii/AAE-8051-2021; Manukhov, Ilya V/L-1375-2014; Tchurikov, Nickolai A./R-4850-2016	Manukhov, Ilya V/0000-0001-8646-7207; 				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; CECH TR, 1993, GENE, V135, P33, DOI 10.1016/0378-1119(93)90046-6; Chistyakova L G, 1990, Biomed Sci, V1, P359; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; RIPPE K, 1990, J BIOMOL STRUCT DYN, V7, P1199, DOI 10.1080/07391102.1990.10508559; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; TCHURIKOV NA, 1992, GENETICA, V87, P113, DOI 10.1007/BF00121001; Tchurikov NA, 1995, J BIOMOL STRUCT DYN, V13, P507, DOI 10.1080/07391102.1995.10508860; TEHURIKOV NA, 1988, P RUSSIAN ACAD SCI, V303, P1254; VANDESANDE JH, 1988, SCIENCE, V241, P551, DOI 10.1126/science.3399890; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAGNER EG, 1994, ANNU REV MICROBIOL, V48, P714; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; ZAVILGELSKII GB, 1994, GENETIKA+, V30, P337	31	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26523	26529		10.1074/jbc.M002833200	http://dx.doi.org/10.1074/jbc.M002833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849423	hybrid			2022-12-27	WOS:000088999700088
J	Scott, SV; Nice, DC; Nau, JJ; Weisman, LS; Kamada, Y; Keizer-Gunnink, I; Funakoshi, T; Veenhuis, M; Ohsumi, Y; Klionsky, DJ				Scott, SV; Nice, DC; Nau, JJ; Weisman, LS; Kamada, Y; Keizer-Gunnink, I; Funakoshi, T; Veenhuis, M; Ohsumi, Y; Klionsky, DJ			Apg13p and Vac8p are part of a complex of phosphoproteins that are required for cytoplasm to vacuole targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; DEFICIENT MUTANTS; YEAST VACUOLE; PROTEIN; AUTOPHAGY; TRANSPORT; PATHWAY; MEMBRANE; GENE	We have been studying protein components that function in the cytoplasm to vacuole targeting (Cvt) pathway and the overlapping process of macroautophagy. The Vac8 and Apg13 proteins are required for the import of aminopeptidase I (API) through the Cvt pathway. We have identified a protein-protein interaction between Vac8p and Apg13p by both two-hybrid and co-immunoprecipitation analysis. Subcellular fractionation of API indicates that Vac8p and Apg13p are involved in the vesicle formation step of the Cvt pathway. Kinetic analysis of the Cvt pathway and autophagy indicates that, although Vac8p is essential for Cvt transport, it is less important for autophagy, In vivo phosphorylation experiments demonstrate that both Vac8p and Apg13p are phosphorylated proteins, and Apg13p phosphorylation is regulated by changing nutrient conditions. Although Apg13p interacts with the serine/threonine kinase Apg1p, this protein is not required for phosphorylation of either Vac8p or Apg13p, Subcellular fractionation experiments indicate that Apg13p and a fraction of Apg1p are membrane-associated, Vac8p and Apg13p may be part of a larger protein complex that includes Apg1p and additional interacting proteins. Together, these components may form a protein complex that regulates the conversion between Cvt transport and autophagy in response to changing nutrient conditions.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Groningen, Dept Microbiol, NL-9751 NN Haren, Netherlands; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	University of California System; University of California Davis; University of Iowa; University of Groningen; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Klionsky, DJ (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.	djklionsky@ucdavis.edu	Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Kamada, Yoshiaki/0000-0001-7395-660X	NIGMS NIH HHS [GM53396, GM50403] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396, R01GM050403] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bai C, 1997, METHOD ENZYMOL, V283, P141; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fleckenstein D, 1998, J CELL SCI, V111, P3109; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARPER JW, 1993, CELL, V75, P805; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; James P, 1996, GENETICS, V144, P1425; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Pan XZ, 1998, J CELL SCI, V111, P2137; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063	42	184	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25840	25849		10.1074/jbc.M002813200	http://dx.doi.org/10.1074/jbc.M002813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837477	Green Published, hybrid			2022-12-27	WOS:000088849400102
J	Saiardi, A; Caffrey, JJ; Snyder, SH; Shears, SB				Saiardi, A; Caffrey, JJ; Snyder, SH; Shears, SB			The inositol hexakisphosphate kinase family - Catalytic flexibility and function in yeast vacuole biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE; SACCHAROMYCES-CEREVISIAE; PROTEIN; TETRAKISPHOSPHATE; PENTAKISPHOSPHATE; CELLS; METABOLISM; TURNOVER; 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4,6-TETRAKISPHOSPHATE	Saiardi et al. (Saiardi, A., Erdjument-Bromage, H., Snowman, A., Tempst, P., and Snyder, S. H. (1999) Curr. Biol. 9, 1323-1326) previously described the cloning of a kinase from yeast and two kinases from mammals (types 1 and 2), which phosphorylate inositol hexakisphosphate (InsP(6)) to diphosphoinositol pentakisphosphate, a "high energy" candidate regulator of cellular trafficking. We have now studied the significance of InsP(6) kinase activity in Saccharomyces cerevisiae by disrupting the kinase gene. These ip6k Delta cells grew more slowly their levels of diphosphoinositol polyphosphates were 60-80% lower than wild-type cells, and the cells contained abnormally small and fragmented vacuoles. Novel activities of the mammalian and yeast InsP(6) kinases mere identified; inositol pentakisphosphate (InsP(5)) was phosphorylated to diphosphoinositol tetrakisphosphate (PP-InsP(4)), which was further metabolized to a novel compound, tentatively identified as bis-diphosphoinositol trisphosphate, The latter is a new substrate for human diphosphoinositol polyphosphate phosphohydrolase. Kinetic parameters for the mammalian type 1 kinase indicate that InsP(5) (K-m = 1.2 mu M) and InsP(6) (K-m = 6.7 mu M) compete for phosphorylation in vivo. This is the first time a PP-InsP(4) synthase has been identified. The mammalian type 2 kinase and the yeast kinase are more specialized for the phosphorylation of InsP(6). Synthesis of the diphosphorylated inositol phosphates is thus revealed to be more complex and interdependent than previously envisaged.	NIEHS, Inositide Signaling Grp, Inositide Signaling Sect, Lab Signal Transduct,NIH, Res Triangle Pk, NC 27709 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Shears, SB (corresponding author), NIEHS, Inositide Signaling Grp, Inositide Signaling Sect, Lab Signal Transduct,NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	Shears@niehs.nih.gov	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00074] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; CONIBEAR E, 1995, CELL, V83, P513, DOI 10.1016/0092-8674(95)90088-8; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUSE AH, 1993, J BIOL CHEM, V268, P7129; HESLOP JP, 1985, J EXP BIOL, V119, P395; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; HUANG KN, 1995, GENETICS, V141, P1275; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHEARS SB, 1997, SIGNALLING INOSITIDE, P33; Srivastava A, 1998, GENETICS, V148, P85; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yamaguchi Y, 1996, J BIOL CHEM, V271, P27838, DOI 10.1074/jbc.271.44.27838; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	37	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24686	24692		10.1074/jbc.M002750200	http://dx.doi.org/10.1074/jbc.M002750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827188	hybrid			2022-12-27	WOS:000088683300062
J	Holopainen, JM; Medina, OP; Metso, AJ; Kinnunen, PKJ				Holopainen, JM; Medina, OP; Metso, AJ; Kinnunen, PKJ			Sphingomyelinase activity associated with human plasma low density lipoprotein - Possible functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROGENIC LIPOPROTEINS; SECRETORY SPHINGOMYELINASE; HUMAN ATHEROSCLEROSIS; ARTERIAL-WALL; CERAMIDE; APOPTOSIS; AGGREGATION; PATHWAY; CELLS; PHOSPHATIDYLCHOLINE	Isolated human plasma low density lipoprotein (LDL) was observed to possess sphingomyelinase activity. Accordingly, the formation of ceramide was catalyzed by LDL at 37 degrees C using tertiary Liposomes composed of sphingomyelin (mole fraction (x) = 0.2), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (x = 0.7), 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol (x = 0.1), and either the fluorescent sphingomyelin analog Bodipy-sphingomyelin or [C-14]sphingomyelin as substrates. However, this activity was not present in either very low density lipoprotein or the high density lipoprotein subfractions HDL2 and HDL3. Oxidation of LDL abrogated its sphingomyelinase activity. Aggregation of the liposomes upon incubation with LDL was evident from the light scattering measurements. Microinjection of LDL to the surface of giant liposomes composed of 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), N-palmitoyl-D-sphingomyelin (C16:0-sphingomyelin), and Bodipy-sphingomyelin as a fluorescent tracer (0.75:-0.20:0.05, respectively) revealed the induction of vectorial budding of vesicles, resembling endocytosis.	Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland	University of Helsinki	Kinnunen, PKJ (corresponding author), Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki Biophys & Biomembrane Grp, POB 8,Siltavuorenpenger 10A, FIN-00014 Helsinki, Finland.		medina, oula penate/G-5136-2012; Penate-Medina, oula/ABB-8198-2021	medina, oula penate/0000-0001-9878-5309; Penate-Medina, oula/0000-0001-9878-5309				ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMEJO G, 1980, ATHEROSCLEROSIS, V35, P307, DOI 10.1016/0021-9150(80)90129-X; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Fanani ML, 1997, MOL MEMBR BIOL, V14, P25, DOI 10.3109/09687689709048166; FONG LG, 1987, J LIPID RES, V28, P1466; GENG YJ, 1995, AM J PATHOL, V147, P251; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; GUYTON JR, 1996, THROMB VASC BIOL, V16, P4; HAN DKM, 1995, AM J PATHOL, V147, P267; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Holopainen JM, 1997, CHEM PHYS LIPIDS, V88, P1, DOI 10.1016/S0009-3084(97)00040-6; HOLOPAINEN JM, 2000, IN PRESS BIOPHYS J; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002; Lauraeus S, 1998, BBA-BIOMEMBRANES, V1373, P147, DOI 10.1016/S0005-2736(98)00102-3; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; Murphy HC, 1997, BIOCHEM BIOPH RES CO, V234, P733, DOI 10.1006/bbrc.1997.6634; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; Parthasarathy S, 1999, J LIPID RES, V40, P2143; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P300; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; REISFELD N, 1993, FEBS LETT, V315, P267, DOI 10.1016/0014-5793(93)81176-Z; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCHNORF M, 1994, EXP CELL RES, V210, P260, DOI 10.1006/excr.1994.1038; SOMMER A, 1992, J BIOL CHEM, V267, P24217; SRINIVAS.SR, 1972, ATHEROSCLEROSIS, V16, P95, DOI 10.1016/0021-9150(72)90012-3; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; TABAS I, 1993, J BIOL CHEM, V268, P20419; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; XU XX, 1991, J BIOL CHEM, V266, P24849; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	53	48	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16484	16489		10.1074/jbc.275.22.16484	http://dx.doi.org/10.1074/jbc.275.22.16484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828058	hybrid			2022-12-27	WOS:000087392200014
J	Legros, C; Pollmann, V; Knaus, HG; Farrell, AM; Darbon, H; Bougis, PE; Martin-Eauclaire, MF; Pongs, O				Legros, C; Pollmann, V; Knaus, HG; Farrell, AM; Darbon, H; Bougis, PE; Martin-Eauclaire, MF; Pongs, O			Grenerating a high affinity scorpion toxin receptor in KcsA-Kv1.3 chimeric potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; STREPTOMYCES-LIVIDANS; CHARYBDOTOXIN BLOCK; SELECTIVITY; MECHANISM; SEQUENCE; PEPTIDES; CELLS; BRAIN; PORE	The crystal structure of the bacterial K+ channel, KcsA (Doyle, D. A., Morais, C. J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77), and subsequent mutagenesis have revealed a high structural conservation from bacteria to human (MacKinnon, R., Cohen, S, L., Kuo, A., Lee, A., and Chait, B. T. (1998) Science 280, 106-109). me have explored this conservation by swapping subregions of the M1-M2 linker of KcsA with those of the S5-S6 linker of the human Kv-channel Kv1.3. The chimeric K+ channel constructs were expressed in Escherichia coli, and their multimeric state was analyzed after purification. We used two scorpion toxins, kaliotoxin and hongotoxin 1, which bind specifically to Kv1.3, to analyze the pharmacological properties of the KcsA-Kv1.3 chimeras. The results demonstrate that the high affinity scorpion toxin receptor of Kv1.3 could be transferred to KcsA. Our biochemical studies with purified KcsA-Kv1.3 chimeras provide direct chemical evidence that a tetrameric channel structure is necessary for forming a functional scorpion toxin receptor. We have obtained KcsA-Kv1.3 chimeras with kaliotoxin affinities (IC50 values of similar to 4 pM) like native Kv1.3 channels. Furthermore, we show that a subregion of the S5-S6 linker may be an important determinant of the pharmacological profile of K+ channels. Using available structural information on KcsA and kaliotoxin, we have developed a structural model for the complex between KcsA-1.3 chimeras and kaliotoxin to aid future pharmacological studies of K+ channels.	Univ Hamburg, ZMNH, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany; Univ Innsbruck, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria; Inst Biol Struct & Microbiol, CNRS, UPR 9039, F-13402 Marseille 20, France; Univ Aix Marseille 2, Fac Med Secteur Nord, Inst Federat Rech Jean Roche, Lab Biochim,CNRS,UMR 6560, F-13916 Marseille 20, France	University of Hamburg; University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Pongs, O (corresponding author), Univ Hamburg, ZMNH, Inst Neurale Signalverarbeitung, Martinistr 52, D-20246 Hamburg, Germany.	pointuri@uke.uni-hamburg.de	Legros, Christian/K-1346-2015; BOUGIS, Pierre E/I-2111-2013	LEGROS, Christian/0000-0002-3346-7059				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARA B, 1995, BIOCHEM PHARMACOL, V49, P1459, DOI 10.1016/0006-2952(94)00524-P; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naini AA, 1996, BIOCHEMISTRY-US, V35, P6181, DOI 10.1021/bi960067s; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; ROMI R, 1993, J BIOL CHEM, V268, P26302; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X	31	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16918	16924		10.1074/jbc.275.22.16918	http://dx.doi.org/10.1074/jbc.275.22.16918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828071	hybrid			2022-12-27	WOS:000087392200074
J	Dunphy, JL; Balic, A; Barcham, GJ; Horvath, AJ; Nash, AD; Meeusen, ENT				Dunphy, JL; Balic, A; Barcham, GJ; Horvath, AJ; Nash, AD; Meeusen, ENT			Isolation and characterization of a novel inducible mammalian galectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDEN CRYSTAL PROTEIN; ENDOGENOUS LECTIN; BINDING PROTEIN; ANIMAL LECTIN; ACTIVATION; FAMILY; CELLS; GENE; RNA; LYSOPHOSPHOLIPASE	A novel mammalian galectin cDNA (ovgal11) was isolated by representational difference analysis from sheep stomach (abomasal) tissue infected with the nematode parasite, Haemonchus contortus. The mRNA is greatly up-regulated in helminth larval infected gastrointestinal tissue subject to inflammation and eosinophil infiltration. Immunohistological analysis indicates that the protein is localized in the cytoplasm and nucleus of upper epithelial cells of the gastrointestinal tract. The protein is also detected in mucus samples collected from infected abomasum but not from uninfected tissue. The restricted and inducible expression of ovgal11 mRNA and limited secretion of the protein support the hypothesis that OVGAL11 may be involved in gastrointestinal immune/inflammatory responses and possibly protection against infection.	Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia; AMRAD Operat Propietary Ltd, Burnley, Vic 3121, Australia	University of Melbourne	Meeusen, ENT (corresponding author), Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia.		Balic, Adam/C-7718-2013	Meeusen, Els/0000-0003-1239-6287				ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Balic A, 2000, VET IMMUNOL IMMUNOP, V75, P109, DOI 10.1016/S0165-2427(00)00189-6; Balic A, 2000, ADV PARASIT, V45, P181, DOI 10.1016/S0065-308X(00)45005-0; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Bresalier RS, 1996, CANCER RES, V56, P4354; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; Dyer KD, 1996, LIFE SCI, V58, P2073, DOI 10.1016/0024-3205(96)00201-9; Fourney R.M., 1988, FOCUS, V10, P5; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; Greenhalgh CJ, 1996, IMMUNOL CELL BIOL, V74, P497, DOI 10.1038/icb.1996.82; Harrison GBL, 1999, INT J PARASITOL, V29, P459, DOI 10.1016/S0020-7519(98)00221-5; HSU DK, 1992, J BIOL CHEM, V267, P14167; HU L, 1994, J BIOL CHEM, V269, P183; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Mehul B, 1997, J CELL SCI, V110, P1169; NAWA Y, 1994, PARASITE IMMUNOL, V16, P333, DOI 10.1111/j.1365-3024.1994.tb00358.x; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Pfeffer A, 1996, INT J PARASITOL, V26, P765, DOI 10.1016/0020-7519(96)00052-5; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; Rainbird MA, 1998, PARASITE IMMUNOL, V20, P93, DOI 10.1046/j.1365-3024.1998.00132.x; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Tate WP, 1995, BIOCHEM CELL BIOL, V73, P1095, DOI 10.1139/o95-118; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Wasano K, 1997, J HISTOCHEM CYTOCHEM, V45, P275, DOI 10.1177/002215549704500212; YAMAOKA A, 1995, J IMMUNOL, V154, P3479	42	83	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32106	32113		10.1074/jbc.M003739200	http://dx.doi.org/10.1074/jbc.M003739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10851241	hybrid			2022-12-27	WOS:000089858900076
J	Yano, JK; Koo, LS; Schuller, DJ; Li, HY; de Montellano, PRO; Poulos, TL				Yano, JK; Koo, LS; Schuller, DJ; Li, HY; de Montellano, PRO; Poulos, TL			Crystal structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; PROGRAM PACKAGE; AMINO-ACID; PROTEIN; MACROMOLECULES; SUBSTRATE; EVOLUTION; STABILITY; SEQUENCE; SITES	The structure of the first P450 identified in Archaea, CYP119 from Sulfolobus solfataricus, has been solved in two different crystal forms that differ by the ligand (imidazole or 4-phenylimidazole) coordinated to the heme iron. A comparison of the two structures reveals an unprecedented rearrangement of the active site to adapt to the different size and shape of ligands bound to the heme iron. These changes involve unraveling of the F helix C-terminal segment to extend a loop structure connecting the F and G helices, allowing the longer loop to dip down into the active site and interact with the smaller imidazole ligand, A comparison of CYP119 with P450cam and P450eryF indicates an extensive clustering of aromatic residues may provide the structural basis for the enhanced thermal stability of CYP119. An additional feature of the 4-phenylimidazole-bound structure is a zinc ion tetrahedrally bound by symmetry-related His and Glu residues.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Francisco	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32668, GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang YT, 2000, BIOCHEMISTRY-US, V39, P2484, DOI 10.1021/bi991966u; Consonni R, 1999, BIOCHEMISTRY-US, V38, P12709, DOI 10.1021/bi9911280; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DiGleria K, 1996, FEBS LETT, V390, P142, DOI 10.1016/0014-5793(96)00648-5; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Georis J, 1999, GENE, V237, P123, DOI 10.1016/S0378-1119(99)00311-X; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Kellner DG, 1997, CURR OPIN BIOTECH, V8, P274, DOI 10.1016/S0958-1669(97)80003-1; Koo LS, 2000, J BIOL CHEM, V275, P14112, DOI 10.1074/jbc.275.19.14112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schuller DJ, 1996, ACTA CRYSTALLOGR D, V52, P425, DOI 10.1107/S0907444995013291; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Wright RL, 1996, FEBS LETT, V384, P235, DOI 10.1016/0014-5793(96)00322-5; Zeikus JG, 1998, EXTREMOPHILES, V2, P179, DOI 10.1007/s007920050058	39	176	178	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31086	31092		10.1074/jbc.M004281200	http://dx.doi.org/10.1074/jbc.M004281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859321	hybrid			2022-12-27	WOS:000089762700049
J	Eriksson, P; Alipour, H; Adler, L; Blomberg, A				Eriksson, P; Alipour, H; Adler, L; Blomberg, A			Rap1p-binding sites in the Saccharomyces cerevisiae GPD1 promoter are involved in its response to NaCl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; DNA-BINDING DOMAIN; MAP KINASE CASCADE; 0.7 M NACL; OSMOTIC-STRESS; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; CHLORAMPHENICOL ACETYLTRANSFERASE; PROTEIN EXPRESSION; SHUTTLE VECTORS; GENE-EXPRESSION	Mechanisms involved in transcriptional regulation of the osmotically controlled GPD1 gene in Saccharomyces cerevisiae were investigated by promoter analysis. The GPD1 gene encodes NAD(+)-dependent glycerol-3-phosphate dehydrogenase, a key enzyme in the production of the compatible solute glycerol. By analysis of promoter deletions, we identified a region at nucleotides -478 to -324, in relation to start of translation, to be of great importance for both basal activity and osmotic induction of GPD1. Electrophoretic mobility shift and DNase I footprint analyses demonstrated protein binding to parts of this region that contain three consensus sequences for Rap1p (repressor activator protein 1)-binding sites. Actual binding of Rap1p to this region was confirmed by demonstrating enhanced electrophoretic mobility of the protein-DNA complex with extracts containing an N-terminally truncated version of Rap1p. The detected Rap1p-DNA interactions were not affected by changes in the osmolarity of the growth medium. Specific inactivation of the Rap1p-binding sites by a C-to-A point mutation in the core of the consensus showed that this factor is a major determinant of GPD1 expression since mutations in all three putative binding sites for Rap1p strongly hampered osmotic induction and drastically lowered basal activity. We also show that the Rap1p-binding sites appear functionally distinct; the most distal site (core of the consensus at position -386) exhibited the highest affinity for Rap1p and was strictly required for low salt induction (less than or equal to 0.6 M NaCl), but not for the response at higher salinities (greater than or equal to 0.8 M NaCl). This indicates that different molecular mechanisms might be operational for low and high salt responses of the GPD1 promoter.	Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol Microbiol, S-41390 Gothenburg, Sweden	University of Gothenburg	Blomberg, A (corresponding author), Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol Microbiol, Medicinaregat 9C, S-41390 Gothenburg, Sweden.	anders.blomberg@gmm.gu.se						Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alipour H, 1999, ANAL BIOCHEM, V270, P153, DOI 10.1006/abio.1999.4069; ANDRE L, 1991, FEBS LETT, V286, P13, DOI 10.1016/0014-5793(91)80930-2; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BLOMBERG A, 1995, J BACTERIOL, V177, P3563, DOI 10.1128/jb.177.12.3563-3572.1995; Blomberg A., 1993, STRESS TOLERANCE FUN, P209; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EDGLEY M, 1983, J GEN MICROBIOL, V129, P3453; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Hohmann S., 1997, YEAST STRESS RESPONS, P101; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MANNHAUPT G, 1988, GENE, V67, P287, DOI 10.1016/0378-1119(88)90405-2; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Marquez JA, 1998, EMBO J, V17, P2543, DOI 10.1093/emboj/17.9.2543; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; Norbeck J, 1996, FEMS MICROBIOL LETT, V137, P1; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Proft M, 1999, MOL CELL BIOL, V19, P537; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SCHULLER HJ, 1994, EUR J BIOCHEM, V225, P213, DOI 10.1111/j.1432-1033.1994.00213.x; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TORNOW J, 1993, EMBO J, V12, P2431, DOI 10.1002/j.1460-2075.1993.tb05897.x; TROLLMO C, 1988, FEMS MICROBIOL LETT, V56, P321, DOI 10.1016/0378-1097(88)90082-1; Uemura H, 1997, GENETICS, V147, P521; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Yu LN, 1999, MOL CELL BIOL, V19, P5279	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29368	29376		10.1074/jbc.M001663200	http://dx.doi.org/10.1074/jbc.M001663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10842169	hybrid			2022-12-27	WOS:000089439800027
J	Ouzzine, M; Gulberti, S; Netter, P; Magdalou, J; Fournel-Gigleux, S				Ouzzine, M; Gulberti, S; Netter, P; Magdalou, J; Fournel-Gigleux, S			Structure/function of the human Gal beta 1,3-glucuronosyltransferase - Dimerization and functional activity are mediated by two crucial cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; GLUCURONOSYLTRANSFERASE-I; MOLECULAR-CLONING; CARBOHYDRATE EPITOPE; GOLGI RETENTION; BIOSYNTHESIS; PROTEOGLYCANS; EXPRESSION; SULFATE; ENZYME	Gal beta 1,3-glucuronosyltransferase (GlcAT-I) that catalyzes the transfer of a glucuronic acid residue onto the trisaccharide primer of the glycosaminoglycan-protein Linkage region plays an essential role in the early steps of the biosynthesis of glycosaminoglycans. In order to gain insight into the structure/function of the enzyme, the human recombinant GlcAT-I was successfully expressed in the yeast Pichia pastoris, with an apparent molecular mass of 43 kDa, Analysis of the electrophoretic mobility of the membrane-bound protein in nonreducing and reducing conditions, together with cross-linking studies, indicated that the membrane-bound GlcAT-I formed active disulfide-linked dimers, GlcAT-I expressed without the predicted N-terminal cytoplasmic tail or secreted as a polypeptide lacking the cytoplasmic tail and transmembrane domain was similarly organized as dimers, suggesting that the structural determinants for the dimerization state are localized in the luminal domain of the protein. In addition, the role of Cys(33) and Cys(301) in that process was investigated by site-directed mutagenesis combined with chemical modification of GlcAT-I by N-phenylmaleimide. Replacement of Cys(33) with alanine abolished the formation of dimers with a concomitant decrease in the catalytic efficiency mainly due to a decrease in apparent maximal velocity and in affinity for UDP-glucuronic acid. On the other hand, N-phenylmaleimide treatment or alanine substitution of the Cys(301) residue inactivated the enzyme, Our study demonstrates that GlcAT-I is organized as a homodimer as a result of disulfide bond formation mediated by Cys(33) localized in the stem region, whereas the residue Cys(301) localized in a conserved C-terminal domain is strictly required for the functional integrity of the enzyme.	Univ Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Nancy 1, Fac Med, CNRS, UMR 7561, BP 184, F-54505 Vandoeuvre Nancy, France.		Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; GULBERTI, Sandrine/0000-0002-9378-4697				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Glavas S, 1999, BIOCHEMISTRY-US, V38, P4106, DOI 10.1021/bi982663n; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HELTING T, 1969, J BIOL CHEM, V244, P2799; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PILLOT T, 1993, J BIOL CHEM, V268, P25636; Pless D, 1999, DRUG METAB DISPOS, V27, P588; POOLE AR, 1986, BIOCHEM J, V236, P1; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; Sugumaran G, 1998, BIOCHEM J, V329, P203, DOI 10.1042/bj3290203; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TOLOV AA, 1990, NUCLEIC ACIDS RES, V18, P3983; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	33	36	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28254	28260						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842173				2022-12-27	WOS:000089197100096
J	Legate, KR; Falcone, D; Andrews, DW				Legate, KR; Falcone, D; Andrews, DW			Nucleotide-dependent binding of the GTPase domain of the signal recognition particle receptor beta-subunit to the alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ELONGATION-FACTOR-TU; H-RAS P21; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; MECHANISM; FTSY; SEQUENCES; INTEGRATION	The signal recognition particle (SRP) receptor (SR) is a heterodimer of two polypeptides (SR alpha and SR beta) that each contain a GTP-binding. domain. The GTP-binding domain in the peripheral membrane SR alpha subunit has a well defined role in regulating targeting of SRP-ribosome-nascent chain complexes to the translocon. The only well established function for the transmembrane SRP subunit is anchoring SR alpha On the endoplasmic reticulum membrane. Deletion of the amino-terminal transmembrane domain of SRP did not affect receptor dimerization, but revealed a cryptic translocation signal that overlaps the GTPase domain. We demonstrate that the domain of SRa that binds SRP does so by binding directly to the nucleotide-bound form of the GTPase domain of SR beta. An SR beta mutant containing an amino acid substitution that allows the GTPase domain to bind XTP dimerized with SRa most efficiently in the presence of XTP or XDP, but not ATP. Our results suggest an additional level of regulation of SRP receptor function based on regulated dissociation of the receptor subunits.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Legate, Kyle/0000-0003-3243-579X; Andrews, David/0000-0002-9266-7157				ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; Falcone D, 1999, J BIOL CHEM, V274, P33661, DOI 10.1074/jbc.274.47.33661; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; Hughes MJG, 1996, BIOTECHNIQUES, V20, P188; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Millman JS, 1999, J BIOL CHEM, V274, P33227, DOI 10.1074/jbc.274.47.33227; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; Young JC, 1996, EMBO J, V15, P172, DOI 10.1002/j.1460-2075.1996.tb00345.x; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	36	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27439	27446						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859309				2022-12-27	WOS:000089144800102
J	Antes, TJ; Goodart, SA; Huynh, C; Sullivan, M; Young, SG; Levy-Wilson, B				Antes, TJ; Goodart, SA; Huynh, C; Sullivan, M; Young, SG; Levy-Wilson, B			Identification and characterization of a 315-base pair enhancer, located more than 55 kilobases 5 ' of the apolipoprotein B gene, that confers expression in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ARTIFICIAL CHROMOSOMES; NUCLEASE-HYPERSENSITIVE SITES; HORMONE FUSION GENES; TRANSGENIC MICE; TRANSCRIPTION FACTORS; 2ND-INTRON ENHANCER; PROMOTER; ELEMENTS; PROTEINS; FAMILY	We recently reported that an 8-kilobase (kb) region, spanning from -54 to -62 kb 5' of the human apolipoprotein B (apoB) gene, contains intestine-specific regulatory elements that control apoB expression in the intestines of transgenic mice. In this study, we further localized the apoB intestinal control region to a 3-kb segment (-54 to -57 kb). DNaseI hypersensitivity studies uncovered a prominent DNaseI hypersensitivity site, located within a 315-base pair (bp) fragment at the 5'-end of the 3-kb segment, in transcriptionally active CaCo-2 cells but not in transcriptionally inactive HeLa cells. Transient transfection experiments with CaCo-2 and HepG2 cells indicated that the 315-bp fragment contained an intestine-specific enhancer, and analysis of the DNA sequence revealed putative binding sites for the tissue-specific transcription factors hepatocyte nuclear factor 3 beta, hepatocyte nuclear factor 4, and CAAT enhancer-binding protein beta. Binding of these factors to the 315-bp enhancer was demonstrated in gel retardation experiments. Transfection of deletion mutants of the 315-bp enhancer revealed the relative contributions of these transcription factors in the activity of the apoB intestinal enhancer. The corresponding segment of the mouse apoB gene (located -40 to -83 kb 5' of the structural gene) exhibited a high degree of sequence conservation in the binding sites for the key transcriptional activators and also exhibited enhancer activity in transient transfection assays with CaCo-2 cells. In transgenic mouse expression studies, the 315-bp enhancer conferred intestinal expression to human apoB transgenes.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Stanford Univ, Dept Med, Div Gastroenterol, Stanford, CA 94303 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Palo Alto Medical Foundation Research Institute; Stanford University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Young, SG (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.			Antes, Travis/0000-0002-2294-8797; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHEN SH, 1990, J BIOL CHEM, V265, P6811; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fraser P, 1998, Curr Opin Hematol, V5, P139; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LEVYWILSON B, 1992, J BIOL CHEM, V267, P18735; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; MCCORMICK SPA, 1997, TRANSGENIC ANIMALS G, P273; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Namciu SJ, 1998, MOL CELL BIOL, V18, P2382, DOI 10.1128/MCB.18.4.2382; Nielsen LB, 1998, J BIOL CHEM, V273, P21800, DOI 10.1074/jbc.273.34.21800; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; Oesterreicher TJ, 1998, BIOCHEM J, V330, P1165; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU GD, 1994, J BIOL CHEM, V269, P17080; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	49	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26637	26648		10.1074/jbc.M003025200	http://dx.doi.org/10.1074/jbc.M003025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859308	hybrid			2022-12-27	WOS:000088999700103
J	Hatai, T; Matsuzawa, A; Inoshita, S; Mochida, Y; Kuroda, T; Sakamaki, K; Kuida, K; Yonehara, S; Ichijo, H; Takeda, K				Hatai, T; Matsuzawa, A; Inoshita, S; Mochida, Y; Kuroda, T; Sakamaki, K; Kuida, K; Yonehara, S; Ichijo, H; Takeda, K			Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; PROTEIN-KINASE; TRANSDUCTION PATHWAYS; MICE LACKING; MAP KINASES; SURVIVAL; FAMILY; BCL-2; CASCADE	ASK1 activates JNK and p38 mitogen-activated protein kinases and constitutes a pivotal signaling pathway in cytokine- and stress-induced apoptosis. However, little is known about the mechanism of how ASK1 executes apoptosis. Here we investigated the roles of caspases and mitochondria in ASK1-induced apoptosis. We found that benzyloxycarbonyl-vaI-Ala-Asp-fluoromethyl ketone (zVAD-fmk), a broad-spectrum caspase inhibitor, mostly inhibited ASK1-induced cell death, suggesting that caspases are required for ASK1-induced apoptosis. Overexpression of ASK1 Delta N, a constitutively active mutant of ASK1, induced cytochrome c release from mitochondria and activation of caspase-9 and caspase-3 but not of caspase 8-like proteases. Consistently, caspase-8-deficient (Casp8 (-/-)) cells were sensitive to ASK1-induced caspase-3 activation and apoptosis, suggesting that caspase-8 is dispensable for ASK1-induced apoptosis, whereas ASK1 failed to activate caspase-3 in caspase-9-dificient (Casp9 (-/-)) cells. Moreover, mitochondrial cytochrome c release, which was not inhibited by zVAD-fmk, preceded the onset of caspase-3 activation and cell death induced by ASK1. ASK1 thus appears to execute apoptosis mainly by the mitochondria-dependent caspase activation.	Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signaling,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Reconstruct & Funct, Div Maxillofacial & Neck Reconstruct,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Regulat Internal Environm & Reprod, Div System Organ Regulat,Bunkyo Ku, Tokyo 1138549, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Vertex Pharmaceut, Cambridge, MA 02139 USA; Kissei Pharmaceut Co Ltd, Cent Res Labs, Nagano 3998304, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University; Vertex Pharmaceuticals; Kissei Pharmaceutical Co Ltd	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signaling,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		Matsuzawa, Atsushi/GLU-1387-2022	Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Matsuzawa, Atsushi/0000-0001-8303-3905; Takeda, Kohsuke/0000-0002-8359-8399; Sakamaki, Kazuhiro/0000-0002-7072-9628				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHRISTINE TR, 1999, NAT CELL BIOL, V1, P69; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Faris M, 1998, J IMMUNOL, V160, P134; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHENG TS, 2000, IN PRESS NAT MED; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	282	299	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26576	26581		10.1074/jbc.M003412200	http://dx.doi.org/10.1074/jbc.M003412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849426	hybrid			2022-12-27	WOS:000088999700095
J	Klemperer, N; Zhang, D; Skangalis, M; O'Donnell, M				Klemperer, N; Zhang, D; Skangalis, M; O'Donnell, M			Cross-utilization of the beta sliding clamp by replicative polymerases of evolutionary divergent organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; DNA-POLYMERASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; STAPHYLOCOCCUS-AUREUS; STRUCTURAL GENE; LAGGING-STRAND; HOLOENZYME; SUBUNIT; PURIFICATION	Chromosomal replicases are multiprotein machines comprised of a DNA polymerase, a sliding clamp, and a clamp loader. This study examines replicase components for their ability to be switched between Grampositive and Gram-negative organisms. These two cell types diverged over 1 billion years ago, and their sequences have diverged widely. Yet the Escherichia coli beta clamp binds directly to Staphylococcus aureus PolC and makes it highly processive, confirming and extending earlier results (Low, R, L,, Rashbaum, S, A., and Cozzarelli, N, R, (1976) J, Biol, Chem, 251, 1311-1325), We have also examined the S. aureus beta clamp. The results show that it functions with S, aureus PolC, but not with E, coli polymerase III core, PolC is a rather potent polymerase by itself and can extend a primer with an intrinsic speed of 80-120 nucleotides per s, Both E, coli beta and S, aureus beta converted PolC to a highly processive polymerase, but surprisingly, beta also increased the intrinsic rate of DNA synthesis to 240-580 nucleotides per s, This finding expands the scope of beta function beyond a simple mechanical tether for processivity to include that of an effector that increases the intrinsic rate of nucleotide incorporation by the polymerase.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1995, MOL GEN GENET, V246, P680, DOI 10.1007/BF00290713; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; BARNES MH, 1994, MOL MICROBIOL, V13, P843, DOI 10.1111/j.1365-2958.1994.tb00476.x; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; COZZARELLI NR, 1973, BIOCHEM BIOPH RES CO, V51, P151, DOI 10.1016/0006-291X(73)90521-4; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; GASS KB, 1973, P NATL ACAD SCI USA, V70, P103, DOI 10.1073/pnas.70.1.103; GASS KB, 1973, J BIOL CHEM, V248, P7688; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEE SH, 1991, J BIOL CHEM, V266, P594; LOW RL, 1974, P NATL ACAD SCI USA, V71, P2973, DOI 10.1073/pnas.71.8.2973; LOW RL, 1976, J BIOL CHEM, V251, P1311; MACKENZIE JM, 1973, P NATL ACAD SCI USA, V70, P512, DOI 10.1073/pnas.70.2.512; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PACITTI DF, 1995, GENE, V165, P51, DOI 10.1016/0378-1119(95)00377-I; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421	42	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26136	26143		10.1074/jbc.M002566200	http://dx.doi.org/10.1074/jbc.M002566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851235	hybrid			2022-12-27	WOS:000088999700036
J	Lukyanov, KA; Fradkov, AF; Gurskaya, NG; Matz, MV; Labas, YA; Savitsky, AP; Markelov, ML; Zaraisky, AG; Zhao, XN; Fang, Y; Tan, WY; Lukyanov, SA				Lukyanov, KA; Fradkov, AF; Gurskaya, NG; Matz, MV; Labas, YA; Savitsky, AP; Markelov, ML; Zaraisky, AG; Zhao, XN; Fang, Y; Tan, WY; Lukyanov, SA			Natural animal coloration can be determined by a nonfluorescent green fluorescent protein homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								It is generally accepted that the colors displayed by living organisms are determined by low molecular weight pigments or chromoproteins that require a prosthetic group. The exception to this rule is green fluorescent protein (GFP) from Aequorea victoria that forms a fluorophore by self-catalyzed protein backbone modification. Here we found a naturally nonfluorescent homolog of GFP to determine strong purple coloration of tentacles in the sea anemone Anemonia sulcata, Under certain conditions, this novel chromoprotein produces a trace amount of red fluorescence (emission lambda(max) = 595 nm), The fluorescence demonstrates unique behavior: its intensity increases in the presence of green light but is inhibited by blue light. The quantum yield of fluorescence can be enhanced dramatically by single amino acid replacement, which probably restores the ancestral fluorescent state of the protein. Other fluorescent Variants of the novel protein have emission peaks that are red-shifted up to 610 nm, They demonstrate that long wavelength fluorescence is attainable in GFP-like fluorescent proteins.	Russian Acad Sci, Shemiakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia; Russian Acad Sci, Inst Biochem, Moscow 117071, Russia; Russian Acad Sci, Inst Ecol & Evolut, Moscow 117071, Russia; Clontech Labs Inc, Palo Alto, CA 94303 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Research Center of Biotechnology RAS; Russian Academy of Sciences; Russian Academy of Sciences	Lukyanov, SA (corresponding author), Russian Acad Sci, Shemiakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117871, Russia.		Gurskaya, Nadya G/Q-1750-2016; Matz, Mikhail V/K-4392-2017; Savitsky, Alexander P/O-9799-2015; Zaraisky, Andrey G/Q-2323-2016; Lukyanov, Sergey/F-9140-2014; Lukyanov, Sergey/HIU-0305-2022; Lukyanov, Konstantin A/D-4030-2013	Gurskaya, Nadya G/0000-0002-8028-8176; Matz, Mikhail V/0000-0001-5453-9819; Savitsky, Alexander P/0000-0002-6820-2341; Zaraisky, Andrey G/0000-0003-4681-8169; Lukyanov, Konstantin A/0000-0001-9845-2088				BLANQUET RS, 1987, MAR BIOL, V94, P423, DOI 10.1007/BF00428249; CHAFLIE M, 1994, SCIENCE, V263, P802; Cheesman D. F., 1967, Biological Reviews, V42, P132; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Dove SG, 1995, BIOL BULL, V189, P288, DOI 10.2307/1542146; Fox DL, 1944, BIOL REV CAMB PHILOS, V19, P121, DOI 10.1111/j.1469-185X.1944.tb00307.x; HERRING PJ, 1972, NATURE, V205, P103; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON FH, 1962, J CELL COMPAR PHYSL, V60, P85, DOI 10.1002/jcp.1030600111; Kendall JM, 1998, TRENDS BIOTECHNOL, V16, P216, DOI 10.1016/S0167-7799(98)01184-6; LEBOEUF RD, 1981, COMP BIOCHEM PHYS B, V68, P25, DOI 10.1016/0305-0491(81)90175-9; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; WEST HH, 1979, COMP BIOCHEM PHYS B, V64, P195, DOI 10.1016/0305-0491(79)90160-3; WICKSTEN MK, 1989, B MAR SCI, V45, P519; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	18	259	292	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25879	25882		10.1074/jbc.C000338200	http://dx.doi.org/10.1074/jbc.C000338200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852900	hybrid			2022-12-27	WOS:000088999700001
J	Lyngso, C; Bouteiller, G; Damgaard, CK; Ryom, D; Sanchez-Munoz, S; Norby, PL; Bonven, BJ; Jorgensen, P				Lyngso, C; Bouteiller, G; Damgaard, CK; Ryom, D; Sanchez-Munoz, S; Norby, PL; Bonven, BJ; Jorgensen, P			Interaction between the transcription factor SPBP and the positive cofactor RNF4 - An interplay between protein binding zinc fingers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; RING-FINGER; AP-1 TRANSCRIPTION; GENE-TRANSCRIPTION; REPRESSOR DOMAIN; CELL-CYCLE; YEAST; EXPRESSION; IDENTIFICATION; CLONING	The activator of stromelysin 1 gene transcription, SPBP, interacts with the RING finger protein RNF4. Both proteins are ubiquitously expressed and localized in the nucleus. RNF4 facilitates accumulation of specific SPBP-DNA complexes in vitro and acts as a positive cofactor in SPBP-mediated transactivation. SPBP harbors an internal zinc finger of the PHD/LAP type. This domain can form intra-chain protein-protein contacts in SPBP resulting in negative modulation of SPBP-RNF4 interaction.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Bonven, BJ (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle 130, DK-8000 Aarhus C, Denmark.	bjb@mbio.aau.dk	Damgaard, Christian/AAR-4075-2020; Damgaard, Christian K/G-7360-2015	Damgaard, Christian/0000-0003-4940-0868				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gstaiger M, 1996, TRENDS GENET, V12, P393, DOI 10.1016/S0168-9525(96)90096-7; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IMAI Y, 1995, MOL BRAIN RES, V31, P1, DOI 10.1016/0169-328X(95)00020-S; James P, 1996, GENETICS, V144, P1425; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; LI FQ, 1994, MOL CELL BIOL, V14, P3013, DOI 10.1128/MCB.14.5.3013; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Lium EK, 1997, J VIROL, V71, P8602, DOI 10.1128/JVI.71.11.8602-8614.1997; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; O'Rourke D, 1998, J GEN VIROL, V79, P537, DOI 10.1099/0022-1317-79-3-537; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; PALLISGAARD N, 1990, ADV AP BIOT, V7, P87; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Prikhodko EA, 1998, J VIROL, V72, P684; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SANZ L, 1995, MOL CELL BIOL, V15, P3164; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONBAUR E, 1996, EMBO J, V15, P110; WASSERMAN RA, 1993, CANCER RES, V53, P3591	47	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26144	26149		10.1074/jbc.M003405200	http://dx.doi.org/10.1074/jbc.M003405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849425	hybrid			2022-12-27	WOS:000088999700037
J	Ireton, GC; Stewart, L; Parker, LH; Champoux, JJ				Ireton, GC; Stewart, L; Parker, LH; Champoux, JJ			Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CLEAVABLE COMPLEXES; CATALYTIC ACTIVITY; REPLICATION FORKS; EUKARYOTIC TOPOISOMERASE; DRUG CAMPTOTHECIN; MAMMALIAN-CELLS; NUCLEIC-ACID; PROTEIN; IDENTIFICATION; YEAST	Human topoisomerase I is a 765-residue protein composed of four major domains as follows: the unconserved and highly charged NH2-terminal domain, a conserved core domain, the positively charged linker region, and the highly conserved COOH-terminal domain containing the active site tyrosine, Previous studies of the domain structure revealed that near full topoisomerase I activity can be reconstituted in vitro by fragment complementation between recombinant polypeptides approximating the core and COOH-terminal domains. Here we demonstrate that deletion of linker residues Asp(660) to Lys(688) yields an active enzyme (topo70 Delta L) that purifies as both a monomer and a dimer, The dimer is shown to result from domain swapping involving the COOH-terminal and core domains of the two subunits, The monomeric form is insensitive to the anti-tumor agent camptothecin and distributive during in vitro plasmid relaxation assays, whereas the dimeric form is camptothecin-sensitive and processive. However, the addition of camptothecin to enzyme/DNA mixtures causes enhancement of SDS-induced breakage by both monomeric and dimeric forms of the mutant enzyme. The similarity of the dimeric form to the wild type enzyme suggests that some structural feature of the dimer is providing a surrogate linker. Yeast cells expressing topo70 Delta L were found to be insensitive to camptothecin.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NIGMS NIH HHS [T32-GM07207, GM49156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON HT, 1973, BIOCHEM BIOPH RES CO, V50, P1048; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENEDETTI P, 1993, CANCER RES, V53, P4343; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Caron P R, 1994, Adv Pharmacol, V29B, P271; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; COVEY JM, 1989, CANCER RES, V49, P5016; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG WK, 1988, MOL PHARMACOL, V34, P755; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN SM, 1995, NAT STRUCT BIOL, V2, P746, DOI 10.1038/nsb0995-746; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HORWITZ SB, 1973, CANCER RES, V33, P2834; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HSIANG YH, 1989, CANCER RES, V49, P4385; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LH, 1972, CANCER RES, V32, P2643; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1994, DNA TOPOISOMERASES A, V29; MADDEN KR, 1992, CANCER RES, V52, P525; MATTERN MR, 1987, CANCER RES, V47, P1793; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; MCLELLAN T, 1982, ANAL BIOCHEM, V126, P94, DOI 10.1016/0003-2697(82)90113-0; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RUBIN E, 1994, J BIOL CHEM, V269, P2433; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SHIN CG, 1990, BIOCHEMISTRY-US, V29, P10934, DOI 10.1021/bi00501a011; SHIN CG, 1990, BIOCHEM BIOPH RES CO, V168, P135, DOI 10.1016/0006-291X(90)91684-K; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; THRASH C, 1984, J BIOL CHEM, V259, P1375; TSAO YP, 1993, CANCER RES, V53, P5908; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	60	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25820	25830		10.1074/jbc.M002144200	http://dx.doi.org/10.1074/jbc.M002144200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827183	hybrid			2022-12-27	WOS:000088849400100
J	Schroeder, F; Frolov, A; Starodub, O; Atshaves, BB; Russell, W; Petrescu, A; Huang, H; Gallegos, AM; McIntosh, A; Tahotna, D; Russell, DH; Billheimer, JT; Baum, CL; Kier, AB				Schroeder, F; Frolov, A; Starodub, O; Atshaves, BB; Russell, W; Petrescu, A; Huang, H; Gallegos, AM; McIntosh, A; Tahotna, D; Russell, DH; Billheimer, JT; Baum, CL; Kier, AB			Pro-sterol carrier protein-2 - Role of the N-terminal presequence in structure, function, and peroxisomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; L-CELL FIBROBLASTS; ACYL-COENZYME-A; FATTY-ACID; RAT-LIVER; INTRACELLULAR TRAFFICKING; MEMBRANE INTERACTION; MAMMALIAN-CELLS; BOVINE LIVER; CHOLESTEROL	Although the 20-amino acid presequence present in 15-kDa pro-sterol carrier protein-2 (pro-SCP-2, the precursor of the mature 13-kDa SCP-2) alters the function of SCP-2 in lipid metabolism, the molecular basis for this effect is unresolved. The presequence dramatically altered SCP-2 structure as determined by circular dichroism, mass spectroscopy, and antibody accessibility such that pro-SCP-2 had 3-fold less alpha-helix, 7-fold more p-structure, 6-fold more reactive C terminus to carboxypeptidase A, 2-fold less binding of anti-SCP-2, and did not enhance sterol transfer from plasma membranes. These differences were not due to protein stability since (i) the same concentration of guanidine hydrochloride was required for 50% unfolding, and (ii) the ligand binding sites displayed the same high affinity (nanomolar K-d values) in the order: cholesterol much greater than straight chain fatty acid > kinked chain fatty acid. Laser scanning confocal microscopy and double immunofluorescence demonstrated that pro-SCP-2 was more efficiently targeted to peroxisomes. Transfection of L-cells or McAR7777 hepatoma cells with cDNA encoding pro-SCP-2 resulted in 45% and 59% of SCP-2, respectively, colocalizing with the peroxisomal marker PMP70. In contrast, L-cells transfected with cDNA encoding SCP-2 exhibited 3-fold lower colocalization of SCP-2 with PMP70. In summary, the data suggest for the first time that the 20-amino acid presequence of pro-SCP-2 alters SCP-2 structure to facilitate peroxisomal targeting mediated by the C-terminal SKL peroxisomal targeting sequence.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Dupont Merck Pharmaceut Co, Cardiovasc Dept, Wilmington, DE 19898 USA; Univ Chicago, Dept Med, Clin Nutr Res Unit, Chicago, IL 60637 USA; Univ Chicago, Gastroenterol Sect, Chicago, IL 60637 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; DuPont; University of Chicago; University of Chicago	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu	Russell, David H/C-3618-2015	Russell, David H/0000-0003-0830-3914	NIDDK NIH HHS [DK41402] Funding Source: Medline; NIEHS NIH HHS [P30-ES0916] Funding Source: Medline; NIGMS NIH HHS [GM 31561] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atshaves BP, 1999, J LIPID RES, V40, P610; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Ferdinandusse S, 2000, J LIPID RES, V41, P336; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Jatzke C, 1999, BBA-PROTEIN STRUCT M, V1432, P265, DOI 10.1016/S0167-4838(99)00114-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; JOHNSON WJ, 1994, J LIPID RES, V35, P563; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; King SM, 1999, PROTEINS, V35, P313, DOI 10.1002/(SICI)1097-0134(19990515)35:3<313::AID-PROT5>3.3.CO;2-T; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; McArthur MJ, 1999, J LIPID RES, V40, P1371; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Murphy EJ, 2000, J LIPID RES, V41, P788; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; Ossendorp BC, 1996, ARCH BIOCHEM BIOPHYS, V334, P251, DOI 10.1006/abbi.1996.0453; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; Pu LX, 1998, PROTEIN EXPRES PURIF, V13, P337, DOI 10.1006/prep.1998.0908; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; STARODUB O, 2000, IN PRESS AM J PHYSL; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; VANDERKRIFT TP, 1985, BIOCHIM BIOPHYS ACTA, V812, P387, DOI 10.1016/0005-2736(85)90313-X; VANHEUSDEN GPH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P315, DOI 10.1016/0005-2760(90)90247-U; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WESTERMAN J, 1985, BIOCHEM BIOPH RES CO, V127, P333, DOI 10.1016/S0006-291X(85)80163-7; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	49	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25547	25555		10.1074/jbc.M000431200	http://dx.doi.org/10.1074/jbc.M000431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833510	hybrid			2022-12-27	WOS:000088849400067
J	Bann, JG; Bachinger, HP				Bann, JG; Bachinger, HP			Glycosylation/hydroxylation-induced stabilization of the collagen triple helix - 4-trans-hydroxyproline in the Xaa position can stabilize the triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMOC AMINO-ACIDS; THERMAL-STABILITY; CUTICLE COLLAGEN; SEQUENCE; PEPTIDE; GLYCOPEPTIDES; WATER	We have shown recently that glycosylation of threonine in the peptide Ac-(Gly-Pro-Thr)(10)-NH2 with beta-D-galactose induces the formation of a collagen triple helix, whereas the nonglycosylated peptide does not. In this report, we present evidence that a collagen triple helix can also be formed in the Ac-(Gly-Pro-Thr)(10)-NH2 peptide, if the proline (Pro) in the Xaa position is replaced with 4-transhydroxyproline (Hyp). Furthermore, replacement of Pro with Hyp in the sequence Ac-(Gly-Pro-Thr(beta-D-Gal))(10)-NH2 increases the T-m of the triple helix by 15.7 degrees C, It is generally believed that Hyp in the Xaa position destabilizes the triple helix because (Pro-Pro-Gly)(10) and (Pro-Hyp-Gly)(10) farm stable triple helices but the peptide (Hyp-Pro-Gly)(10) does not. Our data suggest that the destabilizing effect of Hyp relative to Pro in the Xaa position is only true in the case of (Hyp-Pro-Gly)(10), Increasing concentrations of galactose in the solvent stabilize the triple helix of Ac-(Gly-Hyp-Thr)(10)-NH2 but to a much lesser extent than that achieved by covalently linked galactose. The data explain some of the forces governing the stability of the annelid/vestimentiferan cuticle collagens.	Shriners Hosp Crippled Childrens, Dept Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Crippled Childrens, Dept Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hpb@shcc.org						ADAMS E, 1977, J BIOL CHEM, V252, P7591; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BROWN FR, 1972, J MOL BIOL, V63, P101, DOI 10.1016/0022-2836(72)90524-4; BROWN FR, 1972, J MOL BIOL, V63, P85, DOI 10.1016/0022-2836(72)90523-2; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; ELOFSSON M, 1991, TETRAHEDRON LETT, V32, P7613, DOI 10.1016/0040-4039(91)80548-K; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 2000, IN PRESS MATRIX BIOL; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GOLDSTEIN A, 1970, J BIOL CHEM, V245, P5478; HARRINGTON WILLIAM G., 1967, P513; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Kihlberg J, 1997, METHOD ENZYMOL, V289, P221; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; SHARMA YD, 1984, ANAL BIOCHEM, V141, P205, DOI 10.1016/0003-2697(84)90447-0	23	81	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24466	24469		10.1074/jbc.M003336200	http://dx.doi.org/10.1074/jbc.M003336200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827193	hybrid			2022-12-27	WOS:000088683300031
J	Raney, A; Baron, AC; Mize, GJ; Law, GL; Morris, DR				Raney, A; Baron, AC; Mize, GJ; Law, GL; Morris, DR			In vitro translation of the upstream open reading frame in the mammalian mRNA encoding S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM SYSTEM; MESSENGER-RNA; NASCENT-PEPTIDE; NEUROSPORA-CRASSA; RAT-LIVER; POLYAMINES; TERMINATION; RIBOSOME; LEADER; INITIATION	The upstream open reading frame (uORF) in the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive element that suppresses translation of the associated downstream cistron in vivo. In this paper, we provide the first direct evidence of peptide sysnthesis from the S-adenosylmethionine decarboxylase uORF using an in vitro translation system. We examine both the influence of cation concentration on peptide synthesis and the effect of altering the uORF sequence on peptide synthesis. Synthesis of wild type and altered peptides was similar at all concentrations of magnesium tested. In contrast, synthesis of the wild type peptide was more sensitive than that of altered peptides to elevated concentrations of the naturally occurring polyamines, spermidine and spermine, as well as several polyamine analogs. The sensitivity of in vitro synthesis to spermidine was influenced by both the amino acid sequence and the length of the peptide product of the uORF. Findings from the present study correlate with the effects of the uORF and polyamines on translation of a downstream cistron in vivo and support the hypothesis that polyamines and the structure of the nascent peptide create a rate-limiting step in uORF translation, perhaps through a ribosome stalling mechanism.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA39053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; Cao JH, 1996, MOL CELL BIOL, V16, P603; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GOERTZ B, 1979, BRAIN RES, V173, P125, DOI 10.1016/0006-8993(79)91100-4; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HACKETT PB, 1986, J MOL BIOL, V190, P45, DOI 10.1016/0022-2836(86)90074-4; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; HUNTER AR, 1977, EUR J BIOCHEM, V75, P149, DOI 10.1111/j.1432-1033.1977.tb11512.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; KNAPP D, 1979, HDB ANAL DERIVATIZAT, P253; LARGE PJ, 1992, FEMS MICROBIOL LETT, V88, P249, DOI 10.1111/j.1574-6968.1992.tb04991.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Marton LJ, 1987, INHIB POLYAM METABOL, P79; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MORCH MD, 1986, METHOD ENZYMOL, V118, P154; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, P212; ROGERS EJ, 1994, MOL MICROBIOL, V12, P181, DOI 10.1111/j.1365-2958.1994.tb01007.x; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; SEILER N, 1983, METHOD ENZYMOL, V94, P10; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; SPERRAZZA JM, 1981, BIOCHEMISTRY-US, V20, P5073, DOI 10.1021/bi00520a038; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TABOR H, 1964, PHARMACOL REV, V16, P245; TAKEDA Y, 1969, BIOCHEM BIOPH RES CO, V37, P917, DOI 10.1016/0006-291X(69)90218-6; Wang Z, 1997, J BIOL CHEM, V272, P255; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657	39	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24444	24450		10.1074/jbc.M003364200	http://dx.doi.org/10.1074/jbc.M003364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829027	hybrid			2022-12-27	WOS:000088683300028
J	Waldegger, S; Jentsch, TJ				Waldegger, S; Jentsch, TJ			Functional and structural analysis of ClC-K chloride channels involved in renal disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; BARTTERS-SYNDROME; RAT-KIDNEY; CA2+-SENSING RECEPTOR; PLASMA-MEMBRANE; DENTS-DISEASE; MUTATIONS; MYOTONIA; DOMINANT; LOCALIZATION	CIC-K channels belong to the CLC family of chloride channels and are predominantly expressed in the kidney. Genetic evidence suggests their involvement in transepithelial transport of chloride in distal nephron segments; ClC-K1 gene deletion leads to nephrogenic diabetes insipidus in mice, and mutations of the hClC-Kb gene cause Bartter's syndrome type III in humans. Expression of rClC-K1 in Xenopus oocytes yielded voltage-independent currents that were pH-sensitive, had a Br- > NO3- = Cl- > I- conductance sequence, and were activated by extracellular calcium. A glutamate for valine exchange at amino acid position 166 induced strong voltage dependence and altered the conductance sequence of ClC-K1. This demonstrates that rClC-K1 indeed functions as an anion channel. By contrast, we did not detect currents upon hClC-Kb expression in Xenopus oocytes. Using a chimeric approach, we defined a protein domain that, when replaced by that of rClC-K1, allowed the functional expression of a chimera consisting predominantly of hClC-Kb. Its currents were linear and were inhibited by extracellular acidification. Contrasting with rClC-K1, they displayed a Cl- > Br- > I- > NO3- conductance sequence and mere not augmented by extracellular calcium, Insertion of point mutations associated with Bartter's syndrome type III destroyed channel activity. We conclude that ClC-K proteins form constitutively open chloride channels with distinct physiological characteristics.	Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Waldegger, S (corresponding author), Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, Martinistr 85, D-20246 Hamburg, Germany.	siegfried.waldegger@zmnh.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553				ADACHI S, 1994, J BIOL CHEM, V269, P17677; Asplin JR, 1996, AM J PHYSIOL-RENAL, V270, pF604, DOI 10.1152/ajprenal.1996.270.4.F604; Brown EM, 1995, J AM SOC NEPHROL, V6, P1530; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GUINAMARD R, 1995, J PHYSIOL-LONDON, V485, P97, DOI 10.1113/jphysiol.1995.sp020715; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hebert SC, 1997, J EXP BIOL, V200, P295; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KONDO Y, 1988, AM J PHYSIOL, V254, pF232, DOI 10.1152/ajprenal.1988.254.2.F232; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Ludewig U, 1997, J GEN PHYSIOL, V110, P165, DOI 10.1085/jgp.110.2.165; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; Maulet Y, 1999, BIOCHEM J, V340, P737, DOI 10.1042/bj3400737; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; PAULAIS M, 1990, J MEMBRANE BIOL, V113, P253, DOI 10.1007/BF01870076; Ponting CP, 1997, J MOL MED-JMM, V75, P160; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; Vandewalle A, 1997, AM J PHYSIOL-RENAL, V272, pF678, DOI 10.1152/ajprenal.1997.272.5.F678; Winters CJ, 1999, KIDNEY INT, V55, P1444, DOI 10.1046/j.1523-1755.1999.00401.x; Winters CJ, 1997, AM J PHYSIOL-RENAL, V273, pF1030, DOI 10.1152/ajprenal.1997.273.6.F1030; Zhang J, 2000, J BIOL CHEM, V275, P2999, DOI 10.1074/jbc.275.4.2999; ZIMNIAK L, 1995, KIDNEY INT, V48, P1828, DOI 10.1038/ki.1995.481	42	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24527	24533		10.1074/jbc.M001987200	http://dx.doi.org/10.1074/jbc.M001987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831588	hybrid			2022-12-27	WOS:000088683300040
J	Kim, FJ; Seiliez, I; Denesvre, C; Lavillette, D; Cosset, FL; Sitbon, M				Kim, FJ; Seiliez, I; Denesvre, C; Lavillette, D; Cosset, FL; Sitbon, M			Definition of an amino-terminal domain of the human T-cell leukemia virus type 1 envelope surface unit that extends the fusogenic range of an ecotropic murine leukemia virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS RECEPTOR; ACID TRANSPORTER; SU GLYCOPROTEIN; MOLECULAR CLONE; PROTEIN; FUSION; GENE; ABILITIES; REGIONS; VIRIONS	Murine leukemia viruses (MuLV) and human T-cell leukemia viruses (HTLV) are phylogenetically highly divergent retroviruses with distinct envelope fusion properties. The MuLV envelope glycoprotein surface unit (SU) comprises a receptor-binding domain followed by a proline-rich region which modulates envelope conformational changes and fusogenicity. in contrast, the receptor-binding domain and SU organization of HTLV are undefined. Here, we describe an HTLV/MuLV envelope chimera in which the receptor-binding domain and proline-rich region of the ecotropic MuLV were replaced with the potentially corresponding domains of the HTLV-1 SU. This chimeric HTLV/MuLV envelope was processed, specifically interfered with HTLV-1 envelope-mediated fusion, and similar to MuLV envelopes, required cleavage of its cytoplasmic tail to exert significant fusogenic properties. Furthermore, the HTLV domain defined here broadened ecotropic MuLV envelope-induced fusion to human and simian cell lines.	Inst Genet Mol Montpellier, CNRS, UMR5535, IFR24, F-34293 Montpellier 5, France; Univ Montpellier 2, F-34293 Montpellier 05, France; Ecole Normale Super Lyon, LVRTG, INSERM, U412, F-69367 Lyon 07, France; Inst Cochin Genet Mol, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Sitbon, M (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR5535, IFR24, 1919 Rte Mende, F-34293 Montpellier 5, France.	sitbon@jones.igm.cnrs-mop.fr	Sitbon, Marc/A-6771-2010; Cosset, François-Loïc/M-5862-2019	Sitbon, Marc/0000-0003-3616-2338; Cosset, François-Loïc/0000-0001-8842-3726; Lavillette, Dimitri/0000-0002-4706-1519				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ANDERSEN KB, 1994, J VIROL, V68, P3175, DOI 10.1128/JVI.68.5.3175-3182.1994; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; DELAMARRE L, 1994, J VIROL, V68, P3544, DOI 10.1128/JVI.68.6.3544-3549.1994; Delamarre L, 1997, J VIROL, V71, P259, DOI 10.1128/JVI.71.1.259-266.1997; DENESVRE C, 1995, J VIROL, V69, P4149, DOI 10.1128/JVI.69.7.4149-4157.1995; Denesvre C, 1996, J VIROL, V70, P4380, DOI 10.1128/JVI.70.7.4380-4386.1996; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LANDER MR, 1984, J VIROL, V52, P695, DOI 10.1128/JVI.52.2.695-698.1984; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; PALKER TJ, 1989, J IMMUNOL, V142, P971; PIQUE C, 1990, EMBO J, V9, P4243, DOI 10.1002/j.1460-2075.1990.tb07872.x; RAGHEB JA, 1994, J VIROL, V68, P3220, DOI 10.1128/JVI.68.5.3220-3231.1994; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; REIN A, 1994, J VIROL, V68, P1773, DOI 10.1128/JVI.68.3.1773-1781.1994; SITBON M, 1991, P NATL ACAD SCI USA, V88, P5932, DOI 10.1073/pnas.88.13.5932; Sutton RE, 1996, J VIROL, V70, P7322, DOI 10.1128/JVI.70.10.7322-7326.1996; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEI CM, 1981, J VIROL, V39, P935, DOI 10.1128/JVI.39.3.935-944.1981; ZHAO TM, 1995, J VIROL, V69, P2024, DOI 10.1128/JVI.69.4.2024-2030.1995	27	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23417	23420		10.1074/jbc.C901002199	http://dx.doi.org/10.1074/jbc.C901002199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10851227	hybrid, Green Published			2022-12-27	WOS:000088564200003
J	Cunningham, O; Dunne, A; Sabido, P; Lightner, D; Mantle, TJ				Cunningham, O; Dunne, A; Sabido, P; Lightner, D; Mantle, TJ			Studies on the specificity of the tetrapyrrole substrate for human biliverdin-IX alpha reductase and biliverdin-IX beta reductase - Structure-activity relationships define models for both active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESOBILIRUBIN-XIII-ALPHA; FLAVIN REDUCTASE; BILIRUBIN ANALOGS; LEISHMANIA-MAJOR; HEME OXYGENASE; BILE-PIGMENTS; C57BL/6 MICE; IFN-GAMMA; CELLS; STEREOCHEMISTRY	comparison of the initial rate kinetics for human biliverdin-IX alpha reductase and biliverdin-IX beta reductase with a series of synthetic biliverdins with propionate side chains "moving" from a bridging position across the central methene bridge (alpha isomers) to a "gamma-configuration" reveals characteristic behavior that allows us to propose distinct models for the two active sites. For human biliverdin-IX alpha reductase, as previously discussed for the rat and ox enzymes, it appears that at least one "bridging propionate" is necessary for optimal binding and catalytic activity, whereas two are preferred. All other configurations studied were substrates for human biliverdin-IX alpha reductase, albeit poor ones. In the case of mesobiliverdin-XIIII alpha, extending the propionate side chains to hexanoate resulted in a significant loss of activity, whereas the butyrate derivative retained high activity. For human biliverdin-IX alpha reductase, we suggest that a pair of positively charged side chains play a key role in optimally binding the IX alpha isomers. In the case of human biliverdin-IX beta reductase, the enzyme cannot tolerate even one propionate in the bridging position, suggesting that two negatively charged residues on the enzyme surface may preclude productive binding in this case. The flavin reductase activity of biliverdin-IX beta reductase is potently inhibited by mesobiliverdin-XIII alpha and protohemin, which is consistent with the hypothesis that the tetrapyrrole and flavin substrate bind at a common site.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Nevada, Dept Chem, Reno, NV 89557 USA; Univ Nevada, Dept Biochem, Reno, NV 89557 USA	Trinity College Dublin; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Dunne, A (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.			dunne, aisling/0000-0002-2342-9518				Boiadjiev SE, 1998, J ORG CHEM, V63, P6220, DOI 10.1021/jo980740e; Boiadjiev SE, 1997, TETRAHEDRON, V53, P14547, DOI 10.1016/S0040-4020(97)01066-1; BOIADJIEV SE, 1995, TETRAHEDRON, V51, P10663, DOI 10.1016/0040-4020(95)00658-U; Chuniaud L, 1996, CLIN CHIM ACTA, V256, P103, DOI 10.1016/S0009-8981(96)06407-8; COLLERAN E, 1977, DEP HLTH ED WELFARE; Cunningham O, 2000, BIOCHEM J, V345, P393, DOI 10.1042/0264-6021:3450393; CUNNINGHAM O, 1997, BIOCH SOC T S, V25, P613; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Ennis O, 1997, BIOCHEM J, V328, P33, DOI 10.1042/bj3280033; HEALTPAGLIUSO S, 1998, BIOCHEMISTRY-US, V37, P11508; HOLMES DL, 1995, J HETEROCYCLIC CHEM, V32, P113, DOI 10.1002/jhet.5570320120; Hunt SC, 1996, ARTERIOSCL THROM VAS, V16, P912, DOI 10.1161/01.ATV.16.8.912; IGARASHI T, 1991, J BIOCHEM-TOKYO, V109, P3, DOI 10.1093/oxfordjournals.jbchem.a123346; Kar AK, 1998, TETRAHEDRON-ASYMMETR, V9, P3863, DOI 10.1016/S0957-4166(98)00400-5; KAR AK, 1998, THESIS U NEVADA RENO; Krishnan L, 1996, J IMMUNOL, V156, P644; Krishnan L, 1996, J IMMUNOL, V156, P653; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MORI H, 1991, JPN J CANCER RES, V82, P755, DOI 10.1111/j.1349-7006.1991.tb02698.x; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; Ocarra P., 1970, BIOCHEM J, V119, p42P; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; PHILLIPS O, 1981, Biochemical Society Transactions, V9, P275; PHILLIPS O, 1981, THESIS U DUBLIN TRIN; Pitkanen OM, 1998, ANN MED, V30, P134, DOI 10.3109/07853899808999396; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; RIGNEY E, 1988, BIOCHIM BIOPHYS ACTA, V957, P237, DOI 10.1016/0167-4838(88)90278-6; RIGNEY EM, 1988, BIOCHEM J, V255, P431, DOI 10.1042/bj2550431; SABIDO PM, 1997, THESIS U NEVADA RENO; Sambrook J., 1989, MOL CLONING, pA1; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Shalloe F, 1996, BIOCHEM J, V316, P385, DOI 10.1042/bj3160385; SHROUT DP, 1992, SYNTHESIS-STUTTGART, P328; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; STOKER R, 1987, SCIENCE, V235, P1043; STOKER R, 1987, P NATL ACAD SCI USA, V84, P5918; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; TRULL FR, 1987, J HETEROCYCLIC CHEM, V24, P1573, DOI 10.1002/jhet.5570240614; WALKER PC, 1987, CLIN PHARMACOKINET, V13, P26, DOI 10.2165/00003088-198713010-00002; XU F, 1992, P NATL ACAD SCI USA, V89, P2130, DOI 10.1073/pnas.89.6.2130; XU F, 1993, BIOCHEM BIOPH RES CO, V193, P434, DOI 10.1006/bbrc.1993.1642; YAMAGUCHI T, 1994, J BIOL CHEM, V269, P24343; YAMAGUCHI T, 1995, EUR J BIOCHEM, V233, P467, DOI 10.1111/j.1432-1033.1995.467_2.x; YUBISUI T, 1979, J BIOCHEM, V85, P719	48	25	26	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19009	19017		10.1074/jbc.275.25.19009	http://dx.doi.org/10.1074/jbc.275.25.19009			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858451	hybrid			2022-12-27	WOS:000087815900053
J	Lankiewicz, S; Luetjens, CM; Bui, NT; Krohn, AJ; Poppe, M; Cole, GM; Saido, TC; Prehn, JHM				Lankiewicz, S; Luetjens, CM; Bui, NT; Krohn, AJ; Poppe, M; Cole, GM; Saido, TC; Prehn, JHM			Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; RAT HIPPOCAMPAL-NEURONS; CYTOCHROME-C; GLUTAMATE EXCITOTOXICITY; PROTEOLYTIC CLEAVAGE; INDUCED APOPTOSIS; CORTICAL-NEURONS; NUCLEAR-CHANGES; NITRIC-OXIDE; MITOCHONDRIAL	Glutamate receptor overactivation contributes to neuron death after stroke, trauma, and epileptic seizures. Exposure of cultured rat hippocampal neurons to the selective glutamate receptor agonist N-methyl-D-aspartate (300 mu M, 5 min) or to the apoptosis-inducing protein kinase inhibitor staurosporine (300 nM) induced a delayed neuron death. In both cases, neuron death was preceded by the mitochondrial release of the pro-apoptotic factor cytochrome c. Unlike staurosporine, the N-methyl-D-aspartate-induced release of cytochrome c did not lead to significant activation of caspase-3, the main caspase involved in the execution of neuronal apoptosis. In contrast, activation of the Ca2+-activated neutral protease calpain I was readily detectable after the exposure to N-methyl-D-aspartate. In a neuronal cell-free apoptosis system, calpain I prevented the ability of cytochrome c to activate the caspase cascade by inhibiting the processing of procaspase-3 and -9 into their active subunits. In the hippocampal neuron cultures, the inhibition of calpain activity restored caspase-3-like protease activity after an exposure to N-methyl-D-aspartate. Our data demonstrate the existence of signal transduction pathways that prevent the entry of cells into a caspase-dependent cell death program after the mitochondrial release of cytochrome c.	Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany; Univ Calif Los Angeles, Sepulvda Vet Affairs Med Ctr, GRECC, Sepulveda, CA 91343 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Munster; Geriatric Research Education & Clinical Center; University of California System; University of California Los Angeles; RIKEN	Prehn, JHM (corresponding author), Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res IZKF, Rontgenstr 21, D-48149 Munster, Germany.	prehn@uni-muenster.de	Sado, Takaomi/AAN-2759-2021; Prehn, Jochen HM/A-3928-2010; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Prehn, Jochen HM/0000-0003-3479-7794; Saido, Takaomi C/0000-0003-1970-6903				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Armstrong RC, 1997, J NEUROSCI, V17, P553; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Castilho RF, 1998, J NEUROSCI, V18, P10277; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Didier M, 1996, J NEUROSCI, V16, P2238; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faddis BT, 1997, J NEUROSCI, V17, P951; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROCHEM, V68, P1612; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Llado J, 1999, J NEUROSCI, V19, P10803, DOI 10.1523/JNEUROSCI.19-24-10803.1999; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicotera P, 1997, CELL DEATH DIFFER, V4, P435, DOI 10.1038/sj.cdd.4400265; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SIMAN R, 1989, J NEUROSCI, V9, P1579; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takadera T, 1999, J NEUROCHEM, V73, P548, DOI 10.1046/j.1471-4159.1999.0730548.x; Tenneti L, 1998, J NEUROCHEM, V71, P946; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yang FS, 1998, AM J PATHOL, V152, P379; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	227	231	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17064	17071		10.1074/jbc.275.22.17064	http://dx.doi.org/10.1074/jbc.275.22.17064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828077	hybrid			2022-12-27	WOS:000087392200093
J	Xu, J; Love, LM; Singh, I; Zhang, QX; Dewald, J; Wang, DA; Fischer, DJ; Tigyi, G; Berthiaume, LG; Waggoner, DW; Brindley, DN				Xu, J; Love, LM; Singh, I; Zhang, QX; Dewald, J; Wang, DA; Fischer, DJ; Tigyi, G; Berthiaume, LG; Waggoner, DW; Brindley, DN			RETRACTED: Lipid phosphate phosphatase-1 and Ca2+ control lysophosphatidate signaling through EDG-2 receptors (Retracted Article. See vol 278, pg 38104, 2003)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							CELL-PERMEABLE CERAMIDES; SPHINGOSINE 1-PHOSPHATE; ACID PHOSPHOHYDROLASE; MOLECULAR-CLONING; DNA-SYNTHESIS; GROWTH-FACTOR; G-PROTEINS; FIBROBLASTS; IDENTIFICATION; MOBILIZATION	The serum-derived phospholipid growth factor, lysophosphatidate (LPA), activates cells through the EDG family of G protein-coupled receptors, The present study investigated mechanisms by which dephosphorylation of exogenous LPA by lipid phosphate phosphatase-1 (LPP-1) controls cell signaling. Overexpressing LPP-1 decreased the net specific cell association of LPA with Rats fibroblasts by approximately 50% at 37 degrees C when less than 10% of LPA was dephosphorylated. This attenuated cell activation as indicated by diminished responses, including cAMP, Ca2+, activation of phospholipase D and ERK, DNA synthesis, and cell division. Conversely, decreasing LPP-1 expression increased net LPA association, ERK stimulation, and DNA synthesis. Whereas changing LPP-1 expression did not alter the apparent K-d and B-max for LPA binding at 4 degrees C, increasing Ca2+ from 0 to 50 mu M increased the K-d from 40 to 900 nM. Decreasing extracellular Ca2+ from 1.8 mM to 10 mu M increased LPA binding by 20-fold, shifting the threshold for ERK activation to the nanomolar range. Hence the Ca2+ dependence of the apparent K-d values explains the long-standing discrepancy of why micromolar LPA is often needed to activate cells at physiological Ca2+ levels. In addition, the work demonstrates that LPP-1 can regulate specific LPA association with cells without significantly depleting bulk LPA concentrations in the extracellular medium. This identifies a novel mechanism for controlling EDG-2 receptor activation.	Univ Alberta, Dept Biochem, Signal Transduct Labs, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Lipid Biol Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Tennessee, Dept Physiol, Memphis, TN 38163 USA; Cell Therapeut Inc, Seattle, WA 98119 USA	University of Alberta; University of Alberta; University of Alberta; University of Tennessee System; University of Tennessee Health Science Center	Brindley, DN (corresponding author), Univ Alberta, Dept Biochem, Signal Transduct Labs, 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca		Berthiaume, Luc/0000-0003-0926-059X	NHLBI NIH HHS [HL 61459] Funding Source: Medline; PHS HHS [R01 61751] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; English D, 1997, BIOCHEM J, V324, P941, DOI 10.1042/bj3240941; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; ITO T, 1974, BIOCHIM BIOPHYS ACTA, V352, P29, DOI 10.1016/0005-2736(74)90176-X; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; JALINK K, 1990, J BIOL CHEM, V265, P12232; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NEWTON C, 1978, BIOCHIM BIOPHYS ACTA, V506, P281, DOI 10.1016/0005-2736(78)90398-X; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PERRY DK, 1993, J BIOL CHEM, V268, P25302; Picotto G, 1999, BIOCHEM J, V339, P71, DOI 10.1042/0264-6021:3390071; Rizza C, 1999, LAB INVEST, V79, P1227; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Sasagawa T, 1999, LIPIDS, V34, P17, DOI 10.1007/s11745-999-332-5; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shen Z, 1997, CLIN CHEM, V43, P577; Tabata MJ, 1996, DEVELOPMENT, V122, P1243; Tigyi G, 1996, J NEUROCHEM, V66, P537; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHIM BIOPHYS ACTA, V1125, P110, DOI 10.1016/0005-2760(92)90163-P; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yazaki T, 1996, MOL PHARMACOL, V50, P236; Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181	44	45	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27520	27530						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10849424				2022-12-27	WOS:000089197100004
J	Cheng, HL; Steinway, ML; Russell, JW; Feldman, EL				Cheng, HL; Steinway, ML; Russell, JW; Feldman, EL			GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; GTP-BINDING PROTEIN; STIMULATES TYROSINE PHOSPHORYLATION; NERVOUS-SYSTEM FUNCTION; HUMAN-MELANOMA CELLS; ACTIN CYTOSKELETON; FACTOR-BB; MOLECULAR-BIOLOGY; FACTOR RECEPTOR	Previously, we reported insulin-like growth factor-I (IGF-I) promotes motility and focal adhesion kinase (FAK) activation in neuronal cells. In the current study, we examined the role of IGF-I in Schwann cell (SC) motility. IGF-I increases SC process extension and motility. In parallel, IG;F-I activates IG;F-I receptor, insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3 (PI-3)-kinase, and FAK. LY294002, a PI-3 kinase inhibitor, blocks IGF-I-induced motility and FAK phosphorylation. The Rho family of GTPases is important in the regulation of the cytoskeleton. Overexpression of constitutively active Leu-61 Cdc42 and Val-12 Rad enhances SC motility which is unaffected by LY294002. In parallel, stable transfection of SC with dominant negative Asn-17 Rad blocks IGF-I-mediated SC motility and FAK phosphorylation, implying Pac is an upstream regulator of FAK. Collectively our results suggest that IGF-I regulates SC motility by reorganization of the actin cytoskeleton via the downstream activation of a PI-3 kinase, small GTPase, and FAK pathway.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 200 Zina Pitcher Pl,4414 Kresge 3, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [NS38849, NS01938, NS36778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001938, R01NS036778, R01NS038849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Allen WE, 1997, J CELL SCI, V110, P707; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BARKER FG, 1995, NEUROL CLIN, V13, P701, DOI 10.1016/S0733-8619(18)30014-8; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Cheng HL, 1999, ANN NY ACAD SCI, V883, P124, DOI 10.1111/j.1749-6632.1999.tb08575.x; Cheng HL, 1996, J NEUROCHEM, V66, P525; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GOLD MR, 1992, J IMMUNOL, V148, P2012; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HEPLER JE, 1990, MOL NEUROBIOL, V4, P93, DOI 10.1007/BF02935586; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; Jessen KR, 1999, TRENDS NEUROSCI, V22, P402, DOI 10.1016/S0166-2236(98)01391-5; KANAIAZUMA M, 1993, BIOL REPROD, V48, P252, DOI 10.1095/biolreprod48.2.252; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim BS, 1998, J NEUROCHEM, V71, P1333; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Meier C, 1999, J NEUROSCI, V19, P3847; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Nishida T, 1996, J CELL PHYSIOL, V169, P159, DOI 10.1002/(SICI)1097-4652(199610)169:1<159::AID-JCP16>3.0.CO;2-8; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUSSELL JW, 1994, ANN NEUROL, V36, P221, DOI 10.1002/ana.410360215; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SILLETTI S, 1991, CANCER RES, V51, P3507; Singleton JR, 1996, CANCER RES, V56, P4522; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang MH, 1996, ONCOGENE, V13, P2167; WINDEBANK AJ, 1986, J NEUROPATH EXP NEUR, V45, P683, DOI 10.1097/00005072-198611000-00006; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	60	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27197	27204						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829021				2022-12-27	WOS:000089144800071
J	del Peso, L; Gonzalez, VM; Inohara, N; Ellis, RE; Nunez, G				del Peso, L; Gonzalez, VM; Inohara, N; Ellis, RE; Nunez, G			Disruption of the CED-9 center dot CED-4 complex by EGL-1 is a critical step for programmed cell death in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; C-ELEGANS; CYTOCHROME-C; CED-3 ACTIVATION; X-L; APOPTOSIS; APAF-1; MITOCHONDRIA; BCL-X(L); ENCODES	In the nematode Caenorhabditis elegans, the apoptotic machinery is composed of four basic elements: the caspase CED-3, the Apaf-1 homologue CED-4, and the Bcl-2 family members CED-9 and EGL-1. The ced-9(n1950) gain-of-function mutation prevents most, if not all, somatic cell deaths in C. elegans. It encodes a CED-9 protein with a glycine-to-glutamate substitution at position 169, which is located within the highly conserved Bcl-2 homology 1 domain, We performed biochemical analyses with the CED-9G169E protein to gain insight into the mechanism of programmed cell death, We find that CED-9G169E retains the ability to bind both EGL-1 and CED-4, although its affinity for EGL-1 is reduced. In contrast to the behavior of wild-type CED-9, the interaction between CED-9G169E and CED-4 is not disrupted by expression of EGL-1. Furthermore, CED-4 and CED-9G169E co-localizes with EGL-1 to the mitochondria in mammalian cells, and expression of EGL-1 does not induce translocation of CED-4 to the cytosol, Finally, the ability of EGL-1 to promote apoptosis is impaired by the replacement of wild-type CED-9 with CED-9G169E, and this effect is correlated with the inability of EGL-1 to induce the displacement of CED-4 from the CED-9 CED-4 complex. These studies suggest that the release of CED-4 from the CED-9.CED-4 complex is a necessary step for induction of programmed cell death in C. elegans.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.		Gonzalez, Victor M/F-7396-2010; del Peso, Luis/K-9391-2014	Gonzalez, Victor M/0000-0001-7538-0552; del Peso, Luis/0000-0003-4014-5688	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; CHINNAIYAN A, 1997, NATURE, V388, P6644; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ottilie S, 1997, J BIOL CHEM, V272, P16955, DOI 10.1074/jbc.272.27.16955; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	38	53	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27205	27211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846174				2022-12-27	WOS:000089144800072
J	Eder, M; Stolz, M; Wallimann, T; Schlattner, U				Eder, M; Stolz, M; Wallimann, T; Schlattner, U			A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-METABOLISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUSCLE; ISOENZYMES; RESIDUES; BINDING; RESOLUTION; EXPRESSION; INHIBITION	Creatine kinase catalyzes the reversible transphosphorylation of creatine by MgATP. From the sequence homology and the molecular structure of creatine kinase isoenzymes, we have identified several highly conserved residues with a potential function in the active site: a negatively charged cluster (Glu(226), Glu(227), Asp(228)) and a serine (Ser(280)), Mutant proteins E226Q, E226L, E227Q, E227L, D228N, and S280A/S280D of human sarcomeric mitochondrial creatine kinase were generated by in vitro mutagenesis, expressed in Escherichia coli, and purified to homogeneity, Their overall structural integrity was confirmed by CD spectroscopy and gel filtration chromatography. The enzymatic activity of all proteins mutated in the negatively charged cluster was extremely low (0.002-0.4% of wild type) and showed apparent Michaelis constants (K-m) similar to wild type, suggesting that most of the residual activity may be attributed to wild-type revertants, Mutations of Ser280 led to higher residual activities and altered K-m values; S280A showed an increase of K-m for phosphocreatine (65-fold), creatine (6-fold), and ATP (6-fold); S280D showed a decrease of K-m for creatine (g-fold). These results, together with the transition state structure of the homologous arginine kinase (Zhou, G., Somasundaram, T., Blanc, E., Parthasarathy G., Ellington, W. R., and Chapman, M. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8449-8454), strongly suggest a critical role of Glu(226), Glu(227), and Asp(228) in substrate binding and catalysis and point to Glu(227) as a catalytic base.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schlattner, U (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, Honggerberg, CH-8093 Zurich, Switzerland.	schlattn@cell.biol.ethz.ch	Schlattner, Uwe/D-1267-2009; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Wallimann, Theo/0000-0003-4957-5836				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LH, 1996, BIOCHEMISTRY-US, V35, P7895, DOI 10.1021/bi952798i; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Forstner M, 1997, PROTEIN SCI, V6, P331; Forstner M, 1998, BIOPHYS J, V75, P1016, DOI 10.1016/S0006-3495(98)77590-3; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; HANSEN DE, 1981, J BIOL CHEM, V256, P5967; Kenyon GL, 1996, NATURE, V381, P281, DOI 10.1038/381281a0; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; MARCILLAT O, 1987, BIOCHIM BIOPHYS ACTA, V890, P233, DOI 10.1016/0005-2728(87)90024-7; MCLAUGHLIN AC, 1972, J BIOL CHEM, V247, P4382; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MORRISON JF, 1966, J BIOL CHEM, V241, P673; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Rao JK, 1998, FEBS LETT, V439, P133; ROSENBERGER RF, 1994, DEV BIOL STAND, V83, P21; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMERLIK MI, 1973, J BIOL CHEM, V248, P8418; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Schlattner U, 2000, J BIOL CHEM, V275, P17314, DOI 10.1074/jbc.M001919200; SCORER CA, 1991, NUCLEIC ACIDS RES, V19, P3511, DOI 10.1093/nar/19.13.3511; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; Stroud RM, 1996, NAT STRUCT BIOL, V3, P567, DOI 10.1038/nsb0796-567; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; Wood TD, 1998, P NATL ACAD SCI USA, V95, P3362, DOI 10.1073/pnas.95.7.3362; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449	37	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27094	27099						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829032				2022-12-27	WOS:000089144800058
J	Bellido, T; Huening, M; Raval-Pandya, M; Manolagas, SC; Christakos, S				Bellido, T; Huening, M; Raval-Pandya, M; Manolagas, SC; Christakos, S			Calbindin-D-28k is expressed in osteoblastic cells and suppresses their apoptosis by inhibiting caspase-3 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; GROWTH-FACTOR; CULTURED HIPPOCAMPAL; BONE-MARROW; CYTOKINES; NEURONS; ALPHA; LINES; DIFFERENTIATION; IDENTIFICATION	The rate of osteoblast apoptosis is a critical determinant of the rate of bone formation. Because the calcium-binding protein calbindin-D-28k has anti-apoptotic properties in neuronal cells and lymphocytes, we searched for the presence of this protein in osteoblastic cells and investigated whether it can modify their response to proapoptotic signals. Calbindin-D-28k was expressed at low levels in several osteoblastic cell lines and at high levels in primary cultures of murine osteoblastic cells. Transient transfection of rat calbindin-D-28k cDNA blocked tumor necrosis factor alpha (TNF alpha)-induced apoptosis in osteoblastic MC3T3-E1 cells, as determined by cell viability and nuclear morphology of cells cotransfected with the green fluorescent protein targeted to the nucleus, whereas transfection of the empty vector had no effect. Calbindin-D-28k levels in several stably transfected MC3T3-E1 lines were directly related to protection from TNF alpha-induced apoptosis, Purified rat calbindin-D-28k markedly reduced the activity of caspase-3, a critical molecule for the degradation phase of apoptosis, in a cell-free assay. In addition, cell extracts from MC3T3-E1 cells expressing high levels of calbindin-D-28k decreased caspase-3 activity, compared with extracts from vector-transfected cells. This effect was apparently unrelated to the calcium binding properties of calbindin, as chelation of calcium by EGTA or addition of other calcium-binding proteins such as calbindin-D-9k, S100, calmodulin, and osteocalcin, did not affect caspase-3 activity. Last, calbindin-D-28k interacts with the active form of caspase-3 as demonstrated by a GST pull-down assay. These results demonstrate that calbindin-D-28k is a biosynthetic product of osteoblasts with a role in the regulation of apoptosis. They also reveal that the antiapoptotic properties of calbindin-D-28k may result not only from calcium buffering but also from the ability of the protein to interact with and to inhibit caspase-3 activity, a property that is independent of its calcium binding capability.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Rutgers State University New Brunswick; Rutgers State University Medical Center	Bellido, T (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, 4301 W Markham,Mail Slot 587, Little Rock, AR 72205 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29AR43453] Funding Source: Medline; NIA NIH HHS [P01AG/AMS13918] Funding Source: Medline; NIDDK NIH HHS [DK38961] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; BERDAL A, 1993, DEV BIOL, V155, P172, DOI 10.1006/dbio.1993.1016; Berdal A, 1996, J BONE MINER RES, V11, P768; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHENG B, 1992, J NEUROSCI, V12, P1558; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; HEREMANS H, 1978, ONCOLOGY, V35, P246, DOI 10.1159/000225298; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Hughes DE, 1997, J CLIN PATHOL-MOL PA, V50, P132, DOI 10.1136/mp.50.3.132; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; IACOPINO A, 1992, MOL BRAIN RES, V13, P251, DOI 10.1016/0169-328X(92)90033-8; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Macho A, 1997, J IMMUNOL, V158, P4612; Manolagas SC, 1999, ENDOCRINOLOGY, V140, P4377, DOI 10.1210/en.140.10.4377; MANOLAGAS SC, 1980, J BIOL CHEM, V255, P4414; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MATTSON MP, 1989, J NEUROSCI, V9, P3728; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Motulsky H., 1995, INTUITIVE BIOSTATIST; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIETOBONA MP, 1995, J NEUROSCI RES, V42, P371, DOI 10.1002/jnr.490420311; PANSINI AR, 1984, J BIOL CHEM, V259, P9735; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SONNENBERG J, 1984, ENDOCRINOLOGY, V115, P640, DOI 10.1210/endo-115-2-640; STASHENKO P, 1989, IMMUNOL INVEST, V18, P239, DOI 10.3109/08820138909112240; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZIPORI D, 1985, BLOOD, V66, P447	54	114	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26328	26332		10.1074/jbc.M003600200	http://dx.doi.org/10.1074/jbc.M003600200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835428	hybrid			2022-12-27	WOS:000088999700062
J	Tanaka, K; Hiramoto, T; Fukuda, T; Miyagawa, K				Tanaka, K; Hiramoto, T; Fukuda, T; Miyagawa, K			A novel human Rad54 homologue, Rad54B, associates with Rad51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; RECOMBINATION PROTEINS; DNA-REPAIR; YEAST RAD51; GENE; SACCHAROMYCES; CONFORMATION; RESISTANCE; MUTATIONS; COMPLEX	Members of the SNF2/SWI2 family, characterized with sequence motifs similar to those found in DNA and RNA helicases, play roles in various aspects of cellular fundamental processes such as transcriptional regulation, chromosome stability, nucleotide excision repair, and recombination. We have isolated a novel member of the human SNF2/SWI2 family, RAD54B, which is highly homologous to mammalian RAD54. The RAD54 gene is a member of the RAD52 epistasis group which is involved in the recombinational repair of DNA damage, Here we demonstrate that human Rad54B (hRad54B), like human Rad54 (hRad54), associates with human Rad51 (hRad51). Both hRad54B and hRad54 associate with hRad51 through their NH2-terminal domains, but there are differences in their ways of association with hRad51. In contrast to Rad54, whose association with Rad51 is induced by ionizing radiation, Rad54B associates with Rad51 constitutively in immunoprecipitation experiments, Also, the failure to detect the interaction between hRad54B and hRad51 in the yeast two-hybrid assay suggests that their interaction, unlike that between hRad54 and hRad51, may be indirect. Immunofluorescence microscopy revealed that hRad54B formed nuclear foci that colocalized with hRad51, hRad54, and BRCA1. These findings suggest that Rad54B may be functionally distinct from Rad54, although it may play an active role in recombination processes in concert with other members of the RAD52 epistasis group.	Hiroshima Univ, Dept Mol Pathol, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Miyagawa, K (corresponding author), Hiroshima Univ, Dept Mol Pathol, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Tashiro S, 1996, ONCOGENE, V12, P2165; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	30	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26316	26321		10.1074/jbc.M910306199	http://dx.doi.org/10.1074/jbc.M910306199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851248	hybrid			2022-12-27	WOS:000088999700060
J	Wang, ZP; Juttermann, R; Soloway, PD				Wang, ZP; Juttermann, R; Soloway, PD			TIMP-2 is required for efficient activation of proMMP-2 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; HUMAN GELATINASE-A; TISSUE INHIBITOR; PROGELATINASE-A; BRANCHING MORPHOGENESIS; IV COLLAGENASE; INTRACELLULAR ACTIVATION; ENZYMATIC-PROPERTIES; BASEMENT-MEMBRANE; HUMAN-FIBROBLASTS	Matrix metalloproteinases (MMPs) are synthesized as latent proenzymes. A proteolytic cleavage event involving processing of the cysteine-rich N-terminal propeptide is required for their full activation. Previous in vitro studies indicated that activation of proMMP-2 can occur through formation of a trimolecular complex between MMP-14, TIMP-2, and proMMP-2 at the cell surface. Using TIMP-2-deficient mice and cells derived from them, TIMP-2 was shown to be required for efficient proMMP-2 activation both in vivo and in vitro. The requirement for TIMP-2 was not cell-autonomous as exogenously added TIMP-2 could restore activation of proMMP-2 to TIMP-2-deficient cells. Mutant mice were overtly normal, viable, and fertile on the C57BL/6 background, indicating that both TIMP-2 and activated proMMP-2 are dispensable for normal development.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Soloway, PD (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	psoloway@mcbio.med.buffalo.edu	Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016056, CA 16056] Funding Source: Medline; NEI NIH HHS [R01 EY011279, EY 11279, R01 EY011279-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE S, 1973, J BIOCHEM-TOKYO, V73, P897, DOI 10.1093/oxfordjournals.jbchem.a130153; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hogan B, 1994, MANIPULATING MOUSE E; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Itoh T, 1998, CANCER RES, V58, P1048; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; JUBB RW, 1980, J PATHOL, V130, P159, DOI 10.1002/path.1711300304; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MURPHY G, 1981, CLIN SCI, V61, P711, DOI 10.1042/cs0610711; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Osiewicz K, 1999, ANN NY ACAD SCI, V878, P494, DOI 10.1111/j.1749-6632.1999.tb07706.x; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Stanton H, 1998, J CELL SCI, V111, P2789; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang ZP, 1999, ANN NY ACAD SCI, V878, P519, DOI 10.1111/j.1749-6632.1999.tb07714.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	55	299	308	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26411	26415		10.1074/jbc.M001270200	http://dx.doi.org/10.1074/jbc.M001270200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827175	Green Accepted, hybrid			2022-12-27	WOS:000088999700073
J	Bae, J; Leo, CP; Hsu, SY; Hsueh, AJW				Bae, J; Leo, CP; Hsu, SY; Hsueh, AJW			MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SURVIVAL-PROMOTING PROTEINS; HUMAN FOLLICULAR LYMPHOMA; CYTOCHROME-C RELEASE; INTERACTING PROTEIN; SIGNALING PATHWAY; RAT OVARY; B-CELLS; X-L; GENE	MCL-1 (myeloid cell leukemia-1) is an antiapoptotic BCL-2 family protein discovered as an early induction gene during myeloblastic leukemia cell differentiation. This survival protein has the BCL-2 homology (BH) domains 1, a, and 3 and a C-terminal transmembrane region. We identified a short splicing variant of the MCL-1 mRNA in the human placenta encoding a protein, termed MCL-1 short (MCL-1S), with an altered C terminus as compared with the full-length MCL-1 long (MCL-1L), leading to the loss of BH1, BH2, and the transmembrane domains. Analysis of the human MCL-1 gene indicated that MCL-1S results from the splicing out of exon 2 during mRNA processing. MCL-1S, unlike MCL-1L, does not interact with diverse proapoptotic BCL-2-related proteins in the yeast two-hybrid system. In contrast, MCL-1S dimerizes with MCL-1L in the yeast assay and coprecipitates with MCL-1L in transfected mammalian cells. Overexpression of MCL-1S induces apoptosis in transfected Chinese hamster ovary cells, and the MCL-1S action was antagonized by the antiapoptotic MCL-1L. Thus, the naturally occurring MCL-1S variant represents a new proapoptotic BH3 domain-only protein capable of dimerizing with the antiapoptotic MCL-1L. The fate of MCL-1-expressing cells could be regulated through alternative splicing mechanisms and interactions of the resulting anti- and proapoptotic gene products.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.			Leo, Chandra/0000-0002-4463-3614	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031566] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-31566] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Chang BS, 1999, MOL CELL BIOL, V19, P6673; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; FANG W, 1994, J IMMUNOL, V153, P4388; Gibson L, 1996, ONCOGENE, V13, P665; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kaipia A, 1997, ENDOCRINOLOGY, V138, P5497, DOI 10.1210/en.138.12.5497; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Leo CP, 1999, ENDOCRINOLOGY, V140, P5469, DOI 10.1210/en.140.12.5469; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Moore M., 1993, RNA WORLD, P303; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	54	227	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25255	25261		10.1074/jbc.M909826199	http://dx.doi.org/10.1074/jbc.M909826199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837489	hybrid			2022-12-27	WOS:000088849400030
J	Bernal-Mizrachi, E; Wice, B; Inoue, H; Permutt, MA				Bernal-Mizrachi, E; Wice, B; Inoue, H; Permutt, MA			Activation of serum response factor in the depolarization induction of Egr-1 transcription in pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; TERNARY COMPLEX FACTORS; GROWTH FACTOR-I; C-FOS PROMOTER; PROTEIN-KINASE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; REGULATORY FACTOR; RAT ISLETS; HORMONE	The results of the current studies define the major elements whereby glucose metabolism in islet beta-cells leads to transcriptional activation of an early response gene in insulinoma cell lines and in rat islets, Glucose stimulation (2-20 mM) resulted in a 4-fold increase in Egr-1 mRNA at 30 min, as did the depolarizing agents KCl and tolbutamide. This response was inhibited by diazoxide and EGTA, indicating that beta-cell depolarization and Ca2+ influx, respectively, are essential. Pharmacological inhibition of the Egr-1 induction by H89 (48%) and calmidazolium (35%), but not by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 and 2 or phosphatidylinositol 3-kinase inhibitors, implied that protein kinase A and Ca2+/calmodulin pathways are involved. Deletion mapping of the Egr-1 promoter revealed that the proximal -198 base pairs containing two serum response elements (SREs) and one cAMP-response element retained the depolarization response. Depolarization resulted in phosphorylation of cAMP-response element-binding protein, yet partial inhibition by a dominant negative cAMP-response element-binding protein, along with a robust response of a cAMP-response element-mutated Egr-1 promoter suggested the presence of a second Ca2+-responsive element, Depolarization activation of 5XSRE-LUC and serum response factor (SRF)-GAL4 constructs, along with activation of SRF-GAL4 by co-transfection with constitutively active calmodulin kinase IV and protein kinase A, and binding of Ser(103)-phosphorylated SRF in nuclear extracts, indicated that the SRE.SRF complexes contribute to the Ca2+-mediated transcriptional regulation of Egr-1, The results of the current experiments demonstrate for the first time SRE-dependent transcription and the role of SRF, a transcription factor known to be a major component of growth responses, in glucose-mediated transcriptional regulation in insulinoma cells.	Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Bernal-Mizrachi, E (corresponding author), Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088126, R37DK016746, R01DK016746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16746, R01 DK088126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUSBEL FM, 1989, CURRENT PROTOCOLS MO; Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BRELJE TC, 1991, ENDOCRINOLOGY, V128, P45, DOI 10.1210/endo-128-1-45; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KUWADA M, 1994, MOL PHARMACOL, V46, P587; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MACK KJ, 1995, MOL BRAIN RES, V29, P140, DOI 10.1016/0169-328X(94)00243-8; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104	52	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25681	25689		10.1074/jbc.M003424200	http://dx.doi.org/10.1074/jbc.M003424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829028	hybrid			2022-12-27	WOS:000088849400083
J	Fasshauer, M; Klein, J; Ueki, K; Kriauciunas, KM; Benito, M; White, MF; Kahn, CR				Fasshauer, M; Klein, J; Ueki, K; Kriauciunas, KM; Benito, M; White, MF; Kahn, CR			Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; POTENTIAL ROLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4-CONTAINING VESICLES; PHOSPHOINOSITIDE 3-KINASE; GLYCOGEN-SYNTHESIS; GENE-TRANSFER	Insulin and insulin-like growth factor I signals are mediated via phosphorylation of a family of insulin receptor substrate (IRS) proteins, which may serve both complementary and overlapping functions in the cell. To study the metabolic effects of these proteins in more detail, we established brown adipocyte cell lines from wild type and various IRS knockout (KO) animals and characterized insulin action in these cells in vitro. Preadipocytes derived from both wild type and TRS-S KO mice could be fully differentiated into mature brown adipocytes, In differentiated IRS-2 KO adipocytes, insulin-induced glucose uptake was decreased by 50% compared with their wild type counterparts. This was the result of a decrease in insulin-stimulated Glut4 translocation to the plasma membrane. This decrease in insulin-induced glucose uptake could be partially reconstituted in these cells by retrovirus-mediated reexpression of IRS-2, but not overexpression of IRS-1, Insulin signaling studies revealed a total loss of IRS-2-associated phosphatidylinositol (PI) 3-kinase activity and a reduction in phosphotyrosine-associated PI 3-kinase by 30% (p < 0.05) in the RO cells. The phosphorylation and activity of Akt, a major downstream effector of PI 3-kinase, as well as Akt-dependent phosphorylation of glycogen synthase kinase-3 and p70S6 kinase were not affected by the lack of IRS-2; however, there was a decrease in insulin stimulation of Akt associated with the plasma membrane. These results provide evidence for a critical role of IRS-2 as a mediator of insulin-stimulated Glut4 translocation and glucose uptake in adipocytes, This occurs without effects in differentiation, total activation of Akt and its downstream effecters, but may be caused by alterations in compartmentalization of these downstream signals.	Joslin Diabet Ctr, Dept Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Med Univ Lubeck, Dept Internal Med 1, D-23538 Lubeck, Germany; Univ Complutense Madrid, Fac Farm, E-28040 Madrid, Spain	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Lubeck; Complutense University of Madrid	Kahn, CR (corresponding author), Joslin Diabet Ctr, Dept Res, 1 Joslin Pl, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021; Benito, Manuel/J-5637-2014	Kahn, Ronald/0000-0002-7583-9228; Benito, Manuel/0000-0002-7218-406X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 33201, DK 5545] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks CC, 2000, J BIOL CHEM, V275, P2029, DOI 10.1074/jbc.275.3.2029; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hunter SJ, 1998, AM J MED, V105, P331, DOI 10.1016/S0002-9343(98)00300-3; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RICE KM, 1994, BIOCHEM BIOPH RES CO, V198, P523, DOI 10.1006/bbrc.1994.1077; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	45	144	151	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25494	25501		10.1074/jbc.M004046200	http://dx.doi.org/10.1074/jbc.M004046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829031	hybrid			2022-12-27	WOS:000088849400060
J	Gohara, DW; Crotty, S; Arnold, JJ; Yoder, JD; Andino, R; Cameron, CE				Gohara, DW; Crotty, S; Arnold, JJ; Yoder, JD; Andino, R; Cameron, CE			Poliovirus RNA-dependent RNA polymerase (3D(pol)) - Structural, biochemical, and biological analysis of conserved structural motifs A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; HEPATITIS-C VIRUS; PHI-29 DNA-POLYMERASE; I KLENOW FRAGMENT; ESCHERICHIA-COLI; KINETIC-ANALYSIS; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; BINDING POCKET; HELIX CLAMP	We have constructed a structural model for poliovirus RNA-dependent RNA polymerase (3D(pol)) in complex with a primer-template (sym/sub) and ATP. Residues found in conserved structural motifs A (Asp-238) and B (Asn-297) are involved in nucleotide selection. Asp-238 appears to couple binding of nucleotides with the correct sugar configuration to catalytic efficiency at the active site of the enzyme. Asn-297 is involved in selection of ribonucleoside triphosphates over 2'-dNTPs, a role mediated most likely via a hydrogen bond between the side chain of this residue and the 2'-OH of the ribonucleoside triphosphate. Substitutions at position 238 or 297 of 3D(pol) produced derivatives exhibiting a range of catalytic efficiencies when assayed in vitro for poly(rU) polymerase activity or sym/sub elongation activity. A direct correlation existed between activity on sym/sub and biological phenotypes; a 2.5-fold reduction in polymerase elongation rate produced virus with a temperature-sensitive growth phenotype. These data permit us to propose a detailed, structural model for nucleotide selection by 3D(pol), confirm the biological relevance of the sym/sub system, and provide additional evidence for kinetic coupling between RNA synthesis and subsequent steps in the virus life cycle.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu	Crotty, Shane/AAC-6703-2019; Crotty, Shane/AAE-8446-2019	Crotty, Shane/0000-0002-6484-6262; Gohara, David/0000-0001-8799-9125	NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040085, R21AI040085, R01AI045818] Funding Source: NIH RePORTER; NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI45818, AI40085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Aiyar A, 1996, Methods Mol Biol, V57, P177; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnaud-Barbe N, 1998, NUCLEIC ACIDS RES, V26, P3550, DOI 10.1093/nar/26.15.3550; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Crotty S, 1999, J VIROL, V73, P9485, DOI 10.1128/JVI.73.11.9485-9495.1999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; FERSHT A, 1999, STRUCTURE MECH PROTE, P30; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Gutierrez-Rivas M, 1999, J MOL BIOL, V290, P615, DOI 10.1006/jmbi.1999.2880; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 1999, BIOCHEMISTRY-US, V38, P2617, DOI 10.1021/bi9824285; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Kornberg A., 1991, DNA REPLICATION; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Nugent CI, 1999, J VIROL, V73, P427, DOI 10.1128/JVI.73.1.427-435.1999; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RECHINSKY VO, 1992, FEBS LETT, V306, P129, DOI 10.1016/0014-5793(92)80983-N; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; Richards OC, 1997, J BIOL CHEM, V272, P23261, DOI 10.1074/jbc.272.37.23261; RIENITZ A, 1985, NUCLEIC ACIDS RES, V13, P5685, DOI 10.1093/nar/13.15.5685; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	63	96	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25523	25532		10.1074/jbc.M002671200	http://dx.doi.org/10.1074/jbc.M002671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827187	hybrid			2022-12-27	WOS:000088849400064
J	Higgins, JMG; Cernadas, M; Tan, K; Irie, A; Wang, JH; Takada, Y; Brenner, MB				Higgins, JMG; Cernadas, M; Tan, K; Irie, A; Wang, JH; Takada, Y; Brenner, MB			The role of alpha and beta chains in ligand recognition by beta(7) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; I-DOMAIN; BINDING-SITE; CRYSTAL-STRUCTURE; E-CADHERIN; A-DOMAIN; MONOCLONAL-ANTIBODY; T-CELLS; ALPHA(E)BETA(7) INTEGRIN	Integrins alpha(E)beta(7) and alpha(4)beta(7) are involved in localization of leukocytes at mucosal sites. Although both alpha(E)beta(7) and alpha(4)beta(7) utilize the beta(7) chain, they have distinct binding specificities for E-cadherin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), respectively. We found that mutation of the metal ion-dependent adhesion site (MIDAS) in the alpha(E) A-domain (D190A) abolished E-cadherin binding, as did mutation F298A on the A-domain surface near the MIDAS cleft. A docking model of the A-domain with E-cadherin domain 1 indicates that coordination of the alpha(E) MIDAS metal ion by E-cadherin Glu(31) and a novel projection of Phe(298) into a hydrophobic pocket on E-cadherin provide the basis for the interaction. The location of the binding site on the alpha(E) A-domain resembles that on other integrins, but its structure appears distinctive and particularly adapted to recognize the tip of E-cadherin, a unique integrin ligand. Additionally, mutation of the beta(7) MIDAS motif (D140A) abolished alpha(E)beta(7) binding to E-cadherin and alpha(4)beta(7)-mediated adhesion to MAdCAM-1, and alpha(4) chain mutations that abrogated binding of alpha(4)beta(1) to vascular cell adhesion molecule-1 and fibronectin similarly reduced alpha(4)beta(7) interaction with MAdCAM-1. Thus, although specificity can be determined by the integrin alpha or beta chain, common structural features of both subunits are required for recognition of dissimilar ligands.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Lymphocyte Biol Sect, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Pulm & Crit Care Div, Boston, MA 02115 USA; Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Scripps Research Institute	Higgins, JMG (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Lymphocyte Biol Sect, Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 538D,1 Jimmy Fund Way, Boston, MA 02115 USA.	jhiggins@rics.bwh.harvard.edu		takada, yoshikazu/0000-0001-5481-9589; Higgins, Jonathan/0000-0001-6622-8268				ANDREW DP, 1994, J IMMUNOL, V153, P3847; AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 1998, J BIOL CHEM, V273, P24744, DOI 10.1074/jbc.273.38.24744; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Brenan M, 1997, EUR J IMMUNOL, V27, P3070, DOI 10.1002/eji.1830271145; Briskin MJ, 1996, J IMMUNOL, V156, P719; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; Coligan JE., 1994, CURRENT PROTOCOLS IM; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ERLE DJ, 1994, J IMMUNOL, V153, P517; FLENGHI L, 1990, BRIT J HAEMATOL, V76, P451, DOI 10.1111/j.1365-2141.1990.tb07900.x; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Green N, 1999, CELL ADHES COMMUN, V7, P167, DOI 10.3109/15419069909010800; Hadley GA, 1997, J IMMUNOL, V159, P3748; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Hesterberg PE, 1996, GASTROENTEROLOGY, V111, P1373, DOI 10.1053/gast.1996.v111.pm8898653; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Ludviksson BR, 1999, J IMMUNOL, V162, P4975; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MICKLEM KJ, 1991, AM J PATHOL, V139, P1297; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Newham P, 1997, J BIOL CHEM, V272, P19429, DOI 10.1074/jbc.272.31.19429; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Picarella D, 1997, J IMMUNOL, V158, P2099; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; REILLY PL, 1995, J IMMUNOL, V155, P529; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Ruiz-Velasco N, 2000, J BIOL CHEM, V275, P7052, DOI 10.1074/jbc.275.10.7052; RUSSELL GJ, 1994, EUR J IMMUNOL, V24, P2832, DOI 10.1002/eji.1830241138; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; Schon MP, 1999, J IMMUNOL, V162, P6641; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STRAUCH UG, 1994, INT IMMUNOL, V6, P263, DOI 10.1093/intimm/6.2.263; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; TANAKA T, 1995, INT IMMUNOL, V7, P1183, DOI 10.1093/intimm/7.8.1183; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Taraszka KS, 2000, J EXP MED, V191, P1555, DOI 10.1084/jem.191.9.1555; Tidswell M, 1997, J IMMUNOL, V159, P1497; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WONG WW, 1991, J IMMUNOL, V146, P656; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	89	29	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25652	25664		10.1074/jbc.M001228200	http://dx.doi.org/10.1074/jbc.M001228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837471	hybrid			2022-12-27	WOS:000088849400080
J	Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL				Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL			Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE T-ANTIGEN; NF-KAPPA-B; HBX PROTEIN; GENE-PRODUCT; BINDING PROTEIN; HEPATOMA-CELLS; RECEPTOR GENE; I RECEPTOR; TRANSCRIPTION; KINASE	Transforming growth factor-beta (TGF-beta) is a potent inducer of apoptosis in Hep 3B cells. This work investigated how hepatitis B virus X protein (HBx) affects TGF-beta-induced apoptosis. Trypan blue exclusion and colony formation assays revealed that HBx increased the ID50 toward TGF-beta. In the presence of HBx, TGF-beta-induced DNA laddering was decreased, indicating that HBx had the ability to block TGF-beta-induced apoptosis. Furthermore, HBx did not alter the expression levels of type I and type II TGF-beta receptors. HBx did not affect TGF-beta-induced activation of promoter activities of the plasminogen activator inhibitor-1 (PAI-I) gene. These results indicate that HBx interferes with only a subset of TGF-beta activity. In the presence of phosphatidylinositol (PI) 3-kinase inhibitors, wortmannin or LY294002, the HBx-mediated inhibitory effect on TGF-beta-induced apoptosis was alleviated. In addition, the tyrosine phosphorylation levels of the regulatory subunit p85 of phosphatidylinositol 3-kinase (PI 3-kinase) and PI 3-kinase activity were elevated in stable clones with HBx expression. Transactivation-deficient mutants of HBx lost their ability to inhibit TGF-beta-induced apoptosis. Phosphorylation of the p85 subunit of PI 3-kinase and Akt, a downstream target of PI 3-kinase, was not observed in stable clones with transactivation-deficient HBx mutant's expression. Thus, the anti-apoptotic effect of HBx against TGF-beta can be mediated through the activation of the PI 3-kinase signaling pathway, and the transactivation function of HBx is required for its anti-apoptosis activity.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10019, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10019, Taiwan; Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei 10019, Taiwan; Natl Hlth Res Inst, Taipei 11529, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10019, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital	Doong, SL (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, 1,Sect 1,Jen Ai Rd, Taipei 10019, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; DOONG, SHIN-LIAN/0000-0002-0936-3858; Cheng, Ann-Lii/0000-0002-9152-6512				Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Dahl J, 1998, J VIROL, V72, P3221, DOI 10.1128/JVI.72.4.3221-3226.1998; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Fan GS, 1996, ONCOGENE, V12, P1909; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim SO, 1996, CANCER RES, V56, P3831; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, CLIN CANCER RES, V4, P1711; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LIN JK, 1992, CANCER RES, V52, P385; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NATOLI G, 1994, ONCOGENE, V9, P2837; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TANAKA S, 1996, CANCER RES, V56, P391; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WANG XW, 1995, CANCER RES, V55, P6012; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	55	163	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25858	25864		10.1074/jbc.M003578200	http://dx.doi.org/10.1074/jbc.M003578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835427	hybrid			2022-12-27	WOS:000088849400104
J	Nunomura, W; Takakuwa, Y; Parra, M; Conboy, J; Mohandas, N				Nunomura, W; Takakuwa, Y; Parra, M; Conboy, J; Mohandas, N			Regulation of protein 4.1R, p55, and glycophorin C ternary complex in human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING INTERFACE; SKELETAL PROTEIN-4.1; OPTICAL BIOSENSOR; RESONANT MIRROR; CALMODULIN; IDENTIFICATION; PURIFICATION; MODULATION; HOMOLOG; MEMBER	Three binary protein-protein interactions, glycophorin C (GPC)-4.1R, GPC-p55, and p55-4.1R, constitute the GPC-4.1R-p55 ternary complex in the erythrocyte membrane. Little is known regarding the molecular basis for the interaction of 4.1R with either GPC or p55 and regarding the role of 4.1R in regulating the various protein-protein interactions that constitute the GPC-4.1R-p55 ternary complex. In the present study, we present evidence that sequences in the 30-kDa domain encoded by exon 8 and exon 10 of 4,1R constitute the binding interfaces for GPC and p55, respectively. We further show that 4.1R increases the affinity of p55 binding to GPC by an order of magnitude, implying that 4,1R modulates the interaction between p55 and GPC. Finally, we document that binding of calmodulin to 4.1R decreases the affinity of 4.1R interactions with both p55 and GPC in a Ca2+-dependent manner, implying that the GPC-4.1R-p55 ternary protein complex can undergo dynamic regulation in the erythrocyte membrane. Taken together, these findings have enabled us to identify an important role for 4.1R in regulating the GPC-4.1R-p55 ternary complex in the erythrocyte membrane.	Tokyo Womens Med Univ, Sch Med, Dept Biochem, Shinju Ku, Tokyo 1628666, Japan; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Tokyo Women's Medical University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Mohandas, N (corresponding author), Univ Calif Berkeley, Berkeley Natl Lab, Mail Stop 74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263, R37DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579] Funding Source: Medline; NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; Chishti A H, 1998, Curr Opin Hematol, V5, P116; CHISHTI AH, 1989, J BIOL CHEM, V264, P8985; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HUSAIN A, 1985, BIOCHEM INT, V10, P1; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KARAS M, 1987, INT J MASS SPECTRUM, V78, P58; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; REID ME, 1990, BLOOD, V75, P2229; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010	46	84	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24540	24546		10.1074/jbc.M002492200	http://dx.doi.org/10.1074/jbc.M002492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831591	hybrid			2022-12-27	WOS:000088683300042
J	Tran, K; Wang, YW; DeLong, CJ; Cui, Z; Yao, ZM				Tran, K; Wang, YW; DeLong, CJ; Cui, Z; Yao, ZM			The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A(2) antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; HUMAN PANCREATIC-ISLETS; N-3 FATTY-ACIDS; HEP G2 CELLS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; P388D(1) MACROPHAGES; GOLGI-COMPLEX; PHOSPHATIDYLETHANOLAMINE METHYLATION	In McA-RH7777 cells, the oleate-stimulated assembly and secretion of very low density lipoproteins (VLDL) was associated with enhanced deacylation of phospholipids, which was markedly decreased by inactivation of the cellular phospholipase A(2). Treatment of the cells with antagonists or antisense oligonucleotide of the Ca2+-independent phospholipase A(2) (iPLA(2)) significantly inhibited secretion of apoB100-VLDL and triglyceride, Similar inhibitory effect of the iPLA(2) antagonists was observed on apoB48-VLDL secretion, but secretion of high density lipoprotein particles (such as apoAI- and apoB48-high density lipoprotein) or proteins in general was unaffected. The iPLA(2) antagonist did not affect the synthesis of apoB100 or triglyceride, nor did it affect the activities of phospholipase D, phosphatidate phosphohydrolase, or microsomal triglyceride transfer protein. Inactivation of iPLA(2) resulted in impaired apoB100-VLDL assembly as shown by decreased apoB100-VLDL and triglyceride within the microsomal lumen, with concomitant increase in apoB100 association with the microsomal membranes. The inhibitory effect of iPLA(2) antagonists on apoB100-VLDL assembly/secretion could be abated by pretreatment of cells with oleate. Analysis of molecular species of microsomal phosphatidylcholine and phosphatidylethanolamine by electron spray tandem mass spectrometry revealed that the enrichment of oleoyl moieties was altered by the treatment of iPLA(2) antagonist. These results suggest that the oleate-induced VLDL assembly/secretion may depend upon the establishment of membrane glycerolipids enriched in oleoyl chain, a process mediated by the iPLA(2) activity.	Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Wake Forest University	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.			DeLong, Cynthia/0000-0002-6823-8619	NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NCI NIH HHS [CA09422, CA85757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BARON H, 1971, BIOCHIM BIOPHYS ACTA, V248, P1, DOI 10.1016/0005-2760(71)90068-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P897, DOI 10.1042/bj3100897; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FUJII T, 1979, J BIOCHEM-TOKYO, V86, P1345, DOI 10.1093/oxfordjournals.jbchem.a132651; GIBBONS GF, 1994, J LIPID RES, V35, P1801; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; LANG CA, 1990, J LIPID RES, V31, P2079; LINTON MF, 1993, J LIPID RES, V34, P521; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; REDGRAVE TG, 1979, J LIPID RES, V20, P217; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sjoberg A, 1996, J LIPID RES, V37, P275; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6	62	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25023	25030		10.1074/jbc.M908971199	http://dx.doi.org/10.1074/jbc.M908971199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827200	hybrid			2022-12-27	WOS:000088683300105
J	Xiao, Z; Liu, XD; Lodish, HF				Xiao, Z; Liu, XD; Lodish, HF			Importin beta mediates nuclear translocation of Smad 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNAL; PROTEIN IMPORT; BINDING; IDENTIFICATION; ALPHA; REV	Smad proteins are intracellular mediators of transforming growth factor-beta (TGF-beta) and related cytokines, Although ligand-induced nuclear translocation of Smad proteins is clearly established, the pathway mediating this import is yet to be determined. We previously identified a nuclear localization signal (NLS) in the N-terminal region of Smad 3, the major Smad protein involved in TGF-beta signal transduction. This basic motif (Lys(40)-Lys-Leu-Lys-Lys(44)), conserved among all the pathway-specific Smad proteins, is required for Smad 3 nuclear import in response to ligand, Here we studied the nuclear import pathway of Smad 3 mediated by this NLS, We demonstrate that the isolated Smad 3 MH1 domain displays significant specific binding to importin beta, which is diminished or eliminated by mutations in the NLS, Full-size Smad 3 exhibits weak but specific binding to importin beta, which is enhanced after phosphorylation by the type I TGF-beta receptor. In contrast, no interaction was observed between importin alpha and Smad 3 or its MH1 domain, indicating that nuclear translocation of Smad proteins may occur through direct binding to importin beta, We propose that activation of all of the pathway-specific Smad proteins (Smads 1, 2, 3, 5, 8, and 9) exposes the conserved NLS motif, which then binds directly to importin beta and triggers nuclear translocation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			LIU, XUEDONG/0000-0001-7209-4964	NCI NIH HHS [CA63260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853	20	134	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23425	23428		10.1074/jbc.C000345200	http://dx.doi.org/10.1074/jbc.C000345200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10846168	hybrid			2022-12-27	WOS:000088564200005
J	Yue, LL; Lu, SJ; Garces, J; Jin, TQ; Li, JX				Yue, LL; Lu, SJ; Garces, J; Jin, TQ; Li, JX			Protein kinase C-regulated dynamitin-macrophage-enriched myristoylated alanine-rice C kinase substrate interaction is involved in macrophage cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; CYTOPLASMIC DYNEIN; DYNACTIN COMPLEX; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; MOTOR PROTEINS; PHOSPHORYLATION; MARCKS; MACMARCKS; INTEGRINS	Macrophage spreading requires the microtubule cytoskeleton and protein kinase C (PKC). The mechanism of involvement of the microtubules and PKC in this event is not fully understood. Dynamitin is a subunit of dynactin, which is important for linking the microtubule-dependent motor protein dynein to vesicle membranes. We report that dynamitin is a Ca2+/calmodulin-binding protein and that dynamitin binds directly to macrophage-enriched myristoylated alanine-rice C kinase substrate (MacMARCKS), a membrane-associated PKC substrate involved in macrophage spreading and integrin activation. Dynamitin was found to copurify with MacMARCKS both during MacMARCKS purification with conventional chromatography and during the immunoabsorption of MacMARCKS using anti-MacMARCKS antibody. Vice verse, MacMARCKS was also found to cosediment with the 20 S dynactin complex. We determined that the effector domain of MacMARCKS is required to interact with the N-terminal domain of dynamitin. MacMARCKS and dynamitin also partially colocalized at peripheral regions of macrophages and in the cell-cell border of 293 epithelial cells. Treatment with phorbol esters abolished this colocalization. Disrupting the interaction with a short peptide derived from the MacMARCKS-binding domain of dynamitin caused macrophages to spread and flatten. These data suggest that the dynamitin-MacMARCKS interaction is involved in cell spreading. Furthermore, the regulation of this interaction by PKC and Ca2+/calmodulin provides a possible regulatory mechanism for cell adhesion and spreading.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Pediat, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Canc, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Massachusetts System; University of Massachusetts Worcester	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.	jxli@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; CHEUNG HT, 1980, CELL BIOL INT REP, V4, P1125, DOI 10.1016/0309-1651(80)90050-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DEBRABANDER M, 1977, CELL BIOL INT REP, P453; DILLMAN JF, 1995, BIOPHYS J, V68, pS226; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVANOVA OY, 1976, EXP CELL RES, V101, P207, DOI 10.1016/0014-4827(76)90431-6; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Roghi C, 1999, J CELL SCI, V112, P4673; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652; [No title captured]	68	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23948	23956		10.1074/jbc.M001845200	http://dx.doi.org/10.1074/jbc.M001845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10827182	hybrid			2022-12-27	WOS:000088564200075
J	Forsberg, LS; Bhat, UR; Carlson, RW				Forsberg, LS; Bhat, UR; Carlson, RW			Structural characterization of the O-antigenic polysaccharide of the lipopolysaccharide from Rhizobium etli strain CE3 - A unique O-acetylated glycan of discrete size, containing 3-O-methyl-6-deoxy-L-talose and 2,3,4-tri-O-methyl-L-fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEGUMINOSARUM BIOVAR PHASEOLI; PEA ROOT-NODULES; MONOCLONAL-ANTIBODIES; CHEMICAL CHARACTERIZATION; BRADYRHIZOBIUM-JAPONICUM; LIPID-A; CORE; MUTANT; PLANT; CELL	The O-antigenic polysaccharide of the Rhizobium etli CE3 lipopolysaccharide (LPS) was structurally characterized using chemical degradations (Smith degradation and beta-elimination of uronosyl residues) in combination with alkylation analysis, electrospray, and matrix-assisted laser desorption ionization-time of flight mass spectrometry, tandem mass spectrometry, and H-1 COSY and TOCSY nuclear magnetic resonance spectroscopy analyses of the native polysaccharide and the derived oligosaccharides. The polysaccharide was found to be a unique, relatively low molecular weight glycan having a fairly discrete size, with surprisingly little variation in the number of repeating units (degree of polymerization = 5). The polysaccharide is O-acetylated and contains a variety of O-methylated glycosyl residues, rendering the native glycan somewhat hydrophobic. The molecular mass of the major de-O-acetylated species, including the reducing end 3-deoxy-D-manno-2-octulosonic acid (Kdo) residue, is 3330 Da. The polysaccharide is comprised of a trisaccharide repeating unit having the structure -->4)-alpha-D-GlcpA-(1-->4)-[alpha-3-O-Me-6-deoxy-Talp-(1-->3)]-alpha-L-Fucp-(1-->. The nonreducing end of the glycan is terminated with the capping sequence alpha-2,3,4-tri-O-Me-Fucp-(1-->4)-alpha-D-GlcpA-(1-->, and the reducing end of the molecule consists of the non-repeating sequence -->3)-alpha-L-Fucp-(1-->3)-beta-D-Manp-(1-->3)-beta-QuiNAcp-(1-->4)-alpha-Kdop-(2-->, where QuiNAc is N-acetylquinovosamine (2-N-acetamido-2,6-dideoxyglucose). The reducing end Kdo residue links the O-chain polysaccharide to the core region oligosaccharide, resulting in a unique location for a Kdo residue in LPS, removed four residues distally from the lipid A moiety, Structural heterogeneity in the O-chain arises mainly from the O-acetyl and O-methyl substitution. Methylation analysis using trideuteriomethyl iodide indicates that a portion of the 2,3,4-tri-O-methylfucosyl capping residues, typically 15%, are replaced with 2-O-methyl- and/or 2,3-di-O-methylfucosyl residues. In addition, approximately 25% of the 3,4-linked branching fucosyl residues and 10% of the 3-linked fucosyl residues are 2-O-methylated, A majority of the glucuronosyl residues are methyl-esterified at C-6, These unique structural features may be significant in the infection process.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Miles Cutter Labs, Berkeley, CA 94701 USA	University System of Georgia; University of Georgia	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.				NIGMS NIH HHS [GM39583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allaway D, 1996, J BACTERIOL, V178, P6403, DOI 10.1128/jb.178.21.6403-6406.1996; ASPINALL GO, 1993, J BIOL CHEM, V268, P6263; Banaszek A, 1998, CARBOHYD RES, V306, P379, DOI 10.1016/S0008-6215(97)10073-8; BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BRADE H, 1984, CARBOHYD RES, V134, P157, DOI 10.1016/0008-6215(84)85030-2; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CARLSON RW, 1992, CARBOHYD RES, V231, P205, DOI 10.1016/0008-6215(92)84020-S; CARLSON RW, 1987, PLANT PHYSIOL, V84, P421, DOI 10.1104/pp.84.2.421; CARLSON RW, IN PRESS P 12 INT C; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHAPMAN K, 1990, NITROGEN FIXATION AC, P254; DEMAAGD RA, 1989, J BACTERIOL, V171, P1136, DOI 10.1128/jb.171.2.1136-1142.1989; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; Duelli DM, 1997, MOL PLANT MICROBE IN, V10, P903, DOI 10.1094/MPMI.1997.10.7.903; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GILSERRANO AM, 1995, CARBOHYD RES, V275, P285, DOI 10.1016/0008-6215(95)00178-V; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; Jabbouri S, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P319; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KONDO S, 1990, CARBOHYD RES, V196, P191, DOI 10.1016/0008-6215(90)84119-F; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; LINDBERG B, 1972, ACTA CHEM SCAND, V26, P2231, DOI 10.3891/acta.chem.scand.26-2231; Martinez E., 1993, V17, P171; MAYER H, 1989, PURE APPL CHEM, V61, P1271, DOI 10.1351/pac198961071271; MCNEIL M, 1986, CARBOHYD RES, V146, P307, DOI 10.1016/0008-6215(86)85048-0; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; Noel KD, 1996, MOL PLANT MICROBE IN, V9, P180, DOI 10.1094/MPMI-9-0180; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; OLSEN P, 1994, APPL ENVIRON MICROB, V60, P654, DOI 10.1128/AEM.60.2.654-661.1994; PAZUR JH, 1980, METHODS CARBOHYDR CH, V8, P107; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PERRY MB, 1995, INFECT IMMUN, V63, P3348, DOI 10.1128/IAI.63.9.3348-3352.1995; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; RICHTER WJ, 1990, METHOD ENZYMOL, V193, P607, DOI 10.1016/0076-6879(90)93441-M; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; STEVENSON TT, 1991, CARBOHYD RES, V210, P277, DOI 10.1016/0008-6215(91)80129-B; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; VANDENBOSCH KA, 1989, J BACTERIOL, V171, P4537, DOI 10.1128/jb.171.9.4537-4542.1989; VANRHIJN P, 1995, MICROBIOL REV, V59, P124, DOI 10.1128/MMBR.59.1.124-142.1995; WECKESSER J, 1979, ANNU REV MICROBIOL, V33, P215, DOI 10.1146/annurev.mi.33.100179.001243; WEIBGEN U, 1993, SYST APPL MICROBIOL, V16, P177, DOI 10.1016/S0723-2020(11)80465-0; WILKINSON SG, 1983, CARBOHYD RES, V112, P241, DOI 10.1016/0008-6215(83)88289-5; WRIGHT SF, 1990, APPL ENVIRON MICROB, V56, P2262, DOI 10.1128/AEM.56.7.2262-2264.1990; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZAHRINGER U, 1995, BACTERIAL ENDOTOXINS, P113; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191; [No title captured]	66	73	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18851	18863		10.1074/jbc.M001090200	http://dx.doi.org/10.1074/jbc.M001090200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858446	hybrid			2022-12-27	WOS:000087815900034
J	Hamada, M; Sakulich, AL; Koduru, SB; Maraia, RJ				Hamada, M; Sakulich, AL; Koduru, SB; Maraia, RJ			Transcription termination by RNA polymerase III in fission yeast - A genetic and biochemically tractable model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LA ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; DNA-BINDING; INITIATION-FACTOR; ALPHA-AMANITIN; BETA' SUBUNIT; S-CEREVISIAE; PROTEIN; SEQUENCES; CLEAVAGE	In order for RNA polymerase (pol) III to produce a sufficient quantity of RNAs of appropriate structure, initiation, termination, and reinitiation must be accurate and efficient. Termination-associated factors have been shown to facilitate reinitiation and regulate transcription in some species. Suppressor tRNA genes that differ in the dT(n) termination signal were examined for function in Schizosaccharomyces pombe, We also developed an S. pombe extract that is active for tRNA transcription that is described here for the first time. The ability of this tRNA gene to be transcribed in extracts from different species allowed us to compare termination in three model systems. Although human pol III terminates efficiently at 4 dTs and S. pombe at 5 dTs, Saccharomyces cerevisiae pol III requires 6 dTs to direct comparable but lower termination efficiency and also appears qualitatively distinct. Interestingly, this pattern of sensitivity to a minimal dT(n) termination signal was found to correlate with the sensitivity to alpha-amanitin, as S. pombe was intermediate between human and S. cerevisiae pols III. The results establish that the pols III of S. cerevisiae, S. pombe, and human exhibit distinctive properties and that termination occurs in S. pombe in a manner that is functionally more similar to human than is S. cerevisiae.	NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), 6 Ctr Dr,Rm 416, Bethesda, MD 20892 USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000412] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000412] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADENIYIJONES S, 1984, NUCLEIC ACIDS RES, V12, P1101, DOI 10.1093/nar/12.2.1101; ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Baserga S., 1993, RNA WORLD, P359; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chu WM, 1997, NUCLEIC ACIDS RES, V25, P2077, DOI 10.1093/nar/25.11.2077; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Goodier JL, 1998, J BIOL CHEM, V273, P26110, DOI 10.1074/jbc.273.40.26110; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Gunnery S, 1999, J MOL BIOL, V286, P745, DOI 10.1006/jmbi.1998.2518; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; HOTTINGER H, 1982, MOL GEN GENET, V188, P219, DOI 10.1007/BF00332678; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; INTINE RVA, 2000, IN PRESS MOL CELL; JAOZEIRO CAP, 1996, GENE DEV, V10, P725; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KEENEY JB, 1994, GENETICS, V136, P849; Kohli J, 1989, MOL BIOL FISSION YEA, P75; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McBryant SJ, 1999, J MOL BIOL, V286, P973, DOI 10.1006/jmbi.1999.2539; MURPHY MH, 1983, NUCLEIC ACIDS RES, V11, P7695, DOI 10.1093/nar/11.22.7695; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; Rodicker F, 1999, GENE EXPRESSION, V8, P165; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; VALENZUELA P, 1976, P NATL ACAD SCI USA, V73, P1024, DOI 10.1073/pnas.73.4.1024; Van Horn DJ, 1997, RNA, V3, P1434; VNENCAKJONES CL, 1987, MOL CELL BIOL, V7, P4134, DOI 10.1128/MCB.7.11.4134; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILIS I, 1986, P NATL ACAD SCI USA, V83, P7860; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930	63	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29076	29081		10.1074/jbc.M003980200	http://dx.doi.org/10.1074/jbc.M003980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10843998	hybrid			2022-12-27	WOS:000089330700095
J	Xavier, IJ; Mercier, PA; McLoughlin, CM; Ali, A; Woodgett, JR; Ovsenek, N				Xavier, IJ; Mercier, PA; McLoughlin, CM; Ali, A; Woodgett, JR; Ovsenek, N			Glycogen synthase kinase 3 beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED STRESS-RESPONSE; XENOPUS OOCYTES; FACTOR HSF1; IN-VIVO; SODIUM-SALICYLATE; NUCLEAR-PROTEIN; HSP70 GENE; PHOSPHORYLATION; CELLS	Stress activation of heat shock factor (HSF1) involves the conversion of repressed monomers to DNA-binding homotrimers with increased transcriptional capacity and results in transcriptional up-regulation of the heat shock protein (hsp) gene family. Cells tightly control the activity of HSF1 through interactions with hsp90 chaperone complexes and through integration into a number of different signaling cascades. A number of studies have shown that HSF1 transcriptional activity is negatively regulated by constitutive phosphorylation in the regulatory domain by glycogen synthase kinase (GSK3) isoforms alpha/beta. However, previous studies have not examined the ability of GSK3 to regulate the DNA-binding activity of native HSF1 in vivo under heat shock conditions. Here we show that GSK3 beta inhibits both DNA-binding and transcriptional activities of HSF1 in heat-shocked cells. Specific inhibition of GSK3 increased the levels of DNA binding and transcription after heat shock and delayed the attenuation of HSF1 during recovery. In contrast, the overexpression of GSK3 beta resulted in significant reduction in heat-induced HSF1 activities. These results confirm the role of GSK3 beta as a negative regulator of HSF1 transcription in cells during heat shock and demonstrate for the first time that GSK3 beta functions to repress DNA binding.	Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	University of Saskatchewan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Ovsenek, N (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ovsenekn@duke.usask.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Bharadwaj S, 1998, BBA-MOL CELL RES, V1402, P79, DOI 10.1016/S0167-4889(97)00146-8; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHANG NT, 1993, J BIOL CHEM, V268, P1436; Cheng TJ, 1998, J CELL BIOCHEM, V69, P221, DOI 10.1002/(SICI)1097-4644(19980501)69:2<221::AID-JCB12>3.0.CO;2-H; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Fritsch N, 1999, CELL STRESS CHAPERON, V4, P102; GOODE N, 1992, J BIOL CHEM, V267, P16878; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOJ A, 1994, EMBO J, V13, P2617; Holmberg CI, 1998, J CELL SCI, V111, P3357; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LANDSBERGER N, 1995, DEV BIOL, V170, P62, DOI 10.1006/dbio.1995.1195; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; Mercier PA, 1997, J BIOL CHEM, V272, P14147, DOI 10.1074/jbc.272.22.14147; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PULVERER BJ, 1994, ONCOGENE, V9, P59; RITZ MF, 1993, RECEPTOR, V3, P311; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Winegarden NA, 1996, J BIOL CHEM, V271, P26971, DOI 10.1074/jbc.271.43.26971; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P564; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	53	124	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29147	29152		10.1074/jbc.M002169200	http://dx.doi.org/10.1074/jbc.M002169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10856293	hybrid			2022-12-27	WOS:000089330700104
J	Balendiran, GK; Schnutgen, F; Scapin, G; Borchers, T; Xhong, N; Lim, K; Godbout, R; Spener, F; Sacchettini, JC				Balendiran, GK; Schnutgen, F; Scapin, G; Borchers, T; Xhong, N; Lim, K; Godbout, R; Spener, F; Sacchettini, JC			Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCOSAHEXAENOIC ACID; 3-DIMENSIONAL STRUCTURE; ARACHIDONIC-ACID; LINOLENIC ACID; ANGSTROM RESOLUTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; FREE-RADICALS; RAT-BRAIN; SYSTEM	Expression of brain fatty acid-binding protein (B-FABP) is spatially and temporally correlated with neuronal differentiation during brain development. Isothermal titration calorimetry demonstrates that recombinant human B-FABP clearly exhibits high affinity for the polyunsaturated n-3 fatty acids cy-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and for monounsaturated n-9 oleic acid (K-d from 28 to 53 nM) over polyunsaturated n-6 fatty acids, linoleic acid, and arachidonic acid (K-d from 115 to 206 nhl), B-FABP has low binding affinity for saturated long chain fatty acids. The three-dimensional structure of recombinant human B-FABP in complex with oleic acid shows that the oleic acid hydrocarbon tail assumes a "U-shaped" conformation, whereas in the complex with docosahexaenoic acid the hydrocarbon tail adopts a helical conformation. A comparison of the three dimensional structures and binding properties of human B-FABP with other homologous FABPs, indicates that the binding specificity is in part the result of nonconserved amino acid Phe(104), which interacts with double bonds present in the lipid; hydrocarbon tail. In this context, analysis of the primary and tertiary structures of human B-FABP provides a rationale for its high affinity and specificity for polyunsaturated fatty acids. The expression of B-FABP in glial cells and its high affinity for docosahexaenoic acid, which is known to be an important component of neuronal membranes, points toward a role for B-FABP in sup plying brain abundant fatty acids to the developing neuron.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Munster, Dept Biochem, D-48149 Munster, Germany; Merck & Co Inc, Merck Res Lab, Rahway, NJ 07065 USA; Inst Chem & Biochem Sensor Res, D-48149 Munster, Germany; CUNY Queens Coll, Dept Chem, Flushing, NY 11367 USA; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	Texas A&M University System; Texas A&M University College Station; University of Munster; Merck & Company; City University of New York (CUNY) System; Queens College NY (CUNY); University of Alberta	Balendiran, GK (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	balendra@reddrum.tamu.edu	Godbout, Roseline/I-4639-2016; Schnütgen, Frank/ABD-8637-2020	Godbout, Roseline/0000-0002-4779-9265; Schnütgen, Frank/0000-0002-2426-6685	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT E, 1994, J NEUROCHEM, V63, P1616; BENNING MM, 1992, J MOL BIOL, V228, P208; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; BURTON L, 1989, P NATL ACAD SCI USA, V86, P2903; CHAM BE, 1976, J LIPID RES, V17, P176; CONNOR WE, 1984, T ASSOC AM PHYSICIAN, V97, P1; EADS J, 1993, J BIOL CHEM, V268, P26375; Ek BA, 1997, BBA-LIPID LIPID MET, V1346, P75, DOI 10.1016/S0005-2760(97)00021-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GODBOUT R, 1993, EXP EYE RES, V56, P95, DOI 10.1006/exer.1993.1014; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HASSAM AG, 1975, LIPIDS, V10, P417, DOI 10.1007/BF02532447; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; Hohoff C, 1998, FETT-LIPID, V100, P252; HOWARD AJ, 1986, GUIDE DATA REDUCTION; Innis SM, 1999, LIPIDS, V34, P139, DOI 10.1007/s11745-999-0348-x; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; MAATMAN RGHJ, 1994, EUR J BIOCHEM, V221, P801, DOI 10.1111/j.1432-1033.1994.tb18794.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Nourooz-Zadeh J, 1998, BIOCHEM BIOPH RES CO, V242, P338, DOI 10.1006/bbrc.1997.7883; Nourooz-Zadeh J, 1999, J NEUROCHEM, V72, P734, DOI 10.1046/j.1471-4159.1999.0720734.x; Nouvelot A., 1985, Cahiers de Nutrition et de Dietetique, V20, P123; OBRIEN JS, 1965, J LIPID RES, V6, P545; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILBRICK DJ, 1987, J NUTR, V117, P1663, DOI 10.1093/jn/117.10.1663; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SALEM N, 1980, CHEM PHYS LIPIDS, V27, P289, DOI 10.1016/0009-3084(80)90024-9; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; Schnutgen F, 1996, BIOL CHEM H-S, V377, P211; Schreiber A, 1998, CLIN CHEM LAB MED, V36, P283, DOI 10.1515/CCLM.1998.048; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wolfrum C, 1999, J LIPID RES, V40, P708; Xu LZ, 1996, J BIOL CHEM, V271, P24711; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; YAMAMOTO N, 1987, J LIPID RES, V28, P144; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; [No title captured]	65	151	157	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27045	27054						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854433				2022-12-27	WOS:000089144800052
J	Berrada, K; Plesnicher, CL; Luo, X; Thibonnier, M				Berrada, K; Plesnicher, CL; Luo, X; Thibonnier, M			Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; OXYTOCIN RECEPTOR; OPIOID RECEPTOR; V-2 RECEPTOR; INTERNALIZATION; IDENTIFICATION; EXPRESSION; TERMINUS	Examination of the structure of [Arg(8)]-vasopressin receptors (AVPRs) and oxytocin receptors (OTRs) suggests that G protein-coupled receptor kinases (GBKs) and protein kinase C (PKC) are involved in their signal transduction. To explore the physical association of AVPRs and OTRs with GRKs and PKC, wild types and mutated forms of these receptor subtypes were stably expressed as green fluorescent protein fusion proteins and analyzed by fluorescence, immunoprecipitation, and immunoblotting. Addition of a C-terminal GFP tag did not interfere with ligand binding, internalization, and signal transduction, After agonist stimulation, PKC dissociated from the V1R, did not associate with the V2R, but associated with the V3R and the OTR. After AVP stimulation, only GRK5 briefly associated with AVPRs following a time course that varied with the receptor subtype. No GRK associated with the OTR, Exchanging the V1R and V2R. C termini altered the time course of PKC and GRK5 association. Deletion of the V1R C terminus resulted in no PKC association and a ligand-independent sustained association of GRK5 with the receptor. Deletion of the GRK motif prevented association and reduced receptor phosphorylation, Thus, agonist stimulation of AVP/OT receptors leads to receptor subtype-specific interactions with GRK and PKC through specific motifs present in the C termini of the receptors.	Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Thibonnier, M (corresponding author), Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Sch Med, Rm BRB431,10900 Euclid Ave, Cleveland, OH 44106 USA.	mxt10@po.cwru.edu		, Marc/0000-0002-4546-180X	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039757, P01HL041618] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703] Funding Source: Medline; NHLBI NIH HHS [R01 HL39757, P01 HL41618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Conway BR, 1999, J BIOMOL SCREEN, V4, P75, DOI 10.1177/108705719900400207; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Iacovelli L, 1999, FASEB J, V13, P1; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; KIMURA T, 1995, ENDOCR J, V42, P607, DOI 10.1507/endocrj.42.607; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Milligan G, 1999, BRIT J PHARMACOL, V128, P501, DOI 10.1038/sj.bjp.0702824; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; Thibonnier M, 1998, ADV EXP MED BIOL, V449, P251; THIBONNIER M, IN PRESS AM J PHYSL; THIBONNIER M, 1992, NEUROENDOCRINOLOGY C, V5, P19	37	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27229	27237						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858434				2022-12-27	WOS:000089144800075
J	Corbett, EF; Michalak, KM; Oikawa, K; Johnson, S; Campbell, ID; Eggleton, P; Kay, C; Michalak, M				Corbett, EF; Michalak, KM; Oikawa, K; Johnson, S; Campbell, ID; Eggleton, P; Kay, C; Michalak, M			The conformation of calreticulin is influenced by the endoplasmic reticulum luminal environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLUCOSE-REGULATED PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; CHAIN-BINDING-PROTEIN; MOLECULAR CHAPERONE; ATP-BINDING; IN-VITRO; NUCLEOTIDE SULFATE; SECRETORY PROTEINS; GOLGI-APPARATUS	In order to understand the dynamics of the endoplasmic reticulum (ER) luminal environment, we investigated the role of Ca2+, Zn2+, and ATP on conformational changes of calreticulin. Purified calreticulin was digested with trypsin in the presence or absence of Ca2+, Zn2+, and ATP, At low Ca2+ concentration (<100 mu M), calreticulin is rapidly and fully degraded by trypsin, indicating that under these conditions the protein is in a highly trypsin-susceptible conformation, Increasing Ca2+ concentration up to 500 mu M or 1 mM resulted in protection of the full-length calreticulin and in generation of the 27-kDa fragment highly resistant to trypsin digestion, The 27-kDa protease-resistant core of the protein represented the NH2-terminal half of calreticulin and was identified by its reactivity with specific antibodies and by NH2-terminal amino acid sequence analysis. Ca2+ dependent changes in calreticulin's sensitivity to proteolysis indicate that agonist-induced fluctuation in the free ER luminal Ca2+ concentration may affect the protein conformation and function. Trypsin digestion of calreticulin in the presence of Zn2+ resulted in the formation of a 17-kDa central protease-resistant core in the protein corresponding to the central region of the protein, indicating that under these conditions the N- and C-domains of the protein are in an extended conformation. Here we also show that calreticulin is an ATP-binding protein but that it does not contain detectable ATPase activity, Digestion of the protein with trypsin in the presence of Mg2+-ATP protects the full-length protein. These results indicate that calreticulin may undergo frequent, ion-induced conformation changes, which may affect its function and its ability to interact with other proteins in the lumen of the ER.	Univ Alberta, Dept Biochem, CIHR Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Alberta; University of Alberta; University of Oxford	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, CIHR Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.		; Johnson, Steven/F-9182-2016	Eggleton, Paul/0000-0001-8244-2125; Johnson, Steven/0000-0002-7877-3543				Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERGMEYER HU, 1965, METHOD ENZYMAT AN, P999; Berninsone P, 1998, ANN NY ACAD SCI, V842, P91, DOI 10.1111/j.1749-6632.1998.tb09636.x; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burrell, 1993, ENZYMES MOL BIOL; Cala SE, 1999, BIOCHEM BIOPH RES CO, V259, P233, DOI 10.1006/bbrc.1999.0760; CALA SE, 1994, J BIOL CHEM, V269, P5926; Chen NQ, 1996, BIOCHEMISTRY-US, V35, P8299, DOI 10.1021/bi960296e; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P384, DOI 10.1046/j.1365-2249.2000.01214.x; Eggleton P, 1997, LUPUS, V6, P564, DOI 10.1177/096120339700600703; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783; FURUKAWA T, 1993, J PHYSIOL-LONDON, V466, P707; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; KIRCHGESSNER M, 1980, Z TIERPHYSIOL TIERER, V43, P130; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; Meldolesi J, 1998, J CELL BIOL, V142, P1395, DOI 10.1083/jcb.142.6.1395; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PICELLO E, 1992, BIOCHEM BIOPH RES CO, V186, P659, DOI 10.1016/0006-291X(92)90797-O; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; REDDY AG, 1989, CYTOBIOS, V60, P21; RINDRESS D, 1993, J BIOL CHEM, V268, P5139; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; URADE R, 1993, J BIOL CHEM, V268, P22004; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015	69	106	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27177	27185						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842171				2022-12-27	WOS:000089144800069
J	Hodson, N; Griffiths, G; Cook, N; Pourhossein, M; Gottfridson, E; Lind, T; Lidholt, K; Roberts, IS				Hodson, N; Griffiths, G; Cook, N; Pourhossein, M; Gottfridson, E; Lind, T; Lidholt, K; Roberts, IS			Identification that KfiA, a protein essential for the biosynthesis of the Escherichia coli K5 capsular polysaccharide, is an alpha-UDP-GlcNAc glycosyltransferase - The formation of a membrane-associated K5 biosynthetic complex requires KfiA, KfiB, and KfiC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; ENCODING PROTEINS; EXPRESSION; REGION-1; HEPARIN; ANTIGEN; ENZYME; MOTIF	The Escherichia coli K5 capsular polysaccharide consists of the repeat structure -4)GlcA-beta(1,4)-GlcNAc-alpha(1-and requires the KfiA, KfiB, KfiC, and KfiD proteins for its synthesis, Previously, the KfiC protein was shown to be a beta-UDP-GlcA glycosyltransferase, and KfiD was shown to be a UDP-Glc dehydrogenase. Here, we demonstrate that KfiA is an alpha-UDP-GlcNAc glycosyltransferase and that biosynthesis of the K5 polysaccharide involves the concerted action of the KfiA and KfiC proteins. By site-directed mutagenesis, we determined that the acidic motif of DDD, which is conserved between the C family of glycosyltransferases, is essential for the enzymatic activity of KfiA III addition, by Western blot analysis, we determined that association of KfiA with the cytoplasmic membrane requires KfiC but not KfiB, whereas the interaction of KfiC with the cytoplasmic membrane was dependent on both KfiA and KfiB. Likewise, KfiB was only detectable in cytoplasmic membrane fractions when both KfiA and KfiC were present. These data suggest that the interaction between the KfiA, KfiB, and KfiC proteins is essential for the stable association of these proteins with the cytoplasmic membrane and the biosynthesis of the K5 polysaccharide.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Manchester; Uppsala University	Roberts, IS (corresponding author), Univ Manchester, Sch Biol Sci, 1-800 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Pourhossein, Meraj/W-3666-2017	pourhossein, meraj/0000-0002-9627-8589; Hodson, Nigel/0000-0002-7486-1976; Lind, Thomas/0000-0003-2791-688X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Breton C, 1998, J BIOCHEM, V123, P1000; BRONNER D, 1993, FEMS MICROBIOL LETT, V113, P279, DOI 10.1016/0378-1097(93)90218-Q; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chung JY, 1998, FEMS MICROBIOL LETT, V166, P289, DOI 10.1111/j.1574-6968.1998.tb13903.x; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DURAND P, 1998, THESIS U P M CURIE P; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIND T, 1993, J BIOL CHEM, V268, P20705; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; ROBERSON EB, 1992, APPL ENVIRON MICROB, V58, P1284, DOI 10.1128/AEM.58.4.1284-1291.1992; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; ROBERTS IS, 1995, MICROBIOL-SGM, V141, P2023, DOI 10.1099/13500872-141-9-2023; SIEBERTH V, 1995, J BACTERIOL, V177, P4562, DOI 10.1128/jb.177.15.4562-4565.1995; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	22	61	70	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27311	27315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859322				2022-12-27	WOS:000089144800086
J	Moyer, BD; Duhaime, M; Shaw, C; Denton, J; Reynolds, D; Karlson, KH; Pfeiffer, J; Wang, SS; Mickle, JE; Milewski, M; Cutting, GR; Guggino, WB; Li, M; Stanton, BA				Moyer, BD; Duhaime, M; Shaw, C; Denton, J; Reynolds, D; Karlson, KH; Pfeiffer, J; Wang, SS; Mickle, JE; Milewski, M; Cutting, GR; Guggino, WB; Li, M; Stanton, BA			The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; BETA(2)-ADRENERGIC RECEPTOR; BASOLATERAL MEMBRANE; MOLECULAR-BASIS; GENE-PRODUCT; MDCK CELLS; PROTEIN; LOCALIZATION; CFTR; IDENTIFICATION	Polarization of cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel to the apical plasma membrane in epithelial cells is critical for vectorial chloride transport. Previously, we reported that the C terminus of CFTR constitutes a PDZ-interacting domain that is required for CFTR polarization to the apical plasma membrane and interaction with the PDZ domain-containing protein EBP50 (NHERF). PDZ interacting domains are typically composed of the C-terminal three to five amino acids, which in CFTR are QDTRL. Our goal was to Identify the key amino acid(s) in the PDZ-interacting domain of CFTR with regard to its apical polarization, interaction with EBP50, and ability to mediate transepithelial chloride secretion. Point substitution of the C-terminal leucine (Leu at position 0) with alanine abrogated apical polarization of CFTR, interaction between CFTR and EBP50, efficient expression of CFTR in the apical membrane, and chloride secretion. Point substitution of the threonine (Thr at position -2) with alanine or valine had no effect on the apical polarization of CFTR, but reduced interaction between CFTR and EBP50, efficient expression of CFTR in the apical membrane as well as chloride secretion. By contrast, individual point substitution of the other C-terminal amino acids (Gln at position -4, Asp at position -3 and Arg at position -1) with alanine had no effect on measured parameters. We conclude that the PDZ-interacting domain, in particular the leucine (position 0) and threonine (position -2) residues, are required for the efficient, polarized expression of CFTR in the apical plasma membrane, interaction of CFTR with EBP50, and for the ability of CFTR to mediate chloride secretion, Mutations that delete the C terminus of CFTR may cause cystic fibrosis because CFTR is not polarized, complexed with EBP50, or efficiently expressed in the apical membrane of epithelial cells.	Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Med Genet, Johns Hopkins Hosp, CMSC 104, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Dartmouth College; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Stanton, BA (corresponding author), Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.	bruce.a.stanton@dartmouth.edu	Milewski, Michal/C-7144-2012	Milewski, Michal/0000-0001-7982-2565	NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753, DK 48977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, P50DK048977, R37DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CHENG J, 1999, PEDIATR PULM, V19, P168; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Ciruela F, 1999, FEBS LETT, V448, P91, DOI 10.1016/S0014-5793(99)00341-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Corbeil D, 1999, J CELL SCI, V112, P1023; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mickle JE, 1998, CLIN CHEST MED, V19, P443, DOI 10.1016/S0272-5231(05)70092-7; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; MORRIS AP, 1993, AM J PHYSIOL, V265, pC688, DOI 10.1152/ajpcell.1993.265.3.C688; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 1999, AM J PHYSIOL-RENAL, V277, pF271, DOI 10.1152/ajprenal.1999.277.2.F271; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponce A, 1997, J MEMBRANE BIOL, V159, P149, DOI 10.1007/s002329900278; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang XB, 1999, CHINESE J ORG CHEM, V19, P249; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Zhang L, 1998, P NATL ACAD SCI USA, V95, P10158, DOI 10.1073/pnas.95.17.10158	52	149	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27069	27074						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852925				2022-12-27	WOS:000089144800055
J	Murasawa, S; Matsubara, H; Mori, Y; Masaki, H; Tsutsumi, Y; Shibasaki, Y; Kitabayashi, I; Tanaka, Y; Fujiyama, S; Koyama, Y; Fujiyama, A; Iba, S; Iwasaka, T				Murasawa, S; Matsubara, H; Mori, Y; Masaki, H; Tsutsumi, Y; Shibasaki, Y; Kitabayashi, I; Tanaka, Y; Fujiyama, S; Koyama, Y; Fujiyama, A; Iba, S; Iwasaka, T			Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; N-TERMINAL KINASE; GROWTH-FACTOR RECEPTOR; RAT CARDIAC FIBROBLASTS; PROTEIN-KINASES; DIFFERENTIAL ACTIVATION; EPITHELIAL-CELLS; TYPE-2 RECEPTORS; JNK; CALCIUM	Ca2+-sensitive tyrosine kinase Pyk2 was shown to be involved in angiotensin (Ang) II-mediated activation of extracellular signal-regulated kinase (ERK) via transactivation of epidermal growth factor receptor (EGF-R), In this study, we tested the involvement of Pyk2 and EGF-R in Ang II-induced activation of JNK and c-Jun in cardiac fibroblasts, Ang II markedly stimulated JNK activities, which were abolished by genistein and intracellular Ca2+ chelators but partially by protein kinase C depletion. Inhibition of EGF-R did not affect Pyk2 and JNK activation by Ang II. Stable transfection with a dominant negative (DN) mutant for Pyk2 (PKM) completely blocked JNK activation by Ang II. DN mutants of Rad (DN-Rac1) and MEK kinase (DN-MEKK1) also abolished it, whereas those of Cdc42, RhoA, and Ha-Ras had no effect, Induction of c-Jun gene transcription by Ang II was abolished in PKM, DN-Rac1, and DN-MEKK1, in which Ang II-induced binding of ATF2/c-Jun heterodimer to the activator protein-1 sequence at -190 played a key role. These results suggest that 1) in cardiac fibroblasts activation of JNK and c-Jun by Ang II is initiated by Pyk2-dependent signalings but not by downstream signals of EGF-R or Ras, 2) Rad but not Cdc42 is required for JNK activation by Ang II upstream of NEKK1, and 3) ATF-2/c-Jun binding to the activator protein-1 sequence at -190 plays a key role for induction of c-Jun gene by Ang II.	Kansai Med Univ, Dept Med 2, Moriguchi, Osaka 5708507, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan	Kansai Medical University; National Cancer Center - Japan	Matsubara, H (corresponding author), Kansai Med Univ, Dept Med 2, Fumizonocho 10-15, Moriguchi, Osaka 5708507, Japan.		Kitabayashi, Issay/G-2204-2017	Kitabayashi, Issay/0000-0002-8409-0407				BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Dam H., 1995, EMBO J, V14, P1798; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; INAGAMI T, 1994, HYPERTENS RES, V17, P87; Ishida M, 1998, CIRC RES, V82, P7; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsubara H, 1998, ENDOCR J, V45, P137, DOI 10.1507/endocrj.45.137; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; Murasawa S, 1996, Hypertens Res, V19, P271, DOI 10.1291/hypres.19.271; MURASAWA S, 1995, J BIOL CHEM, V270, P24282, DOI 10.1074/jbc.270.41.24282; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Ohkubo N, 1997, CIRCULATION, V96, P3954; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Yano P, 1998, CIRC RES, V83, P752, DOI 10.1161/01.RES.83.7.752; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOHN I, 1995, MOL CELL BIOL, V15, P6160; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	48	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26856	26863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856308				2022-12-27	WOS:000089144800027
J	Yang, Y; Janota, K; Tabei, K; Huang, N; Siegel, MM; Lin, YI; Rasmussen, BA; Shlaes, DM				Yang, Y; Janota, K; Tabei, K; Huang, N; Siegel, MM; Lin, YI; Rasmussen, BA; Shlaes, DM			Mechanism of inhibition of the class A beta-lactamases PC1 and TEM-1 by tazobactam - Observation of reaction products by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAVULANIC ACID; ESCHERICHIA-COLI; SULBACTAM; SEQUENCE	The reactions of class A beta-lactamases PC1 and TEM-1 with tazobactam (TZB), a potent penicillanic sulfone inhibitor for class A beta-lactamases, were studied using electrospray ionization mass spectrometry (ESI/MS). Following inactivation of the beta-lactamases by TZB, new abundant high mass components were observed including three with molecular masses of 52, 70, and 88 Da greater than PC1 and TEM-1, respectively, and a component with a molecular mass of 300 Da greater than PC1. In addition, three TZB reaction products with molecular masses of 248, 264, and 280 Da were observed, High performance liquid chromatography (HPLC)/ESI/MS analysis of the TZB-PC1 adduct digested with Glu-C revealed three new components with masses 52, 70, and 88 Da greater than that of the peptide composed of amino acid residues 58-82 and one new component with a mass 70 Da greater than that of the peptide composed of amino acid residues 125-141, HPLC/ESI/MS/MS analysis of the two digested peptides whose masses increased by 70 Da indicated that Ser-70 and Ser-130 were the most likely TZB-modified amino acid residues. Based on these data, a mechanism for the inactivation of the class A beta-lactamases by TZB is proposed. In this scheme, initial acylation of Ser-70 by TZB and opening of the lactam ring are followed by one of several different events: (1) the rapid decomposition of TZB with loss of the enamine moiety to form the propiolylated enzyme, (2) an intramolecular nucleophilic displacement of the imine or enamine moiety by Ser-130 to form a cross-linked vinyl ether, and (3) hydrolysis of the imine or enamines to form a Ser-70-linked aldehyde.	Wyeth Ayerst Res, Infect Dis Res Div, Pearl River, NY 10965 USA	Pfizer	Yang, Y (corresponding author), Wyeth Ayerst Res, Infect Dis Res Div, 401 N Middletown Rd,Bldg 205,Rm 227, Pearl River, NY 10965 USA.							AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; AMBLER RP, 1975, BIOCHEM J, V151, P197, DOI 10.1042/bj1510197; APLIN RT, 1993, J CHEM SOC CHEM COMM, P121, DOI 10.1039/c39930000121; Bonomo RA, 1997, FEMS MICROBIOL LETT, V148, P59, DOI 10.1016/S0378-1097(97)00013-X; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; BUSH K, 1993, ANTIMICROB AGENTS CH, V37, P851, DOI 10.1128/AAC.37.4.851; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; KUCK NA, 1989, ANTIMICROB AGENTS CH, V33, P1964, DOI 10.1128/AAC.33.11.1964; McLaughlin J R, 1981, J Biol Chem, V256, P11272; Mirgorodskaya E, 1999, ANAL CHEM, V71, P4431, DOI 10.1021/ac990578v; MURRAY PR, 1994, DIAGN MICR INFEC DIS, V19, P111, DOI 10.1016/0732-8893(94)90121-X; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PAYNE DJ, 1994, ANTIMICROB AGENTS CH, V38, P767, DOI 10.1128/AAC.38.4.767; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; RASMUSSEN BA, 1991, MOL MICROBIOL, V5, P1211, DOI 10.1111/j.1365-2958.1991.tb01895.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3731; TABEI K, 1998, P AM SOC MASS SPECTR, P186; YANG Y, 1997, 37 INT C ANT AG CHEM, P82	22	50	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26674	26682						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837472				2022-12-27	WOS:000089144800003
J	Kariya, Y; Kyogashima, M; Suzuki, K; Isomura, T; Sakamoto, T; Horie, K; Ishihara, M; Takano, R; Kamei, K; Hara, S				Kariya, Y; Kyogashima, M; Suzuki, K; Isomura, T; Sakamoto, T; Horie, K; Ishihara, M; Takano, R; Kamei, K; Hara, S			Preparation of completely 6-O-desulfated heparin and its ability to enhance activity of basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR COMPLEX; BINDING SEQUENCE; CELL-SURFACE; SULFATE PROTEOGLYCANS; BIOLOGICAL-ACTIVITY; LIPOPROTEIN-LIPASE; 6-O-SULFATE GROUPS; ENDOTHELIAL-CELLS; SELF-ASSOCIATION; FGF RECEPTOR	Although regioselective removal of 6-O-sulfate groups of heparin has been undertaken by several researchers, complete 6-O-desulfation with little side reaction has not been attained successfully. In this work, a modified method with a certain silylating reagent, N-methyl-N-(trimethylsilyl)trifluoroacetamide, has been established to produce completely 6-O-desulfated heparin with few other chemical changes. The degrees of 6-O-desulfation were estimated by means of chemical disaccharide analyses and/or C-13 NMR spectra. Although the completely 6-O-desulfated heparin lost about 20% of 2-O-sulfate groups, any other chemical changes and depolymerization were not detected. The completely 6-O-desulfated heparin displayed strong inhibition of COS-1 cell adhesion to basic fibroblast growth factor (bFGF)-coated well in a dose-dependent manner, as was clarified by the competitive cell-adhesion assay. Furthermore, the completely 6-O-desulfated heparin was shown to promote in vitro A31 fibroblast proliferation in a dose-dependent manner in the presence of bFGF. These results suggest that signal transduction through bFGF/bFGF receptor in A31 cells occurs in the absence of 6-O-sulfate groups in heparin. The involvement of 6-O-sulfate group(s) of heparin/heparan sulfate in the promotion of bFGF mitogenic activity was reported by several groups. This discrepancy between our results and those of other groups would be due to the differences in molecular size of heparin/heparan sulfate derivatives and/or cell species used for the assay.	Seikagaku Corp, Tokyo Res Inst, Tokyo 2070021, Japan; Natl Def Med Coll, Inst Res, Div Biomed Engn, Tokorozawa, Saitama 3598513, Japan; Kyoto Inst Technol, Sakyo Ku, Kyoto 6068585, Japan	Seikagaku Corporation; National Defense Medical College - Japan; Kyoto Institute of Technology	Kariya, Y (corresponding author), Seikagaku Corp, Tokyo Res Inst, 3-1253 Tateno, Tokyo 2070021, Japan.	kariya@to.seikagaku.co.jp						AVIEZER D, 1994, J BIOL CHEM, V269, P114; AYOTTE L, 1986, CARBOHYD RES, V145, P267, DOI 10.1016/S0008-6215(00)90434-8; Baumann H, 1998, CARBOHYD RES, V308, P381, DOI 10.1016/S0008-6215(98)00097-4; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; Ishihara M, 1993, TRENDS GLYCOSCI GLYC, V5, P343, DOI 10.4052/tigg.5.343; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 1998, J BIOCHEM-TOKYO, V123, P240; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; Lam K, 1998, J BIOMOL STRUCT DYN, V15, P1009, DOI 10.1080/07391102.1998.10508997; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PIANI S, 1993, J CARBOHYD CHEM, V12, P507, DOI 10.1080/07328309308019404; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; TAKANO R, 1995, J CARBOHYD CHEM, V14, P885, DOI 10.1080/07328309508005382; TAKANO R, 1998, CARBOHYDR LETT, V3, P71; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Van den Berghe L, 1998, BIOCHEM BIOPH RES CO, V252, P420, DOI 10.1006/bbrc.1998.9668; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	54	58	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25949	25958		10.1074/jbc.M004140200	http://dx.doi.org/10.1074/jbc.M004140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10837484	hybrid			2022-12-27	WOS:000088999700011
J	Matias, PM; Donner, P; Coelho, R; Thomaz, M; Peixoto, C; Macedo, S; Otto, N; Joschko, S; Scholz, P; Wegg, A; Basler, S; Schafer, M; Egner, U; Carrondo, MA				Matias, PM; Donner, P; Coelho, R; Thomaz, M; Peixoto, C; Macedo, S; Otto, N; Joschko, S; Scholz, P; Wegg, A; Basler, S; Schafer, M; Egner, U; Carrondo, MA			Structural evidence for ligand specificity in the binding domain of the human androgen receptor - Implications for pathogenic gene mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; INSENSITIVITY SYNDROME; CRYSTAL-STRUCTURE; MACROMOLECULAR STRUCTURES; RAR-GAMMA; ACID; REFINEMENT; RECOGNITION; ANTAGONISM; RESISTANCE	The crystal structures of the human androgen receptor (hAR) and human progesterone receptor ligand-binding domains in complex with the same ligand metribolone (R1881) have been determined. Both three-dimensional structures show the typical nuclear receptor fold. The change of two residues in the ligand-binding pocket between the human progesterone receptor and hAR is most likely the source for the specificity of R1881 to the hAR. The structural implications of the 14 known mutations in the ligand-binding pocket of the hAR ligand-binding domains associated with either prostate cancer or the partial or complete androgen receptor insensitivity syndrome were analyzed. The effects of most of these mutants could be explained on the basis of the crystal structure.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Schering AG, Res Labs, D-13342 Berlin, Germany; Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal	Universidade Nova de Lisboa; Schering AG	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2780 Oeiras, Portugal.	carrondo@itqb.unl.pt	Matias, Pedro M/B-7180-2008; Peixoto, Cristina/K-8945-2014	Matias, Pedro M/0000-0001-6170-451X; Thomaz, Monica/0000-0002-3133-0278; Peixoto, Cristina/0000-0002-0995-6637; Carrondo, Maria Armenia/0000-0002-1261-1162				Albers N, 1997, J PEDIATR-US, V131, P386, DOI 10.1016/S0022-3476(97)80063-7; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLIS AD, 1992, MOL ENDOCRINOL, V6, P1909; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bevan CL, 1996, HUM MOL GENET, V5, P265, DOI 10.1093/hmg/5.2.265; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cabral DF, 1998, BRAZ J MED BIOL RES, V31, P775, DOI 10.1590/S0100-879X1998000600008; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; JAKUBICZKA S, 1992, HUM GENET, V90, P311; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Komori S, 1998, ARCH GYNECOL OBSTET, V261, P95, DOI 10.1007/s004040050206; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Letz M, 1999, BBA-PROTEIN STRUCT M, V1429, P391, DOI 10.1016/S0167-4838(98)00249-0; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Lumbroso S, 1996, J CLIN ENDOCR METAB, V81, P1984, DOI 10.1210/jc.81.5.1984; MARCELLI M, 1994, J CLIN INVEST, V94, P1642, DOI 10.1172/JCI117507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PINSKY L, 1992, CLIN INVEST MED, V15, P456; PRECIGOUX G, 1981, ACTA CRYSTALLOGR B, V37, P291, DOI 10.1107/S0567740881002835; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TEUTSCH G, 1994, J STEROID BIOCHEM, V48, P111, DOI 10.1016/0960-0760(94)90257-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yong EL, 1998, MOL CELL ENDOCRINOL, V137, P41, DOI 10.1016/S0303-7207(97)00229-3; [No title captured]	54	477	526	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26164	26171		10.1074/jbc.M004571200	http://dx.doi.org/10.1074/jbc.M004571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840043	hybrid			2022-12-27	WOS:000088999700040
J	Chung, SH; Polgar, J; Reed, GL				Chung, SH; Polgar, J; Reed, GL			Protein kinase C phosphorylation of syntaxin 4 in thrombin-activated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOME-ASSOCIATED PROTEIN; SYNAPTIC VESICLE FUSION; MEMBRANE-FUSION; SNARE PROTEINS; GRANULE SECRETION; COMPLEX-FORMATION; CORE COMPLEX; EXOCYTOSIS; MACHINERY; SYNAPTOTAGMIN	We postulated that the syntaxins, because of their key role in SNARE complex formation and exocytosis, could be important targets for signaling by intracellular kinases involved in secretion. We found that syntaxin 4 was phosphorylated in human platelets treated with a physiologic agent that induces secretion (thrombin) but not when they were treated with an agent that prevents secretion (prostacyclin). Syntaxin 4 phosphorylation was blocked by inhibitors of activated protein kinase C (PKC), and, in parallel assays, PKC inhibitors also blocked secretion from thrombin-activated platelets. In platelets, cellular activation by thrombin or phorbol 12-myristate 13-acetate decreased the binding of syntaxin 4 with SNAP-23, another platelet t-SNARE. Phosphatase inhibitors increased syntaxin 4 phosphorylation and further decreased syntaxin 4-SNAP-23 binding induced by cell activation. Conversely, a PKC inhibitor blocked syntaxin 4 phosphorylation and returned binding of syntaxin 4-SNAP-23 to that seen in nonstimulated platelets. In vitro, PKC directly phosphorylated platelet syntaxin 4 and recombinant syntaxin 4. PKC phosphorylation in vitro inhibited (71 +/- 8%) the binding of syntaxin 4 to SNAP-23, These results provide evidence that extracellular activation can be coupled through intracellular PKC signaling so as to modulate SNARE protein interactions involved in platelet exocytosis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave,2-127, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-64057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Hilfiker S, 1999, J PHYSIOL-LONDON, V515, P1, DOI 10.1111/j.1469-7793.1999.001ad.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Richards-Smith B, 1999, MOL GENET METAB, V68, P14, DOI 10.1006/mgme.1999.2891; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Sloan DC, 1997, BIOCHEM J, V328, P13; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Ware JA, 1997, HANDB EXP PHARM, V126, P247; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	41	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25286	25291		10.1074/jbc.M004204200	http://dx.doi.org/10.1074/jbc.M004204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10856305	hybrid			2022-12-27	WOS:000088849400033
J	Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU				Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU			Expression cloning of a new member of the ABO blood group glycosyltransferases, iGb(3) synthase, that directs the synthesis of isoglobo-glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SMALL-INTESTINE; ANTI-GAL; GENE; SERIES; ISOGLOBOTETRAOSYLCERAMIDE; CHROMATOGRAPHY; SYNTHETASE; ANTIBODIES; MICE	The large array of different glycolipids described in mammalian tissues is a reflection, in part, of diverse glycosyltransferase expression. Herein, we describe the cloning of a UDP-galactose: beta-D-galactosyl-1,4-glucosyl-ceramide alpha-1,3-galactosyltransferase (iGb(3) synthase) from a rat placental cDNA expression library. iGb(3) synthase acts on lactosylceramide, LacCer (Ga1 beta 1,4Glc-beta 1Cer) to form iGb(3) (Ga1 alpha 1,3Gal beta 1,4Glc beta 1Cer) initiating the synthesis of the isoglobo-series of glycosphingolipids. The isolated cDNA encoded a predicted protein of 339 amino acids, which shows extensive homology (40-50% identity) to members of the ABO gene family that includes: murine alpha 1,3-galactosyltransferase, Forssman (Gb,) synthase, and the ABO glycosyltransferases. In contrast to the murine alpha 1,3-galactosyltransferase, iGb(3) synthase preferentially modifies glycolipids over glycoprotein substrates, Reverse transcriptase-polymerase chain reaction revealed a widespread tissue distribution of iGb(3) synthase RNA expression, with high levels observed in spleen, thymus, and skeletal muscle. As an indirect consequence of the expression cloning strategy used, we have been able to identify several potential glycolipid biosynthetic pathways where iGb(3) functions, including the globo- and isoglobo-series of glycolipids.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center	Keusch, JJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	jkeusch@pathbox.wustl.edu	Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK 41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1995, J LIPID RES, V36, P611; ANGSTROM J, 1982, ARCH BIOCHEM BIOPHYS, V213, P708, DOI 10.1016/0003-9861(82)90601-4; ARIGA T, 1995, BBA-LIPID LIPID MET, V1254, P257, DOI 10.1016/0005-2760(94)00186-3; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREIMER ME, 1982, J BIOL CHEM, V257, P557; CARLSEN SA, 1993, CANCER RES, V53, P2906; FALK P, 1986, BIOCHIM BIOPHYS ACTA, V878, P296, DOI 10.1016/0005-2760(86)90161-X; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; Galili U, 1989, Prog Clin Biol Res, V319, P225; GLASGOW J, 1998, P 6 INT C INT SYST M, P175; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LaTemple DC, 1999, CANCER RES, V59, P3417; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; OSTRANDER GK, 1988, J BIOL CHEM, V263, P18716; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; SLOMIANY BL, 1974, EUR J BIOCHEM, V43, P161, DOI 10.1111/j.1432-1033.1974.tb03396.x; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SUNG SSJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P295, DOI 10.1016/0005-2760(79)90031-6; THURIN J, 1989, BIOCHIM BIOPHYS ACTA, V1002, P267, DOI 10.1016/0005-2760(89)90339-1; Wiegandt H, 1985, GLYCOLIPIDS, P1; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WINAND RJ, 1994, J IMMUNOL, V153, P1386; Xu HJ, 1999, J BIOL CHEM, V274, P29390, DOI 10.1074/jbc.274.41.29390; Yamamoto H, 1999, J BIOCHEM-TOKYO, V125, P923, DOI 10.1093/oxfordjournals.jbchem.a022370; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	35	92	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25308	25314		10.1074/jbc.M002629200	http://dx.doi.org/10.1074/jbc.M002629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854427	hybrid			2022-12-27	WOS:000088849400036
J	Mizobata, T; Kawagoe, M; Hongo, K; Nagai, J; Kawata, Y				Mizobata, T; Kawagoe, M; Hongo, K; Nagai, J; Kawata, Y			Refolding of target proteins from a "rigid" mutant chaperonin demonstrates a minimal mechanism of chaperonin binding and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMERIC GLUTAMINE-SYNTHETASE; INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; FOLDING REACTION; ATPASE CYCLE; GROEL; POLYPEPTIDE; INTERMEDIATE	One of the most interesting facets of GroEL-facilitated protein folding lies in the fact that the requirement for a successful folding reaction of a given protein target depends upon the refolding conditions used. In this report, we utilize a mutant of GroEL (GroEL T89W) whose domain movements have been drastically restricted, producing a chaperonin that is incapable of utilizing the conventional cyclic mechanism of chaperonin action. This mutant was, however, still capable of improving the refolding yield of lactate dehydrogenase in the absence of both GroES and ATP hydrolysis. A very rapid interconversion of conformations was detected in the mutant immediately after ATP binding, and this interconversion was inferred to form part of the target release mechanism in this mutant. The possibility exists that some target proteins, although dependent on GroEL for improved refolding yields, are capable of refolding successfully by utilizing only portions of the entire mechanism provided by the chaperonins.	Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6800945, Japan	Tottori University	Kawata, Y (corresponding author), Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6800945, Japan.		Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Katsumata K, 1996, J MOL BIOL, V258, P827, DOI 10.1006/jmbi.1996.0290; KAWATA Y, 1994, FEBS LETT, V345, P229, DOI 10.1016/0014-5793(94)00456-0; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBO T, 1993, J BIOL CHEM, V268, P19346; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	40	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25600	25607		10.1074/jbc.M000795200	http://dx.doi.org/10.1074/jbc.M000795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837467	hybrid			2022-12-27	WOS:000088849400074
J	O'Hare, MJ; Hou, ST; Morris, EJ; Cregan, SP; Xu, Q; Slack, RS; Park, DS				O'Hare, MJ; Hou, ST; Morris, EJ; Cregan, SP; Xu, Q; Slack, RS; Park, DS			Induction and modulation of cerebellar granule neuron death by E2F-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTION-INDEPENDENT MECHANISMS; ALZHEIMERS-DISEASE BRAIN; S-PHASE ENTRY; CELL-CYCLE; CEREBRAL-ISCHEMIA; PC12 CELLS; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; DNA-SYNTHESIS	Growing evidence suggests that certain cell cycle regulators also mediate neuronal death. Of relevance, cyclin D1-associated kinase activity is increased and the retinoblastoma protein (Rb), a substrate of the cyclin D1-Cdk4/6 complex, is phosphorylated during K+ deprivation-evoked death of cerebellar granule neurons (CGNs), Cyclin-dependent kinase (CDK) inhibitors block this death, suggesting a requirement for the cyclin D1/Cdk4/6-Rb pathway. However, the downstream target(s) of this pathway are not well defined. The transcription factor E2F-1 is regulated by Rb and is reported to evoke death in proliferating cells when overexpressed. Accordingly, we examined whether E2F-1 was sufficient to evoke death of CGNs and whether it was required for death evoked by low K+. We show that adenovirus-mediated expression of E2F-1 in CGNs results in apoptotic death, which is independent of p53, dependent upon Bax, and associated with caspase 3-like activity. In addition, we demonstrate that levels of E2F-1 mRNA and protein increase during K+ deprivation-evoked death. The increase in E2F-1 protein is blocked by the CDK inhibitor flavopiridol, Finally, E2F-1-deficient neurons are modestly resistant to death induced by low K+. These results indicate that E2F-1 expression is sufficient to promote neuronal apoptosis and that endogenous E2F-1 modulates the death of CGNs evoked by low K+.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Massachusetts Gen Hosp, Ctr Canc, Oncol Mol Lab, Charlestown, MA 02129 USA	University of Ottawa; National Research Council Canada; Harvard University; Massachusetts General Hospital	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Hou, Sheng Tao/AAM-7756-2020; Hou, Sheng Tao/O-3202-2018; Cregan, Sean/M-3205-2013	Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835; Hou, Sheng Tao/0000-0001-9736-342X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Busser J, 1998, J NEUROSCI, V18, P2801; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cregan SP, 1999, J NEUROSCI, V19, P7860; Deckwerth TL, 1998, EXP NEUROL, V152, P150, DOI 10.1006/exnr.1998.6846; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; GALLO V, 1987, J NEUROSCI, V7, P2203; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hou ST, 1997, BIOCHEM CELL BIOL, V75, P383, DOI 10.1139/bcb-75-4-383; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lavia P, 1999, BIOESSAYS, V21, P221; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; McShea A, 1997, AM J PATHOL, V150, P1933; MELLO D, 1993, P NATL ACAD SCI USA, V90, P10989; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Namura S, 1998, J NEUROSCI, V18, P3659; NEVINS JR, 1992, SCIENCE, V258, P424; NITATORI T, 1995, J NEUROSCI, V15, P1001; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Schulz JB, 1996, J NEUROSCI, V16, P4696; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Stefanis L, 1999, J NEUROSCI, V19, P6235; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vincent I, 1997, J NEUROSCI, V17, P3588; Watson A, 1998, J NEUROSCI, V18, P751; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YAN GZ, 1995, J NEUROSCI, V15, P6200	64	131	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25358	25364		10.1074/jbc.M001725200	http://dx.doi.org/10.1074/jbc.M001725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851232	hybrid			2022-12-27	WOS:000088849400043
J	Stockando, JD; Bao, HF; Schenck, J; Malik, B; Middleton, P; Schlanger, LE; Eaton, DC				Stockando, JD; Bao, HF; Schenck, J; Malik, B; Middleton, P; Schlanger, LE; Eaton, DC			Differential effects of protein kinase C on the levels of epithelial Na+ channel subunit proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ALPHA-SUBUNIT; ALDOSTERONE; CELLS; TRANSPORT	Regulation of epithelial Na+ channel (ENaC) subunit levels by protein kinase C (PKC) was investigated in A6 cells. PKC activation altered ENaC subunit levels, differentially decreasing the levels of both beta and gamma, but not alpha ENaC. Temporal regulation of beta and gamma ENaC by PKC differed; gamma ENaC decreased with a time constant of 3.7 +/- 1.0 h, whereas beta ENaC decreased in 13.9 +/- 3.0 h. Activation of PRC also resulted in a decrease in trans-epithelial Na+ reabsorption for up to 48 h. PIMA activation of PRC resulted in negative feedback inhibition of PKC protein levels beginning within 4 h, Both beta and gamma ENaC levels, as well as transport tended toward pretreatment values after 48 h of PMA treatment. PKC inhibitors attenuated the effects of PMA on ENaC subunit levels and Na+ transport. These results directly show for the first time that PRC differentially regulates ENaC subunit levels by decreasing the levels of beta and gamma but not alpha ENaC protein. These results imply a PKC-dependent, long term decrease in Na+ reabsorption.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Emory Univ, Dept Physiol, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	University of Texas System; University of Texas Health San Antonio; Emory University	Stockando, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Stockand, James/0000-0002-3817-4319; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009729, R37DK037963, R01DK037963] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09729, DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Els WJ, 1998, AM J PHYSIOL-CELL PH, V275, pC120; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; LING BN, 1990, MOL CELL BIOCHEM, V99, P141, DOI 10.1007/BF00230344; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; MIDDLETON P, 2000, IN PRESS AM J PHYSL; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rokaw MD, 1996, J BIOL CHEM, V271, P32468, DOI 10.1074/jbc.271.50.32468; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Verrey F, 1998, EXP NEPHROL, V6, P294; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	22	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25760	25765		10.1074/jbc.M003615200	http://dx.doi.org/10.1074/jbc.M003615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829029	hybrid			2022-12-27	WOS:000088849400092
J	Dapic, V; Oliver, D				Dapic, V; Oliver, D			Distinct membrane binding properties of N- and C-terminal domains of Escherichia coli SecA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ATPASE; PREPROTEIN TRANSLOCASE; PLASMA-MEMBRANE; INNER MEMBRANE; IN-VIVO; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; SECRETORY PROTEIN; CATALYTIC CYCLE; REGION	SecA is a motor protein that drives protein translocation at the Escherichia coli translocon. SecA membrane binding has been shown to occur with high affinity at SecYE and low affinity at anionic phospholipids. To dissect SecA-membrane interaction with reference to SecA structure, the membrane binding properties of N- and C-terminal SecA domains, denoted SecA-N664 and SecA-619C, respectively, were characterized. Remarkably, only SecA-N664 bound to the membrane with high affinity, whereas SecA-619C bound with low affinity in a nonsaturable manner through partitioning with phospholipids. Moreover, SecA-N664 and SecA-619C associated with each other to reconstitute wild type binding affinity. Corroborative results were also obtained from membrane binding competition and subcellular fractionation studies along with binding studies to membranes prepared from strains overproducing SecYE protein. Together, these findings indicate that the specific interaction of SecA with SecYE occurs through its N-terminal domain and that the C-terminal domain, although important in SecA membrane cycling at a later stage of translocation, appears to initially assist SecA membrane binding by interaction with phospholipids. These results provide the first evidence for distinct membrane binding characteristics of the two SecA primary domains and their importance for optimal binding activity, and they are significant for understanding SecA dynamics at the translocon.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Wesleyan University	Oliver, D (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; ITO K, 1992, MOL MICROBIOL, V6, P2423; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 1999, J BIOL CHEM, V274, P23868, DOI 10.1074/jbc.274.34.23868; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Miller J. H., 1972, EXPT MOL GENETICS, P431; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mori H, 1998, J BIOCHEM, V124, P122, DOI 10.1093/oxfordjournals.jbchem.a022070; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; Ramamurthy V, 1998, J BACTERIOL, V180, P6419; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Snyders S, 1997, J BIOL CHEM, V272, P11302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; WINZOR DJ, 1995, QUANTITATIVE CHARACT	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25000	25007		10.1074/jbc.M001100200	http://dx.doi.org/10.1074/jbc.M001100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835419	hybrid			2022-12-27	WOS:000088683300102
J	Fouassier, L; Yun, CC; Fitz, JG; Doctor, RB				Fouassier, L; Yun, CC; Fitz, JG; Doctor, RB			Evidence for ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) self-association through PDZ-PDZ interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA(2)-ADRENERGIC RECEPTOR; DOMAINS; PROTEINS; FAMILY; MEMBRANE; PSD-95	Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 (EBP50) is a versatile membrane-cytoskeleton linking protein that binds to the COOH-tail of specific integral membrane proteins through its two PDZ domains. These EBP50 binding interactions have been implicated in sequestering interactive sets of proteins into common microdomains, regulating the activity of interacting proteins, and modulating membrane protein trafficking. With only two PDZ domains, it is unclear how EBP50 forms multiprotein complexes. Other PDZ proteins increase their breadth and diversity of protein interactions through oligomerization. Hypothesizing that EBP50 self-associates to amplify its functional capacity, far-Western blotting of cholangiocyte epithelial cell proteins with EBP50 fusion protein revealed that EBP50 binds to a 50-kDa protein. Far-Western blotting of EBP50 isolated by two-dimensional gel electrophoresis or immunoprecipitation demonstrates that the 50-kDa binding partner is itself EBP50, Further, co-transfection/co-precipitation studies show the self-association can occur in an intracellular environment, In vitro analysis of the EBP50-EBP50 binding interaction indicates it is both saturable and of relatively high affinity. Analysis of truncated EBP50 proteins indicates EBP50 self-association is mediated through its PDZ domains. The ability to self-associate provides a mechanism for EBP50 to expand its capacity to form multiprotein complexes and regulate membrane transport events.	Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Denver, CO 80262 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21205 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University	Doctor, RB (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, 4200 E 9th Ave,Box B158, Denver, CO 80262 USA.		Fouassier, Laura/M-7556-2017	Fouassier, Laura/0000-0001-6377-5610	NIDDK NIH HHS [DK 44484, DK 43278, R01 DK 46082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046082, R01DK043278, P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	13	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25039	25045		10.1074/jbc.C000092200	http://dx.doi.org/10.1074/jbc.C000092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10859298	hybrid			2022-12-27	WOS:000088683300107
J	Stasiolek, M; Gavrilyuk, V; Sharp, A; Horvath, P; Selmaj, K; Feinstein, DL				Stasiolek, M; Gavrilyuk, V; Sharp, A; Horvath, P; Selmaj, K; Feinstein, DL			Inhibitory and stimulatory effects of lactacystin on expression of nitric oxide synthase type 2 in brain glial cells - The role of I kappa B-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; UBIQUITIN-PROTEASOME PATHWAY; INTERFERON-GAMMA; NUCLEAR TRANSLOCATION; REACTIVE ASTROCYTES; MULTIPLE-SCLEROSIS; GENE-TRANSCRIPTION; INDUCIBLE FORM; ACTIVATION; INDUCTION	Expression of inflammatory nitric oxide synthase (NOS2) is mediated by transcription factor NF kappa B. By using the specific proteasome inhibitor lactacystin to examine I kappa B degradation, we observed a paradoxical increase in lipopolysaccharide- and cytokine-dependent NOS2 expression at low concentrations or when lactacystin was added subsequent to cytokines. Lactacystin reduced the initial accumulation of NOS2 mRNA but reduced its subsequent decrease. Lactacystin increased NOS2 promoter activation after 24 h, but not after 4 h, and similarly prevented initial NF kappa B activation and at later times caused NF kappa B reactivation. Lactacystin reduced initial degradation of I kappa B-alpha and I kappa B-beta, however, at later times selectively increased I kappa B-beta, which was predominantly non-phosphorylated. Expression of full-length rat I kappa B-beta, but not a carboxyl-terminal truncated form, inhibited NOS2 induction and potentiation by lactacystin, Lactacystin increased I kappa B-beta expression in the absence of NOS2 inducers, as well as expression of heat shock protein 70, and the heat shock response due to hyperthermia increased I kappa B-beta expression. These results suggest that I kappa B-beta contributes to persistent NF kappa B activation and NOS2 expression in glial cells, that I kappa B-beta is a stress protein inducible by hyperthermia or proteasome inhibitors, and that delayed addition of proteasome inhibitors can have stimulatory rather than inhibitory actions.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60607 USA; Med Univ Lodz, Dept Neurol, PL-90153 Lodz, Poland	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University Lodz	Feinstein, DL (corresponding author), Univ Illinois, Dept Anesthesiol, 900 S Ashland Ave,MC513, Chicago, IL 60607 USA.	dlfeins@uic.edu	feinstein, doug/M-9414-2019; Stasiołek, Mariusz/M-3732-2014; Stasiolek, Mariusz Pawel/S-9546-2016	Stasiolek, Mariusz Pawel/0000-0002-2582-1708; Selmaj, Krzysztof/0000-0003-1213-7218				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DeGroot CJA, 1997, J NEUROPATH EXP NEUR, V56, P10, DOI 10.1097/00005072-199701000-00002; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; deVera ME, 1996, SURGERY, V120, P144, DOI 10.1016/S0039-6060(96)80281-9; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Feinstein DL, 1998, J NEUROCHEM, V70, P1484; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fiebich BL, 1999, NEUROPHARMACOLOGY, V38, P1325, DOI 10.1016/S0028-3908(99)00055-6; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Hao W, 1999, AUTOIMMUNITY, V29, P93, DOI 10.3109/08916939908995378; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Hori K, 1999, BLOOD, V93, P1843, DOI 10.1182/blood.V93.6.1843.406k40_1843_1850; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Ju WK, 1998, J NEUROVIROL, V4, P445; Kemler I, 1999, GLIA, V26, P212, DOI 10.1002/(SICI)1098-1136(199905)26:3<212::AID-GLIA3>3.0.CO;2-F; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kloetzel PM, 1998, GENE THER, V5, P1297, DOI 10.1038/sj.gt.3300724; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mellgren RL, 1997, J BIOL CHEM, V272, P29899, DOI 10.1074/jbc.272.47.29899; Meng XZ, 1996, AM J PHYSIOL-CELL PH, V271, pC1316, DOI 10.1152/ajpcell.1996.271.4.C1316; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Scarim AL, 1998, ENDOCRINOLOGY, V139, P5050, DOI 10.1210/en.139.12.5050; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zhang HF, 1998, BIOCHEM PHARMACOL, V55, P1873, DOI 10.1016/S0006-2952(98)00078-1; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	64	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24847	24856		10.1074/jbc.M910284199	http://dx.doi.org/10.1074/jbc.M910284199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827092	hybrid			2022-12-27	WOS:000088683300082
J	Nishio, K; Nakai, M				Nishio, K; Nakai, M			Transfer of iron-sulfur cluster from NifU to apoferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; PROTEINS; IDENTIFICATION; MITOCHONDRIA; METABOLISM; BIOGENESIS; NFS1P	Iron-sulfur proteins are present in a wide variety of organisms and are known to play important physiological roles, not only in electron transfer and metabolic reactions, but also in transcriptional regulation. However, little is known about how iron-sulfur clusters themselves are synthesized and assembled within polypeptides. Here we show that a [2Fe-2S] cluster-containing NifU of cyanobacterium Synechocystis PCC6803, SyNifU, possesses the ability to deliver its [2Fe-2S] cluster to an apoferredoxin without the aid of other proteinaceous or nonproteinaceous factor(s), Upon delivery the reconstituted holoferredoxin regained electron transfer ability. The [2Fe-2S] cluster contained within SyNifU was labile upon exposure to the iron-chelating reagent EDTA, suggesting that the iron-sulfur cluster is abnormally exposed to solvent. We propose that NifU serves as a scaffold for iron-sulfur cluster assembly and functions as a mediator for iron-sulfur cluster delivery.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Nakai, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nakai@protein.osaka-u.ac.jp						Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nishio K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3155; OUZOUNIS C, 1994, TRENDS BIOCHEM SCI, V19, P199, DOI 10.1016/0968-0004(94)90021-3; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	25	102	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22615	22618		10.1074/jbc.C000279200	http://dx.doi.org/10.1074/jbc.C000279200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837463	hybrid			2022-12-27	WOS:000088419400003
J	Okada, Y; Sawa, H; Tanaka, S; Takada, A; Suzuki, S; Hasegawa, H; Umemura, T; Fujisawa, J; Tanaka, Y; Hall, WW; Nagashima, K				Okada, Y; Sawa, H; Tanaka, S; Takada, A; Suzuki, S; Hasegawa, H; Umemura, T; Fujisawa, J; Tanaka, Y; Hall, WW; Nagashima, K			Transcriptional activation of JC virus by human T-lymphotropic virus type I tax protein in human neuronal cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NF-KAPPA-B; HUMAN POLYOMAVIRUS JC; HTLV-I; ENHANCER; DNA; SEQUENCE; ELEMENT; P40TAX; KINASE	Polyomavirus JC (JCV) causes the human demyelinating disease, progressive multifocal leukoencephalopathy (PML). The recent demonstration of cases of PML in association with human T-lymphotropic virus type I (HTLV-I) infection prompted us to examine whether the HTLV-I-encoded regulatory protein Tax activates JCV transcription. By employing a dual luciferase assay, we initially found that the expression of Tax activated the transcriptional potential of both early and late promoters of JCV in human neuronal but not in non-neuronal cells. We subsequently analyzed the mechanism of Tax-induced activation of the JCV promoter in neuronal cells with the following results: 1) the JCV promoter that lacks the NF-kappa B-binding motif could not be activated by Tax; 2) the overexpression of I kappa B alpha abolished Tax-induced transcriptional activation of the JCV promoter; 3) a Tax mutant M22) lacking the potential for activation via the NF-kappa B pathway did not activate the JCV promoter. Furthermore, Tax enhances the gene expression of JCV T antigen and VP1. We examined mechanisms of the cell-specific activation of the JCV promoter by Tax. Electrophoretic mobility shift assay demonstrated the presence of Tax-bound protein(s) that were specifically present in non-neuronal cells. This study is the first demonstration of the activation of JCV promoter by HTLV-I Tax in an NF-kappa B-dependent manner.	Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Comparat Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Sapporo Municipal Hosp, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608604, Japan; Sapporo Municipal Hosp, Japan Sci & Technol, CREST, Chuo Ku, Sapporo, Hokkaido 0608604, Japan; Natl Inst Infect Dis, Dept Infect Pathol, Shinjuku Ku, Tokyo 1620052, Japan; Kansai Med Univ, Dept Microbiol, Osaka 5708506, Japan; Univ Ryukyu, Dept Immunol & Infect Dis, Nishihara, Okinawa 9030125, Japan; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med Microbiol, Dublin 2, Ireland	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID); Kansai Medical University; University of the Ryukyus; University College Dublin	Sawa, H (corresponding author), Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.		Sawa, Hirofumi/AAW-8816-2021; Umemura, Takashi/A-6938-2012; Tanaka, Shinya/D-3586-2011; Hasegawa, Hideki/C-7978-2014; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755				DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; MOCH H, 1992, J VIROL, V66, P7346, DOI 10.1128/JVI.66.12.7346-7354.1992; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; Shimizu N, 1999, INTERNAL MED, V38, P932, DOI 10.2169/internalmedicine.38.932; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; SUZUKI T, 1993, ONCOGENE, V8, P2391; TAKAHASHI H, 1992, ACTA NEUROPATHOL, V83, P105, DOI 10.1007/BF00308469; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wakutani Y, 1998, NEUROPATHOLOGY, V18, P347, DOI 10.1111/j.1440-1789.1998.tb00126.x; Weber T, 1997, INTERVIROLOGY, V40, P98, DOI 10.1159/000150537; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17016	17023		10.1074/jbc.275.22.17016	http://dx.doi.org/10.1074/jbc.275.22.17016			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828075	hybrid			2022-12-27	WOS:000087392200087
J	Chotani, MA; Touhalisky, K; Chiu, IM				Chotani, MA; Touhalisky, K; Chiu, IM			The small GTPases Ras, Rac, and Cdc42 transcriptionally regulate expression of human fibroblast growth factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; RHO-GTPASES; CELLS; PROMOTER; BINDING; PHOSPHORYLATION; GENE; PHENOTYPE; FAMILY	Four distinct promoters (1A, 1B, 1C, and 1D) of fibroblast growth factor 1 (FGF1), spaced up to 70 kilobase pairs apart, direct the expression of alternatively spliced transcript variants (FGF1.A, -1.B, -1.C, and -1.D) that encode FGF1. These FGF1 transcripts can be detected in cultured cells as well as in normal and diseased tissues. These transcripts are differentially regulated in a cell-specific manner. To further delineate the biological function of multiple promoter usage by a single gene, we investigated the transcriptional regulation of these promoters by defined signaling pathways associated with cell proliferation and cell survival. Here we show a specific association of two of the FGF1 promoters, 1C and 1D, with signaling cascades of the Ras superfamily of GTPases. A serum-response element, comprised of the Ets and CArG motifs, present in promoter 1D was shown to be the target of distinct signaling cascades; the Ets motif target of Ras, Rac1, and Cdc42 regulation; and the CArG motif target of de novo protein synthesis-independent cascade. Ras and Rac1 also activated the FGF2 promoter. Further, the transcription factor Ets2 synergistically activated FGF1 gene, but not FGF2, in a Ras- and Rac1-dependent signaling pathway. In support of these conclusions high levels of intracellular FGF1 were detected in cells undergoing cytokinesis. Altogether, our results suggest that FGF1 may play a fundamental role in cell division, spreading, and migration, in addition to cell proliferation.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.		Chotani, Maqsood/E-2891-2011; Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Chotani MA, 1996, GENET ANAL-BIOMOL E, V12, P133, DOI 10.1016/1050-3862(95)00124-7; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Payson RA, 1998, J STEROID BIOCHEM, V66, P93, DOI 10.1016/S0960-0760(98)00051-X; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEGER R, 1994, J BIOL CHEM, V269, P25699; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; Treisman R, 1990, Semin Cancer Biol, V1, P47; Trinh T, 1994, FOCUS, V16, P78; Yang BS, 1996, MOL CELL BIOL, V16, P538	32	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30432	30438		10.1074/jbc.M003545200	http://dx.doi.org/10.1074/jbc.M003545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10849427	hybrid			2022-12-27	WOS:000089577900070
J	Scoltock, AB; Bortner, CD; Bird, GS; Putney, JW; Cidlowski, JA				Scoltock, AB; Bortner, CD; Bird, GS; Putney, JW; Cidlowski, JA			A selective requirement for elevated calcium in DNA degradation, but not early events in anti-Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DEPENDENT ENDONUCLEASE; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; CYTOSOLIC CA2+; ACTIVATION; BCL-2; SUPPRESSION; THYMOCYTES; FRAGMENTATION	Jurkat cells undergo apoptosis in response to anti-Fas antibody through a caspase-dependent death cascade in which calcium signaling has been implicated. We have now evaluated the role of calcium during this death cascade at the single cell level in real time utilizing flow cytometric analysis and confocal microscopy. Fluo-3 and propidium iodide were employed to evaluate calcium fluxes and to discriminate between viable and non-viable cells, respectively. Anti-Fas treatment of Jurkat cells resulted in a sustained increase in intracellular calcium commencing between 1 and 2 h after treatment and persisting until subsequent loss of cell membrane integrity. The significance of this rise in calcium was evaluated by buffering intracellular calcium with BAPTA and/or removing calcium from the extracellular medium and monitoring the effects of these manipulations on calcium signaling and components of the apoptotic process. Complete inhibition of the anti-Fas induced rise in intracellular calcium required both chelation of [Ca2+](i) and removal of extracellular calcium. Interestingly, this condition did not abrogate several events in Fas-induced apoptosis including cell shrinkage, mitochondrial depolarization, annexin binding, caspase activation, and nuclear poly(A)DP-ribose polymerase cleavage. Furthermore, calcium-free conditions in the absence of anti-Fas antibody weakly induced these apoptotic components. In marked contrast, calcium depletion did not induce DNA degradation in control cells, and inhibited apoptotic DNA degradation in response to anti-Fas. These data support the concept that the rise in intracellular calcium is not a necessary component for the early signal transduction pathways in anti-Fas-induced apoptosis in Jurkat cells, but rather is necessary for the final degradation of chromatin via nuclease activation.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021; Cidlowski, John A/G-2548-2019	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748; Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087, ZIAES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; COHEN JJ, 1984, J IMMUNOL, V132, P38; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; DOWD DR, 1991, J BIOL CHEM, V266, P18423; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; Marin MC, 1996, ONCOGENE, V12, P2259; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; OSHIMI Y, 1995, J IMMUNOL, V154, P599; Palaga T, 1996, EXP CELL RES, V228, P92, DOI 10.1006/excr.1996.0303; Preston GA, 1997, CANCER RES, V57, P537; Putney JW, 1999, BIOESSAYS, V21, P38; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245	35	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30586	30596		10.1074/jbc.M004058200	http://dx.doi.org/10.1074/jbc.M004058200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10859318	hybrid			2022-12-27	WOS:000089577900092
J	Welm, AL; Mackey, SL; Timchenko, LT; Darlington, GJ; Timchenko, NA				Welm, AL; Mackey, SL; Timchenko, LT; Darlington, GJ; Timchenko, NA			Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA ISOFORMS; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; HEPATOCYTE PROLIFERATION; PARTIAL-HEPATECTOMY; GENE PROMOTER; CELL-CYCLE; EXPRESSION; MICE	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP), In this paper, we investigate the pathway for LIP induction during APR and the role of LIP in regulation of the C/EBP alpha promoter. The 5' region of C/EBP beta mRNA has been shown to be involved in the regulation of LIP translation. Our data demonstrate that binding of cytoplasmic proteins to the 5' region of C/EBP beta mRNA is altered in response to LPS administration, One of the major changes is induced binding of a cytoplasmic protein that is immunologically identical to the previously characterized RNA-binding protein CUGBP1. Induction of CUGBP1 binding activity in liver cytoplasm during APR is accompanied by the elevation of CUGBP1 binding activity on polysomes, CUGBP1 immunoprecipitated from livers of LPS-treated mice, but not from normal animals, is capable of inducing LIP translation in a cell-free translation system. The ability of CUGBP1 to induce LIP translation during APR depends on phosphorylation of CUGBP1, We show that elevation of LIP during APR and after partial hepatectomy leads to increased binding of LIP to the C/EBP consensus site found within the mouse C/EBPa promoter. This binding correlates with reduction of C/EBP alpha mRNA levels in both biological situations. Co-transfection experiments showed that full-length C/EBP alpha activates the C/EBP alpha promoter, while LIP blocks this activation. Our data suggest that the dominant negative isoform of C/EBP beta, LIP, down-regulates the C/EBP alpha promoter in liver and in cultured hepatocytes, Because full-length C/EBP alpha and C/EBP beta proteins regulate liver proliferation, this function of LIP may be important in liver growth and differentiation.	Baylor Coll Med, Huffington Ctr Aging, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Timchenko, NA (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Dept Pathol, N803,1 Baylor Pl, Houston, TX 77030 USA.				NIAMS NIH HHS [AR10D44387-01] Funding Source: Medline; NIA NIH HHS [AG00756] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044387] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; An MR, 1996, MOL CELL BIOL, V16, P2295; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Welm AL, 1999, MOL CELL BIOL, V19, P1695; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	34	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27406	27413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854425				2022-12-27	WOS:000089144800099
J	Bi, RF; Rong, YQ; Bernard, A; Khrestchatisky, M; Baudry, M				Bi, RF; Rong, YQ; Bernard, A; Khrestchatisky, M; Baudry, M			Src-mediated tyrosine phosphorylation of NR2 subunits of N-methyl-D-aspartate receptors protects from calpain-mediated truncation of their C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR; KINASE-C; BRAIN SPECTRIN; RAT-BRAIN; IN-VIVO; 2B; POTENTIATION; PROTEOLYSIS; NEURONS; PSD-95	Src-mediated tyrosine phosphorylation of N-methyl-D-aspartate receptor subunits has been shown to modify the functional properties of N-methyl-D-aspartate receptors. Moreover, calpain-mediated truncation of N-methyl-D-aspartate receptor subunits has been found to alter the structure of the receptors. In the present study, we first used immunoprecipitation with a variety of antibodies against N-methyl-D-aspartate receptor subunits and anti-phosphotyrosine antibodies to show that tyrosine-phosphorylated subunits of N-methyl-D-aspartate receptor are protected against calpain-mediated truncation of their C-terminal domains. A GST fusion protein containing the C-terminal domain of NR2A was used to identify the calpain cutting sites in the C-terminal domain. One site was identified at residues 1278-1279, corresponding to one of the preferred calpain truncation sites. This site is adjacent to a consensus sequence for Src-mediated tyrosine phosphorylation, and Src mediated tyrosine phosphorylation of the GST-NR2A C-terminal fusion protein also inhibited calpain-mediated truncation of the fusion protein. We propose that phosphorylation of NR2 subunits and the resulting inhibition of calpain-mediated truncation of their C-terminal domains provide for the stabilization of the N-methyl-D-aspartate receptors in postsynaptic structures.	Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA; INSERM, U 29, INMED, F-13273 Marseille, France	University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Baudry, M (corresponding author), Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA.				NIA NIH HHS [AG-14751] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014751] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bi RF, 1998, BRAIN RES, V797, P154, DOI 10.1016/S0006-8993(98)00433-8; Bi XN, 1997, J NEUROCHEM, V68, P1484; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FERHAT L, 1994, NEUROCHEM INT, V25, P327, DOI 10.1016/0197-0186(94)90139-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIBERMAN DN, 1994, NATURE, V369, P235; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; Lynch G, 1998, NEUROBIOL LEARN MEM, V70, P82, DOI 10.1006/nlme.1998.3840; MASSICOTTE G, 1990, MOL PHARMACOL, V32, P278; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Takagi N, 1997, J NEUROCHEM, V69, P1060; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634	46	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26477	26483		10.1074/jbc.M003763200	http://dx.doi.org/10.1074/jbc.M003763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846184	hybrid			2022-12-27	WOS:000088999700082
J	Sabroe, I; Peck, MJ; Van Keulen, BJ; Jorritsma, A; Simmons, G; Clapham, PR; Williams, TJ; Pease, JE				Sabroe, I; Peck, MJ; Van Keulen, BJ; Jorritsma, A; Simmons, G; Clapham, PR; Williams, TJ; Pease, JE			A small molecule antagonist of chemokine receptors CCR1 and CCR3 - Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG MODEL; ENDOTHELIAL-CELLS; EOTAXIN RECEPTOR; IN-VIVO; CHEMOATTRACTANT CYTOKINE; CROSS-DESENSITIZATION; CHEMOTACTIC CYTOKINES; MONOCLONAL-ANTIBODY; MESSENGER-RNA; BONE-MARROW	We describe a small molecule chemokine receptor antagonist, UCB35625 (the trans-isomer J113863 published by Banyu Pharmaceutical Co., patent WO98/04554), which is a potent, selective inhibitor of CCR1 and CCR3. Nanomolar concentrations of UCB35625 were sufficient to inhibit eosinophil shape change responses to MIP-1 alpha; MCP-4, and eotaxin, while greater concentrations could inhibit the chemokine induced internalization of both CCR1 and CCR3. UCB35625 also inhibited the CCR3-mediated entry of the human immunodeficiency virus-1 primary isolate 89.6 into the glial cell line, NP-2 (IC50 = 57 nM). Chemotaxis of transfected cells expressing either CCR1 or CCR3 was inhibited by nanomolar concentrations of the compound (IC50 values of CCR1-MIP-1 alpha = 9.6 nM, CCR3-eotaxin = 93.7 nM). However, competitive ligand binding assays on the same transfectants revealed that considerably larger concentrations of UCB35625 were needed for effective ligand displacement than were needed far the inhibition of receptor function. Thus, it appears that the compound may interact with a region present in both receptors that inhibits the conformational change necessary to initiate intracellular signaling. By virtue of its potency at the two major eosinophil chemokine receptors, UCB35625 is a prototypic therapy for the treatment of eosinophil-mediated inflammatory disorders, such as asthma and as an inhibitor of CCR3-mediated human immunodeficiency virus-1 entry.	Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, London SW7 2AZ, England; UCB, Pharma Res & Dev, B-1420 Braine Lalleud, Belgium; UCL, Sch Med, Wohl Vir Ctr, Dept Mol Pathol & Clin Biochem, London W1P 6DB, England	Imperial College London; UCB Pharma SA; University of London; University College London; UCL Medical School	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	j.pease@ic.ac.uk	Sabroe, Ian/I-5981-2013; Pease, James/X-4521-2018; Sabroe, Ian/AAE-5858-2019; Simmons, Graham/G-3523-2012	Sabroe, Ian/0000-0001-9750-8975; Pease, James/0000-0003-3749-0341; Simmons, Graham/0000-0002-9615-7023				Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955; Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954; HASLETT C, 1985, AM J PATHOL, V119, P101; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946; Li L, 1999, J IMMUNOL, V162, P2477; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; NAYA A, 1998, Patent No. 9804554; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; Reeves JD, 2000, METH MOL B, V138, P209; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Shinkai A, 1999, J IMMUNOL, V163, P1602; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Soda Y, 1999, BIOCHEM BIOPH RES CO, V258, P313, DOI 10.1006/bbrc.1999.0633; SPRY CJF, 1992, IMMUNOL TODAY, V13, P384, DOI 10.1016/0167-5699(92)90085-L; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; Wang ZX, 1999, J BIOL CHEM, V274, P28413, DOI 10.1074/jbc.274.40.28413; Williams CMM, 1998, IMMUNOGENETICS, V47, P178, DOI 10.1007/s002510050345; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	58	187	199	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25985	25992		10.1074/jbc.M908864199	http://dx.doi.org/10.1074/jbc.M908864199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854442	hybrid			2022-12-27	WOS:000088999700016
J	Cabezon, E; Butler, PJG; Runswick, MJ; Walker, JE				Cabezon, E; Butler, PJG; Runswick, MJ; Walker, JE			Modulation of the oligomerization state of the bovine F-1-ATPase inhibitor protein, IF1, by pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; HEART-MITOCHONDRIA; ATP SYNTHASE; IDENTIFICATION; PURIFICATION	Bovine IF1, a basic protein of 84 amino acids, is involved in the regulation of the catalytic activity of the F-1 domain of ATP synthase, At pH 6.5, but not at basic pH values, it inhibits the ATP hydrolase activity of the enzyme. The oligomeric state of bovine LF, has been investigated at various pH values by sedimentation equilibrium analytical ultracentrifugation and by covalent cross-linking. Both techniques confirm that the protein forms a tetramer at pH 8, and below pH 6.5, the protein is predominantly dimeric, By covalent cross-linking, it has been found that at pH 8.0 the fragment of IF, consisting of residues 44-84 forms a dimer, whereas the fragment from residues 32-84 is tetrameric. Therefore, some or all of the residues between positions 32 and 43 are necessary for tetramer formation and are involved in the pH-sensitive interconversion between dimer and tetramer, One important residue in the interconversion is histidine 49, Mutation of this residue to lysine abolishes the pH-dependent activation-inactivation, and the mutant protein is active and dimeric at all pH values investigated. It is likely from MMR studies that the inhibitor protein dimerizes by forming an antiparallel alpha-helical coiled-coil over its C-terminal region and that at high pH values, where the protein is tetrameric, the inhibitory regions are masked. The mutation of histidine 49 to lysine is predicted to abolish coiled-coil formation over residues 32-43 preventing interaction between two dimers, forcing the equilibrium toward the dimeric state, thereby freeing the N-terminal inhibitory regions and allowing them to interact with F-1.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Cabezon, Elena/K-5874-2014	Walker, John/0000-0001-7929-2162; Cabezon, Elena/0000-0002-6177-5016				Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Eisenberg H, 1976, BIOL MACROMOLECULES; HASHIMOTO T, 1981, J BIOCHEM-TOKYO, V90, P1151, DOI 10.1093/oxfordjournals.jbchem.a133567; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; Kratky O, 1973, Methods Enzymol, V27, P98; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZMEDIAVILLA C, 1993, EUR J BIOCH, V215; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; NORLING B, 1990, EUR J BIOCHEM, V188, P247, DOI 10.1111/j.1432-1033.1990.tb15396.x; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; Papa S, 1996, EUR J BIOCHEM, V240, P461, DOI 10.1111/j.1432-1033.1996.0461h.x; PEDERSEN PL, 1981, CURR TOP BIOENERG, V11, P149; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schnizer R, 1996, BBA-PROTEIN STRUCT M, V1292, P241, DOI 10.1016/0167-4838(95)00208-1; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; vanRaaij MJ, 1996, BIOCHEMISTRY-US, V35, P15618, DOI 10.1021/bi960628f; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	25	150	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25460	25464		10.1074/jbc.M003859200	http://dx.doi.org/10.1074/jbc.M003859200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831597	hybrid			2022-12-27	WOS:000088849400055
J	Tortorella, M; Pratta, M; Liu, RQ; Abbaszade, I; Ross, H; Burn, T; Arner, E				Tortorella, M; Pratta, M; Liu, RQ; Abbaszade, I; Ross, H; Burn, T; Arner, E			The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; CARTILAGE AGGRECAN; ARTICULAR-CARTILAGE; CELL-ADHESION; FAMILY; BINDING; PROTEIN; MATRIX; OSTEOARTHRITIS	Aggrecanase-1 (ADAMTS-4) is a member of the a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS) protein family that was recently identified. Aggrecanase-1 is one of two ADAMTS cartilage-degrading enzymes purified from interleukin-1-stimulated bovine nasal cartilage (Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. Ri., Liu, R., Rosenfeld, S. A,, Copeland, R. A., Decicco, C. P., Wynn, R., Rockwell, A, Yang, F., Duke, J. L., Solomon, K., George, R, Bruckner, R., Nagase, H., Itoh, Y., Ellis, D. M., Boss, H., Wiswall, B. H., Murphy, K., Hillman, M. C., Jr., Hollis, G. F., and Arner, E.C. (1999) Science 284, 1664-1666; 2 Abbaszade, I., Liu, R. Q., Yang, F., Rosenfeld, S. A., Boss, O. H., Link, J. R., Ellis, D. M., Tortorella, M. D., Pratta, M. A., Hollis, J. M., Wynn, R., Duke, J. L., George, H. J., Hillman, M. C., Jr., Murphy, K., Wiswall, B. H., Copeland, R. A., Decicco, C. P., Bruckner, R., Nagase, H., Itoh, Y., Newton, R. C., Magolda, R. L., Trzaskos, J. M., and Burn, T. C. (1999) J. Biol. Chem. 274, 23443-23450). The aggrecan products generated by this enzyme are found in cartilage cultures stimulated with cytokines and in synovial fluid from patients with arthritis, suggesting that aggrecanase-1 may be important in diseases involving cartilage destruction. Here we demonstrate that the thrombospondin type-1 (TSP-1) motif located within the C terminus of aggrecanase-1 binds to the glycosaminoglycans of aggrecan. Data from several studies indicate that this binding of aggrecanase-1 to aggrecan through the TSP-1 motif is necessary for enzymatic cleavage of aggrecan. 1) A truncated form of aggrecanase-1 lacking the TSP-I motif was not effective in cleaving aggrecan. 2) Several peptides representing different regions of the TSP-1 motif effectively blocked aggrecanase-1 cleavage of aggrecan by preventing the enzyme from binding to the substrate. 3) Aggrecanase-1 was not effective in cleaving glycosaminoglycan-free aggrecan. Taken together, these data suggest that the TSP-1 motif of aggrecanase-1 is critical for substrate recognition and cleavage.	Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Appl Biotechnol, Wilmington, DE 19880 USA	DuPont; DuPont	Tortorella, M (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.			Burn, Timothy/0000-0001-6648-4333				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Ghosh P, 1996, OSTEOARTHR CARTILAGE, V4, P43, DOI 10.1016/S1063-4584(96)80006-9; GUO NH, 1992, J BIOL CHEM, V267, P19349; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Magnetto S, 1998, CELL BIOCHEM FUNCT, V16, P211, DOI 10.1002/(SICI)1099-0844(199809)16:3<211::AID-CBF788>3.3.CO;2-Q; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PRATTA MA, 1997, T ORTHOP RES SOC, V22, P453; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 2000, IN PRESS J BIOL CHEM, V275; TORTORELLA MD, 1999, T ORTHOP RES SOC, V24, P84; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WOLSBERG TG, 1996, DEV BIOL, V180, P389	38	155	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25791	25797		10.1074/jbc.M001065200	http://dx.doi.org/10.1074/jbc.M001065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827174	hybrid			2022-12-27	WOS:000088849400096
J	Touriol, C; Roussigne, M; Gensac, MC; Prats, H; Prats, AC				Touriol, C; Roussigne, M; Gensac, MC; Prats, H; Prats, AC			Alternative translation initiation of human fibroblast growth factor 2 mRNA controlled by its 3 '-untranslated region involves a poly(A) switch and a translational enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCAPPED MESSENGER-RNA; HUMAN FIBROBLAST-GROWTH-FACTOR-2; REGULATES TRANSLATION; EXPRESSION; PROTEIN; FORMS; CELLS; SEQUENCE; CUG; POLYADENYLATION	Five fibroblast growth factor 2 (FGF-2) isoforms are synthesized from human FGF-2 mRNA by a process of alternative initiation of translation. The regulation of FGF-2 isoform expression by the mRNA 5823-nucleotide-long 3'-untranslated region containing eight alternative polyadenylation sites was examined. Because previous studies had shown that FGF-2 expression was regulated in primary cells but not in transformed cells, primary human skin fibroblasts were used in this study. Using an approach of cell transfection with synthetic reporter mRNAs, a novel translational enhancer (3'-TE) was identified in the 1370-nucleotide mRNA segment located upstream from the eighth poly(A) site, Deletion mutagenesis showed that the 3'-TE was composed of two domains with additive effects. The 3'-TE exhibited the unique feature of modulating the use of FGF-2 alternative initiation codons, which favored the relative expression of CUG-initiated isoforms. Interestingly, the use of an alternative polydenylation site removing the 3'-TE was detected in skin fibroblasts in response to heat shock and cell density variations. At high cell densities, 3'-TE removal was correlated with a loss of CUG-initiated FGF-2 expression. These data show that the FGF-2 mRNA 3'-untranslated region is able to modulate FGF-2 isoform expression by the coupled processes of translation activation and alternative polyadenylation.	CHU Rangueil, Inst Louis Bugnard, INSERM, U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U397, Ave Jean Poulhes, F-31403 Toulouse 04, France.		Prats, Anne-Catherine/E-5051-2016; TOURIOL, Christian/O-8949-2014	Prats, Anne-Catherine/0000-0002-5282-3776; TOURIOL, Christian/0000-0003-1219-4693; Roussigne, Myriam/0000-0002-4240-4105; Prats, Herve/0000-0002-4861-2167				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BENSAID M, 1989, EXP EYE RES, V45, P801; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BOST LM, 1993, GROWTH FACTORS, V9, P195, DOI 10.3109/08977199309010832; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Davis MG, 1997, J MOL CELL CARDIOL, V29, P1061, DOI 10.1006/jmcc.1997.0383; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gallie DR, 1996, NUCLEIC ACIDS RES, V24, P1954, DOI 10.1093/nar/24.10.1954; Galy B, 1999, CANCER RES, V59, P165; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; KNEE RS, 1994, BIOCHEM BIOPH RES CO, V205, P577, DOI 10.1006/bbrc.1994.2704; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEATHERS V, 1993, MOL CELL BIOL, V13, P5331, DOI 10.1128/MCB.13.9.5331; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	39	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19361	19367		10.1074/jbc.M908431199	http://dx.doi.org/10.1074/jbc.M908431199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858460	Green Published, hybrid			2022-12-27	WOS:000087815900096
J	Guerre-Millo, M; Gervois, P; Raspe, E; Madsen, L; Poulain, P; Derudas, B; Herbert, JM; Winegar, DA; Willson, TM; Fruchart, JC; Berge, RK; Staels, B				Guerre-Millo, M; Gervois, P; Raspe, E; Madsen, L; Poulain, P; Derudas, B; Herbert, JM; Winegar, DA; Willson, TM; Fruchart, JC; Berge, RK; Staels, B			Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PPAR-GAMMA ACTIVATORS; IMPAIRED GLUCOSE-TOLERANCE; HIGH-FAT DIET; IN-VIVO; LIPOPROTEIN METABOLISM; RESISTANCE SYNDROME; LIPID AVAILABILITY; INDUCED INHIBITION; ZUCKER RATS	Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia and insulin resistance (IR), respectively. Whereas glitazones are insulin sensitizers acting via activation of the peroxisome proliferator-activated receptor (PPAR) gamma subtype, fibrates exert their lipid-lowering activity via PPAR alpha. To determine whether PPAR alpha activators also improve insulin sensitivity, we measured the capacity of three PPAR alpha-selective agonists, fenofibrate, ciprofibrate, and the new compound GW9578, in two rodent models of high fat diet-induced (C57BL/6 mice) or genetic (obese Zucker rats) IR. At doses yielding serum concentrations shown to activate selectively PPAR alpha, these compounds markedly lowered hyperinsulinemia and, when present, hyperglycemia in both animal models. This effect relied on the improvement of insulin action on glucose utilization, as indicated by a lower insulin peak in response to intraperitoneal glucose in ciprofibrate-treated IR obese Zucker rats. In addition, fenofibrate treatment prevented high fat diet-induced increase of body weight and adipose tissue mass without influencing caloric intake. The specificity for PPAR alpha activation in vivo was demonstrated by marked alterations in the expression of PPAR alpha target genes, whereas PPAR gamma target gene mRNA levels did not change in treated animals. These results indicate that compounds with a selective PPAR alpha activation profile reduce insulin resistance without having adverse effects on body weight and adipose tissue mass in animal models of IR.	Inst Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Univ Bergen, Haukeland Hosp, Dept Biol Clin, Div Biochem, N-5021 Bergen, Norway; Sanofi Rech, F-31036 Toulouse, France; Glaxo Wellcome Res & Dev, Res Triangle Pk, NC 27709 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; University of Bergen; Haukeland University Hospital; Sanofi-Aventis; Sanofi France; GlaxoSmithKline	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Guerre-Millo, Michele/G-7253-2017; feinstein, doug/M-9414-2019; Madsen, Lise/C-6246-2012; Staels, Bart/N-9497-2016	Madsen, Lise/0000-0003-4468-1947; Staels, Bart/0000-0002-3784-1503				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; BAZIN R, 1982, J LIPID RES, V23, P839; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601; DESOUZA CJ, 1995, DIABETES, V44, P984, DOI 10.2337/diabetes.44.8.984; Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006; DESPRES JP, 1993, NUTRITION, V9, P452; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Goodpaster BH, 1998, CURR OPIN LIPIDOL, V9, P231, DOI 10.1097/00041433-199806000-00008; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HUTTUNEN JK, 1991, ANN MED, V23, P155, DOI 10.3109/07853899109148041; Inoue I, 1995, METABOLISM, V44, P1626, DOI 10.1016/0026-0495(95)90085-3; INOUE I, 1994, DIABETES RES CLIN PR, V25, P199, DOI 10.1016/0168-8227(94)90009-4; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES IR, 1990, DIABETES CARE, V13, P855, DOI 10.2337/diacare.13.8.855; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Madej A, 1998, INT J CLIN PHARM TH, V36, P345; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; Mayorek N, 1997, DIABETES, V46, P1958, DOI 10.2337/diabetes.46.12.1958; MIKHAILIDIS DP, 1990, J CARDIOVASC PHARM, V16, pS26, DOI 10.1097/00005344-199006169-00006; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Morin CL, 1997, ENDOCRINOLOGY, V138, P4665, DOI 10.1210/en.138.11.4665; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; OAKES ND, 1994, DIABETES, V43, P1203, DOI 10.2337/diabetes.43.10.1203; Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	46	517	547	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16638	16642		10.1074/jbc.275.22.16638	http://dx.doi.org/10.1074/jbc.275.22.16638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828060	hybrid			2022-12-27	WOS:000087392200035
J	Bell, R; Stevens, WK; Jia, ZC; Samis, J; Cote, HCF; MacGillivray, RTA; Nesheim, ME				Bell, R; Stevens, WK; Jia, ZC; Samis, J; Cote, HCF; MacGillivray, RTA; Nesheim, ME			Fluorescence properties and functional roles of tryptophan residues 60d, 96, 148, 207, and 215 of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ALPHA-THROMBIN; PRO-TRP INSERTION; PROTEIN-C; FACTOR-V; FIBRINOLYSIS INHIBITOR; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; EXTINCTION COEFFICIENTS; CATALYZED ACTIVATION; KUNITZ INHIBITORS	Conservative Trp-to-Phe mutations were individually created in human thrombin at positions 60d, 96, 148, 207, and 215. Fluorescence intensities for these residues varied by a factor of 6. Residues 60d, 96, 148, and 215 transferred energy to the thrombin inhibitor 5-dimethylaminonaphthalene-1-sulfonylarginine-N- (3-ethyl-1,5-pentanediyl)amide efficiently, but residue 207 did not. Intensities correlated inversely with exposure to solvent, and measured and theoretical energy transfer efficiencies agreed well. Function was measured with respect to fibrinogen clotting, platelet and factor V activation, inhibition by antithrombin, and the thrombomodulin-dependent activation of protein C and thrombin-activable fibrinolysis inhibitor (TAFI). All activities of W96F and W207F ranged from 74 to 154% of the wild-type activity. This was also true for W148F, except for inhibition by antithrombin, where it showed 60% activity. W60dF was deficient by 30, 57, and 43% with fibrinogen clotting, platelet activation, and factor V cleavage (Arg(1006)), respectively. W215F was deficient by 90, 55, and 56% with fibrinogen clotting, platelet activation, and factor V cleavage (Arg(1536)). With protein C and TAFI, W96F, W148F, and W207F were normal. W60dF, however, was 76 and 23% of normal levels with protein C and TAFI, respectively. In contrast, W215F was 25 and 124% of normal levels in these reactions. Thus, many activities of thrombin are retained upon substitution of Trp with Phe at positions 96, 148, and 207. Trp(60d), however, appears to be very important for TAFI activation, and Trp(215) appears to very important for clotting and protein C activation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; University of British Columbia	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Botterell Hall,Rm A212,Stuart St, Kingston, ON K7L 3N6, Canada.		Cote, Helene/K-7896-2012					Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOUTON MC, 1995, EUR J BIOCHEM, V229, P526, DOI 10.1111/j.1432-1033.1995.0526k.x; Callis PR, 1997, METHOD ENZYMOL, V278, P113; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30, DOI 10.1111/j.1749-6632.1991.tb43689.x; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG CS, 1987, BLOOD, V69, P867; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; Kokame K, 1998, J BIOL CHEM, V273, P12135, DOI 10.1074/jbc.273.20.12135; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LEBONNIEC BF, 1994, BIOCHEMISTRY-US, V33, P3959, DOI 10.1021/bi00179a023; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LORD ST, 1990, J BIOL CHEM, V265, P838; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUNDBLAD RL, 1984, J BIOL CHEM, V259, P6991; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NOWAK W, 1993, J MOL STRUCT THEOCHE, V283, P1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SILVERBERG SA, 1980, J BIOL CHEM, V255, P8550; STEINBERG IZ, 1971, ANNU REV BIOCHEM, V40, P83, DOI 10.1146/annurev.bi.40.070171.000503; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THOMPSON EA, 1988, THROMB HAEMOSTASIS, V59, P415; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; UHTEG LC, 1977, BIOCHIM BIOPHYS ACTA, V491, P551, DOI 10.1016/0005-2795(77)90300-2; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200	58	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29513	29520		10.1074/jbc.M001759200	http://dx.doi.org/10.1074/jbc.M001759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10831587	hybrid			2022-12-27	WOS:000089439800045
J	Bai, Y; Fox, DT; Lacy, JA; Van Lanen, SG; Iwata-Reuyl, D				Bai, Y; Fox, DT; Lacy, JA; Van Lanen, SG; Iwata-Reuyl, D			Hypermodification of tRNA in thermophilic archaea - Cloning, overexpression, and characterization of tRNA-guanine transglycosylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSCRIPTIONAL MODIFICATION; TRANSFER RIBONUCLEIC-ACID; ACTIVE-SITE NUCLEOPHILE; MODIFIED NUCLEOSIDE-Q; TRANSFER-RNA; ESCHERICHIA-COLI; SEQUENCE; PRECURSOR; QUEUINE; IDENTIFICATION	tRNA is structurally unique among nucleic acids in harboring an astonishing diversity of modified nucleosides. Two structural variants of the hypermodified nucleoside 7-deazaguanosine have been identified in tRNA: queuosine, which is found at the wobble position of the anticodon in bacterial and eukaryotic tRNA, and archaeosine, which is found at position 15 of the D-loop in archaeal tRNA. From homology searching of the Methanococcus jannaschii genome, a gene coding for an enzyme in the biosynthesis of archaeosine (tgt) was identified and cloned. The tgt gene was overexpressed in an Escherichia coli expression system, and the recombinant tRNA-guanine transglycosylase enzyme was purified and characterized. The enzyme catalyzes a transglycosylation reaction in which guanine is eliminated from position 15 of the tRNA and an archaeosine precursor (preQ(0)) is inserted. The enzyme is able to utilize both guanine and the 7-deazaguanine base pre/Q(0) as substrates, but not other 7-deazaguanine bases, and is able to modify tRNA from all three phylogenetic domains. The enzyme shows optimal activity at high temperature and acidic pH, consistent with the optimal growth conditions of M. jannaschii. The nature of the temperature dependence is consistent with a requirement for some degree of tRNA tertiary structure in order for recognition by the enzyme to occur.	Portland State Univ, Dept Chem, Portland, OR 97201 USA	Portland State University	Iwata-Reuyl, D (corresponding author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.		Fox, David/B-3222-2011					AKIMOTO H, 1988, J CHEM SOC PERK T 1, P1637, DOI 10.1039/p19880001637; Bjork G. R., 1990, CHOMATOGRAPHY MODIFI, P13; Bjork Glenn R., 1995, P165; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GUPTA R, 1984, J BIOL CHEM, V259, P9461; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KERSTEN H, 1988, Biofactors, V1, P27; KERSTEN H, 1990, CHROMATOGRAPHY MODIF, P69; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; Maniatis T., 1982, MOL CLONING LAB MANU; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; Migawa MT, 1996, SYNTHETIC COMMUN, V26, P3317, DOI 10.1080/00397919608004641; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; ROBB FT, 1995, ARCHAEA LAB MANUAL, P4; Romier C, 1997, FEBS LETT, V416, P93, DOI 10.1016/S0014-5793(97)01175-7; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146	37	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28731	28738		10.1074/jbc.M002174200	http://dx.doi.org/10.1074/jbc.M002174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862614	hybrid			2022-12-27	WOS:000089330700054
J	de Vocht, ML; Reviakine, I; Wosten, HAB; Brisson, A; Wessels, JGH; Robillard, GT				de Vocht, ML; Reviakine, I; Wosten, HAB; Brisson, A; Wessels, JGH; Robillard, GT			Structural and functional role of the disulfide bridges in the hydrophobin SC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGAL HYDROPHOBIN; AERIAL HYPHAE; SCHIZOPHYLLUM-COMMUNE; RODLET LAYER; PROTEINS; SURFACE; DISEASE	Hydrophobins function in fungal development by self-assembly at hydrophobic-hydrophilic interfaces such as the interface between the fungal cell wall and the air or a hydrophobic solid. These proteins contain eight conserved cysteine residues that form four disulfide bonds. To study the effect of the disulfide bridges on the self-assembly, the disulfides of the SC3 hydrophobin were reduced with 1,4-dithiothreitol, The free thiols were then blocked with either iodoacetic acid (IAA) or iodoacetamide (WM), introducing eight or zero negative charges, respectively. Circular dichroism and infrared spectroscopy showed that after opening of the disulfide bridges SC3 is initially unfolded. IAA-SC3 did not self-assemble at the air-water interface upon shaking an aqueous solution. Remarkably, after drying down IAA-SC3 or after exposing it to Teflon, it refolded into a structure similar to that observed for native SC3 at these interfaces. Iodoacetamide-SC3 on the other hand, which does not contain extra charges, spontaneously refolded in water in the amyloid-like beta-sheet conformation, characteristic for SC3 assembled at the water-air interface. From this we conclude that the disulfide bridges of SC3 are not directly involved in self-assembly but keep hydrophobin monomers soluble in the fungal cell or its aqueous environment, preventing premature self-assembly.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Reviakine, Ilya/B-2631-2013; Wösten, Han AB/K-2769-2016	Reviakine, Ilya/0000-0002-3448-5072; Wösten, Han AB/0000-0002-0399-3648				BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; BRASH JL, 1995, ACS SYM SER, V602, P1; de Vocht ML, 1998, BIOPHYS J, V74, P2059, DOI 10.1016/S0006-3495(98)77912-3; DEVRIES OMH, 1993, ARCH MICROBIOL, V159, P330, DOI 10.1007/BF00290915; Dufrene YF, 1999, J BACTERIOL, V181, P5350; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; HAYNES CA, 1995, J COLLOID INTERF SCI, V169, P313, DOI 10.1006/jcis.1995.1039; HOLLECKER M, 1989, PROTEIN STRUCTURE PR, P145; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lugones LG, 1998, MICROBIOL-UK, V144, P2345, DOI 10.1099/00221287-144-8-2345; Talbot NJ, 1996, PLANT CELL, V8, P985, DOI 10.1105/tpc.8.6.985; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; Wessels JGH, 1997, ADV MICROB PHYSIOL, V38, P1; WESSELS JGH, 1991, PLANT CELL, V3, P793; WESSELS JGH, 1991, J GEN MICROBIOL, V137, P2439, DOI 10.1099/00221287-137-10-2439; Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0; WOSTEN HAB, 1993, PLANT CELL, V5, P1567; WOSTEN HAB, 1994, EMBO J, V13, P5848, DOI 10.1002/j.1460-2075.1994.tb06929.x; WOSTEN HAB, 1994, EUR J CELL BIOL, V63, P122; YAGUCHI M, 1993, DUTCH ELM DISEASE RESEARCH, P152	21	87	97	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28428	28432		10.1074/jbc.M000691200	http://dx.doi.org/10.1074/jbc.M000691200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10829014	hybrid, Green Published			2022-12-27	WOS:000089330700014
J	Richard, DE; Berra, E; Pouyssegur, J				Richard, DE; Berra, E; Pouyssegur, J			Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 alpha in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; FACTOR GENE-EXPRESSION; ANGIOTENSIN-II; TRANSCRIPTIONAL ACTIVATION; CRITICAL COMPONENT; OXIDASE; HIF-1-ALPHA; PROTEIN; TRANSACTIVATION	Hypoxia-inducible factor-1 (HIF-1) controls the expression of a number of genes such as vascular endothelial growth factor (VEGF) and Erythropoietin in low oxygen conditions (hypoxia), VEGF is strongly induced at both the mRNA and protein expression level by a number of hormones and growth factors in vascular smooth muscle cells (VSMC) independently of the oxygen environment. However, the role of HIF-1 alpha in this induction has not been studied. We report here that HIF-1 alpha protein levels are strongly increased by fetal calf serum in quiescent VSMC, More interestingly, Angiotensin II (Ang II), thrombin, platelet-derived growth factor, and other hormones can also increase HIF-1 alpha in VSMC to levels that are substantially more elevated than the hypoxic treatment. HIF-1 alpha induced by Ang II is located in the nucleus, binds to the hypoxic response element, and is transcriptionally active. The induction of HIF-1 alpha by hormones is mediated through the production of reactive oxygen species (ROS), since it can be blocked by the ROS inhibitors, diphenyleneiodonium and catalase. Finally, strong induction of VEGF mRNA by Ang II can also be inhibited by these ROS inhibitors. These results implicate HIF-1 alpha and HIF-1-dependent transcriptional activity in the induction of VEGF expression after agonist stimulation and define novel hypoxia-independent mechanisms that should play a major role in vascular remodeling.	Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Richard, DE (corresponding author), Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Berra, Edurne/F-9692-2011; Richard, Darren E./K-6760-2019	Berra, Edurne/0000-0002-3820-5744; Richard, Darren/0000-0003-2690-0480				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; LI H, 1994, J BIOL CHEM, V269, P28098; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	44	538	572	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26765	26771						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837481				2022-12-27	WOS:000089144800015
J	Castagliuolo, I; Valenick, L; Liu, J; Pothoulakis, C				Castagliuolo, I; Valenick, L; Liu, J; Pothoulakis, C			Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INFLAMMATORY BOWEL-DISEASE; SMOOTH-MUSCLE CELLS; EGF RECEPTOR; FACTOR-I; SIGNALING CASCADES; ASTROCYTOMA-CELLS; HORMONE RECEPTORS; EPITHELIAL-CELLS; ANGIOTENSIN-II	Ligand-induced activation of G protein-coupled receptors is emerging as an important pathway leading to the activation of certain receptors with intrinsic tyrosine kinase activity, such as the epidermal growth factor receptor (EGFR). Substance P (SP) exerts many effects via activation of its G protein-coupled receptor (neurokinin-l, NIF-l). SP participates in acute inflammation and activates hey proteins involved in mitogenic pathways, such mitogen-activated protein kinases (MAPKs), stimulating DNA synthesis. We tested the hypothesis that SP-induced MAPK activation and DNA synthesis require activation of the EGFR. In U-373 MG cells, which express functional NK-1, SP induced tyrosine phosphorylation of several proteins including EGFR. SP induced formation of an activated EGFR complex containing the adapter proteins SHC and Grb2, but not c-Src. SP activated the MAPK pathway as shown by increased Erk2 kinase activity. SP induced Erk2 activation, and DNA synthesis was inhibited in cells transfected with a dominant negative EGFR plasmid lacking kinase activity, as well as in cells treated with a specific EGFR inhibitor. In addition, pertussis toxin, an inhibitor of G alpha(i) protein subunits, prevented SP-induced EGFR transactivation and subsequent DNA synthesis. Our results implicate EGFR as an essential regulator in SP/NK-1-induced activation of the MAPK pathway and cell proliferation in U-373 MG cells, and these events are mediated by a pertussis toxin-sensitive G alpha protein. We suggest that this mechanism by which SP controls cell proliferation is an important pathway in tissue restoration and healing.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Castagliuolo, I (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.		CASTAGLIUOLO, IGNAZIO/K-9963-2016	CASTAGLIUOLO, IGNAZIO/0000-0001-9888-7030				BARSHAVIT Z, 1980, BIOCHEM BIOPH RES CO, V94, P1445, DOI 10.1016/0006-291X(80)90581-1; BENRATH J, 1995, NEUROSCI LETT, V200, P17, DOI 10.1016/0304-3940(95)12062-9; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; BOSIC CR, 1996, SCIENCE, V273, P1722; Brain SD, 1997, IMMUNOPHARMACOLOGY, V37, P133, DOI 10.1016/S0162-3109(97)00055-6; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Chiarugi V, 1998, INT J MOL MED, V2, P715; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EISTETTER HR, 1992, GLIA, V6, P89, DOI 10.1002/glia.440060203; GALANDIUK S, 1993, ARCH SURG-CHICAGO, V128, P637; GARCIA M, 1994, BIOCHEM PHARMACOL, V48, P1735, DOI 10.1016/0006-2952(94)90459-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; KAHLER CM, 1993, J CELL PHYSIOL, V156, P579, DOI 10.1002/jcp.1041560318; Kahler CM, 1996, J CELL PHYSIOL, V166, P601; KJARTANSSON J, 1987, PLAST RECONSTR SURG, V79, P218, DOI 10.1097/00006534-198702000-00012; LEE CM, 1989, BRAIN RES, V488, P328, DOI 10.1016/0006-8993(89)90724-5; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; Luo WH, 1996, CANCER RES, V56, P4983; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; Nakamura M, 1998, BIOCHEM BIOPH RES CO, V246, P777, DOI 10.1006/bbrc.1998.8704; Nakamura M, 1997, EXP EYE RES, V65, P321, DOI 10.1006/exer.1997.0345; Nakamura M, 1999, BRIT J PHARMACOL, V127, P489, DOI 10.1038/sj.bjp.0702550; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Nishimura K, 1998, J RECEPT SIGNAL TR R, V18, P51, DOI 10.3109/10799899809039164; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PALMA C, 1995, J NEUROIMMUNOL, V59, P155, DOI 10.1016/0165-5728(95)00040-9; PAYAN DG, 1983, J IMMUNOL, V131, P1613; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PERNOW B, 1983, PHARMACOL REV, V35, P85; Pothoulakis C, 1998, AM J PHYSIOL-GASTR L, V275, pG68, DOI 10.1152/ajpgi.1998.275.1.G68; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Reubi JC, 1996, GASTROENTEROLOGY, V110, P1719, DOI 10.1053/gast.1996.v110.pm8964396; Roush ED, 1998, FEBS LETT, V428, P291, DOI 10.1016/S0014-5793(98)00553-5; RUFF MR, 1985, PEPTIDES S, V2, P107; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; SHARKEY KA, 1992, ANN NY ACAD SCI, V664, P425; Solomon MJ, 1998, WORLD J SURG, V22, P352, DOI 10.1007/s002689900396; VAN BT, 1995, NATURE, V376, P781; WEIDERMANN CJ, 1989, N-S ARCH PHARMACOL, V340, P185; Wiedermann CJ, 1996, EUR J PHARMACOL, V298, P335, DOI 10.1016/0014-2999(95)00818-7	55	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26545	26550		10.1074/jbc.M003990200	http://dx.doi.org/10.1074/jbc.M003990200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846186	hybrid			2022-12-27	WOS:000088999700091
J	Tcherepanova, I; Bhattacharyya, L; Rubin, CS; Freedman, JH				Tcherepanova, I; Bhattacharyya, L; Rubin, CS; Freedman, JH			Aspartic proteases from the nematode Caenorhabditis elegans - Structural organization and developmental and cell-specific expression of asp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; ONCHOCERCA-VOLVULUS; CYSTEINE PROTEASE; CATHEPSIN-D; HAEMONCHUS-CONTORTUS; REGULATED EXPRESSION; GENE-EXPRESSION; VIT-2 PROMOTER; C-ELEGANS; CLONING	A Caenorhabditis elegans gene (asp-1) and cDNA that encode a homologue of cathepsin D aspartic protease were cloned and characterized. The asp-1 mRNA is transcribed from a single exon, and it begins with the SL1 trans-splice leader sequence. The protein (ASP-1) is expressed as a 396-amino acid, 42.7-kDa pre-pro-peptide that is post-translationally processed into a similar to 40-kDa lysosomal protein. ASP-1 shares similar to 60% sequence identity with the aspartic protease precursor from the nematode Strongyloides stercoralis. The amino acid sequences adjacent to the two active site aspartic acid residues in ASP-1 are 100% identical to those in other eukaryotic aspartic proteases. In addition, ASP-1 contains conserved, potential disulfide bond-forming cysteine residues and N-glycosylation sites. The asp-1 gene is exclusively transcribed in the intestinal cells, with the highest levels of expression observed at late embryonic and early larval stages of development. asp-1 transcription is not observed in adult nematodes or mature larvae. Furthermore, transcription predominantly occurs in eight anterior cells of the intestine (int6-int8). Analyses of ASP-1 nucleotide and amino acid sequences revealed the presence of five additional C. elegans aspartic proteases.	Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Yeshiva Univ Albert Einstein Coll Med, Atran Labs, Dept Mol Pharmacol, Bronx, NY 10461 USA	Duke University; Duke University; Yeshiva University; Albert Einstein College of Medicine	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu			NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1998, CURRENT PROTOCOLS MO; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; Delany NS, 1998, MOL BIOCHEM PARASIT, V97, P177, DOI 10.1016/S0166-6851(98)00148-0; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; Favello A, 1995, METHOD CELL BIOL, V48, P551; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 1996, DEV BIOL, V178, P276, DOI 10.1006/dbio.1996.0218; Gallego SG, 1998, ACTA TROP, V71, P17, DOI 10.1016/S0001-706X(98)00050-3; Geier G, 1999, EUR J BIOCHEM, V264, P872, DOI 10.1046/j.1432-1327.1999.00679.x; Gomez-Escobar N, 1998, EXP PARASITOL, V88, P200, DOI 10.1006/expr.1998.4248; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; HU ED, 1990, J BIOL CHEM, V265, P5072; IRVINE M, 1994, MOL BIOCHEM PARASIT, V65, P135, DOI 10.1016/0166-6851(94)90122-8; IslasTrejo A, 1997, J BIOL CHEM, V272, P6629, DOI 10.1074/jbc.272.10.6629; JACOBSON LA, 1988, GENETICS, V119, P355; Jolodar A, 1997, INT J PARASITOL, V27, P1087, DOI 10.1016/S0020-7519(97)00069-6; Jolodar A, 1998, BBA-PROTEIN STRUCT M, V1382, P13, DOI 10.1016/S0167-4838(97)00141-6; KAGEYAMA T, 1995, ADV EXP MED BIOL, V362, P211; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRIEGER TJ, 1992, BIOCHEMISTRY-US, V31, P4223, DOI 10.1021/bi00132a011; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Liao VHC, 1998, J BIOL CHEM, V273, P31962, DOI 10.1074/jbc.273.48.31962; Liddell S, 1998, PARASITOLOGY, V116, P383, DOI 10.1017/S0031182098002418; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; Loukas A, 1998, MOL BIOCHEM PARASIT, V92, P275, DOI 10.1016/S0166-6851(97)00245-4; MACMORRIS M, 1992, MOL CELL BIOL, V12, P1652, DOI 10.1128/MCB.12.4.1652; MACMORRIS M, 1994, MOL CELL BIOL, V14, P484, DOI 10.1128/MCB.14.1.484; MCGHEE JD, 1990, GENETICS, V125, P505; Mello C, 1995, METHOD CELL BIOL, V48, P451; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; SLICE LW, 1990, J BIOL CHEM, V265, P256; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SOMMERFELT MA, 1992, J VIROL, V66, P4220, DOI 10.1128/JVI.66.7.4220-4227.1992; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; SULSTON J, 1988, NEMATODE CAENORHABDI, P608; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waterston Robert H., 1997, V33, P23; White J., 1988, NEMATODE CAENORHABDI, V17, P81; [No title captured]	65	56	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26359	26369		10.1074/jbc.M000956200	http://dx.doi.org/10.1074/jbc.M000956200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854422	hybrid			2022-12-27	WOS:000088999700066
J	Leonard, DM; Stachelek, SJ; Safran, M; Farwell, AP; Kowalik, TF; Leonard, JL				Leonard, DM; Stachelek, SJ; Safran, M; Farwell, AP; Kowalik, TF; Leonard, JL			Cloning, expression, and functional characterization of the substrate binding subunit of rat type II iodothyronine 5 '-deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE METABOLISM; STIMULATED GLIAL-CELLS; CEREBRAL-CORTEX; ACTIN POLYMERIZATION; INTRACELLULAR 3,5,3'-TRIIODOTHYRONINE; REVERSE TRIIODOTHYRONINE; 3'-UNTRANSLATED REGION; SELENIUM DEFICIENCY; ENZYME INACTIVATION; DIFFERENT PATHWAYS	Type II iodothyronine 5'-deiodinase catalyzes the bioactivation of thyroid hormone in the brain. In astrocytes, this similar to 200-kDa, membrane-bound enzyme is composed of at least one p29 subunit, an similar to 60-kDa, cAMP-induced activation protein, and one or more unidentified catalytic subunit(s), Recently, an artificial type II-like selenodeiodinase was engineered by fusing two independent cDNAs together; however, no native type II selenodeiodinase polypeptide is translated in the brain or brown adipose tissue of rats. These data suggest that the native type II 5'-deiodinase in rat brain is unrelated to this artificial selenoprotein. In this report, we describe the cloning of the 29-kDa subunit (p29) of type II 5'-deiodinase from a lambda zapII cDNA library prepared from cAMP-induced astrocytes, The 3.3-kilobase (kb) cDNA encodes an similar to 30-kDa, 277-amino acid long, hydrophobic protein lacking selenocysteine, Northern blot analysis showed that a 3.5-kb p29 mRNA was present in tissues showing type II 5'-deiodinase activity such as brain and cAMP-stimulated astrocytes, Domain-specific, anti-p29 antibodies specifically immunoprecipitated enzyme activity. Overexpression of exogenous p29 or a green fluorescence protein (GFP)-tagged p29 fusion protein led to a > 100-fold increase in deiodinating activity in cAMP-stimulated astrocytes, and the increased activity was specifically immunoprecipitated by anti-GFP antibodies. Steady-state reaction kinetics of the enzyme in GFP-tagged p29-expressing astrocytes are identical to those of the native enzyme in brain. Direct injection of replication-deficient Ad5-p29(GFP) virus particles into the cerebral cortex of neonatal rats leads to a similar to 2-fold increase in brain type II 5'-deiodinating activity. These data show 1) that the 3.3-kb p29 cDNA encodes an essential subunit of rat type II iodothyronine 5'-deiodinase and 2) identify the first non-selenocysteine containing subunit of the deiodinase family of enzymes.	Univ Massachusetts, Med Ctr,Sch Med, Dept Cellular & Mol Physiol, Mol Endocrinol Labs, Worcester, MA 01655 USA; Univ Massachusetts, Med Ctr,Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Med Ctr,Sch Med, Dept Cellular & Mol Physiol, Mol Endocrinol Labs, 55 Lake Ave N, Worcester, MA 01655 USA.			Farwell, Alan/0000-0001-7716-2719				ABEND SL, 1991, J CLIN INVEST, V88, P898, DOI 10.1172/JCI115392; ARTHUR JR, 1991, CAN J PHYSIOL PHARM, V69, P1648, DOI 10.1139/y91-243; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P1787, DOI 10.1210/en.131.4.1787; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P479, DOI 10.1210/en.131.1.479; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRANTZ FR, 1980, J CLIN INVEST, V65, P935, DOI 10.1172/JCI109749; CRANTZ FR, 1982, ENDOCRINOLOGY, V110, P367, DOI 10.1210/endo-110-2-367; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; Davey JC, 1999, ENDOCRINOLOGY, V140, P1022, DOI 10.1210/endo.140.2.6678; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gondou A, 1998, THYROID, V8, P615, DOI 10.1089/thy.1998.8.615; Guadano-Ferraz A, 1999, J NEUROSCI, V19, P3430; GuadanoFerraz A, 1997, P NATL ACAD SCI USA, V94, P10391, DOI 10.1073/pnas.94.19.10391; KAISER CA, 1986, ENDOCRINOLOGY, V119, P762, DOI 10.1210/endo-119-2-762; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; LEONARD JL, 1985, BRAIN RES, V327, P1, DOI 10.1016/0006-8993(85)91493-3; Leonard JL, 1999, ENDOCRINOLOGY, V140, P2206, DOI 10.1210/en.140.5.2206; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; MEINHOLD H, 1992, ACTA MED AUST, V19, P8; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; Pallud S, 1997, J BIOL CHEM, V272, P18104, DOI 10.1074/jbc.272.29.18104; Ramauge M, 1996, ENDOCRINOLOGY, V137, P3021, DOI 10.1210/en.137.7.3021; Safran M, 1996, J BIOL CHEM, V271, P16363, DOI 10.1074/jbc.271.27.16363; SAFRAN M, 1993, J BIOL CHEM, V268, P14224; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; Salvatore D, 1999, BIOCHIMIE, V81, P535, DOI 10.1016/S0300-9084(99)80106-0; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Salvatore D, 1996, J CLIN INVEST, V98, P962, DOI 10.1172/JCI118880; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN QC, 1995, RNA, V1, P519; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SILVA JE, 1984, J CLIN INVEST, V73, P898, DOI 10.1172/JCI111313; SILVA JE, 1982, J CLIN INVEST, V69, P1176, DOI 10.1172/JCI110554; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; StGermain DL, 1997, THYROID, V7, P655; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; Tu HM, 1997, ENDOCRINOLOGY, V138, P3359, DOI 10.1210/en.138.8.3359; VANDOORN J, 1982, ACTA ENDOCRINOL-COP, V101, P386, DOI 10.1530/acta.0.1010386; VANDOORN J, 1986, ACTA ENDOCRINOL-COP, V113, P59, DOI 10.1530/acta.0.1130059; VANDOORN J, 1983, J CLIN INVEST, V72, P1778, DOI 10.1172/JCI111138; VANDOORN J, 1984, ENDOCRINOLOGY, V115, P174, DOI 10.1210/endo-115-1-174; VISSER TJ, 1981, BIOCHEM BIOPH RES CO, V101, P1297, DOI 10.1016/0006-291X(81)91588-6; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; VISSER TJ, 1983, J CLIN INVEST, V71, P992, DOI 10.1172/JCI110854; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080	65	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25194	25201		10.1074/jbc.M002036200	http://dx.doi.org/10.1074/jbc.M002036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829019	hybrid			2022-12-27	WOS:000088849400022
J	Nogami, K; Shima, M; Hosokawa, K; Nagata, M; Koide, T; Saenko, EL; Tanaka, I; Shibata, M; Yoshioka, A				Nogami, K; Shima, M; Hosokawa, K; Nagata, M; Koide, T; Saenko, EL; Tanaka, I; Shibata, M; Yoshioka, A			Factor VIIIC2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg(1689)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ABNORMAL FACTOR-VIII; ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; FACTOR-XA; VONWILLEBRAND-FACTOR; LIGHT-CHAIN; PROCOAGULANT ACTIVITY; COMPLEX	Thrombin-catalyzed factor WI activation is an essential positive feedback mechanism regulating intrinsic blood coagulation. A factor VIII human. antibody, A-FF, with C2 epitope, exclusively inhibited factor VIII activation and cleavage at Arg(1689) by thrombin. The results suggested that A-FF prevented the interaction of thrombin with factor Vm and that the C2 domain was involved in the interaction with thrombin. We performed direct binding assays using anhydro-thrombin, a catalytically inactive derivative of thrombin in which the active-site serine is converted to dehydroalanine. Intact factor VIII, 80-kDa light chain, 72-kDa light chain, and heavy chain fragments bound dose-dependently to anhydro-thrombin, and the K-d values were 48, 150, 106, and 180 nM, respectively. The C2 and A2 domains also dose-dependently bound to anhydro-thrombin, and the K-d values were 440 and 488 nM, respectively. The Al domain did not bind to anhydro-thrombin. A-FF completely inhibited C2 domain binding to anhydro-thrombin (IC50, 18 nM), whereas it did not inhibit A2 domain binding. Furthermore, CS-specific affinity purified F(ab)'(2) of A-FF, and the recombinant Ca domain inhibited thrombin cleavage at Arg(1689). Our results indicate that the C2 domain contains the thrombin-binding site responsible for the cleavage at Arg(1689).	Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan; Fujimori Kogyo Co, Nakahara Ku, Kawasaki, Kanagawa 2110067, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima, Hyogo 6781297, Japan; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Nara Medical University; University of Hyogo; American Red Cross	Shima, M (corresponding author), Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	mshima@nmu-gw.cc.naramed-u.ac.jp						EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HOYER LW, 1981, BLOOD, V58, P1; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1989, BLOOD, V74, P1612; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; Suzuki H, 1997, THROMB HAEMOSTASIS, V77, P862; Thompson AR, 1997, BLOOD, V90, P1902, DOI 10.1182/blood.V90.5.1902; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	37	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25774	25780		10.1074/jbc.M002007200	http://dx.doi.org/10.1074/jbc.M002007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831589	hybrid			2022-12-27	WOS:000088849400094
J	Chen, B; Borinstein, SC; Gillis, J; Sykes, VW; Bogler, O				Chen, B; Borinstein, SC; Gillis, J; Sykes, VW; Bogler, O			The glioma-associated protein SETA interacts with AIP1/Alix and AZIG-2 and modulates apoptosis in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ALG-3; IN-VITRO; TRANSFORMATION; CLONING	Expression of the are homology 3 (SH3) domain-containing expressed in tumorigenic astrocytes (SETA) gene is associated with the tumorigenic state in astrocytes. SETA encodes a variety of adapter proteins containing either one or two SH3 domains, as suggested by the sequence heterogeneity of isolated cDNAs, Using both SH3 domains in a yeast two-hybrid screen of a glial progenitor cell cDNA library, we isolated the rat homolog of the ALG-2-interacting protein 1 or ALG-2-interacting protein X (AIP1/Alix), In vitro confrontation experiments showed that the SH3-N domain of SETA interacted with the proline-rich C terminus of AIP1, In co-immunoprecipitation experiments, SETA and AIP1 interacted and could form a complex with apoptosis-linked gene 2 protein, Endogenous SETA and AIP1 proteins showed similar patterns of staining in primary rat astrocytes, Misexpression of a variety of SETA protein isoforms in these astrocytes revealed that they localized to the actin cytoskeleton. Furthermore, SETA proteins containing the SH3-N domain were able to sensitize astrocytes to apoptosis induced by UV irradiation. Expression of the isolated SH3-N domain had the greatest effect in these experiments, indicating that interference in the interaction between endogenous SETA and AIP1 sensitizes astrocytes to apoptosis in response to DNA damage.	Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Bogler, O (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd, Detroit, MI 48202 USA.			Bogler, Oliver/0000-0002-3700-0480				Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; BOGLER O, 1995, CANCER RES, V55, P2746; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Lacana E, 1997, J IMMUNOL, V158, P5129; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; SUGIMOTO Y, 1994, BIO-TECHNOL, V12, P694, DOI 10.1038/nbt0794-694; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521	14	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19275	19281		10.1074/jbc.M908994199	http://dx.doi.org/10.1074/jbc.M908994199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858458	hybrid			2022-12-27	WOS:000087815900086
J	Panse, VG; Vogel, P; Trommer, WE; Varadarajan, R				Panse, VG; Vogel, P; Trommer, WE; Varadarajan, R			A thermodynamic coupling mechanism for the disaggregation of a model peptide substrate by chaperone SecB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; MOLTEN GLOBULE; TRANSLOCATION; AGGREGATION; INVITRO; LIGAND; STATE; FRAME	Molecular chaperones prevent protein aggregation in vivo and in vitro. In a few cases, multichaperone systems are capable of dissociating aggregated state(s) of substrate proteins, although little is known of the mechanism of the process. SecB is a cytosolic chaperone, which forms part of the precursor protein translocation machinery in Escherichia coli, We have investigated the interaction of the B-chain of insulin with chaperone SecB by light scattering, pyrene excimer fluorescence, and electron spin resonance spectroscopy. We show that SecB prevents aggregation of the B-chain of insulin. We show that SecB is capable of dissociating soluble B-chain aggregates as monitored by pyrene fluorescence spectroscopy. The kinetics of dissociation of the B-chain aggregate by SecB has been investigated to understand the mechanism of dissociation. The data suggests that SecB does not act as a catalyst in dissociation of the aggregate to individual B-chains, rather it binds the small population of free B-chains with high affinity, thereby shifting the equilibrium from the ensemble of the aggregate toward the individual B-chains, Thus SecB can rescue aggregated, partially folded/misfolded states of target proteins by a thermodynamic coupling mechanism when the free energy of binding to SecB is greater than the stability of the aggregate, Pyrene excimer fluorescence and ESR methods have been used to gain insights on the bound state conformation of the B chain to chaperone SecB, The data suggests that the B chain is bound to SecB in a flexible extended state in a hydrophobic cleft on SecB and that the binding site accommodates approximately 10 residues of substrate.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem Biol Unit, Bangalore 560004, Karnataka, India; Univ Kaiserslautern, Fachbereich Chem Biochem, D-67663 Kaiserslautern, Germany	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); University of Kaiserslautern	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	varadar@mbu.iisc.ernet.in		Panse, Vikram/0000-0001-7950-5746; Vogel, Pia/0000-0002-8135-4649				ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BREUKINK E, 1992, EUR J BIOCHEM, V208, P419, DOI 10.1111/j.1432-1033.1992.tb17203.x; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Creighton T. E., 1990, PROTEIN STRUCTURE PR, P155; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Joachimiak A, 1997, NAT STRUCT BIOL, V4, P430, DOI 10.1038/nsb0697-430; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2420, DOI 10.1021/bi992065o; Panse VG, 1998, BIOCHEMISTRY-US, V37, P14477, DOI 10.1021/bi980777t; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; Schuler J, 1999, BIOPHYS J, V77, P1117, DOI 10.1016/S0006-3495(99)76962-6; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Stopar D, 1996, BIOCHEMISTRY-US, V35, P15467, DOI 10.1021/bi961770j; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; Zhao M, 1999, BIOCHEMISTRY-US, V38, P15970, DOI 10.1021/bi991754x	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18698	18703		10.1074/jbc.275.25.18698	http://dx.doi.org/10.1074/jbc.275.25.18698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858444	hybrid			2022-12-27	WOS:000087815900013
J	MacKenzie, SJ; Baillie, GS; McPhee, I; Bolger, GB; Houslay, MD				MacKenzie, SJ; Baillie, GS; McPhee, I; Bolger, GB; Houslay, MD			ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases - The involvement of COOH-terminal docking sites and NH2-terminal UCR regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MAP KINASE; TYROSINE-PHOSPHATASE; ROLIPRAM INHIBITION; INTERACTION MOTIF; PTP-SL; FAMILY; PATHWAY; CELLS	The cAMP-specific phosphodiesterase family 4, sub- family D, isoform 3 (PDE4D3) is shown to have FQF and RIM docking sites for extracellular signal-regulated kinase 2 (ERK2) (p42(MAPK)). These straddle the target residue, Ser(579), for ERK2 phosphorylation of PDE4D3. Mutation of either or both of these docking sites prevented ERK2 from being co-immunoprecipitated with PDE4D3, ablated the ability of epidermal growth factor to inhibit PDE4D3 through ERK2 action in transfected COS cells, and attenuated the ability of ERK2 to phosphorylate PDE4D3 in vitro. The two conserved NH2-terminal blocks of sequence, called upstream conserved regions 1 and 2 (UCR1 and UCR2), that characterize PDE4 long isoforms, are proposed to amplify the small, inherent inhibitory effect that ERK2 phosphorylation exerts on the PDE4D catalytic unit, In contrast to this, the lone intact UCR2 region found in PDE4D1 directs COOH-terminal ERK2 phosphorylation to cause the activation of this short isoform. From the analysis of PDE4D3 truncates, it is suggested that UCR1 and UCR2 provide a regulatory signal integration module that serves to orchestrate the functional consequences of ERK2 phosphorylation. The PDE4D gene thus encodes a series of isoenzymes that are either inhibited or activated by ERK2 phosphorylation and thereby offers the potential for ERK2 activation either to increase or decrease cAMP levels in cellular compartments.	Univ Glasgow, Div Biochem & Mol Biol, Mol Pharmacol Grp, IBLS, Glasgow G12 8QQ, Lanark, Scotland; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Huntsman Canc Inst, Salt Lake City, UT 84132 USA	University of Glasgow; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Houslay, MD (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Mol Pharmacol Grp, IBLS, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Houslay@bio.gla.ac.uk	Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091	NIGMS NIH HHS [R01-GM58553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad F, 1999, J IMMUNOL, V162, P4864; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HEYWORTH CM, 1983, BIOCHEM J, V214, P93, DOI 10.1042/bj2140093; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kolch W, 1996, ONCOGENE, V13, P1305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rogers DF, 1998, TRENDS PHARMACOL SCI, V19, P160, DOI 10.1016/S0165-6147(98)01198-5; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Turko IV, 1998, BIOCHEM J, V329, P505; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	44	193	197	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16609	16617		10.1074/jbc.275.22.16609	http://dx.doi.org/10.1074/jbc.275.22.16609			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828059	hybrid			2022-12-27	WOS:000087392200031
J	Que, NLS; Ribeiro, AA; Raetz, CRH				Que, NLS; Ribeiro, AA; Raetz, CRH			Two-dimensional NMR spectroscopy and structures of six lipid A species from Rhizobium etli CE3 - Detection of an acyloxyacyl residue in each component and origin of the aminogluconate moiety	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLGLYCEROL-DEFICIENT MUTANT; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; GLUCOSAMINE 1-PHOSPHATE; SALMONELLA-TYPHIMURIUM; A PRECURSORS; HOST-DEFENSE; LEGUMINOSARUM; LIPOPOLYSACCHARIDE; BIOSYNTHESIS	The chemical structures of six lipid A species (A, B, C, D-1, D-2, and E) purified from Rhizobium etli CE3 were investigated by one- and two-dimensional NMR spectroscopy. The R. etli lipid A subtypes each contain an unusual acyloxyacyl residue at position 2' as part of a conserved distal glucosamine moiety but differ in their proximal units. All R. etli lipid A species lack phosphate groups. However, they are derivatized with an alpha-linked galacturonic acid group at position 4', as shown by nuclear Overhauser effect spectroscopy. Component B, which had been not been reported in previous studies, features a beta, 1'-6 linked disaccharide of glucosamine acylated at positions 2, 3, 2', and 3' in a pattern that is typical of lipid A found in other Gram-negative bacteria. D-1 contains an acylated aminogluconate unit in place of the proximal glucosamine residue of B. C and E lack ester-linked beta-hydroxyacyl chains at position 3, as judged by their H-3 chemical shifts, and may be synthesized from B and D-1, respectively, by the R. etli 3-O-deacylase. D-2 is an isomer of D-1 that forms nonenzymatically by acyl chain migration. A may be an elimination product derived from D-1 during hydrolysis at 100 degrees C (pH 4.5), a step needed to release lipid A from lipopolysaccharide. Based on these findings, we propose a biosynthetic scheme for R. etli lipid A in which B is generated first by a variation of the E. coli pathway. The aminogluconate unit of D-1 could then be made from B by enzymatic oxidation of the proximal glucosamine. As predicted by our hypothesis, enzyme(s) can be demonstrated in extracts of R. etli that convert C-14-labeled B to D-1.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NCI NIH HHS [P30 CA014236, P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [R37 GM051796, R37 GM051796-05, R37-GM-51796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal P.K., 1994, ADV BIOPHYS CHEM, V4, P179; AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Breedveld MW., 1998, RHIZOBIACEAE, P81, DOI [10.1007/978-94-011-5060-6_5, DOI 10.1007/978-94-011-5060-6_5]; BREWIN NJ, 1982, J GEN MICROBIOL, V128, P1817; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Carlson R. W., 1992, Plant biotechnology and development., P33; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GRAHAM TL, 1977, APPL ENVIRON MICROB, V34, P424, DOI 10.1128/AEM.34.4.424-432.1977; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KARUNARATNE DN, 1992, ARCH BIOCHEM BIOPHYS, V299, P368, DOI 10.1016/0003-9861(92)90289-9; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MASOUD H, 1994, EUR J BIOCHEM, V220, P209, DOI 10.1111/j.1432-1033.1994.tb18616.x; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 1998, FASEB J, V12, pA1284; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TAKAYAMA K, 1983, J BIOL CHEM, V258, P2801; TAKAYAMA K, 1983, J BIOL CHEM, V258, P4245; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; VANHALBEEK H, 1996, ENCY NMR, V2, P1107; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	43	75	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28017	28027						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856304				2022-12-27	WOS:000089197100066
J	Ramsdale, M; Lakin-Thomas, PL				Ramsdale, M; Lakin-Thomas, PL			sn-1,2-diacylglycerol levels in the fungus Neurospora crassa display circadian rhythmicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CLOCK GENE-FREQUENCY; TEMPERATURE COMPENSATION; CHOLINE DEPLETION; FISSION YEAST; FATTY-ACIDS; CELL-CYCLE; DIACYLGLYCEROL; ACTIVATION; INHIBITOR	The fungus Neurospora crassa is a model organism for investigating the biochemical mechanism of circadian (daily) rhythmicity. When a choline-requiring strain (chob-1) is depleted of choline, the period of the conidiation rhythm lengthens. We have found that the levels of sn-1,2-diacylglycero1 (DAG) increase in proportion to the increase in period. Other clock mutations that change the period do not affect the levels of DAG. Membrane-permeant DAGs and inhibitors of DAG kinase were found to further lengthen the period of choline-depleted cultures. The level of DAG oscillates with a period comparable to the rhythm of conidiation in wild-type strains, choline-depleted cultures, and frq mutants, including a null frq strain. The DAG rhythm is present at the growing margin and also persists in older areas that have completed development. The phase of the DAG rhythm can be set by the Light-to-dark transition, but the level of DAG is not immediately affected by light. Our results indicate that rhythms in DAG levels in Neurospora are driven by a light-sensitive circadian oscillator that does not require the frq gene product. High levels of DAG may feed back on that oscillator to lengthen its period.	Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	University of Cambridge; University of Aberdeen	Lakin-Thomas, PL (corresponding author), Univ Cambridge, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.			Lakin-Thomas, Patricia/0000-0002-0545-9561				ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Arpaia G, 1999, MOL GEN GENET, V262, P314, DOI 10.1007/s004380051089; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BLEST AD, 1994, J COMP PHYSIOL A, V175, P611; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; CHOPRA A, 1984, CRC CR REV MICROBIOL, V11, P209, DOI 10.3109/10408418409105904; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; Cote GG., 1996, MEMBRANE CIRCADIAN R, P13; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DHARMANANDA S, 1979, PLANT PHYSIOL, V63, P1049, DOI 10.1104/pp.63.6.1049; Dickman MB, 1999, FUNGAL GENET BIOL, V26, P99, DOI 10.1006/fgbi.1999.1118; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Edmunds LN, 1988, CELLULAR MOL BASES B; Feldman J.F., 1982, PHOTOCHEM PHOTOBIOL, V7, P319; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HUBBARD SC, 1975, J BIOL CHEM, V250, P7173; Jinks RN, 1996, J PHOTOCH PHOTOBIO B, V35, P45, DOI 10.1016/1011-1344(96)07307-1; Johnson CH, 1999, ANNU REV MICROBIOL, V53, P389, DOI 10.1146/annurev.micro.53.1.389; JURETIC D, 1977, BIOCHIM BIOPHYS ACTA, V469, P137, DOI 10.1016/0005-2736(77)90176-6; Lakin-Thomas PL, 2000, P NATL ACAD SCI USA, V97, P256, DOI 10.1073/pnas.97.1.256; Lakin-Thomas PL, 2000, TRENDS GENET, V16, P135, DOI 10.1016/S0168-9525(99)01945-9; Lakin-Thomas PL, 1998, J BIOL RHYTHM, V13, P268, DOI 10.1177/074873098129000101; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; LAKINTHOMAS PL, 1992, J BIOL RHYTHM, V7, P227, DOI 10.1177/074873049200700304; LAKINTHOMAS PL, 1993, BIOCHEM J, V292, P805, DOI 10.1042/bj2920805; LAKINTHOMAS PL, 1985, GENETICS, V109, P49; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LakinThomas PL, 1996, BIOL RHYTHM RES, V27, P12, DOI 10.1076/brhm.27.1.12.12933; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MAZZEI GJ, 1993, J BIOL CHEM, V268, P7401; Merrow M, 1999, NATURE, V399, P584, DOI 10.1038/21190; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; Oeser B, 1998, FEMS MICROBIOL LETT, V165, P273, DOI 10.1111/j.1574-6968.1998.tb13157.x; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; ROEDER PE, 1982, BIOCHEMISTRY-US, V21, P4909, DOI 10.1021/bi00263a012; SCARBOROUGH GA, 1967, J BIOL CHEM, V242, P238; Shinohara ML, 1998, J BIOL CHEM, V273, P446, DOI 10.1074/jbc.273.1.446; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; White B., 1995, FUNGAL GENET NEWSL, V42, P79	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27541	27550						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859307				2022-12-27	WOS:000089197100006
J	Varea, J; Saiz, JL; Lopez-Zumel, C; Monterroso, B; Medrano, FJ; Arrondo, JLR; Iloro, I; Laynez, J; Garcia, JL; Menendez, M				Varea, J; Saiz, JL; Lopez-Zumel, C; Monterroso, B; Medrano, FJ; Arrondo, JLR; Iloro, I; Laynez, J; Garcia, JL; Menendez, M			Do sequence repeats play an equivalent role in the choline-binding module of pneumococcal LytA amidase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR CHARACTERIZATION; ULTRAVIOLET-ABSORPTION; THERMAL-DENATURATION; SCANNING CALORIMETRY; AQUEOUS-SOLUTIONS; AUTOLYSIN	LytA amidase breaks down the N-acetylmuramoyl-L-alanine bonds in the peptidoglycan backbone of Streptococcus pneumoniae, Its polypeptide chain has two modules: the NH2-terminal module, responsible for the catalytic activity, and the COOH-terminal module, constructed by six tandem repeats of 20 or 21 amino acids (p1-p6) and a short COOH-terminal tail. The polypeptide chain must contain at least four repeats to efficiently anchor the autolysin to the choline residues of the cell wall. Nevertheless, the catalytic efficiency decreases by 90% upon deletion of the final tail. The structural implications of deleting step by step the two last (p5 and p6) repeats and the final COOH-tail and their effects on choline-amidase interactions have been examined by comparing four truncated mutants with LytA amidase by means of different techniques. Removal of this region has minor effects on secondary structure content but significantly affects the stability of native conformations. The last 11 amino acids and the p5 repeat stabilize the COOH-terminal module; each increases the module transition temperature by about 6 degrees C, Moreover, the p5 motif also seems to participate, in a choline-dependent way, in the stabilization of the NH2-terminal module. The effects of choline binding on the thermal stability profile of the mutant lacking the p5 repeat might reflect a cooperative pathway providing molecular communication between the choline-binding module and the NH2-terminal region, The three sequence motives favor the choline-amidase interaction, but the tail is an essential factor in the monomer <----> dimer self-association equilibrium of LytA and its regulation by choline, The final tail is required for preferential interaction of choline with LytA dimers and for the existence of different sets of choline-binding sites. The p6 repeat scarcely affects the amidase stability but could provide the proper three dimensional orientation of the final tail.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Basque Country, Dept Bioquim, Unidad Asociada CSIC, Grp Biomembranes, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Menendez, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	mmenendez@iqfr.csic.es	Menendez, Margarita/M-1795-2014; Medrano, Francisco Javier/ABF-9860-2020; Iloro, Ibon/L-6022-2014; Monterroso, Begoña/J-9748-2014; Garcia Lopez, Jose Luis/G-9139-2015	Menendez, Margarita/0000-0002-3267-4443; Iloro, Ibon/0000-0002-9537-1714; Monterroso, Begoña/0000-0003-2538-084X; Medrano, Francisco/0000-0002-8185-9751; Garcia Lopez, Jose Luis/0000-0002-9238-2485				ARRONDO JLR, 1989, FEBS LETT, V252, P118, DOI 10.1016/0014-5793(89)80901-9; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; AUER HE, 1973, J AM CHEM SOC, V95, P3003, DOI 10.1021/ja00790a046; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; CAMPOSOLIVAS R, 1995, BIOCHEMISTRY-US, V34, P3009, DOI 10.1021/bi00009a032; CASTRESANA J, 1988, BIOCHEM BIOPH RES CO, V152, P69, DOI 10.1016/S0006-291X(88)80681-8; DAY LA, 1973, BIOCHEMISTRY-US, V12, P5329, DOI 10.1021/bi00750a017; Echabe I, 1998, PROTEIN SCI, V7, P1172, DOI 10.1002/pro.5560070511; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; Garcia JL, 1998, MICROB DRUG RESIST, V4, P25, DOI 10.1089/mdr.1998.4.25; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; Garcia P, 1999, MOL MICROBIOL, V31, P1275, DOI 10.1046/j.1365-2958.1999.01238.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; Medrano FJ, 1996, J BIOL CHEM, V271, P29152, DOI 10.1074/jbc.271.46.29152; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Romero A, 1996, EUR J BIOCHEM, V241, P453, DOI 10.1111/j.1432-1033.1996.00453.x; Sanchez-Beato AR, 1998, FEMS MICROBIOL LETT, V164, P207, DOI 10.1016/S0378-1097(98)00206-7; Sanchez-Ruiz J M, 1995, Subcell Biochem, V24, P133; SanchezBeato AR, 1996, GENE, V180, P13, DOI 10.1016/S0378-1119(96)00390-3; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZPUELLES JM, 1987, GENE, V61, P13, DOI 10.1016/0378-1119(87)90360-X; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; Susi H., 1969, STRUCTURE STABILITY, P575; TODD M, 1993, BIOPHYS J, V64, P166; TUOMANEN E, 1986, EUR J CLIN MICROBIOL, V5, P682, DOI 10.1007/BF02013304; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; WYMAN J, 1990, BINDING LINKAGE FUNC, P33; YANG JT, 1986, METHOD ENZYMOL, V130, P208	55	38	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26842	26855						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10849429				2022-12-27	WOS:000089144800026
J	Wang, H; Liu, CJ; Lu, YB; Chatterjee, G; Ma, XY; Eisenman, RN; Lengyel, P				Wang, H; Liu, CJ; Lu, YB; Chatterjee, G; Ma, XY; Eisenman, RN; Lengyel, P			The interferon- and differentiation-inducible p202a protein inhibits the transcriptional activity of c-Myc by blocking its association with Max	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GENE 200 CLUSTER; MURINE CHROMOSOME-1; ACTIVATABLE GENES; INDUCED APOPTOSIS; HIN-200 FAMILY; GROWTH-FACTOR; TARGET GENES; PEF-BOS; EXPRESSION	p202a is a murine protein that is induced during the fusion of myoblasts to myotubes and can also be induced by interferon. Even 23-fold overexpression of p202a in cells retards proliferation. p202a was shown to modulate transcription by binding, and inhibiting the activity of several transcription factors including c-Fos, c-Jun, AP-2, E2F1, E2F4, NF-kappa B, MyoD, and myogenin, Here we report that p202a also bound the c-Myc protein in vitro and in vivo; the C-terminal p202a b segment bound the C-terminal basic region helix-loop-helix-leucine zipper (bHLHLZ) region of c-Myc. The transfection of a p202a expression plasmid inhibited the c-Myc-dependent expression of reporter plasmids in transient assays; moreover, overexpression of p202a in stable cell lines decreased the endogenous levels of mRNAs whose expression is driven by c-Myc, These effects of p202a are consistent with our finding that the binding of p202a to c-Myc inhibited the binding of c-Myc to Max in vitro and in vivo. p202a also inhibited the e-Myc-induced anchorage-independent growth and apoptosis of Rat-1 cells. The inhibition of c-Myc-dependent transcription, proliferation, and apoptosis by p202a is in line with the involvement of p202a in differentiation.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Yale University; Fred Hutchinson Cancer Center	Lengyel, P (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	peter.lengyel@yale.edu		liu, chuanju/0000-0002-7181-8032; Wang, Hong/0000-0003-4130-8741	NCI NIH HHS [CA20525] Funding Source: Medline; NIAID NIH HHS [R37-AI12320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020525, R37CA020525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouck N, 1979, Methods Enzymol, V58, P296; BRIGGS JA, 1992, J CELL BIOCHEM, V49, P82, DOI 10.1002/jcb.240490114; BRIGGS RC, 1994, J CELL BIOCHEM, V56, P559, DOI 10.1002/jcb.240560417; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1999, BBA-REV CANCER, V1423, pM37, DOI 10.1016/S0304-419X(99)00012-8; Gariglio M, 1998, J LEUKOCYTE BIOL, V64, P608, DOI 10.1002/jlb.64.5.608; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KARN J, 1989, ONCOGENE, V4, P773; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MAREU KB, 1992, ANNU REV BIOCHEM, V61, P809; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Min W, 1996, MOL CELL BIOL, V16, P359; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OPDENAKKER G, 1989, VIROLOGY, V171, P568, DOI 10.1016/0042-6822(89)90626-0; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RYSECK RP, 1991, ONCOGENE, V6, P533; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; SEN GC, 1998, TRANSCRIPTIONAL REGU; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	86	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27377	27385						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10835425				2022-12-27	WOS:000089144800095
J	Asp, L; Claesson, C; Boren, J; Olofsson, SO				Asp, L; Claesson, C; Boren, J; Olofsson, SO			ADP-ribosylation factor 1 and its activation of phospholipase D are important for the assembly of very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; GUANINE-NUCLEOTIDE; MCA-RH7777 CELLS; APOLIPOPROTEIN-B; COATED VESICLES; GOLGI MEMBRANES; PULSE-CHASE; FACTOR ARF	The role of ADP-ribosylation factor 1 (ARF-1) in the assembly of very low density lipoproteins (VLDL) was investigated by expressing dominant-negative mutants in McA-RH7777 cells, Transient expression of ARF-1(T31N), a GDP-restrictive mutant, significantly inhibited apolipoprotein B-100 (apoB-100) VLDL production without influencing the biosynthesis of apoB-100 low density lipoproteins or total apoB production (indicating that it inhibited the second step of VLDL assembly) and without altering total protein production or biosynthesis of transferrin, phosphatidylcholine, or triglycerides, These effects were confirmed in stable inducible transfectants. In contrast, expression of an ARF-1 mutant lacking the N-terminal 17 amino acids, which has no myristoylation site and cannot interact with the microsomal membrane, did not affect VLDL assembly, Thus, active ARF-1 is needed for the second step of the process. To further explore these observations, we developed a cell-free system based on the postnuclear supernatant isolated from McA-RH7777 cells. In this system, 10-15% of the apoB-100 pool was converted to VLDL in a time- and temperature-dependent way. The assembly process was highly dependent on a heat-stable factor in the d > 1.21 g/ml infranatant of fetal calf serum; this factor was not present in low density lipoproteins or VLDL, Brefeldin A inhibited VLDL assembly in this system, as did a synthetic peptide (corresponding to N-terminal amino acids 2-17 of ARF-1) that displaces ARF-1 from the membrane, Thus, active ARF-1 is also needed for cell-free assembly of VLDL, Guanosine 5'-3-O-(thio)triphosphate also inhibited VLDL assembly in this system, indicating that the process requires ongoing hydrolysis of GTP. 1-Butanol, which inhibits the formation of phosphatidic acid (PA) and instead gives rise to phosphatidylbutanol, inhibited VLDL assembly, whereas a-butanol, which does not inhibit PA formation, failed to do so. Thus, phospholipase D (PLD)-catalyzed formation of PA from phosphatidylcholine is essential for VLDL assembly. In support of this conclusion, exogenous PLD prevented brefeldin A from inhibiting the assembly process. Our results indicate that ARF-1 participates in the second step of VLDL assembly through a process that involves activation of PLD and production of PA.	Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Wallenberg Lab Cardiovasc Res, SE-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Olofsson, SO (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, SE-40530 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011					ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON M, 1994, J LIPID RES, V35, P535; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KERNS BG, 1997, NATURE, V387, P101; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Martin TFJ, 1997, NATURE, V387, P21, DOI 10.1038/387021a0; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; OLEGARD R, 1970, ACTA PAEDIATR SCAND, V59, P637, DOI 10.1111/j.1651-2227.1970.tb17698.x; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; ORCI L, 1991, CELL, V64, P1183; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHEKMAN R, 1996, SCIENCE, V271, P1525; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Vasudevan C, 1998, J CELL SCI, V111, P1277; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; ZHAO L, 1997, P NATL ACAD SCI USA, V94, P4417	46	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26285	26292		10.1074/jbc.M003520200	http://dx.doi.org/10.1074/jbc.M003520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843997	hybrid			2022-12-27	WOS:000088999700056
J	Guillemot, L; Levy, A; Zhao, ZJ; Bereziat, G; Rothhut, B				Guillemot, L; Levy, A; Zhao, ZJ; Bereziat, G; Rothhut, B			The protein-tyrosine phosphatase SHP-2 is required during angiotensin II-mediated activation of cyclin D1 promoter in CHO-AT(1A) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR RECEPTOR; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3'-KINASE; EGF-RECEPTOR; SH2 DOMAIN; COUPLED RECEPTORS; G(1) PROGRESSION	Angiotensin II (Ang II) binds to specific G protein-coupled receptors and is mitogenic in Chinese hamster ovary (CHO) cells stably expressing a rat vascular angiotensin II type LA receptor (CHO-AT(1A)). Cyclin D1 protein expression is regulated by mitogens, and its assembly with the cyclin-dependent kinases induces phosphorylation of the retinoblastoma protein pRb, a critical step in G(1) to S phase cell cycle progression contributing to the proliferative responses. In the present study, we found that in CHO-AT(1A) cells, Ang II induced a rapid and reversible tyrosine phosphorylation of various intracellular proteins including the protein-tyrosine phosphatase SHP-2. Ang II also induced cyclin D1 protein expression in a phosphatidylinositol 3-kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)-dependent manner. Using a pharmacological and a co-transfection approach, we found that p21(ras), Raf-1, phosphatidylinositol 3-kinase and also the catalytic activity of SHP-2 and its Src homology 2 domains are required for cyclin D1 promoter/reporter gene activation by Ang II through the regulation of MAPK/ERK activity. Our findings suggest for the first time that SHP-2 could play an important role in the regulation of a gene involved in the control of cell cycle progression resulting from stimulation of a G protein-coupled receptor independently of epidermal growth factor receptor transactivation.	Univ Paris 06, Lab Signalisat Cellulaire Mediateurs Lipid & Cont, CNRS, UPRESA 7079, F-75005 Paris, France; Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Vanderbilt University	Rothhut, B (corresponding author), Univ Paris 06, Lab Signalisat Cellulaire Mediateurs Lipid & Cont, CNRS, UPRESA 7079, 7 Quai St Bernard,Batiment A,5eme Etage, F-75005 Paris, France.	rothhut@ccr.jussieu.fr		Rothhut, Bernard/0000-0001-6467-8134	NATIONAL CANCER INSTITUTE [R01CA075218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NCI NIH HHS [CA75218] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FILMUS J, 1994, ONCOGENE, V9, P3627; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GRIENDLING KK, 1993, SEMIN NEPHROL, V13, P558; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERBER B, 1994, ONCOGENE, V9, P1295; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; INAGAMI T, 1994, J HYPERTENS, V12, pS83; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATO J, 1993, GENE DEV, V7, P331; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TURNER CE, 1995, J CELL SCI, V108, P333; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	87	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26349	26358		10.1074/jbc.M001614200	http://dx.doi.org/10.1074/jbc.M001614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843991	hybrid			2022-12-27	WOS:000088999700065
J	Hashiguchi, M; Sobue, K; Paudel, HK				Hashiguchi, M; Sobue, K; Paudel, HK			14-3-3 zeta is an effector of tau protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PSEUDOMONAS-AERUGINOSA; BINDING-SITE; EXOENZYME-S; KINASE-C; T-CELLS; 14-3-3-PROTEINS; BRAIN; ACTIVATION	Neurofibrillary tangles associated with Alzheimer's disease are composed mainly of paired helical filaments that are formed by the aggregation of abnormally phosphorylated microtubule-associated protein tau. 14-3-3, a highly conserved protein family that exists as seven isoforms and regulates diverse cellular processes is present in neurofibrillary tangles (Layfield, R., Fergusson, J., Aitken, k, Lowe, J., Landon, NI., Mayer, R. J. (1996) Neurosci. Lett. 209, 57-60). The role of 14-3-3 in Alzheimer's disease pathogenesis is not known. In this study, we found that the 14-3-3 zeta isoform is associated with tau in brain extract and profoundly stimulates cAMP-dependent protein kinase catalyzed in vitro phosphorylation on Ser(262)/Ser(356) located within the microtubule-binding region of tan. 14-3-3 zeta binds to both phosphorylated and nonphosphorylated tau, and the binding site is located within the microtubule-binding region of tan. From brain extract, 14-3-3 zeta co-purifies with microtubules, and tubulin blocks 14-3-3 zeta-tau binding. Among four 14-3-3 isoforms tested, beta and zeta but not gamma and epsilon associate with tau. Our data suggest that 14-3-3(zeta) is a tau protein effector and may be involved in the abnormal tau phosphorylation occurring during Alzheimer's disease ontogeny.	Sir Mortimer B Davis Jewish Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdhp@musica.mcgill.ca						Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11776; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CORREAS I, 1992, J BIOL CHEM, V267, P15721; Craparo A, 1997, J BIOL CHEM, V272, P11663; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jicha GA, 1999, J NEUROSCI, V19, P7486, DOI 10.1523/JNEUROSCI.19-17-07486.1999; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PADILLA R, 1990, MOL CELL BIOCHEM, V97, P35; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PATEL Y, 1994, BBA-MOL CELL RES, V1222, P405, DOI 10.1016/0167-4889(94)90048-5; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	59	173	185	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25247	25254		10.1074/jbc.M003738200	http://dx.doi.org/10.1074/jbc.M003738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840038	hybrid			2022-12-27	WOS:000088849400029
J	Iwasaki, T; Watanabe, E; Ohmori, D; Imai, T; Urushiyama, A; Akiyama, M; Hayashi-Iwasaki, Y; Cosper, NJ; Scott, RA				Iwasaki, T; Watanabe, E; Ohmori, D; Imai, T; Urushiyama, A; Akiyama, M; Hayashi-Iwasaki, Y; Cosper, NJ; Scott, RA			Spectroscopic investigation of selective cluster conversion of archaeal zinc-containing ferredoxin from Sulfolobus sp strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PROTON MAGNETIC-RESONANCE; RAY-ABSORPTION SPECTROSCOPY; PUTIDA 7-IRON FERREDOXINS; AZOTOBACTER-VINELANDII; PYROCOCCUS-FURIOSUS; THERMOACIDOPHILIC ARCHAEON; 4FE-4S CLUSTER; EVOLUTIONARY IMPLICATIONS; 3FE-4S CLUSTERS	Archaeal zinc-containing ferredoxin from Sulfolobus sp. strain 7 contains one [3Fe-4S] cluster (cluster I), one [4Fe-4S] cluster (cluster II), and one isolated zinc center. Oxidative degradation of this ferredoxin led to the formation of a stable intermediate with 1 zinc and similar to 6 iron atoms. The metal centers of this intermediate were analyzed by electron paramagnetic resonance (EPR), low temperature resonance Raman, x-ray absorption, and H-1 NMR spectroscopies. The spectroscopic data suggest that (i) cluster II was selectively converted to a cubane [3Fe-4S](1+) cluster in the intermediate, without forming a stable radical species, and that (ii) the local metric environments of cluster I and the isolated zinc site did not change significantly in the intermediate. It is concluded that the initial step of oxidative degradation of the archaeal zinc-containing ferredoxin is selective conversion of cluster II, generating a novel intermediate containing two [3Fe-4S] clusters and an isolated zinc center, At this stage, significant structural rearrangement of the protein does not occur. We propose a new scheme for oxidative degradation of dicluster ferredoxins in which each cluster converts in a stepwise manner, prior to apoprotein formation, and discuss its structural and evolutionary implications.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Rikkyo St Pauls Univ, Dept Chem, Tokyo 1718501, Japan; Juntendo Univ, Dept Chem, Chiba 2701695, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Nippon Medical School; Rikkyo University; Juntendo University; Tokyo University of Pharmacy & Life Sciences; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42025] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; Aono S, 1998, BIOCHEMISTRY-US, V37, P9812, DOI 10.1021/bi972818b; ARMSTRONG FA, 1989, FEBS LETT, V259, P15, DOI 10.1016/0014-5793(89)81483-8; ARMSTRONG FA, 1992, ADV INORG CHEM, V38, P117, DOI 10.1016/S0898-8838(08)60063-X; BEAR CA, 1975, ACTA CRYSTALLOGR B, V31, P2713, DOI 10.1107/S056774087500859X; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bentrop D, 1996, EUR J BIOCHEM, V236, P92, DOI 10.1111/j.1432-1033.1996.00092.x; Bentrop D, 1999, BIOCHEMISTRY-US, V38, P4669, DOI 10.1021/bi982647q; Bertini I, 1999, CURR OPIN CHEM BIOL, V3, P145, DOI 10.1016/S1367-5931(99)80026-X; BERTINI I, 1993, FEBS LETT, V332, P268, DOI 10.1016/0014-5793(93)80647-D; Bertini I, 1997, BIOCHEMISTRY-US, V36, P3570, DOI 10.1021/bi962799q; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BUSSE SC, 1992, BIOCHEMISTRY-US, V31, P11952, DOI 10.1021/bi00162a038; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; Butt JN, 1997, J AM CHEM SOC, V119, P9729, DOI 10.1021/ja971403a; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHENG H, 1990, J BIOL CHEM, V265, P12388; CHENG H, 1992, J BIOL CHEM, V267, P8073; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Cosper NJ, 1999, J BIOL CHEM, V274, P23160, DOI 10.1074/jbc.274.33.23160; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; Fujii T, 1996, NAT STRUCT BIOL, V3, P834, DOI 10.1038/nsb1096-834; Fujii T, 1997, BIOCHEMISTRY-US, V36, P1505, DOI 10.1021/bi961966j; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; Gomes CM, 1998, J BIOL INORG CHEM, V3, P499, DOI 10.1007/s007750050260; GORST CM, 1995, BIOCHEMISTRY-US, V34, P600, DOI 10.1021/bi00002a027; HARROCKS WD, 1980, J INORG BIOCHEM, V12, P131; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IMAI T, 1995, FEBS LETT, V368, P23, DOI 10.1016/0014-5793(95)00601-5; IMAI T, 1995, B CHEM SOC JPN, V68, P2923, DOI 10.1246/bcsj.68.2923; INUBUSHI T, 1983, J MAGN RESON, V51, P128, DOI 10.1016/0022-2364(83)90109-9; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iwasaki T, 1997, FEBS LETT, V417, P223, DOI 10.1016/S0014-5793(97)01286-6; Iwasaki T, 1997, J BIOL CHEM, V272, P3453, DOI 10.1074/jbc.272.6.3453; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1977, FEBS LETT, V83, P197, DOI 10.1016/0014-5793(77)81004-1; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; NAGAYAMA K, 1983, FEBS LETT, V158, P208, DOI 10.1016/0014-5793(83)80579-1; NAGAYAMA K, 1984, FEBS LETT, V173, P15, DOI 10.1016/0014-5793(84)81007-8; NAGAYAMA K, 1984, FEBS LETT, V169, P79, DOI 10.1016/0014-5793(84)80293-8; Nakajima Y, 1998, J BIOCHEM-TOKYO, V123, P521; PARK JB, 1991, J BIOL CHEM, V266, P19351; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; SCOTT RA, 1983, INORG CHIM A-BIOINOR, V79, P142, DOI 10.1016/S0020-1693(00)95178-8; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SCOTT RA, 1984, EXAFS NEAR EDGE STRU, V3, P105; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; TENG Q, 1994, BIOCHEMISTRY-US, V33, P6316, DOI 10.1021/bi00186a035; Wakagi T, 1996, BIOCHEM BIOPH RES CO, V225, P489, DOI 10.1006/bbrc.1996.1200; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	74	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25391	25401		10.1074/jbc.M909243199	http://dx.doi.org/10.1074/jbc.M909243199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827091	hybrid			2022-12-27	WOS:000088849400047
J	Jafferji, A; Allen, JWA; Ferguson, SJ; Fulop, V				Jafferji, A; Allen, JWA; Ferguson, SJ; Fulop, V			X-ray crystallographic study of cyanide binding provides insights into the structure-function relationship for cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-STUTZERI; ESCHERICHIA-COLI; HEME; PURIFICATION; PROTEIN; ENZYME; COMPLEX; PRODUCTS; MODELS	We present a 1.59-Angstrom resolution crystal structure of reduced Paracoccus pantotrophus cytochrome ed, with cyanide bound to the d(1) heme and His/Met coordination of the c heme. Fe-C-N bond angles are 146 degrees for the A subunit and 164 degrees for the B subunit of the dimer, The nitrogen atom of bound cyanide is within hydrogen bonding distance of His(345) and His(388) and either a water molecule in subunit A or Tyr(25), subunit B. The ferrous heme-cyanide complex is unusually stable (K-d similar to 10-(6) M); we propose that this reflects both the design of the specialized d(1) heme ring and a general feature of anion reductases with active site heme, Oxidation of crystals of reduced, cyanide-bound, cytochrome cd(1) results in loss of cyanide and return to the native structure with Tyr(25) as a ligand to the d(1) heme iron and switching to His/His coordination at the c-type heme, No reason for unusually weak binding of cyanide to the ferric state can be identified; rather it is argued that the protein is designed such that a chelate-based effect drives displacement by tyrosine of cyanide or a weaker ligand, like reaction product nitric oxide, from the ferric d(1) heme.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Oxford; University of Oxford; University of Warwick	Fulop, V (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Pk Rd, Oxford OX1 3QU, England.	vilmos@globin.bio.warwick.ac.uk	Fulop, Vilmos/AAZ-7720-2021					Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BARKIGIA KM, 1992, J AM CHEM SOC, V114, P1701, DOI 10.1021/ja00031a025; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BESSON S, 1995, ANAEROBE, V1, P219, DOI 10.1006/anae.1995.1021; BLACKMORE RS, 1990, BIOCHEM J, V271, P253, DOI 10.1042/bj2710253; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BRUNORI M, 1992, J BIOL CHEM, V267, P2258; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12120, DOI 10.1021/bi971066i; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; HILLIARD NP, 1991, ARCH BIOCHEM BIOPHYS, V291, P195, DOI 10.1016/0003-9861(91)90123-Z; JONES CW, 1982, ASPECTS MICROBIOLOGY, V5, P41; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEILIN D, 1955, BIOCHEM J, V61, P153, DOI 10.1042/bj0610153; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1974, BIOCHIM BIOPHYS ACTA, V333, P28, DOI 10.1016/0005-2728(74)90159-5; STEUP MB, 1989, J INORG BIOCHEM, V37, P233, DOI 10.1016/0162-0134(89)80045-5; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VEGA JM, 1977, J BIOL CHEM, V252, P896; Viola F, 1996, J INORG BIOCHEM, V62, P213, DOI 10.1016/0162-0134(95)00155-7; VOGEL AI, 1989, VOGELS TXB QUANTITAT, P309; WEEGAERSSENS E, 1991, J BIOL CHEM, V266, P7496; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; YAMANAKA T, 1963, BIOCHEM Z, V338, P62; YU NT, 1986, METHOD ENZYMOL, V130, P350; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	43	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25089	25094		10.1074/jbc.M001377200	http://dx.doi.org/10.1074/jbc.M001377200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827177	hybrid			2022-12-27	WOS:000088849400008
J	Wang, YP; Robledo, O; Kinzie, E; Blanchard, F; Richards, C; Miyajima, A; Baumann, H				Wang, YP; Robledo, O; Kinzie, E; Blanchard, F; Richards, C; Miyajima, A; Baumann, H			Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACUTE-PHASE RESPONSE; RAT ALPHA-2-MACROGLOBULIN GENE; CILIARY NEUROTROPHIC FACTOR; GP130 SIGNAL TRANSDUCER; PLASMA-PROTEINS; GROWTH-FACTOR; LIF RECEPTOR; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAINS	The related cytokines, interleukin-6 (IL-6), oncostatin M (OSM), and leukemia inhibitory factor (LIF) direct the formation of specific heteromeric receptor complexes to achieve signaling. Each complex includes the common signal-transducing subunit gp130. OSM and LIF also recruit the signaling competent, but structurally distinct OSMR beta and LIFR alpha subunits, respectively. To test the hypothesis that the particularly prominent cell regulation by OSM is due to signals contributed by OSMR beta, we introduced stable expression of human or mouse OSMR beta in rat hepatoma cells which have endogenous receptors for IL-6 and LIF, but not OSM. Both mouse and human OSM engaged gp130 with their respective OSMR beta subunits, but only human OSM also acted through LIFR. Signaling by OSMR beta-containing receptors was characterized by highest activation of STATE and ERK, recruitment of the insulin receptor substrate and Jun-N-terminal kinase pathways, and induction of a characteristic pattern of acute phase proteins. Since LIF together with LIFR alpha appear to form a more stable complex with gp130 than OSM with gp130 and OSMR beta, co-activation of LIFR and OSMR resulted in a predominant LIF-like response. These results suggest that signaling by IL-6 cytokines is not identical, and that a hierarchical order of cytokine receptor action exists in which LIFR ranks as dominant member.	Roswell Pk Canc Inst, Dept Cellular & Mol Biol, Buffalo, NY 14263 USA; McMaster Univ, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Roswell Park Cancer Institute; McMaster University; University of Tokyo	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Cellular & Mol Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	baumann@sc3101.med.buffalo.edu	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Richards, Carl/0000-0002-0081-2231	NATIONAL CANCER INSTITUTE [R01CA026122, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Barton BE, 1996, INFECT IMMUN, V64, P714, DOI 10.1128/IAI.64.3.714-718.1996; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; CHEN HM, 1991, J BIOL CHEM, V266, P2946; Chevalier S, 1995, ANN NY ACAD SCI, V762, P482; Clegg CH, 1999, EXP HEMATOL, V27, P712, DOI 10.1016/S0301-472X(98)00084-8; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; DAMELL JE, 1997, SCIENCE, V277, P1630; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Giordano V, 1997, J IMMUNOL, V158, P4097; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Harrison P, 1996, BRIT J HAEMATOL, V95, P443, DOI 10.1046/j.1365-2141.1996.d01-1941.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Kaibara A, 1998, CYTOKINE, V10, P452, DOI 10.1006/cyto.1997.0313; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Loy JK, 1999, TOXICOL PATHOL, V27, P151, DOI 10.1177/019262339902700201; MACKIEWICZ A, 1994, ACUTE PHASE PROTEINS, P1; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; Nakashima K, 1999, J NEUROSCI, V19, P5429; NORTHEMANN W, 1988, BIOCHEMISTRY-US, V27, P9194, DOI 10.1021/bi00426a018; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Richards CD, 1997, J IMMUNOL, V159, P2431; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schiemann WP, 1998, ONCOGENE, V16, P2671, DOI 10.1038/sj.onc.1201800; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; Shimon I, 1997, J CLIN INVEST, V100, P357, DOI 10.1172/JCI119541; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	83	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25273	25285		10.1074/jbc.M002296200	http://dx.doi.org/10.1074/jbc.M002296200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854424	hybrid			2022-12-27	WOS:000088849400032
J	Yang, HY; Zhou, BHP; Hung, MC; Lee, MH				Yang, HY; Zhou, BHP; Hung, MC; Lee, MH			Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; TUMOR SUPPRESSION; POINT MUTATION; P27(KIP1); EXPRESSION; SURVIVAL; OVEREXPRESSION; DEGRADATION; CARCINOMA	Overexpression and activation of HER-2/neu, a proto-oncogene, play a pivotal role in cancer formation. Strong expression of HER-2/neu in cancers has been associated with poor prognosis. Reduced expression of p27(Kip1), a cyclin-dependent kinase inhibitor, correlates with poor clinical outcome in many types of carcinomas. Because many cancers with the overexpression of HER-2/neu overlap with those affected by reduced p27 expression, we studied the link between HER-2/neu oncogenic signals and p27 regulation. We found that down-regulation of p27 correlates with HER-2/neu overexpression, To address the molecular mechanism of this inverse correlation, we found that reduction of p27 is caused by enhanced ubiquitin-mediated degradation, and the HER-2/Grb2/MAPK pathway is involved in the decrease of p27 stability. Also, HER-2/neu activity causes mislocation of p27 and Jun activation domain-binding protein 1 (JAB1), an exporter of p27, into the cytoplasm, thereby facilitating p27 degradation. These results reveal that HER-2/neu signals reduce p27 stability and thus present potential points for therapeutic intervention in HER-2/neu-associated cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 18,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Baselga J, 1998, CANCER RES, V58, P2825; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERCHUCK A, 1990, CANCER RES, V50, P4087; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Masciullo V, 1999, CANCER RES, V59, P3790; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Singh SP, 1998, CANCER RES, V58, P1730; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	34	109	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24735	24739		10.1074/jbc.C000147200	http://dx.doi.org/10.1074/jbc.C000147200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10859299	hybrid			2022-12-27	WOS:000088683300069
J	Zheng, XL; Matsubara, S; Diao, C; Hollenberg, MD; Wong, NCW				Zheng, XL; Matsubara, S; Diao, C; Hollenberg, MD; Wong, NCW			Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; REVERSE CHOLESTEROL TRANSPORT; HIGH-DENSITY-LIPOPROTEIN; MOLECULAR MECHANISMS; MESSENGER-RNA; DNA-BINDING; FACTOR AP-2; PHOSPHORYLATION; INHIBITOR; PROMOTER	Our previous finding that insulin induces apolipoprotein AI (apoAI) transcription points to the participation of intracellular signaling. This finding prompted us to ask whether two classical G-protein-coupled signaling pathways requiring activated protein kinase A (PKA) or kinase C (PKC) may also regulate apoAI. Therefore, human hepatoma, Rep G2 cells stably transfected with pAI.474-CAT, a reporter construct spanning -474 to -7 of apoAI DNA fused to chloramphenicol acetyltransferase (CAT) were treated with 10 mu M forskolin (FSK) or 50 nM phorbol dibutyrate (PDBu) to activate PKA and PKC, respectively, Results showed that the apoAI promoter activity increased 4-5-fold following 24 h of treatment with either FSK or PDBu. Induction by either agent was blocked with actinomycin D but not the protein synthesis inhibitor, cycloheximide. The PKA inhibitor, PKI 14-22 amide, abrogated induction by FSK, 100 mu M 8-bromo-cAMP, or 100 ng/ml cholera toxin, but it had no effect on activation via PKC. Similarly, PDBu induction was attenuated by 2 mu M Of the PKC inhibitor, GF109203X, but it did not affect FSK activity. Next we used deletional constructs to show that the actions of FSK and PDBu required the insulin-responsive core element (IRCE). This motif matched the consensus binding site for the transcription factor, Spl. The binding of Spl to the IRCE was confirmed by gel-retardation and supershift analysis. Site-directed mutagenesis of the IRCE eliminated Spl action and induction by FSK or PDBu. Whereas overexpression of Spl enhanced basal and FSK or PDBu induced promoter activity, transfection of an antisense oligomer against Spl mRNA attenuated both parameters. In summary, activation of PKA or PKC increases apoAI promoter activity. The activity of both signaling pathways is mediated by the IRCE, a motif that binds the transcription factor, Spl.	Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Med,Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Calgary	Wong, NCW (corresponding author), Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Med,Endocrine Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Hollenberg, Morley/AFV-6966-2022	Zheng, Xi-Long/0000-0002-0889-1827				Andersson LO, 1997, CURR OPIN LIPIDOL, V8, P225, DOI 10.1097/00041433-199708000-00006; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; de Backer G, 1998, ATHEROSCLEROSIS, V137, pS1, DOI 10.1016/S0021-9150(97)00310-9; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Hargrove GM, 1999, J MOL ENDOCRINOL, V22, P103, DOI 10.1677/jme.0.0220103; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Luoma PV, 1997, PHARMACOL TOXICOL, V81, P57, DOI 10.1111/j.1600-0773.1997.tb00032.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; Murao K, 1998, J BIOL CHEM, V273, P18959, DOI 10.1074/jbc.273.30.18959; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ries S, 1998, J LIPID RES, V39, P2125; Rohlff C, 1998, INT J ONCOL, V12, P383; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; Sakai T, 2000, ATHEROSCLEROSIS, V149, P43, DOI 10.1016/S0021-9150(99)00292-0; SOYAL SM, 1995, J BIOL CHEM, V270, P3996, DOI 10.1074/jbc.270.8.3996; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; Wu JYJ, 1999, AM J PHYSIOL-CELL PH, V277, pC537, DOI 10.1152/ajpcell.1999.277.3.C537; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zheng XL, 1999, J PHARMACOL EXP THER, V289, P632	36	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31747	31754		10.1074/jbc.M000621200	http://dx.doi.org/10.1074/jbc.M000621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10829013	hybrid			2022-12-27	WOS:000089858900030
J	Matsumoto, M; Sudo, T; Saito, T; Osada, A; Tsujimoto, M				Matsumoto, M; Sudo, T; Saito, T; Osada, A; Tsujimoto, M			Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; BONE MORPHOGENETIC PROTEIN-2; LYMPH-NODE ORGANOGENESIS; DEFECTIVE INTERLEUKIN-1; TRANSDUCTION PATHWAY; POTENT STIMULATOR; MARROW CULTURES; CELL-FORMATION; MAP KINASES	The receptor activator of NF-kappa B ligand (RANKL) induces osteoclast differentiation from bone marrow cells in the presence of macrophage colony-stimulating factor, We found that treatment of bone marrow cells with SB203580 inhibited osteoclast differentiation via inhibition of the RANKL-mediated signaling pathway. To elucidate the role of p38 mitogen-activated protein (MAP) kinase pathway in osteoclastogenesis, we employed RAW264 cells which could differentiate into osteoclastlike cells following treatment with RANKL. In a dose-dependent manner, SB203580 but not PD98059, inhibited RANKL-induced differentiation. Among three MAP kinase families tested, this inhibition profile coincided only with the activation of p38 MAP kinase. Expression in RAW264 cells of the dominant negative form of either p38 alpha MAP kinase or MAP kinase kinase (MKK) 6 significantly inhibited RAM(L-induced differentiation of the cells, These results indicate that activation of the p38 MAP kinase pathway plays an important role in RANKL-induced osteoclast differentiation of precursor bone marrow cells.	RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; RIKEN, Lab Antibiot, Wako, Saitama 3510198, Japan	RIKEN; RIKEN	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tsujimot@postman.riken.go.jp	Matsumoto, Masahito/AGS-0755-2022; Osada, Hiroyuki/N-4305-2014					ABE E, 1983, P NATL ACAD SCI-BIOL, V80, P5583, DOI 10.1073/pnas.80.18.5583; AKATSU T, 1989, ENDOCRINOLOGY, V125, P20, DOI 10.1210/endo-125-1-20; AKATSU T, 1989, J BONE MINER RES, V4, P29; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097-4652(199703)170:3<241::AID-JCP4>3.0.CO;2-O; Hayashi SI, 1998, BIOCHEM CELL BIOL, V76, P911; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KURIHARA N, 1989, BLOOD, V74, P1295; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SHERR CJ, 1990, BLOOD, V75, P1; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	57	449	464	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31155	31161		10.1074/jbc.M001229200	http://dx.doi.org/10.1074/jbc.M001229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859303	hybrid			2022-12-27	WOS:000089762700058
J	Masai, H; Matsui, E; You, ZY; Ishimi, Y; Tamai, K; Arai, K				Masai, H; Matsui, E; You, ZY; Ishimi, Y; Tamai, K; Arai, K			Human Cdc7-related kinase complex - In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a critical threonine residue of Cdc7 by Cdks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; DNA HELICASE ACTIVITY; CELL-CYCLE REGULATION; LARGE TUMOR-ANTIGEN; PROTEIN-KINASE; S-PHASE; REPLICATION ORIGINS; G(1)/S TRANSITION; MAMMALIAN-CELLS; FISSION YEAST	huCdc7 encodes a catalytic subunit for Saccharomyces cerevisae Cdc7-related kinase complex of human. ASK, whose expression is cell cycle-regulated, binds and activates huCdc7 kinase in a cell cycle-dependent manner (Kumagai, H., Sato, N., Yamada, M., Mahony, D., Seghezzi, W., Lees, E., Arai, K., and Masai, H. (1999) Mel. Cell. Biol. 19, 5083-5095). We have expressed huCdc7 complexed with ASK regulatory subunit using the insect cell expression system. To facilitate purification of the kinase complex, glutathione S-transferase (GST) was fused to huCdc7 and GST-huCdc7-ASK complex was purified. GST-huCdc7 protein is inert as a kinase on its own, and phosphorylation absolutely depends on the presence of the ASK subunit, It autophosphorylates both subunits in vitro and phosphorylates a number of replication proteins to different extents. Among them, MCM2 protein, either in a free form or in a MCM2-4-6-7 complex, serves as an excellent substrate for huCdc7-ASK kinase complex in vitro. MCM4 and MCM6 are also phosphorylated by huCdc7 albeit to less extent. MCM2 and -4 in the MCM2-4-6-7 complex are phosphorylated by Cdks as well, and prior phosphorylation of the MCM2-4-6-7 complex by Cdks facilitates phosphorylation of MCM2 by huCdc7, suggesting collaboration between Cdks and Cdc7 in phosphorylation of MCM for initiation of S phase. huCdc7 and ASK proteins can also be phosphorylated by Cdks in vitro. Among four possible Cdk phosphorylation sites of huCdc7, replacement of Thr-376, corresponding to the activating threonine of Cdk, with alanine (T376A mutant) dramatically reduces kinase activity, indicative of kinase activation by phosphorylation of this residue. In vitro, Cdk2-Cyclin E, Cdk2-Cyclin A, and Cdc2-Cyclin B, but not Cdk4-Cyclin D1, phosphorylates the Thr-376 residue of huCdc7, suggesting possible regulation of huCdc7 by Cdks.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; CREST, Japan Sci & Technol Corp, JST, Machida, Tokyo 1940031, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1940031, Japan; Med & Biol Labs Co Ltd, Nagano 1063103, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Masai, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; BUCK V, 1991, MOL GEN GENET, V227, P452, DOI 10.1007/BF00273937; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Draetta G.F., 1997, CURR BIOL, V7, P50; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FUJITA M, 1999, FRONT BIOSCI, V4, P816; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITADA K, 1992, GENETICS, V131, P21; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H., 1999, FRONT BIOSCI, V4, pD834; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Ohtoshi A, 1997, MOL GEN GENET, V254, P562, DOI 10.1007/s004380050452; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; QUINTANA DG, 1999, FRONT BIOSCI, V4, P802; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; Takeda T, 1999, MOL CELL BIOL, V19, P5535; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; You ZY, 1999, MOL CELL BIOL, V19, P8003	44	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29042	29052		10.1074/jbc.M002713200	http://dx.doi.org/10.1074/jbc.M002713200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10846177	hybrid			2022-12-27	WOS:000089330700091
J	Wing, HJ; Green, J; Guest, JR; Busby, SJW				Wing, HJ; Green, J; Guest, JR; Busby, SJW			Role of activating region 1 of Escherichia coli FNR protein in transcription activation at class II promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-SUBUNIT; C-TERMINAL DOMAIN; CAP-DNA COMPLEX; RNA-POLYMERASE; RECEPTOR PROTEIN; SPACING REQUIREMENTS; GENE-EXPRESSION; CONTACT SITE; OXYGEN; CAMP	FNR is an Escherichia coli transcription factor that activates gene expression in response to anaerobiosis at a large number of promoters by making direct contacts with RNA polymerase, At class II FNR-dependent promoters, where the DNA site for FNR overlaps the -35 element, activating region 1 of FNR is proposed to interact with the C-terminal domain of the RNA polymerase alpha-subunit. Using a model class II FNR-dependent promoter, FF(-41.5), we have performed in vivo and in vitro experiments to investigate the role of this interaction. Our results show that FNR, carrying substitutions in activating region 1, is compromised in its ability to promote open complex formation and thus to activate transcription. Abortive initiation assays were used to assess the contribution of activating region 1 of FNR to open complex formation. A new method for the purification of the FNR protein is also described.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England	University of Birmingham; University of Sheffield	Wing, HJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept IID, 665 Huntington Ave,Bldg 1,Rm 902, Boston, MA 02115 USA.	hwing@hsph.harvard.edu	Busby, Stephen/C-2712-2015	Busby, Stephen/0000-0003-2148-1758; Wing, Helen J./0000-0003-0123-5568				ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby Stephen, 1994, V30, P397; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest John R., 1996, P317; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Lloyd GS, 1998, BIOCHEM J, V330, P413; LODGE J, 1992, FEMS MICROBIOL LETT, V95, P271; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Miller J. H, 1972, EXPT MOL GENETICS; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Savery N. J., 1996, ESSENTIAL TECHNIQUES, P1; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1988, MOL MICROBIOL, V2, P701, DOI 10.1111/j.1365-2958.1988.tb00080.x; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995	28	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29061	29065		10.1074/jbc.M000390200	http://dx.doi.org/10.1074/jbc.M000390200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10846171	hybrid			2022-12-27	WOS:000089330700093
J	Cik, M; Masure, S; Lesage, ASJ; Van der Linden, I; Van Gompel, P; Pangalos, MN; Gordon, RD; Leysen, JE				Cik, M; Masure, S; Lesage, ASJ; Van der Linden, I; Van Gompel, P; Pangalos, MN; Gordon, RD; Leysen, JE			Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2 - Influence of cRET and cooperative interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TYROSINE KINASE; NEGATIVE COOPERATIVITY; INSULIN-RECEPTOR; LIGAND FAMILY; GROWTH-FACTOR; RET; GFR-ALPHA-3; ACTIVATION; KINETICS	The members of the glial cell line-derived neurotrophic factor (GDNF) family signal via binding to the glycosyl phosphatidylinositol-anchored membrane proteins, the GDNF family receptors alpha (GFR alpha), and activation of cRET. We performed a detailed analysis of the binding of GDNF and neurturin to their receptors and investigated the influence of cRET on the binding affinities. We show that the rate of dissociation of I-125-GDNF from GFR alpha 1 is increased in the presence of 50 nM GDNF, an effect that can be explained by the occurrence of negative cooperativity. Scatchard plots of the ligand concentration binding isotherms reveal a pronounced downward curvature at low I-125-GDNF concentrations suggesting the presence of positive cooperativity. This effect is observed in the range of GDNF concentrations responsible for biological activity (1-20 pM) and may have an important role in cRET-independent signaling, A high affinity site with a K-D of 11 pM for I-125-GDMF is detected only when GFR alpha 1 is co-expressed with cRET at a DNA ratio of 1:3, These results suggest an interaction of GFR alpha 1 and cRET in the absence of GDNF and demonstrate that the high affinity binding can be measured only when cRET is present.	Janssen Res Fdn, Dept Biochem Pharmacol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biotechnol & High Throughput Screening, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Cik, M (corresponding author), Janssen Res Fdn, Dept Biochem Pharmacol, Turnhoutseweg 30, B-2340 Beerse, Belgium.							Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BALOH RH, 1997, J NEURON, V18, P793; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CREDOON DJ, 1997, P NATL ACAD SCI USA, V89, P9509; Davies AM, 1997, NEURON, V19, P485; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GU JL, 1988, BIOCHEM BIOPH RES CO, V150, P694, DOI 10.1016/0006-291X(88)90447-0; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARSH JW, 1984, J BIOL CHEM, V259, P6641; Masure S, 1998, EUR J BIOCHEM, V251, P622, DOI 10.1046/j.1432-1327.1998.2510622.x; MEYTS PD, 1976, J BIOL CHEM, V251, P1877; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; TAIT JF, 1981, J BIOL CHEM, V256, P1086; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Widenfalk J, 1998, EUR J NEUROSCI, V10, P1508, DOI 10.1046/j.1460-9568.1998.00192.x; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502	34	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27505	27512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10829012				2022-12-27	WOS:000089197100002
J	Costet, P; Luo, Y; Wang, N; Tall, AR				Costet, P; Luo, Y; Wang, N; Tall, AR			Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; REVERSE CHOLESTEROL TRANSPORT; TANGIER-DISEASE; NUCLEAR RECEPTOR; CELLULAR CHOLESTEROL; RESPONSE PATHWAY; LXR-ALPHA; EFFLUX; GENE; OXYSTEROLS	Tangier disease, a condition characterized by low levels of high density lipoprotein and cholesterol accumulation in macrophages, is caused by mutations in the ATP-binding cassette transporter ABC1. In cultured macrophages, ABC1 mRNA was induced in an additive fashion by 22(R)-hydroxycholesterol and 9-cis-retinoic acid (9CRA), suggesting induction by nuclear hormone receptors of the liver X receptor (LXR) and retinoid X receptor (RXR) family. We cloned the 5'-end of the human ABC1 transcript from cholesterol-loaded THP1 macrophages. When transfected into RAW macrophages, the upstream promoter was induced 7-fold by 22(R)-hydrosyeholesterol, 8-fold by 9CRA, and 37-fold by 9CRA and 22(R)-hydroxycholesterol. Furthermore, promoter activity was increased in a sterol-responsive fashion when cotransfected with LXR alpha/RXR or LXR beta/RXR, Further experiments identified a direct repeat spaced by four nucleotides (from -70 to -55 base pairs) as a binding site for LXR alpha/RXR or LXR beta/RXR, Mutations in this element abolished the sterol-mediated activation of the promoter. The results show sterol-dependent transactivation of the ABC1 promoter by LXR/RXR and suggest that small molecule agonists of LXR could be useful drugs to reverse foam cell formation and atherogenesis.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		costet, philippe/A-5314-2010; Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, P50HL056984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Feltkamp D, 1999, J BIOL CHEM, V274, P10421, DOI 10.1074/jbc.274.15.10421; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hulten LM, 1996, J CLIN INVEST, V97, P461, DOI 10.1172/JCI118436; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; Sambrook J., 2002, MOL CLONING LAB MANU; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	39	826	859	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28240	28245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10858438				2022-12-27	WOS:000089197100094
J	Oliveira, DM; Nakaie, CR; Sousa, AD; Farah, CS; Reinach, FC				Oliveira, DM; Nakaie, CR; Sousa, AD; Farah, CS; Reinach, FC			Mapping the domain of troponin T responsible for the activation of actomyosin ATPase activity - Identification of residues involved in binding to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TROPONIN; THIN FILAMENT; ALPHA-TROPOMYOSIN; ESCHERICHIA-COLI; REGULATORY PROPERTIES; INTEGRAL-EQUATIONS; CA2+ REGULATION; CONTRACTION; FRAGMENTS; SENSITIVITY	The in vitro Ca2+ regulation of the actomyosin Mg2+-ATPase at physiological ratios of actin, tropomyosin, and troponin occurs only in the presence of troponin T. We have previously demonstrated that a polypeptide corresponding to the first 191 amino acids of troponin T (TnT-(1-191)) activates the actomyosin Mg2+-ATPase in the presence of tropomyosin. In order to further characterize this activation domain, we constructed troponin T fragments corresponding to residues 1-157 (Tn-T(1-157)), 1-76 (TnT-(1-76)), 77-157 (TnT-(77-157)), 77-191 (TnT-(77-191)), and 158-191 (TnT-(158-191)). Assays using these fragments demonstrated the following: (a) residues 1-76 do not bind to tropomyosin or actin; (b) residues 158-191 bind to actin cooperatively but not to tropomyosin; (c) the sequence 77-157 is necessary for troponin interaction with residue 263 of tropomyosin; (d) TnT-(77-191) on its own activates the actomyosin ATPase activity as described previously for TnT-(1-191). TnT-(1-157), TnT-(1-76), TnT-(77-157), TnT-(158-191), and combinations of TnT-(158-191) with TnT-(1-157) or TnT-(77-157) showed no effect on the ATPase activity. We conclude that the activation of actomyosin ATPase activity is mediated by a direct interaction between amino acids 77 and 191 of troponin T, tropomyosin, and actin.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Reinach, FC (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26 077, BR-05599970 Sao Paulo, Brazil.	fdcreina@quim.iq.usp.br	Nakaie, Clovis R./B-3444-2014; Farah, Chuck Shaker/G-5565-2012; Oliveira, Daniela/G-6540-2014	Farah, Chuck Shaker/0000-0003-3110-6302; Sousa, Aurea/0000-0002-9153-7414; Oliveira, Daniela/0000-0002-2832-5726				BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; Cilli EM, 1996, J ORG CHEM, V61, P8992, DOI 10.1021/jo9611632; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GREASER ML, 1971, J BIOL CHEM, V246, P4226; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HASELGROVE JC, 1973, COLD SPRING HARB SYM, V37, P341, DOI 10.1101/SQB.1973.037.01.044; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; Korman VL, 1999, J BIOL CHEM, V274, P22191, DOI 10.1074/jbc.274.32.22191; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MALNIC B, 1994, EUR J BIOCHEM, V222, P49, DOI 10.1111/j.1432-1033.1994.tb18840.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANOKURA M, 1984, J BIOCHEM, V95, P1417, DOI 10.1093/oxfordjournals.jbchem.a134749; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; WALSH TP, 1985, J MOL BIOL, V182, P265, DOI 10.1016/0022-2836(85)90344-4; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	55	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27513	27519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10852909				2022-12-27	WOS:000089197100003
J	Zuk, PA; Elferink, LA				Zuk, PA; Elferink, LA			Rab15 differentially regulates early endocytic trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SMALL GTPASE RAB5; MEMBRANE-FUSION; AUTOANTIGEN EEA1; WILD-TYPE; ENDOSOMES; TRANSFERRIN; PATHWAY; MUTANT; BIOGENESIS	Rab GTPases play an important regulatory role in early endocytosis. We recently demonstrated that epitope-tagged Rab15 (HArab15) co-localizes with Rab4, -5, and -11 on early endosomal membranes in CHO cells (Zuk, P, A, and Elferink, L, A. (1999) J, Biol. Chem. 274, 22303-22312). To characterize the role of Rab15 in endocytosis, we prepared functional mutants of HArab15 and examined their effects on early endocytic trafficking, Wild-type HArab15 and its constitutively active, GTP-bound mutant (Q67L) reduce fluid phase and receptor-mediated endocytosis without affecting the rate of recycling from early endosomal compartments, Inhibition of early endocytosis appears to be due to a reduction in the rate of homotypic early endosome fusion, Conversely, mutations that constitutively inactivate HArab15 stimulate early endocytosis and the homotypic fusion of early endosomes in vitro. Unlike active forms of HArab15, constitutively inactive HArab15 mutants also affect recycling from early endosomal compartments. Moreover, the two constitutively inactive mutants, GDP-bound HArab15-T22N and the non-nucleotide binding mutant RArab15-N121I, differentially regulate the transit of fluid phase and receptor-mediated endocytic tracers through early/sorting endosomes, Together, these data suggest that HArab15 may counteract the reported stimulatory effect of Rab5 on early endocytosis. Consistent with this, overexpression of constitutively active HArab15-Q67L attenuates Rab5-stimulated endocytosis, whereas Rab5-stimulated endocytosis is augmented in cells overexpressing a constitutively inactive HArab15 mutant defective in guanine nucleotide binding (N121I), Our data indicate that HArab15 differentially regulates distinct steps in membrane trafficking through early/sorting and pericentriolar recycling endosomes.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Elferink, LA (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall, Detroit, MI 48202 USA.							Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; ESCOLA JM, 1995, J CELL SCI, V108, P2337; GHOSH RN, 1994, J CELL SCI, V107, P2177; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1993, NATO ASI SERIES H, V74, P269; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Nagelkerken B, 1997, ELECTROPHORESIS, V18, P2694, DOI 10.1002/elps.1150181427; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; WANG RH, 1990, J BIOL CHEM, V265, P20179; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303	42	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26754	26764						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837464				2022-12-27	WOS:000089144800014
J	Babaev, VR; Patel, MB; Semenkovich, CF; Fazio, S; Linton, MF				Babaev, VR; Patel, MB; Semenkovich, CF; Fazio, S; Linton, MF			Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; IV HYPERTRIGLYCERIDEMIC VLDL; SMOOTH-MUSCLE CELLS; OXIDIZED LDL; KNOCKOUT MICE; PPAR-GAMMA; IN-VIVO; METABOLISM; INCREASES; LESIONS	The role of macrophage lipoprotein lipase (LPL) expression in atherosclerotic lesion formation was examined in low density lipoprotein receptor (LDLR-/-) mice using dietary conditions designed to induce either fatty streak lesions or complex atherosclerotic lesions. First, LDLR-/- mice chimeric for macrophage LPL expression were created by transplantation of lethally irradiated female LDLR-/- mice with LPL-/- (n = 12) or LPL+/+ (n = 14) fetal liver cells as a source of hematopoietic cells. To induce fatty streak lesions, these mice were fed a Western diet for 8 weeks, resulting in severe hypercholesterolemia, There were no differences in plasma postheparin LPL activity, serum lipid levels, or lipoprotein distribution between these two groups. The mean lesion area in the proximal aorta in LPL-/- --> LDLR-/- mice was significantly reduced by 33% compared with LPL+/+ --> LDLR-/- mice, and a similar reduction (38%) in lesion area was found by en face analysis of the aortae. To induce complex atherosclerotic lesions, female LDLR-/- mice were lethally irradiated, transplanted with LPL-/-(n = 14), LPL+/- (n = 13), or LPL+/+ (n = 14) fetal liver cells, and fed the Western diet for 19 weeks. Serum cholesterol and triglyceride levels did not differ between the three groups. After 19 weeks of diet, the lesions in the proximal aorta were complex with relatively few macrophages expressing LPL protein and mRNA in LPL+/+ --> LDLR-/- mice. Analysis of cross-sections of the proximal aorta demonstrated no differences in the extent of lesion area between the groups, whereas en face analysis of the aortae revealed a dose-dependent effect of macrophage LPL on mean aortic lesion area in LPL-/- --> LDLR-/-, LPL-/+ --> LDLR-/-, and LPL+/+ --> LDLR-/- mice (1.8 +/- 0,2%, 3.5 +/- 0.5% and 5.9 +/- 0,8%, respectively). Taken together, these data indicate that macrophage LPL expression in the artery wall promotes atherogenesis during foam cell lesion formation, but this impact may be limited to macrophage-rich lesions.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Med,Div Cardiovasc Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Washington Univ, St Louis, MO 63110 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Washington University (WUSTL)	Fazio, S (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Med,Div Cardiovasc Med, Rm 312,Med Res Bldg 2, Nashville, TN 37232 USA.		Patel, Mayur/K-2363-2013	Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053989, R01HL058427] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427, HL53989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1988, J BIOL CHEM, V263, P15416; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Balagopalakrishna C, 1999, J LIPID RES, V40, P1347; Beisiegel U, 1996, ATHEROSCLEROSIS, V124, P1, DOI 10.1016/0021-9150(95)05792-7; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Brunzell JD, 1995, METABOLIC BASIS INHE, P1913; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goldberg IJ, 1996, J LIPID RES, V37, P693; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; Makoveichuk E, 1998, BIOCHEM BIOPH RES CO, V252, P703, DOI 10.1006/bbrc.1998.9596; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MULDER M, 1993, J BIOL CHEM, V268, P9369; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; OBREIN KD, 1992, J CLIN INVEST, V89, P1544; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SAXENA U, 1992, BIOCHEM BIOPH RES CO, V189, P1653, DOI 10.1016/0006-291X(92)90267-O; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; TABAS I, 1993, J BIOL CHEM, V268, P20419; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Whitman SC, 1998, J LIPID RES, V39, P1008; Whitman SC, 1999, J LIPID RES, V40, P1017; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	40	134	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26293	26299		10.1074/jbc.M002423200	http://dx.doi.org/10.1074/jbc.M002423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858435	hybrid			2022-12-27	WOS:000088999700057
J	Chrestensen, CA; Starke, DW; Mieyal, JJ				Chrestensen, CA; Starke, DW; Mieyal, JJ			Acute cadmium exposure inactivates thioltransferase (glutaredoxin), inhibits intracellular reduction of protein-glutathionyl-mixed disulfides, and initiates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Experimental Biology 99 Meeting	APR 17-21, 1999	WASHINGTON, D.C.				S-THIOLATION; OXIDATIVE STRESS; IN-VITRO; MAMMALIAN THIOREDOXIN; ENDOTHELIAL-CELLS; REDOX REGULATION; SYSTEM; HEPATOCYTES; PURIFICATION; DETHIOLATION	Oxidative stress broadly impacts cells, initiating regulatory pathways as well as apoptosis and necrosis. A key molecular event is protein S-glutathionylation, and thioltransferase (glutaredoxin) is a specific and efficient catalyst of protein-SSG reduction. In this study 30-min exposure of H9 and Jurkat cells to cadmium inhibited intracellular protein-SSG reduction, and this correlated with inhibition of the thioltransferase system, consistent with thioltransferase being the primary intracellular catalyst of deglutathionylation. The thioredoxin system contributed very little to total deglutathionylase activity. Thioltransferase and GSSG reductase in situ displayed similar dose-response curves (50% inhibition near 10 mu M cadmium in extracellular buffer). Acute cadmium exposure also initiated apoptosis, with H9 cells being more sensitive than Jurkat. Moreover, transfection with antisense thioltransferase cDNA was incompatible with cell survival. Collectively, these data suggest that thioltransferase has a vital role in sulfhydryl homeostasis and cell survival. In separate experiments, cadmium inhibited the isolated component enzymes of the thioltransferase and thioredoxin systems, consistent with the vicinal dithiol nature of their active sites: thioltransferase (IC50 approximate to 1 mu M), GSSG reductase (IC50 approximate to mu M), thioredoxin (IC50 approximate to 8 mu M), thioredoxin reductase (IC50 approximate to 0.2 mu M) Disruption of the vicinal dithiol on thioltransferase (via oxidation to C22-SS-C25; or C25S mutation) protected against cadmium, consistent with a dithiol chelation mechanism of inactivation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.	jjm5@po.cwru.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36219] Funding Source: Medline; NIA NIH HHS [AG15885] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELLO PA, 1994, SHOCK, V2, P79, DOI 10.1097/00024382-199408000-00001; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Baker A, 2000, BIOCHEM BIOPH RES CO, V268, P78, DOI 10.1006/bbrc.1999.1908; Baker A, 1997, CANCER RES, V57, P5162; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Biaglow JE, 2000, ANAL BIOCHEM, V281, P77, DOI 10.1006/abio.2000.4533; Biswal SS, 2000, TOXICOL SCI, V53, P77, DOI 10.1093/toxsci/53.1.77; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Dafre AL, 1996, ARCH BIOCHEM BIOPHYS, V332, P288, DOI 10.1006/abbi.1996.0344; DAVIS DA, 1995, ARCH BIOCHEM BIOPHYS, V322, P127, DOI 10.1006/abbi.1995.1444; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Di Simplicio P, 1998, ARCH BIOCHEM BIOPHYS, V355, P145, DOI 10.1006/abbi.1998.0694; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Jung R, 1997, PLANT CELL, V9, P2037, DOI 10.1105/tpc.9.11.2037; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; MANNERVIK B, 1983, BIOCHEM J, V213, P519, DOI 10.1042/bj2130519; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P177; Meyer EB, 1999, FREE RADICAL BIO MED, V26, P770, DOI 10.1016/S0891-5849(98)00247-0; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MULLER L, 1986, TOXICOL LETT, V30, P259, DOI 10.1016/0378-4274(86)90164-5; OCHI T, 1987, MUTAT RES, V180, P257, DOI 10.1016/0027-5107(87)90222-3; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SATO N, 1995, J IMMUNOL, V154, P3194; SCHUPPEKOISTINEN I, 1994, ARCH BIOCHEM BIOPHYS, V315, P226, DOI 10.1006/abbi.1994.1494; Seres T, 1996, J IMMUNOL, V156, P1973; SHIN SH, 1993, PLANTA, V189, P557, DOI 10.1007/BF00198219; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; SRINIVASAN U, 1998, THESIS CASE W RESERV; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STEFFENSEN IL, 1994, GEN PHARMACOL-VASC S, V25, P1621, DOI 10.1016/0306-3623(94)90364-6; THOMAS JA, 1995, METHOD ENZYMOL, V251, P423, DOI 10.1016/0076-6879(95)51145-8; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; *US DEP HLTH HUM S, 1997, TOXICOLOGICAL PROFIL; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	63	258	264	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26556	26565		10.1074/jbc.M004097200	http://dx.doi.org/10.1074/jbc.M004097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	348RF	10854441	hybrid			2022-12-27	WOS:000088999700093
J	Ogut, O; Jin, JP				Ogut, O; Jin, JP			Cooperative interaction between developmentally regulated troponin T and tropomyosin isoforms in the absence of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL VARIABLE REGION; SKELETAL-MUSCLE; THIN FILAMENT; ALPHA-TROPOMYOSIN; MOLECULAR-BASIS; BINDING; GENE; CONTRACTION; EXPRESSION; FRAGMENTS	Troponin T (TnT) is the tropomyosin (Tm) binding subunit of the troponin complex that mediates the Ca2+ regulation of actomyosin interaction in striated muscles. Troponin T isoform diversity is marked by a developmentally regulated acidic to basic switch that may modulate muscle contractility. We previously reported that transgenic expression of fast skeletal muscle TnT altered the cooperativity of cardiac muscle. In the present study, we have demonstrated that the binding of acidic TnT to troponin I is weaker than that of basic TnT. However, affinity chromatography experiments showed that Tm bound to acidic TnT with a greater affinity than to basic TnT, consistent with the significantly higher maximal binding of acidic TnT to Tm in solid phase binding assays. Competition and co-immunoprecipitation experiments demonstrated that the binding of TnT to Tm was cooperative in the absence of F-actin. The cooperativity between TnT molecules for Tm binding can be initiated by the conserved COOH-terminal T2 fragment of TnT. This indicates that the interaction of TnT with Tm induces a conformational change in Tm, promoting interaction of TnT with adjacent Tm dimers. This finding suggests a role for TnT and its acidic and basic isoforms in the cooperative release of the inhibition of striated muscle actomyosin interaction.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.			Jin, JP/0000-0001-9932-1063				AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRIGGS MM, 1993, DEV BIOL, V158, P503, DOI 10.1006/dbio.1993.1208; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; Bucher EA, 1999, J BIOL CHEM, V274, P17661, DOI 10.1074/jbc.274.25.17661; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; EBASHI S, 1963, NATURE, V200, P1010, DOI 10.1038/2001010a0; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Huang QQ, 1999, GENE, V229, P1, DOI 10.1016/S0378-1119(99)00051-7; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; JIN JP, 1988, J BIOL CHEM, V263, P7309; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Miyazaki JI, 1999, J MUSCLE RES CELL M, V20, P655, DOI 10.1023/A:1005504018059; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1981, FEBS LETT, V128, P119, DOI 10.1016/0014-5793(81)81095-2; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SCHACHAT F, 1995, DEV BIOL, V171, P233, DOI 10.1006/dbio.1995.1274; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26089	26095		10.1074/jbc.M910360199	http://dx.doi.org/10.1074/jbc.M910360199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10844003	hybrid			2022-12-27	WOS:000088999700029
J	Pages, G; Berra, E; Milanini, J; Levy, AP; Pouyssegur, J				Pages, G; Berra, E; Milanini, J; Levy, AP; Pouyssegur, J			Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; INDUCED TRANSCRIPTIONAL ACTIVATION; INTERNAL RIBOSOME ENTRY; FACTOR GENE; FACTOR EXPRESSION; MAMMALIAN-CELLS; HYPOXIA; STABILIZATION; ANGIOGENESIS; MITOGEN	Stability of the vascular endothelial growth factor (VEGF) mRNA is tightly regulated through its 3'-untranslated region (3'-UTR). Here, we demonstrate that VEGF mRNA levels are increased by anisomycin, a strong activator of stress-activated protein kinases. Hence, VEGF mRNA induction is inhibited by SB202190, an inhibitor of JNK and p38/HOG kinase, Furthermore, VEGF mRNA expression is increased in cells that overexpress JNK and p38/HOG; by an increase in its stability. We show by two different approaches that anisomycin exerts its effect on the VEGF mRNA 3'-UTR. First, by using an in vitro mRNA degradation assay, the half-life of the VEGF mRNA 3'-UTR region transcript was found to be increased when incubated with extracts from anisomycin-treated cells; and second, the 3'-UTR was also sufficient to confer mRNA instability to the Nhe3 (Na+/H+ exchanger 3) heterologous reporter gene, and anisomycin treatment stabilized the chimeric mRNA (Nhe3 fused to the VEGF mRNA 3'-UTR). This chimeric mRNA is also more stable in cells overexpressing p38/HOG and JNK that have been stimulated by anisomycin. We show that such regulation is mediated through an AU-rich region of the 3'-UTR contained within a stable hairpin structure. By RNA electrophoretic mobility shift assays, we show that this region binds proteins specifically induced by anisomycin treatment. These findings clearly demonstrate a major role of stress-activated protein kinases in the post-transcriptional regulation of VEGF.	CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Pages, G (corresponding author), CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Berra, Edurne/F-9692-2011; Pages, Gilles/N-7135-2017	Berra, Edurne/0000-0002-3820-5744; Milanini, Julie/0000-0002-5861-2830				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NAKAMAKI T, 1995, J CELL PHYSL, V165, P482; Noel J, 1996, J CELL SCI, V109, P929; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; TSE CM, 1992, J BIOL CHEM, V267, P9340; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; ZUCKER M, 1989, SCIENCE, V244, P48	51	158	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26484	26491		10.1074/jbc.M002104200	http://dx.doi.org/10.1074/jbc.M002104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849421	hybrid			2022-12-27	WOS:000088999700083
J	Pronin, AN; Morris, AJ; Surguchov, A; Benovic, JL				Pronin, AN; Morris, AJ; Surguchov, A; Benovic, JL			Synucleins are a novel class of substrates for G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; PHOSPHOLIPASE-D; PHOSPHORYLATES TUBULIN; BINDING; INHIBITION; DOMAIN; FAMILY; GENE; IDENTIFICATION	G protein-coupled receptor kinases (GRKs) specifically recognize and phosphorylate the agonist-occupied form of numerous G protein-coupled receptors (GPCRs), ultimately resulting in desensitization of receptor signaling. Until recently, GPCRs were considered to be the only natural substrates for GRKs, However, the recent discovery that GRKs also phosphorylate tubulin raised the possibility that additional GRK substrates exist and that the cellular role of GRKs may be much broader than just GPCR regulation. Here we report that synucleins are a novel class of GRK substrates, Synucleins (alpha, beta, gamma, and synoretin) are 14-kDa proteins that are highly expressed in brain but also found in numerous other tissues, alpha-Synuclein has been linked to the development of Alzheimer's and Parkinson's diseases. We found that all synucleins are GRK substrates, with GRK2 preferentially phosphorylating the alpha and beta isoforms, whereas GRK5 prefers alpha-synuclein as a substrate. GRK-mediated phosphorylation of synuclein is activated by factors that stimulate receptor phosphorylation, such as lipids (all GRKs) and G beta gamma subunits (GRK2/3), suggesting that GPCR activation may regulate synuclein phosphorylation, GRKs phosphorylate synucleins at a single serine residue within the C-terminal domain. Although the function of synucleins remains largely unknown, recent studies have demonstrated that these proteins can interact with phospholipids and are potent inhibitors of phospholipase D2 (PLDS) in vitro, PLDS regulates the breakdown of phosphatidylcholine and has been implicated in vesicular trafficking. We found that GRK-mediated phosphorylation inhibits synuclein's interaction with both phospholipids and PLD2, These findings suggest that GPCRs may be able to indirectly stimulate PLD2 activity via their ability to regulate GRK-promoted phosphorylation of synuclein.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA	Jefferson University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Washington University (WUSTL)	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.		Morris, Andrew/B-7869-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Ji HJ, 1997, CANCER RES, V57, P759; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; KIM CM, 1993, RECEPTOR, V3, P39; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SMITH BJ, 1997, PROTEIN SEQUENCING P, P64; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735	34	324	336	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26515	26522		10.1074/jbc.M003542200	http://dx.doi.org/10.1074/jbc.M003542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852916	hybrid			2022-12-27	WOS:000088999700087
J	Hidaka, Y; Shimono, C; Ohno, M; Okumura, N; Adermann, K; Forssmann, WG; Shimonishi, Y				Hidaka, Y; Shimono, C; Ohno, M; Okumura, N; Adermann, K; Forssmann, WG; Shimonishi, Y			Dual function of the propeptide of prouroguanylin in the folding of the mature peptide - Disulfide-coupled folding and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PEPTIDE; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; GUANYLATE-CYCLASE; ESCHERICHIA-COLI; GCAP-II; PROTEIN; UROGUANYLIN; SUBTILISIN; INTESTINE	Guanylyl cyclase activating peptide II (GCAP-II), an endogenous ligand of guanylyl cyclase C, is produced via the processing of the precursor protein (prepro-GCAP-II), We have previously shown that the propeptide in pro-GCAP-II functions as an intramolecular chaperone in the proper folding of the mature peptide, GCAP-II (Hidaka, Y., Ohno, M., Hemmasi, B,, Hill, O., Forssmann, W.-G., and Shimonishi, Y. (1998) Biochemistry 37, 8498-8507). Here, we report an essential region in pro-GCAP-II for the correct disulfide pairing of the mature peptide, GCAP-II. Five mutant proteins, in which amino acid residues were sequentially deleted from the N terminus, and three mutant proteins of pro-GCAP-II, in which N-terminal 6, 11, or 17 amino acid residues were deleted, were overproduced using Escherichia coli or human kidney 293T cells respectively, Detailed analysis of in vivo or in vitro folding of these mutant proteins revealed that one or two amino acid residues at the N terminus of pro-GCAP-II are critical, not only for the chaperone function in the folding but also for the net stabilization of pro-GCAP-II. In addition, size exclusion chromatography revealed that pro-GCAP-II exists as a dimer in solution. These data indicate that the propeptide has two roles in proper folding: the disulfide-coupled folding of the mature region and the dimerization of pro-GCAP-II.	Osaka Univ, Inst Prot Res, Div Organ Chem, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan; Lower Saxony Inst Peptide Res, D-30625 Hannover, Germany	Osaka University; Osaka University	Hidaka, Y (corresponding author), Osaka Univ, Inst Prot Res, Div Organ Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yuji@protein.osaka-u.ac.jp		HIDAKA, YUJI/0000-0002-3131-2619				BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUURIE MG, 1992, P NATL ACAD SCI USA, V89, P947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; Fan XH, 1996, BIOCHEM BIOPH RES CO, V219, P457, DOI 10.1006/bbrc.1996.0255; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; Hamra FK, 1996, ENDOCRINOLOGY, V137, P257, DOI 10.1210/en.137.1.257; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HESS R, 1995, FEBS LETT, V374, P34, DOI 10.1016/0014-5793(95)01075-P; Hidaka Y, 1998, BIOCHEMISTRY-US, V37, P8498, DOI 10.1021/bi9731246; HILL O, 1995, BBA-PROTEIN STRUCT M, V1253, P146, DOI 10.1016/0167-4838(95)00204-4; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; Hober S, 1997, BIOCHEMISTRY-US, V36, P4616, DOI 10.1021/bi9611265; Hu ZX, 1996, J BIOL CHEM, V271, P3375; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; KATO I, 1969, J BIOL CHEM, V244, P1004; LABHARDT AM, 1979, J MOL BIOL, V135, P245, DOI 10.1016/0022-2836(79)90350-4; LABHARDT AM, 1979, J MOL BIOL, V135, P231, DOI 10.1016/0022-2836(79)90349-8; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Schulz A, 1999, PROTEIN SCI, V8, P1850, DOI 10.1110/ps.8.9.1850; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHULTZ S, 1992, J BIOL CHEM, V267, P16019; SHULTZ S, 1990, CELL, V63, P941; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; Whitaker TL, 1997, GASTROENTEROLOGY, V113, P1000, DOI 10.1016/S0016-5085(97)70197-5; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	34	31	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25155	25162		10.1074/jbc.M000543200	http://dx.doi.org/10.1074/jbc.M000543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827170	hybrid			2022-12-27	WOS:000088849400017
J	Rossig, L; Haendeler, J; Hermann, C; Malchow, P; Urbich, C; Zeiher, AM; Dimmeler, S				Rossig, L; Haendeler, J; Hermann, C; Malchow, P; Urbich, C; Zeiher, AM; Dimmeler, S			Nitric oxide down-regulates MKP-3 mRNA levels - Involvement in endothelial cell protection from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FLUID SHEAR-STRESS; CYTOCHROME-C RELEASE; INHIBITS APOPTOSIS; TYROSINE-PHOSPHATASE; S-NITROSYLATION; BCL-2; PHOSPHORYLATION; MITOCHONDRIA; SYNTHASE	MAP kinase-dependent phosphorylation processes have been shown to interfere with the degradation of the antiapoptotic protein Bcl-2. The cytosolic MAP kinase phosphatase MAP kinase phosphatase-3 (MKP-3) induces apoptosis of endothelial cells in response to tumor necrosis factor cu (TNF alpha) via dephosphorylation of the MAP kinase ERK1/2, Leading to Bcl-2 proteolysis. Here we report that the endothelial cell survival factor nitric oxide (NO) down-regulated MKP-3 by destabilization of MKP-3 mRNA. This effect of NO was paralleled by a decrease in MKP-3 protein levels. Moreover, ERK1/2 was found to be protected against TNF alpha-induced dephosphorylation by coincubation of endothelial cells with the NO donor. Subsequently, both the decrease in Bcl-2 protein levels and the mitochondrial release of cytochrome c in response to TNF alpha were largely prevented by exogenous NO. In cells overexpressing MKP-3, no differences in phosphatase activity in the presence or absence of NO were found, excluding potential posttranslational modifications of MKP-3 protein by NO. These data demonstrate that upstream of the S-nitrosylation of caspase-3, NO exerts additional antiapoptotic effects in endothelial cells, which rely on the down-regulation of MKP-3 mRNA.	Univ Frankfurt, Div Cardiol, Dept Internal Med 4, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Div Cardiol, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Haendeler, Judith/0000-0001-8507-4540; Dimmeler, Stefanie/0000-0002-1045-2436				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Batt DB, 1998, METH MOL B, V86, P15; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, J MOL CELL CARDIOL, V31, P5, DOI 10.1006/jmcc.1998.0839; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Muda M, 1996, J BIOL CHEM, V271, P4319; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walter DH, 1998, CIRCULATION, V98, P1153, DOI 10.1161/01.CIR.98.12.1153; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	41	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25502	25507		10.1074/jbc.M002283200	http://dx.doi.org/10.1074/jbc.M002283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10846176	hybrid			2022-12-27	WOS:000088849400061
J	Christendat, D; Saridakis, V; Dharamsi, A; Bochkarev, A; Pai, EF; Arrowsmith, CH; Edwards, AM				Christendat, D; Saridakis, V; Dharamsi, A; Bochkarev, A; Pai, EF; Arrowsmith, CH; Edwards, AM			Crystal structure of dTDP-4-keto-6-deoxy-D-hexulose 3,5-epimerase from Methanobacterium thermoautotrophicum complexed with dTDP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIFFRACTION DATA; ALIGNMENT; MECHANISM; PROGRAM	Deoxythymidine diphosphate (dTDP)-4-keto-6-deoxy-D-hexulose 3,5-epimerase (RmlC) is involved in the biosynthesis of dTDP-L-rhamnose, which is an essential component of the bacterial cell wall. The crystal structure of RmlC from Methanobacterium thermoautotrophicum was determined in the presence and absence of dTDP, a substrate analogue. RmlC is a homodimer comprising a central jelly roll motif, which extends in two directions into longer beta-sheets, Binding of dTDP is stabilized by ionic interactions to the phosphate group and by a combination of ionic and hydrophobic interactions with the base, The active site, which is located in the center of the jelly roll, is formed by residues that are conserved in all known RmlC sequence homologues, The conservation of the active site residues suggests that the mechanism of action is also conserved and that the RmlC structure may be useful in guiding the design of antibacterial drugs.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5W 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5W 1L6, Canada; Integrated Proteom Inc, Toronto, ON M5G 2M9, Canada; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Oklahoma System; University of Oklahoma Health Sciences Center	Edwards, AM (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013	Pai, Emil/0000-0002-1162-7242; Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kopp J, 1999, J MOL BIOL, V287, P761, DOI 10.1006/jmbi.1999.2643; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRIT EA, 1991, ACTA CRYSTALLOGR D, V50, P869; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schafer SL, 1996, BIOCHEMISTRY-US, V35, P5662, DOI 10.1021/bi960174m; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	16	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24608	24612		10.1074/jbc.C000238200	http://dx.doi.org/10.1074/jbc.C000238200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827167	hybrid			2022-12-27	WOS:000088683300052
J	Liu, X; Brzeska, H; Korn, ED				Liu, X; Brzeska, H; Korn, ED			Functional analysis of tail domains of Acanthamoeba myosin IC by characterization of truncation and deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIN-BINDING SITE; ACTIVATED ATPASE ACTIVITY; SH3 DOMAIN; IN-VIVO; PHOSPHORYLATION SITE; 3RD ISOFORM; LIGHT-CHAIN; AMINO-ACID; TEDS RULE	Acanthamoeba myosin IC has a single 129-kDa heavy chain and a single l7-kDa light chain. The heavy chain comprises a 75-kDa catalytic head domain with an ATP-sensitive F-actin-binding site, a 3-kDa neck domain, which binds a single 17-kDa light chain, and a 50-kDa tail domain, which binds F-actin in the presence or absence of ATP. The actin-activated MgATPase activity of myosin IC exhibits triphasic actin dependence, apparently as a consequence of the two actin-binding sites, and is regulated by phosphorylation of Ser-329 in the head. The 50-kDa tail consists of a basic domain, a glycine/proline/alanine-rich (GPA) domain, and a Src homology 3 (SH3) domain, often referred to as tail homology (TH)-1, -2, and -3 domains, respectively. The SH3 domain divides the TH-3 domain into GPA-1 and GPA-2. To define the functions of the tail domains more precisely, we determined the properties of expressed wild type and six mutant myosins, an SH3 deletion mutant and five mutants truncated at the C terminus of the SH3, GPA-2, TH-1, neck and head domains, respectively. We found that both the TH-1 and GPA-2 domains bind F-actin in the presence of ATP, Only the mutants that retained an actin-binding site in the tail exhibited triphasic actin-dependent MgATPase activity, in agreement with the F-actin-cross-linking model, but truncation reduced the MgATPase activity at both low and high actin concentrations. Deletion of the SH3 domain had no effect. Also, none of the tail domains, including the SH3 domain, affected either the K-m or V-max for the phosphorylation of Ser-329 by myosin I heavy chain kinase.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 3,Rm B1-22, Bethesda, MD 20892 USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000506, ZIAHL000506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, NATURE, V340, P505; ALBANESI JP, 1985, J BIOL CHEM, V260, P3276; ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1988, J BIOL CHEM, V263, P427; Brzeska HZ, 1999, MOL BIOL CELL, V10, p161A; COTE GP, 1985, J BIOL CHEM, V260, P4543; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; FUJISAKI H, 1985, J BIOL CHEM, V260, P11182; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; HAMMER JA, 1983, J BIOL CHEM, V258, P168; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; Jung G, 1999, MOL BIOL CELL, V10, p6A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1993, J BIOL CHEM, V268, P20923; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Osherov N, 1998, J BIOL CHEM, V273, P27017, DOI 10.1074/jbc.273.41.27017; PANTALONI D, 1985, J BIOL CHEM, V260, P1180; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stoffler HE, 1998, J BIOL CHEM, V273, P14605, DOI 10.1074/jbc.273.23.14605; SZEZEPANOWSKA JR, 1998, P NATL ACAD SCI USA, V95, P4146; Wang ZY, 1998, P NATL ACAD SCI USA, V95, P15200, DOI 10.1073/pnas.95.26.15200; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685	52	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24886	24892		10.1074/jbc.M004287200	http://dx.doi.org/10.1074/jbc.M004287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10840041	hybrid			2022-12-27	WOS:000088683300087
J	Lacourciere, GM; Mihara, H; Kurihara, T; Esaki, N; Stadtman, TC				Lacourciere, GM; Mihara, H; Kurihara, T; Esaki, N; Stadtman, TC			Escherichia coli NifS-like proteins provide selenium in the pathway for the biosynthesis of selenophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE LYASE; HAEMOPHILUS-INFLUENZAE; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; PURIFICATION; ENZYME; SYNTHETASE; CLONING; MECHANISM; CLUSTER	Selenophosphate synthetase (SPS), the selD gene product from Escherichia coli, catalyzes the biosynthesis of monoselenophosphate, AMP, and orthophosphate in a 1:1:1 ratio from selenide and ATP. Kinetic characterization revealed the K-m value for selenide approached levels that; are toxic to the cell, Our previous demonstration that a Se-0-generating system consisting of L-selenocysteine and the Azotobacter vinelandii NifS protein can replace selenide for selenophosphate biosynthesis in vitro suggested a mechanism whereby cells can overcome selenide toxicity. Recently, three E. coli NifS-like proteins, CsdB, CSD, and IscS, have been overexpressed and characterized. All three enzymes act on selenocysteine and cysteine to produce Se-0 and S-0, respectively. In the present study, we demonstrate the ability of each E. coli NifS-like protein to function as a selenium delivery protein for the in vitro biosynthesis of selenophosphate by E. coli wild-type SPS. Significantly, the SPS (C17S) mutant, which is inactive in the standard in vitro assay with selenide as substrate, was found to exhibit detectable activity in the presence of CsdB, CSD, or IscS and L-selenocysteine. Taken together the ability of the NifS-like proteins to generate a selenium substrate for SPS and the activation of the SPS (C17S) mutant suggest a selenium delivery function for the proteins in vivo.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kyoto University	Lacourciere, GM (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3 Rm 103,9000 Rockville Pike, Bethesda, MD 20892 USA.	lacourcg@nhlbi.nih.gov	Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000319, Z01HL000205] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; CHOCAT P, 1985, J BACTERIOL, V163, P669, DOI 10.1128/JB.163.2.669-676.1985; ESAKI N, 1982, J BIOL CHEM, V257, P4386; ESAKI N, 1988, J BACTERIOL, V170, P751, DOI 10.1128/jb.170.2.751-756.1988; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, J BIOL CHEM, V271, P16068; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; HIDALGO E, 1996, J BIOL CHEM, V271, P16068; Jacob C, 1999, P NATL ACAD SCI USA, V96, P1910, DOI 10.1073/pnas.96.5.1910; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KIM IY, 1992, J BIOL CHEM, V267, P19650; KIM IY, 1993, J BIOL CHEM, V268, P27020; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Lacourciere GM, 1999, P NATL ACAD SCI USA, V96, P44, DOI 10.1073/pnas.96.1.44; Lacourciere GM, 1998, J BIOL CHEM, V273, P30921, DOI 10.1074/jbc.273.47.30921; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; MANDRANDBERTHELOT MA, 1978, FEMS MICROBIOL LETT, V4, P37; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Muller S, 1997, ARCH MICROBIOL, V168, P421, DOI 10.1007/s002030050517; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; STADTMAN T C, 1989, Biofactors, V2, P35; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; VERES Z, 1994, J BIOL CHEM, V269, P10597; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; Walker H, 1998, P NATL ACAD SCI USA, V95, P2180, DOI 10.1073/pnas.95.5.2180; Yamamoto Y, 1997, DNA Res, V4, P91, DOI 10.1093/dnares/4.2.91; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	39	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23769	23773		10.1074/jbc.M000926200	http://dx.doi.org/10.1074/jbc.M000926200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10829016	hybrid			2022-12-27	WOS:000088564200051
J	Seharaseyon, J; Sasaki, N; Ohler, A; Sato, T; Fraser, H; Johns, DC; O'Rourke, B; Marban, E				Seharaseyon, J; Sasaki, N; Ohler, A; Sato, T; Fraser, H; Johns, DC; O'Rourke, B; Marban, E			Evidence against functional heteromultimerization of the K-ATP channel subunits Kir6.1 and Kir6.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; PANCREATIC-ISLETS; GENE-TRANSFER; SUPPRESSION; MEMBRANE; MUSCLE; HEART; CARDIOPROTECTION; MITOCHONDRIA	K-ATP channels consist of pore-forming potassium inward rectifier (Kir6.x) subunits and sulfonylurea receptors (SURs), Although Kir6.1 or Kir6.2 coassemble with different SUR isoforms to form heteromultimeric functional K-ATP, channels, it is not known whether Kir6.1 and Kir6.2 coassemble with each other. To define the molecular identity of K-ATP channels, we used adenoviral gene transfer to express wild-type and dominant-negative coustructs of Kir6.1 and Kir6.2 in a heterologous expression system (A549 cells) and in native cells (rabbit ventricular myocytes), Dominant-negative (DN) Kir6.2 gene transfer suppressed current through heterologously expressed SUR2A + Kir6.2 channels. Conversely, DN Kir6.1 suppressed SUR2B + Kir6.1 current but had no effect on coexpressed SUR2A + Kir6.2, We next probed the ability of Kir6.1 and Kir6.2 to affect endogenous K-ATP channels in adult rabbit ventricular myocytes, using adenoviral vectors to achieve efficient gene transfer. Infection with the DN Kir6.2 virus for 72 h suppressed pinacidil-inducible K-ATP current density measured by whole-cell patch clamp. However, there was no effect of infection with the DN Kir6.1 on the K-ATP current. Based on these functional assays, we conclude that Kir6.1 and Kir6.2 do not heteromultimerize with each other and that Kir6.2 is the sole K-ATP pore-forming subunit in the surface membrane of heart cells.	Johns Hopkins Univ, Dept Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Marban, E (corresponding author), Johns Hopkins Univ, Dept Med, Inst Mol Cardiobiol, Ross 844,720 Rutland Ave, Baltimore, MD 21205 USA.		Ohler, Annemarie/AAB-7721-2019; Marban, Eduardo/GWC-8514-2022	Ohler, Annemarie/0000-0001-6531-464X; O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R37HL36957, F32HL09586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036957, F32HL009586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Akao M, 1997, J CLIN INVEST, V100, P3053, DOI 10.1172/JCI119860; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Baron A, 1999, CIRC RES, V85, P707, DOI 10.1161/01.RES.85.8.707; Garlid KD, 1997, CIRC RES, V81, P1072; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hu H, 1999, MOL PHARMACOL, V55, P1000, DOI 10.1124/mol.55.6.1000; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Lalli MJ, 1998, PFLUG ARCH EUR J PHY, V436, P957, DOI 10.1007/s004240050729; Liu Y, 1996, BASIC RES CARDIOL, V91, P450, DOI 10.1007/BF00788726; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; SATO T, 2000, IN PRESS CIRCULATION; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	27	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17561	17565		10.1074/jbc.275.23.17561	http://dx.doi.org/10.1074/jbc.275.23.17561			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837494	hybrid			2022-12-27	WOS:000087485000050
J	Wada, H; Yeh, ETH; Kamitani, T				Wada, H; Yeh, ETH; Kamitani, T			A dominant-negative UBC12 mutant sequesters NEDD8 and inhibits NEDD8 conjugation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; KAPPA-B-ALPHA; F-BOX PROTEIN; BETA-CATENIN; COMPLEX; IDENTIFICATION; DEGRADATION; CULLIN-2; SYSTEM; PATHWAY	NEDD8, a novel ubiquitin-like protein, has been shown to conjugate to proteins in a manner analogous to ubiquitination and sentrinization. Recently, human UBC12 was identified as a putative NEDD8 conjugation enzyme (E2). While investigating the in vivo function of UBC12, we found that the point mutant, UBC12(C111S), showed a dominant-negative effect on NEDD8 conjugation. This mutant,with a single Cys-to-Ser substitution at the conserved Cys residue in the E2 family, could specifically inhibit NEDD8 conjugation. We observed the dominant-negative effect on NEDD8 conjugation to substrates, including the C-terminal fragment of cullin-2 (Cul-2-Delta N), full-length cullin-1, and also other uncharacterized target proteins, interestingly, UBC12(C111S) formed a heterodimeric conjugate with NEDD8. This conjugate was stable under stringent conditions, including 6 M guanidine HCl, 8 M urea, 2% SDS, or 5% beta-mercaptoethanol. Our results are consistent with the hypothesis that UBC12(C111S) sequesters the NEDD8 monomer by forming a UBC12(C111S)-NEDD8 conjugate and, in turn, inhibits the subsequent transfer of NEDD8 to its targets. To examine the biological role of NEDD8 conjugation, this dominant-negative form of UBC12 was applied to a cell growth assay. Overexpression of UBC12(C111S) led to inhibition of growth in U2OS and HEK293 cells. Thus, this dominant-negative form of UBC12 could be useful in defining the role of NEDD8 modification in other biological systems.	Univ Texas, Houston Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Kamitani, T (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	tetsuk@heart.med.uth.tmc.edu	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NIDDK NIH HHS [1 RO1 DK56298-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Haas AL, 1997, FASEB J, V11, P1257; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Okura T, 1996, J IMMUNOL, V157, P4277; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; YEH ETH, 2000, IN PRESS GENE AMST; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	31	67	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17008	17015		10.1074/jbc.275.22.17008	http://dx.doi.org/10.1074/jbc.275.22.17008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828074	hybrid			2022-12-27	WOS:000087392200086
J	Xu, BE; English, JM; Wilsbacher, JL; Stippec, S; Goldsmith, EJ; Cobb, MH				Xu, BE; English, JM; Wilsbacher, JL; Stippec, S; Goldsmith, EJ; Cobb, MH			WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; BINDING SITE; IDENTIFICATION; ADENOSINE; PURIFICATION; ACTIVATION; SUBUNIT; CLONING; CASCADE	We have cloned and characterized a novel mammalian serine/threonine protein kinase WNK1 ((w) under bar ith (n) under bar o lysine (K) under bar)) from a rat brain cDNA library. WNK1 has 2126 amino acids and can be detected as a protein of similar to 230 kDa in various cell lines and rat tissues. WNK1 contains a small N-terminal domain followed by the kinase domain and a long C-terminal tail. The WNK1 kinase domain has the greatest similarity to the MEKK protein kinase family. However, overexpression of WNK1 in HEK293 cells exerts no detectable effect on the activity of known, co transfected mitogen-activated protein kinases, suggesting that it belongs to a distinct pathway. WNK1 phosphorylates the exogenous substrate myelin basic protein as well as itself mostly on serine residues, confirming that it is a serine/threonine protein kinase. The demonstration of activity was striking because WNK1, and its homologs in other organisms lack the invariant catalytic lysine in subdomain II of protein kinases that is crucial for binding to ATP. A model of WNK1 using the structure of cAMP-dependent protein kinase suggests that lysine 233 in kinase subdomain I may provide this function. Mutation of this lysine residue to methionine eliminates WNK1 activity, consistent with the conclusion that it is required for catalysis. This distinct organization of catalytic residues indicates that WNK1 belongs to a novel family of serine/threonine protein kinases.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SEGER R, 1992, J BIOL CHEM, V267, P25628; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1983, METHOD ENZYMOL, V99, P140; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	31	391	408	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16795	16801		10.1074/jbc.275.22.16795	http://dx.doi.org/10.1074/jbc.275.22.16795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828064	hybrid			2022-12-27	WOS:000087392200057
J	Legesse-Miller, A; Sagiv, Y; Glozman, R; Elazar, Z				Legesse-Miller, A; Sagiv, Y; Glozman, R; Elazar, Z			Aut7p, a soluble autophagic factor, participates in multiple membrane trafficking processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; SYNAPTIC VESICLE DOCKING; ENDOPLASMIC-RETICULUM; GOLGI TRANSPORT; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; VACUOLE INHERITANCE; BINDING-PROTEIN; V-SNARE; T-SNARE	Aut7p, a protein recently implicated in autophagic events in the yeast Saccharomyces cerevisiae, exhibits significant homology to a mammalian protein, p16, herein termed GATE-16 (Golgi-associated ATPase Enhancer of 16 kDa), a novel intra-Golgi transport factor. Here we provide evidence for the involvement of Aut7p in different membrane trafficking processes. Aut7p largely substitutes for the activity of GATE-16 in mammalian intra-Golgi transport in vitro. In vivo, AUT7 interacts genetically with endoplasmic reticulum to Golgi SNAREs, specifically with BET1 and SEC22. Aut7p interacts physically with the following two v-SNAREs: Bet1p, which is involved in endoplasmic reticulum to Golgi vesicular transport, and Nyv1p, implicated in vacuolar inheritance. We suggest that, in addition to its role in autophagocytosis, Aut7p has pleiotropic effects and participates in at least two membrane traffic events.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Aalto MK, 1997, P NATL ACAD SCI USA, V94, P7331, DOI 10.1073/pnas.94.14.7331; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Guthrie C., 1991, GUIDE YEAST GENETICS, P194; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lustgarten V, 1999, MOL CELL BIOL, V19, P4480; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	65	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32966	32973		10.1074/jbc.M000917200	http://dx.doi.org/10.1074/jbc.M000917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10837468	hybrid			2022-12-27	WOS:000090003800081
J	Li, RK; Ennis, IL; Velez, P; Tomaselli, GF; Marban, E				Li, RK; Ennis, IL; Velez, P; Tomaselli, GF; Marban, E			Novel structural determinants of mu-conotoxin (GIIIB) block in rat skeletal muscle (mu 1) Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SODIUM-CHANNELS; CYSTEINE MUTAGENESIS; BINDING-SITE; CONUS-GEOGRAPHUS; OUTER VESTIBULE; PORE; PEPTIDE; TETRODOTOXIN; RESIDUES; MUTANT	mu-Conotoxin (mu-CTX) specifically occludes the pore of voltage-dependent Na+ channels. In the rat skeletal muscle Na+ channel (mu 1), we examined the contribution of charged residues between the P loops and S6 in all four domains to mu-CTX block. Conversion of the negatively charged domain II (DII) residues Asp-762 and Glu-765 to cysteine increased the IC50 for mu-CTX block by similar to 100-fold (wild-type = 22.3 +/- 7.0 nM; D762C = 2558 +/- 250 nM; E765C = 2020 +/- 379 nM). Restoration or reversal of charge by external modification of the cysteine-substituted channels with methanethiosulfonate reagents (methanethiosulfonate ethylsulfonate (MTSES) and methanethiosulfonate ethylammonium (MTSEA)) did not affect mu-CTX block (D762C: IC50, MTSEA+ = 2165.1 +/- 250 nM; IC50, MTSES- = 2753.5 +/- 456.9 nM; E765C: IC50, MTSEA+ = 2200.1 +/- 550.3 nM; IC50, (MTSES-) = 3248.1 +/- 2011.9 nM) compared with their unmodified counterparts. In contrast, the charge-conserving mutations D762E (IC50 = 21.9 +/- 4.3 nM) and E765D (IC50 = 22.0 +/- 7.0 nM) preserved wild-type blocking behavior, whereas the charge reversal mutants D762K (IC50 = 4139.9 +/- 687.9 nM) and E765K (IC50 = 4202.7 +/- 1088.0 nM) destabilized CL-CTX block even further, suggesting a prominent electrostatic component of the interactions between these DII residues and mu-CTX. Kinetic analysis of mu-CTX block. reveals that the changes in toxin sensitivity are largely due to accelerated toxin dissociation (k(off)) rates with little changes in association (k(on)) rates. We conclude that the acidic residues at positions 762 and 765 are key determinants of mu-CTX block, primarily by virtue of their negative charge. The inability of the bulky MTSES or MTSEA side chain to modify mu-CTX sensitivity places steric constraints on the sites of toxin interaction.	Johns Hopkins Univ, Sch Med, Inst Med Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Marban, E (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [R01 HL-50411, R01 HL-52768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050411, R01HL052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; CHAHINE M, 1995, RECEPTOR CHANNEL, V3, P164; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, PFLUG ARCH EUR J PHY, V422, P90, DOI 10.1007/BF00381519; HIDAKA Y, 1990, FEBS LETT, V264, P29, DOI 10.1016/0014-5793(90)80756-9; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; KONTIS KJ, 1993, MOL PHARMACOL, V43, P635; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; LI RA, 2000, BIOPHYS J, V78, P87; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SATO K, 1991, J BIOL CHEM, V266, P16989; STEPHAN MM, 1994, J MEMBRANE BIOL, V137, P1; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YANAGAWA Y, 1986, NEUROSCI LETT, V64, P7, DOI 10.1016/0304-3940(86)90654-3	43	28	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27551	27558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859326				2022-12-27	WOS:000089197100007
J	Tanuma, N; Nakamura, K; Shima, H; Kikuchi, K				Tanuma, N; Nakamura, K; Shima, H; Kikuchi, K			Protein-tyrosine phosphatase PTP epsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED JAK/STAT PATHWAY; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; MOLECULAR-CLONING; NEGATIVE REGULATOR; SH2 DOMAIN; ACTIVATION; KINASE; EXPRESSION	We engineered and expressed bath a wild-type and mutant cytosolic isoform of PTP epsilon (PTP epsilon C) in murine M1 leukemic cells, which can be induced to growth arrest and monocytic differentiation by interleukin (IL)-6 and leukemia inhibitory factor (LIF). Forced expression of PTP epsilon C inhibited IL-6- and LIF-induced monocytic differentiation and apoptosis in M1 cells, whereas expression of PTP epsilon M, a transmembrane isoform of PTP epsilon, did not. PTP epsilon C expression resulted in lower levels of IL-6-induced tyrosine phosphorylation of Jak1, Tyk2, gp130, and Stat3 compared with parent cells. In MI transfectants expressing an inactive mutant of PTP epsilon C, both tyrosine phosphorylation and apoptosis induced by IL-6- and LIF were potentiated rather than inhibited. These results suggest an important role for PTP epsilon C in negative regulation of IL-6- and LIF-induced Jak-STAT signaling.	Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Kikuchi, K (corresponding author), Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Tanuma, Naoyuki/V-7911-2019					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SHABO Y, 1988, BLOOD, V72, P2070; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Urushibara N, 1998, INT J ONCOL, V12, P603; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YIN TG, 1993, J IMMUNOL, V151, P2555; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	73	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28216	28221						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859312				2022-12-27	WOS:000089197100091
J	Fuh, G; Garcia, KC; de Vos, AM				Fuh, G; Garcia, KC; de Vos, AM			The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; EXON 7-ENCODED DOMAIN; CRYSTAL-STRUCTURE; TYROSINE KINASE; SEMAPHORIN-III; BINDING SITE; TUMOR-CELLS; IN-VITRO; ANGIOGENESIS; MICE	Neuropilin-1 (NP-1) was first identified as a semaphorin receptor involved in neuron guidance. Subsequent studies demonstrated that NP-1 also binds an isoform of vascular endothelial growth factor (VEGF) as well as several VEGF homologs, suggesting that NP-1 may also function in angiogenesis. Here we report in vitro binding experiments that shed light on the interaction between VEGF165 and NP-1, as well as a previously unknown interaction between NP-1 and one of the VEGF receptor tyrosine kinases, VEGFR1 or Flt-1. BIA-core analysis demonstrated that, with the extracellular domain (ECD) of NP-1 immobilized at low density, VEGF165 bound with low affinity (K-d = 2 mu M) and fast kinetics. The interaction was dependent on the heparin-binding domain of VEGF165 and increased the affinity of VEGF165 for its signaling receptor VEGFR2 or kinase insert domain-containing receptor. The affinity of VEGF165 for the NP-1 ECD was greatly enhanced either by increasing the density of immobilized NP-1 (K-d = 113 aw) or by the addition of heparin (K-d = 25 nM). We attribute these affinity enhancements to avidity effects mediated by the bivalent VEGF165 homodimer or multivalent heparin. We also show that the NP-1 ECD binds with high affinity (K-d = 1.8 nM) to domains 3 and 4 of Flt-1 and that this interaction inhibits the binding of NP-1 to VEGF165. Based on these results, we propose that NP-1 acts as a coreceptor for various ligands and that these functions are dependent on the density of NP-1 on the cell membrane. Furthermore, Flt-1 may function as a negative regulator of angiogenesis by competing for NP-1.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Dept Biol Struct, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Roche Holding; Genentech; Stanford University	Fuh, G (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.							Banerjee SK, 2000, INT J ONCOL, V16, P253; Cai HB, 1999, J NEUROSCI, V19, P6519; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	239	250	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26690	26695						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842181				2022-12-27	WOS:000089144800005
J	Jin, L; Briggs, SL; Chandrasekhar, S; Chirgadze, NY; Clawson, DK; Schevitz, RW; Smiley, DL; Tashjian, AH; Zhang, FM				Jin, L; Briggs, SL; Chandrasekhar, S; Chirgadze, NY; Clawson, DK; Schevitz, RW; Smiley, DL; Tashjian, AH; Zhang, FM			Cry stal structure of human parathyroid hormone 1-34 at 0.9-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTROSCOPY; BONE MASS; TERMINAL FRAGMENTS; RECEPTOR; PROTEIN; REGION; ANALOG; CONFORMATION; OSTEOPOROSIS; ANTAGONISTS	The N-terminal fragment 1-34 of parathyroid hormone (PTH), administered intermittently, results in increased bone formation in patients with osteoporosis. PTH and a related molecule, parathyroid hormone-related peptide (PTHrP), act on cells via a common PTH/PTHrP receptor. To define more precisely the ligand-receptor interactions, we have crystallized human PTH (hPTH)-(1-34) and determined the structure to 0.9-Angstrom resolution. hPTH-(1-34) crystallizes as a slightly bent, long helical dimer, Analysis reveals that the extended helical conformation of hPTH-(1-34) is the likely bioactive conformation. We have developed molecular models for the interaction of hPTH-(1-34) and hPTHrP-(1-34) with the PTH/PTHrP receptor. A receptor binding pocket for the N terminus of hPTH-(1-34) and a hydrophobic interface with the receptor for the C terminus of hPTH-(1-34) are proposed.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Lab, Indianapolis, IN 46285 USA	Eli Lilly	Zhang, FM (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Lab, Drop Code 0403, Indianapolis, IN 46285 USA.		ID, IMCACAT/D-5867-2014					Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BLIND E, 1993, EXP CLIN ENDOCRINOL, V101, P150, DOI 10.1055/s-0029-1211222; Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Canalis Ernesto, 1994, P65; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOREV M, 1995, BIOPOLYMERS, V36, P485, DOI 10.1002/bip.360360411; Chorev Michael, 1996, P305; CIVITELLI R, 1988, AM J PHYSIOL, V255, P660; Condon SM, 2000, J AM CHEM SOC, V122, P3007, DOI 10.1021/ja994033u; FISKIN AM, 1997, J BIOL CHEM, V252, P8261; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gronwald W, 1997, BIOL CHEM, V378, P1501, DOI 10.1515/bchm.1997.378.12.1501; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; MOSEKILDE L, 1991, ENDOCRINOLOGY, V129, P421, DOI 10.1210/endo-129-1-421; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1997, J MED CHEM, V40, P3025, DOI 10.1021/jm970181o; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; POTTS JT, 1995, ENDOCRINOLOGY, V2, P920; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SONE T, 1995, MINER ELECTROL METAB, V21, P232; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; Vickery BH, 1996, J BONE MINER RES, V11, P1943; Weidler M, 1999, FEBS LETT, V444, P239, DOI 10.1016/S0014-5793(98)01658-5; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010	42	108	131	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27238	27244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837469				2022-12-27	WOS:000089144800076
J	Zhu, CY; Johansson, M; Karlsson, A				Zhu, CY; Johansson, M; Karlsson, A			Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; DEOXYGUANOSINE KINASE; DEOXYCYTIDINE KINASE; CYTOCHROME-C; SUBSTRATE-SPECIFICITY; THYMIDINE KINASE-1; APOPTOTIC PROGRAM; ARA-C; TOXICITY; 2-CHLORODEOXYADENOSINE	Nucleoside analogs used in cancer chemotherapy and in treatment of virus infections are phosphorylated in cells by nucleoside and nucleotide kinases to their pharmacologically active form. The phosphorylated nucleoside analogs are incorporated into DNA and cause cell death or inhibit viral replication. Cellular DNA is replicated both in the nucleus and in the mitochondria, and nucleoside analogs may interfere with DNA replication in both these subcellular locations, In the present study we created a cell model system where nucleoside analogs were phosphorylated, and thereby pharmacologically activated, in either the nucleus, cytosol, or mitochondria of cancer cells. The system was based on the reconstitution of deoxycytidine kinase (dCK)-deficient Chinese hamster ovary cells with genetically engineered dCK targeted to the different subcellular compartments. The nucleoside analogs phosphorylated by dCK in the mitochondria were predominantly incorporated into mitochondrial DNA, whereas the nucleoside analogs phosphorylated in the nucleus or cytosol were incorporated into nuclear DNA, We further show that the nucleoside analogs phosphorylated in the mitochondria induced cell death by an apoptotic program. These data showed that the subcellular site of nucleoside analog phosphorylation is an important determinant for incorporation of nucleoside analogs into nuclear or mitochondrial DNA.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden	Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BALZARINI J, 1994, PHARM WORLD SCI, V16, P113, DOI 10.1007/BF01880662; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHEN CH, 1991, MOL PHARMACOL, V39, P625; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; GOWER WR, 1979, J BIOL CHEM, V254, P2180; HARRIS BA, 1981, MOL PHARMACOL, V20, P200; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Iwasaki H, 1997, BLOOD, V90, P270; Kim CN, 1997, CANCER RES, V57, P3115; KUFE D, 1984, BLOOD, V64, P54; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; Wang JH, 1996, ANTIMICROB AGENTS CH, V40, P1555, DOI 10.1128/AAC.40.6.1555; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3; WYLIE AH, 1980, NATURE, V284, P555; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707; Zhu CY, 1998, BIOCHEM PHARMACOL, V56, P1035, DOI 10.1016/S0006-2952(98)00150-6	33	33	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26727	26731						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827186				2022-12-27	WOS:000089144800010
J	Malhi, H; Irani, AN; Rajvanshi, P; Suadicani, SO; Spray, DC; McDonald, TV; Gupta, S				Malhi, H; Irani, AN; Rajvanshi, P; Suadicani, SO; Spray, DC; McDonald, TV; Gupta, S			K-ATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines - Implications for liver growth control and potential therapeutic targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; DNA-SYNTHESIS; ACTIVATION; EXPRESSION; CALCIUM; OPENERS; GLIBENCLAMIDE; BINDING; SUBUNIT	To determine whether K-ATP channels control liver growth, we used primary rat hepatocytes and several human cancer cell lines for assays. K-ATP channel openers (minoxidil, cromakalim, and pinacidil) increased cellular DNA synthesis, whereas K-ATP channel blockers (quinidine and glibenclamide) attenuated DNA synthesis. The channel inhibitor glibenclamide decreased the clonogenicity of HepG2 cells without inducing cytotoxicity or apoptosis. To demonstrate the specificity of drugs for K+ channels, whole-cell patch-clamp recordings were made. Hepatocytes revealed K+ currents with K-ATP channel properties. These K+ currents were augmented by minoxidil and pinacidil and attenuated by glibenclamide as well as tetraethylammonium, in agreement with established responses of K+, channels. Reverse transcription of total cellular RNA followed by polymerase chain reaction showed expression of K-ATP channel-specific subunits in rat hepatocytes and human liver cell lines. Calcium fluxes were unperturbed in glibenclamide-treated HepG(2) cells and primary rat hepatocytes following induction with ATP and hepatocyte growth factor, respectively, suggesting that the effect of K-ATP channel activity upon hepatocyte proliferation was not simply due to indirect modulation of intracellular calcium. The regulation of mitogen-related hepatocyte proliferation by K-ATP channels advances our insights into liver growth control. The findings have implications in mechanisms concerning liver development, regeneration, and oncogenesis.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Canc Res, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Sao Judas Tadeu, BR-03166000 Sao Paulo, Brazil	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Sao Judas Tadeu	Gupta, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave,Ullmann 625, Bronx, NY 10461 USA.			Spray, David/0000-0001-8368-5073	NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIDDK NIH HHS [R01 DK46952, P33 DK41296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BAFFY G, 1992, J CELL PHYSIOL, V153, P332, DOI 10.1002/jcp.1041530213; CAMERON IL, 1989, MAGNESIUM, V8, P31; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; CHIU SY, 1989, J PHYSIOL-LONDON, V408, P199, DOI 10.1113/jphysiol.1989.sp017455; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CROOKS MJ, 1974, J PHARM PHARMACOL, V26, P304, DOI 10.1111/j.2042-7158.1974.tb09280.x; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; EDWARDS G, 1995, CARDIOVASC DRUG THER, V9, P185, DOI 10.1007/BF00878465; GRAF J, 1988, RENAL PHYSIOL BIOCH, V11, P202; GRUDER JT, 1992, GENE DEV, V6, P545; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA S, 1992, HEPATOLOGY, V15, P485, DOI 10.1002/hep.1840150322; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARMON CS, 1993, SKIN PHARMACOL, V6, P170; HENDERSON RM, 1989, AM J PHYSIOL, V256, pG1028, DOI 10.1152/ajpgi.1989.256.6.G1028; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; HUANG Y, 1994, J BIOL CHEM, V269, P31183; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE Y, 1995, EUR J PHARMACOL, V284, P77, DOI 10.1016/0014-2999(95)00368-U; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lee K, 1998, J PHYSIOL-LONDON, V510, P441, DOI 10.1111/j.1469-7793.1998.441bk.x; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Lu CW, 1997, FEBS LETT, V412, P121, DOI 10.1016/S0014-5793(97)00760-6; Luzi L, 1997, ACTA DIABETOL, V34, P239, DOI 10.1007/s005920050081; MENDOZA SA, 1988, PEDIATR NEPHROL, V2, P118, DOI 10.1007/BF00870391; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ott M, 1998, J BIOL CHEM, V273, P11954, DOI 10.1074/jbc.273.19.11954; PARTISETI M, 1993, J IMMUNOL, V151, P2462; Pon DC, 1997, J CELL PHYSIOL, V171, P87; Rajvanshi P, 1996, HEPATOLOGY, V23, P482; Russ U, 1999, J PHYSIOL-LONDON, V517, P781, DOI 10.1111/j.1469-7793.1999.0781s.x; Saw D, 1996, DIGEST DIS SCI, V41, P322, DOI 10.1007/BF02093822; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; Schofl C, 1999, AM J PHYSIOL-GASTR L, V276, pG164, DOI 10.1152/ajpgi.1999.276.1.G164; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SPURCE AE, 1985, NATURE, V316, P736; STANLEY RG, 1999, ADV 2 MESSENGER PHOS, V33, P107; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wellman GC, 1999, BRIT J PHARMACOL, V128, P909, DOI 10.1038/sj.bjp.0702868; Wondergem R, 1998, J MEMBRANE BIOL, V161, P257, DOI 10.1007/s002329900332; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; Zahler MH, 2000, J GENE MED, V2, P186	49	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26050	26057		10.1074/jbc.M001576200	http://dx.doi.org/10.1074/jbc.M001576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862612	hybrid			2022-12-27	WOS:000088999700024
J	Ringvall, M; Ledin, J; Holmborn, K; van Kuppevelt, T; Ellin, F; Eriksson, I; Olofsson, AM; Kjellen, L; Forsberg, E				Ringvall, M; Ledin, J; Holmborn, K; van Kuppevelt, T; Ellin, F; Eriksson, I; Olofsson, AM; Kjellen, L; Forsberg, E			Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; MAST-CELLS; EXPRESSION; DROSOPHILA; PROTEOGLYCANS; MOUSE; GENE; ENZYME; IDENTIFICATION	Heparan sulfate is a sulfated polysaccharide present on most cell surfaces and in the extracellular matrix. In vivo functions of heparan sulfate can be studied in mouse strains lacking enzymes involved in the biosynthesis of heparan sulfate. Glucosaminyl N-deacetylase/N-suLfotransferase (NDST) catalyzes the first modifying step in the biosynthesis of the polysaccharide. This bifunctional enzyme occurs in several isoforms. We here report that targeted gene disruption of NDST-1 in the mouse results in a structural alteration of heparan sulfate in most basement membranes as revealed by immunohistochemical staining of fetal tissue sections using antibodies raised against heparan sulfate. Biochemical analysis of heparan sulfate purified from fibroblast cultures, lung, and liver of NDST-1-deficient embryos demonstrated a dramatic reduction in N-sulfate content. Most NDST-1-deficient embryos survive until birth; however, they turn out to be cyanotic and die neonatally in a condition resembling respiratory distress syndrome. In addition, a minor proportion of NDST-1 deficient embryos die during the embryonic period. The cause of the embryonic lethality is still obscure, but incompletely penetrant defects of the skull and the eyes have been observed.	Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Uppsala, Dept Cell & Mol Biol, S-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences; Radboud University Nijmegen; Uppsala University	Forsberg, E (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden.		van Kuppevelt, A.H.M.S.M./L-4463-2015; Kjellen, Lena/F-1362-2011	Ellin, Fredrik/0000-0001-9034-5966; Ledin, Johan/0000-0002-7319-7735				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; AVERY ME, 1959, AM J DIS CHILD, V97, P17; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sannes PL, 1998, AM J PHYSIOL-LUNG C, V275, pL701, DOI 10.1152/ajplung.1998.275.4.L701; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002	42	200	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25926	25930		10.1074/jbc.C000359200	http://dx.doi.org/10.1074/jbc.C000359200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852901	hybrid			2022-12-27	WOS:000088999700008
J	Zhu, KJ; Debreceni, B; Li, R; Zheng, Y				Zhu, KJ; Debreceni, B; Li, R; Zheng, Y			Identification of Rho GTPase-dependent sites in the Dbl homology domain of oncogenic Dbl that are required for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING PATHWAY; GDP/GTP EXCHANGE; BINDING PROTEINS; CDC42; PRODUCT; CELL; VAV; RAS; GENE	The Dbl family guanine-nucleotide exchange factors (GEFs) for Rho GTPases share the structural array of a Dbl homology (DH) domain in tandem with a Pleckstrin homology (PH) domain. For oncogenic Dbl, the DH domain is responsible for the GEF activity, and the DH-PH module constitutes the minimum structural unit required for cellular transformation. To understand the structure-function relationship of the DH domain, we have investigated the role of specific residues of the DH domain of Dbl in interaction with Rho GTPases and in Dbl-induced transformation. Alanine substitution mutagenesis identified a panel of DH mutants made in the alpha 1, alpha 6, and alpha 9 regions and the PH junction site that suffer complete or partial loss of GEF activity toward Cdc42 and RhoA. Kinetic and binding analysis of these mutants revealed that although most displayed decreased k(cat) values in the GEF reaction, the substrate binding activities of T506A and R634A were significantly reduced. E502A Q633A, and N673A/D674A, on the other hand, retained the binding capability to the Rho GTPases but lost the GEF catalytic activity. In general, the in vitro GEF activity of the DH mutants correlated with the in vivo Cdc42- and RhoA-activating potential, and the GEF catalytic efficiency mirrored the transforming activity in MH 3T3 cells, Moreover, the N673A/D674A mutant exhibited a potent dominant-negative effect on serum-induced cell growth and caused retraction of actin structures, These studies identify important sites of the DH domain involved in binding or catalysis of Rho proteins and demonstrate that maintaining a threshold of GEF catalytic activity, in addition to the Rho GTPase binding activity, is essential for efficient transformation by oncogenic Dbl.	Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM 53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Olivo C, 2000, ONCOGENE, V19, P1428, DOI 10.1038/sj.onc.1203440; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RON D, 1991, NEW BIOL, V3, P372; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	45	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25993	26001		10.1074/jbc.M003780200	http://dx.doi.org/10.1074/jbc.M003780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854437	hybrid			2022-12-27	WOS:000088999700017
J	Bai, JH; Earles, CA; Lewis, JL; Chapman, ER				Bai, JH; Earles, CA; Lewis, JL; Chapman, ER			Membrane-embedded synaptotagmin penetrates cis or trans target membranes and clusters via a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; CALCIUM-DEPENDENCE; C(2)A DOMAIN; BINDING; FUSION; CA2+; DEPTH; DROSOPHILA; EXOCYTOSIS; BILAYERS	The synaptic vesicle protein synaptotagmin I has been proposed to serve as a Ca2+ sensor for rapid exocytosis, Synaptotagmin spans the vesicle membrane once and possesses a cytoplasmic domain largely comprised of two C2 domains designated C2A and C2B. We have determined how deep the Ca2+-binding loops of Ca2+ C2A penetrate into the lipid bilayer and report mutations in synaptotagmin that can uncouple membrane penetration from Ca2+-triggered interactions with the SNARE complex. To determine whether C2A penetrates into the vesicle ("cis") or plasma ("trans") membrane, we reconstituted a fragment of synaptotagmin that includes the membrane-spanning and C2A domain (C2A-TMR) into proteoliposomes. Kinetics experiments revealed that cis interactions are rapid (less than or equal to 500 mu s). Binding in the trans mode was distinguished by the slow diffusion of trans target vesicles, Both modes of binding were observed, indicating that the linker between the membrane anchor and C2A domain functions as a flexible tether. C2A-TMR assembled into oligomers via a novel N-terminal oligomerization domain suggesting that synaptotagmin may form clusters on the surface of synaptic vesicles. This novel mode of clustering may allow for rapid Ca2+- triggered oligomerization of the protein via the membrane distal C2B domain.	Univ Wisconsin, Dept Physiol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Dept Physiol, Sch Med, 1300 Univ Ave,SMI 129, Madison, WI 53706 USA.			Chapman, Edwin/0000-0001-9787-8140	NIGMS NIH HHS [GM 56827-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	45	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25427	25435		10.1074/jbc.M906729199	http://dx.doi.org/10.1074/jbc.M906729199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840045	hybrid			2022-12-27	WOS:000088849400051
J	Knoop, LL; Baker, SJ				Knoop, LL; Baker, SJ			The splicing factor U1C represses EWS/FLI-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; EXTRASKELETAL MYXOID CHONDROSARCOMA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEINS; EWINGS-SARCOMA TRANSLOCATION; PRO-ONCOPROTEIN TLS/FUS; BINDING PROTEIN; DNA-BINDING; TRANSCRIPTION FACTOR; CHROMOSOME-TRANSLOCATION; MYELOID-LEUKEMIA	EWS is an RNA-binding protein involved in human tumor-specific chromosomal translocations, In approximately 85% of Ewing's sarcomas, such translocations give rise to the chimeric gene EWS/FLI. In the resulting fusion protein, the RNA binding domains from the C terminus of EWS are replaced by the DNA-binding domain of the ETS protein FLI-1, EWS/FLI can function as a transcription factor with the same DNA binding specificity as FLI-1. EWS and EWS/FLI can associate with the RNA polymerase II holoenzyme as well as with SF1, an essential splicing factor, Here we report that U1C, one of three human U1 small nuclear ribonucleoprotein-specific proteins, interacts in vitro and in vivo with both EWS and EWS/FLI. U1C interacts with other splicing factors and is important in the early stages of spliceosome formation. Importantly, co-expression of U1C represses EWS/FLI-mediated transactivation, demonstrating that this interaction can have functional ramifications. Our findings demonstrate that U1C, a well characterized splicing protein, can also function in transcriptional regulation. Furthermore, they suggest that EWS and EWS/FLI may function both in transcriptional and post-transcriptional processes.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Baker, SJ (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Suzanne.baker@stjude.org			NCI NIH HHS [P30 CA21765, P01-CA-71907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arning S, 1996, RNA, V2, P794; Attwooll C, 1999, ONCOGENE, V18, P7599, DOI 10.1038/sj.onc.1203156; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brody RI, 1997, AM J PATHOL, V150, P1049; BROWN AD, 1995, ONCOGENE, V10, P1749; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Galjaard H., 1980, GENETIC METABOLIC DI; Ghigna C, 1998, CANCER RES, V58, P5818; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; LADANYI M, 1994, CANCER RES, V54, P2837; LESSNICK SL, 1995, ONCOGENE, V10, P423; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Panagopoulos I, 1999, ONCOGENE, V18, P7594, DOI 10.1038/sj.onc.1203155; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; Sjogren H, 1999, CANCER RES, V59, P5064; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	56	99	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24865	24871		10.1074/jbc.M001661200	http://dx.doi.org/10.1074/jbc.M001661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827180	hybrid			2022-12-27	WOS:000088683300084
J	Hashimoto, T; Cook, WS; Qi, C; Yeldandi, AV; Reddy, JK; Rao, MS				Hashimoto, T; Cook, WS; Qi, C; Yeldandi, AV; Reddy, JK; Rao, MS			Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BETA-OXIDATION; COA SYNTHASE GENE; ACYL-COA; PPAR-ALPHA; OMEGA-HYDROXYLATION; ADAPTIVE RESPONSE; GAMMA ACTIVATORS; MICE LACKING; RAT-LIVER; EXPRESSION	Fasting causes lipolysis in adipose tissue leading to the release of large quantities of free fatty acids into circulation that reach the liver where they are metabolized to generate ketone bodies to serve as fuels for other tissues. Since fatty acid-metabolizing enzymes in the liver are transcriptionally regulated by peroxisome proliferator-activated receptor alpha (PPAR alpha), we investigated the role of PPAR alpha in the induction of these enzymes in response to fasting and their relationship to the development of hepatic steatosis in mice deficient in PPAR alpha (PPAR alpha(-/-)), peroxisomal fatty acyl-CoA oxidase (AOX(-/-)), and in both PPAR alpha and AOX (double knockout (DKO)), Fasting for 48-72 h caused profound impairment of fatty acid oxidation in both PPAR alpha(-/-) and DKO mice, and DKO mice revealed a greater degree of hepatic steatosis when compared with PPAR alpha(-/-) mice. The absence of PPAR alpha in both PPAR alpha(-/-) and DKO mice impairs the induction of mitochondrial beta-oxidation in liver following fasting which contributes to hypoketonemia and hepatic steatosis, Pronounced steatosis in DRO mouse livers is due to the added deficiency of peroxisomal beta-oxidation system in these animals due to the absence of AOX. In mice deficient in AOX alone, the sustained hyperactivation of PPAR alpha and up-regulation of mitochondrial beta-oxidation and microsomal omega-oxidation systems as well as the regenerative nature of a majority of hepatocytes containing numerous spontaneously proliferated peroxisomes, which appear refractory to store triglycerides, blunt the steatotic response to fasting. Starvation for 48-72 h caused a decrease in PPAR alpha hepatic mRNA levels in wild type mice, with no perceptible compensatory increases in PPAR gamma and PPAR delta mRNA levels. PPAR gamma and PPAR delta hepatic mRNA levels were lower in fed PPAR alpha(-/-) and DKO mice when compared with wild type mice, and fasting caused a slight increase only in PPAR gamma levels and a decrease in PPAR delta levels. Fasting did not change the PPAR isoform levels in AOX(-/-) mouse liver. These observations point to the critical importance of PPAR alpha in the transcriptional regulatory responses to fasting and in determining the severity of hepatic steatosis.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AOYAMA T, 1990, J LIPID RES, V31, P1477; Bergmeyer H, 1974, METHODS ENZYMATIC AN, P1205; Berk PD, 1999, HEPATOLOGY, V29, P1607, DOI 10.1002/hep.510290538; Boukaftane Y, 1997, GENE, V195, P121, DOI 10.1016/S0378-1119(97)00067-X; DRYER C, 1992, CELL, V68, P879; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GUTMANN I, 1974, METHOD ENZYMAT AN, V2, P1464; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; HILLGARTNER FB, 1995, PHYSIOL REV, V75, P583; Huang MT, 1997, LIFE SCI, V60, P1915, DOI 10.1016/S0024-3205(97)00153-7; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LANDS WEM, 1995, ALCOHOL CLIN EXP RES, V19, P928, DOI 10.1111/j.1530-0277.1995.tb00969.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; PEARSON DJ, 1974, METHOD ENZYMAT AN, P1758; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Roe C. R., 1995, METABOLIC MOL BASES, P1501; ROEHRIG KL, 1974, ANAL BIOCHEM, V58, P414, DOI 10.1016/0003-2697(74)90210-3; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; SEITZ HJ, 1977, ARCH BIOCHEM BIOPHYS, V183, P647, DOI 10.1016/0003-9861(77)90399-X; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; SOLERARGILAGA C, 1976, J LIPID RES, V17, P605; Song XQ, 1997, BBA-MOL BASIS DIS, V1360, P151; SORRENTINO D, 1994, GASTROENTEROLOGY, V107, P1415, DOI 10.1016/0016-5085(94)90544-4; Taroni F, 1996, CURR OPIN NEUROL, V9, P477, DOI 10.1097/00019052-199612000-00015; WILLIAMS.DH, 1971, BIOCHEM J, V121, P41, DOI 10.1042/bj1210041; WILLIAMSON DH, 1974, METHOD ENZYMAT AN, P1837; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	44	340	356	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28918	28928		10.1074/jbc.M910350199	http://dx.doi.org/10.1074/jbc.M910350199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10844002	hybrid			2022-12-27	WOS:000089330700077
J	Miao, F; Bouziane, M; Dammann, R; Masutani, C; Hanaoka, F; Pfeifer, G; O'Connor, TR				Miao, F; Bouziane, M; Dammann, R; Masutani, C; Hanaoka, F; Pfeifer, G; O'Connor, TR			3-methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; METHYLPURINE-DNA GLYCOSYLASE; DIHYDROFOLATE-REDUCTASE GENE; COCKAYNE-SYNDROME PATIENTS; UBIQUITIN-LIKE DOMAIN; HUMAN-CELLS; POLYMERASE-BETA; MAMMALIAN-CELLS; N-METHYLPURINES	Human 3-methyladenine-DNA glycosylase (MPG protein) initiates base excision repair by severing the glycosylic bond of numerous damaged bases. In comparison, homologues of the Rad23 proteins (hHR23) and the hXPC protein are involved in the recognition of damaged bases in global genome repair, a subset of nucleotide excision repair. In this report, we show that the hHR23A and -B also interact with the MPG protein and can serve as accessory proteins for DNA damage recognition in base excision repair. Furthermore, the MPG.hHR23 protein complex elevates the rate of MPG protein-catalyzed excision from hypoxanthine-containing substrates. This increased excision rate is correlated with a greater binding affinity of the MPG protein-hHR23 protein complex for damaged DNA. These data suggest that the hHR23 proteins function as universal DNA damage recognition accessory proteins in both of these major excision repair pathways.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Osaka Univ, Dept Mol & Cellular Biol, Suita, Osaka 565, Japan	City of Hope; Beckman Research Institute of City of Hope; Osaka University	O'Connor, TR (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; O'Connor, Timothy/0000-0001-5848-3592	NATIONAL CANCER INSTITUTE [P30CA033572, P01CA069449] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA33572, 1PO11CA69449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; BOHR VA, 1987, CANCER RES, V47, P6426; Bouziane M, 1998, ACTA BIOCHIM POL, V45, P191, DOI 10.18388/abp.1998_4333; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; James P, 1996, GENETICS, V144, P1425; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; LARMINAT F, 1993, J BIOL CHEM, V268, P2649; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; MITCHELL DL, 1988, MUTAT RES, V194, P227, DOI 10.1016/0167-8817(88)90024-7; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Sambrook J., 2002, MOL CLONING LAB MANU; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; SNYDERWINE EG, 1992, CANCER RES, V52, P4182; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TANG MS, 1989, J BIOL CHEM, V264, P14455; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; WANG W, 1995, BIOCHEMISTRY-US, V34, P1798, DOI 10.1021/bi00005a037; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138	62	108	110	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28433	28438		10.1074/jbc.M001064200	http://dx.doi.org/10.1074/jbc.M001064200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10854423	hybrid			2022-12-27	WOS:000089330700015
J	Chang, CCY; Sakashita, N; Ornvold, K; Lee, O; Chang, ET; Dong, R; Lin, S; Lee, CYG; Strom, SC; Kashyap, R; Fung, JJ; Farese, RV; Patoiseau, JF; Delhon, A; Chang, TY				Chang, CCY; Sakashita, N; Ornvold, K; Lee, O; Chang, ET; Dong, R; Lin, S; Lee, CYG; Strom, SC; Kashyap, R; Fung, JJ; Farese, RV; Patoiseau, JF; Delhon, A; Chang, TY			Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; COA-CHOLESTEROL ACYLTRANSFERASE; AFRICAN-GREEN MONKEYS; APOLIPOPROTEIN-B; MESSENGER-RNA; LIPOPROTEIN PARTICLES; MOLECULAR-CLONING; SECRETION; CELLS; EXPRESSION	By using specific anti-ACAT-1 antibodies in immunodepletion studies, we previously found that ACAT-1, a 50-kDa protein, plays a major catalytic role in the adult human liver, adrenal glands, macrophages, and kidneys but not in the intestine. Acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity in the intestine may be largely derived from a different ACAT protein. To test this hypothesis, we produced specific polyclonal anti-ACAT-2 antibodies that quantitatively immunodepleted human ACAT-2, a 46-kDa protein expressed in Chinese hamster ovary cells. In hepatocyte-like HepG2 cells, ACAT-1 comprises 85-90% of the total ACAT activity, with the remainder attributed to ACAT-2. In adult intestines, most of the ACAT activity can be immunodepleted by anti-ACAT-2. ACAT-1 and ACAT-2 do not form heterooligomeric complexes. In differentiating intestinal enterocyte-like Caco-2 cells, ACAT-2 protein content increases by 5-10-fold in 6 days, whereas ACAT-1 protein content remains relatively constant. In the small intestine, ACAT-2 is concentrated at the apices of the villi, whereas ACAT-1 is uniformly distributed along the villus-crypt axis. In the human liver, ACAT-1 is present in both fetal and adult hepatocytes. In contrast, ACAT-2 is evident in fetal but not adult hepatocytes. Our results collectively suggest that in humans, ACAT-2 performs significant catalytic roles in the fetal liver and in intestinal enterocytes.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Kumamoto Univ, Sch Med, Dept Pathol 2, Kumamoto 8600811, Japan; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA; Univ British Columbia, Androl Lab, Vancouver, BC V6T 2B5, Canada; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, TE Starzl Transplantat Inst, Pittsburgh, PA 15261 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, San Francisco, CA 94141 USA; Ctr Rech Pierre Fabre, F-81106 Castres, France	Dartmouth College; Kumamoto University; Dartmouth College; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Ta.yuan.Chang@dartmouth.edu	FUNG, John Julian/A-2679-2012; Chang, Ellen/E-3168-2010; Chang, Ellen/G-5700-2010	FUNG, John Julian/0000-0002-3038-0441; 	NHLBI NIH HHS [HL 60306, HL 36709] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036709, R01HL060306, R01HL036709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Brewer HB, 2000, J CLIN INVEST, V105, P703, DOI 10.1172/JCI9664; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; FIELD FJ, 1995, PROG LIPID RES, V34, P185, DOI 10.1016/0163-7827(95)00005-K; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Joyce C, 1999, CURR OPIN LIPIDOL, V10, P89, DOI 10.1097/00041433-199904000-00002; KRAUSE BR, 1993, J LIPID RES, V34, P279; KRAUSE BR, 1995, ACAT INHIBITORS PHYS, P173; Lee O, 1998, J LIPID RES, V39, P1722; LEVIN MS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P293, DOI 10.1016/0005-2760(89)90235-X; Levy E, 2000, J LIPID RES, V41, P12; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; PAPE ME, 1995, J LIPID RES, V36, P823; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; STANGE EF, 1983, J BIOL CHEM, V258, P2868; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TANAKA M, 1993, J BIOL CHEM, V268, P12713; Thompson GR, 1996, J LIPID RES, V37, P439; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Young SG, 1998, CURR OPIN LIPIDOL, V9, P81; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zhang ZJ, 1999, ARTERIOSCL THROM VAS, V19, P743, DOI 10.1161/01.ATV.19.3.743	46	175	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28083	28092						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846185				2022-12-27	WOS:000089197100074
J	Barneche, F; Steinmetz, F; Echeverria, M				Barneche, F; Steinmetz, F; Echeverria, M			Fibrillarin genes encode both a conserved nucleolar protein and a novel small nucleolar RNA involved in ribosomal RNA methylation in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; MAMMALIAN GENE; GUIDE SNORNAS; BOX-C/D; YEAST; COMMON; INTRONS; COMPONENT; BIOGENESIS	Fibrillarin is a key nucleolar protein in eukaryotes which associates with box C/D small nucleolar RNAs (snoRNAs) directing 2'-O-ribose methylation of the rRNA. In this study we describe two genes in Arabidopsis thaliana, AtFib1 and AtFib2, encoding nearly identical proteins conserved with eukaryotic fibrillarins, We demonstrate that AtFib1 and AtFib2 proteins are functional homologs of the yeast Nop1p (fibrillarin) and can rescue a yeast NOP1-null mutant strain. Surprisingly, for the first time in plants, we identified two isoforms of a novel box C/D snoRNA, U60.1f and U60.2f, nested in the fifth intron of AtFib1 and AtFib2, Interestingly after gene duplication the host intronic sequences completely diverged, but the snoRNA was conserved, even in other crucifer fibrillarin genes. We show that the U60f snoRNAs accumulate in seedlings and that their targeted residue on the 25 S rRNA is methylated. Our data reveal that the three modes of expression of snoRNAs, single, polycistronic, and intronic, exist in plants and suggest that the mechanisms directing rRNA methylation, dependent on fibrillarin and box C/D snoRNAs, are evolutionarily conserved in plants.	Univ Perpignan, Lab Genome & Dev Plantes, URM CNRS 5096, F-66860 Perpignan, France	Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia	Echeverria, M (corresponding author), Univ Perpignan, Lab Genome & Dev Plantes, URM CNRS 5096, 52 Ave Villeneuve, F-66860 Perpignan, France.		Barneche, Fredy/M-4228-2015; BARNECHE, Fredy/AAB-5054-2019	Barneche, Fredy/0000-0002-7014-7097; BARNECHE, Fredy/0000-0002-7014-7097				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bachellerie J. P., 1998, MODIFICATION EDITING, P255; Beven AF, 1996, J CELL SCI, V109, P1241; BLANC G, IN PRESS PLANT CELL; BOORSTEIN WJ, 1990, METHOD ENZYMOL, V180, P347; Brown JWS, 1998, PLANT CELL, V10, P649, DOI 10.1105/tpc.10.5.649; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; CECCHINI JP, 1979, EUR J BIOCHEM, V98, P203, DOI 10.1111/j.1432-1033.1979.tb13178.x; CERDIDO A, 1995, CHROMOSOMA, V103, P625; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Cooke R, 1996, PLANT J, V9, P101, DOI 10.1046/j.1365-313X.1996.09010101.x; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; David E, 1997, MOL BIOL CELL, V8, P1051, DOI 10.1091/mbc.8.6.1051; de Carcer G, 1999, J STRUCT BIOL, V128, P139, DOI 10.1006/jsbi.1999.4187; Doyle JJ, 1989, FOCUS, V12, P13; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JOHNSTON JR, 1994, MOL GENETICS YEAST; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Pelczar P, 1998, MOL CELL BIOL, V18, P4509, DOI 10.1128/MCB.18.8.4509; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; PRISLEI S, 1993, NUCLEIC ACIDS RES, V21, P5824, DOI 10.1093/nar/21.25.5824; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Saez-Vasquez J, 2000, PLANT SCI, V156, P35, DOI 10.1016/S0168-9452(00)00229-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Sicard H, 1998, MOL BIOL CELL, V9, P2011, DOI 10.1091/mbc.9.8.2011; SONNHAMMER ELL, 1995, GENE-COMBIS, V167, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	60	108	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27212	27220						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829025				2022-12-27	WOS:000089144800073
J	Miwa, N; Uebi, T; Kawamura, S				Miwa, N; Uebi, T; Kawamura, S			Characterization of p26olf, a novel calcium-binding protein in the frog olfactory epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NEURONS; TRANSDUCTION; LOCALIZATION; SUBTYPES; CLONING; CYCLASE	We have previously shown that p26olf is a novel S100-like Ca2+-binding protein in the frog olfactory epithelium, In this paper, we characterized the Ca2+ binding property of p26olf, examined the precise localization in the frog olfactory epithelium, and searched for the possible target proteins of p26olf. By flow dialysis experiments using Ca-45, p26olf was suggested to bind similar to 4 Ca2+ Circular dichroism measurement showed that binding of Ca2+ to p26olf induces an increase in the apparent content of both alpha-helix and beta-sheet with an apparent K-d value of 2.4 mu M. Electron microscopic observation disclosed p26olf immunoreactivity in the cilia, dendritic knob, and dendrite of olfactory receptor cells. Blot overlay analysis and affinity purification of p26olf-binding proteins showed that p26olf binds to a frog beta-adrenergic receptor kinase-like protein in a Ca2+-dependent manner. These results suggested that p26olf has some roles in the olfactory transduction or adaptation.	Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Osaka University	Miwa, N (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Machikane Yama 1-1, Toyonaka, Osaka 5600043, Japan.							ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BORISY FF, 1992, J NEUROSCI, V12, P915; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; Iacovelli L, 1999, FASEB J, V13, P1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Kretsinger RH, 1997, NAT STRUCT BIOL, V4, P514, DOI 10.1038/nsb0797-514; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTES T, 1998, J IMMUNOL, V141, P3135; MCCUBBIN WD, 1986, FEBS LETT, V195, P17, DOI 10.1016/0014-5793(86)80121-1; MENCO BPM, 1992, NEURON, V8, P441, DOI 10.1016/0896-6273(92)90272-F; Miwa N, 1998, BIOCHEM BIOPH RES CO, V251, P860, DOI 10.1006/bbrc.1998.9571; REED RR, 1992, COLD SPRING HARB SYM, V57, P501, DOI 10.1101/SQB.1992.057.01.055; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tanaka T, 1999, PROTEIN ENG, V12, P395, DOI 10.1093/protein/12.5.395; TSUGA H, 1994, J BIOL CHEM, V269, P32522	26	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27245	27249						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852910				2022-12-27	WOS:000089144800077
J	Silverman, GL; Qin, KF; Moore, RC; Yang, Y; Mastrangelo, P; Tremblay, P; Prusiner, SB; Cohen, FE; Westaway, D				Silverman, GL; Qin, KF; Moore, RC; Yang, Y; Mastrangelo, P; Tremblay, P; Prusiner, SB; Cohen, FE; Westaway, D			Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein - Expression in testis and ectopic production in the brains of Prnp(o/o) mice predisposed to Purkinje cell loss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PRION PROTEIN; CLEAVAGE ATTACHMENT SITE; MEMBRANE-PROTEINS; SCRAPIE ISOFORM; PRP GENE; PHOSPHATIDYLINOSITOL; DEFICIENT; SEQUENCE; REGION; ATAXIA	The Prnd gene encodes a homolog of the cellular prion protein (PrPC) called doppel (Dpl), Up-regulation of Prnd mRNA in two distinct lines of PrP gene ablated (Prnp(0/0)) mice, designated Rcm0 and Ngsk, is associated with death of Purkinje cells. Using recombinant Dpl expressed in Escherichia coli and mouse neuroblastoma cells we demonstrate that wild type (wt) Dpl, like PrPC, adopts a predominantly alpha-helical conformation, forms intramolecular disulfide bonds, has two N-linked oligosaccharides, and is presented on the cell surface via a glycosylphosphatidylinositol anchor. Dpl protein was detected in testis of wt mice. Using Triton X-114 phase partitioning to enrich for glycosylphosphatidylinositol-anchored proteins, Dpl was detected in brain samples from Rcm0 Prnp(0/0) mice but was absent in equivalent samples from wt mice and ZrchI Prnp(0/0) mice, indicating that ectopic expression of this protein may cause cerebellar pathology in Rcm0 mice. Biochemical and structural similarities between PrPC and Dpl documented here parallel the observation that ataxic Ngsk Prnp(0/0) mice can be rescued by overexpression of wild-type PrP transgenes, and suggest that cell surface PrPC can antagonize the toxic effect of Dpl expressed in the central nervous system.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Mol Med Res Ctr, Mass Spectrometry Lab, Toronto, ON M5S 3H2, Canada; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Cres W, Toronto, ON M5S 3H2, Canada.							BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Furukawa Y, 1997, BBA-BIOMEMBRANES, V1328, P185, DOI 10.1016/S0005-2736(97)00084-9; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Lee IY, 1998, GENOME RES, V8, P1022, DOI 10.1101/gr.8.10.1022; Loftus B, 1997, GENE, V184, P215, DOI 10.1016/S0378-1119(96)00598-7; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; MORAN P, 1991, J BIOL CHEM, V266, P1250; Nishida N, 1999, LAB INVEST, V79, P689; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STROBL S, 1995, BIOCHEMISTRY-US, V34, P8281, DOI 10.1021/bi00026a009; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A	28	139	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26834	26841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842180				2022-12-27	WOS:000089144800025
J	Steet, RA; Melancon, P; Kuchta, RD				Steet, RA; Melancon, P; Kuchta, RD			3 '-azidothymidine potently inhibits the biosynthesis of highly branched N-linked oligosaccharides and poly-N-acetyllactosamine chains in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMIA TYPE-II; HEMATOPOIETIC PROGENITOR CELLS; ALTERS GLYCOSPHINGOLIPID SYNTHESIS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ALPHA-MANNOSIDASE-II; PROTEIN GLYCOSYLATION; PHASEOLUS-VULGARIS; DOLICHYL PHOSPHATE; HEPARAN-SULFATE; MOLECULAR-BASIS	Previous studies in our laboratory have characterized 3'-azido-3'-deoxythymidine (AZT) as a potent inhibitor of glycosphingolipid biosynthesis in cultured cells (Steet, R,, Alizadeh, M,, Melancon, P,, and Kuchta, R, D, (1999) Glycoconj. J. 16, 237-245; Yan, J.-P,, Ilsley, D, D,, Frohlick, C,, Steet, R,, Hall, E, T,, Kuchta, R, D,, and Melancon, P, (1995) J, Biol, Chem, 270, 22836-22841), Here, we report that AZT treatment of K562 cells results in significant alterations in the profile of N-linked oligosaccharides, Fractionation of [H-3]mannose-labeled oligosaccharides from AZT-treated K562 cells using lectin affinity chromatography revealed striking changes in the branching and processing of N-linked glycoconjugates, AZT treatment resulted in the production of fewer highly branched complex glycans (60% of control at 20 mu M AZT) and a significant accumulation of core-fucosylated biantennary oligosaccharides, In addition, extension of branched oligosaccharides with multiple poly-N-acetyllactosamine repeats is nearly abolished by AZT concentrations as low as 2 mu M, A Shift from multiantennary to moderately branched oligosaccharides was also apparent in the melanoma cell line SK-MEL-30 upon AZT treatment. N-Linked glycans from both cell lines exhibited increased affinity for the beta-galactoside-binding lectin RCA-I in the presence of AZT, suggesting that the addition of terminal sialic acid is sensitive to the drug. These results demonstrate the ability of AZT to modulate strongly the processing of asparagine-linked glycoconjugates in whole cells and reveal a novel mechanism by which AZT treatment may cause anemia.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Alberta, Dept Cell Biol & Anat, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Boulder; University of Alberta	Kuchta, RD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM55709] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada M, 1997, CANCER RES, V57, P1073; BRESALIER RS, 1990, CANCER RES, V50, P1299; Chui D, 1997, CELL, V90, P157, DOI 10.1016/S0092-8674(00)80322-0; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DAINIAK N, 1988, BRIT J HAEMATOL, V69, P299, DOI 10.1111/j.1365-2141.1988.tb02366.x; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; DO KY, 1993, J BIOL CHEM, V268, P22028; Drzeniek Z, 1999, BLOOD, V93, P2884; DU DL, 1992, BRIT J HAEMATOL, V80, P437, DOI 10.1111/j.1365-2141.1992.tb04555.x; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1986, BLOOD, V68, P521; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GAHMBERG CG, 1984, P NATL ACAD SCI-BIOL, V81, P6752, DOI 10.1073/pnas.81.21.6752; GAHMBERG CG, 1988, J CELL BIOCHEM, V37, P91, DOI 10.1002/jcb.240370109; GANSER A, 1989, EXP HEMATOL, V17, P321; Hakomori S, 1996, CANCER RES, V56, P5309; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HALL ET, 1994, J BIOL CHEM, V269, P14355; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE N, 1990, J BIOL CHEM, V265, P20476; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; ROUX L, 1988, J BIOL CHEM, V263, P8879; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Steet R, 1999, GLYCOCONJUGATE J, V16, P237, DOI 10.1023/A:1007032522001; Suzuki T, 2000, GLYCOBIOLOGY, V10, P51, DOI 10.1093/glycob/10.1.51; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Toma L, 1996, J BIOL CHEM, V271, P3897; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; Wickramasinghe SN, 1998, BLOOD REV, V12, P178, DOI 10.1016/S0268-960X(98)90016-9; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	53	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26812	26820						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842182				2022-12-27	WOS:000089144800022
J	Yu, G; Chen, FS; Nishimura, M; Steiner, H; Tandon, A; Kawarai, T; Arawaka, S; Supala, A; Song, YQ; Rogaeva, E; Holmes, E; Zhang, DM; Milman, P; Fraser, PE; Haass, C; St George-Hyslop, P				Yu, G; Chen, FS; Nishimura, M; Steiner, H; Tandon, A; Kawarai, T; Arawaka, S; Supala, A; Song, YQ; Rogaeva, E; Holmes, E; Zhang, DM; Milman, P; Fraser, PE; Haass, C; St George-Hyslop, P			Mutation of conserved aspartates affects maturation of both aspartate mutant and endogenous presenilin 1 and presenilin 2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; TRANSFECTED CELLS; BETA-CATENIN; MISSENSE MUTATIONS; TRANSGENIC MICE; IN-VIVO; NOTCH; DEFICIENCY; GENE	Presenilin (PS1 and PS2) holoproteins are transiently incorporated into low molecular weight (MW) complexes. During subsequent incorporation into a higher MW complex, they undergo endoproteolysis to generate stable N- and C-terminal fragments. Mutation of either of two conserved aspartate residues in transmembrane domains inhibits both presenilin endoproteolysis and the proteolytic processing of beta-amyloid precursor protein and Notch. We show that although PS1/PS2 endoproteolysis is not required for inclusion into the higher MW N- and C-terminal fragment-containing complex, aspartate mutant holoprotein presenilins are not incorporated into the high MW complexes. Aspartate mutant presenilin holoproteins also preclude entry of endogenous wild type PS1/PS2 into the high MW complexes but do not affect the incorporation of wild type holoproteins into lower MW holoprotein complexes. These data suggest that the loss of function effects of the aspartate mutants result in altered PS complex maturation and argue that the functional presenilin moieties are contained in the high molecular weight complexes.	Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Hlth Network, Toronto Western Hosp, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Munich, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Munich	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Rm 118,Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Song, You-Qiang/0000-0001-9407-2256; Arawaka, Shigeki/0000-0002-1505-3012				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CHEN F, 2000, IN PRESS J BIOL CHEM; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kim TW, 1997, J BIOL CHEM, V272, P11006; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	35	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27348	27353						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856299				2022-12-27	WOS:000089144800091
J	Herreros, L; Rodriguez-Fernandez, JL; Brown, MC; Alonso-Lebrero, JL; Cabanas, C; Sanchez-Madrid, F; Longo, N; Turner, CE; Sanchez-Mateos, P				Herreros, L; Rodriguez-Fernandez, JL; Brown, MC; Alonso-Lebrero, JL; Cabanas, C; Sanchez-Madrid, F; Longo, N; Turner, CE; Sanchez-Mateos, P			Paxillin localizes to the lymphocyte microtubule organizing center and associates with the microtubule cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; FOCAL ADHESION LOCALIZATION; GAMMA-TUBULIN; T-CELL; TYROSINE PHOSPHORYLATION; CROSS-LINKING; LIM DOMAINS; BINDING; PROTEIN; ACTIVATION	Paxillin is a focal adhesion-associated protein that functions as a multi-domain adapter protein, binding several structural and signaling molecules. alpha-Tubulin was identified as an interacting protein in a two-hybrid screen using the paxillin C-terminal LIM domain as a bait. In vitro binding assays with glutathione S-transferase-paxillin demonstrated an interaction of cy-tubulin with the C terminus of paxillin. Another member of the tubulin family, gamma-tubulin, bound to both the N and the C terminus of paxillin. The interaction between paxillin and both alpha- and gamma-tubulin in vivo was confirmed by immunoprecipitation from human T lymphoblasts. Immunofluorescence studies revealed that, in adherent T cells, paxillin localized to sites of cell-matrix interaction as well as to a large perinuclear region. Confocal microscopy revealed that this region corresponds to the lymphocyte microtubule organizing center, where paxillin colocalizes with alpha- and gamma-tubulin. The localization of paxillin to this area was observed in cells in suspension as well as during adhesion to integrin ligands. These data constitute the first characterization of the interaction of paxillin with the microtubule cytoskeleton, and suggest that paxillin, in addition to its well established role at focal adhesions, could also be associated with the lymphocyte microtubule network.	Hosp Gen Univ Gregorio Maranon, Sern Inmunol, Madrid 28007, Spain; Univ Complutense Madrid, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	General University Gregorio Maranon Hospital; Complutense University of Madrid; Hospital de La Princesa; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sanchez-Mateos, P (corresponding author), Hosp Gen Univ Gregorio Maranon, Sern Inmunol, C Dr Esquerdo 46, Madrid 28007, Spain.		Sanchez-Madrid, Francisco/M-7889-2016; Rodriguez-Fernandez, Jose Luis/Q-5021-2019; CABAÑAS, CARLOS/J-4595-2012; Sanchez-Mateos, Paloma/E-8931-2013	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425; CABAÑAS, CARLOS/0000-0002-8767-060X; Sanchez-Mateos, Paloma/0000-0001-6589-4445	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047607, R01GM047607] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERENDT AR, 1992, CELL, V14, P9; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Fava F, 1999, J CELL BIOL, V147, P857, DOI 10.1083/jcb.147.4.857; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Gavin RH, 1997, INT REV CYTOL, V173, P207; Gismondi A, 1997, J IMMUNOL, V159, P4729; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Moudjou M, 1996, J CELL SCI, V109, P875; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SANCHEZMATEOS P, 1993, EUR J IMMUNOL, V23, P2642, DOI 10.1002/eji.1830231038; Sancho D, 2000, J CELL BIOL, V149, P1249, DOI 10.1083/jcb.149.6.1249; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Sedwick CE, 1999, J IMMUNOL, V162, P1367; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; TURNER CE, 1990, J CELL BIOL, V111, P1058; Volkov Y, 1998, J IMMUNOL, V161, P6487; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	40	88	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26436	26440		10.1074/jbc.M003970200	http://dx.doi.org/10.1074/jbc.M003970200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840040	Green Published, hybrid			2022-12-27	WOS:000088999700077
J	Hsing, A; Faller, DV; Vaziri, C				Hsing, A; Faller, DV; Vaziri, C			DNA-damaging aryl hydrocarbons induce mdm2 expression via p53-independent post-transcriptional mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC GROWTH-FACTORS; MURINE 3T3 FIBROBLASTS; MESSENGER-RNA; P53; GENE; RECEPTOR; ADDUCTS; PROTEIN; TRANSACTIVATION; CARCINOGENESIS	During previous studies, we found that mdm2 mRNA levels were elevated in benzo[a]pyrene (BaP, a polycyclic aryl hydrocarbon)-treated cells under conditions of DNA damage-induced cell cycle arrest (Vaziri, C,, and Faller, D, V, (1997) J. Biol, Chem. 272, 2762-2769), We have identified potential aryl-hydrocarbon receptor-binding sites in the mdm2 promoter. However, we show that induction of mdm2 mRNA by BaP is entirely dependent upon aryl-hydrocarbon-induced genotoxicity and does not involve direct aryl-hydrocarbon receptor-mediated transcriptional activation of the mdm2 gene. Heterologous mdm2 promoter-reporter constructs containing p53-response elements were not responsive to BaP treatment. Therefore the p53-response elements in the mdm2 promoter are insufficient to confer DNA damage-dependent expression of mdm2, Furthermore, mdm2 transcripts were induced by BaP in p53 null cells from transgenic mice (although both basal and BaP-induced mdm2 expression levels were reduced in these cells relative to p53(+/+) cultures). These data show that p53-mediated mechanisms cannot account for BaP/DNA damage-induced mdma expression. Mdm2 promoter-reporter gene assays and nuclear run-off analyses of nascent mdm2 transcripts showed that transcriptional induction was unable to account for the large changes in mdma transcript levels following BaP treatment. However, mdm2 mRNA half-life measurements showed stabilization of the mdm2 transcript (from similar to 1 h to >4 h) in response to BaP, To our knowledge, this is the first report of control of mdma at the post-transcriptional level and in a p53-independent manner. Transient ectopic expression of mdm2 strongly augmented aryl-hydrocarbon-induced apoptosis, demonstrating that mdma levels can have a profound effect on the cellular response to DNA damage. Overall, our results suggest a potentially important link between DNA damage signaling and RNA stability that may be relevant to cell cycle regulation, tumor suppression, and environmental carcinogenesis.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Vaziri, C (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St, Boston, MA 02118 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R15ES005998] Funding Source: NIH RePORTER; NCI NIH HHS [CA50454] Funding Source: Medline; NIEHS NIH HHS [ES05998] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAUM EJ, 1978, POLYCYCLIC HYDROCARB, P45; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CONNEY AH, 1982, CANCER RES, V42, P4875; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007; JUVEN T, 1993, ONCOGENE, V8, P3411; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mastrangelo G, 1996, ENVIRON HEALTH PERSP, V104, P1166, DOI 10.2307/3432909; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PRICE BD, 1994, CANCER RES, V54, P896; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wu JX, 1999, MOL CELL BIOL, V19, P8292; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	32	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26024	26031		10.1074/jbc.M002455200	http://dx.doi.org/10.1074/jbc.M002455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856296	hybrid			2022-12-27	WOS:000088999700021
J	Moir, RD; Puglia, KV; Willis, IM				Moir, RD; Puglia, KV; Willis, IM			Interactions between the tetratricopeptide repeat-containing transcription factor TFIIIC131 and its ligand, TFIIIB70 - Evidence for a conformational change in the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; TFIIB-RELATED FACTOR; YEAST TFIIIB; ACETYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FUNCTIONAL DOMAINS; DNA COMPLEXES	In the transcription of tRNA and 5 S genes by RNA polymerase Ill, recruitment of the transcription factor (TF)IIIB is mediated by the promoter-bound assembly factor TFIIIC. A critical limiting step in this process is the interaction between the tetratricopeptide repeat (TPR)-containing subunit of TFIIIC (TFIIIC131) and the TFIIB-related factor Brf1p/TFIIIB70. To facilitate biochemical studies of this interaction, we expressed a fragment of TFIIIC131, TFIIIC131-(1-580), that includes the minimal TFIIIB70 interaction domain defined by two-hybrid studies together with adjacent sequences, up to the end of TPR9, implicated in the assembly reaction. TFIIIC131-(1-580) interacts with TFIIIB70 in solution and inhibits the formation of TFIIIB70 TFIIIC DNA complexes. In a coupled equilibrium binding assay, the formation of TFIIIC131-(1-580) TFIIIB70 complexes was adequately described by a single-site binding model and yielded an apparent equilibrium dissociation constant of 334 +/- 23 nM. CD spectroscopy and limited proteolysis experiments defined a well structured and largely protease-resistant core in TFIIIC131-(1-580) comprising part of the hydrophilic amino terminus, TPR1-5, the intervening non-TPR region, and TPR6-8, CD spectra showed that trifluoroethanol induced significant alpha-helical structure in TFIIIC131-(1-580). A more modest monovalent ion-dependent CD difference was observed in mixtures of TFIIIC131-(1-580) and TFIIIB70, suggesting that formation of the binary complex may proceed with the acquisition of alpha-helicity.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P217; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Persinger J, 1999, MOL CELL BIOL, V19, P5218; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SETHY I, 1995, J BIOL CHEM, V270, P28463; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WHITE RJ, 1998, RNA POLYMERASE 3 TRA, P82	42	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26591	26598		10.1074/jbc.M003991200	http://dx.doi.org/10.1074/jbc.M003991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859316	hybrid			2022-12-27	WOS:000088999700097
J	Phan, UT; Arunachalam, B; Cresswell, P				Phan, UT; Arunachalam, B; Cresswell, P			Gamma-interferon-inducible lysosomal thiol reductase (GILT) - Maturation, activity, and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; PROTEIN DISULFIDE-ISOMERASE; BETA-GALACTOSIDASE; ENDOPLASMIC-RETICULUM; CYSTEINE; ANTIGEN; EXPRESSION; MOLECULES; TRANSPORT; DEFECT	We recently identified a gamma-interferon-inducible lysosomal thiol reductase (GILT), constitutively expressed in antigen-presenting cells, that catalyzes disulfide bond reduction both in vitro and in vivo and is optimally active at acidic pH. GILT is synthesized as a 35-kDa precursor, and following delivery to major histocompatibility complex (MHC) class II-containing compartments (MIICs), is processed to the mature 30-kDa form via cleavage of N- and C-terminal propeptides. The generation of MHC class II epitopes requires both protein denaturation and reduction of intra- and interchain disulfide bonds prior to proteolysis. GILT may be important in disulfide bond reduction of proteins delivered to MIICs and consequently in antigen processing. In this report we show that, like its mature form, precursor GILT reduces disulfide bonds with an acidic pH optimum, suggesting that it may also be involved in disulfide bond reduction in the endocytic pathway. We also show that processing of precursor GILT can be mediated by multiple lysosomal proteases and provide evidence that the mechanism of action of GILT resembles that of other thiol oxidoreductases.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 310 Cedar St, New Haven, CT 06510 USA.			Arunachalam, Arun/0000-0001-6486-5722	NIAID NIH HHS [AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Arunachalam B, 1998, J IMMUNOL, V160, P5797; Chivers PT, 1998, PROLYL HYDROXYLASE P, P487; COLLINS DS, 1991, J IMMUNOL, V147, P4054; DAVIS JE, 1990, J IMMUNOL, V144, P990; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Gainey D, 1996, J CELL PHYSIOL, V168, P248, DOI 10.1002/(SICI)1097-4652(199608)168:2<248::AID-JCP3>3.0.CO;2-P; GILBERT HF, 1998, PROLYL HYDROXYLASE P, P341; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUNTER WM, 1964, BIOCHEM J, V91, P43, DOI 10.1042/bj0910043; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; Krepela E, 1999, BIOL CHEM, V380, P541, DOI 10.1515/BC.1999.069; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MEGO JL, 1985, BIOCHIM BIOPHYS ACTA, V841, P139, DOI 10.1016/0304-4165(85)90014-5; MERKEL BJ, 1995, J IMMUNOL, V154, P128; MOBBS CV, 1998, PROLYL HYDROXYLASE P, P237; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1990, J IMMUNOL, V144, P1849; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Woo JT, 1996, EUR J PHARMACOL, V300, P131, DOI 10.1016/0014-2999(95)00858-6; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; ZHANG SQ, 1994, BIOCHEM J, V304, P281, DOI 10.1042/bj3040281	37	156	160	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25907	25914		10.1074/jbc.M003459200	http://dx.doi.org/10.1074/jbc.M003459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852914	hybrid			2022-12-27	WOS:000088999700005
J	Solorzano, A; Rodriguez-Cousino, N; Esteban, R; Fujimura, T				Solorzano, A; Rodriguez-Cousino, N; Esteban, R; Fujimura, T			Persistent yeast single-stranded RNA viruses exist in vivo as genomic RNA center dot RNA polymerase complexes in 1 : 1 stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPHIOSTOMA-NOVO-ULMI; ELM DISEASE FUNGUS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MITOCHONDRIAL GENOME; HYPOVIRULENT STRAIN; MOLECULAR-CLONING; GENE-EXPRESSION; CELL-GROWTH; T-DSRNA	Yeast narnavirus 20 S and 23 S RNAs encode RNA-dependent RNA polymerases p91 and p104, respectively, but do not encode coat proteins. Both RNAs form ribonucleoprotein complexes with their cognate polymerases. Here we show that these complexes are not localized in mitochondria, unlike the closely related mitoviruses, which reside in these organelles. Cytoplasmic localization of these polymerases was demonstrated by immunofluorescence and by fluorescence emitted from green fluorescent protein-fused polymerases. These fusion proteins were able to form ribonucleoprotein complexes as did the wild-type polymerases. Fluorescent observations and cell fractionation experiments suggested that the polymerases were stabilized by complex formation with their viral RNA genomes. Immunoprecipitation experiments with anti-green fluorescent protein antibodies demonstrated that a single polymerase molecule binds to a single viral RNA genome in the complex. Moreover, the majority (if not all) of 20 S and 23 S RNA molecules were found to form complexes with their cognate RNA polymerases. Since these viral RNAs were not encapsidated, ribonucleoprotein complex formation with their cognate RNA polymerases appears to be their strategy to survive in the host as persistent viruses.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Avda Campo Ccharro S-N, Salamanca 37007, Spain.		Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014; Rodríguez-Cousiño, Nieves/K-6465-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Solorzano, Alicia/0000-0003-0072-3463				Ahmed Rafi, 1996, P207; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CHAN WKY, 1988, GENE, V73, P295, DOI 10.1016/0378-1119(88)90494-5; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Fernandez-Abalos JM, 1998, MOL MICROBIOL, V27, P121, DOI 10.1046/j.1365-2958.1998.00664.x; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1986, P NATL ACAD SCI USA, V83, P4433, DOI 10.1073/pnas.83.12.4433; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GarciaCuellar MP, 1997, RNA, V3, P27; GRIFFITHS AJF, 1995, MICROBIOL REV, V59, P673, DOI 10.1128/MMBR.59.4.673-685.1995; HARLAND R, 1988, DEVELOPMENT, V102, P837; Hong YG, 1999, VIROLOGY, V258, P118, DOI 10.1006/viro.1999.9691; Hong YG, 1998, VIROLOGY, V246, P158, DOI 10.1006/viro.1998.9178; ICHO T, 1988, J BIOL CHEM, V263, P1467; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; Koonin EV, 1992, SEMIN VIROL, V3, P327; Lakshman DK, 1998, P NATL ACAD SCI USA, V95, P6425, DOI 10.1073/pnas.95.11.6425; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Paquin B, 1997, CURR GENET, V31, P380, DOI 10.1007/s002940050220; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLASHOCK JJ, 1994, P NATL ACAD SCI USA, V91, P8680, DOI 10.1073/pnas.91.18.8680; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WICKNER RB, 1999, VIRUS TAXONOMY, P651	46	19	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26428	26435		10.1074/jbc.M002281200	http://dx.doi.org/10.1074/jbc.M002281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833519	hybrid			2022-12-27	WOS:000088999700076
J	Takemoto, L; Boyle, D				Takemoto, L; Boyle, D			Specific glutamine and asparagine residues of gamma-S crystallin are resistant to in vivo deamidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A CRYSTALLIN; HUMAN LENS	It has been hypothesized that resistance to nonenzymatic deamidation of asparagine and glutamine residues may be an important determinant of protein stability in vivo, As a test of this hypothesis, we analyzed the central region of old human lenses, which contain proteins such as gamma-S crystallin that were synthesized during the fetal-embryonic periods of development. Total protein from the fetal embryonic region of old human lenses was digested with trypsin, followed by resolution of tryptic fragments containing amidated and deamidated forms using high pressure liquid chromatography-reverse phase chromatography together with synthetic peptide standards and mass spectral analysis. The results demonstrate no detectable deamidation of glutamine 92, glutamine 96, asparagine 143, and glutamine 170 from gamma-S crystallin from old human lenses, consistent with the hypothesis that very long-lived pro proteins can contain asparagine and glutamine residues that are extremely resistant to in vivo deamidation.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Takemoto, L (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.				NEI NIH HHS [2 RO1 EY02932-19] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002932] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GUO D, 1987, J CHROMATOGR, V386, P205; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; Robinson A.B., 1974, CURR TOP CELL REGUL, V8, P248; Shestopalov VI, 2000, J CELL SCI, V113, P1913; Takemoto L, 1998, EXP EYE RES, V67, P119, DOI 10.1006/exer.1998.0529; Takemoto L, 1998, BIOCHEMISTRY-US, V37, P13681, DOI 10.1021/bi981542k; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Xie ML, 1999, J PHARM SCI, V88, P8, DOI 10.1021/js9802493; ZARINA S, 1994, PROTEIN SCI, V3, P1840, DOI 10.1002/pro.5560031023	11	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26109	26112		10.1074/jbc.M002809200	http://dx.doi.org/10.1074/jbc.M002809200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843993	hybrid			2022-12-27	WOS:000088999700032
J	Bhattacharyya, A; Ear, US; Koller, BH; Weichselbaum, RR; Bishop, DK				Bhattacharyya, A; Ear, US; Koller, BH; Weichselbaum, RR; Bishop, DK			The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; STRAND EXCHANGE; NUCLEAR FOCI; RADIATION HYPERSENSITIVITY; RECOMBINATION PROTEIN; EMBRYONIC LETHALITY; OVARIAN-CANCER; IN-VIVO	Mutations in breast cancer tumor susceptibility genes, BRCA1 and BRCA2, predispose women to early onset breast cancer and other malignancies. The Brca genes are involved in multiple cellular processes in response to DNA damage including checkpoint activation, gene transcription, and DNA repair. Biochemical interaction with the recombinational repair protein Rad51 (Scully, R., Chen, J., Ochs, R. L., Keegan, M., Hoekstra, M., Feunteun, J., and Livingston, D. M. (1997) Cell 90, 425-435), as well as genetic evidence (Moynahan, M. E., Chiu, J.W., holler, B. H., and Jasin, M. (1999) Mol. Cell 4, 511-818 and Snouwaert, J. N., Gowen, L. C., Latour, A. M., Mohn, A. R., Xiao, A., DiBiase, L., and Roller, B. H. (1999) Oncogene 18, 7900-7907), demonstrates that Brca1 is involved in recombinational repair of DNA double strand breaks. Using isogenic Brca1(+/+) and brca1(-/-) mouse embryonic stem (ES) cell lines, we investigated the rob of Brca1 in the cellular response to two different categories of DNA damage: x-ray induced damage and cross-linking damage caused by the chemotherapeutic agent, cisplatinum, Immunoflourescence studies with normal and brca1(-/-) mutant mouse ES cell lines indicate that Brca1 promotes assembly of subnuclear Rad51 foci following both types of DNA damage. These foci are likely to be oligomeric complexes of Rad51 engaged in repair of DNA lesions or in processes that allow cells to tolerate such lesions during DNA replication. Clonogenic assays show that brca1(-/-) mutants are 5-fold more sensitive to cisplatinum compared with wild-type cells. Our studies suggest that Brca1 contributes to damage repair and/or tolerance by promoting assembly of Rad51. This function appears to be shared with Brca2.	Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Chicago; University of Chicago Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Bishop, DK (corresponding author), Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Room O-055,5841 S Maryland Ave,MC1105, Chicago, IL 60637 USA.							Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; ANDERSON D, 1995, MUTAT RES-FUND MOL M, V330, P115, DOI 10.1016/0027-5107(95)00039-L; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; FRAVAL HNA, 1978, CHEM-BIOL INTERACT, V23, P99, DOI 10.1016/0009-2797(78)90044-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoffmann JS, 1997, J MOL BIOL, V270, P539, DOI 10.1006/jmbi.1997.1143; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Husain A, 1998, CANCER RES, V58, P1120; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KADYK LC, 1992, GENETICS, V132, P387; KADYK LC, 1993, GENETICS, V133, P469; KOHN KW, 1977, CANCER RES, V37, P1450; Larson JS, 1997, CANCER RES, V57, P3351; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; SHOUWAERT JN, 1999, ONCOGENE, V18, P7900; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; TONG WP, 1982, CANCER RES, V42, P3102; Wang Y, 2000, GENE DEV, V14, P927; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	470	496	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23899	23903		10.1074/jbc.C000276200	http://dx.doi.org/10.1074/jbc.C000276200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10843985	Green Published, hybrid			2022-12-27	WOS:000088564200068
J	Schaefer, M; Plant, TD; Obukhov, AG; Hofmann, T; Gudermann, T; Schultz, G				Schaefer, M; Plant, TD; Obukhov, AG; Hofmann, T; Gudermann, T; Schultz, G			Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; LIGHT-SENSITIVE CHANNELS; CURRENT I-CRAC; STORE DEPLETION; CA2+ ENTRY; G-PROTEIN; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; HEK293 CELLS	Mammalian transient receptor potential channels (TRPCs) form a family of Ca2+-permeable cation channels currently consisting of seven members, TRPC1-TRPC7. These channels have been proposed to be molecular correlates for capacitative Ca2+ entry channels. There are only a few studies on the regulation and properties of the subfamily consisting of TRPC4 and TRPC5, and there are contradictory reports concerning the possible role of intracellular Ca2+ store depletion in channel activation. We therefore investigated the regulatory and biophysical properties of murine TRPC4 and TRPC5 (mTRPC4/5) heterologously expressed in human embryonic kidney cells. Activation of G(q/11)-coupled receptors or receptor tyrosine kinases induced Mn2+ entry in fura-2-loaded mTRPC4/5-expressing cells. Accordingly, in whole-cell recordings, stimulation of G(q/11)-coupled receptors evoked large, nonselective cation currents, an effect mimicked by infusion of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). However, depletion of intracellular Ca2+ stores failed to activate mTRPC4/5, In inside-out patches, single channels with conductances of 42 and 66 picosiemens at -60 mV for mTRPC4 and mTRPC5, respectively, were stimulated by GTP gamma S in a membrane-confined manner. Thus, mTRPC4 and mTRPC5 form nonselective cation channels that integrate signaling pathways from G-protein-coupled receptors and receptor tyrosine kinases independently of store depletion. Furthermore, the biophysical properties of mTRPC4/5 are inconsistent with those of I-crac the most extensively characterized store-operated current.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	gschultz@zedat.fu-berlin.de	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004				Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; Inoue Ryuji, 1998, Journal of Smooth Muscle Research, V34, P69; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Otsuka Y, 1998, TOHOKU J EXP MED, V185, P139, DOI 10.1620/tjem.185.139; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	39	330	344	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17517	17526		10.1074/jbc.275.23.17517	http://dx.doi.org/10.1074/jbc.275.23.17517			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837492	hybrid			2022-12-27	WOS:000087485000044
J	Zaffran, Y; Meyer, SC; Negrescu, E; Reddy, KB; Fox, JEB				Zaffran, Y; Meyer, SC; Negrescu, E; Reddy, KB; Fox, JEB			Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha(IIb)beta(3) activation both in platelets and a transfected Chinese hamster ovary cell system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ACTIN-BINDING PROTEIN; VONWILLEBRAND-FACTOR BINDING; GP-IIB-IIIA; MEMBRANE SKELETON; CYTOPLASMIC DOMAIN; SHEAR-STRESS; THROMBUS FORMATION; TYROSINE KINASE; COMPLEX	In platelets, alpha(IIb)beta(3) exists in a form that cannot bind adhesive proteins in the plasma; although it can interact with immobilized fibrinogen it cannot interact with immobilized von Willebrand factor in the vessel wall. Soluble agonists such as thrombin convert alpha(IIb)beta(3) to a form that recognizes soluble and immobilized ligands. Attempts to reconstitute alpha(IIb)beta(3) activation in a non-hematopoietic, nucleated cell system have been unsuccessful. In the present study, we have developed a transfected Chinese hamster ovary cell model in which alpha(IIb)beta(3) activation is induced by signaling across glycoprotein (GP) Ib-IX by its ligand, von Willebrand factor. GPIb-IX activates not only the transfected alpha(IIb)beta(3) but also endogenous alpha(V)beta(3). Activation of the pathways leading to integrin activation occurred even in cells transfected with GPIb-IX lacking the domain on GPIb alpha that binds 14-3-3 or that which binds actin-binding protein. These studies demonstrate that signals induced by interaction of GPIb-IX with von Willebrand factor lead to alpha(IIb)beta(3) activation and suggest that the signaling pathways by which GPIb-IX induces alpha(IIb)beta(3) activation are different to those used by thrombin. Elucidation of these differences may provide insights into therapeutic ways in which to inhibit integrin activation in selective clinical settings.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R01HL056264, R37HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; CHOW TW, 1992, BLOOD, V80, P113; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, THROMB DIATH HAEMO, P170; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; Giblin PA, 1997, J IMMUNOL, V159, P3498; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Kroll MH, 1996, BLOOD, V88, P1525; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; READ MS, 1989, BLOOD, V74, P1031; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; WEISS HJ, 1986, BLOOD, V67, P322	52	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16779	16787		10.1074/jbc.275.22.16779	http://dx.doi.org/10.1074/jbc.275.22.16779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828063	hybrid			2022-12-27	WOS:000087392200055
J	Tu, G; Kirchmaier, AL; Liggitt, D; Liu, Y; Liu, SQ; Yu, WH; Heath, TD; Thor, A; Debs, RJ				Tu, G; Kirchmaier, AL; Liggitt, D; Liu, Y; Liu, SQ; Yu, WH; Heath, TD; Thor, A; Debs, RJ			Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE GROWTH TRANSFORMATION; CYTOTOXIC T-LYMPHOCYTES; FIREFLY LUCIFERASE GENE; LONG-TERM EXPRESSION; NUCLEAR ANTIGEN-1; TRANSGENE EXPRESSION; SKELETAL-MUSCLE; MAMMALIAN-CELLS; VECTOR; MICE	To date, no gene transfer vector has produced prolonged gene expression following a single intravenous injection and then efficiently re-expressed the delivered gene following repeated systemic injection into immunocompetent hosts. To overcome these limitations, a gene therapy regimen using non-replicating Epstein-Barr virus (EBV)-based expression plasmids was developed. One plasmid contains the FR (EBV family of repeats) sequence and the expressed gene. The other encodes Epstein-Barr nuclear antigen 1 (EBNA-1), but lacks FR. Although unable to replicate in mice, intravenous co-injection of EBV-based plasmids in cationic liposome-DNA complexes (CLDCs) substantially prolonged luciferase gene expression. The use of a two-vector system limited host exposure to the EBNA-1 gene product. Furthermore, this EBV-based vector system could be intravenously re-injected multiple times into immunocompetent mice without loss of transfection efficiency. Use of this vector system significantly improved the therapeutic efficacy of the biologically important human granulocyte colony-stimulating factor gene. Delivery of the human granulocyte colony-stimulating factor gene in EBV-based plasmids increased circulating white blood counts for at least 2 months following a single CLDC-based intravenous co-injection. Conversely, white blood counts were never elevated following injection of CLDCs lacking EBV-derived elements. Thus, this EBV-based plasmid vector system both markedly prolongs gene expression at therapeutic levels and efficiently and repeatedly re-transfects immunocompetent hosts. These properties of EBV-based plasmid vectors appear to be due, at least in part, to the documented abilities of the EBNA-1 protein both to retain FR-containing DNA intracellularly and within the nucleus and to block anti-EBNA-1 cytotoxic T cell responses.	Calif Pacific Med Res Inst, San Francisco, CA 94115 USA; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Northwestern Univ, Sch Med, Dept Pathol, Evanston, IL 60201 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Wisconsin System; University of Wisconsin Madison; University of Washington; University of Washington Seattle; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Debs, RJ (corresponding author), Calif Pacific Med Res Inst, 2330 Clay St, San Francisco, CA 94115 USA.		Liu, Shu Q/B-7626-2009	Kirchmaier, Ann/0000-0001-9938-9105	NCI NIH HHS [CA07175, R01 CA82575, CA22443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082575, P30CA007175, P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bicknell R, 1992, Semin Cancer Biol, V3, P399; Bonham L, 1996, HUM GENE THER, V7, P1423, DOI 10.1089/hum.1996.7.12-1423; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; Clark KR, 1997, HUM GENE THER, V8, P659, DOI 10.1089/hum.1997.8.6-659; Cooper MJ, 1997, P NATL ACAD SCI USA, V94, P6450, DOI 10.1073/pnas.94.12.6450; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038/bjc.1982.16; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; Goddard CA, 1997, GENE THER, V4, P1231, DOI 10.1038/sj.gt.3300515; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JANKELEVICH S, 1992, EMBO J, V11, P1165, DOI 10.1002/j.1460-2075.1992.tb05157.x; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; KIRCHMAIER AL, 2000, EBV PROTOCOLS; KIRCHMAIER AL, 1997, THESIS U WISCONSIN M; KRYSAN PJ, 1993, GENE, V136, P137, DOI 10.1016/0378-1119(93)90457-E; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; Langle-Rouault F, 1998, J VIROL, V72, P6181; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu Y, 1999, J BIOL CHEM, V274, P13338, DOI 10.1074/jbc.274.19.13338; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; Mittal SK, 1996, J GEN VIROL, V77, P1, DOI 10.1099/0022-1317-77-1-1; MITTAL SK, 1993, VIRUS RES, V28, P67, DOI 10.1016/0168-1702(93)90090-A; Mizuguchi H, 2000, FEBS LETT, V472, P173, DOI 10.1016/S0014-5793(00)01450-2; Mukherjee S, 1998, J EXP MED, V187, P445, DOI 10.1084/jem.187.3.445; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Saeki Y, 1998, GENE THER, V5, P1031, DOI 10.1038/sj.gt.3300711; SCHIRMBECK R, 1992, EUR J IMMUNOL, V22, P759, DOI 10.1002/eji.1830220320; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; SOLDEVILA G, 1995, J IMMUNOL, V155, P5590; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WU GY, 1991, J BIOL CHEM, V266, P14338; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	58	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30408	30416		10.1074/jbc.M004782200	http://dx.doi.org/10.1074/jbc.M004782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10856307	hybrid			2022-12-27	WOS:000089577900067
J	Huber, MD; Dworet, JH; Shire, K; Frappier, L; McAlear, MA				Huber, MD; Dworet, JH; Shire, K; Frappier, L; McAlear, MA			The budding yeast homolog of the human EBNA1-binding protein 2 (Ebp2p) is an essential nucleolar protein required for pre-rRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; CELLS; DNA; RIBONUCLEOPROTEIN; IDENTIFICATION; LOCALIZATION; REPLICATION; BIOGENESIS	The human EBP2 protein was found by two-hybrid analysis to interact with the Epstein-Barr virus nuclear antigen 1 (EBNA1), Homologs of human EBP2 can be found in Caenorhabditis elegans, Schizosaccharomyces pombe, and in Saccharomyces cerevisiae, and they all share a conserved 200-300-amino acid block of residues at their C termini, To understand the cellular function of EBP2, we have begun to study the protein in S. cerevisiae, The yeast Ebp2 protein contains N-terminal, nucleolar-associated KKE motifs, and deletion analysis reveals that the C-terminal conserved region is required for the activity of the protein. The EBP2 gene codes for an essential protein that localizes to the nucleolus. Temperature-sensitive ebp2-1 mutants become depleted of ribosomes and cease to divide after several generations at the restrictive temperature of 36 degrees C. This decline in ribosome levels is accompanied by a diminution in the levels of the 35 S-derived recombinant RNAs (rRNAs) (in particular the 25 S and 5.8 S rRNAs), Pulse-chase, Northern, and primer extension analysis of the rRNA biosynthetic pathway indicates that ebp2-1 mutants are defective in processing the 27 SA precursor into the 27 SE pre-rRNA.	Wesleyan Univ, Mol Biol & Biochem Dept, Middletown, CT 06459 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Wesleyan University; University of Toronto	McAlear, MA (corresponding author), Wesleyan Univ, Mol Biol & Biochem Dept, Middletown, CT 06459 USA.	mmcalear@wesleyan.edu	Huber, Michael/C-4176-2008					ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHATTERJEE A, 1987, CANCER RES, V47, P1123; Clarke EM, 1996, J BIOL CHEM, V271, P22189, DOI 10.1074/jbc.271.36.22189; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P565; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Moore DD, 1995, GLOB MOB SURV; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7026, DOI 10.1073/pnas.88.16.7026; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; Sherman F., 1986, METHODS YEAST GENETI; Shire K, 1999, J VIROL, V73, P2587, DOI 10.1128/JVI.73.4.2587-2595.1999; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS A, 1995, J BIOL CHEM, V270, P16063, DOI 10.1074/jbc.270.27.16063; Stolc V, 1998, P NATL ACAD SCI USA, V95, P6716, DOI 10.1073/pnas.95.12.6716; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	33	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28764	28773		10.1074/jbc.M000594200	http://dx.doi.org/10.1074/jbc.M000594200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10849420	hybrid			2022-12-27	WOS:000089330700058
J	Oda, Y; Nakayama, K; Abdul-Rahman, B; Kinoshita, M; Hashimoto, O; Kawasaki, N; Hayakawa, T; Kakehi, K; Tomiya, N; Lee, YC				Oda, Y; Nakayama, K; Abdul-Rahman, B; Kinoshita, M; Hashimoto, O; Kawasaki, N; Hayakawa, T; Kakehi, K; Tomiya, N; Lee, YC			Crocus sativus lectin recognizes Man(3)GlcNAc in the N-glycan core structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING SPECIFICITY; CONCANAVALIN-A; LINKED OLIGOSACCHARIDES; TRIMANNOSIDE; CELLS; THERMODYNAMICS; EUROPIUM; BULBS	Crocus sativus lectin (CSL) is one of the truly mannose-specific plant lectins that has a unique binding specificity that sets it apart from others. We studied sugar-binding specificity of CSL in detail by a solution phase method (fluorescence polarization) and three solid phase methods (flow injection, surface plasmon resonance, and microtiter plate), using a number of different glycopeptides and oligosaccharides. CSL binds the branched mannotriose structure in the N-glycan core. Substitution of the terminal Man in the Man alpha(1-3)Man branch with GlcNAc drastically decreases binding affinity much more than masking of the terminal Man in the Man alpha(l-G)Man branch, Most interestingly, the beta-Man-linked GlcNAc in N-glycan core structure contributes greatly to the binding. The effect of this GlcNAc is so strong that it can substantially offset the negative effect of substitution on the nonreducing terminal Man residues. On the other hand, the GlcNAc that is usually attached to Asn in N-glycans and the L-FUC linked at the 6-position of the GlcNAc are irrelevant to the binding. A bisecting GlcNAc neither contributes to nor interferes with the binding. This unique binding specificity of CSL offers many possibilities of its use in analytical and preparative applications.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Kinki Univ, Fac Pharmaceut Sci, Higashiosaka, Osaka 2778502, Japan; Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, Tokyo 1588501, Japan	Johns Hopkins University; Kindai University (Kinki University); National Institute of Health Sciences - Japan	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.							ALONSO JM, 1988, EUR J BIOCHEM, V177, P187, DOI 10.1111/j.1432-1033.1988.tb14361.x; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; CAMILLERI P, 1995, ANAL BIOCHEM, V230, P115, DOI 10.1006/abio.1995.1445; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; DUBOIS M, 1956, ANAL CHEM, V28, P356; FAN JQ, 1994, ANAL BIOCHEM, V219, P375, DOI 10.1006/abio.1994.1280; FREDERICQ E, 1949, J BIOL CHEM, V181, P499; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; Kato I, 1976, PROTIDES BIOL FLUIDS, V23, P235; Kawasaki N, 1997, ANAL BIOCHEM, V250, P260, DOI 10.1006/abio.1997.2233; LEE YC, 1969, ANAL BIOCHEM, V27, P559, DOI 10.1016/0003-2697(69)90070-0; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MINOBE S, 1979, J BIOCHEM-TOKYO, V86, P1851, DOI 10.1093/oxfordjournals.jbchem.a132707; Misaki A, 1997, J BIOL CHEM, V272, P25455, DOI 10.1074/jbc.272.41.25455; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Oda Y, 1997, ANAL BIOCHEM, V254, P41, DOI 10.1006/abio.1997.2396; Oda Y, 1999, ANAL BIOCHEM, V269, P230, DOI 10.1006/abio.1999.4020; Oda Y, 1998, BIOL PHARM BULL, V21, P1215; ODA Y, 1993, BIOL PHARM BULL, V16, P978; ODA Y, 1997, B PHARM RES TECHNOL, V6, P45; PARENTE JP, 1982, J CHROMATOGR, V249, P199, DOI 10.1016/S0021-9673(00)80250-2; PARENTE JP, 1982, J BIOL CHEM, V275, P13173; QI XY, 1988, ANAL BIOCHEM, V175, P139, DOI 10.1016/0003-2697(88)90371-5; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1	30	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26772	26779						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837483				2022-12-27	WOS:000089144800016
J	Wang, Y; Shen, JS; Arenzana, N; Tirasophon, W; Kaufman, RJ; Prywes, R				Wang, Y; Shen, JS; Arenzana, N; Tirasophon, W; Kaufman, RJ; Prywes, R			Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; FAMILIAL ALZHEIMERS-DISEASE; CCAAT REGULATORY ELEMENT; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; INTRACELLULAR DOMAIN; MISSENSE MUTATIONS; GRP78/BIP PROMOTER; NUCLEAR ACCESS	ATF6 is a member of the basic-leucine zipper family of transcription factors. It contains a transmembrane domain and is located in membranes of the endoplasmic reticulum, ATF6 has been implicated in the endoplasmic reticulum (ER) stress response pathway since it can activate expression of GRP78 and other genes induced by the ER stress response. ER stress appears to activate ATF6 by cleavage from the ER membrane and translocation to the nucleus, However, direct DNA binding by ATF6 had not been demonstrated. In this report, we have identified a consensus DNA binding sequence for ATF6. This site is related to but distinct from ATF1/CREB binding sites. The site was placed in a reporter gene and was specifically activated by ATF6 overexpression and was strongly induced by the ER stress response. A dominant negative form of ATF6 blocked ER stress induction of both ATF6 site and GRP78 reporter genes. We further found that GAL4-ATF6 could be activated by ER stress. These results demonstrate that ATF6 is a direct target of the ER stress response. A proximal sensor of the ER stress response, human IRE1 (hIRE1), was sufficient to activate the ATF6 reporter gene, while a dominant negative form of hIRE1 blocked ER stress activation, suggesting that: hIRE1 is upstream of ATF6 in the ER stress signaling pathway.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Columbia University; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420,1212 Amsterdam Ave, New York, NY 10027 USA.		Longo, Kenneth A/A-5631-2010	SHEN, JINGSHI/0000-0001-9595-1148	NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MORI K, 1993, CELL, V74, P743; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROY B, 1995, MOL CELL BIOL, V15, P2263; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	44	418	447	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27013	27020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856300				2022-12-27	WOS:000089144800047
J	Liu, HG; Palmer, D; Jimmo, SL; Tilley, DG; Dunkerley, HA; Pang, SC; Maurice, DH				Liu, HG; Palmer, D; Jimmo, SL; Tilley, DG; Dunkerley, HA; Pang, SC; Maurice, DH			Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways - A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; VASCULAR SMOOTH-MUSCLE; JURKAT T-CELLS; NUCLEOTIDE PHOSPHODIESTERASE; SELECTIVE-INHIBITION; ADENOSINE-MONOPHOSPHATE; RECEPTOR AGONISTS; MESSENGER-RNA; RAT AORTA; PHOSPHORYLATION	Multiple families of cyclic nucleotide phosphodiesterases (PDE) have been described, and the regulated expression of these genes in cells is complex. Although cAMP is known to control the expression of certain PDE in cells, presumably reflecting a system of feedback on cAMP signaling, relatively little is known about the influence of non-cAMP signaling systems on PDE expression. In this study, we describe a novel mechanism by which activators of the protein kinase C (PKC)-Raf-MEK-ERK cascade regulate phosphodiesterase 4D (PDE4D) expression in vascular smooth muscle cells (VSMC) and assess the functional consequences of this effect. Whereas a prolonged elevation of cAMP in VSMC resulted in a protein kinase A (PHA)-dependent induction of expression of two PDE4D variants (PDE4D1 and PDE4D2), simultaneous activation of both the cAMP/-PKA and PRC-Raf-MER-ERK signaling cascades blunted this cAMP-mediated increase in PDE4D expression. By using biochemical, molecular biological, and pharmacological approaches, we demonstrate that this PDE4D-selective effect of activators of the PKC-Raf-MEK-ERK cascade was mediated through a mechanism involving altered PDE4D mRNA stability and markedly attenuated the cAMP-mediated desensitization that results from prolonged activation of the cAMP signaling system in cells. The data are presented in the context of activators of the PKC-Raf-MEK-ERK cascade having both short and long term effects on PDE4D activity and expression in cells that may influence cAMP signaling.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Maurice, DH (corresponding author), Queens Univ, Dept Pathol, Botterell Hall,A221, Kingston, ON K7L 3N6, Canada.	Mauriced@post.queensu.ca	Palmer, Daniel/J-2967-2014; Palmer, Daniel/Q-7595-2016; Maurice, Donald/AAE-9332-2019	Palmer, Daniel/0000-0002-7954-9332; Palmer, Daniel/0000-0002-7954-9332; Tilley, Douglas/0000-0002-9681-3377				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Erdogan S, 1997, BIOCHEM J, V321, P165, DOI 10.1042/bj3210165; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; HARTZELMANN A, 1996, HDB IMMUNOPHARMACOLO, P147; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Johnson-Mills K, 1998, BIOCHEM PHARMACOL, V56, P1065, DOI 10.1016/S0006-2952(98)00239-1; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; KOMAS N, 1991, BRIT J PHARMACOL, V104, P495, DOI 10.1111/j.1476-5381.1991.tb12457.x; Kostic MM, 1997, J MOL CELL CARDIOL, V29, P3135, DOI 10.1006/jmcc.1997.0544; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; MAURICE DH, 1990, EUR J PHARMACOL, V191, P471, DOI 10.1016/0014-2999(90)94182-W; MAURICE DH, 1991, EUR J PHARMACOL, V192, P235, DOI 10.1016/0014-2999(91)90048-U; MAURICE DH, 1993, ANAL BIOCHEM, V215, P110, DOI 10.1006/abio.1993.1562; Mehats C, 2000, J PHARMACOL EXP THER, V292, P817; Mehats C, 1999, ENDOCRINOLOGY, V140, P3228, DOI 10.1210/en.140.7.3228; Movsesian MA, 1999, J AM COLL CARDIOL, V34, P318, DOI 10.1016/S0735-1097(99)00220-X; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; Palmer D, 1998, CIRC RES, V82, P852; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; RASCON A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P149, DOI 10.1016/0167-4889(92)90038-D; Rose RJ, 1997, BRIT J PHARMACOL, V122, P233, DOI 10.1038/sj.bjp.0701376; Rybalkin SD, 1997, J CLIN INVEST, V100, P2611, DOI 10.1172/JCI119805; SCHOEFFTER P, 1987, BIOCHEM PHARMACOL, V36, P3965, DOI 10.1016/0006-2952(87)90465-5; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; SOUNESS JE, 1992, BIOCHEM PHARMACOL, V44, P857, DOI 10.1016/0006-2952(92)90116-Z; Spence S, 1997, BIOCHEM J, V321, P157, DOI 10.1042/bj3210157; SPENCE S, 1995, BIOCHEM J, V310, P975, DOI 10.1042/bj3100975; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9	48	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26615	26624		10.1074/jbc.M001634200	http://dx.doi.org/10.1074/jbc.M001634200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851231	hybrid			2022-12-27	WOS:000088999700100
J	Zhuang, SG; Demirs, JT; Kochevar, IE				Zhuang, SG; Demirs, JT; Kochevar, IE			p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OXIDATIVE STRESS; HL-60 CELLS; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; ENDOTHELIAL-CELLS; DEATH RECEPTORS; PATHWAY; FAS	p38 mitogen-activated protein kinase is activated and involved in cleavage of caspase-3 during apoptosis induced by a number of stimuli. However, the signaling events triggered by p38 that result in caspase-3 activation are still unknown. In human leukemia cells, two reactive oxygen species, singlet oxygen and hydrogen peroxide (H2O2), selectively stimulated the phosphorylation of p38, Preincubation of cells with SB203580, a specific inhibitor of p38, dose dependently inhibited DNA fragmentation induced by singlet oxygen but not by H2O2. Protection from apoptosis by SB203580 correlated with inhibition of caspase-3, and several events that are associated with caspase-3 activation, including Bid cleavage, decrease in mitochondrial transmembrane potential and release of cytochrome c from mitochondria, whereas caspase-8 cleavage was not affected by this inhibitor. In contrast, blockade of caspase-8 with Ile-Glu-Thr-Asp-fluoromethyl ketone is sufficient to prevent formation of DNA fragments and to inhibit all the above signaling events, with exception of p38 phosphorylation, in both singlet oxygen- and H2O2-treated cells. These data suggest that caspase-3 activation is regulated through redundant signaling pathways that involve p38 and caspase-8 acting upstream of Bid during singlet oxygen-induced apoptosis, whereas the activation of caspase-3 by H2O2 is only governed by a caspase-8-mediated apoptotic pathway.	Harvard Univ, Wellman Labs Photomed, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Wellman Labs Photomed, Sch Med, Massachusetts Gen Hosp, WEL-224,55 Fruit St, Boston, MA 02114 USA.				NIGMS NIH HHS [GM 30955] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cook SA, 1999, CIRC RES, V85, P940; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hale KK, 1999, J IMMUNOL, V162, P4246; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Herrmann JL, 1996, BIOCHEM SOC T, V24, P1059, DOI 10.1042/bst0241059; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KANOFSKY JR, 1991, PHOTOCHEM PHOTOBIOL, V53, P93, DOI 10.1111/j.1751-1097.1991.tb08472.x; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kyriakis JM, 1999, GENE EXPRESSION, V7, P217; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; Poynter ME, 1999, FREE RADICAL BIO MED, V27, P1164, DOI 10.1016/S0891-5849(99)00202-6; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Suhara T, 1998, J IMMUNOL, V160, P4042; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Umansky V, 2000, INT J ONCOL, V16, P109; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhuang SG, 1998, FEBS LETT, V437, P158, DOI 10.1016/S0014-5793(98)01222-8; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501	56	241	251	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25939	25948		10.1074/jbc.M001185200	http://dx.doi.org/10.1074/jbc.M001185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10837470	hybrid			2022-12-27	WOS:000088999700010
J	Thirunavukkarasu, K; Halladay, DL; Miles, RR; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE				Thirunavukkarasu, K; Halladay, DL; Miles, RR; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE			The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; RUNT HOMOLOGY DOMAIN; CLEIDOCRANIAL DYSPLASIA; OSTEOCALCIN GENE; PARATHYROID-HORMONE; FACTOR OSF2/CBFA1; BONE-RESORPTION; DNA-BINDING; IN-VITRO; T-CELLS	Bone formation and resorption are tightly coupled under normal conditions, and the interaction of osteoclast precursors with cells of the osteoblast lineage is a prerequisite for osteoclast formation. Cbfa1 is an osteoblast-specific transcription factor that is essential for osteoblast differentiation and bone formation. At present, it is not known whether Cbfa1 regulates any of the osteoblast-derived factors involved in the bone resorption pathway. Osteoprotegerin (OPG) is an osteoblast-secreted glycoprotein that functions as a potent inhibitor of osteoclast differentiation and bone resorption, Cloning and computer analysis of a 5,9-kilobase human OPG promoter sequence revealed the presence of 12 putative Cbfa1 binding elements (osteoblast-specific element 2 (OSE2)), suggesting a possible regulation of OPG by Cbfa1, We cloned the promoter upstream of the beta-galactosidase reporter gene (pOPGEi.Bpgal) and evaluated whether Cbfa1 could regulate its expression in transient transfection assays. The 5,9-kilobase promoter directed increased levels of reporter gene expression, reminiscent of OPG protein levels in osteoblastic cell lines (BALC and U2OS) as compared with the nonosteoblastic cell line COS1, Cotransfection of a Cbfa1 expression construct along with pOPG5.9 beta gal reporter construct led to 39-, 7-, and 16-fold increases in beta-galactosidase activity in COS1, BALC, and U2OS cells, respectively. Removal of all the putative OSE2 elements led to an almost complete loss of transactivation, Mutational analysis demonstrated that the proximal OSE, element contributes to a majority of the effects of Cbfa1, and Cbfa1 bound to the proximal element in a sequence-specific manner. Further, overexpression of Cbfa1 led to a 54% increase in OPG protein levels in U2OS cells. These results indicate that Cbfa1 regulates the expression of OPG, thereby further contributing to a molecular link between bone formation and resorption.	Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Eli Lilly; St. Vincent's Institute of Medical Research	Onyia, JE (corresponding author), Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Drop Code 0403, Indianapolis, IN 46285 USA.	JEO@lilly.com						Akatsu T, 1998, BONE, V23, P495, DOI 10.1016/S8756-3282(98)00141-0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Galvin RJS, 1998, BONE, V23, P233, DOI 10.1016/S8756-3282(98)00096-9; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hakeda Y, 1998, BIOCHEM BIOPH RES CO, V251, P796, DOI 10.1006/bbrc.1998.9523; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; John V, 1996, ENDOCRINOLOGY, V137, P2457, DOI 10.1210/en.137.6.2457; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Morinaga T, 1998, EUR J BIOCHEM, V254, P685, DOI 10.1046/j.1432-1327.1998.2540685.x; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagai M, 1999, BIOCHEM BIOPH RES CO, V257, P719, DOI 10.1006/bbrc.1999.0524; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; OBRIEN CA, 1998, BONE, V23, pS149; Onyia JE, 2000, J BONE MINER RES, V15, P863, DOI 10.1359/jbmr.2000.15.5.863; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Thirunavukkarasu K, 2000, BIOTECHNIQUES, V28, P506, DOI 10.2144/00283st09; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	47	158	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25163	25172		10.1074/jbc.M000322200	http://dx.doi.org/10.1074/jbc.M000322200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833509	hybrid			2022-12-27	WOS:000088849400018
J	Zhang, BL; Zhang, YQ; Wang, ZX; Zheng, Y				Zhang, BL; Zhang, YQ; Wang, ZX; Zheng, Y			The role of Mg2+ cofactor in the guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVATING PROTEINS; GTPASES CDC42; CELL-ADHESION; RAS; DBL; FINGER; ANALOG; RAC1; CYTOSKELETON	The biological activities of Rho family GTPases are controlled by their guanine nucleotide binding states in cells. Here we have investigated the role of Mg2+ cofactor in the guanine nucleotide binding and hydrolysis processes of the Rho family members, Cdc42, Rad, and RhoA. Differing from Ras and Rab proteins, which require Mg2+ for GDP and GTP binding, the Rho GTPases bind the nucleotides in the presence or absence of Mg2+ similarly, with dissociation constants in the submicromolar concentration. The presence of Mg2+, however, resulted in a marked decrease in the intrinsic dissociation rates of the nucleotides. The catalytic activity of the guanine nucleotide exchange factors (GEFs) appeared to be negatively regulated by free Mg2+, and GEF binding to Rho GTPase resulted in a 10-fold decrease in affinity for Mg2+, suggesting that one role of GEF is to displace bound Mg2+ from the Rho proteins. The GDP dissociation rates of the GTPases could be further stimulated by GEF upon removal of bound Mg2+, indicating that the GEF-catalyzed nucleotide exchange involves a Mg2+-independent as well as a Mg2+-dependent mechanism. Although Mg2+ is not absolutely required for GTP hydrolysis by the Rho GTPases, the divalent ion apparently participates in the GTPase reaction, since the intrinsic GTP hydrolysis rates were enhanced 4-10-fold upon binding to Mg2+, and k(cat) values of the Rho GTPase-activating protein (RhoGAP)-catalyzed reactions were significantly increased when Mg2+ was present. Furthermore, the p50RhoGAP specificity for Cdc42 was lost in the absence of Mg2+ cofactor. These studies directly demonstrate a role of Mg2+ in regulating the kinetics of nucleotide binding and hydrolysis and in the GEF- and GAP-catalyzed reactions of Rho family GTPases, The results suggest that GEF facilitates nucleotide exchange by destabilizing both bound nucleotide and Mg2+, whereas RhoGAP utilizes the Mg2+ cofactor to achieve high catalytic efficiency and specificity.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Acad Sinica, Inst Biophys, Beijing 100101, Peoples R China	University of Tennessee System; University of Tennessee Health Science Center; Chinese Academy of Sciences; Institute of Biophysics, CAS	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRECH M, 1990, J BIOL CHEM, V265, P6353; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; PAN JY, 1996, J BIOL CHEM, V271, P13322; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	47	128	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25299	25307		10.1074/jbc.M001027200	http://dx.doi.org/10.1074/jbc.M001027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10843989	hybrid			2022-12-27	WOS:000088849400035
J	Zhang, Y; Neo, SY; Han, JH; Lin, SC				Zhang, Y; Neo, SY; Han, JH; Lin, SC			Dimerization choices control the ability of axin and dishevelled to activate c-jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; NEGATIVE REGULATOR; DOMAINS; TRANSCRIPTION; JNK; POLARITY; PHOSPHORYLATION; IDENTIFICATION	Axin and Dishevelled are two downstream components of the Wnt signaling pathway. Dishevelled is a positive regulator and is placed genetically between Frizzled and glycogen synthase kinase-3 beta, whereas Axin is a negative regulator that acts downstream of glycogen synthase kinase-3 beta. It is intriguing that they each can activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) when expressed in the cell. We set out to address if Axin and Dishevelled are functionally cooperative, antagonistic, or entirely independent, in terms of the JNK activation event. We found that in contrast to Axin, Dv12 activation of JNK does not require MEKK1, and complex formation between Dv12 and Axin is independent of Axin-MEKK1 binding. Furthermore, Dv12-DIX and Dv12-Delta DEP proteins deficient for JNK activation can attenuate Axin-activated JNK activity by disrupting Axin dimerization. However, Axin-Delta MID, and Axin-Delta T proteins deficient for JNK activation cannot interfere with Dv12-activated JMK activity. These results indicate that unlike the strict requirement of homodimerization for Axin function, Dv12 can activate JNK either as a monomer or homodimer/heterodimer. We suggest that there may be a switch mechanism based on dimerization combinations, that commands cells to activate Wnt signaling or JNK activation, and to turn on specific activators of JNK in response to various environmental cues.	Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Scripps Research Institute	Lin, SC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		Han, J/G-4671-2010; Lin, SC/G-4666-2010	Zhang, Yi/0000-0003-2785-1780	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	38	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25008	25014		10.1074/jbc.M002491200	http://dx.doi.org/10.1074/jbc.M002491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829020	hybrid			2022-12-27	WOS:000088683300103
J	Knox, JD; Araujo, FD; Bigey, P; Slack, AD; Price, GB; Zannis-Hadjopoulos, M; Szyf, M				Knox, JD; Araujo, FD; Bigey, P; Slack, AD; Price, GB; Zannis-Hadjopoulos, M; Szyf, M			Inhibition of DNA methyltransferase inhibits DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG ISLAND METHYLATION; SIGNALING PATHWAY; HUMAN CANCERS; CELL LINES; ORIGINS; TUMORIGENESIS; EXPRESSION; NEOPLASIA; ANTISENSE; GROWTH	Ectopic expression of DNA methyltransferase transforms vertebrate cells, and inhibition of DNA methyltransferase reverses the transformed phenotype by an unknown mechanism. me tested the hypothesis that the presence of an active DNA methyltransferase is required for DNA replication in human non-small cell lung carcinoma A549 cells. We show that the inhibition of DNA methyltransferase by two novel mechanisms negatively affects DNA synthesis and progression through the cell cycle, Competitive polymerase chain reaction of newly synthesized DNA shows decreased origin activity at three previously characterized origins of replication following DNA methyltransferase inhibition. We suggest that the requirement of an active DNA methyltransferase for the functioning of the replication machinery has evolved to coordinate DNA replication and inheritance of the DNA methylation pattern.	McGill Univ, Ctr Canc, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Szyf, M (corresponding author), McGill Univ, Ctr Canc, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca		bigey, pascal/0000-0002-6795-8569				Ahuja N, 1997, CANCER RES, V57, P3370; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Bender CM, 1998, CANCER RES, V58, P95; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CONTREAS G, 1992, BIOTECHNIQUES, V12, P824; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Gerbi SA, 1997, METHODS, V13, P271, DOI 10.1006/meth.1997.0526; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LUI Y, 1998, NUCLEIC ACIDS RES, V26, P1038; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SZYF M, 1985, J BIOL CHEM, V260, P8653; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1998, CURR RES MOL THER, V1, P93; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; Tsvetkov LM, 1997, CANCER RES, V57, P2252; YOSHIURA K, 1994, P NATL ACAD SCI USA, V91, P9700	34	65	67	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17986	17990		10.1074/jbc.C900894199	http://dx.doi.org/10.1074/jbc.C900894199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849434	hybrid			2022-12-27	WOS:000087659400013
J	Li, M; Pritchard, PH				Li, M; Pritchard, PH			Characterization of the effects of mutations in the putative branchpoint sequence of intron 4 on the splicing within the human lecithin : cholesterol acyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; U2 SNRNA; LCAT DEFICIENCY; TACTAAC BOX; SITE; POINT; EXPRESSION; INVITRO; YEAST; CONSEQUENCES	We have previously identified a point mutation (intervening sequence (TVS) 4: T --> C) in the branchpoint consensus sequence of intron 4 of the lecithin:cholesterol acyltransferase (LCAT) gene in patients with fish-eye disease. To investigate the possible mechanisms responsible for the defective splicing, we made a series of mutations in the branchpoint sequence and expressed these mutants in HEK-293 cells followed by the analysis of pre-mRNA splicing using reverse transcriptase-polymerase chain reaction as well as LCAT activity assay. The results reveal that 1) the mutation of the branchpoint adenosine to any other nucleotide completely abolishes splicing; 2) the insertion of a normal branch site into the intronic sequence of the natural (IVS4-22c) or the branchpoint (IVS4-20t) mutant completely restores splicing; 3) the natural mutation can be partially rescued by making a single nucleotide change (G --> A) within the branchpoint consensus sequence; and 4) other single base changes, particularly around the branchpoint adenosine residue, significantly decrease the efficiency of splicing and thus enzyme activity. Surprisingly, the nucleotide transversion at the last position of the branchpoint sequence (i.e. IVS4-25a or -25g) results in a 2.7-fold increase in splicing efficiency. Therefore, these observations clearly establish the functional significance of the branchpoint sequence of intron 4 for the splicing of the human LCAT mRNA precursors.	St Pauls Hosp, Healthy Heart Program, Atherosclerosis Specialty Lab, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Pritchard, PH (corresponding author), St Pauls Hosp, Healthy Heart Program, Atherosclerosis Specialty Lab, Dept Pathol & Lab Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.							Brand K, 1996, J LIPID RES, V37, P1213; Burrows NP, 1998, AM J HUM GENET, V63, P390, DOI 10.1086/301948; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HIXSON JE, 1993, GENE, V128, P295, DOI 10.1016/0378-1119(93)90578-Q; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KADOLITSCH YV, 1999, CIRCULATION, V100, P693; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1996, J CLIN INVEST, V98, P358, DOI 10.1172/JCI118800; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; Li M, 1998, BBA-LIPID LIPID MET, V1391, P256, DOI 10.1016/S0005-2760(97)00198-7; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Pascolo E, 1997, MOL CELL BIOL, V17, P3469, DOI 10.1128/MCB.17.7.3469; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RISSTALPERS C, 1994, AM J HUM GENET, V54, P609; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; Sambrook J., 2002, MOL CLONING LAB MANU; TEISBERG P, 1975, ANN HUM GENET, V38, P327, DOI 10.1111/j.1469-1809.1975.tb00617.x; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Webb JC, 1996, HUM MOL GENET, V5, P1325, DOI 10.1093/hmg/5.9.1325; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	35	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18079	18084		10.1074/jbc.M910197199	http://dx.doi.org/10.1074/jbc.M910197199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849435	hybrid			2022-12-27	WOS:000087659400025
J	Choi, KH; Kremer, L; Besra, GS; Rock, CO				Choi, KH; Kremer, L; Besra, GS; Rock, CO			Identification and substrate specificity of beta-ketoacyl (Acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI K-12; ISONIAZID TARGET; THIOLACTOMYCIN; INHIBITION; COMPLEX; INHA; FABH; BCG	The long-chain alpha-alkyl-beta-hydroxy fatty acids, termed mycolic acids, which are characteristic components of the mycobacterial cell wall are produced by successive rounds of elongation catalyzed by a multifunctional (type I) fatty acid synthase complex followed by a dissociated (type II) fatty acid synthase, In bacterial type II systems, the first initiation step in elongation is the condensation of acetyl-CoA with malonyl-acyl carrier protein (ACP) catalyzed by beta-ketoacyl-ACP III (FabH), An open reading frame in the Mycobacterium tuberculosis genome (Rv0533c), now termed mtfabH, was 37.3% identical to Escherichia coli ecFabH and contained the Cys-His-Asn catalytic triad signature. However, the purified recombinant mtFabH clearly preferred long-chain acyl-CoA substrates rather than acyl-ACP primers and did not utilize acetyl-CoA as a primer in comparison to ecFabH, In addition, purified mtFabH was sensitive to thiolactomycin and resistant to cerulenin in an in vitro assay, However, mtFabH overexpression in Mycobacterium bovis BCG did not confer thiolactomycin resistance, suggesting that mtFabH may not be the primary target of thiolactomycin inhibition in vivo and led to several changes in the lipid composition of the bacilli. The data presented is consistent with a role for mtFabH as the pivotal link between the type I and type II fatty acid elongation systems in M. tuberculosis. This study opens up new avenues for the development of selective and novel anti-mycobacterial agents targeted against mtFabH.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Newcastle University - UK; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; Besra, Gurdyal/0000-0002-5605-0395	NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI-38087] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Baulard A.R., 1999, MYCOBACTERIA MOL BIO, P240; BELISLE JT, 1994, RES MICROBIOL, V145, P237, DOI 10.1016/0923-2508(94)90024-8; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V65, P215; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Dobson G., 1985, CHEM METHODS BACTERI, P237; GLOBE M, 1993, NEW ENGL J MED, V328, P527; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1991, EMERGING TARGETS ANT, P151; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Snider Dixie E. Jr., 1994, P3; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; vanSoolingen D, 1997, INT J SYST BACTERIOL, V47, P1236, DOI 10.1099/00207713-47-4-1236; *WHO, 1997, ANTITUBERCULOSIS DRU; WOOD WI, 1977, J BIOL CHEM, V252, P5745	47	159	169	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28201	28207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10840036				2022-12-27	WOS:000089197100089
J	Huston, E; Beard, M; McCallum, F; Pyne, NJ; Vandenabeele, P; Scotland, G; Houslay, MD				Huston, E; Beard, M; McCallum, F; Pyne, NJ; Vandenabeele, P; Scotland, G; Houslay, MD			The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3 - Consequences for altered intracellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; N-TERMINAL DOMAIN; MONOPHOSPHATE PHOSPHODIESTERASE; MEMBRANE ASSOCIATION; RPDE-6 RNPDE4A5; SPLICE VARIANT; PC12 CELLS; APOPTOSIS	The unique N-terminal region of the cAMP-specific phosphodiesterase PDE4A5, which confers an ability to bind to certain protein SH3 domains, is cleaved during apoptosis in both Rat-1 fibroblasts and PC12 cells. Cleavage was abolished by the caspase-3-selective inhibitor, z-DEVD-CHO but not the caspase-1 selective inhibitor, z-YVAD-CHO, Caspase-3 treatment of PDE4A5, expressed either transiently in COS cells or generated in vitro by coupled transcription translation, generated a similar cleavage product of 100 kDa compared with the native 110-kDa PDE4A5. This product could be detected immunochemically with an antibody raised to a C-terminal PDE4A5 peptide but not an antibody raised to the N terminus of PDE4A5, indicating that caspase-3 caused N-terminal cleavage of PDE4A5. Deletion of the putative caspase-3 cleavage site, (69)DAVD(72), in PDE4A5, or generation of either the D72A or the D69A mutants, ablated the ability of caspase-3 to cause cleavage. The N-terminal truncate PDE4A5-Delta P3 was engineered to mimic the caspase-cleaved product of PDE4A5. This showed altered catalytic activity and, unlike PDE4A5, was unable to interact with the SH3 domain of the tyrosyl kinase, LYN, Although both PDE4A5 and PDE4A5-Delta P3 mere localized at cell cortical regions (ruffles), the distinct perinuclear association noted for both PDE4A5 and LYN mas not seen for PDE4A5-Delta P3. Staurosporine-induced apoptosis caused a marked redistribution of PDE4A5 but not PDE4A8 in stably transfected Rat-1 cells. The PDE4-selective inhibitor, rolipram together with the adenylyl cyclase activator forskolin, caused a synergistic increase in the apoptosis of Rat-1 cells. Overexpression of PDE4A5 in Rat-1 cells protected against staurosporine-induced apoptosis in contrast to overexpression of PDE4A8, which potentiated apoptosis, PDE4A5 may be the sole PDE4 family member to provide a substrate for caspase-3 cleavage and this action serves to remove the SH3 binding domain that is unique to this isoform within the PDE4A family and to alter its intracellular targeting.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; State Univ Ghent VIB, Dept Mol Biol, Mol Signalling Lab, B-9000 Ghent, Belgium	University of Glasgow; University of Strathclyde; Flanders Institute for Biotechnology (VIB); Ghent University	Houslay, MD (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.houslay@bio.gla.ac.uk	Houslay, Miles D/A-6825-2011; Vandenabeele, Peter/AAD-5793-2022; Houslay, Miles/AAM-5281-2020; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; Pyne, Nigel/0000-0002-5657-4578; Houslay, Miles/0000-0002-3826-8091				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Houslay MD, 1997, BIOCHEM SOC T, V25, P374, DOI 10.1042/bst0250374; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; Kim JE, 1999, J NEUROCHEM, V72, P2456, DOI 10.1046/j.1471-4159.1999.0722456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LOBBAN M, 1994, BIOCHEM J, V304, P399, DOI 10.1042/bj3040399; LOMO J, 1995, J IMMUNOL, V154, P1634; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; POOLEY L, 1997, BIOCHEM J, V271, P177; Rogers DF, 1998, TRENDS PHARMACOL SCI, V19, P160, DOI 10.1016/S0165-6147(98)01198-5; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhu WH, 1998, LIFE SCI, V63, P265, DOI 10.1016/S0024-3205(98)00270-7	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28063	28074						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10829034				2022-12-27	WOS:000089197100072
J	Stad, R; Ramos, YFM; Little, N; Grivell, S; Attema, J; van der Eb, AJ; Jochemsen, AG				Stad, R; Ramos, YFM; Little, N; Grivell, S; Attema, J; van der Eb, AJ; Jochemsen, AG			Hdmx stabilizes Mdm2 and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-CELL TUMORS; P53-BINDING PROTEIN; DEGRADATION; EXPRESSION; APOPTOSIS; DOMAINS; PRODUCT; GROWTH; GENES	The Mdma protein is a key regulator of p53 activity and stability. Upon binding, Mdma inhibits the transcription regulatory activity of p53 and promotes its rapid degradation. In this study we investigated the effect of the human Mdm2 homologue Hdmx on p53 stability. We found that Hdmx does not target p53 for degradation, although, like Mdm2, it inhibits p53-mediated transcription activation. On the contrary, Hdmx was found to counteract the degradation of p53 by Mdma, and to stabilize both p53 and Mdma, The RING finger of Hdmx was found to be necessary and sufficient for this stabilization, and it probably involves hetero-oligomerization with the RING finger of Mdm2, which may lead to inhibition of Mdma's ubiquitin ligase activity. However, Hdmx does not relieve the inhibition by Mdm2 of transcription activation by p53, probably due to the formation of a trimeric complex consisting of Hdmx, Mdm2, and p53, We propose a model in which Hdmx secures a pool of largely inactive p53, which, upon the induction of stress, can be quickly activated.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, POB 9503, NL-2300 RA Leiden, Netherlands.		Ramos, Yolande F. M./C-3774-2018	Ramos, Yolande F. M./0000-0003-1459-413X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; EL DW, 1993, CELL, V75, P817; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Guillou L, 1996, AM J PATHOL, V149, P1221; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; STEEGENGA WT, 1995, ONCOGENE, V11, P49; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; van der Eb A J, 1980, Methods Enzymol, V65, P826	28	122	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28039	28044						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10827196				2022-12-27	WOS:000089197100069
J	Kim, Y; Shin, J; Li, RB; Cheong, C; Kim, K; Kim, S				Kim, Y; Shin, J; Li, RB; Cheong, C; Kim, K; Kim, S			A novel anti-tumor cytokine contains an RNA binding motif present in aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING POLYPEPTIDE-II; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; RESOLUTION; MOLSCRIPT; PRECURSOR; SEQUENCE; COMPLEX	Endothelial monocyte-activating polypeptide II (EMAP II) is a novel pro apoptotic cytokine that shares sequence homology with the C-terminal regions of several tRNA synthetases, Pro-EMAP II, the precursor of EMAP II, is associated with the multi-tRNA synthetase complex and facilitates aminoacylation activity. The structure of human EMAP II, solved at 1.8 Angstrom resolution, revealed the oligomer-binding fold for binding different tRNAs and a domain that is structurally homologous to other chemokines. The similar structures to the RNA binding motif of EMAP II was previously observed in the anticodon binding domain of yeast Asp-tRNA synthetase (AspRSSC) and the B2 domain of Thermus thermophilus Phe tRNA synthetase. The RNA binding pattern of EMAP II is likely to be nonspecific, in contrast to the AspRSSC, The peptide sequence that is responsible for cytokine activity is located, for the most part, in the pi strand. It is divided into two regions by a neighboring loop.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Yeungnam Univ, Sch Chem Engn, Kyongsan 712749, South Korea; Korea Basic Sci Inst, Magnet Resonance Team, Eon Dong Daejon 305333, South Korea; Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, Suwon 440746, South Korea	University of Washington; University of Washington Seattle; Yeungnam University; Korea Basic Science Institute (KBSI); Sungkyunkwan University (SKKU)	Kim, Y (corresponding author), Univ Washington, Dept Biol Struct, Hlth Sci Bldg,K-428,Box 357742, Seattle, WA 98195 USA.	ykim1@u.washington.edu	Cheong, Chaejoon/GWC-3135-2022; Kim, Sunghoon/AAE-8314-2020; Kim, Youngsoo/D-6046-2012					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM S, 1993, BIOCHEMISTRY-US, V32, P13026, DOI 10.1021/bi00211a011; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCMINNEL P, 1995, J MOL EVOL, V40, P531; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Wilken J, 1999, CHEM BIOL, V6, P43, DOI 10.1016/S1074-5521(99)80019-2	37	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27062	27068						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852899				2022-12-27	WOS:000089144800054
J	Scheidegger, KJ; James, RW; Delafontaine, P				Scheidegger, KJ; James, RW; Delafontaine, P			Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; MESSENGER-RNA LEVELS; I GENE-EXPRESSION; ATHEROSCLEROTIC LESIONS; RAT AORTA; PROLIFERATION; INCREASE; ACTIVATION; STIMULATE; MIGRATION	Low density lipoproteins (LDLs) play an important role in the pathogenesis of atherosclerosis. LDL has been shown to be mitogenic and proapoptotic for vascular smooth muscle cells. However, the mechanisms are poorly understood and may result from an alteration in intracellular mitogenic signaling either directly by LDL or indirectly through an autocrine effect involving growth factor secretion and/or growth factor receptor expression. Insulin-like growth factor-1 (IGF-1) is an autocrine/paracrine factor for vascular smooth muscle cells and has potent anti-apoptotic effects. Thus, we hypothesized that part of the proliferative responses to LDLs may be explained by its modulation of IGF-1 or IGF-1 receptor (IGF-1R) expression. Treatment of rat vascular smooth muscle cells with increasing doses of native LDL dose-dependently increased IGF-1 mRNA by up to 2.6-fold; however, native LDL had no effect on IGF-1R mRNA expression. In contrast, the same doses of oxidized LDL significantly reduced IGF-1 and IGF-1R mRNA by 80 and 61%, respectively, and reduced IGF-1 and IGF-IR protein expression by 63 and 46%. In addition, native and oxidized LDL significantly increased IGF-l-binding protein-a and IGF l-binding protein-4 expression as measured by Western ligand blot. Most interestingly, anti-IGF-l antiserum completely inhibited LDL-induced but not serum-induced increase in H-3-thymidine incorporation, indicating a requirement for IGF-I in the LDL-stimulated mitogenic signaling pathway. In summary, these results suggest that native and oxidized LDLs have differential effects on IGF-1 and IGF-1R expression. Because IGF-1 is a potent survival factor for vascular smooth muscle cells, our findings suggest that moderately oxidized LDL may favor proliferation of smooth muscle cells, whereas oxidized LDL may contribute to plaque apoptosis by local depletion of IGF-I and IGF-1R.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Endocrinol & Diabet, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.			Delafontaine, Patrice/0000-0003-3744-3617	NHLBI NIH HHS [HL45317, HL47035] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R29HL045317, R01HL045317] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anwar A, 2000, ARTERIOSCL THROM VAS, V20, P370, DOI 10.1161/01.ATV.20.2.370; ANWAR A, 1994, HYPERTENSION, V24, P679, DOI 10.1161/01.HYP.24.6.679; ARKINS S, 1993, ENDOCRINOLOGY, V133, P2334, DOI 10.1210/en.133.5.2334; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BOMFELDT KE, 1994, J CLIN INVEST, V93, P1266; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chambery D, 1998, J ENDOCRINOL, V159, P227, DOI 10.1677/joe.0.1590227; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; Delafontaine P, 1997, CARDIOVASC RES, V33, P216, DOI 10.1016/S0008-6363(96)00179-4; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; Dimmeler S, 1997, CIRCULATION, V95, P1760; Duan CM, 1996, J BIOL CHEM, V271, P4280; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOCHBERG Z, 1992, ENDOCRINOLOGY, V131, P430, DOI 10.1210/en.131.1.430; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Kim HH, 1999, EUR J PHARMACOL, V383, P373, DOI 10.1016/S0014-2999(99)00552-X; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MOREL DW, 1983, J LIPID RES, V24, P1070; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; Polanco JI, 1996, BIOCHEM BIOPH RES CO, V226, P917, DOI 10.1006/bbrc.1996.1450; POLANCO JI, 1995, BIOCHEM BIOPH RES CO, V209, P182, DOI 10.1006/bbrc.1995.1487; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Steinberg D, 1996, ISRAEL J MED SCI, V32, P469; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; VERVERIS J, 1994, AM J MED SCI, V307, P77, DOI 10.1097/00000441-199402000-00001; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	57	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26864	26869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862615				2022-12-27	WOS:000089144800028
J	Dube, P; DeCostanzo, A; Konopka, JB				Dube, P; DeCostanzo, A; Konopka, JB			Interaction between transmembrane domains five and six of the alpha-factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR PHEROMONE RECEPTOR; DOMINANT-NEGATIVE MUTATIONS; MEMBRANE-SPANNING SEGMENT; DOPAMINE D2 RECEPTOR; BINDING-SITE CREVICE; SACCHAROMYCES-CEREVISIAE; SCANNING MUTAGENESIS; LIGAND SPECIFICITY; PLASMA-MEMBRANE	The a-factor pheromone receptor (STE2) activates a G protein signal pathway that induces conjugation of the yeast Saccharomyces cerevisiae, Previous studies implicated the third intracellular loop of this receptor in G; protein activation. Therefore, the roles of transmembrane domains five and six (TMD5 and -6) that bracket the third intracellular loop were analyzed by scanning mutagenesis in which each residue was substituted with cysteine. Out of 42 mutants examined, four constitutive mutants and two strong loss-of-function mutants were identified, Double mutants combining Cys substitutions in TMD5 and TMD6 gave a broader range of phenotypes, Interestingly, a V223C mutation in TMD5 caused constitutive activity when combined with the L247C, L248C, or S251C mutations in TMD6, Also, the L226C mutation in TMD5 caused constitutive activity when combined with either the M250C or S251C mutations in TMD6. The residues affected by these mutations are predicted to fall on one side of their respective helices, suggesting that they may interact. In support of this, cysteines substituted at position 223 in TMD5 and position 247 in TMD6 formed a disulfide bond, providing the first direct evidence of an interaction between these transmembrane domains in the ct-factor receptor. Altogether, these results identify an important region of interaction between conserved hydrophobic regions at the base of TMD5 and TMD6 that is required for the proper regulation of receptor signaling.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Konopka, JB (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	james.konopka@sunysb.edu		Konopka, James/0000-0001-5989-4086	NCI NIH HHS [T32CAO9176] Funding Source: Medline; NIGMS NIH HHS [R01 GM055107, GM55107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bukusoglu G, 1996, MOL CELL BIOL, V16, P4818; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CLARK CD, 1994, J BIOL CHEM, V269, P8831; Colson AO, 1998, MOL PHARMACOL, V54, P968, DOI 10.1124/mol.54.6.968; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MARSH L, 1988, P NATL ACAD SCI USA, V85, P3855, DOI 10.1073/pnas.85.11.3855; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; MILLER JH, 1972, EXPT MOL GENETICS, P325; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN M, 1994, J BIOL CHEM, V269, P968; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	46	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26492	26499		10.1074/jbc.M002767200	http://dx.doi.org/10.1074/jbc.M002767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846179	hybrid			2022-12-27	WOS:000088999700084
J	Hurne, AM; Chai, CLL; Waring, P				Hurne, AM; Chai, CLL; Waring, P			Inactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; ACTIVE-SITE; THIOL; MITOCHONDRIA; APOPTOSIS; EPIPOLYTHIODIOXOPIPERAZINES; DENATURATION; SUBUNIT	The biological activity of gliotoxin is dependent on the presence of a strained disulfide bond that can react with accessible cysteine residues on proteins. Rabbit muscle creatine kinase contains 4 cysteines per 42-kDa subunit and is active in solution as a dimer. Only Cys-282 has been identified as essential for activity. Modification of this residue results in loss of activity of the enzyme. Treatment of creatine kinase with gliotoxin resulted in a time-dependent loss of activity abrogated in the presence of reducing agents. Activity was restored when the inactivated enzyme was treated with reducing agents. Inactivation of creatine kinase by gliotoxin was accompanied by the formation of a 37-kDa form of the enzyme. This oxidized form of creatine kinase was rapidly reconverted to the 42-kDa species by the addition of reducing agents concomitant with restoration of activity. A 1:1 mixture of the oxidized and reduced monomer forms of creatine kinase as shown on polyacrylamide gel electrophoresis was equivalent to the activity of the fully reduced form of the enzyme consistent with only one reduced monomer of the dimer necessary for complete activity. Conversion of the second monomeric species of the dimer to the oxidized form by gliotoxin correlated with loss of activity. Our data are consistent with gliotoxin inducing the formation of an internal disulfide bond in creatine kinase by initially binding and possibly activating a cysteine residue on the protein, followed by reaction with a second neighboring thiol. The recently published crystal structure of creatine kinase suggests the disulfide is formed between Cys-282 and Cys-73.	Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia; Australian Natl Univ, The Faculities, Dept Chem, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Waring, P (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Mills Rd, Canberra, ACT 2601, Australia.		Chai, Christina L/A-3133-2014	Chai, Christina/0000-0002-9199-851X				BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BODEY G, 1992, EUR J CLIN MICROBIOL, V11, P99, DOI 10.1007/BF01967060; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; CLOTTES E, 1994, BBA-PROTEIN STRUCT M, V1209, P171, DOI 10.1016/0167-4838(94)90181-3; DAWSON DM, 1965, BIOCHEM BIOPH RES CO, V21, P346, DOI 10.1016/0006-291X(65)90200-7; DECLERCQ E, 1978, BIOCHEM PHARMACOL, V27, P635, DOI 10.1016/0006-2952(78)90497-5; DEGANI Y, 1979, BIOCHEMISTRY-US, V18, P5917, DOI 10.1021/bi00593a024; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSSMAN SH, 1986, ARCH BIOCHEM BIOPHYS, V248, P234, DOI 10.1016/0003-9861(86)90421-2; HAMES BD, GEL ELECTROPHORESIS, P1; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hou LX, 1996, BIOCHIMIE, V78, P219, DOI 10.1016/0300-9084(96)82184-5; HOU LX, 1994, BBA-PROTEIN STRUCT M, V1205, P83, DOI 10.1016/0167-4838(94)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1993, CANCER RES, V53, P3172; MULLBACHER A, 1986, MOL IMMUNOL, V23, P231, DOI 10.1016/0161-5890(86)90047-7; MUNDAY R, 1987, J APPL TOXICOL, V7, P17, DOI 10.1002/jat.2550070105; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PRICE NC, 1976, BIOCHIM BIOPHYS ACTA, V445, P364, DOI 10.1016/0005-2744(76)90090-5; Rao JK, 1998, FEBS LETT, V439, P133; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SCHWEIZER M, 1994, BIOCHEMISTRY-US, V33, P13401, DOI 10.1021/bi00249a028; Silva JP, 1997, REDOX REP, V3, P331, DOI 10.1080/13510002.1997.11747131; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Tanaka N, 1997, BBA-PROTEIN STRUCT M, V1339, P226, DOI 10.1016/S0167-4838(97)00003-4; TANZER ML, 1959, J BIOL CHEM, V234, P3201; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WANG XC, 1990, BIOCHIM BIOPHYS ACTA, V1039, P313, DOI 10.1016/0167-4838(90)90264-G; WANG XC, 1994, SCI CHINA SER B, V37, P964; WANG ZX, 1988, BIOCHEMISTRY-US, V27, P5095, DOI 10.1021/bi00414a022; WARING P, 1994, TOXICON, V32, P491, DOI 10.1016/0041-0101(94)90301-8; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1995, BIOCHEM PHARMACOL, V49, P1195, DOI 10.1016/0006-2952(95)00039-3; WARING P, 1988, MED RES REV, V8, P499, DOI 10.1002/med.2610080404; Watts D. C., 1973, ENZYMES, V8, P384; YAO QZ, 1984, BIOCHEMISTRY-US, V23, P2740, DOI 10.1021/bi00307a032	40	55	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25202	25206		10.1074/jbc.M002278200	http://dx.doi.org/10.1074/jbc.M002278200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827185	hybrid			2022-12-27	WOS:000088849400023
J	Krise, JP; Sincock, PM; Orsel, JG; Pfeffer, SR				Krise, JP; Sincock, PM; Orsel, JG; Pfeffer, SR			Quantitative analysis of TIP47-receptor cytoplasmic domain interactions - Implications for endosome-to-trans Golgi network trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; ADAPTER COMPLEXES; LOCALIZATION; TGN38; FURIN; PROTEIN; NEF	TIP47 (tail-interacting protein of 47 kDa) binds to the cytoplasmic domains of the cation-independent and cation-dependent mannose 6-phosphate receptors and is required for their transport from late endosomes to the trans Golgi network in vitro and in vivo. We report here a quantitative analysis of the interaction of recombinant TIP47 with mannose 6-phosphate receptor cytoplasmic domains. Recombinant TIP47 binds more tightly to the cation-independent mannose 6-phosphate receptor (K-D = 1 mu M) than to the cation-dependent mannose 6-phosphate receptor (K-D = 3 mu M) In addition, TIP47 fails to interact with the cytoplasmic domains of the hormone-processing enzymes, furin, phosphorylated furin, and metallocarboxypeptidase D, as well as the cytoplasmic domain of TGN38, proteins that are also transported from endosomes to the trans Golgi network. Although these proteins failed to bind TIP47, furin and TGN38 were readily recognized by the clathrin adaptor, AP-2. These data suggest that TIP47 recognizes a very select set of cargo molecules. Moreover, our data suggest unexpectedly that furin, TGN38, and carboxypeptidase D may use a distinct vesicular carrier and perhaps a distinct route for transport between endosomes and the trans Golgi network.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.			Orsel, Joke/0000-0003-0303-4735	NIDDK NIH HHS [DK37336] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Varlamov O, 1998, J CELL SCI, V111, P877; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WONG SH, 1993, J BIOL CHEM, V268, P22853	40	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25188	25193		10.1074/jbc.M001138200	http://dx.doi.org/10.1074/jbc.M001138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829017	hybrid			2022-12-27	WOS:000088849400021
J	Strack, S; Robison, AJ; Bass, MA; Colbran, RJ				Strack, S; Robison, AJ; Bass, MA; Colbran, RJ			Association of calcium/calmodulin-dependent kinase II with developmentally regulated splice variants of the postsynaptic density protein densin-180	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; PHOSPHORYLATION; TRANSLOCATION; LOCALIZATION; FAMILY; BRAIN	In a continuing search for proteins that target calcium/calmodulin-dependent protein kinase II (CaMKII) to postsynaptic density (PSD) substrates important in synaptic plasticity, we showed that the PSD protein densin-180 binds CaMKII, Four putative splice variants (A-D) of the cytosolic tail of densin-180 are shown to be differentially expressed during brain development. Densin-180 splicing affects CaMKII phosphorylation of specific serine residues. Variants A, B, and D, but not C, bind CaMKII stoichiometrically and with high affinity, mediated by a differentially spliced domain. Densin-180 differs from the previously identified CaMKII-binding protein NR2B in that binding does not strictly require CaMKII autophosphorylation. Binding of densin-180 and NR2B to CaMKII is noncompetitive, indicating different interaction sites on CaMKII. Expression of the membrane-targeted CaMKII-binding domain of densin-180 confers membrane localization to coexpressed CaMKII without requiring calcium mobilization, suggesting that densin-180 plays a role in the constitutive association of CaMKII with PSDs.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Rm 762,MRB-1, Nashville, TN 37232 USA.	Roger.Colbran@mcmail.vanderbilt.edu	Colbran, Roger/AAU-7708-2021; Robison, Alfred J/P-8521-2018	Colbran, Roger/0000-0001-7401-8244; Robison, Alfred J/0000-0002-4150-9570; Strack, Stefan/0000-0002-6175-7280	NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apperson ML, 1996, J NEUROSCI, V16, P6839; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Elgersma Y, 1999, CURR OPIN NEUROBIOL, V9, P209, DOI 10.1016/S0959-4388(99)80029-4; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2; Zlatkine P, 1997, J CELL SCI, V110, P673	16	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25061	25064		10.1074/jbc.C000319200	http://dx.doi.org/10.1074/jbc.C000319200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827168	hybrid			2022-12-27	WOS:000088849400003
J	Asagoshi, K; Yamada, T; Okada, Y; Terato, H; Ohyama, Y; Seki, S; Ide, H				Asagoshi, K; Yamada, T; Okada, Y; Terato, H; Ohyama, Y; Seki, S; Ide, H			Recognition of formamidopyrimidine by Escherichia coli and mammalian thymine glycol glycosylases - Distinctive paired base effects and biological and mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; GENERATED FREE-RADICALS; ENDONUCLEASE-III; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; REPAIR ENZYME; HUMAN NTH1; PROTEIN; EXCISION; CLONING	The activity of prokaryotic and mammalian thymine glycol (Tg) glycosylases including Escherichia coli endonuclease III (Endo III) and endonuclease VIII (Endo VIII) and mouse Endo III homologue (mNth1) for formamidopyrimidine (Fapy) has been investigated using defined oligonucleotide substrates, 2,6-Diamino-4-hydroxy-5-N-methylformamidopyrimidine, a methylated Fapy derived from guanine, was site specifically incorporated in the oligonucleotide, The substrates containing Fapy:N pairs (N = A, G, C, T) as well as a Tg:A pair, a physiological substrate of Endo HI, Endo VIII, and mNth1, were treated by the enzymes and nicked products were quantified by gel electrophoresis. The activity of Endo III and Endo VIII for Fapy varied markedly depending on the paired base, being the highest with G (activity relative to Tg = 0.55 (Endo III) and 0.41 (Endo VIII)) and the lowest with C (0.05 (Endo III) and 0.06 (Endo VIII)). In contrast, mNth1 recognized all Fapy pairs equally well and the activity was comparable to Tg, The results obtained in the nicking assay were further substantiated by the analysis of the Schiff base intermediate using NaBH4 trapping assays. These results indicate that Escherichia coli and mammalian Tg glycosylases have a potential activity to recognize Fapy. However, as demonstrated for Fapy:C pairs, their distinctive activities implicate unequal participation in the repair of Fapy lesions in cells.	Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan; Okayama Univ, Sch Med, Inst Cellular & Mol Biol, Dept Mol Biol, Okayama 7008558, Japan	Hiroshima University; Okayama University	Ide, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan.			Terato, Hiroaki/0000-0002-7070-5263				Alseth I, 1999, MOL CELL BIOL, V19, P3779; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Cysewski P, 1999, Z NATURFORSCH C, V54, P239; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; HICKSON ID, 1997, BASE EXCISION REPAIR; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; JIANG D, 1997, J BACTERIOL, V179, P2773; Jurado J, 1998, BIOCHEMISTRY-US, V37, P7757, DOI 10.1021/bi972982z; KAO JY, 1993, J BIOL CHEM, V268, P17787; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Karahalil B, 1998, BIOCHEMISTRY-US, V37, P590, DOI 10.1021/bi971660s; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5878; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Senturker S, 1998, NUCLEIC ACIDS RES, V26, P5270, DOI 10.1093/nar/26.23.5270; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TUDEK B, 1992, NUCLEIC ACIDS RES, V20, P3079, DOI 10.1093/nar/20.12.3079; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; Wang D, 1997, BIOCHEMISTRY-US, V36, P8628, DOI 10.1021/bi970341y; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h	41	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24781	24786		10.1074/jbc.M000576200	http://dx.doi.org/10.1074/jbc.M000576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827172	hybrid			2022-12-27	WOS:000088683300075
J	Ma, WP; Kaiser, MW; Lyamicheva, N; Schaefer, JJ; Allawi, HT; Takova, T; Neri, BP; Lyamichev, VI				Ma, WP; Kaiser, MW; Lyamicheva, N; Schaefer, JJ; Allawi, HT; Takova, T; Neri, BP; Lyamichev, VI			RNA template-dependent 5 ' nuclease activity of Thermus aquaticus and Thermus thermophilus DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LARGE FRAGMENT; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; GENOMIC DNA; I KLENOW; REPLICATION; CLEAVAGE; IDENTIFICATION; EUBACTERIAL	DNA replication and repair require a specific mechanism to join the 3'- and 5'-ends of two strands to maintain DNA continuity. In order to understand the details of this process, we studied the activity of the 5' nucleases with substrates containing an RNA template strand. By comparing the eubacterial and archaeal 5' nucleases, we show that the polymerase domain of the eubacterial enzymes is critical for the activity of the 5' nuclease domain on RNA containing substrates. Analysis of the activity of chimeric enzymes between the DNA polymerases from Thermus aquaticus (TaqPol) and Thermus thermophilus (TthPol) reveals two regions, in the "thumb" and in the "palm" subdomains, critical for RNA-dependent 5' nuclease activity. There are two critical amino acids in those regions that are responsible for the high activity of TthPol on RNA containing substrates. Mutating glycine 418 and glutamic acid 507 of TaqPol to lysine and glutamine, respectively, increases its RNA-dependent 5' nuclease activity 4-10-fold, Furthermore, the RNA-dependent DNA polymerase activity is controlled by a completely different region of TaqPol and TthPol, and mutations in this region do not affect the 5' nuclease activity. The results presented here suggest a novel substrate binding mode of the eubacterial DNA polymerase enzymes, called a 5' nuclease mode, that is distinct from the polymerizing and editing modes described previously. The application of the enzymes with improved RNA-dependent 5' nuclease activity for RNA detection using the invasive signal amplification assay is discussed.	Third Wave Technol Inc, Madison, WI 53719 USA		Ma, WP (corresponding author), Third Wave Technol Inc, 502 S Rosa Rd, Madison, WI 53719 USA.							BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Griffin TJ, 1999, P NATL ACAD SCI USA, V96, P6301, DOI 10.1073/pnas.96.11.6301; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Kwiatkowski RW, 1999, MOL DIAGN, V4, P353, DOI 10.1016/S1084-8592(99)80012-5; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Lyamichev V, 1999, NAT BIOTECHNOL, V17, P292, DOI 10.1038/7044; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MAY LT, 1986, P NATL ACAD SCI USA, V83, P8957, DOI 10.1073/pnas.83.23.8957; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANDEY VN, 1993, EUR J BIOCHEM, V214, P59, DOI 10.1111/j.1432-1033.1993.tb17896.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ryan D, 1999, MOL DIAGN, V4, P135, DOI 10.1016/S1084-8592(99)80037-X; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923	31	15	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24693	24700		10.1074/jbc.M002268200	http://dx.doi.org/10.1074/jbc.M002268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827184	hybrid			2022-12-27	WOS:000088683300063
J	Martin, ME; Hidalgo, J; Rosa, JL; Crottet, P; Velasco, A				Martin, ME; Hidalgo, J; Rosa, JL; Crottet, P; Velasco, A			Effect of protein kinase A activity on the association of ADP-ribosylation factor 1 to Gel membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; CANINE KIDNEY-CELLS; PHOSPHOLIPASE-D; COATED VESICLES; ARF PROTEINS; BREFELDIN-A; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM	The small GTP-binding protein ADP-ribosylation factor 1 (ARF1) is an essential component of the molecular machinery that catalyzes the formation of membrane-bound transport intermediates. By using an in vitro assay that reproduces recruitment of cytosolic proteins onto purified, high salt-washed Golgis membranes, we have analyzed the role of cAMP-dependent protein kinase A (PRA) on ARF1 incorporation. Addition to this assay of either pure catalytic subunits of PKA (C-PKA) or cAMP increased ARF1 binding. By contrast, ARF1 association was inhibited following C-PKA inactivation with either PKA inhibitory peptide or RII alpha as well as after cytosol depletion of C-PKA. C-PKA also stimulated recruitment and activation of a recombinant form of human ARF1 in the absence of additional cytosolic components. The binding step could be dissociated from the activation reaction and found to be independent of guanine nucleotides and saturable. This step was stimulated by C-PRA in an ATP-dependent manner. Dephosphorylated Golgis membranes exhibited a decreased ability to recruit ARF1, and this effect was reverted by addition of C-PKA. Following an increase in the intracellular level of cAMP, ARF proteins redistributed from cytosol to the perinuclear Golgi region of intact cells. Collectively, the results show that PKA exerts a key regulatory role in the recruitment of ARF1 onto Golgi membranes. In contrast, PKA modulators did not affect recruitment of beta-COP onto Golgis membranes containing prebound ARF1.	Univ Seville, Fac Biol, Dept Cell Biol, E-41012 Seville, Spain; Univ Barcelona, Dept Ciencias Fisiol 2, Barcelona 08907, Spain; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Sevilla; University of Barcelona; University of Basel	Velasco, A (corresponding author), Univ Seville, Fac Biol, Dept Cell Biol, Avd Reina Mercedes S-N, E-41012 Seville, Spain.		Martín, María/HDL-9512-2022; Rosa, Jose Luis/K-6685-2014; Martín, María/ACU-3685-2022	Rosa, Jose Luis/0000-0002-6161-5688; Martín, María/0000-0002-3204-1726				BALCH WE, 1992, J BIOL CHEM, V267, P13053; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; EKER P, 1994, J BIOL CHEM, V269, P18607; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Goretzki L, 1997, J CELL SCI, V110, P1395; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Jilling T, 1996, J BIOL CHEM, V271, P4381; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Martin ME, 1999, J CELL SCI, V112, P3869; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Monier S, 1998, J CELL SCI, V111, P3427; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Simon JP, 1998, P NATL ACAD SCI USA, V95, P1073, DOI 10.1073/pnas.95.3.1073; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TAKUMA T, 1994, J BIOL CHEM, V269, P22124; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	80	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19050	19059		10.1074/jbc.275.25.19050	http://dx.doi.org/10.1074/jbc.275.25.19050			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858454	Green Published, hybrid			2022-12-27	WOS:000087815900058
J	Hehner, SP; Hofmann, TG; Dienz, O; Droge, W; Schmitz, ML				Hehner, SP; Hofmann, TG; Dienz, O; Droge, W; Schmitz, ML			Tyrosine-phosphorylated Vav1 as a point of integration for T-cell receptor- and CD28-mediated activation of JNK, p38, and interleukin-2 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK/SAPK SIGNALING PATHWAY; EXCHANGE FACTOR VAV; PROTOONCOGENE PRODUCT; IL-2 PROMOTER; RHO-FAMILY; CYTOSKELETAL REORGANIZATION; PROTEIN; KINASE; LYMPHOCYTES; CD28	In this study Re identified tyrosine-phosphorylated Vav1 as an early point of integration between the signaling routes triggered by the T-cell receptor and CD28 in human T-cell leukemia cells. Costimulation resulted in a prolonged and sustained phosphorylation and membrane localization of Vav1 in comparison to T-cell receptor activation alone. T-cell stimulation induced the recruitment of Vav1 to an inducible multiprotein T-cell activation signaling complex at the plasma membrane. Vav1 activated the mitogen-activated protein kinases JNK and p38. The Vav1-mediated activation of JNK employed a pathway involving Rac, HPK1, MLK3, and MKK7. The costimulation-induced activation of p38 was inhibited by dominant negative forms of Vav1, Pac, and MKK6. Here we show that Vav1 also induces transcription factors that bind to the CD28RE/AP element contained in the interleukin-2 promoter. A detailed mutational analysis of Vav1 revealed a series of constitutively active and nonfunctional forms of Vav1. Almost all inactive versions were mutated in their Dbl homology domain and behaved as dominant negative mutants that impaired costimulation-induced activation of JNK, p38, and CD28RE/AP-dependent transcription. In contrast to NF-AT-dependent transcription, Vav1-mediated transcriptional induction of the CD28RE/AP element in the interleukin-a promoter could only partially be inhibited by cyclosporin A, suggesting a dual role of Vav1 for controlling Ca2+-dependent and -independent events.	Deutsch Krebsforschungszentrum, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), Deutsch Krebsforschungszentrum, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Germani A, 1999, MOL CELL BIOL, V19, P3798; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Hobert O, 1996, ONCOGENE, V12, P1577; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; McGuire KL, 1997, J IMMUNOL, V159, P1319; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Musci MA, 1997, J IMMUNOL, V159, P1639; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Song JS, 1999, J IMMUNOL, V163, P802; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	62	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18160	18171		10.1074/jbc.275.24.18160	http://dx.doi.org/10.1074/jbc.275.24.18160			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849438	hybrid			2022-12-27	WOS:000087659400036
J	Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S				Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S			Transcription elongation factor S-II confers yeast resistance to 6-azauracil by enhancing expression of the SSM1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ASCITES TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; FACTOR-SII; DEPENDENT TRANSCRIPTION; PURIFICATION; COMPLEX; SEQUENCE; DNA; CLEAVAGE	Loss of function of S-II makes yeast sensitive to 6-azauracil. Here, we identified a multi-copy suppressor gene of this phenotype, termed SSM1 (suppressor of 6-azauracil sensitivity of the S-II null mutant 1), that encodes a novel protein consisting of 280 amino acid residues. Although both the SSM1 null mutant and the S-II/SSM1 double null mutant were viable under normal growth conditions, they resembled the S-II null mutant in being sensitive to 6-azauracil. Expression of the SSM1 gene was found to be repressed in the S-II null mutant but was restored by overexpression of chimeric S-II molecules that were able to stimulate transcription elongation by RNA polymerase II in vitro. Furthermore, we identified two transcription arrest sites within the transcription unit of the SSM1 gene in vitro that could be relieved by S-II. These results indicate that S-II confers yeast resistance to 6-azauracil by stimulating transcription elongation of the SSM1 gene.	Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), Inst Phys & Chem Res, Natori Special Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	natori@postman.riken.go.ap		Kubo, Takeo/0000-0002-5914-5269				AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; OHYA Y, 1991, J BIOL CHEM, V266, P12356; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PIPER PW, 1990, CURR GENET, V17, P119, DOI 10.1007/BF00312855; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shimoaraiso M, 1997, J BIOL CHEM, V272, P26550, DOI 10.1074/jbc.272.42.26550; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0	46	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29623	29627		10.1074/jbc.M910371199	http://dx.doi.org/10.1074/jbc.M910371199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10858443	hybrid			2022-12-27	WOS:000089439800060
J	Brodin, G; Ahgren, A; ten Dijke, P; Heldin, CH; Heuchel, R				Brodin, G; Ahgren, A; ten Dijke, P; Heldin, CH; Heuchel, R			Efficient TGF-beta induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; DNA METHYLATION; TRANSCRIPTION FACTOR; FAMILY MEMBERS; BINDING; ACTIVATION; IDENTIFICATION; SEQUENCES; CELLS	Sma- and Mad-related protein 7 (Smad7) is an antagonist of transforming growth factor-beta (TGF-beta) signaling, which has been shown to be induced by TGF-beta itself and also by other stimuli. In an effort to understand the molecular mechanisms underlying the transcriptional regulation of the Smad7 gene by TGF-beta, we cloned and functionally characterized a mouse genomic DNA fragment encompassing the mouse Smad7 proximal promoter. This region was found to contain a CpG island and to be devoid of a classical TATA box. Cloned upstream of a promoter-lacking luciferase reporter gene, this region conferred robust TGF-beta-induced transcription. Point mutations in a palindromic Smad binding element, abolished TGF-beta inducibility completely. Through the use of electrophoretic mobility shift assays, we showed the presence of Smad2, Smad3, and Smad4 in complexes binding to the Smad binding element. Interestingly, we also found that point mutation and/or deletion of binding sites for the transcription factors activator protein-1 and Spl led to an attenuation of the basal promoter activity, as well as of the TGF-beta-mediated induction of Smad7. Taken together, our data imply that Smads, together with activator protein-1 and Spl transcription factors, are essential for efficient Smad7 promoter activity.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; Netherlands Cancer Institute	Heuchel, R (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021; Heuchel, Rainer/P-7875-2019	Dijke, Peter ten/0000-0002-7234-342X; Heuchel, Rainer/0000-0002-2782-585X				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 1999, CANCER RES, V59, P2731; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Potchinsky MB, 1997, EXP CELL RES, V231, P96, DOI 10.1006/excr.1996.3422; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	41	135	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29023	29030		10.1074/jbc.M002815200	http://dx.doi.org/10.1074/jbc.M002815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10843994	hybrid			2022-12-27	WOS:000089330700089
J	Dickinson, EK; Adams, DL; Schon, EA; Glerum, DM				Dickinson, EK; Adams, DL; Schon, EA; Glerum, DM			A human SCO2 mutation helps define the role of Sco1p in the cytochrome oxidase assembly pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COPPER RECRUITMENT; C-OXIDASE; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; YEAST; GENE; PURIFICATION; DEFICIENCY; MUTANTS; COX17	Deficiencies in cytochrome oxidase, the terminal enzyme of the mitochondrial respiratory chain, are most often caused by an inability to complete assembly of the enzyme. Pathogenic mutations in SCO2, which encodes a cytochrome oxidase assembly factor, were recently described in several cases of fatal infantile cardioencephalomyopathy. To determine the molecular etiology of these disorders, we describe the generation and characterization of the parallel mutations in the homologous yeast SCO1 gene. We show that the E155K yeast sco1 mutant is respiration-competent, whereas the S240F mutant is not. Interestingly, the S240F mutation allows partial but incorrect assembly of cytochrome oxidase, as judged by an altered cytochrome aa(3) peak, Immunoblot analysis reveals a specific absence of subunit 2 from the cytochrome oxidase in this mutant. Taken together, our data suggest that Sco1p provides copper to the Cu-A site on subunit 2 at a step occurring late in the assembly pathway. This is the first instance of a yeast cytochrome oxidase assembly mutant that is partially assembled. The S240F mutant also represents a powerful new tool with which to elucidate further steps in the cytochrome oxidase assembly pathway.	Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	University of Alberta; Columbia University; Columbia University	Glerum, DM (corresponding author), Univ Alberta, Dept Med Genet, 8-33 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	moira.glerum@ualberta.ca	Glerum, Moira/AHD-3271-2022					Adams PL, 1997, ANN NEUROL, V41, P268, DOI 10.1002/ana.410410219; Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; Glerum DM, 1998, ANAL BIOCHEM, V260, P38, DOI 10.1006/abio.1998.2683; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1988, FEBS LETT, V236, P100, DOI 10.1016/0014-5793(88)80293-X; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; ROBINSON BH, 1987, J PEDIATR-US, V110, P216, DOI 10.1016/S0022-3476(87)80157-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1974, BIOGENESIS MITOCHOND, P405	34	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26780	26785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854440				2022-12-27	WOS:000089144800017
J	Scott, EE; Paster, EV; Olson, JS				Scott, EE; Paster, EV; Olson, JS			The stabilities of mammalian apomyoglobins vary over a 600-fold range and can be enhanced by comparative mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FREE-ENERGY CHANGES; MOLTEN GLOBULE INTERMEDIATE; LINEAR EXTRAPOLATION METHOD; STRUCTURAL CHARACTERIZATION; INTRABODY CONSTRUCTION; FOLDING INTERMEDIATE; COLD DENATURATION; PROTEIN STABILITY; ESCHERICHIA-COLI	Apomyoglobins from 13 different mammals were examined for resistance to denaturation by guanidinium chloride. Unfolding was followed by circular dichroism and tryptophan fluorescence and analyzed globally using the two-step, three-state mechanism first described by Barrick and Baldwin (Barrrick, D., and Baldwin, R. L. (1993) Biochemistry 32, 3790-3796), With one exception, the rise and fall of Trp fluorescence intensity correlates quantitatively with the native to intermediate to unfolded steps seen in the CD curves. Although the O-2 binding properties of the holoproteins are nearly identical, the unfolding transitions of the apomyoglobins show 600-fold differences in resistance to guanidinium chloride denaturation. Apomyoglobins from diving mammals, particularly from sperm whales, are the most stable, whereas the apoproteins from pig; horse, and sheep are the least stable, indicating selective pressure for resistance to denaturation in the whale proteins. Sequence comparisons suggest that the key stabilizing residues in whale globins are Ala(5), His(12), Ile(28), Thr(51), Ala(53), Ala(74), Lys(87), Lys(140), and Ile(142). Combinations of these residues were substituted into pig myoglobin, The resultant multiple mutants showed stabilities approaching that of recombinant sperm whale apomyoglobin, Thus, comparative mutagenesis can be used to increase heme protein stability and improve expression yields in bacteria without compromising function.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Rice University; Rice University	Olson, JS (corresponding author), Rice Univ, Dept Biochem, MS 140, Houston, TX 77005 USA.			Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM08280, GM35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; Ascoli F, 1981, Methods Enzymol, V76, P72; BALESTRIERI C, 1976, FEBS LETT, V66, P60, DOI 10.1016/0014-5793(76)80585-6; BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Cashon RE, 1997, COMP BIOCHEM PHYS B, V117, P613, DOI 10.1016/S0305-0491(97)00011-4; DEKOSTER GT, 1995, J MOL BIOL, V249, P529, DOI 10.1006/jmbi.1995.0315; DELPINO IMP, 1992, BIOCHEMISTRY-US, V31, P11196, DOI 10.1021/bi00160a033; Eliezer D, 1997, FEBS LETT, V417, P92, DOI 10.1016/S0014-5793(97)01256-8; Eliezer D, 1996, J MOL BIOL, V263, P531, DOI 10.1006/jmbi.1996.0596; ELWELL ML, 1979, BIOCHIM BIOPHYS ACTA, V580, P327, DOI 10.1016/0005-2795(79)90145-4; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; FLANAGAN MA, 1983, BIOCHEMISTRY-US, V22, P6027, DOI 10.1021/bi00294a051; GOSS DJ, 1982, COMP BIOCHEM PHYS B, V71, P229, DOI 10.1016/0305-0491(82)90245-0; Haney PJ, 1999, P NATL ACAD SCI USA, V96, P3578, DOI 10.1073/pnas.96.7.3578; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; HU CQ, 1992, BIOCHEMISTRY-US, V31, P4876, DOI 10.1021/bi00135a019; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; Jamin M, 1998, J MOL BIOL, V276, P491, DOI 10.1006/jmbi.1997.1543; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; KIEFHABER T, 1995, J MOL BIOL, V252, P122, DOI 10.1006/jmbi.1995.0479; Kooyman GL, 1998, ANNU REV PHYSIOL, V60, P19, DOI 10.1146/annurev.physiol.60.1.19; LIAO H, 1986, P NATL ACAD SCI USA, V83, P576, DOI 10.1073/pnas.83.3.576; LOH SN, 1995, P NATL ACAD SCI USA, V92, P5446, DOI 10.1073/pnas.92.12.5446; Luo YZ, 1997, NAT STRUCT BIOL, V4, P925, DOI 10.1038/nsb1197-925; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MAYR LM, 1993, BIOCHEMISTRY-US, V32, P7994, DOI 10.1021/bi00082a021; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NISHII I, 1995, J MOL BIOL, V250, P223, DOI 10.1006/jmbi.1995.0373; NISHII I, 1994, BIOCHEMISTRY-US, V33, P4903, DOI 10.1021/bi00182a019; Ohage E, 1999, J MOL BIOL, V291, P1119, DOI 10.1006/jmbi.1999.3019; Ohage EC, 1999, J MOL BIOL, V291, P1129, DOI 10.1006/jmbi.1999.3020; Olson JS, 1997, ARTIF CELL BLOOD SUB, V25, P227, DOI 10.3109/10731199709118912; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PFEIL W, 1998, PROTEIN STABILITY CO; Ramos CHI, 1999, BIOCHEMISTRY-US, V38, P9783, DOI 10.1021/bi9828627; RAMSAY G, 1995, BIOPHYS J, V69, P701, DOI 10.1016/S0006-3495(95)79945-3; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SMERDON SJ, 1990, ACTA CRYSTALLOGR B, V46, P370, DOI 10.1107/S0108768189012450; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SNYDER GK, 1983, RESP PHYSIOL, V54, P269, DOI 10.1016/0034-5687(83)90072-5; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Tang Q, 1998, BIOCHEMISTRY-US, V37, P7047, DOI 10.1021/bi9729413; Wirtz P, 1999, PROTEIN SCI, V8, P2245; Wittenberg J.B., 1981, Methods in Enzymology, V76, P29; Yang M, 1999, BIOCHEMISTRY-US, V38, P11216, DOI 10.1021/bi9909400; YAO M, 1995, BIOCHEMISTRY-US, V34, P3771, DOI 10.1021/bi00011a035; ZAPOL WM, 1979, J APPL PHYSIOL, V47, P968, DOI 10.1152/jappl.1979.47.5.968	68	40	42	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27129	27136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852902				2022-12-27	WOS:000089144800063
J	Bader, MW; Xie, T; Yu, CA; Bardwell, JCA				Bader, MW; Xie, T; Yu, CA; Bardwell, JCA			Disulfide bonds are generated by quinone reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; IN-VIVO; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN; FORMATION INVIVO; PROTEIN DSBD; ISOMERASE; PATHWAY	The chemistry of disulfide exchange in biological systems is well studied. However, very little information is available concerning the actual origin of disulfide bonds. Here we show that DsbB, a protein required for disulfide bond formation in vivo, uses the oxidizing power of quinones to generate disulfides de novo, This is a novel catalytic activity, which to our knowledge has not yet been described. This catalytic activity is apparently the major source of disulfides in vivo. We developed a new assay to characterize further this previously undescribed enzymatic activity, and we show that quinones get reduced during the course of the reaction. DsbB contains a single high affinity quinone-binding site. We reconstitute oxidative folding in vitro in the presence of the following components that are necessary in vivo: DsbA, DsbB, and quinone. We show that the oxidative refolding of ribonuclease A is catalyzed by this system in a quinone-dependent manner. The disulfide isomerase DsbC is required to regain ribonuclease activity suggesting that the DsbA-DsbB system introduces at least some non-native disulfide bonds. We show that the oxidative and isomerase systems are kinetically isolated in vitro. This helps explain how the cell avoids oxidative inactivation of the disulfide isomerization pathway.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	University of Michigan System; University of Michigan; Oklahoma State University System; Oklahoma State University - Stillwater	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu			NIGMS NIH HHS [GM 30721, GM 57039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057039, R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Darby NJ, 1998, BIOCHEMISTRY-US, V37, P783, DOI 10.1021/bi971888f; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Glockshuber R, 1999, NATURE, V401, P30, DOI 10.1038/43344; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; YU CA, 1982, J BIOL CHEM, V257, P6127; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	37	127	133	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26082	26088		10.1074/jbc.M003850200	http://dx.doi.org/10.1074/jbc.M003850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854438	hybrid			2022-12-27	WOS:000088999700028
J	Jha, N; Jurma, O; Lalli, G; Liu, Y; Pettus, EH; Greenamyre, JT; Liu, RM; Forman, HJ; Andersen, JK				Jha, N; Jurma, O; Lalli, G; Liu, Y; Pettus, EH; Greenamyre, JT; Liu, RM; Forman, HJ; Andersen, JK			Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity - Implications for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; BRAIN MITOCHONDRIA; ELECTRON-TRANSPORT; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; THIOL OXIDATION; RAT-KIDNEY; METABOLISM; REDUCTION; NEURONS	Oxidative stress appears to play an important role in degeneration of dopaminergic neurons of the substantia nigra (SN) associated with Parkinson's disease (PD), The SN of early PD patients have dramatically decreased levels of the thiol tripeptide glutathione (GSH), GSH plays multiple roles in the nervous system both as an antioxidant and a redox modulator. We have generated dopaminergic PC12 cell lines in which levels of GSH can be inducibly down-regulated via doxycycline induction of antisense messages against both the heavy and light subunits of gamma-glutamyl-cysteine synthetase, the rate-limiting enzyme in glutathione synthesis. Down-regulation of glutamyl-cysteine synthetase results in reduction in mitochondrial GSH levels, increased oxidative stress, and decreased mitochondrial function. Interestingly, decreases in mitochondrial activities in GSH-depleted PC12 cells appears to be because of a selective inhibition of complex I activity as a result of thiol oxidation. These results suggest that the early observed GSH losses in the SN may be directly responsible for the noted decreases in complex I activity and the subsequent mitochondrial dysfunction, which ultimately leads to dopaminergic cell death associated with PD.	Univ So Calif, Dept Biol Sci, Program Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biol Sci, Program Neurobiol, Los Angeles, CA 90089 USA; Univ So Calif, Andrus Gerontol Ctr, Div Neurogerontol, Los Angeles, CA 90089 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, Birmingham, AL 35294 USA	University of Southern California; University of Southern California; University of Southern California; Emory University; Emory University; University of Alabama System; University of Alabama Birmingham	Andersen, JK (corresponding author), Univ So Calif, Dept Biol Sci, Program Mol Biol, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	andersen@almaak.usc.edu	Greenamyre, J. Timothy/B-4049-2011	Andersen, Julie/0000-0003-1324-4875; Forman, Henry Jay/0000-0001-5838-2791; Greenamyre, J. Timothy/0000-0003-3468-7878	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES005511, R01ES005511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009793, R01AG012141, R29AG012141] Funding Source: NIH RePORTER; NIA NIH HHS [AG09793, AG12141] Funding Source: Medline; NIEHS NIH HHS [ES05511] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen JK, 1996, J NEUROCHEM, V67, P2164; Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; BANNON MJ, 1984, BIOCHEM PHARMACOL, V33, P2697, DOI 10.1016/0006-2952(84)90682-8; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; DELCORSO A, 1994, INT J BIOCHEM, V26, P745, DOI 10.1016/0020-711X(94)90103-1; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HALLMAN H, 1985, J NEUROCHEM, V44, P117, DOI 10.1111/j.1471-4159.1985.tb07120.x; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Hung HC, 1998, FREE RADICAL BIO MED, V24, P76, DOI 10.1016/S0891-5849(97)00206-2; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; JHA N, 1999, RRD NEUROCHEMISTRY 1, V2, P99; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; Lenaz G, 1997, MOL CELL BIOCHEM, V174, P329, DOI 10.1023/A:1006854619336; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; PERRY TL, 1986, NEUROSCI LETT, V67, P269, DOI 10.1016/0304-3940(86)90320-4; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Pettus E. H., 1997, Society for Neuroscience Abstracts, V23, P1640; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sechi G, 1996, PROG NEURO-PSYCHOPH, V20, P1159, DOI 10.1016/S0278-5846(96)00103-0; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; SIAN J, 1994, ANN NEUROL, V36, P356, DOI 10.1002/ana.410360306; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Sriram K, 1998, J NEUROSCI, V18, P10287; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Wullner U, 1996, NEUROREPORT, V7, P921; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	42	222	227	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26096	26101		10.1074/jbc.M000120200	http://dx.doi.org/10.1074/jbc.M000120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846169	hybrid			2022-12-27	WOS:000088999700030
J	Zhao, RB; Titus, S; Gao, F; Moran, RG; Goldman, ID				Zhao, RB; Titus, S; Gao, F; Moran, RG; Goldman, ID			Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED FOLATE CARRIER; GAMMA-GLUTAMATE SYNTHETASE; GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; ONE-CARBON METABOLISM; METHOTREXATE RESISTANCE; DIHYDROFOLATE-REDUCTASE; LYMPHOBLASTIC-LEUKEMIA; ANTIFOLATE RESISTANCE; THYMIDYLATE SYNTHASE; MEMBRANE-TRANSPORT	Four L1210 murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate (DDATHF) and other folate analogs, but sensitive to continuous exposure to methotrexate, were developed by chemical mutagenesis followed by DDATHF selective pressure. Endogenous folate pools were modestly reduced but polyglutamate derivatives of DDATHF and ALIMTA (LY231514, MTA) were markedly decreased in these mutant cell lines. Membrane transport was not a factor in drug resistance; rather, folypolyglutamate synthetase (FPGS) activity was decreased by >98%. In each cell line, FPGS mRNA expression was unchanged but both alleles of the FPGS gene bore a point mutation in highly conserved domains of the coding region. Four mutations were in the predicted ATP-, folate-, and/or glutamate-binding sites of FPGS, and two others were clustered in a peptide predicted to be beta sheet 5, based on the crystal structure of the Lactobacillus casei enzyme. Transfection of cDNAs for three mutant enzymes into FPGS-null Chinese hamster ovary cells restored a reduced level of clonal growth, whereas a T339I mutant supported growth at a level comparable to that of the wild-type enzyme. The two mutations predicted to be in beta sheet 5, and one in the loop between NH2- and COOH-terminal domains did not support cell growth. When sets of mutated cDNAs were co-transfected into FPGS-null cells to mimic the genotype of drug-selected resistant cells, clonal growth was restored. These results demonstrate for the first time that single amino acid substitutions in several critical regions of FPGS can cause marked resistance to tetrahydrofolate antimetabolites, while still allowing cell survival.	Albert Einstein Coll Med, Ctr Comprehens Canc, Bronx, NY 10461 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Yeshiva University; Albert Einstein College of Medicine; Virginia Commonwealth University; Virginia Commonwealth University	Goldman, ID (corresponding author), Albert Einstein Coll Med, Ctr Comprehens Canc, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu			NCI NIH HHS [CA-82621, CA-39687, CA-39807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807, R01CA039687, R01CA082621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONSSON B, 1990, ANAL BIOCHEM, V186, P8, DOI 10.1016/0003-2697(90)90563-O; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Atkinson IJ, 1998, PHYTOCHEMISTRY, V49, P2221, DOI 10.1016/S0031-9422(98)00317-3; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; Boyer J, 1996, YEAST, V12, P1575, DOI 10.1002/(SICI)1097-0061(199612)12:15<1575::AID-YEA45>3.0.CO;2-E; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; FRY DW, 1982, J BIOL CHEM, V257, P1890; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; JACKMAN AL, 1993, INHIBITION THYMIDYLA, P274; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; LACKS SA, 1995, J BACTERIOL, V177, P66, DOI 10.1128/jb.177.1.66-74.1995; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; LIN BF, 1993, J BIOL CHEM, V268, P21674; MARGOLIS PS, 1993, J BACTERIOL, V175, P528, DOI 10.1128/JB.175.2.528-540.1993; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1995, BLOOD, V85, P500; MCBURNEY MW, 1974, CELL, V2, P183, DOI 10.1016/0092-8674(74)90092-0; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1983, DEV TARGET ORIENTED, P97; Mendelsohn LG, 1996, INVEST NEW DRUG, V14, P287, DOI 10.1007/BF00194532; MORAN RG, 1989, J BIOL CHEM, V264, P21047; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1988, CANCER RES, V48, P2149; RHEE MS, 1993, CANCER RES, V53, P2227; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sanghani PC, 2000, PROTEIN EXPRES PURIF, V18, P36, DOI 10.1006/prep.1999.1173; Sanghani SP, 1999, J BIOL CHEM, V274, P27018, DOI 10.1074/jbc.274.38.27018; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHANE B, 1989, VITAM HORM, V45, P263; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Sierra EE, 1998, BIOCHEM PHARMACOL, V55, P1505, DOI 10.1016/S0006-2952(97)00673-4; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; Spinella MJ, 1996, BIOCHEM PHARMACOL, V52, P703, DOI 10.1016/0006-2952(96)00347-4; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; TAYLOR EC, 1992, J MED CHEM, V35, P4450, DOI 10.1021/jm00101a023; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TOY J, 1994, ARCH BIOCHEM BIOPHYS, V314, P344, DOI 10.1006/abbi.1994.1452; TOY J, 1990, J BIOL CHEM, V265, P2492; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yoshioka S, 1997, DNA Res, V4, P363, DOI 10.1093/dnares/4.6.363; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	65	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26599	26606		10.1074/jbc.M002580200	http://dx.doi.org/10.1074/jbc.M002580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856298	hybrid			2022-12-27	WOS:000088999700098
J	Zolle, O; Lawrie, AM; Simpson, AWM				Zolle, O; Lawrie, AM; Simpson, AWM			Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATRIAL-NATRIURETIC-PEPTIDE; VASCULAR SMOOTH-MUSCLE; CYCLIC-GMP; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; ENDOTHELIAL-CELLS; CALCIUM CHANNELS; STORES; ENTRY	We examined whether localized increases in cytosolic cGMP have distinct regulatory effects on the concentration of cytosolic free Ca2+ in ECV304 cells. Stimulation of the particulate guanylate cyclase by brain-type natriuretic peptide in fura-a-loaded cells caused a profound potentiation of the ATP-stimulated and thapsigargin-stimulated rise in cytosolic free Ca2+. This effect is mediated by the inhibition of Ca2+ extrusion via the plasma membrane Ca2+-ATPase pump. Furthermore, the addition of brain-type natriuretic peptide caused the partial inhibition of cation influx in ATP-stimulated cells. In contrast, elevation of cytosolic cGMP by activation of the soluble guanylate cyclase induced by the addition of sodium nitroprusside causes an increased reuptake of Ca2+ into the intracellular stores without affecting cation influx or Ca2+ efflux, Thus, localized pools of cGMP play distinct regulatory roles in the regulation of Ca2+ homeostasis within individual cells. We define a new role for natriuretic peptides in the inhibition of Ca2+ efflux that leads to the potentiation of agonist-evoked increases in cytosolic free Ca2+.	Univ Liverpool, Dept Human Anat & Cell Biol, New Med Sch, Liverpool, Merseyside, England; Univ Aberdeen, IMS, Aberdeen AB25 2DZ, Scotland	University of Liverpool; University of Aberdeen	Simpson, AWM (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, New Med Sch, Ashton St, Liverpool, Merseyside, England.	awms@liv.ac.uk						Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURNS F, 1996, INTRACELLULAR SIGNAL, P29; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; Fang Y, 1999, CELL CALCIUM, V26, P15, DOI 10.1054/ceca.1999.0046; FERESENKO EE, 1985, NATURE, V313, P310; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; GOLD GH, 1987, TRENDS PHARMACOL SCI, V8, P312, DOI 10.1016/0165-6147(87)90126-X; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOBAI IA, 1998, J PHYSIOL-LONDON, V511, P80; Holschermann H, 1997, AM J PHYSIOL-HEART C, V272, pH91, DOI 10.1152/ajpheart.1997.272.1.H91; HOPEGILL HF, 1979, HORM METAB RES, V11, P698, DOI 10.1055/s-0028-1095813; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HSU YT, 1994, J BIOL CHEM, V269, P29765; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; Jin XH, 1999, J CLIN INVEST, V103, P167, DOI 10.1172/JCI4327; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MITTAL CK, 1985, EUR J PHARMACOL, V115, P127, DOI 10.1016/0014-2999(85)90596-5; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V274, pC1199, DOI 10.1152/ajpcell.1998.274.5.C1199; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RIZZUTO R, 1993, METHOD CELL BIOL, V40, P339; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SABINE B, 1995, BIOCHEM BIOPH RES CO, V214, P75, DOI 10.1006/bbrc.1995.2258; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; SIMPSON AWM, 1990, BIOCHEM J, V267, P277, DOI 10.1042/bj2670277; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; Uneyama C, 1998, EUR J PHARMACOL, V347, P355, DOI 10.1016/S0014-2999(98)00123-X; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; Willmott NJ, 1996, FEBS LETT, V386, P39, DOI 10.1016/0014-5793(96)00413-9; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	49	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25892	25899		10.1074/jbc.M000786200	http://dx.doi.org/10.1074/jbc.M000786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851228	hybrid			2022-12-27	WOS:000088999700003
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			Interaction between nucleoside triphosphate phosphohydrolase I and the H4L subunit of the viral RNA polymerase is required for vaccinia virus early gene transcript release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; NUCLEOTIDE-SEQUENCE; TERMINATION FACTOR; TERNARY COMPLEXES; EXPRESSION SYSTEM; CELLULAR PROTEIN; STAGE GENES; NASCENT RNA; VIRIONS; PURIFICATION	Signal-dependent termination is restricted to early poxvirus genes whose transcription is catalyzed by the virion form of RNA polymerase. Two termination factors have been identified. Vaccinia termination factor/capping enzyme is a multifunctional heterodimer that also catalyzes the first three steps of mRNA cap formation and is an essential intermediate gene transcription initiation factor. Nucleoside triphosphate phosphohydrolase I (NPH I) is a single-stranded DNA-dependent ATPase. COOH-terminal deletion mutations of NPH I retain both ATPase and DNA binding activities but are unable either to terminate transcription or to act as dominant negative mutants in vitro, One appealing model posits that the COOH-terminal region of NPH I binds to one or more components in the termination complex. In an attempt to identify NPH I-related protein/protein interactions involved in transcription termination, a series of pull-down experiments were done. Among several vaccinia virus proteins tested, the H4L subunit, unique to the virion form of RNA polymerase, was shown. to bind glutathione S-transferase (GST)-NPH I. To further confirm this interaction in virus-infected cells, we constructed recombinant vaccinia virus, vNPHINGST, that expresses GST-tagged NPH I. The H4L subunit of virion RNA polymerase specifically co-purified with GST-NPH I, consistent with a physical interaction. Through the analysis of a series of NH2- and COOH-terminal truncation mutations of H4L, the NPH I interaction site was localized to the NH2-terminal 195 amino acids of the H4L protein. The H4L binding site on NPH I was mapped to the COOH-terminal region between 457 and 631, Furthermore, COOH-terminal deletion mutations of NPH I failed to bind the NH2-terminal region of H4L, explaining their inability to support transcription termination. The COOH-terminal end of NPH I was also shown to be required for transcript release activity and for dominant negative inhibition of release. The requirement for an essential interaction between NPH I and H4L provides an explanation for the observed restriction of transcription termination to early viral genes.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.		Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NIAID NIH HHS [AI43933] Funding Source: Medline; NIGMS NIH HHS [GM54816] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054816] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1996, POXVIRIDAE VIRUSES T, V2, P2637; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSEL J, 1985, J VIROL, V56, P830, DOI 10.1128/JVI.56.3.830-838.1985; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIR JP, 1983, J VIROL, V46, P530, DOI 10.1128/JVI.46.2.530-537.1983; WITTEK R, 1984, J VIROL, V49, P371, DOI 10.1128/JVI.49.2.371-378.1984; YUEH L, 1986, J VIROL, V60, P3020; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	40	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25798	25804		10.1074/jbc.M002250200	http://dx.doi.org/10.1074/jbc.M002250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833518	hybrid			2022-12-27	WOS:000088849400097
J	Rivera-Walsh, I; Cvijic, ME; Xiao, G; Sun, SC				Rivera-Walsh, I; Cvijic, ME; Xiao, G; Sun, SC			The NF-kappa B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SEQUENCE; T-CELL; INDUCED APOPTOSIS; CD28 COSTIMULATION; KINASE-ALPHA; RESPONSE ELEMENT; ANTIGEN RECEPTOR; BINDING-PROTEINS; DEFICIENT MICE; DNA-BINDING	Stimulation of T cells by antigens or mitogens triggers multiple signaling pathways leading to activation of genes encoding interleukin-2 and other growth-regulatory cytokines. The same stimuli also activate the gene encoding an apoptosis-inducing molecule, Fas ligand (FasL), which contributes to activation-induced cell death. It has been proposed that the signaling pathways involved in cytokine gene induction also contribute to activation-induced Fast expression; however, genetic evidence for this proposal is lacking. In the present study, the role of the NF-kappa B signaling pathway in Fast gene expression was examined using a mutant T cell line deficient in an essential NF-kappa B signaling component, I kappa B kinase gamma, These mutant cells have a blockade in signal-induced activation of NF-kappa B but remained normal in the activation of NF-AT and AP-1 transcription factors. Interestingly, the NF-kappa B signaling defect has no effect on mitogen-stimulated Fast gene expression, although it completely blocks the interleukin-2 gene induction. We further demonstrate that NF-kappa B activation is required for protecting T cells from apoptosis induction by mitogens and an agonistic anti-Fas antibody. These genetic results suggest that the NF-kappa B signaling pathway is not required for activation-induced Fast expression but rather mediates cell growth and protection from activation-induced cell death.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA068471, F32CA083280] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA83280-1, CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1997, AM J PATHOL, V151, P891; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, Behring Inst Mitt, P161; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Desai SH, 1997, J BIOL CHEM, V272, P12809, DOI 10.1074/jbc.272.19.12809; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FRASER JD, 1992, J EXP MED, V175, P1131, DOI 10.1084/jem.175.4.1131; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KASSIM OO, 1978, EXP PARASITOL, V46, P218, DOI 10.1016/0014-4894(78)90134-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LAI JH, 1994, J BIOL CHEM, V269, P30077; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsui K, 1998, J IMMUNOL, V161, P3469; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Noel PJ, 1996, J IMMUNOL, V157, P636; Parra E, 1998, J IMMUNOL, V160, P5374; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Torgerson TR, 1998, J IMMUNOL, V161, P6084; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1993, FUND IMMUNOL, V13, P467; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	94	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25222	25230		10.1074/jbc.M000444200	http://dx.doi.org/10.1074/jbc.M000444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837465	hybrid			2022-12-27	WOS:000088849400026
J	Sayer, MS; Tilbrook, PA; Spadaccini, A; Ingley, E; Sarna, MK; Williams, JH; Andrews, NC; Klinken, SP				Sayer, MS; Tilbrook, PA; Spadaccini, A; Ingley, E; Sarna, MK; Williams, JH; Andrews, NC; Klinken, SP			Ectopic expression of transcription factor NF-E2 alters the phenotype of erythroid and monoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; HEMATOPOIETIC LINEAGE SWITCH; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEIN; GLOBIN GENE; MESSENGER-RNA; MICE LACKING; J2E CELLS; MACROPHAGE DIFFERENTIATION; MAMMALIAN-CELLS	In this study, regulation of transcription factor NF-EP was examined in differentiating erythroid and myeloid cells, and the impact of raising NF-EB concentrations within these cell types was assessed. NF-EB was expressed in the J2E erythroid cell line, but the levels increased only marginally during erythropoietin-induced differentiation. In contrast, rare myeloid variants of J2E cells did not express NF-E2, Although NF-EB was present in M1 monoblastoid cells, it was undetectable as these cells matured into macrophages. Compared with erythroid cells, transcription of the NF-ES gene was reduced, and the half-life of the mRNA was significantly shorter in monocytoid cells. Ectopic expression of NF-EB had a profound impact upon the J2E cells; morphologically mature erythroid cells spontaneously emerged in culture, but the cells failed to synthesize hemoglobin, even in the presence of erythropoietin, Although proliferation and viability increased in the NF-EB-transfected J2E cells, their responsiveness to erythropoietin was severely diminished. Strikingly, increasing the expression of NF-EB in M1 cells produced sublines that contained erythroid or immature megakaryocytic cells. Finally, overexpression of NF-E2 in primary hemopoietic progenitors from fetal liver increased erythroid colony formation in the absence of erythropoietin. These data demonstrate that elevated NF-E2 (i) had a dominant effect on the phenotype and maturation of J2E erythroid cells, (ii) was able to reprogram the M1 monocytoid line, and (iii) promoted the development of erythroid colonies by normal progenitors.	Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Royal Perth Hospital; University of Western Australia; University of Western Australia; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Klinken, SP (corresponding author), Western Australian Inst Med Res, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Sarna, Mohinder/GYR-3271-2022	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Andrews, Nancy/0000-0003-0243-4462				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; BUSFIELD SJ, 1995, CELL GROWTH DIFFER, V6, P429; CALLUS BA, 1995, HEMOGLOBIN, V19, P7; CHAPPELL D, 1997, CELL DEATH DIFFER, V4, P103; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; Chenais B, 1997, LEUKEMIA, V11, P1575, DOI 10.1038/sj.leu.2400755; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Levin J, 1999, BLOOD, V94, P3037, DOI 10.1182/blood.V94.9.3037.421k42_3037_3047; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOTEM J, 1989, LEUKEMIA, V3, P804; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NEUZ B, 1995, NATURE, V375, P316; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PERKINS AC, 1995, NATURE, V375, P318; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Shivdasani R A, 1996, Stem Cells, V14 Suppl 1, P112; Shivdasani RA, 1997, BLOOD, V90, P1821, DOI 10.1182/blood.V90.5.1821; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TANIGAWA T, 1995, BLOOD, V85, P379; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Whyatt David J., 1997, Genes and Function, V1, P11; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; YonedaKato N, 1996, ONCOGENE, V12, P265	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25292	25298		10.1074/jbc.M908695199	http://dx.doi.org/10.1074/jbc.M908695199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10842186	hybrid			2022-12-27	WOS:000088849400034
J	Walter, HJ; McMahon, T; Dadgar, J; Wang, D; Messing, RO				Walter, HJ; McMahon, T; Dadgar, J; Wang, D; Messing, RO			Ethanol regulates calcium channel subunits by protein kinase C delta-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY NIGHT BLINDNESS; BETA-SUBUNIT; CA2+ CHANNEL; NEUROHYPOPHYSEAL TERMINALS; FUNCTIONAL EXPRESSION; ALCOHOL-CONSUMPTION; PREFERRING RATS; NEURAL CELLS; PC12 CELLS; PKC-DELTA	Chronic exposure to ethanol increases the number of functional L-type voltage-gated calcium channels in neural cells. In PC12 cells, this adaptive response is mediated by protein kinase C delta (PKC delta), but the mechanisms by which this occurs are not known. Since expression of several different calcium channel subunits can increase the abundance of functional L-type channels, we sought to identify which subunits are regulated by ethanol. Incubation of PC12 cells with 120-150 mM ethanol for 6 days increased levels of alpha(1C), alpha(2), and beta(1b) subunit immunoreactivity in cell membranes and selectively increased the abundance of mRNA encoding the alpha(1C-1) splice variant of alpha(1C). In cells expressing a fragment of PKC delta (delta V1) that selectively inhibits PKC delta, there was no increase in membrane-associated alpha(1C), alpha(2), and beta(1b) immunoreactivity following chronic ethanol exposure. However, ethanol still increased levels of alpha(1C-1) mRNA in these cells. These results indicate that ethanol increases the abundance of L-type channels by at least two mechanisms; one involves increases in mRNA encoding a splice variant of alpha(1C) and the other is post-transcriptional, rate-limiting, and requires PKC delta.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Programs Neurosci & Biomed Sci, San Francisco, CA 94143 USA; Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Messing, RO (corresponding author), 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.		Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431; Walter, Helen/0000-0003-2274-6172	NIAAA NIH HHS [AA08117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008117] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; BONE GHA, 1989, PSYCHOPHARMACOLOGY, V99, P386, DOI 10.1007/BF00445563; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COLOMBO G, 1994, EUR J PHARMACOL, V265, P167, DOI 10.1016/0014-2999(94)90427-8; COLOMBO G, 1995, ALCOHOL ALCOHOLISM, V30, P125; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FADDA F, 1992, ALCOHOL CLIN EXP RES, V16, P449, DOI 10.1111/j.1530-0277.1992.tb01398.x; GAYER GG, 1991, J BIOL CHEM, V266, P22279; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GRANT AJ, 1993, BRAIN RES, V600, P280, DOI 10.1016/0006-8993(93)91384-5; GUPPY LJ, 1995, ALCOHOL ALCOHOLISM, V30, P607; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hogan K, 1996, GENOMICS, V31, P392, DOI 10.1006/geno.1996.0066; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Li WQ, 1996, ONCOGENE, V13, P731; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LITTLETON JM, 1990, PSYCHOPHARMACOLOGY, V100, P387, DOI 10.1007/BF02244612; Liu HY, 1996, J NEUROSCI, V16, P7557; MASSA E, 1995, MOL PHARMACOL, V47, P707; MESSING RO, 1986, P NATL ACAD SCI USA, V83, P6213, DOI 10.1073/pnas.83.16.6213; MILES MF, 1991, J BIOL CHEM, V266, P2409; MILES MF, 1994, MOL PHARMACOL, V46, P873; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; REZVANI AH, 1991, ALCOHOL ALCOHOLISM, V26, P161, DOI 10.1093/oxfordjournals.alcalc.a045097; REZVANI AH, 1990, PROG NEURO-PSYCHOPH, V14, P623, DOI 10.1016/0278-5846(90)90013-7; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SKATTEBOL A, 1987, BIOCHEM PHARMACOL, V36, P2227, DOI 10.1016/0006-2952(87)90156-0; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Walter HJ, 1999, ENDOCRINOLOGY, V140, P520, DOI 10.1210/en.140.1.520; WANG XM, 1991, J PHARMACOL EXP THER, V259, P705; WANG XM, 1994, J NEUROSCI, V14, P5453; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	53	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25717	25722		10.1074/jbc.M910282199	http://dx.doi.org/10.1074/jbc.M910282199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835432	hybrid			2022-12-27	WOS:000088849400087
J	Zheng, DQ; Woodard, AS; Tallini, G; Languino, LR				Zheng, DQ; Woodard, AS; Tallini, G; Languino, LR			Substrate specificity of alpha(nu)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROSTATE CARCINOMA-CELLS; PROTEIN-KINASE; GROWTH-FACTOR; ALPHA(V)BETA(3) INTEGRIN; ALPHA-V-BETA-3 INTEGRIN; SURVIVAL PATHWAY; HUMAN-MELANOMA; PHOSPHOINOSITIDE 3-KINASE; EPITHELIAL-CELLS	The alpha(v)beta(3) integrin has been shown to bind several ligands, including osteopontin and vitronectin. Its role in modulating cell migration and downstream signaling pathways in response to specific extracellular matrix Ligands has been investigated in this study. Highly invasive prostate cancer PC3 cells that constitutively express alpha(v)beta(3) adhere and migrate on osteopontin and vitronectin in an alpha(v)beta(3)-dependent manner. However, exogenous expression of alpha(v)beta(3) in noninvasive prostate cancer LNCaP (beta(3)-LNCaP) cells mediates adhesion and migration on vitronectin but not on osteopontin. Activation of alpha(v)beta(3) by epidermal growth factor stimulation is required to mediate adhesion to osteopontin but is not sufficient to support migration on this substrate, We show that alpha(v)beta(3)-mediated cell migration requires activation of the phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (PKB/AKT) pathway since wortmannin, a PI 3-kinase inhibitor, prevents PC3 cell migration on both osteopontin and vitronectin; furthermore, alpha(v)beta(3) engagement by osteopontin and vitronectin activates the PI 3-kinase/AKT pathway. Migration of beta(3)-LNCaP cells on vitronectin also occurs through activation of the PI 3-kinase pathway; however, AKT phosphorylation is not increased upon engagement by osteopontin. Furthermore, phosphorylation of focal adhesion kinase (FAK), known to support cell migration in beta(3)-LNCaP cells, is detected on both substrates. Thus, in PC3 cells, alpha(v)beta(3) mediates cell migration and PI 3-kinase/AKT pathway activation on vitronectin and osteopontin; in beta(3)-LNCaP cells, alpha(v)beta(3) mediates cell migration and PI 3-kinase/AKT pathway activation on vitronectin, whereas adhesion to osteopontin does not support alpha(v)beta(3)-mediated cell migration and PI 3-kinase/AKT pathway activation. We conclude therefore that alpha(v)beta(3) exists in multiple functional states that can bind either selectively vitronectin or both vitronectin and osteopontin and that can differentially activate cell migration and intracellular signaling pathways in a ligand-specific manner.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Languino, LR (corresponding author), Yale Univ, Sch Med, Dept Pathol, POB 208023,310 Cedar St, New Haven, CT 06520 USA.	lucia.languino@yale.edu	Tallini, Giovanni/F-7850-2013	Tallini, Giovanni/0000-0003-0113-6682; Languino, Lucia/0000-0001-9011-7031	NCI NIH HHS [CA-71870] Funding Source: Medline; NIDDK NIH HHS [DK-52670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayless KJ, 1998, J CELL SCI, V111, P1165; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BROWN LF, 1994, AM J PATHOL, V145, P610; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Cairns P, 1997, CANCER RES, V57, P4997; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Crawford HC, 1998, CANCER RES, V58, P5206; Davies MA, 1999, CANCER RES, V59, P2551; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elgavish A, 1998, PROSTATE, V35, P83; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HAAPASALMI K, 1995, AM J PATHOL, V147, P193; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Katagiri YU, 1999, CANCER RES, V59, P219; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lin JQ, 1999, CANCER RES, V59, P2891; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Oates AJ, 1996, ONCOGENE, V13, P97; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Petitclerc E, 1999, CANCER RES, V59, P2724; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rittling SR, 1999, EXP NEPHROL, V7, P103; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAEGUSA Y, 1990, J CELL PHYSIOL, V142, P488, DOI 10.1002/jcp.1041420307; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; Senger DR, 1996, AM J PATHOL, V149, P293; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Woodard AS, 1998, J CELL SCI, V111, P469; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zheng DQ, 1999, CANCER RES, V59, P1655	79	122	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24565	24574		10.1074/jbc.M002646200	http://dx.doi.org/10.1074/jbc.M002646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835423	hybrid			2022-12-27	WOS:000088683300046
J	Lin, FB; Wang, HY; Malbon, CC				Lin, FB; Wang, HY; Malbon, CC			Gravin-mediated formation of signaling complexes in beta(2)-adrenergic receptor desensitization and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE-C; AGONIST-INDUCED DESENSITIZATION; COUPLED RECEPTORS; ADENYLATE-CYCLASE; PHORBOL ESTER; ARRESTIN/CLATHRIN INTERACTION; BETA-2-ADRENERGIC RECEPTOR; LINKED RECEPTORS; PHOSPHORYLATION	Agonist-induced desensitization and resensitization of G-protein-linked receptors involve the interaction of receptors with protein kinases, phosphatases, beta-arrestin, and clathrin organized by at least one scaffold protein. The dynamic composition of the signaling complexes and the role of the scaffold protein AKAP250 (gravin) in agonist-induced attenuation and recovery of beta-adrenergic receptors were explored by co-immunoprecipitation of target elements, antisense suppression, and confocal microscopy. Gravin associated with unstimulated receptor, and the association was increased significantly after agonist stimulation for up to 60 min. Agonist stimulation also induced a robust association of the receptor-gravin complex with protein kinases A and C, G-protein-linked receptor kinase-2, beta-arrestin, and clathrin, Confocal microscopy of the green fluorescence protein-tagged beta(2)-adrenergic receptor showed that the receptor underwent sequestration after agonist stimulation. Suppression of gravin expression via antisense oligodeoxynucleotides disrupted agonist-induced association of the receptor with G-protein-linked receptor kinase-2, beta-arrestin, and clathrin as well as receptor recovery from desensitization. Gravin deficiency also inhibited agonist-induced sequestration. These data reveal that gravin-mediated formation of signaling complexes with protein kinases/phosphatases, beta-arrestin, and clathrin is essential in agonist-induced internalization and resensitization of G-protein-linked receptors.	SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COWLEN MS, 1987, J PHARMACOL EXP THER, V243, P527; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; HANSON AS, 1995, AM J PHYSIOL-RENAL, V268, pF553, DOI 10.1152/ajprenal.1995.268.4.F553; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HO AK, 1988, J BIOL CHEM, V263, P9292; HO AK, 1988, BIOCHEM PHARMACOL, V37, P1015, DOI 10.1016/0006-2952(88)90503-5; Hosey MM, 1996, PROG BRAIN RES, V109, P169; HOUSLAY MD, 1992, CLIN ENDOCRINOL, V36, P525, DOI 10.1111/j.1365-2265.1992.tb02260.x; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KASHLES O, 1987, BIOCHEM PHARMACOL, V36, P1531, DOI 10.1016/0006-2952(87)90122-5; KILFEATHER SA, 1991, LIFE SCI, V49, P713, DOI 10.1016/0024-3205(91)90103-I; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Neill JD, 1998, ENDOCRINOLOGY, V139, P1781, DOI 10.1210/en.139.4.1781; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; REUPCKE C, 1993, CARDIOVASC RES, V27, P2179, DOI 10.1093/cvr/27.12.2179; Scott JD, 1997, SOC GEN PHY, V52, P227; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1; SIBLEY DR, 1984, J BIOL CHEM, V259, P9742; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	51	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19025	19034		10.1074/jbc.275.25.19025	http://dx.doi.org/10.1074/jbc.275.25.19025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858453	hybrid			2022-12-27	WOS:000087815900055
J	Verdier, F; Walrafen, P; Hubert, N; Chretien, S; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Walrafen, P; Hubert, N; Chretien, S; Gisselbrecht, S; Lacombe, C; Mayeux, P			Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INDUCED ERYTHROID-DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ERYTHROLEUKEMIA-CELLS; STAT5 ACTIVATION; GROWTH-HORMONE; MEDIATED ENDOCYTOSIS; PATHWAY	The binding of erythropoietin (Epo) to its receptor leads to the transient phosphorylation of the Epo receptor (EpoR) and the activation of intracellular signaling pathways. Inactivation mechanisms are simultaneously turned on, and Epo-induced signaling pathways return to nearly basal levels after 30-60 min of stimulation. me show that proteasomes control these inactivation mechanisms. In cells treated with the proteasome inhibitors N-Ac-Leu-Leu-norleucinal (LLnL) or lactacystin, EpoR tyrosine phosphorylation and activation of intracellular signaling pathways (Jak2, STAT5, phosphatidylinositol S-kinase) were sustained for at least 2 h, We show that this effect was due to the continuous replenishment of the cell surface pool of EpoRs in cells treated with proteasome inhibitors. Proteasome inhibitors did not modify the internalization and degradation of Epo EpoR complexes, but they allowed the continuous replacement of the internalized receptors by newly synthesized receptors, Proteasome inhibitors did not modify the synthesis of EpoRs, but they allowed their transport to the cell surface. N-Ac-Leu-Leu-norleucinal, but not lactacystin, also inhibited the degradation of internalized Epo EpoR complexes, most probably through cathepsin inhibition. The internalized EpoRs were not tyrosinephosphorylated, and they did not activate intracellular signaling pathways. Our results show that the proteasome controls the down-regulation of EpoRs in Epo-stimulated cells by inhibiting the cell surface replacement of internalized EpoRs.	Univ Paris 05, Hop Cochin, INSERM U363, Inst Cochin Genet Mol, F-75014 Paris, France; Univ Paris 05, Hop Cochin, Serv Hematol, F-75014 Paris, France; Inst Natl Transfus Sanguine, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Mayeux, P (corresponding author), Univ Paris 05, Hop Cochin, INSERM U363, Inst Cochin Genet Mol, 27 Rue Fraubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018					Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; CHRETIEN S, 1994, BLOOD, V83, P1813; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fontenay-Roupie M, 1999, BRIT J HAEMATOL, V106, P464, DOI 10.1046/j.1365-2141.1999.01539.x; FUKAMACHI H, 1987, INT J CELL CLONING, V5, P209, DOI 10.1002/stem.5530050305; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HE TC, 1993, BLOOD, V82, P3530; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hermine O, 1996, BLOOD, V87, P1746; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Komatsu N, 1997, BLOOD, V89, P1182, DOI 10.1182/blood.V89.4.1182; KOMATSU N, 1992, BLOOD, V80, P53; KOMATSU N, 1991, CANCER RES, V51, P341; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Malek RL, 1999, CYTOKINE, V11, P192, DOI 10.1006/cyto.1998.0421; MAYEUX P, 1987, J BIOL CHEM, V262, P13985; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MUFSON RA, 1987, BLOOD, V69, P1485; Neumann D, 1996, BIOCHEM J, V313, P391, DOI 10.1042/bj3130391; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Strous GJ, 1997, J BIOL CHEM, V272, P40; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	49	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18375	18381		10.1074/jbc.275.24.18375	http://dx.doi.org/10.1074/jbc.275.24.18375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849444	hybrid			2022-12-27	WOS:000087659400064
J	Ashar, HR; James, L; Gray, K; Carr, D; Black, S; Armstrong, L; Bishop, WR; Kirschmeier, P				Ashar, HR; James, L; Gray, K; Carr, D; Black, S; Armstrong, L; Bishop, WR; Kirschmeier, P			Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SOMATIC-CELLS; PROTEIN TRANSFERASE; IN-VITRO; CHROMOSOME ALIGNMENT; RAS FARNESYLATION; KI-RAS; N-RAS; ANAPHASE; KINETOCHORES; MITOSIS	Human tumor cell lines that are sensitive to the effects of farnesyl transferase inhibitors accumulate in G(2) --> M (except for cells with an activated Ha-ras that accumulate in G(1)). A search for CAAX box proteins from Swiss-Prot revealed more than 300 peptides. Of these, the centromeric proteins CENP-E and CENP-F are preferentially expressed during mitosis and are implicated as mediators of the G(2) --> M checkpoint. Experiments performed here show that peptides from the COOH-terminal CAAX box of CENP-E and CENP-F are substrates for farnesyl transferase but not geranylgeranyl transferase-I. Although both proteins are prenylated in the human tumor cell line DLD-1, their prenylation is completely inhibited by the farnesyl transferase inhibitor, SCH 66336. Immunohistochemical data with the lung carcinoma cell line, A549, showed that preventing the farnesylation of CENP-E and CENP-F by treatment with the farnesyl transferase inhibitor SCH 66336 does not affect their localization to the kinetochores. However, the presence of farnesyl transferase inhibitors alters the association between CENP-E and the microtubules. Our results imply that the inhibition of CENP-E farnesylation results in the alteration of the microtubule-centromere interaction during mitosis and results in the accumulation of cells prior to metaphase.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Kirschmeier, P (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, Mail Stop 4950,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	Paul.kirschmeier@spcorp.com						Adjei AA, 2000, CANCER RES, V60, P1871; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Brown KD, 1996, J CELL SCI, V109, P961; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DER J, 1991, CANCER CELL, V3, P331; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Hill BT, 2000, CRIT REV ONCOL HEMAT, V33, P7, DOI 10.1016/S1040-8428(99)00053-0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KEATES RAB, 1984, CAN J BIOCHEM CELL B, V62, P803, DOI 10.1139/o84-102; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu M, 1998, CANCER RES, V58, P4947; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; Miquel K, 1997, CANCER RES, V57, P1846; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Njoroge FG, 1997, J MED CHEM, V40, P4290, DOI 10.1021/jm970464g; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Wright J, 1999, Oncology (Williston Park), V13, P1533; WRIGHT J, 1999, ONCOLOGY, V13, P1530; WRIGHT J, 1999, ONCOLOGY, V13, P1533; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang FL, 1997, J BIOL CHEM, V272, P10232; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zhu XL, 1999, MOL CELL BIOL, V19, P1016; Zhu XL, 1997, J CELL BIOCHEM, V66, P441, DOI 10.1002/(SICI)1097-4644(19970915)66:4<441::AID-JCB3>3.0.CO;2-L; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	55	285	295	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30451	30457		10.1074/jbc.M003469200	http://dx.doi.org/10.1074/jbc.M003469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10852915	hybrid			2022-12-27	WOS:000089577900073
J	Ogden, SK; Lee, KC; Barton, MC				Ogden, SK; Lee, KC; Barton, MC			Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; TATA-BINDING PROTEIN; P53 RESPONSE ELEMENT; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; LIVER-CANCER; DNA-BINDING; REGULATORY ELEMENTS; SYNTHETIC NUCLEI; WILD-TYPE	Chronic infection with hepatitis B virus (HBV) is associated with development of hepatocellular carcinoma (HCC). The exact mechanism by which chronic infection with HBV contributes to onset of HCC is unknown, However, previous studies have implicated the HBV transactivator protein, HBx, in progression of HCC through its ability to bind the human tumor suppressor protein, p53. In this study, we have examined the ability of HBx to modify p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP). By utilizing in vitro chromatin assembly of DNA templates prior to transcription analysis, we hare demonstrated that HBx functionally disrupts p53-mediated repression of AFP transcription through protein-protein interaction. HBx modification of p53 gene regulation is both tissue-specific and dependent upon the p53 binding element. Our data suggest that the mechanism by which HBx alleviates p53 repression of AFP transcription is through an association with DNA-bound p53, resulting in a loss of p53 interaction with liver-specific transcriptional co-repressors.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Barton, MC (corresponding author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, POB 670524, Cincinnati, OH 45267 USA.	Michelle.Barton@UC.edu	Ogden, Stacey K/N-2528-2018; Ogden, Stacey K/P-9585-2019	Ogden, Stacey K/0000-0001-8991-3065; Barton, Michelle/0000-0002-4042-1374	NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59268] Funding Source: Medline; NIGMS NIH HHS [GM53683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrisani OM, 1999, INT J ONCOL, V15, P373; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barton MC, 1996, METHOD ENZYMOL, V274, P299; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CAMPAGNA JC, 1991, LEGIS STUD QUART, V16, P81, DOI 10.2307/439968; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CRANDALL BF, 1981, CRC CR REV CL LAB SC, V15, P127, DOI 10.3109/10408368109105870; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; CROWE AJ, 1993, ONCOGENE, V8, P181; Crowe AJ, 1999, METHODS, V17, P173, DOI 10.1006/meth.1998.0728; Crowe AJ, 1999, METHOD ENZYMOL, V304, P63; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Hildt E, 1998, RECENT RES CANCER, V154, P315; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIA CC, 1992, J NATL CANCER I, V84, P1638, DOI 10.1093/jnci/84.21.1638; HSIA CC, 1992, HEPATOLOGY, V16, P1327, DOI 10.1002/hep.1840160604; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin DK, 1998, P NATL ACAD SCI USA, V95, P8767, DOI 10.1073/pnas.95.15.8767; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAMESH TM, 1995, MOL CELL BIOL, V15, P4947; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SPEAR BT, 1994, MOL CELL BIOL, V14, P6497, DOI 10.1128/MCB.14.10.6497; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Wang XW, 1998, LIFE SCI, V64, P17, DOI 10.1016/S0024-3205(98)00529-3; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	68	45	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27806	27814						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842185				2022-12-27	WOS:000089197100040
J	Cicmil, M; Thomas, JM; Sage, T; Barry, FA; Leduc, M; Bon, C; Gibbins, JM				Cicmil, M; Thomas, JM; Sage, T; Barry, FA; Leduc, M; Bon, C; Gibbins, JM			Collagen, convulxin, and thrombin stimulate aggregation-independent tyrosine phosphorylation of CD31 in platelets - Evidence for the involvement of Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; RECEPTOR-GAMMA-CHAIN; MEDIATED SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GLYCOPROTEIN-VI; PECAM-1 CD31; ENDOTHELIAL-CELLS; T-CELLS; ACTIVATION; PROTEIN	Platelet endothelial cell adhesion molecule-1 (CD31) is a 130-kDa glycoprotein receptor present on the surface of platelets, neutrophils, monocytes, certain T-lymphocytes, and vascular endothelial cells, CD31 is involved in adhesion and signal transduction and is implicated in the regulation of a number of cellular processes. These include transendothelial migration of leukocytes, integrin regulation, and T-cell function, although its function in platelets remains unclear, In this study, we demonstrate the ability of the platelet agonists collagen, convulxin, and thrombin to induce tyrosine phosphorylation of CD31, Furthermore, we show that this event is independent of platelet aggregation and secretion and is accompanied by an increase in surface expression of CD31, A kinase capable of phosphorylating CD31 was detected in CD31 immunoprecipitates, and its activity was increased following activation of platelets. CD31 tyrosine phosphorylation was reduced or abolished by the Src family kinase inhibitor PP2, suggesting a role for these enzymes. In accordance with this, each of the Src family members expressed in platelets, namely Fyn, Lyn, Src, Yes, and Hck, was shown to co-immunoprecipitate with CD31. The involvement of Src family kinases in this process was confirmed through the study of mouse platelets deficient in Fyn.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Inst Pasteur, Unite Venins, F-75724 Paris 15, France	University of Reading; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gibbins, JM (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Gibbins, Jonathan/0000-0002-0372-5352				ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; BRIER G, 1996, BLOOD, V87, P630; Buckley CD, 1996, J CELL SCI, V109, P437; BURG DL, 1994, J BIOL CHEM, V269, P28136; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CRAMER EM, 1994, BLOOD, V84, P1722; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Deaglio S, 1998, J IMMUNOL, V160, P395; Duchemin AM, 1997, J IMMUNOL, V158, P865; Duncan GS, 1999, J IMMUNOL, V162, P3022; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Matsumura T, 1997, J IMMUNOL, V158, P3408; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Newton-Nash DK, 1999, J IMMUNOL, V163, P682; OHTO H, 1985, BLOOD, V66, P873; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Wang R, 1998, BLOOD, V92, p548A	49	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27339	27347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858437				2022-12-27	WOS:000089144800090
J	Gadina, M; Sudarshan, C; Visconti, R; Zhou, YJ; Gu, HH; Neel, BG; O'Shea, JJ				Gadina, M; Sudarshan, C; Visconti, R; Zhou, YJ; Gu, HH; Neel, BG; O'Shea, JJ			The docking molecule Gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; RECEPTOR-BETA-CHAIN; COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; IL-2 RECEPTOR; TRANSDUCTION PATHWAYS; KINASE ACTIVATION; JANUS KINASE; PROTEIN; SHC	Interleukin (IL)-2, a critical cytokine with indispensable functions in regulating lymphoid homeostasis, induces the activation of several biochemical pathways. Precisely how these pathways are linked and how they relate to the biological action of IL-2 is incompletely understood. We previously identified SHP-2 (Src homology 2 domain containing phosphatase 2) as an important intermediate in IL-S-dependent MAPK activation and showed its association with a 98-kDa phosphoprotein in response to IL-2. Were, we demonstrate that Gaba, a recently identified adapter molecule, is the major SHP-2 and phosphatidylinositol 31-kinase-associated 98 kDa protein in normal, IL-a-activated lymphocytes. We further demonstrate that phosphorylation of both Gab2 and SHP-2 is largely dependent upon tyrosine 338 of the IL-2 receptor beta chain. Gaba can be a substrate of all the three major classes of non-receptor tyrosine kinases associated with the IL-SR, but in terms of IL-2 signaling, JAK3 but not Lck or Syk is essential for Gabs phosphorylation, We also demonstrate that only IL-2 and IL-15, but not other gamma c cytokines induce Gabs phosphorylation; the ability to phosphorylate Gaba correlates with Shc phosphorylation and ERK1/ERK2 activation. Finally, we also show that Gaba levels are regulated by T cell activation, and resting T cells express little Gaba. Therefore, up-regulation and activation of Gaba may be important in linking the IL-2 receptor to activation of MAPK and may be an important means of achieving specificity in cytokine signaling.	NIAMS, Lymphocyte Cell Biol Sect, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol,Dept Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gadina, M (corresponding author), Bldg 10,Rm 9N228,10 Ctr Dr,MSC 1820, Bethesda, MD 20892 USA.		Visconti, Roberta/C-5299-2009; Gadina, Massimo/R-4195-2019		NCI NIH HHS [CA72144] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA072144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi M, 1997, ONCOGENE, V14, P1629, DOI 10.1038/sj.onc.1200981; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BURNS LA, 1993, J BIOL CHEM, V268, P17659; Cho SS, 1996, J IMMUNOL, V157, P4781; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gadina M, 1999, J IMMUNOL, V162, P2081; Gadina M, 1998, J IMMUNOL, V160, P4657; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MERIDA I, 1991, J IMMUNOL, V147, P2202; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Taniguchi T, 1995, ANN NY ACAD SCI, V766, P235, DOI 10.1111/j.1749-6632.1995.tb26671.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; Zhou YJ, 2000, MOL CELL BIOL, V20, P4371, DOI 10.1128/MCB.20.12.4371-4380.2000	40	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26959	26966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10849428				2022-12-27	WOS:000089144800040
J	Kim, YG; Lowenhaupt, K; Maas, S; Herbert, A; Schwartz, T; Rich, A				Kim, YG; Lowenhaupt, K; Maas, S; Herbert, A; Schwartz, T; Rich, A			The Zab domain of the human RNA editing enzyme ADAR1 recognizes Z-DNA when surrounded by B-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; Z-ALPHA DOMAIN; Z JUNCTION FORMATION; ADENOSINE-DEAMINASE; BINDING DOMAIN; RESTRICTION-ENDONUCLEASE; PHYSIOLOGICAL CONDITIONS; ANTIBODY-BINDING; ENERGETICS; TRANSITION	The Zab domain of the editing enzyme ADAR1 binds tightly and specifically to Z-DNA stabilized by bromination or supercoiling. A stoichiometric amount of protein has been shown to convert a substrate of suitable sequence to the Z form, as demonstrated by a characteristic change in the CD spectrum of the DNA. Now we show that Zab can bind not only to isolated Z-forming d(CG)(n) sequences but also to d(CG;), embedded in B-DNA, The binding of Zab to such sequences results in a complex including Z-DNA B-DNA, and two B-Z junctions. In this complex, the d(CG), sequence, but not the flanking region, is in the Z conformation. The presence of Z-DNA was detected by cleavage with a Z-DNA specific nuclease, by undermethylation using Z-DNA sensitive SssI methylase, and by circular dichroism. It is possible that Zab binds to B-DNA with low affinity and flips any favorable sequence into Z-DNA, resulting in a high affinity complex. Alternatively, Zab may capture Z-DNA that exists transiently in solution. The binding of Zab to potential as well as established Z-DNA segments suggests that the range of biological substrates might be wider than previously thought.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Schwartz, Thomas/K-9029-2017; Schwartz, Thomas/ABA-1770-2021; Herbert, Alan/AAY-4286-2020	Schwartz, Thomas/0000-0001-8012-1512; Schwartz, Thomas/0000-0001-8012-1512; /0000-0002-8187-6498; Herbert, Alan/0000-0002-0093-1572				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; DOKTYCZ MJ, 1990, J MOL BIOL, V212, P3, DOI 10.1016/0022-2836(90)90297-Y; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; Kim YG, 1999, J BIOL CHEM, V274, P19081, DOI 10.1074/jbc.274.27.19081; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; LAFER EM, 1985, EMBO J, V4, P3655, DOI 10.1002/j.1460-2075.1985.tb04131.x; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; NORDHEIM A, 1982, CELL, V31, P309, DOI 10.1016/0092-8674(82)90124-6; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Schade M, 1999, FEBS LETT, V458, P27, DOI 10.1016/S0014-5793(99)01119-9; Schade M, 1999, P NATL ACAD SCI USA, V96, P12465, DOI 10.1073/pnas.96.22.12465; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; Schwartz T, 1999, ACTA CRYSTALLOGR D, V55, P1362, DOI 10.1107/S090744499900582X; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; SHEARDY RD, 1993, J MOL BIOL, V231, P475, DOI 10.1006/jmbi.1993.1295; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; Vardimon L, 1985, Prog Clin Biol Res, V198, P23; VARDIMON L, 1984, P NATL ACAD SCI-BIOL, V81, P3268, DOI 10.1073/pnas.81.11.3268; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564	25	48	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26828	26833						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10843996				2022-12-27	WOS:000089144800024
J	Shahs, FS; Curr, KA; Hamburgh, ME; Parniak, M; Mitsuya, H; Arnez, JG; Prasad, VR				Shahs, FS; Curr, KA; Hamburgh, ME; Parniak, M; Mitsuya, H; Arnez, JG; Prasad, VR			Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; MISPAIR EXTENSION; DRUG-RESISTANT; WILD-TYPE; HIV-1; FIDELITY; PROCESSIVITY; BINDING; MUTANTS; M184V	Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) variants with the K65R or L74V substitution display resistance to several nucleoside analogs. An in vitro dNTP exclusion assay revealed an increased fidelity for K65R RT compared with wild-type RT, but little change for L74V RT. When the forward mutation rates were measured via a gap-filling assay, the K65R variant displayed an 8-fold decrease in the overall mutation rate (1.0 x 10(-8) versus 8.6 x 10(-5) for wild-type HIV-1 RT), whereas the rate for the L74V variant was closer to that for wild-type RT (5.0 x 10(-3)). The increase in overall fidelity observed for K65R RT is the largest reported for any drug-resistant HIV-1 RT variant. Nucleotide sequence analysis of locZ alpha mutants generated by variant RTs indicated that K65R RT displays uniform reduction in most types of errors, whereas L74V RT does not. Modeling the substitutions into the x-ray structure of the ternary complex revealed that the major influence of Leu(74) in stabilizing the templating base is unaffected by Val substitution, whereas the K65R substitution appears to increase the stringency of dNTP binding. It is speculated that the increased fidelity of K65R RT is due to an altered interaction with the dNTP substrate.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Childrens Hosp Montefiore, Div Pediat Infect Dis, Bronx, NY 10467 USA; McGill Univ, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; NCI, Expt Retrovirol Sect, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Lady Davis Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Prasad, VR (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007501, R01AI040375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40375, T32-AI07501] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P13152, DOI 10.1073/pnas.93.23.13152; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Hamburgh ME, 1998, NUCLEIC ACIDS RES, V26, P4389, DOI 10.1093/nar/26.19.4389; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JI JP, 1994, VIROLOGY, V199, P323, DOI 10.1006/viro.1994.1130; Jonckheere H, 2000, EUR J BIOCHEM, V267, P2658, DOI 10.1046/j.1432-1327.2000.01272.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; KIM B, 1995, P NATL ACAD SCI USA, V92, P684, DOI 10.1073/pnas.92.3.684; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; Rubinek T, 1997, EUR J BIOCHEM, V247, P238, DOI 10.1111/j.1432-1033.1997.00238.x; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P1484, DOI 10.1128/AAC.42.6.1484; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757	41	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27037	27044						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10833521				2022-12-27	WOS:000089144800051
J	Arozarena, I; Aaronson, DS; Matallanas, D; Sanz, V; Ajenjo, N; Tenbaum, SP; Teramoto, H; Ighishi, T; Zabala, JC; Gutkind, JS; Crespo, P				Arozarena, I; Aaronson, DS; Matallanas, D; Sanz, V; Ajenjo, N; Tenbaum, SP; Teramoto, H; Ighishi, T; Zabala, JC; Gutkind, JS; Crespo, P			The Rho family GTPase Cdc42 regulates the activation of Ras/MAP kinase by the exchange factor Ras-GRF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED SIGNALS; DBL HOMOLOGY DOMAIN; SACCHAROMYCES-CEREVISIAE; DEPENDENT ACTIVATION; BINDING PROTEINS; PH DOMAIN; CALCIUM; VAV; TRANSFORMATION; PATHWAYS	The Ras guanine-nucleotide exchange factor Ras-GRF/Cdc25(Mn) harbors a complex array of structural motifs that include a Dbl-homology (DH) domain, usually found in proteins that interact functionally with the Rho family GTPases, and the role of which is not yet fully understood. Here, we present evidence that Ras-GRF requires its DH domain to translocate to the membrane, to stimulate exchange on Ras, and to activate mitogen-activated protein kinase (MAPK), In an unprecedented fashion, we have found that these processes are regulated by the Rho family GTPase Cdc42. We show that GDP- but not GTP-bound Cdc42 prevents Ras-GRF recruitment to the membrane and activation of Ras/MAPK, although no direct association of Ras-GrRF with Cdc42 was detected, We also demonstrate that catalyzing GDP/GTP exchange on Cdc42 facilitates Ras-GRF-induced MAPK activation. Moreover, we show that the potentiating effect of ionomycin on Ras-GRF-mediated MAPK stimulation is also regulated by Cdc42. These results provide the first evidence for the involvement of a Rho family G protein in the control of the activity of a Ras exchange factor.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Cantabria, Dept Mol Biol, Santander 39011, Spain; NIDR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universidad de Cantabria; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Crespo, P (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	pcrespo@iib.uam.es	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Zabala, Juan Carlos/K-5163-2014; gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014; Arozarena, Imanol/A-5981-2017	Gutkind, J. Silvio/0000-0002-5150-4482; Zabala, Juan Carlos/0000-0003-2679-5473; gomez, david/0000-0002-2360-3141; Crespo, Piero/0000-0003-2825-7783; Arozarena, Imanol/0000-0001-6349-2442; Ajenjo Diez, Nuria/0000-0002-9435-6467	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Byrne JL, 1996, ONCOGENE, V13, P2055; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Guerrero C, 1996, ONCOGENE, V12, P1097; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTTINGLY RR, 1996, NATURE, V382, P268; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VAN AL, 1997, GENE DEV, V11, P2295; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zippel R, 1996, ONCOGENE, V12, P2697	47	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26441	26448		10.1074/jbc.M002992200	http://dx.doi.org/10.1074/jbc.M002992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840034	hybrid			2022-12-27	WOS:000088999700078
J	Belisle, B; Abo, A				Belisle, B; Abo, A			N-formyl peptide receptor ligation induces Rac-dependent actin reorganization through G beta gamma subunits and class Ia phosphoinositide 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACTIVATED HUMAN NEUTROPHILS; ALDRICH-SYNDROME PROTEIN; BINDING PROTEIN; ARP2/3 COMPLEX; CYTOSKELETON; KINASE; EXCHANGE; GTPASES; FAMILY	The N-formyl peptide receptor is a G protein-coupled transmembrane receptor involved in stimulating a variety of differential responses in neutrophils including chemotaxis, degranulation, superoxide production, transcriptional activation, and actin reorganization. Although it is known that N-formyl-Met-Leu-Phe induces actin reorganization, the sequence of events from the receptor to the actin cytoskeleton is not well characterized. To study the signaling pathway from the N-formyl peptide receptor to the actin cytoskeleton, we developed a model system utilizing microinjection techniques with a nonhematopoietic cell line. An expression vector coding for the N-formyl peptide receptor was microinjected into porcine aortic endothelial cells and stimulated with N-formyl-Met-Leu-Phe to induce actin reorganization and membrane ruffling. The receptor-mediated signal was blocked by pertussis toxin and by a dominant negative Rac-N17, indicating the involvement of G(1)alpha subunit and the small guanosine triphosphatase Rac, respectively. Moreover, G beta gamma subunits and membrane targeted forms of phosphatidylinositol (PI) 3-kinase alpha were sufficient to induce similar actin reorganization, and coexpression of various mutants of PI 3-kinase with the N-formyl peptide receptor identified a link to class Ia PI-3 kinase-mediated actin reorganization.	Onyx Pharmaceut, Richmond, CA 94806 USA		Abo, A (corresponding author), Onyx Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.							Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Dharmawardhane S, 1999, J LEUKOCYTE BIOL, V66, P521, DOI 10.1002/jlb.66.3.521; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Katada T, 1999, CHEM PHYS LIPIDS, V98, P79, DOI 10.1016/S0009-3084(99)00020-1; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; ROLLET E, 1994, J IMMUNOL, V153, P353; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Suzuki T, 1996, BBA-MOL CELL RES, V1313, P72, DOI 10.1016/0167-4889(96)00048-1; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26225	26232		10.1074/jbc.M002743200	http://dx.doi.org/10.1074/jbc.M002743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843992	hybrid			2022-12-27	WOS:000088999700048
J	Dong, MQ; Asmann, YW; Zang, MW; Pinon, DI; Miller, LJ				Dong, MQ; Asmann, YW; Zang, MW; Pinon, DI; Miller, LJ			Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE (PTH)/PTH-RELATED PEPTIDE; PHOTOAFFINITY CROSS-LINKING; PARATHYROID-HORMONE; AGONIST-BINDING; TRANSMEMBRANE HELICES; VIP RECEPTOR; FAMILY; ACTIVATION	The carboxyl-terminal domains of secretin family peptides have been shown to contain key determinants for high affinity binding to their receptors. In this work, we have examined the interaction between carboxyl-terminal residues within secretin and the prototypic secretin receptor. We previously utilized photoaffinity labeling to demonstrate spatial approximation between secretin residue 22 and the receptor domain that includes the first 30 residues of the amino terminus (Dong, M., Wang, Y., Pinon, D. I., Hadac, E. M., and Miller, L. J. (1999) J. Biol. Chem. 274, 903-909), Here, we further refined the site of labeling with the p-benzoyl-phenylalanine (Bpa(22)) probe to receptor residue Leu(17) using progressive cleavage of wild type and mutant secretin receptors (V13M and V16M) and sequence analysis, We also developed a new probe incorporating a photolabile Bpa at position 26 of secretin, closer to its carboxyl terminus. This analogue was also a potent agonist (EC50 = 72 +/- 6 pM) and bound to the secretin receptor specifically and with high affinity (K-i = 10.3 +/- 2.4 nM). It covalently labeled the secretin receptor at a single site saturably and specifically. This was localized to the segment between residues Gly(34) and Ala(41) using chemical and enzymatic cleavage of labeled wild type and A41M mutant receptor constructs and immunoprecipitation of epitope-tagged receptor fragments. Radiochemical sequencing identified the site of covalent attachment as residue Leu(36), These new insights, along with our recent report of contact between residue 6 within the aminoterminal half of secretin and this same amino-terminal region of this receptor (Dong, M,, Wang, Y,, Hadac, E, M., Pinon, D, I., Holicky, E. L., and Miller, L. J. (1999) J. Biol. Chem. 274, 19161-19167), support a key role for this region, making the molecular details of this interaction of major interest.	Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Guggenheim 17, Rochester, MN 55905 USA.	miller@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BODANSZKY M, 1986, PEPTIDES, V7, P43, DOI 10.1016/0196-9781(86)90162-2; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRONENBORN AM, 1987, FEBS LETT, V215, P88, DOI 10.1016/0014-5793(87)80119-9; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN M, 1989, EUR J BIOCHEM, V186, P95, DOI 10.1111/j.1432-1033.1989.tb15182.x; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Knudsen SM, 1997, FEBS LETT, V412, P141, DOI 10.1016/S0014-5793(97)00714-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Momany FA, 1996, ANN NY ACAD SCI, V805, P172; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pang RTK, 1999, ENDOCRINOLOGY, V140, P5102, DOI 10.1210/en.140.11.5102; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; ROBBERECHT P, 1984, BIOCHIM BIOPHYS ACTA, V773, P271, DOI 10.1016/0005-2736(84)90091-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Tams JW, 1997, RECEPTOR CHANNEL, V5, P79; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Wulff B, 1997, FEBS LETT, V413, P405, DOI 10.1016/S0014-5793(97)00942-3; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	45	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26032	26039		10.1074/jbc.M000612200	http://dx.doi.org/10.1074/jbc.M000612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859300	hybrid			2022-12-27	WOS:000088999700022
J	Eggleston, AK; West, SC				Eggleston, AK; West, SC			Cleavage of holliday junctions by the Escherichia coli RuvABC complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD51 PROTEIN; BRANCH MIGRATION; RECA PROTEIN; IN-VITRO; CRYSTAL-STRUCTURE; STRAND EXCHANGE; RUVB PROTEINS; SUBSTRATE-SPECIFICITY; GENETIC-RECOMBINATION; HEXAMERIC RINGS	The Escherichia coli RuvABC proteins process recombination intermediates during genetic recombination and recombinational repair. Although early biochemical studies indicated distinct RuvAB-mediated branch migration and RuvC-mediated Holliday junction resolution reactions, more recent studies have shown that the three proteins act together as a "resolvasome" complex. In this work we have used recombination intermediates made by Reck to determine whether the RuvAB proteins affect the sequence specificity of the RuvC resolvase. We find that RuvAB proteins do not alter significantly the site specificity of RuvC-dependent cleavage, although under certain conditions, they do affect the efficiency of cleavage at particular sites. The presence of RecA also influences cleavage at some sites. We also show that the RuvAB proteins act upon transient strand exchange intermediates made using substrates that have the opposite polarity of those preferred by Reck Together, our results allow us to develop further a model for the recombinational repair of DNA lesions that lead to the formation of post-replication gaps during DNA replication. The novel features of this model are as follows: (i) the RuvABC resolvasome recognizes joints made by Reck (ii) resolution by RuvABC occurs at specific sites containing the RuvC consensus cleavage sequence 5'-(A/T)TT down arrow (G/C)-3'; and (iii) Holliday junction resolution often occurs close to the initiating gap without significant heteroduplex DNA formation.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Eggleston, Angela/0000-0001-8682-397X; West, Stephen/0000-0001-8848-9418				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Fogg JM, 1999, BIOCHEMISTRY-US, V38, P11349, DOI 10.1021/bi990926n; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hagan NFP, 1998, J MOL BIOL, V281, P17, DOI 10.1006/jmbi.1998.1934; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Rafferty JB, 1998, J MOL BIOL, V278, P105, DOI 10.1006/jmbi.1998.1697; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; ROSS P, 1977, J MOL BIOL, V117, P137, DOI 10.1016/0022-2836(77)90028-6; ROSS P, 1977, J MOL BIOL, V117, P159, DOI 10.1016/0022-2836(77)90029-8; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; Shida T, 1996, J BIOL CHEM, V271, P26105, DOI 10.1074/jbc.271.42.26105; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; West SC, 1998, CELL, V94, P699, DOI 10.1016/S0092-8674(00)81729-8; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	54	37	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26467	26476		10.1074/jbc.M001496200	http://dx.doi.org/10.1074/jbc.M001496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851230	hybrid			2022-12-27	WOS:000088999700081
J	Ott, CM; Smith, BD; Portis, AR; Spreitzer, RJ				Ott, CM; Smith, BD; Portis, AR; Spreitzer, RJ			Activase region on chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase - Nonconservative substitution in the large subunit alters species specificity of protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CHLAMYDOMONAS-REINHARDTII; CO2/O-2 SPECIFICITY; OXYGENASE RUBISCO; 1,5-BISPHOSPHATE; TOBACCO; GENE	In the active form of ribulose-1,5 bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39), a carbamate at lysine 201 binds Mg2+, which then interacts with the carboxylation transition state. Rubisco activase facilitates this spontaneous carbamylation/metal-binding process by removing phosphorylated inhibitors from the Rubisco active site. Activase from Solanaceae plants (e.g. tobacco) fails to activate Rubisco from non-Solanaceae plants (e.g. spinach and Chlamydomonas reinhardtii), and non-Solanaceae activase fails to activate Solanaceae Rubisco. Directed mutagenesis and chloroplast transformation previously showed that a proline 89 to arginine substitution on the surface of the large subunit of Chlamydomonas Rubisco switched its specificity from non-Solanaceae to Solanaceae activase activation. To define the size and function of this putative activase binding region, substitutions were created at positions flanking residue 89. As in the past, these substitutions changed the identities of Chlamydomonas residues to those of tobacco. Whereas an aspartate 86 to arginine substitution had little effect, aspartate 94 to lysine Rubisco was only partially activated by spinach activase but now fully activated by tobacco activase. In an attempt to eliminate the activase/tubisco interaction, proline 89 was changed to alanine, which is not present in either non-Solanaceae or Solanaceae Rubisco. This substitution also caused reversal of activase specificity, indicating that amino acid identity alone does not determine the specificity of the interaction.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; ARS, Photosynth Res Unit, USDA, Urbana, IL 61801 USA	University of Nebraska System; University of Nebraska Lincoln; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.							Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; BERRY JA, 1987, P NATL ACAD SCI USA, V84, P734, DOI 10.1073/pnas.84.3.734; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1991, PLANT PHYSIOL, V95, P604, DOI 10.1104/pp.95.2.604; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; MATE CJ, 1993, PLANT PHYSIOL, V102, P1119, DOI 10.1104/pp.102.4.1119; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; ROBINSON SP, 1988, FEBS LETT, V233, P413, DOI 10.1016/0014-5793(88)80473-3; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Spalding MH, 1998, MOL BIOL CHLOROPLAST, P529; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6293, DOI 10.1073/pnas.80.20.6293; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; van de Loo FJ, 1998, BIOCHEMISTRY-US, V37, P4621, DOI 10.1021/bi972566e; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yen A, 1998, ACTA CRYSTALLOGR D, V54, P668, DOI 10.1107/S0907444997016211; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	38	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26241	26244		10.1074/jbc.M004580200	http://dx.doi.org/10.1074/jbc.M004580200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858441	hybrid			2022-12-27	WOS:000088999700050
J	Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU				Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU			Cloning of Gb(3) synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1,4-glycosyltransferases conserved in plants, insects, and mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-P; SHIGA TOXIN; EXPRESSION CLONING; GLYCOLIPID ANTIGEN; BIOSYNTHESIS; TYPE-1; CELLS; GLYCOSYLTRANSFERASES; VEROTOXIN; RECEPTORS	We have cloned Gb, synthase, the key alpha 1,4-galactosyl-transferase in globe-series glycosphingolipid (GSL) synthesis, via a phenotypic screen, which previously yielded iGb(3) synthase, the alpha 1,3-galactosyltransferase required in iso-globe-series GSL (Keusch, J,J., Manzella, S. M., Nyame, K. A., Cummings, R. D., and Baenziger, J. U. (2000) J. Biol. Chem. 33), Both transferases act on lactosylceramide, Gal beta 1,4Glc beta 1Cer (LacCer), to produce Gb(3) (Gal alpha 1,4LacCer) or iGb(3) (Ga1 alpha 1,3LacCer), respectively. GalNAc can be added sequentially to either Gb(3) or iGb(3) yielding globoside and Forssman from Gb,, and isogloboside and isoForssman hem iGb(3). Gb, synthase is not homologous to iGb(3) synthase but shows 43% identity to a human alpha 1,4GlcNAc transferase that transfers a UDP-sugar in an alpha 1,4-linkage to a beta-linked Gal found in mucin. Extensive homology (35% identity) is also present between Gb, synthase and genes in Drosophila melanogaster and Arabidopsis thaliana, supporting conserved expression of an alpha 1,4-glycosyltransferase, possibly Gb, synthase, throughout evolution. The isolated Gb, synthase cDNA encodes a type II transmembrane glycosyltransferase of 360 amino acids. The highest tissue expression of Gb, synthase RNA is found in the kidney, mesenteric lymph node, spleen, and brain. Gb, glycolipid, also called pk antigen or CD77, is a known receptor for verotoxins. CHO cells that do not express Gb, and are resistant to verotoxin become susceptible to the toxin following transfection with Gb, synthase cDNA.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center	Keusch, JJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	jkeusch@pathbox.wustl.edu	Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK 41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1995, J LIPID RES, V36, P611; BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cooling LLW, 1998, INFECT IMMUN, V66, P4355; DENNIS RD, 1985, J BIOL CHEM, V260, P5370; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GLASGOW J, 1998, P 6 INT C INT SYST M, P175; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; JACEWICZ MS, 1994, J INFECT DIS, V169, P538, DOI 10.1093/infdis/169.3.538; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KISHIMOTO T, 1997, LEUKOCYTE TYPING, V6, P175; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kolter T, 1998, BRAIN PATHOL, V8, P79; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Li YT, 1999, ANAL BIOCHEM, V273, P1, DOI 10.1006/abio.1999.4191; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; Lingwood CA, 1999, BBA-MOL BASIS DIS, V1455, P375, DOI 10.1016/S0925-4439(99)00062-9; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MAKITA A, 1964, J BIOCHEM-TOKYO, V55, P269, DOI 10.1093/oxfordjournals.jbchem.a127880; MAKITA A, 1962, J BIOCHEM, V51, P124, DOI 10.1093/oxfordjournals.jbchem.a127509; MANGENEY M, 1993, CANCER RES, V53, P5314; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MOBASSALEH M, 1994, AM J PHYSIOL-GASTR L, V267, pG618, DOI 10.1152/ajpgi.1994.267.4.G618; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; STOFFYN P, 1973, BIOCHIM BIOPHYS ACTA, V306, P283, DOI 10.1016/0005-2760(73)90233-6; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Wiels J, 1996, GLYCOCONJUGATE J, V13, P529, DOI 10.1007/BF00731440; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YANG ZT, 1994, J BIOL CHEM, V269, P14620	41	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25315	25321		10.1074/jbc.M002630200	http://dx.doi.org/10.1074/jbc.M002630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854428	hybrid			2022-12-27	WOS:000088849400037
J	Smith, CC; Yu, YX; Kulka, M; Aurelian, L				Smith, CC; Yu, YX; Kulka, M; Aurelian, L			A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EARLY MESSENGER RNA-4; NEOPLASTIC TRANSFORMATION; MEDIATED ACTIVATION; R1 SUBUNIT; ONCOGENE; HSV-2; FAMILY; ATP; TRANSCRIPTION	The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is a multifunctional protein that contains a serine-threonine protein kinase (PK) activity (Nelson, J. W,, Zhu, J,, Smith, C. C,, Kulka, M., and Aurelian, L. (1996) J, Biol. Chem. 271, 17021-17027). Phylogenetic analyses indicated that ICP10 PK belongs to a distinct subfamily of growth factor receptor serine-threonine PKs that are characterized by their ability to function with a limited number of conserved catalytic motifs (Hunter, J. C. R., Smith, C. C., and Aurelian, L. (1995) Int. J. One. 7, 515-522). Here, we report the isolation and characterization of a novel gene, designated H11, that contains an open reading frame of 588 nucleotides, which encodes a protein similar to ICP10 ph, The H11 protein has Mn2+-dependent serine-threonine-specific PK activity as determined with a GST-H11 fusion protein and by immunocomplex PK immunoblotting assays of 293 cells transfected with a H11 eukaryotic expression vector. PK activity is ablated by mutation of Lys(113) within the presumtive catalytic motif II (invariant Lys), 293 cells stably transfected with H11 acquire anchorage-independent growth. Endogenous H11 RNA and the H11 phosphoprotein are expressed in melanoma cell lines and primary melanoma tissues at levels higher than in normal melanocytes and in benign nevi. Melanoma cell proliferation is inhibited by treatment with antisense oligonucleotides that inhibit H11 translation, suggesting that H11 expression is associated with cell growth.	Univ Maryland, Sch Med, Virol Immunol Labs, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Expt Therapeut, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Sch Med, Virol Immunol Labs, Dept Pharmacol, 10 S Pine St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA075453] Funding Source: NIH RePORTER; NCI NIH HHS [CA75453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Alahari SK, 1998, J PHARMACOL EXP THER, V286, P419; Aurelian L, 1999, VACCINE, V17, P1951, DOI 10.1016/S0264-410X(98)00470-8; AURELIAN L, 1989, CANCER CEL, V7, P187; Aurelian L, 1998, FRONT BIOSCI, V3, P237, DOI 10.2741/A238; Bartkova J, 1996, CANCER RES, V56, P5475; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; BAUER SR, 1989, ONCOGENE, V4, P615; Care A, 1996, MOL CELL BIOL, V16, P4842; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; Citro G, 1998, CANCER RES, V58, P283; CONNER J, 1995, VIROLOGY, V213, P615, DOI 10.1006/viro.1995.0033; COOPER J, 1995, J VIROL, V69, P4979, DOI 10.1128/JVI.69.8.4979-4985.1995; Feng CP, 1996, ANTISENSE NUCLEIC A, V6, P25, DOI 10.1089/oli.1.1996.6.25; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HONNEGER AM, 1987, CELL, V51, P199; Hosokawa Y, 1998, INT J CANCER, V76, P791, DOI 10.1002/(SICI)1097-0215(19980610)76:6<791::AID-IJC4>3.3.CO;2-M; HUNTER JCR, 1995, INT J ONCOL, V7, P515; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Keller-Melchior R, 1998, J INVEST DERMATOL, V110, P932, DOI 10.1046/j.1523-1747.1998.00211.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kokuba H, 1998, BRIT J DERMATOL, V138, P952; KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z; KULKA M, 1989, P NATL ACAD SCI USA, V86, P6868, DOI 10.1073/pnas.86.18.6868; Langelier Y, 1998, J BIOL CHEM, V273, P1435, DOI 10.1074/jbc.273.3.1435; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LEADER DP, 1985, GENE, V36, P369, DOI 10.1016/0378-1119(85)90193-3; LEE MS, 1993, ONCOGENE, V8, P387; LIVINGSTONE A, 1994, EUR J CANCER, V30A, P382, DOI 10.1016/0959-8049(94)90260-7; LUO JH, 1992, J BIOL CHEM, V267, P9645; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Nelson JW, 1996, J BIOL CHEM, V271, P17021, DOI 10.1074/jbc.271.29.17021; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peng T, 1996, VIROLOGY, V216, P184, DOI 10.1006/viro.1996.0045; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SMITH CC, 1994, VIROLOGY, V200, P598, DOI 10.1006/viro.1994.1223; Smith CC, 1996, VIROLOGY, V217, P425, DOI 10.1006/viro.1996.0136; Smith CC, 1998, J VIROL, V72, P9131, DOI 10.1128/JVI.72.11.9131-9141.1998; SMITH CC, 1992, J GEN VIROL, V73, P1417, DOI 10.1099/0022-1317-73-6-1417; Smith JB, 2000, METHOD ENZYMOL, V314, P537; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; WACHSMAN M, 1989, J INFECT DIS, V159, P625, DOI 10.1093/infdis/159.4.625; YANG DJ, 1994, CARCINOGENESIS, V15, P2167, DOI 10.1093/carcin/15.10.2167; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zachos G, 1998, ONCOGENE, V16, P3013, DOI 10.1038/sj.onc.1201836; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	54	89	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25690	25699		10.1074/jbc.M002140200	http://dx.doi.org/10.1074/jbc.M002140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833516	hybrid			2022-12-27	WOS:000088849400084
J	Storz, P; Hausser, A; Link, G; Dedio, J; Ghebrehiwet, B; Pfizenmaier, K; Johannes, FJ				Storz, P; Hausser, A; Link, G; Dedio, J; Ghebrehiwet, B; Pfizenmaier, K; Johannes, FJ			Protein kinase C mu is regulated by the multifunctional chaperon protein p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SIGNAL-TRANSDUCTION; CELLULAR PROTEIN; MITOCHONDRIAL MATRIX; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; DOWN-REGULATION; GLOBULAR HEADS; IN-VITRO; ACTIVATION	We identified the multifunctional chaperon protein p32 as a protein kinase C (PKC)-binding protein interacting with PKC alpha, PKC zeta, PKC delta, and PKC mu. We have analyzed the interaction of PKC mu with p32 in detail, and we show here in vivo association of PKC mu, as revealed from yeast two-hybrid analysis, precipitation assays using glutathione S-transferase fusion proteins, and reciprocal coimmunoprecipitation. In SKW 6.4 cells, PKC mu is constitutively associated with p32 at mitochondrial membranes, evident from colocalization with cytochrome c, p32 interacts with PKC mu in a compartment-specific manner, as it can be coimmunoprecipitated mainly from the particulate and not from the soluble fraction, despite the presence of p32 in both fractions. Although p32 binds to the kinase domain of PKC mu, it does not serve as a substrate. Interestingly, PKC mu-p32 immunocomplexes precipitated from the particulate fraction of two distinct cell lines, SKW 6.4 and 293T, show no detectable substrate phosphorylation, In support of a kinase regulatory function of p32, addition of p32 to in vitro kinase assays blocked, in a dose-dependent manner, aldolase but not autophosphorylation of PKC mu, suggesting a steric hindrance of substrate within the kinase domain. Together, these findings identify p32 as a novel, compartment-specific regulator of PKC mu kinase activity.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany; Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; SUNY Stony Brook, Dept Med & Pathol, Stony Brook, NY 11794 USA	University of Stuttgart; Fraunhofer Gesellschaft; Johannes Gutenberg University of Mainz; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Johannes, FJ (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Hausser, Angelika/AAC-4531-2021					AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; Dedio J, 1998, J IMMUNOL, V160, P3534; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Ghebrehiwet B, 1996, HYBRIDOMA, V15, P333, DOI 10.1089/hyb.1996.15.333; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Peerschke EIB, 1998, BLOOD COAGUL FIBRIN, V9, P29, DOI 10.1097/00001721-199801000-00004; Peterson KL, 1997, CLIN IMMUNOL IMMUNOP, V84, P17, DOI 10.1006/clin.1997.4374; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995	47	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24601	24607		10.1074/jbc.M002964200	http://dx.doi.org/10.1074/jbc.M002964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831594	hybrid			2022-12-27	WOS:000088683300051
J	Jakubowski, H				Jakubowski, H			Accelerated publication - Translational incorporation of S-nitrosohomocysteine into protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINO-ACIDS; ESCHERICHIA-COLI; PROOFREADING INVIVO; IN-VIVO; HOMOCYSTEINE; FLAVOHEMOGLOBIN; MECHANISM; SELECTION; SITE	The non-protein amino acid homocysteine (Hcy), owing to its structural similarity to the protein amino acids methionine, isoleucine, and leucine, enters first steps of protein synthesis and is activated by methionyl-, isoleucyl-, and leucyl-tRNA synthetases in vivo. However, translational incorporation of Hcy into protein is prevented by editing mechanisms of these synthetases, which convert misactivated Hey into thiolactone. The lack of efficient interactions of the side chain of Hcy with the specificity subsite of the synthetic/editing active site is a prerequisite for editing of Hcy. Thus, if the side chain thiol of Hcy were reversibly modified with a small molecule that would enhance its binding to the specificity subsite and prevent editing, such modified Hcy is predicted to he transferred to tRNA and incorporated translationally into protein. Here I show that S-nitroso-Hcy is in fact transferred to tRNA by methionyl-tRNA synthetase and incorporated into protein by the bacterium Escherichia coli. S-Nitroso-Hcy-tRNA also supports translation of mRNAs in a rabbit reticulocyte system. Removal of the nitroso group yields Hcy-tRNA and protein containing Hcy in peptide bonds. S-Nitrosylation-mediated translational incorporation of Hey into protein may occur under natural conditions in cells and contribute to Hey-induced pathogenesis in atherosclerosis.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Baernstein HD, 1934, J BIOL CHEM, V106, P451; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FIRST EA, 1998, COMPREHENSIVE BIOL C, V1, P573; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 1996, BIOCHEMISTRY-US, V35, P8252, DOI 10.1021/bi960344v; Jakubowski H, 1996, NUCLEIC ACIDS RES, V24, P2505, DOI 10.1093/nar/24.13.2505; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2000, HOMOCYSTEINE HLTH DI; JAKUBOWSKI H, 2000, ENCY LIFE SCI; KIM HY, 1993, P NATL ACAD SCI USA, V90, P11553, DOI 10.1073/pnas.90.24.11553; *PROM, 1998, PROM TECHN B, V127; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; van Hest JCM, 1998, FEBS LETT, V428, P68, DOI 10.1016/S0014-5793(98)00489-X	29	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21813	21816		10.1074/jbc.C000280200	http://dx.doi.org/10.1074/jbc.C000280200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10829011	hybrid			2022-12-27	WOS:000088363800010
J	Qin, KF; Yang, DS; Yang, Y; Chishti, MA; Meng, LJ; Kretzschmar, HA; Yip, CM; Fraser, PE; Westaway, D				Qin, KF; Yang, DS; Yang, Y; Chishti, MA; Meng, LJ; Kretzschmar, HA; Yip, CM; Fraser, PE; Westaway, D			Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP - Effect of protein age and deamidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEIN; SECONDARY STRUCTURE; ASPARTYL RESIDUES; COPPER-BINDING; NONENZYMATIC DEAMIDATION; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; INFECTED BRAIN; BOVINE BRAIN; N-TERMINUS	While PrPC rearranges in the area of codons 104-113 to form PrPSc during prion infections, the events that initiate sporadic Creutzfeldt-Jakob disease are undefined. AS Cu(II) is a putative ligand for PrPC and has been implicated in the pathogenesis of Creutzfeldt-Jakob disease and other neurodegenerative diseases, we investigated the structural effects of binding. Incubation of brain microsomes with Cu(II) generated similar to 30-kDa proteinase K-resistant PrP. Cu(II) had little effect on fresh recombinant PrP23-231, but aged protein characterized by conversion of Asn-107 to Asp decreased cu-helical content by similar to 30%, increased beta-sheet content 100%, formed aggregates, and acquired proteinase K resistance in the presence of Cu(II), These transitions took place without need for acid pH, organic solvents, denaturants, or reducing agents. Since conversion of Asn to Asp proceeds by a spontaneous pathway involving deamidation, our data suggest that covalent variants of PrPC arising in this manner may, in concert with Cu(II), generate PrPSc-like species capable of initiating sporadic prion disease.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Modern Med Res Ctr, Mass Spectrometry Lab, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3H2, Canada; Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 3H2, Canada; Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Gottingen	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca		Yip, Christopher/0000-0003-4507-556X				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BLACKWELL RQ, 1972, BIOCHIM BIOPHYS ACTA, V278, P482, DOI 10.1016/0005-2795(72)90008-6; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brennan T. V., 1995, DEAMIDATION ISOASPAR, P66; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1996, PRION DIS, P223; Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CLARKE S, 1992, STABILITY PROTEIN PH, P1; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GEIGER T, 1987, J BIOL CHEM, V262, P785; Gibbs C.J., 1979, SLOW TRANSMISSIBLE D, V1, P87; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kanyo ZF, 1999, J MOL BIOL, V293, P855, DOI 10.1006/jmbi.1999.3193; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1994, PHILOS T R SOC B, V343, P425, DOI 10.1098/rstb.1994.0039; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LAN S, 1971, J BIOL CHEM, V246, P5938; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Maeda H, 1997, LANGMUIR, V13, P4150, DOI 10.1021/la962105e; Marcotte EM, 1999, BIOCHEMISTRY-US, V38, P667, DOI 10.1021/bi981487f; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; McIntire WE, 1998, BIOCHEMISTRY-US, V37, P14651, DOI 10.1021/bi981642q; MCKINLEY M P, 1987, P197; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; Negro A, 1997, FEBS LETT, V412, P359, DOI 10.1016/S0014-5793(97)00798-9; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Paleari R, 1999, CLIN CHEM, V45, P21; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; POTTER SM, 1992, BIOCHEMISTRY-US, V31, P6339, DOI 10.1021/bi00142a025; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sandmeier E, 1999, BIOCHEM BIOPH RES CO, V261, P578, DOI 10.1006/bbrc.1999.1056; Shaked Y, 1999, J BIOL CHEM, V274, P32153, DOI 10.1074/jbc.274.45.32153; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SULKOWSKI E, 1992, FEBS LETT, V307, P129, DOI 10.1016/0014-5793(92)80750-B; Takemoto LJ, 1995, DEAMIDATION ISOASPAR, P157; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; WAJCMAN H, 1992, BIOCHIM BIOPHYS ACTA, V1138, P127, DOI 10.1016/0925-4439(92)90052-O; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; Weber DJ, 1998, BIOCHEM BIOPH RES CO, V246, P606, DOI 10.1006/bbrc.1998.8672; WESTAWAY D, 1989, TRENDS NEUROSCI, V12, P221, DOI 10.1016/0166-2236(89)90126-4; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Wong BS, 1999, BIOCHEM BIOPH RES CO, V259, P352, DOI 10.1006/bbrc.1999.0802; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; Xie ML, 1999, J PHARM SCI, V88, P8, DOI 10.1021/js9802493	88	142	149	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19121	19131		10.1074/jbc.275.25.19121	http://dx.doi.org/10.1074/jbc.275.25.19121			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858456	hybrid			2022-12-27	WOS:000087815900067
J	Yamit-Hezi, E; Nir, S; Wolstein, O; Dikstein, R				Yamit-Hezi, E; Nir, S; Wolstein, O; Dikstein, R			Interaction of TAF(II)105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL ACTIVATION; CELL-DEATH; INDUCED APOPTOSIS; FACTOR-ALPHA; A20; PROMOTER; TNF; INHIBITOR	TAF(II)105, a substoichiometric coactivator subunit of TFIID, is important for activation of anti-apoptotic genes by NF-kappa B in response to the cytokine tumor necrosis factor (TNF)-alpha In the present study we have analyzed the mechanism of TAF(II)105 function with respect to its regulation of p65/RelA, a component of NF-kappa B. We found two independent p65/RelA-binding domains within the N terminus of TAF(II)105. One of these domains appears to be crucial for TAF(II)105-mediated anti-apoptotic gene activation in response to TNF-alpha, Analysis of the interaction between TAF(II)105 and different NF-kappa B complexes has revealed substantial differences in the affinity of TAF(II)105 toward different p65/RelA-containing dimers. We hare identified the TNF-alpha induced anti-apoptotic A20 gene as a target gene of TAF(II)105. A20 has a differential protective effect on cell death induced by TNF-alpha in the presence of either the dominant negative mutant of TAF(II)105 (TAF(II)105 Delta C) or the superdominant I kappa B alpha. The results suggest that the inhibitory effect of TAF(II)105 Delta C on NF-K kappa-dependent genes is restricted to a subset of anti-apoptotic genes while the effect of I kappa B alpha is more general. Thus, an interaction between NF-kappa B and a specific coactivator is important for specifying target gene activation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	hcrivka@wiccmail.weizmann.ac.il						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Foo SY, 1999, TRENDS GENET, V15, P229; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Jaattela M, 1996, J IMMUNOL, V156, P1166; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TEWARI M, 1995, J IMMUNOL, V154, P1699; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wissing D, 1998, FREE RADICAL BIO MED, V25, P57, DOI 10.1016/S0891-5849(98)00043-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161	38	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18180	18187		10.1074/jbc.275.24.18180	http://dx.doi.org/10.1074/jbc.275.24.18180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849440	hybrid			2022-12-27	WOS:000087659400038
J	Guha, M; Bai, W; Nadler, JL; Natarajan, R				Guha, M; Bai, W; Nadler, JL; Natarajan, R			Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; INDUCED ACTIVATION; DIABETES-MELLITUS; OXIDATIVE STRESS; PROMOTER REGION; BINDING-SITES; GLUCOSE; SUPEROXIDE	Increased oxidative stress has been reported in vivo in the diabetic state via the production of reactive oxygen species (ROS), Such stress is bound to play a key role on activation of circulating monocytes, leading to the accelerated atherosclerosis observed in diabetics. However the exact molecular mechanisms of monocyte activation by high glucose is currently unclear. Here, we demonstrate that chronic high glucose (CHG) causes a dramatic increase in the release of the inflammatory cytokine tumor necrosis factor alpha (TNF alpha), at least in part through enhanced TNF alpha mRNA transcription, mediated by ROS via activation of transcription factors nuclear factor kappa B (NF-kappa B) and activating protein-1 (AP-1), TNF alpha accumulation in the conditioned media was increased 10-fold and mRNA levels were increased 11.5-fold by CHG, The following observations supported that both NF-kappa B and AP-1 mediated enhanced TNF alpha transcription by CHG: 1) A 295-base pair fragment of the proximal TNF alpha promoter containing NF-kappa B and AP-1 sites reproduced the effects of CHG on TNF alpha transcription in a luciferase reporter assay, 2) mutational analyses of both NF-kappa B and the AP-1 sites abrogated 90% of the luciferase activity, 3) gel-shift analysis using the binding sites showed activation of NF-kappa B and AP-1 in CHG nuclear extracts, and 4) Western blot analyses demonstrated elevated nuclear levels of p65 and p50 and decreased cytosolic levels of I kappa B alpha in CHG-treated monocytes, That ROS acted as a key intermediate in the CHG pathway was supported by the following evidence: 1) increased superoxide levels similar to those observed with PMA or TNF alpha, 2) increased phosphorylation of stress-responsive mitogen-activated protein kinases p38 and JNK-1, 3) counteraction of the effects of CHG on TNF alpha production, the 295TNFluc reporter activity, activation of NF kappa B, and repression of I kappa B alpha by antioxidants and p38 mitogen-activated protein kinase inhibitors. The study suggests that ROS function as key components in the regulatory pathway progressing from elevated glucose to monocyte activation.	City Hope Natl Med Ctr, Grad Sch Biol Sci, Dept Diabet & Endocrinol, Duarte, CA 91010 USA; Genet Inst, Pasadena, CA 91105 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA	City of Hope; University of Virginia	Natarajan, R (corresponding author), City Hope Natl Med Ctr, Grad Sch Biol Sci, Dept Diabet & Endocrinol, 1500 E Duarte Rd, Duarte, CA 91010 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0I HL55798] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Brehm M, 1996, TOXICOL LETT, V87, P131, DOI 10.1016/0378-4274(96)03768-X; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Ceolotto G, 1999, DIABETES, V48, P1316, DOI 10.2337/diabetes.48.6.1316; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Cosentino F, 1997, CIRCULATION, V96, P25; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Desfaits AC, 1998, DIABETES CARE, V21, P487, DOI 10.2337/diacare.21.4.487; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FAN ST, 1995, J IMMUNOL, V154, P3266; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Hill JR, 1998, J BIOL CHEM, V273, P3308, DOI 10.1074/jbc.273.6.3308; HORMANN MA, 1999, CELL, V97, P889; IDO Y, 1997, DIABETOLOGIA, V40, P115; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; JOVIAGE S, 1996, ARTERIOSCLER THROMB, P1573; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kashiwagi A., 1996, DIABETES, V45, P84; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Lee C, 1998, J BIOL CHEM, V273, P25272, DOI 10.1074/jbc.273.39.25272; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; Ogura M, 1998, J IMMUNOL, V161, P3569; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Patel NA, 1999, FASEB J, V13, P103, DOI 10.1096/fasebj.13.1.103; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; SATO H, 1993, ONCOGENE, V8, P395; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; TESFAMARIAM B, 1992, AM J PHYSIOL, V263, P321; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wilmer WA, 1999, DIABETES, V48, pA36; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Yamakawa T, 1999, ENDOCRINOLOGY, V140, P3562, DOI 10.1210/en.140.8.3562; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YIM HS, 1995, J BIOL CHEM, V270, P28228; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	47	249	263	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17728	17739		10.1074/jbc.275.23.17728	http://dx.doi.org/10.1074/jbc.275.23.17728			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837498	hybrid			2022-12-27	WOS:000087485000073
J	Osheroff, WP; Beard, WA; Yin, S; Wilson, SH; Kunkel, TA				Osheroff, WP; Beard, WA; Yin, S; Wilson, SH; Kunkel, TA			Minor groove interactions at the DNA polymerase beta active site modulate single-base deletion error rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; DIFFERENT SEQUENCE CONTEXTS; ESCHERICHIA-COLI; TEMPLATE-PRIMER; NUCLEOTIDE INCORPORATION; MUTATIONAL SPECIFICITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; III HOLOENZYME; FIDELITY	The structures of open and closed conformations of DNA polymerase beta (pol beta) suggests that the rate of single-nucleotide deletions during synthesis may be modulated by interactions in the DNA minor groove that align the templating base with the incoming dNTP. To test this hypothesis, we measured the single-base deletion error rates of wild-type pol beta and lysine and alanine mutants of Arg(283), whose side chain interacts with the minor groove edge of the templating nucleotide at the active site. The error rates of both mutant enzymes are increased > 100-fold relative to wild-type pol beta, Template engineering experiments performed to distinguish among three possible models for deletion formation suggest that most deletions in repetitive sequences by pol beta initiate by strand slippage. However, pol beta also generates deletions by a different mechanism that is strongly enhanced by the substitutions at Arg283. Analysis of error specificity suggests that this mechanism involves nucleotide misinsertion followed by primer relocation, creating a misaligned intermediate. The structure of pol beta bound to non-gapped DNA also indicates that the templating nucleotide and its downstream neighbor are out of register in the open conformation and this could facilitate misalignment (dNTP or primer terminus) with the next template base.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1993, REVERSE TRANSCRIPTAS, V23, P85; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CAI H, 1993, J BIOL CHEM, V268, P23567; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Efrati E, 1997, J BIOL CHEM, V272, P2559; Fujii S, 1999, J MOL BIOL, V289, P835, DOI 10.1006/jmbi.1999.2802; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroutil LC, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P699; Kroutil LC, 1999, NUCLEIC ACIDS RES, V27, P3481, DOI 10.1093/nar/27.17.3481; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KUNKEL TA, 2000, IN PRESS ANN REV BIO, V69; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pham PT, 1999, J BIOL CHEM, V274, P3705, DOI 10.1074/jbc.274.6.3705; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202	44	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28033	28038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10851238				2022-12-27	WOS:000089197100068
J	El Khattabi, M; Van Gelder, P; Bitter, W; Tommassen, J				El Khattabi, M; Van Gelder, P; Bitter, W; Tommassen, J			Role of the lipase-specific foldase of Burkholderia glumae as a steric chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; GRAM-NEGATIVE BACTERIA; PRO-REGION; PSEUDOMONAS-AERUGINOSA; ACTIVE-SITE; ACTIVATION; PROPEPTIDE; SECRETION; ELASTASE; SEQUENCE	Most lipases of Gram-negative bacteria require a lipase-specific foldase (Lif) in order to fold in the periplasm into their active, protease-resistant conformation prior to their secretion. The periplasmic domain of the Lif (amino acids 44-353) of Burkholderia glumae was purified as a His-tagged protein, and its function in the folding of lipase was studied In vitro, Refolding of the denatured lipase into its active conformation was dependent on the presence of the Lif, Circular dichroism revealed that the lipase refolded in the absence of Lif into a form with a native-like conformation, which was more stable against heat-induced denaturation than the native form, but was enzymatically inactive. This form of the protein could he activated by adding Lif after several hours, which demonstrates that the function of this chaperone is to help lipase to overcome an energetic barrier in the productive folding pathway rather than to prevent it from entering a non-productive pathway. The Lif was shown to interact with the native lipase in protease-protection experiments as well as by affinity chromatography, consistent with a role of the Lif late in the folding process. These results demonstrate that the Lif functions in a way analogous to the propeptides of many bacterial proteases and indicate that the amino acid sequence of the lipase does not contain all the information required for the protein to adopt its three-dimensional structure.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Utrecht University; Utrecht University; University of Basel	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Bitter, Wilbert/ABG-3726-2020; Bitter, W/CAJ-5778-2022; Tommassen, Jan/I-1690-2016; Bitter, Wilbert/AAA-6872-2019	Bitter, Wilbert/0000-0001-8347-6511; Tommassen, Jan/0000-0001-7633-4945; Van Gelder, Patrick/0000-0003-1785-4435				AAMAND JL, 1994, MOL GEN GENET, V245, P556, DOI 10.1007/BF00282218; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Braun P, 1998, TRENDS MICROBIOL, V6, P6, DOI 10.1016/S0966-842X(97)01188-8; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; El Khattabi M, 1999, MOL GEN GENET, V261, P770; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P468, DOI 10.1016/S0968-0004(98)01324-3; FRENKEN LGJ, 1993, MOL MICROBIOL, V9, P591, DOI 10.1111/j.1365-2958.1993.tb01719.x; Gerritse G, 1998, APPL ENVIRON MICROB, V64, P2644; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOBSON AH, 1993, P NATL ACAD SCI USA, V90, P5682, DOI 10.1073/pnas.90.12.5682; HOBSON AH, 1995, J BIOCHEM, V118, P575, DOI 10.1093/oxfordjournals.jbchem.a124948; IHARA F, 1995, J BACTERIOL, V177, P1254, DOI 10.1128/jb.177.5.1254-1258.1995; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Kagami Y, 1998, MOL MICROBIOL, V27, P221, DOI 10.1046/j.1365-2958.1998.00679.x; KESSLER E, 1994, J BIOL CHEM, V269, P22726; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; Michel G, 2000, J BACTERIOL, V182, P696, DOI 10.1128/JB.182.3.696-703.2000; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; NOBLE MEM, 1994, PROTEIN ENG, V7, P559, DOI 10.1093/protein/7.4.559; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rariy RV, 1997, P NATL ACAD SCI USA, V94, P13520, DOI 10.1073/pnas.94.25.13520; Sambrook J., 2002, MOL CLONING LAB MANU; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; Shibata H, 1998, J BIOCHEM-TOKYO, V123, P136; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; STARK GR, 1960, J BIOL CHEM, V235, P3177; TOMMASSEN J, 1992, FEMS MICROBIOL LETT, V103, P73; Yang JH, 2000, J BACTERIOL, V182, P295, DOI 10.1128/JB.182.2.295-302.2000	38	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26885	26891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859310				2022-12-27	WOS:000089144800031
J	Salvador, N; Aguado, C; Horst, M; Knecht, E				Salvador, N; Aguado, C; Horst, M; Knecht, E			Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; PEPTIDE SEQUENCES; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRACELLULAR PROTEINS; PRECURSOR PROTEIN; SELECTIVE UPTAKE; DEGRADATION; MITOCHONDRIA; BINDING; TRANSLOCATION	We have analyzed the folding state of cytosolic proteins imported in vitro into lysosomes, using an approach originally developed by filers and Schatz, (Eilers, M., and Schatz, G. (1986) Nature 322, 228-232) to investigate protein import into mitochondria. The susceptibility toward proteases of mouse dihydrofolate reductase (DHFR), synthesized in a coupled transcription-translation system with rabbit reticulocytes, decreased in the presence of its substrate analogue, methotrexate. This analogue complexes with high affinity with the in vitro synthesized DHFR and locks it into a protease-resistant folded conformation. DHFR was taken up by freshly isolated rat liver lysosomes and methotrexate reduced this uptake by about 80%. A chimeric DHFR protein, which carries the N-terminal presequence of subunit 9 of ATP synthase preprotein from Neurospora crassa fused to its N terminus, was taken up by lysosomes more efficiently. Again, methotrexate abolished the lysosomal uptake of the fusion protein, which was partially restored by washing of methotrexate from DHFR or by adding together methotrexate and dihydrofolate, the natural substrate of DHFR. Immunoblot analysis with anti-DHFR of liver lysosomes and of other fractions, isolated from rats starved for 88 h and treated with lysosomal inhibitors, suggests that DHFR is degraded by chaperone-mediated autophagy, Competition with ribonuclease A and stimulation by ATP/Mg2+ and the heat shock cognate protein of 73 kDa show that the lysosomal uptake of the fusion protein also occurs by this pathway. It is concluded that the lysosomal uptake of cytosolic proteins by chaperone-mediated autophagy mainly occurs by passage of the unfolded proteins through the lysosomal membrane. Therefore, this mechanism is different from protein transport into peroxisomes, but similar to the import of proteins into the endoplasmic reticulum and mitochondria.	Fdn Valenciana Invest Biomed, Inst Invest Citol, Valencia, Spain; Univ Basel, Fac Phil II, CH-4055 Basel, Switzerland	University of Basel	Knecht, E (corresponding author), Fdn Valenciana Invest Biomed, Inst Invest Citol, Amadeo Saboya 4, Valencia, Spain.		Knecht, Erwin/A-9366-2014; Knecht, Erwin/K-2432-2014; Aguado, Carmen/K-4354-2014	Knecht, Erwin/0000-0002-7208-3832; Aguado, Carmen/0000-0002-3113-4269				Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Aniento F, 1997, ELECTROPHORESIS, V18, P2638, DOI 10.1002/elps.1150181420; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BENNETT JP, 1982, TECHNIQUES LIFE SC B, V4, P15; Blobel G, 1995, COLD SPRING HARB SYM, V60, P1; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; DAEMS WT, 1972, LYSOSOMES LAB HDB, P156; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; deLlano CJM, 1996, ANAL BIOCHEM, V243, P210; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; HOLTZMANN E, 1976, LYSOSOMES SURVEY; Horst M, 1999, MOL BIOL CELL, V10, P2879, DOI 10.1091/mbc.10.9.2879; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; Huang SH, 1999, NAT STRUCT BIOL, V6, P1132; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Knecht E, 1998, ADV MOL CEL, V27, P201, DOI 10.1016/S1569-2558(08)60462-2; KOMINAMI E, 1983, J BIOL CHEM, V258, P6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1991, EUR J CELL BIOL, V56, P201; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; Teter SA, 1999, TRENDS CELL BIOL, V9, P428, DOI 10.1016/S0962-8924(99)01652-9; Ueno T, 1999, J BIOL CHEM, V274, P15222, DOI 10.1074/jbc.274.21.15222; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Wilson AJ, 1993, PROCEDURES ELECT MIC; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165	51	171	176	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27447	27456						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862611				2022-12-27	WOS:000089144800103
J	Burtelow, MA; Kaufmann, SH; Karnitz, LM				Burtelow, MA; Kaufmann, SH; Karnitz, LM			Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); FISSION YEAST; HUMAN HOMOLOG; ATAXIA-TELANGIECTASIA; STRUCTURAL HOMOLOG; CDC25 PHOSPHATASE; PROTEIN-KINASE; CONTROL GENE; ATM; PATHWAYS	Studies in yeasts and mammals have identified many genes important for DNA damage-induced checkpoint activation, including Rad9, Hus1, and Rad1; however, the functions of these gene products are unknown. In this study we show by immunolocalization that human Rad9 (hRad9) is localized exclusively in the nucleus. However, hRad9 was readily released from the nucleus into the soluble extract upon biochemical fractionation of un-irradiated cells. In contrast, DNA damage promptly converted hRad9 to an extraction-resistant form that was retained at discrete sites within the nucleus. Conversion of hRad9 to the extraction-resistant nuclear form occurred in response to diverse DNA damaging agents and the replication inhibitor hydroxyurea but not other cytotoxic stimuli. Additionally, extraction-resistant hRad9 interacted with its binding partners, hHus1 and an inducibly phosphorylated form of hRad1. Thus, these studies demonstrate that hRad9 is a nuclear protein that becomes more firmly anchored to nuclear components after DNA damage, consistent with a proximal function in DNA damage-activated checkpoint signaling pathways.	Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Radiat Oncol, Guggenheim 13, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bao SD, 1999, CANCER RES, V59, P2023; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; FIELDS AP, 1986, EXP CELL RES, V164, P139, DOI 10.1016/0014-4827(86)90461-1; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	43	95	95	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26343	26348		10.1074/jbc.M001244200	http://dx.doi.org/10.1074/jbc.M001244200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852904	hybrid			2022-12-27	WOS:000088999700064
J	Cheriyath, V; Roy, AL				Cheriyath, V; Roy, AL			Alternatively spliced isoforms of TFII-I - Complex formation, nuclear translocation, and differential gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; WILLIAMS-BEUREN-SYNDROME; V-BETA PROMOTER; NF-KAPPA-B; BINDING PROTEIN; TRANSCRIPTION INITIATION; EXPRESSION; ELEMENT; IDENTIFICATION	TFII-I is a multifunctional phosphoprotein with roles in transcription and signal transduction. Here we report characterization of three additional alternatively spliced isoforms of TFII-I. Employing isoform-specific antibodies, we show that the isoforms form a stable complex in vivo preferentially in the nucleus compared with the cytoplasm. We further show that both homomeric and heteromeric interactions are possible and that the heteromeric interactions between a wild type and a nuclear localization-deficient mutant result in nuclear translocation of the complex, leading us to postulate that complex formation might aid in nuclear translocation. In functional assays all four isoforms individually bind to DNA and transactivate reporter genes to a similar extent. However, although co-expression of different TFII-I isoforms leads to enhanced basal activity, it results in attenuated signal responsive activity. Thus, TFII-I might differentially regulate its target genes via complex or subcomplex formation.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA	Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.	aroy@opal.tufts.edu						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Novina CD, 1997, METHODS, V12, P254, DOI 10.1006/meth.1997.0477; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	28	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26300	26308		10.1074/jbc.M002980200	http://dx.doi.org/10.1074/jbc.M002980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854432	hybrid			2022-12-27	WOS:000088999700058
J	Bell, LM; Leong, MLL; Kim, B; Wang, E; Park, J; Hemmings, BA; Firestone, GL				Bell, LM; Leong, MLL; Kim, B; Wang, E; Park, J; Hemmings, BA; Firestone, GL			Hyperosmotic stress stimulates promoter activity and regulates cellular utilization of the serum- and glucocorticoid-inducible protein kinase (Sgk) by a p38 MAPK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; OSMOTIC-STRESS; TRANSCRIPTIONAL REGULATION; INFLAMMATORY CYTOKINES; GLUT4 TRANSLOCATION; MAMMALIAN-CELLS	We have established that the serum- and glucocorticold-inducible protein kinase (Sgk) is a new component of the hyperosmotic stress response. Treatment of NMuMg mammary epithelial cells with the organic osmolyte, sorbitol, caused the stable accumulation of Sgk transcripts and protein after an approximately 4-h lag. Transient transfection of a series of sgk-CAT reporter plasmids containing either 5' deletions or continuous 6-base pair substitutions identified a hyperosmotic stress-regulated element that is GC-rich and is necessary for the sorbitol stimulation of sgk gene promoter activity. Gel shift analysis identified four major DNA-protein complexes in the hyperosmotic stress-regulated element that, by competition with excess consensus wild type and mutant oligonucleotides and by antibody supershifts, contains the Spl transcription factor. Several lines of evidence suggest that the p38 MAPK signaling pathway mediates the hyperosmotic stress stimulation of sgk: gene expression. Treatment with pharmacological inhibitors of p38 MAPK or with a dominant negative form of MKK3, an upstream regulator of p38 MAPK, significantly reduced or ablated the sorbitol induction of sgk promoter activity or protein production. Using an in vitro peptide transphosphorylation assay, sorbitol treatment activates either endogenous or exogenous Sgk that is localized to the cytoplasmic compartment. Thus, we propose that the stimulated expression of enzymatically active Sgk after sorbitol treatment is a newly defined component of the p38 MAPK-mediated response to hyperosmotic stress.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Friedrich Miescher Inst, CH-4056 Basel, Switzerland	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Friedrich Miescher Institute for Biomedical Research	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 591 LSA, Berkeley, CA 94720 USA.		Park, Jongsun/E-7465-2010	Park, Jongsun/0000-0002-4690-1854	NATIONAL CANCER INSTITUTE [R01CA071514] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delmolino LM, 1997, J CELL PHYSIOL, V173, P371; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar JM, 1999, J AM SOC NEPHROL, V10, P2488; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waldegger S, 1999, GASTROENTEROLOGY, V116, P1081, DOI 10.1016/S0016-5085(99)70011-9; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watts BA, 1998, AM J PHYSIOL-RENAL, V275, pF478, DOI 10.1152/ajprenal.1998.275.4.F478; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	78	136	137	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25262	25272		10.1074/jbc.M002076200	http://dx.doi.org/10.1074/jbc.M002076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10842172	hybrid			2022-12-27	WOS:000088849400031
J	Esperet, C; Sabatier, S; Deville, MA; Ouazana, R; Bouhassira, EE; Godet, J; Morle, F; Bernet, A				Esperet, C; Sabatier, S; Deville, MA; Ouazana, R; Bouhassira, EE; Godet, J; Morle, F; Bernet, A			Non-erythroid genes inserted on either side of human HS-40 impair the activation of its natural alpha-globin gene targets without being themselves preferentially activated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; REGULATORY ELEMENT HS-40; MEDIATED CASSETTE EXCHANGE; ZETA-GLOBIN; IN-VIVO; HOMOLOGOUS RECOMBINATION; TRANSGENIC MICE; FAR UPSTREAM; THALASSEMIA; EXPRESSION	The human cu-globin gene complex includes three functional globin genes (5'-zeta 2-alpha 2-alpha 1-3') regulated by a common positive regulatory element named HS-40 displaying strong erythroid-specific enhancer activity. How this enhancer activity can be shared between different promoters present at different positions in the same complex is poorly understood. To address this question, we used homologous recombination to target the insertion of marker genes driven by cytomegalovirus or long terminal repeat promoters in both possible orientations either upstream or downstream from the HS-40 region into the single human alpha-globin gene locus present in hybrid mouse erythroleukemia cells. We also used CRE recombinase-mediated cassette exchange to target the insertion of a tagged alpha-globin gene at the same position downstream from HS-40. All these insertions led to a similar decrease in the HS-40-dependent transcription of downstream human alpha-globin genes in differentiated cells. Interestingly, this decrease is associated with the strong activation of the proximal newly inserted alpha-globin gene, whereas in marked contrast, the transcription of the non-erythroid marker genes remains insensitive to HS-40. Taken together, these results indicate that the enhancer activity of HS-40 can be trapped by non-erythroid promoters in both upstream and downstream directions without necessarily leading to their own activation.	Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, F-69622 Villeurbanne, France; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Yeshiva University; Albert Einstein College of Medicine	Bernet, A (corresponding author), Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, Bat 741,43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	bernet@biomserv.univ-lyon1.fr	Bouhassira, Eric/AAZ-4184-2021					Baron MH, 1996, GENE EXPRESSION, V6, P129; BERNET A, 1995, BLOOD, V86, P1202; BERNETGRANDAUDI A, 1994, CR ACAD SCI III-VIE, V314, P1; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Chen HL, 1997, NUCLEIC ACIDS RES, V25, P2917, DOI 10.1093/nar/25.14.2917; CRADDOCK CF, 1995, EMBO J, V14, P1718, DOI 10.1002/j.1460-2075.1995.tb07161.x; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; Fiering S, 1999, METHOD ENZYMOL, V306, P42; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HATTON CSR, 1990, BLOOD, V76, P221; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KROWZYNSKI A, 1985, J MOL BIOL, V18, P231; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LIEBHABER SA, 1990, P NATL ACAD SCI USA, V87, P9431, DOI 10.1073/pnas.87.23.9431; MANSOUR SL, 1988, CELL, V44, P319; MORLE F, 1986, NUCLEIC ACIDS RES, V14, P3279, DOI 10.1093/nar/14.8.3279; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; NANDI AK, 1988, P NATL ACAD SCI USA, V85, P3845, DOI 10.1073/pnas.85.11.3845; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; REN SC, 1993, BLOOD, V81, P1058; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROMAO L, 1991, BLOOD, V78, P1589; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; SHARPE JA, 1992, EMBO J, V11, P4565, DOI 10.1002/j.1460-2075.1992.tb05558.x; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; Wen SC, 2000, MOL CELL BIOL, V20, P1993, DOI 10.1128/MCB.20.6.1993-2003.2000; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501	45	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25831	25839		10.1074/jbc.M001757200	http://dx.doi.org/10.1074/jbc.M001757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827181	hybrid			2022-12-27	WOS:000088849400101
J	Gotthardt, M; Trommsdorff, M; Nevitt, MF; Shelton, J; Richardson, JA; Stockinger, W; Nimpf, J; Herz, J				Gotthardt, M; Trommsdorff, M; Nevitt, MF; Shelton, J; Richardson, JA; Stockinger, W; Nimpf, J; Herz, J			Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PDZ DOMAIN; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; APOLIPOPROTEIN-E; VLDL RECEPTOR; MICE LACKING; INTEGRIN; BINDING; REELIN	The members of the low density lipoprotein (LDL) receptor gene family bind a broad spectrum of extracellular ligands, Traditionally, they had been regarded as mere cargo receptors that promote the endocytosis and lysosomal delivery of these ligands, However, recent genetic experiments in mice have revealed critical functions for two LDL receptor family members, the very low density lipoprotein receptor and the apoE receptor-a, in the transmission of extracellular signals and the activation of intracellular tyrosine kinases, This process regulates neuronal migration and is crucial for brain development. Signaling through these receptors requires the interaction of their cytoplasmic tails with the intracellular adaptor protein Disabled-1 (DAB1), Here, we identify an extended set of cytoplasmic proteins that might also participate in signal transmission by the LDL receptor gene family. Most of these novel proteins are adaptor or scaffold proteins that contain PID or PDZ domains and function in the regulation of mitogen-activated protein kinases, cell adhesion, vesicle trafficking, or neurotransmission, We show that binding of DAB1 interferes with receptor internalization suggesting a mechanism by which signaling through this class of receptors might be regulated. Taken together, these findings imply much broader physiological functions for the LDL receptor family than had previously been appreciated. They form the basis for the elucidation of the molecular pathways by which cells respond to the diversity of ligands that bind to these multifunctional receptors on the cell surface.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63762, HL20948, R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng M, 1999, ANN NY ACAD SCI, V868, P483, DOI 10.1111/j.1749-6632.1999.tb11317.x; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	38	387	415	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25616	25624		10.1074/jbc.M000955200	http://dx.doi.org/10.1074/jbc.M000955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827173	hybrid			2022-12-27	WOS:000088849400076
J	Mullin, JL; Gorkun, OV; Binnie, CG; Lord, ST				Mullin, JL; Gorkun, OV; Binnie, CG; Lord, ST			Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; LATERAL AGGREGATION; TERMINAL DOMAIN; ALPHA-THROMBIN; POLYMERIZATION; HIRUDIN; CONVERSION; INHIBITORS; TURBIDITY; FRAGMENTS	During cleavage of fibrinogen by thrombin, fibrinopeptide A (FpA) release precedes fibrinopeptide B (FpB) release. To examine the basis for this ordered release, we synthesized A'beta fibrinogen, replacing FpB with a fibrinopeptide A-like peptide, FpA' (G14V). Analyses of fibrinopeptide release from A'beta fibrinogen showed that FpA release and FpA' release were similar; the release of either peptide followed simple first-order kinetics. Specificity constants for FpA and FpA' were similar, demonstrating that these peptides are equally competitive substrates for thrombin. In the presence of Gly-Pro-Arg-Pro, an inhibitor of fibrin polymerization, the rate of FEB release from normal fibrinogen was reduced 3-fold, consistent with previous data; in contrast, the rate of FpA' release from A'beta fibrinogen was unaffected. Thus, with A'beta fibrinogen, fibrinopeptide release from the beta chain is similar to fibrinopeptide release from the alpha chain. We conclude that the ordered release of fibrinopeptides is dictated by the specificity of thrombin for its substrates. We analyzed polymerization, following changes in turbidity, and found that polymerization of A'beta fibrinogen was similar to that of normal fibrinogen. We analyzed clot structure by scanning electron microscopy and found that clots from A'beta fibrinogen were similar to clots from normal fibrinogen. We conclude that premature release of the fibrinopeptide from the N terminus of the beta chain does not affect polymerization of fibrinogen.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lord, ST (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, CB 7525,605 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.		Ariel, Pablo/AGJ-4118-2022		NHLBI NIH HHS [R01-HL31048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BINNIE CG, 1993, BLOOD, V81, P3186; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P208; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; ECKHARDT T, 1981, J CLIN INVEST, V67, P809, DOI 10.1172/JCI110098; Everse SJ, 1999, BIOCHEMISTRY-US, V38, P2941, DOI 10.1021/bi982626w; FERRY JD, 1947, J AM CHEM SOC, V69, P388, DOI 10.1021/ja01194a066; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HenschenEdman AH, 1997, CELL MOL LIFE SCI, V53, P29, DOI 10.1007/PL00000577; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER BG, 1988, J BIOL CHEM, V263, P15056; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LEWIS SD, 1985, J BIOL CHEM, V260, P192; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORD ST, 1990, J BIOL CHEM, V265, P838; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; MARTINELLI RA, 1980, BIOCHEMISTRY-US, V19, P2343, DOI 10.1021/bi00552a010; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NG AS, 1993, METHOD ENZYMOL, V222, P341; RUF W, 1988, BIOCHIM BIOPHYS ACTA, V965, P169, DOI 10.1016/0304-4165(88)90053-0; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TAKEBE M, 1995, THROMB HAEMOSTASIS, V73, P662; VANDERDRIFT ACM, 1983, FIBRINOGEN STRUCTURE, P3; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1	36	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25239	25246		10.1074/jbc.M004142200	http://dx.doi.org/10.1074/jbc.M004142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837485	hybrid, Green Published			2022-12-27	WOS:000088849400028
J	Petropoulos, H; Skesjanc, IS				Petropoulos, H; Skesjanc, IS			Analysis of the inhibition of MyoD activity by ITF-2B and full-length E12/E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; MUSCLE DIFFERENTIATION PROGRAM; CREATINE-KINASE ENHANCER; DNA-BINDING; CARDIAC-MUSCLE; REGULATORY ELEMENTS; MAMMALIAN-CELLS; E-BOX; GENE-EXPRESSION; TRANSGENIC MICE	MyoD heterodimerizes with E type factors (E12/E47 and ITF-2A/ITF-2B) and binds E box sequences within promoters of muscle-specific genes. In transient transfection assays, MyoD activates transcription in the presence of ITF-2A but not ITF-28, which contains a 182-amino acid N-terminal extension. The first 83 amino acids of the inhibitory N terminus of ITF-2B show high sequence homology to the N terminus of full-length E12/E47. Previous studies that showed activation of MyoD by E12 used an artificially N-terminally truncated form. Here we show that the full-length form of E12 inhibits MyoD function. A conserved cu-helix motif, capable of interacting with the transcriptional machinery, was not essential for inhibition, Furthermore, the fusion of N-terminal ITF-2B sequences or non-inhibiting ITF-2A sequences to truncated E12 was sufficient in converting the activator into an inhibitor. Overexpression of ITF-2B did not inhibit C2C12 myogenesis or affect levels of endogenous muscle gene expression, consistent with the finding that inhibitory E type proteins are present in muscle. Furthermore, we found that MyoD co-transfected with either ITF-2B or ITF-2A converted fibroblasts into myoblasts with the same frequency. Our findings suggest that the ability of E type proteins to inhibit MyoD activity is dependent on the context of the E box.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skesjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENARDI C, 1993, J CELL BIOL, V123, P823, DOI 10.1083/jcb.123.4.823; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Filvaroff EH, 1996, DEV BIOL, V178, P459, DOI 10.1006/dbio.1996.0231; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 1996, MOL CELL BIOL, V16, P121; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 2002, MOL CLONING LAB MANU; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Shield MA, 1996, MOL CELL BIOL, V16, P5058; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; SKERJANC IS, 1994, MOL CELL BIOL, V1464, P8451; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	65	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25095	25101		10.1074/jbc.M004251200	http://dx.doi.org/10.1074/jbc.M004251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833525	hybrid			2022-12-27	WOS:000088849400009
J	Shapiro, MJ; Weiss, EJ; Faruqi, TR; Coughlin, SR				Shapiro, MJ; Weiss, EJ; Faruqi, TR; Coughlin, SR			Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR; PROTEOLYTIC MECHANISM; ENDOTHELIAL-CELLS; INTERNALIZATION; DESENSITIZATION; TRAFFICKING; CLONING; RESENSITIZATION; DETERMINANTS; SPECIFICITY	Protease-activated receptors 1 and 4 (PAR1 and PAR4) mediate thrombin signaling in human platelets. Whether these receptors are redundant, interact, or serve only partially overlapping functions is unknown. We report that PAR1 and PAR4 signal with distinct tempos, In transfected fibroblasts, PARA triggered substantially more phosphoinositide hydrolysis per activated receptor than PAR1 and was shut off more slowly than PAR1, Shutoff and internalization of PAR1 depends upon phosphorylation of its carboxyl tail upon receptor activation. In contrast to PAR1, phosphorylation of PARA was undetectable, and activation-dependent internalization of PAR4 was much slower than that seen for PAR1. Mutation of potential phosphorylation sites in the carboxyl tail of PAR1 enhanced PAR1 signaling, whereas analogous mutations in PAR4 had no effect. Thus PAR4 signaling is shut off less rapidly than PAR1, probably due to differences in receptor phosphorylation, PAR1 and PARA also signaled with distinct tempos in platelets. PAR1 triggered a rapid and transient increase in intracellular calcium, whereas PAR4 triggered a more prolonged response. Together, the tempo of these responses accounted for that triggered by thrombin, Thus differences in the rates at which PAR1 and PAR4 are shut off allow thrombin to trigger intracellular signaling with distinct temporal characteristics.	Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, HSE-1300,505 Parnassus Ave, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAGE SO, 1996, USE FLUORESCENT INDI, P67; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	35	186	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25216	25221		10.1074/jbc.M004589200	http://dx.doi.org/10.1074/jbc.M004589200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837487	hybrid			2022-12-27	WOS:000088849400025
J	Feldman, DH; Harvey, WR; Stevens, BR				Feldman, DH; Harvey, WR; Stevens, BR			A novel electrogenic amino acid transporter is activated by K+ or Na+, is alkaline pH-dependent, and is Cl--independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ENERGIZATION; L-PROLINE TRANSPORTER; GATED ION-CHANNEL; SEROTONIN TRANSPORTERS; XENOPUS-OOCYTES; GABA TRANSPORTER; V-ATPASES; CLONING; EXPRESSION; COTRANSPORTER	A new eukaryotic nutrient amino acid transporter has been cloned from an epithelium that is exposed to high voltages and alkaline pH. The full-length cDNA encoding this novel CAATCH1 (cation-anion-activated Amino acid transporter/channel) was isolated using a polymerase chain reaction-based strategy, and its expression product in Xenopus oocytes displayed a combination of several unique, unanticipated functional properties. CAATCH1 electrophysiological properties resembled those of Na+,Cl--coupled neurotransmitter amine transporters, although CAATCH1 was cloned from a gut absorptive epithelium rather than from an excitable tissue. Amino acids such as L-proline, L-threonine, and L-methionine elicited complex current-voltage relationships in alkaline pH-dependent CAATCH1 that were reminiscent of the behavior of the dopamine, serotonin, and norepinephrine transporters (DAT, SERT, NET) in the presence of their substrates and pharmacological inhibitors such as cocaine or antidepressants, These I-V relationships indicated a combination of substrate-associated carrier current plus an independent CAATCH1-associated leakage current that could be blocked by certain amino acids. However, unlike all structurally related proteins, CAATCH1 activity is absolutely independent of Cl-. Unlike related KAAT1, CAATCH1 possesses a methionine-inhibitable constitutive leakage current and is able to switch its narrow substrate selectivity, preferring threonine in the presence of K+ but preferring proline in the presence of Na+.	Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32652 USA; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Stevens, BR (corresponding author), Univ Florida, Coll Med, Dept Physiol, 1600 SW Archer Rd,Box 100274, Gainesville, FL 32652 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030464] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI30464] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara S G, 1998, Adv Pharmacol, V42, P164; AMARAVADI L, 1994, BIOTECHNIQUES, V16, P98; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Bossi E, 1999, PFLUG ARCH EUR J PHY, V438, P788, DOI 10.1007/s004240051108; Bossi E, 1999, J PHYSIOL-LONDON, V515, P729, DOI 10.1111/j.1469-7793.1999.729ab.x; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Cao YW, 1997, J NEUROSCI, V17, P2257; Cao YW, 1998, J NEUROSCI, V18, P7739; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Colville C, 1994, MEMBRANE PROTEIN EXP, P243; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DeFelice L J, 1998, Adv Pharmacol, V42, P186; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481, DOI 10.1152/ajprenal.1999.277.4.F481; Feldman DH, 1999, BIOPHYS J, V76, pA249; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; Galli A, 1999, J NEUROSCI, V19, P6290; Galli A, 1997, J NEUROSCI, V17, P3401; Galli A, 1998, P NATL ACAD SCI USA, V95, P13260, DOI 10.1073/pnas.95.22.13260; GERENCSER GA, 1994, J EXP BIOL, V196, P59; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRIFFITH JK, 1998, TRANSPORTER FACTS BO; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Harvey WR, 1997, J EXP BIOL, V200, P203; Harvey WR, 1998, AM ZOOL, V38, P426; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Hille B., 1992, IONIC CHANNELS EXCIT; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MBUNGU D, 1995, ARCH BIOCHEM BIOPHYS, V318, P489, DOI 10.1006/abbi.1995.1258; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; STEVENS BR, 1987, J BIOL CHEM, V262, P6546; STEVENS BR, 1992, MAMMALIAN AMINO ACID TRANSPORT, P149; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	48	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24518	24526		10.1074/jbc.M907582199	http://dx.doi.org/10.1074/jbc.M907582199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829035	hybrid			2022-12-27	WOS:000088683300039
J	Muller, B; Link, J; Smythe, C				Muller, B; Link, J; Smythe, C			Assembly of U7 small nuclear ribonucleoprotein particle and histone RNA 3 ' processing in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HAIRPIN BINDING-PROTEIN; COILED BODIES; CELL-CYCLE; STEM-LOOP; GERMINAL VESICLE; END FORMATION; INVITRO; 3'-END; SNRNA	In animals, replication-dependent histone genes are expressed in dividing somatic cells during S phase to maintain chromatin condensation. Histone mRNA 3'-end formation is an essential regulatory step producing an mRNA with a hairpin structure at the 3'-end. This requires the interaction of the U7 small nuclear ribonucleoprotein particle (snRNP) with a purine-rich spacer element and of the hairpin-binding protein with the hairpin element, respectively, in the 3'-untranslated region of histone RNA. Here, we demonstrate that bona fide histone RNA 3' processing takes place in Xenopus egg extracts in a reaction dependent on the addition of synthetic U7 RNA that is assembled into a ribonucleoprotein particle by protein components available in the extract. In addition to reconstituted U7 snRNP, Xenopus hairpin-binding protein SLBP1 is necessary for efficient processing. Histone RNA 3' processing is not affected by addition of non-destructible cyclin B, which drives the egg extract into M phase, but SLBP1 is phosphorylated in this extract. SPH-1, the Xenopus homologue of human p80-coilin found in coiled bodies, is associated with U7 snRNPs. However, this does not depend on the U7 RNA being able to process histone RNA and also occurs with U1 snRNPs; therefore, association of SPH1 cannot be considered as a hallmark of a functional U7 snRNP.	Univ Bern, Inst Zool, Abt Entwicklungsbiol, CH-3012 Bern, Switzerland; Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Univ Dundee, Inst Med Sci, Dept Biochem, Prot Phosphorylat Unit,MRC, Dundee DD1 4HN, Scotland	University of Bern; University of Aberdeen; University of Dundee	Muller, B (corresponding author), Univ Bern, Inst Zool, Abt Entwicklungsbiol, Baltzerstr 4, CH-3012 Bern, Switzerland.			Muller, Berndt/0000-0003-1279-5421				Abbott J, 1999, MOL BIOL CELL, V10, P487, DOI 10.1091/mbc.10.2.487; ADAMSON ED, 1974, J MOL BIOL, V88, P263, DOI 10.1016/0022-2836(74)90481-1; BAUER DW, 1994, MOL BIOL CELL, V5, P633, DOI 10.1091/mbc.5.6.633; Bauer DW, 1997, MOL BIOL CELL, V8, P73, DOI 10.1091/mbc.8.1.73; Bellini M, 1998, MOL BIOL CELL, V9, P2987, DOI 10.1091/mbc.9.10.2987; BIRCHMEIER C, 1984, P NATL ACAD SCI-BIOL, V81, P1057, DOI 10.1073/pnas.81.4.1057; BIRCHMEIER C, 1983, CELL, V35, P433, DOI 10.1016/0092-8674(83)90176-9; BIRCHMEIER C, 1982, CELL, V26, P739; BOND UM, 1991, GENE DEV, V5, P1709, DOI 10.1101/gad.5.9.1709; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTEN M, 1988, EMBO J, V7, P801, DOI 10.1002/j.1460-2075.1988.tb02878.x; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Dominski Z, 1999, MOL CELL BIOL, V19, P3561; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Furger A, 1998, RNA, V4, P246; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; GALLI G, 1983, CELL, V34, P823, DOI 10.1016/0092-8674(83)90539-1; GEORGIEV O, 1984, NUCLEIC ACIDS RES, V12, P8539, DOI 10.1093/nar/12.22.8539; GICK O, 1987, P NATL ACAD SCI USA, V84, P8937, DOI 10.1073/pnas.84.24.8937; GRAVES RA, 1985, J MOL BIOL, V183, P179, DOI 10.1016/0022-2836(85)90211-6; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; GRUBER A, 1990, GENE, V95, P303, DOI 10.1016/0378-1119(90)90377-4; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; Marzluff William F., 1992, Gene Expression, V2, P93; MELIN L, 1992, EMBO J, V11, P691, DOI 10.1002/j.1460-2075.1992.tb05101.x; MOWRY KL, 1987, MOL CELL BIOL, V7, P1663, DOI 10.1128/MCB.7.5.1663; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; Muller B, 1997, SEMIN CELL DEV BIOL, V8, P567, DOI 10.1006/scdb.1997.0182; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1994, MOL CELL BIOL, V14, P1709, DOI 10.1128/MCB.14.3.1709; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; Schaller A, 1997, J BIOL CHEM, V272, P10435; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, FUNCTIONAL ORG NUCL, P449; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STAUBER C, 1990, METHOD ENZYMOL, V181, P74; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; STREIT A, 1993, NUCLEIC ACIDS RES, V21, P1569, DOI 10.1093/nar/21.7.1569; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; STRUB K, 1986, EMBO J, V5, P1675, DOI 10.1002/j.1460-2075.1986.tb04411.x; Tuma RS, 1999, CHROMOSOMA, V108, P337, DOI 10.1007/s004120050385; TUMA RS, 1993, J CELL BIOL, V122, P767, DOI 10.1083/jcb.122.4.767; VANDONGEN W, 1981, DEV BIOL, V86, P303, DOI 10.1016/0012-1606(81)90188-3; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; Wang ZF, 1999, MOL CELL BIOL, V19, P835; WOODLAND HR, 1980, FEBS LETT, V121, P1, DOI 10.1016/0014-5793(80)81252-X; Wu CHH, 1996, RNA, V2, P811; WU CHH, 1993, P NATL ACAD SCI USA, V90, P6257, DOI 10.1073/pnas.90.13.6257; ZELLER R, 1984, EMBO J, V3, P1075, DOI 10.1002/j.1460-2075.1984.tb01931.x	62	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24284	24293		10.1074/jbc.M003253200	http://dx.doi.org/10.1074/jbc.M003253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827192	hybrid			2022-12-27	WOS:000088683300009
J	Witherow, DS; Wang, Q; Levay, K; Cabrera, JL; Chen, J; Willars, GB; Slepak, VZ				Witherow, DS; Wang, Q; Levay, K; Cabrera, JL; Chen, J; Willars, GB; Slepak, VZ			Complexes of the G protein subunit G beta(5) with the regulators of G protein signaling RGS7 and RGS9 - Characterization in native tissues and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; BETA-GAMMA-DIMERS; ADULT-RAT BRAIN; ALPHA-SUBUNIT; TRANSITION-STATE; PHOSPHOLIPASE-C; IN-VITRO; TRANSDUCIN	A novel protein class, termed regulators of G protein signaling (RGS), negatively regulates G protein pathways through a direct interaction with G alpha subunits and stimulation of GTP hydrolysis. An RGS subfamily including RGS6, -7, -9, and -11, which contain a characteristic G gamma-like domain, also has the unique ability to interact with the G protein beta subunit G beta(5). Here, we examined the behavior of G beta(5), RGS7, RGS9, and G alpha in tissue extracts using immunoprecipitation and conventional chromatography. Native G beta(5) and RGS7 from brain, as well as photoreceptor-specific G beta(5)L and RGS9, always co-purified as tightly associated dimers, and neither RGS-free G beta(5) nor G beta(5)-free RGS could be detected, Co-expression in COS-7 cells of G beta(5), dramatically increased the protein level of RGS7 and vice versa, indicating that cells maintain G beta(5) : RGS stoichiometry in a manner similar to G beta gamma complexes. This mechanism is non-transcriptional and is based on increased protein stability upon dimerization. Thus, analysis of native G beta(5)-RGS and their coupled expression argue that in vivo, G beta(5) and G gamma-like domain-containing RGSs only exist as heterodimers. Native G beta(5)-RGS7 did not co-precipitate or co-purify with G alpha(o) or G alpha(q); nor did G beta(5)-L-RGS9 with G alpha(t). However, in transfected cells, RGS7 and G beta(5)-RGS7 inhibited G alpha(q)-mediated Ca2+ response to muscarinic M3 receptor activation. Thus, G beta(5)-RGS dimers differ from other RGS proteins in that they do not bind to G alpha with high affinity, but they can still inhibit G protein signaling.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Program Neurosci, Miami, FL 33136 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Miami; University of Miami; University of Southern California; University of Leicester	Slepak, VZ (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	vslepak@newssun.med.miami.edu		Witherow, D. Scott/0000-0002-7344-1574	NEI NIH HHS [EY12155, EY12703] Funding Source: Medline; NIGMS NIH HHS [R01 GM60019] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012703, R01EY012155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Betty M, 1998, NEUROSCIENCE, V85, P475, DOI 10.1016/S0306-4522(97)00623-4; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; EULER T, 1995, J COMP NEUROL, V361, P461, DOI 10.1002/cne.903610310; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Gold SJ, 1997, J NEUROSCI, V17, P8024; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hirschman JE, 1997, J BIOL CHEM, V272, P240; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Liang JJ, 2000, J NEUROSCI RES, V60, P58, DOI 10.1002/(SICI)1097-4547(20000401)60:1<58::AID-JNR6>3.0.CO;2-L; Liang JJ, 1998, J NEUROCHEM, V71, P345; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Nahorski SR, 1997, LIFE SCI, V60, P1039, DOI 10.1016/S0024-3205(97)00045-3; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Pham K, 1998, BIOTECHNIQUES, V25, P198, DOI 10.2144/98252bm04; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sullivan E, 1999, METH MOL B, V114, P125; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; Wieland T, 1997, J BIOL CHEM, V272, P8853; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	62	128	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24872	24880		10.1074/jbc.M001535200	http://dx.doi.org/10.1074/jbc.M001535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10840031	hybrid			2022-12-27	WOS:000088683300085
J	Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R				Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R			Generation of structurally and functionally distinct factors from the basic helix-loop-helix gene Hes3 by alternative first exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MAMMALIAN NEURONAL DIFFERENTIATION; ACHAETE-SCUTE HOMOLOG-1; TRANSCRIPTION FACTORS; CHROMOSOMAL LOCUS; PROMOTER ANALYSIS; DROSOPHILA HAIRY; WRPW MOTIF; STEM-CELLS; ENHANCER	The basic helix-loop-helix gene Hes3 is expressed by differentiating and mature Purkinje cells in the cerebellum and by neural precursor cells in the embryonal nervous system. We here found that the transcript of cerebellar Hes3, designated Hes3a, has a distinct 5'-terminal structure from that of embryonal Hes3, designated Hes3b, and that the two types of Hes3 transcripts are generated from different first exons. Hes3a lacks the amino-terminal half of the basic region and thus does not bind to the DNA, whereas Hes3b contains a complete basic region and binds to the N box sequence with a high affinity like Hes1, another member of the Hes family. Both types of Hes3 proteins functionally antagonize the neuronal determination factor Mash1, but only Hes3b represses transcription from the N box-containing promoter like Hes1. Furthermore, misexpression of Hes3b with retrovirus in neural precursor cells inhibits neuronal differentiation like Hes1, whereas Hes3a does not, Thus, alternative promoters and first exons that are differentially utilized during neural development generate structurally and functionally distinct proteins from a single Hes3 gene locus.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Shogoin Kawahara, Kyoto 6068507, Japan.			Hirata, Hiromi/0000-0002-3769-7441				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Allen T, 1999, CELL MOL BIOL, V45, P687; Anderson D, 1997, MOL CELLULAR APPROAC, P26; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaugrund E, 1996, DEVELOPMENT, V122, P309; Brown NL, 1998, DEVELOPMENT, V125, P4821; Casarosa S, 1999, DEVELOPMENT, V126, P525; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cau E, 1997, DEVELOPMENT, V124, P1611; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Guillemot F, 1995, BIOL CELL, V84, P3, DOI 10.1016/0248-4900(96)81312-8; HOJO M, 2000, IN PRESS DEVELOPMENT; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito M, 1984, CEREBELLUM NEURAL CO; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lobe CG, 1997, MECH DEVELOP, V62, P227, DOI 10.1016/S0925-4773(97)00665-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SAKAGAMI T, 1994, BIOCHEM BIOPH RES CO, V203, P594, DOI 10.1006/bbrc.1994.2224; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Torii MA, 1999, DEVELOPMENT, V126, P443; Tsuda H, 1998, J BIOL CHEM, V273, P6327, DOI 10.1074/jbc.273.11.6327; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	46	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19083	19089		10.1074/jbc.M001075200	http://dx.doi.org/10.1074/jbc.M001075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858455	hybrid			2022-12-27	WOS:000087815900062
J	Jorgensen, R; Sogaard, TMM; Rossing, AB; Martensen, PM; Justesen, J				Jorgensen, R; Sogaard, TMM; Rossing, AB; Martensen, PM; Justesen, J			Identification and characterization of human mitochondrial tryptophanyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; INTERFERON-GAMMA; NADH DEHYDROGENASE; BACILLUS-SUBTILIS; HUMAN-FIBROBLASTS; OUTER-MEMBRANE; PROTEINS; EXPRESSION; CELLS; SEQUENCE	A full-length cDNA clone encoding the human mitochondrial tryptophanyl-tRNA synthetase (h(mt)TrpRS) has been identified. The deduced amino acid sequence shows high homology to both the mitochondrial tryptophanyl-tRNA synthetase ((mt)TrpRS) from Saccharomyces cerevisiae and to different eubacterial forms of tryptophanyl-tRNA synthetase (TrpRS). Using the baculovirus expression system, we have expressed and purified the protein with a carboxyl-terminal histidine tag. The purified His-tagged h(mt)TrpRS catalyzes Trp-dependent exchange of PPi in the PPi-ATP exchange assay. Expression of h(mt)TrpRS in both human and insect cells leads to high levels of h(mt)TrpRS localizing to the mitochondria, and in insect cells the first 18 amino acids constitute the mitochondrial localization signal sequence, Until now the human cytoplasmic tryptophanyl-tRNA synthetase (hTrpRS) was thought to function as the h(mt)TrpRS, possibly in the form of a splice variant. However, no mitochondrial localization signal sequence was ever detected and the present identification of a different (mt)TrpRS almost certainly rules out that possibility. The h(mt)TrpRS shows kinetic properties similar to human mitochondrial phenylalanyl-tRNA synthetase (h(mt)-PheRS), and h(mt)TrpRS is not induced by interferon-gamma as is hTrpRS.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Justesen, J (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Moellers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Jørgensen, René/P-5619-2014; Martensen, Pia/I-3996-2012	Jørgensen, René/0000-0003-0672-466X; Martensen, Pia Moller/0000-0002-1259-0226; Sogaard, Teit Max Moscote/0000-0001-6224-4818				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERESTEN SF, 1989, EUR J BIOCHEM, V184, P575, DOI 10.1111/j.1432-1033.1989.tb15052.x; Borglum AD, 1996, CYTOGENET CELL GENET, V73, P99, DOI 10.1159/000134317; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; CELIS JE, 1987, LEUKEMIA, V1, P800; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FLECKNER J, 1995, CYTOKINE, V7, P70, DOI 10.1006/cyto.1995.1009; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FROHMAN MA, 1994, PCR METH APPL, V4, pS40; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; Hogue CWV, 1996, J MOL BIOL, V260, P446, DOI 10.1006/jmbi.1996.0413; KISSELEV L, 1993, TRENDS BIOCHEM SCI, V18, P263, DOI 10.1016/0968-0004(93)90178-P; Kisselev L L, 1979, Methods Enzymol, V59, P234; KISSELEV LL, 1993, BIOCHIMIE, V75, P1027, DOI 10.1016/0300-9084(93)90002-A; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; Martinez-Dominguez MT, 1998, CYTOGENET CELL GENET, V83, P249, DOI 10.1159/000015196; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; PENNEYS NS, 1974, BIOCHEMISTRY-US, V13, P560, DOI 10.1021/bi00700a024; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; POPENKO VI, 1993, EUR J CELL BIOL, V62, P248; Possee RD., 1992, BACULOVIRUS EXPRESSI; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; Shaw AC, 1999, ELECTROPHORESIS, V20, P984, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<984::AID-ELPS984>3.0.CO;2-R; STUBBS L, 1992, MAMM GENOME, V3, P127, DOI 10.1007/BF00352457; TAKAGI Y, 1992, BIOCHEM BIOPH RES CO, V184, P471, DOI 10.1016/0006-291X(92)91218-F; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wright G, 1997, EXP CELL RES, V234, P78, DOI 10.1006/excr.1997.3579; XU ZJ, 1989, J BIOL CHEM, V264, P4304; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1	45	40	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16820	16826		10.1074/jbc.275.22.16820	http://dx.doi.org/10.1074/jbc.275.22.16820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828066	hybrid			2022-12-27	WOS:000087392200060
J	Vairapandi, M; Azam, N; Balliet, AG; Hoffman, B; Liebermann, DA				Vairapandi, M; Azam, N; Balliet, AG; Hoffman, B; Liebermann, DA			Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains - PCNA impedes MyD118 and Gadd45-mediated negative growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED PROTEIN GADD45; CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; POLYMERASE-DELTA; REPAIR; GENES; TRANSCRIPTION; P21(WAF1/CIP1); ACTIVATION; INHIBITORS	MyD118 and Gadd45 are related genes encoding for proteins that play important roles in negative growth control, including growth suppression and apoptosis. MyD118 and Gadd45 are related proteins that previously were shown to interact with proliferating cell nuclear antigen (PCNA), implicated in DNA replication, DNA repair, and cell cycle progression. To establish the role of MyD118 and Gadd45 interactions with PCNA, in this work we sought to identify the interacting domains and analyze the significance of this interaction in negative growth control. Using complementary in vivo and in vitro interaction assays the N-terminal (1-46) and middle (100-127) regions of PCNA were identified as harboring MyD118- and Gadd45 interacting domains, whereas PCNA interacting domains within MyD118 and Gadd45 were localized to the C termini of these proteins (amino acids 114-156 and 131-165, respectively). These findings provide first evidence that similar domains within MyD118 and Gadd45 mediate interactions with PCNA. Importantly, ectopic expression of MyD118 or Gadd45 N-terminal peptides, lacking the PCNA interacting domain, was found to suppress colony formation or induce apoptosis more efficiently than the full-length proteins. These findings suggest that interaction of MyD118 or Gadd45 with PCNA, in essence, serves to impede negative growth control.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu			NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GRANA X, 1995, ONCOGENE, V11, P211; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	44	110	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16810	16819		10.1074/jbc.275.22.16810	http://dx.doi.org/10.1074/jbc.275.22.16810			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828065	hybrid			2022-12-27	WOS:000087392200059
J	Gunnewijk, MGW; Poolman, B				Gunnewijk, MGW; Poolman, B			Phosphorylation state of HPr determines the level of expression and the extent of phosphorylation of the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; GRAM-POSITIVE BACTERIA; KINASE-CATALYZED PHOSPHORYLATION; PHOSPHOCARRIER PROTEIN; CATABOLITE REPRESSION; BACILLUS-SUBTILIS; SERYL RESIDUE; PHOSPHOENOLPYRUVATE; PHOSPHATE; RECONSTITUTION	The lactose transport protein (LacS) of Streptococcus thermophilus is composed of a translocator domain and a regulatory domain that is phosphorylated by HPr(His-P), the general energy coupling protein of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS). Lactose transport is affected by the phosphorylation state of HPr through changes in the activity of the LacS protein as well as expression of the lacS gene. To address whether or not CcpA-HPr(Ser-P)mediated catabolite control is involved, the levels of LacS were determined under conditions in which the cellular phosphorylation state of HPr greatly differed. It appears that HPr(Ser-P) is mainly present in the exponential phase of growth, whereas HPr(His similar toP) dominates in the stationary phase. The transition from HPr(Ser-P) to HPr(His similar toP) parallels an increase in LacS level, a drop in lactose and an increase in galactose concentration in the growth medium. Because the K-m(out) for lactose is higher than that for galactose, the lactose transport capacity decreases as lactose concentration decreases and galactose accumulates in the medium. Our data indicate that S. thermophilus compensates for the diminished transport capacity by synthesizing more LacS and phosphorylating the protein, which results in increased transport activity. The link between transport capacity and lacS expression levels and LacS phosphorylation are discussed.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012					Brochu D, 1999, J BACTERIOL, V181, P709, DOI 10.1128/JB.181.3.709-717.1999; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; DEUTSCHER J, 1984, FEMS MICROBIOL LETT, V23, P57; DUINE JA, 1982, ARCH MICROBIOL, V131, P27, DOI 10.1007/BF00451494; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gunnewijk MGW, 2000, J BIOL CHEM, V275, P34080, DOI 10.1074/jbc.M003513200; Gunnewijk MGW, 1999, J BACTERIOL, V181, P632, DOI 10.1128/JB.181.2.632-641.1999; GUNNEWIJK MGW, 1997, MOL MECH SIGNALING M, V101, P319; Heuberger EHML, 2000, EUR J BIOCHEM, V267, P228, DOI 10.1046/j.1432-1327.2000.00993.x; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; KONINGS WN, 1989, CRC CR REV MICROBIOL, V16, P419, DOI 10.3109/10408418909104474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON PW, 1981, J BIOL CHEM, V256, P1861; MATTOO RL, 1984, ANAL BIOCHEM, V139, P1, DOI 10.1016/0003-2697(84)90383-X; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REIZER J, 1989, BIOCHIMIE, V71, P989, DOI 10.1016/0300-9084(89)90102-8; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Sambrook J., 2002, MOL CLONING LAB MANU; THEVENOT T, 1995, J BACTERIOL, V177, P2751, DOI 10.1128/jb.177.10.2751-2759.1995; THOMPSON J, 1984, J BACTERIOL, V158, P791, DOI 10.1128/JB.158.3.791-800.1984; VADEBONCOEUR C, 1991, ANAL BIOCHEM, V196, P24, DOI 10.1016/0003-2697(91)90112-7; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4499	32	33	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34073	34079		10.1074/jbc.M003512200	http://dx.doi.org/10.1074/jbc.M003512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10842177	hybrid, Green Published			2022-12-27	WOS:000165095300013
J	Chopin, V; Salzet, M; Baert, JL; Vandenbulcke, F; Sautiere, PE; Kerckaert, JP; Malecha, J				Chopin, V; Salzet, M; Baert, JL; Vandenbulcke, F; Sautiere, PE; Kerckaert, JP; Malecha, J			Therostasin, a novel clotting factor Xa inhibitor from the rhynchobdellid leech, Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; AMINO-ACID-SEQUENCE; BLOOD-COAGULATION; PROTEASE INHIBITOR; HIRUDO-MEDICINALIS; ANTISTASIN; ANTICOAGULANT; PROTEINS; SARAFOTOXINS; ENDOTHELINS	Therostasin is a potent naturally occurring tight-binding inhibitor of mammalian Factor Xa (K-i, 34 pM), isolated from the rhynchobdellid leech Theromyzon tessulatum, Therostasin is a cysteine-rich protein (8991 Dal consisting of 82 amino acid residues with 16 cysteine residues. Its amino acid sequence has been determined by a combination of techniques, including Edman degradation, enzymatic cleavage, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) on the native and s-beta -pyridylethylated compound. Sequence analysis reveals that it shares no significant homology with other Factor Xa inhibitors except for the putative reactive site. Moreover, it contains a signature pattern for proteins of the endothelin family, potent vasoconstrictors isolated in mammal and snake venom. Therostasin cDNA (825 bp) codes for a polypeptide of 82 amino acid residues preceded by 19 residues, representing a signal peptide sequence. As for the other known inhibitors of Factor Xa, therostasin is expressed and stored in the cells of the leech salivary glands.	CNRS, UMR 8526, Inst Biol Lille, F-59019 Lille, France; INSERM, U524, Lab Oncohematol, F-59045 Lille, France; Univ Sci & Technol Lille, CNRS, UPRESA 8017, Lab Endocrinol Annelides,SN 3, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille		michel.salzet@univ-lille1.fr	Salzet, Michel/A-7675-2011	Salzet, Michel/0000-0003-4318-0817; SAUTIERE, Pierre-Eric/0000-0003-4974-7116; Vandenbulcke, Franck/0000-0002-9735-1784				BIETH JG, 1980, CLIN RES PROC, V16, P183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANKAMP RG, 1990, J LAB CLIN MED, V115, P89; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Chopin V, 1998, EUR J BIOCHEM, V258, P662, DOI 10.1046/j.1432-1327.1998.2580662.x; HAN JH, 1989, GENE, V75, P47, DOI 10.1016/0378-1119(89)90382-X; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOLSTEIN TW, 1992, FEBS LETT, V309, P288, DOI 10.1016/0014-5793(92)80791-E; JUNG HI, 1995, J BIOL CHEM, V270, P13879, DOI 10.1074/jbc.270.23.13879; Kim DR, 1998, EUR J BIOCHEM, V254, P692, DOI 10.1046/j.1432-1327.1998.2540692.x; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MANIATIS T, 1989, MOL CLONIN LAB MANUA, V1; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; NUTT E, 1988, J BIOL CHEM, V263, P10162; OHTA N, 1994, THROMB HAEMOSTASIS, V72, P825; ROTERS FJ, 1992, J COMP PHYSIOL B, V162, P85, DOI 10.1007/BF00257940; Salzet M, 2000, J BIOL CHEM, V275, P30774, DOI 10.1074/jbc.M000787200; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; SALZET M, 2000, IN PRESS PARASITOL T; Sawyer R. T, 1986, LEECH BIOL BEHAV, V1; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; Stefano GB, 1999, INT REV CYTOL, V187, P261, DOI 10.1016/S0074-7696(08)62420-1; THEUNISSEN HJM, 1994, THROMB RES, V75, P41, DOI 10.1016/0049-3848(94)90138-4; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Whitlow M, 1999, ACTA CRYSTALLOGR D, V55, P1395, DOI 10.1107/S0907444999007350	34	45	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32701	32707		10.1074/jbc.M909217199	http://dx.doi.org/10.1074/jbc.M909217199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10852926	hybrid			2022-12-27	WOS:000090003800046
J	Clabecq, A; Henry, JP; Darchen, F				Clabecq, A; Henry, JP; Darchen, F			Biochemical characterization of Rab3-GTPase-activating protein reveals a mechanism similar to that of Ras-GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TRANSITION-STATE ANALOG; STRUCTURAL BASIS; CA2+-DEPENDENT EXOCYTOSIS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; RAB3 SUBFAMILY; BINDING; COMPLEX; IDENTIFICATION	Small G proteins of the Rab family are regulators of intracellular vesicle traffic. Their intrinsic rate of GTP hydrolysis is very low but is enhanced by specific GTPase-activating proteins (GAPs) that switch G proteins to their inactive form. We have characterized the activity of recombinant Rab3-GAP on Rab3A in solution. The K-m and K-d values (75 mu M) indicate a low affinity of Rab3-GAP for its substrate. The affinity is higher for the transition state analog Rab3A:GDP:AlFX (15 mu M). The k(cat) (1 s(-1)) is within the range of values reported for other GAPs. A mutation in the switch I region of Rab3A disrupted the interaction with Rab3-GAP. Furthermore, Rabphilin, a putative target of Rab3, inhibited the activity of Rab3-GAP on Rab3, Therefore, the Rab3-GAP-binding site involves the switch I region of Rab3 and overlaps with the Rabphilin-binding domain. Substitution of a single arginine residue (Arg-728) of Rab3-GAP disrupted its catalytic activity but not its interaction with Rab3A We propose that Rab3-GAP, like Ras- and Rho-GAPs, stabilizes the transition state of Rab3 and provides a critical arginine residue to accelerate the GTPase reaction.	Inst Biol Physicochim, CNRS, UPR 1929, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Darchen, F (corresponding author), Inst Biol Physicochim, CNRS, UPR 1929, 13 Rue P & M Curie, F-75005 Paris, France.							Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Johannes L, 1996, EUR J BIOCHEM, V239, P362, DOI 10.1111/j.1432-1033.1996.0362u.x; Johannes L, 1998, J NEUROCHEM, V71, P1127; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Jones S, 1998, MOL BIOL CELL, V9, P2819, DOI 10.1091/mbc.9.10.2819; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOLLOY DP, 1995, FEBS LETT, V368, P297, DOI 10.1016/0014-5793(95)00657-U; Nagano F, 1998, J BIOL CHEM, V273, P24781, DOI 10.1074/jbc.273.38.24781; Oishi H, 1998, J BIOL CHEM, V273, P34580, DOI 10.1074/jbc.273.51.34580; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vollmer P, 1999, EUR J BIOCHEM, V260, P284, DOI 10.1046/j.1432-1327.1999.00192.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	43	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31786	31791		10.1074/jbc.M003705200	http://dx.doi.org/10.1074/jbc.M003705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10859313	hybrid			2022-12-27	WOS:000089858900035
J	Kampranis, SC; Damianova, R; Atallah, M; Toby, G; Kondi, G; Tsichlis, PN; Makris, AM				Kampranis, SC; Damianova, R; Atallah, M; Toby, G; Kondi, G; Tsichlis, PN; Makris, AM			A novel plant glutathione S-transferase/peroxidase suppresses Bax lethality in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; PROGRAMMED CELL-DEATH; PROAPOPTOTIC PROTEIN BAX; MAMMALIAN-CELLS; HYPERSENSITIVE RESPONSE; MITOCHONDRIAL CONTROL; HYDROGEN-PEROXIDE; FATTY-ACIDS; APOPTOSIS; TRANSFERASES	The mammalian inducer of apoptosis Bax is lethal when expressed in yeast and plant cells. To identify potential inhibitors of Bax in plants we transformed yeast cells expressing Bax with a tomato cDNA library and we selected for cells surviving after the induction of Bax. This genetic screen allows for the identification of plant genes, which inhibit either directly or indirectly the lethal phenotype of Bax. Using this method a number of cDNA clones were isolated, the more potent of which encodes a protein homologous to the class theta glutathione S-transferases. This Bax-inhibiting (BI) protein was expressed in Escherichia coli and found to possess glutathione S-transferase (GST) and weak glutathione peroxidase (GPX) activity. Expression of Bax in yeast decreases the intracellular levels of total glutathione, causes a substantial reduction of total cellular phospholipids, diminishes the mitochondrial membrane potential, and alters the intracellular redox potential. Co-expression of the BI-GST/GPX protein brought the total glutathione levels back to normal and re-established the mitochondrial membrane potential but had no effect on the phospholipid alterations. Moreover, expression of BI-GST/GPX in yeast was found to significantly enhance resistance to H2O2-induced stress. These results underline the relationship between oxidative stress and Bax-induced death in yeast cells and demonstrate that the yeast-based genetic strategy described here is a powerful tool for the isolation of novel antioxidant and anti-apoptotic genes.	Mediterranean Agron Inst Chania, Alsyll Agrokep, Khania 73100, Greece; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	CIHEAM; CIHEAM IAM Chania; Fox Chase Cancer Center; Jefferson University	Kampranis, SC (corresponding author), Mediterranean Agron Inst Chania, Alsyll Agrokep, POB 85, Khania 73100, Greece.		Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684	NCI NIH HHS [R01CA57436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Asoh S, 1998, J BIOL CHEM, V273, P11384, DOI 10.1074/jbc.273.18.11384; BARRY MA, 1993, CANCER RES, V53, P2349; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Callard D, 1996, PLANT PHYSIOL, V112, P705, DOI 10.1104/pp.112.2.705; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GODIARD L, 1994, CURR OPIN GENET DEV, V4, P662, DOI 10.1016/0959-437X(94)90132-M; Golemis E A, 1997, Methods Mol Biol, V63, P197; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; KOMAGATA K, 1987, METHOD MICROBIOL, V19, P161; KOPRIVA S, 1995, PLANT PHYSIOL, V107, P271, DOI 10.1104/pp.107.1.271; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MITTLER R, 1995, PLANT PHYSIOL, V108, P489, DOI 10.1104/pp.108.2.489; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Richberg MH, 1998, CURR OPIN PLANT BIOL, V1, P480, DOI 10.1016/S1369-5266(98)80039-3; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; SATO N, 1995, J IMMUNOL, V154, P3194; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; UCKER DS, 1991, NEW BIOL, V3, P103; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WELCH JW, 1973, J BACTERIOL, V115, P464, DOI 10.1128/JB.115.1.464-466.1973; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	57	176	202	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29207	29216		10.1074/jbc.M002359200	http://dx.doi.org/10.1074/jbc.M002359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10859306	hybrid			2022-12-27	WOS:000089439800006
J	Versteeg, HH; Hoedemaeker, I; Diks, SH; Stam, JC; Spaargaren, M; Henegouwen, PMPVE; van Deventer, SJH; Peppelenbosch, MP				Versteeg, HH; Hoedemaeker, I; Diks, SH; Stam, JC; Spaargaren, M; Henegouwen, PMPVE; van Deventer, SJH; Peppelenbosch, MP			Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; CANINE KIDNEY-CELLS; HUMAN TISSUE FACTOR; FACTOR VIIA; ACTIN CYTOSKELETON; ESCHERICHIA-COLI; HUMAN MONOCYTES; IN-VITRO	Tissue factor (TF), apart from activating the extrinsic pathway of the blood coagulation, is a principal regulator of embryonic angiogenesis and oncogenic neoangiogenesis, but also influences inflammation, leukocyte diapedesis and tumor progression. The intracellular domain of TF lacks homology to other classes of receptors and hence the signaling mechanism is poorly understood. Here we demonstrate that factor VIIa (the natural ligand for TF) induces the activation of the Src family members c-Src, Lyn, and Yes, and subsequently phosphatidylinositol 3-kinase (PI3K), followed by stimulation of c-Akt/protein kinase B as well as the small GTPases Rac and Cdc42. In turn Rac mediates p38 mitogen-activated protein (MAP) kinase activation and cytoskeletal reorganization, whereas factor VIIa-induced p42/p44 MAP kinase stimulation required PI3R enzymatic activity but was not inhibited by dominant negative Rac proteins. We propose that this Src family member/PI3K/Rac-dependent signaling pathway is a major mediator of factor VIIa/TF effects in pathophysiology.	Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University	Peppelenbosch, MP (corresponding author), Acad Med Ctr, Lab Expt Internal Med, G2-130,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Spaargaren, Marcel/AAU-1298-2021; Versteeg, Henri/G-1783-2018; van Bergen en Henegouwen, Paul/B-8870-2011	Spaargaren, Marcel/0000-0002-3135-5109; Versteeg, Henri/0000-0003-4294-175X; van Bergen en Henegouwen, Paul/0000-0001-6050-9042; Peppelenbosch, Maikel/0000-0001-9112-6028				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; FUKUI Y, 1991, ONCOGENE, V6, P407; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; JUCKER M, 1995, J BIOL CHEM, V270, P27817; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; Masuda M, 1996, EUR J IMMUNOL, V26, P2529, DOI 10.1002/eji.1830261037; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Min W, 1997, J IMMUNOL, V159, P3508; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Stephens L, 1996, PHILOS T R SOC B, V351, P211, DOI 10.1098/rstb.1996.0018; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	59	91	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28750	28756		10.1074/jbc.M907635199	http://dx.doi.org/10.1074/jbc.M907635199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10844001	Green Published, hybrid			2022-12-27	WOS:000089330700056
J	Bhattacharjee, G; Asplin, IR; Wu, SM; Gawdi, G; Pizzo, SV				Bhattacharjee, G; Asplin, IR; Wu, SM; Gawdi, G; Pizzo, SV			The conformation-dependent interaction of alpha(2)-macroglobulin with vascular endothelial growth factor - A novel mechanism of alpha(2)-macroglobulin/growth factor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RECOGNIZED ALPHA-2-MACROGLOBULIN; PROLIFERATIVE DIABETIC-RETINOPATHY; RHEUMATOID-ARTHRITIS; ALPHA-MACROGLOBULIN; PROTEASE INHIBITORS; HUMAN-PLASMA; FACTOR-BETA; FAST FORMS; SERUM; PROTEINS	alpha(2)-Macroglobulin (alpha(2)M) is a highly conserved proteinase inhibitor present in human plasma at high concentration (2-4 mg/ml), alpha(2)M exists in two conformations, a native form and an activated, receptor-recognized form. While alpha(2)M binds to numerous cytokines and growth factors, in most cases, the nature of the alpha(2)M interaction with these factors is poorly understood. We examined in detail the interaction between alpha(2)M and vascular endothelial growth factor (VEGF) and found a novel and unexpected mechanism of interaction as demonstrated by the following observations: 1) the binding of VEGF to alpha(2)M occurs at a site distinct from the recently characterized growth factor binding site; 2) VEGF binds different forms of alpha(2)M with distinct spatial arrangement, namely to the interior of methylamine or ammonia-treated alpha(2)M and to the exterior of native and proteinase-converted alpha(2)M; and 3) VEGF (molecular mass similar to 40 kDa) can access the interior of receptor-recognized alpha(2)M in the absence of proteinase trapped within the molecule. VEGF bound to receptor-recognized forms of alpha(2)M is internalized VEGF bound to receptor-recognized forms of alpha(2)M is internalize and degraded by macrophages via the alpha(2)M receptor, the low density lipoprotein receptor-related protein, Oxidation of both native and receptor-recognized alpha(2)M results in significant inhibition of VEGF binding. We also examined the biological significance of this interaction by studying the effect of alpha(2)M On VEGF-induced cell proliferation and VEGF-induced up-regulation of intracellular Ca2+ levels. We demonstrate that under physiological conditions, alpha(2)M does not impact the ability of VEGF to induce cell proliferation or up-regulate Ca2+.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.			Wu, Sean/0000-0002-0000-3821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; ADES EW, 1982, SCAND J IMMUNOL, V15, P109, DOI 10.1111/j.1365-3083.1982.tb00628.x; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bhattacharjee G, 1999, BBA-PROTEIN STRUCT M, V1432, P49, DOI 10.1016/S0167-4838(99)00072-2; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1989, J BIOL CHEM, V264, P5818; CAWSTON TE, 1987, BRIT J RHEUMATOL, V26, P354; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; CUMMINGS HS, 1983, ANN NY ACAD SCI, V421, P143, DOI 10.1111/j.1749-6632.1983.tb18101.x; CUMMINGS HS, 1984, BIOCHEMISTRY-US, V23, P105, DOI 10.1021/bi00296a017; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; Dean RT, 1997, BIOCHEM J, V324, P1; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GEOKAS MC, 1977, J BIOL CHEM, V252, P61; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Gron H, 1998, BIOCHEMISTRY-US, V37, P6009, DOI 10.1021/bi973027c; Gron H, 1996, BIOCHEM J, V318, P539, DOI 10.1042/bj3180539; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUSSAIN A, 1970, J PHARM SCI, V59, P1168, DOI 10.1002/jps.2600590824; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; KOCH AE, 1994, J IMMUNOL, V152, P4149; LAMARRE J, 1990, LAB INVEST, V62, P545; MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028; MATSUDA T, 1989, J IMMUNOL, V142, P148; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MULLERTZ S, 1974, BIOCHEM J, V143, P273; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSADA T, 1987, BIOCHEM BIOPH RES CO, V146, P26, DOI 10.1016/0006-291X(87)90685-1; PEJOVIC M, 1995, BRIT J RHEUMATOL, V34, P520; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RINDERKNECHT H, 1975, BIOCHIM BIOPHYS ACTA, V377, P158, DOI 10.1016/0005-2744(75)90296-X; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SOKER S, 1993, J BIOL CHEM, V268, P7685; STRAUSS S, 1992, LAB INVEST, V66, P223; TAKESHITA S, 1994, CIRCULATION, V90, P228; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; Webb DJ, 1998, J BIOL CHEM, V273, P13339, DOI 10.1074/jbc.273.21.13339; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265; Wu SM, 1997, J BIOL CHEM, V272, P20627, DOI 10.1074/jbc.272.33.20627; Wu SM, 1998, J IMMUNOL, V161, P4356	57	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26806	26811						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862607				2022-12-27	WOS:000089144800021
J	Bochkareva, E; Korolev, S; Bochkarev, A				Bochkareva, E; Korolev, S; Bochkarev, A			The role for zinc in replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING DOMAIN; 70-KDA SUBUNIT; CRYSTAL-STRUCTURE; A INTERACTIONS; METAL-IONS; FINGER; COMPLEXES; REVEALS; 3'-END	Heterotrimeric human single stranded DNA (ssDNA)binding protein, replication protein A (RPA), is a central player in DNA replication, recombination, and repair. The C terminus of the largest subunit, RPA70, contains a putative zinc-binding motif and is implicated in complex formation with two smaller subunits, RPA14 and RPA32, The C-terminal domain of RPA70 (RPA70-CTD) was characterized using proteolysis and x-ray fluorescence emission spectroscopy. The proteolytic core of this domain comprised amino acids 432-616, X-ray fluorescence spectra revealed that RPA70-CTD possesses a coordinated Zn(II). The trimeric complex of RPA70-CTD, the ssDNA-binding domain of RPA32 (amino acids 43-171), and RPA14 had strong DNA binding activity. When properly coordinated with zinc, the trimer's affinity to ssDNA was only 3-10-fold less than that of the ssDNA-binding domain in the middle of RPA70. However, the DNA-binding activity of the trimer was dramatically reduced in the presence of chelating agents. Our data indicate that (i) Zn(II) is essential to stabilize the tertiary structure of RPA70-CTD; (ii) RPA70-CTD possesses DNA-binding activity, which is modulated by Zn(II); and (iii) ssDNA binding by the trimer is a synergistic effect generated by the RPA70-CTD and RPA32.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; United States Department of Energy (DOE); Argonne National Laboratory	Bochkarev, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC-466, Oklahoma City, OK 73190 USA.		Korolev, Sergey/ABA-7517-2020	Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061192] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61192-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BEARDEN JA, 1967, REV MOD PHYS, V39, P78, DOI 10.1103/RevModPhys.39.78; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; DEWALD HD, 1986, ANAL CHEM, V58, P2968, DOI 10.1021/ac00127a016; Dong JW, 1999, BIOCHEM J, V337, P311, DOI 10.1042/0264-6021:3370311; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HAINAUT P, 1993, CANCER RES, V53, P1739; Hard T, 2000, J MOL BIOL, V296, P169, DOI 10.1006/jmbi.1999.3433; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	33	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27332	27338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856290				2022-12-27	WOS:000089144800089
J	Elisseeva, EL; Slupsky, CM; Crump, MP; Clark-Lewis, I; Sykes, BD				Elisseeva, EL; Slupsky, CM; Crump, MP; Clark-Lewis, I; Sykes, BD			NMR studies of active N-terminal peptides of stromal cell-derived factor-1 - Structural basis for receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; LYMPHOCYTE CHEMOATTRACTANT; PROTEIN STRUCTURES; CHEMICAL-SHIFTS; CC-CHEMOKINE; HIV-1 ENTRY; FACTOR-I; INTERLEUKIN-8; IDENTIFICATION; SDF-1	Stromal cell-derived factor 1 (SDF-1), a member of the CXC chemokine family, is the only chemokine to bind to the receptor CXCR4 This receptor is also a co-receptor for syncytia-inducing forms of HIV in CD4(+) cells. In addition, SDF-1. is responsible for attracting mature lymphocytes to the bone marrow and can therefore contribute to host versus graft rejection in bone marrow transplantation, Clearly, by manipulating SDF-1 activity, we could find a possible anti-viral AIDS treatment and aid in bone marrow transplantation. SDF-1 binds to CXCR4 primarily via the N terminus, which appears flexible in the recently determined three-dimensional structure of SDF-1. Strikingly, short N-terminal SDF-1 peptides have been shown to have significant SDF-1 activity, By using NMR, we have determined the major conformation of the N terminus of SDF-1 in a 17-mer (residues 1-17 of SDF-1) and a g-mer dimer (residues 1-9 of SDF-1 linked by a disulfide bond at residue 9). Residues 5-8 and 11-14 form similar structures that can be characterized as a beta-turn of the beta-alpha R type. These structural motifs are likely to be interconverting with other states, but the major conformation may be important for recognition in receptor binding. These results suggest for the first time that there may be a link between structuring of short N-terminal chemokine peptides and their ability to activate their receptor. These studies will act as a starting point for synthesizing non-peptide analogs that act as CXCR4 antagonists.	Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Heritage Med Res Ctr 713, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada.			Crump, Matthew/0000-0002-7868-5818				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Andersen NH, 1997, J AM CHEM SOC, V119, P8547, DOI 10.1021/ja963250h; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BRUNGER AT, X PLOR VERSION 3 1 Y; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Maghazachi AA, 1998, FASEB J, V12, P913, DOI 10.1096/fasebj.12.11.913; MERTUKA G, 1995, J BIOMOL NMR, V5, P14; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1993, J BIOL CHEM, V268, P7125; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Xin XM, 1999, FEBS LETT, V457, P219, DOI 10.1016/S0014-5793(99)01035-2	39	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26799	26805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846182				2022-12-27	WOS:000089144800020
J	Janez, A; Worrall, DS; Imamura, T; Sharma, PM; Olefsky, JM				Janez, A; Worrall, DS; Imamura, T; Sharma, PM; Olefsky, JM			The osmotic shock-induced glucose transport pathway in 3T3-L1 adipocytes is mediated by Gab-1 and requires Gab-1 associated phosphatidylinositol 3-kinase activity for full activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; GROWTH-FACTOR; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); SIGNALING PATHWAY; DOCKING PROTEIN; SKELETAL-MUSCLE; BINDING-SITE; INSULIN; RECEPTOR; KINASE	Osmotic shock treatment of 3T3-L1 adipocytes causes an increase in glucose transport activity and translocation of GLUT4 protein similar to that elicited by insulin treatment. Insulin stimulation of GLUT4 translocation and glucose transport activity was completely inhibited by wortmannin, however, activation by osmotic shock was only partially blocked. Additionally, we have found that the newly identified insulin receptor substrate Gab-l (Grb2-associated binder-1) is tyrosine-phosphorylated following sorbitol stimulation. Treatment of cells with the tyrosine kinase inhibitor genistein inhibited osmotic shock-stimulated Gab-l phosphorylation as well as shock-induced glucose transport. Furthermore, pretreatment with the selective Src family kinase inhibitor PP2 completely inhibited the ability of sorbitol treatment to cause tyrosine phosphorylation of Gab-1. We have also shown that microinjection of anti-Gab-1 antibody inhibits osmotic shock-induced GLUT4 translocation. Furthermore, phosphorylated Gab-l binds and activates phosphatidylinositol 3-kinase (PI3K) in response to osmotic shock. The PI3K activity associated with Gab-1 was 82% of that associated with anti-phosphotyrosine antibodies, indicating that Gab-l is the major site for PI3K recruitment following osmotic shock stimulation, Although wortmannin only causes a partial block of osmotic shock-stimulated glucose uptake, wortmannin completely abolishes Gab-l associated PI3K activity. This suggests that other tyrosine kinase-dependent pathways, in addition to the Gab-1-PI3K pathway, contribute to osmotic shock-mediated glucose transport. To date, Gab-l is the first protein identified as a member of the osmotic shock signal transduction pathway.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu			NIDDK NIH HHS [DK-33651, DK09595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, F32DK009595, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Imamura T, 1999, MOL CELL BIOL, V19, P6765; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V91, P9931; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; SHEPHERD PR, 1998, BIOCHEM J, V25, P471; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wojtaszewski JFP, 1998, BBA-GEN SUBJECTS, V1380, P396, DOI 10.1016/S0304-4165(98)00011-7; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	31	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26870	26876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842168				2022-12-27	WOS:000089144800029
J	Leitolf, H; Tong, KPT; Grossmann, M; Weintraub, BD; Szkudlinski, MW				Leitolf, H; Tong, KPT; Grossmann, M; Weintraub, BD; Szkudlinski, MW			Bioengineering of human thyrotropin superactive analogs by site-directed "lysine-scanning" mutagenesis - Cooperative effects between peripheral loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-STIMULATING HORMONE; HUMAN CHORIONIC-GONADOTROPIN; ALPHA-SUBUNIT; GLYCOPROTEIN HORMONES; BETA-SUBUNIT; HUMAN CHORIOGONADOTROPIN; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; RECEPTOR; BINDING	We have previously engineered the first superactive analogs of human thyrotropin (hTSH) by using a novel design strategy. In this study, we have applied homology comparisons focusing on the alpha L3 loop of the common alpha-subunit of human glycoprotein hormones. Seven highly variable amino acid residues were identified, and charge-scanning mutagenesis revealed three previously unrecognized modification permissive domains and four gain-of-function lysine substitutions. Such gain-of-function mutations were hormone- and receptor-specific and dependent on location and basic charge. Cooperativity of individual substitutions was established in double and triple lysine mutants, In combinations of the most potent alpha L3 loop analog with two previously characterized loop analogs, a higher degree of cooperativity for the alpha L3 loop analog compared with both the alpha L1 loop analog and the hTSH-beta L3 loop analog was observed. We demonstrated that spatially distinct regions of the common alpha-subunit contribute differentially to the interaction of hTSH with its receptor and that combinations of two modified loops on the same and on opposite sides of the hTSH molecule display similar increases in in vitro biopotency. In addition, combination of all three superactive loops showed cooperativity in receptor binding and activation resulting in the most potent hTSH superactive analog described to date.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol,Sect Prot Engn, Inst Human Virol,Div Basic Sci,Lab Mol Endocrinol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Endocrinol Diab & Nutr, Mol Endocrinol Lab, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Szkudlinski, MW (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol,Sect Prot Engn, Inst Human Virol,Div Basic Sci,Lab Mol Endocrinol, Rm N457,725 W Lombard St, Baltimore, MD 21201 USA.	szkudlin@umbi.umd.edu						Arnold CJ, 1998, BIOCHEMISTRY-US, V37, P1762, DOI 10.1021/bi971816o; Bidart JM, 1997, ANN ENDOCRINOL-PARIS, V58, P125; BLITHE DL, 1991, ENDOCRINOLOGY, V129, P2257, DOI 10.1210/endo-129-4-2257; CHENG KW, 1973, J BIOL CHEM, V248, P7930; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLE ES, 1993, BIO-TECHNOL, V11, P1014, DOI 10.1038/nbt0993-1014; EASTPALMER J, 1995, THYROID, V5, P55, DOI 10.1089/thy.1995.5.55; Fares FA, 1996, ENDOCRINOLOGY, V137, P555, DOI 10.1210/en.137.2.555; GRIFFITH DL, 1994, J MOL BIOL, V244, P657, DOI 10.1006/jmbi.1994.1761; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Grossmann M, 1998, NAT BIOTECHNOL, V16, P871, DOI 10.1038/nbt0998-871; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; KRYSTEK SR, 1992, PEPTIDE RES, V5, P165; LADENSON PW, 1997, NEW ENGL J MED, V337, P688; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MEIER CA, 1994, J CLIN ENDOCR METAB, V78, P188, DOI 10.1210/jc.78.1.188; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PARSONS TF, 1979, J BIOL CHEM, V254, P6010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROTH KE, 1995, MOL CELL ENDOCRINOL, V109, P143, DOI 10.1016/0303-7207(95)03494-R; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shao K, 1996, MOL CELL ENDOCRINOL, V122, P173, DOI 10.1016/0303-7207(96)03882-8; Shao K, 1997, MOL CELL ENDOCRINOL, V127, P179, DOI 10.1016/S0303-7207(97)04007-0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Szkudlinski MW, 1996, TRENDS ENDOCRIN MET, V7, P277, DOI 10.1016/S1043-2760(96)00129-4; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; SZKUDLINSKI MW, 1997, CURR OPIN ENDOCRINOL, V4, P354, DOI DOI 10.1097/00060793-199710000-00007; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; VAITUKAITIS JL, 1975, ENDOCRINOLOGY, V97, P215, DOI 10.1210/endo-97-1-215; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEINER RS, 1990, ENDOCRINOLOGY, V127, P573, DOI 10.1210/endo-127-2-573; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27457	27465						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859314				2022-12-27	WOS:000089144800104
J	Chang, P; Marians, KJ				Chang, P; Marians, KJ			Identification of a region of Escherichia coli DnaB required for functional interaction with DnaG at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; N-TERMINAL DOMAIN; PHI-X174-TYPE PRIMOSOME; CRYSTAL-STRUCTURE; HELICASE-PRIMASE; ATP HYDROLYSIS; PROTEINS; COMPLEX	The fundamental activities of the replicative primosomes of Escherichia coli are provided by DnaB, the replication fork DNA helicase, and DnaG, the Okazaki fragment primase. As we have demonstrated previously, DnaG is recruited to the replication fork via a transient protein-protein interaction with DnaB. Here, using site-directed amino acid mutagenesis, we have defined the region on DnaB required for this protein-protein interaction. Mutations in this region of DnaB affect the DnaB-DnaG; interaction during both general priming-directed and phi X174 complementary strand DNA synthesis, as well as at replication forks reconstituted in rolling circle DNA replication reactions. The behavior of the purified mutant DnaB proteins in the Various replication systems suggests that access to the DnaG binding pocket on DnaB may be restricted at the replication fork.	Cornell Univ, Weill Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Chang, P (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10919, DOI 10.1021/bi990048t; BISWAS SB, 1994, BIOCHEMISTRY-US, V33, P11307, DOI 10.1021/bi00203a028; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fass D, 1999, STRUCTURE, V7, P691, DOI 10.1016/S0969-2126(99)80090-2; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P4315; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LIU J, 1996, J BIOL CHEM, V271, P15649; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Stordal L, 1996, J BACTERIOL, V178, P4620, DOI 10.1128/jb.178.15.4620-4627.1996; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WICKNER S, 1977, P NATL ACAD SCI USA, V72, P2815; WU CA, 1992, J BIOL CHEM, V267, P4030; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	40	35	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26187	26195		10.1074/jbc.M001800200	http://dx.doi.org/10.1074/jbc.M001800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833513	hybrid			2022-12-27	WOS:000088999700043
J	Hermand, P; Huet, M; Callebaut, I; Gane, P; Ihanus, E; Gahmberg, CG; Cartron, JP; Bailly, P				Hermand, P; Huet, M; Callebaut, I; Gane, P; Ihanus, E; Gahmberg, CG; Cartron, JP; Bailly, P			Binding sites of leukocyte beta(2) integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-3; FUNCTION-ASSOCIATED ANTIGEN-1; HUMAN-ERYTHROCYTE-MEMBRANE; MONOCLONAL-ANTIBODIES; NEURONAL GLYCOPROTEIN; LIGAND; TELENCEPHALIN; RHINOVIRUS; EXPRESSION; SURFACE	The red cell ICAM-4/LW blood group glycoprotein, which belongs to the family of intercellular adhesion molecules (ICAMs), has been reported to interact with CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1) beta(2) integrins. To better define the basis of the ICAM-4/beta(2) integrin interaction, we have generated wild-type, domain-deleted and mutated recombinant chimeric ICAM-4-Fc proteins and analyzed their interaction in a cellular adhesion assay with LFA-1 and Mac-1 L-cell stable transfectants. We found that monoclonal antibodies against CD11a, CD11b, CD18, or LWab block adhesion of transfectant L-cells to immobilized ICAM-4-Fc protein and that the ICAM-4/beta(2) integrin interaction was highly sensitive to the presence of the divalent cations Ca2+ and Mg2+. Deletion of individual Ig-domains D1 or D2 of the extracellular part of ICAM-8 showed that LFA-1 binds to the first Ig-like domain, whereas the Mac-1 binding site encompassed both the first and the second Ig-like domains. Based on the crystal structure of ICAM-8, we propose a model for the Ig-like domains D1 and D2 of ICAM-4. Accordingly, by site-directed mutagenesis of 22 amino acid positions spread out on all faces of the ICAM-4 molecule, we identified four exposed residues, Leu(80), Trp(93), and Arg(97) On the CFG face and Trp(77) On the E-F loop of domain D1 that may contact LFA-1 as part of the binding site. However, the single and double mutants R52E and T91Q on the CFG face of domain D1, which correspond to the key residues Glu(34) and Gln(73) for ICAM-1 binding to LFA-1, had no effect on LFA-1 binding. In contrast, all mutants on the CFG face of domain D1 and residues Glu(151) and Thr(154) in the C'-E loop of the domain D2 seem to play a dominant role in Mac-1 binding. These data suggest that the binding site for LFA-1 on ICAM-4 overlaps but is distinct from the Mac-1 binding site.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Univ Paris 06, LMCP, CNRS UMR 7590, F-75252 Paris, France; Univ Paris 07, LMCP, CNRS UMR 7590, F-75252 Paris, France; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; University of Helsinki	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296; HERMAND, Patricia/0000-0003-0628-9733				BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; Bell ED, 1998, J IMMUNOL, V161, P1363; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BLOY C, 1990, J BIOL CHEM, V265, P21482; BOSSY D, 1994, GENOMICS, V23, P712, DOI 10.1006/geno.1994.1565; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; HERMAND P, 1995, BLOOD, V86, P1590, DOI 10.1182/blood.V86.4.1590.bloodjournal8641590; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI R, 1993, J BIOL CHEM, V268, P17513; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; Mizuno T, 1997, J BIOL CHEM, V272, P1156, DOI 10.1074/jbc.272.2.1156; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANSOM D, 1991, GENOMICS, V11, P462, DOI 10.1016/0888-7543(91)90157-A; SONNEBORN HH, 1984, DEV BIOLOGICALS, V57, P61; SONNEBORN HH, 1994, VOX SANGUINIS S2, V67, P114; Spring FA, 1998, BLOOD, V92, p589A; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stanley P, 1998, J BIOL CHEM, V273, P3358, DOI 10.1074/jbc.273.6.3358; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Tian L, 1997, J IMMUNOL, V158, P928; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; YOSHIHARA Y, 1994, NEURON, V12, P541, DOI 10.1016/0896-6273(94)90211-9; [No title captured]	41	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26002	26010		10.1074/jbc.M002823200	http://dx.doi.org/10.1074/jbc.M002823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846180	hybrid			2022-12-27	WOS:000088999700018
J	Kohler, K; Forster, IC; Lambert, G; Biber, J; Murer, H				Kohler, K; Forster, IC; Lambert, G; Biber, J; Murer, H			The functional unit of the renal type IIa Na+/P-i cotransporter is a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; XENOPUS-LAEVIS OOCYTES; P-I; MOLECULAR-SIZE; SUBUNIT STOICHIOMETRY; RAT-KIDNEY; PHOSPHATE COTRANSPORTER; RADIATION-INACTIVATION; TRANSPORTER; NAPI-2	The composition of the functional unit of the rat renal type IIa Na+/P-i cotransporter (NaPi-IIa) was investigated by using two approaches based on the differential sensitivities of the wild type (WT) and mutant S460C proteins to 2-aminoethyImethanethiosulfonate hydrobromide (MTSEA), a charged cysteine modifier. Transport activity of S460C is completely blocked after incubation in MTSEA, whereas that of the WT remains unaffected. First, Xenopus laevis oocytes were coinjected with cRNAs coding for the WT and S460C in different proportions, and the transport inhibition after MTSEA incubation was assayed by electrophysiology. The relationship between MTSEA inhibition and proportion of cRNA was consistent with that for a functional monomer, Second, concatameric proteins were constructed that either comprised two WT proteins (WT-WT), two S460C mutants (S460C-S460C), or one of each (WT-S460C), Western blots of oocytes injected with fusion protein cRNA showed bands at similar to 200 kDa, whereas a main band at similar to 90 kDa was obtained for the WT cRNA alone. The kinetic properties of concatamers were the same as for the single proteins. Transport activity of the WT-WT concatamer was unaffected by MTSEA incubation, fully inhibited for S460C-S460C, but 50% inhibited for WT-S460C, This behavior was also consistent with NaPi-IIa being a functional monomer.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Forster, IC (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Forster, Ian/0000-0003-3087-9952				Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; Busch AE, 1995, J AM SOC NEPHROL, V6, P1547; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; DELISLE MC, 1994, BIOCHEMISTRY-US, V33, P9105, DOI 10.1021/bi00197a012; DELISLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1104, P132, DOI 10.1016/0005-2736(92)90141-8; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; FOSTER I, 2000, BIOPHYS J, V79, P215; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Jette M, 1996, BIOCHEMISTRY-US, V35, P15209, DOI 10.1021/bi960940p; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lambert G, 1999, J GEN PHYSIOL, V114, P637, DOI 10.1085/jgp.114.5.637; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Murer H, 1999, AM J PHYSIOL-RENAL, V277, pF676, DOI 10.1152/ajprenal.1999.277.5.F676; MURER H, 2000, IN PRESS PHYSL REV; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; Tatsumi S, 1998, J BIOL CHEM, V273, P28568, DOI 10.1074/jbc.273.44.28568; TENENHOUSE HS, 1990, BIOCHEM BIOPH RES CO, V170, P1288, DOI 10.1016/0006-291X(90)90533-S; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WERNER A, 1990, J BIOL CHEM, V265, P12331; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	36	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26113	26120		10.1074/jbc.M003564200	http://dx.doi.org/10.1074/jbc.M003564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859311	hybrid, Green Accepted			2022-12-27	WOS:000088999700033
J	Liu, J; Brautigan, DL				Liu, J; Brautigan, DL			Glycogen synthase association with the striated muscle glycogen-targeting subunit of protein phosphatase-1 - Synthase activation involves scaffolding regulated by beta-adrenergic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; BINDING SUBUNIT; PHOSPHORYLASE ACTIVITY; CLYCOGEN PARTICLE; CATALYTIC SUBUNIT; CYCLIC-AMP; MECHANISM; KINASE; TYPE-1	Glycogen-binding subunits for protein phosphatase-1 (PP1) target the PP1 catalytic subunit (PP1C) to glycogen particles, where the enzymes glycogen synthase and glycogen phosphorylase are concentrated. Here we identify sites within the striated muscle glycogen-binding subunit (GM) that mediate direct binding to glycogen synthase, Both PP1C and glycogen synthase were coimmunoprecipitated with a full-length FLAG-tagged GM transiently expressed in COS7 cells or C2C12 myotubes, Deletion and mutational analysis of a glutathione S-transferase (GST) fusion of the N-terminal domain of GM (residues 1-240) identified two putative sites for binding to glycogen synthase, one of which is the WXNXGX-NYX(I/L) motif that is conserved among the family of PP1 glycogen-binding subunits. Either deletion of this motif or Ala substitution of Asn-228 in this motif disrupted the binding of glycogen synthase, Expression of full-length FLAG-G(M) in cells increased the activity of endogenous glycogen synthase, but protein disabled in either PP1 binding or glycogen synthase binding did not produce synthase activation. The results show that efficient activation of glycogen synthase requires a scaffold function of G(M) that involves simultaneous binding of both PP1C and glycogen synthase. Isoproterenol and forskolin treatment of cells decreased glycogen synthase binding to FLAG-G(M), thereby limiting synthase activation by PP1, This response was insensitive to inhibition by H-89, therefore probably not involving cAMP-dependent protein kinase, but did require inclusion of microcystin-LR during cell lysis, implying that phosphorylation was modulating binding of glycogen synthase, Phosphorylation control of binding to a scaffold site on the G(M) subunit of PP1 offers a new mechanism for regulation of muscle glycogen synthase in response to beta-adrenergic signals.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng C, 1997, YEAST, V13, P1; COHEN P, 1986, ENZYMES, P461; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIETZ MR, 1980, J BIOL CHEM, V255, P2301; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HASCHKE RH, 1970, J BIOL CHEM, V245, P6657; HEILMEYER LM, 1970, J BIOL CHEM, V245, P6649; Hirano K, 1997, BBA-PROTEIN STRUCT M, V1339, P177, DOI 10.1016/S0167-4838(97)00048-4; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; MEYER F, 1970, J BIOL CHEM, V245, P6642; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Souchet M, 1999, PROTEIN SCI, V8, P2570; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26074	26081		10.1074/jbc.M003843200	http://dx.doi.org/10.1074/jbc.M003843200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856301	hybrid			2022-12-27	WOS:000088999700027
J	Luong, A; Hannah, VC; Brown, MS; Goldstein, JL				Luong, A; Hannah, VC; Brown, MS; Goldstein, JL			Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; LOW-DENSITY-LIPOPROTEIN; COENZYME-A SYNTHETASE; TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; CULTURED-CELLS; BLOOD ACETATE; MESSENGER-RNA; CHOLESTEROL; GENE	Through suppressive subtractive hybridization, we identified a new gene whose transcription is induced by sterol regulatory element-binding proteins (SREBPs). The gene encodes acetyl-CoA synthetase (ACS), the cytosolic enzyme that activates acetate so that it can be used for lipid synthesis or for energy generation. ACS genes were isolated previously from yeast, but not from animal cells. Recombinant human ACS was produced by expressing the cloned cDNA transiently in human cells. After purification by nickel chromatography, the 701-amino acid cytosolic enzyme was shown to function as a monomer. The recombinant enzyme produced acetyl-CoA from acetate in a reaction that required ATP. As expected for a gene controlled by SREBPs, ACS mRNA was induced when cultured cells were deprived of sterols and repressed by sterol addition. The pattern of regulation resembled the regulation of enzymes of fatty acid synthesis. ACS mRNA was also elevated in livers of transgenic mice that express dominant-positive versions of all three isoforms of SREBP. We conclude that ACS mRNA, and hence the ability of cells to activate acetate, is regulated by SREBPs in parallel with fatty acid synthesis in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.	mbrow1@mednet.swmed.edu; jgolds@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014, GM08203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BARTH C, 1972, BIOCHIM BIOPHYS ACTA, V260, P1, DOI 10.1016/0005-2760(72)90067-7; BERG P, 1956, J BIOL CHEM, V222, P991; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUCKLEY BM, 1977, BIOCHEM J, V166, P539, DOI 10.1042/bj1660539; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hiesinger M, 1997, FEBS LETT, V415, P16, DOI 10.1016/S0014-5793(97)01085-5; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HOWARD BV, 1974, J BIOL CHEM, V249, P7912; HUANG KP, 1970, ANAL BIOCHEM, V37, P98, DOI 10.1016/0003-2697(70)90263-0; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; KORNBERG HL, 1966, BIOCHEM J, V99, P1; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SCHEPPACH W, 1991, CLIN SCI, V80, P177, DOI 10.1042/cs0800177; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; VANDENBERG MA, 1995, EUR J BIOCHEM, V231, P704; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; WEBSTER LT, 1963, J BIOL CHEM, V238, P4010; WOLCZUNOWICZ M, 1977, LIFE SCI, V20, P1347, DOI 10.1016/0024-3205(77)90360-5; WOODNUTT G, 1986, COMP BIOCHEM PHYS B, V85, P487, DOI 10.1016/0305-0491(86)90033-7; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	43	185	196	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26458	26466		10.1074/jbc.M004160200	http://dx.doi.org/10.1074/jbc.M004160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843999	hybrid			2022-12-27	WOS:000088999700080
J	Nika, J; Yang, WM; Pavitt, GD; Hinnebusch, AG; Hannig, EM				Nika, J; Yang, WM; Pavitt, GD; Hinnebusch, AG; Hannig, EM			Purification and kinetic analysis of eIF2B from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; INITIATION FACTOR-II; POLYPEPTIDE-CHAIN INITIATION; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; EUKARYOTIC INITIATION-FACTOR-2; ALPHA-SUBUNIT; GAMMA-SUBUNIT; DROSOPHILA-MELANOGASTER; RABBIT RETICULOCYTES	Eukaryotic translation initiation factor 2B (eIF2B) is the heteropentameric guanine nucleotide exchange factor for translation initiation factor 2 (eIF2). Recent studies in the yeast Saccharomyces cerevisiae have served to characterize genetically the exchange factor. However, enzyme kinetic studies of the yeast enzyme have been hindered by the lack of sufficient quantities of protein suitable for biochemical analysis. We have purified yeast eIF2B and characterized its catalytic properties in vitro. Values for K-m and V-max were determined to be 12.2 nM and 250.7 fmol/min, respectively, at 0 degrees C. The calculated turnover number (K-cat) of 43.2 pmol of GDP released per min/pmol of eIF2B at 30 degrees C is approximately 1 order of magnitude lower than values previously reported for the mammalian factor. Reciprocal plots at varying fixed concentrations of the second substrate were linear and intersected to the left of the gamma axis. This is consistent with a sequential catalytic mechanism and argues against a ping-pong mechanism similar to that proposed for EF-Tu/EF-Ts. In support of this model, our yeast eIF2B preparations bind guanine nucleotides, with an apparent dissociation constant for GTP in the low micromolar range.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Dallas; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hannig, EM (corresponding author), Univ Texas, Dept Mol & Cell Biol, Mail Stn FO 3-1,POB 8306888, Richardson, TX 75083 USA.	hannig@utdallas.edu	Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418; Hannig, Ernest/0000-0002-2260-3342	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD MF, 1985, J BIOL CHEM, V260, P6960; AKKARAJU GR, 1991, J BIOL CHEM, V266, P24451; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; HANNIG EM, 1990, GENETICS, V126, P549; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HWANG YW, 1985, J BIOL CHEM, V260, P1498; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1994, BIOCHIMIE, V76, P729, DOI 10.1016/0300-9084(94)90077-9; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOONIN EV, 1995, PROTEIN SCI, V4, P1608, DOI 10.1002/pro.5560040819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manchester KL, 1997, BIOCHEM BIOPH RES CO, V239, P223, DOI 10.1006/bbrc.1997.7462; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Olsen DS, 1998, GENETICS, V149, P1495; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Sherman F., 1986, METHODS YEAST GENETI, P163; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh L P, 1996, SAAS Bull Biochem Biotechnol, V9, P1; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yang WM, 1996, MOL CELL BIOL, V16, P6603	65	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26011	26017		10.1074/jbc.M003718200	http://dx.doi.org/10.1074/jbc.M003718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852917	hybrid			2022-12-27	WOS:000088999700019
J	Fukamizo, T; Juffer, AH; Vogel, HJ; Honda, Y; Tremblay, H; Boucher, I; Neugebauer, WA; Brzezinski, R				Fukamizo, T; Juffer, AH; Vogel, HJ; Honda, Y; Tremblay, H; Boucher, I; Neugebauer, WA; Brzezinski, R			Theoretical calculation of pk(a) reveals an important role of Arg(205) in the activity and stability of Streptomyces sp N174 chitosanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUUM ELECTROSTATIC MODEL; ACID-DISSOCIATION CONSTANTS; HORDEUM-VULGARE L; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; IONIZABLE GROUPS; AMINO-ACIDS; PROTEINS; CATALYSIS; MECHANISM	Based on the crystal structure of chitosanase from Streptomyces sp, N174, we have calculated theoretical pK(alpha) values of the ionizable groups of this protein using a combination of the boundary element method and continuum electrostatics. The pK(alpha) value obtained for Arg(205), which is located in the catalytic cleft, was abnormally high (>20.0), indicating that the guanidyl group may interact strongly with nearby charges. Chitosanases possessing mutations in this position (R205A, R205H, and R205Y), produced by Streptomyces lividans expression system, were found to have less than 0.3% of the activity of the wild type enzyme and to possess thermal stabilities 4-5 kcal/mol lower than that of the wild type protein. In the crystal structure, the Arg205 Side chain is in close proximity to the Asp(145) Side chain (theoretical pK(alpha), -1.6), which is in turn close to the Arg(190) side chain (theoretical pK(alpha), 17,7), These theoretical pK(alpha) values are abnormal, suggesting that both of these residues may participate in the Arg(205) interaction network. Activity and stability experiments using Asp(145)- and Arg(190)-mutated chitosanases (D145A and R190A) provide experimental data supporting the hypothesis derived from the theoretical pK(alpha) data and prompt the conclusion that Arg(205) forms a strong interaction network with Asp(145) and Arg(190) that stabilizes the catalytic cleft.	Kinki Univ, Fac Agr, Biophys Chem Lab, Nara 6318505, Japan; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Sherbrooke, Dept Biol, Fac Sci, Grp Rech Biol Actinoycetes, Sherbrooke, PQ J1K 2R1, Canada; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1K 5N4, Canada; Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	Kindai University (Kinki University); University of Calgary; University of Sherbrooke; University of Sherbrooke; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Fukamizo, T (corresponding author), Kinki Univ, Fac Agr, Biophys Chem Lab, 3327-204 Nakamachi, Nara 6318505, Japan.	fukamizo@nara.kindai.ac.jp	Brzezinski, Ryszard/A-3192-2008; Fukamizo, Tamo/AAY-7251-2020	Juffer, Andre/0000-0003-3533-0520; Brzezinski, Ryszard/0000-0002-9090-5051				Andersen MD, 1997, BIOCHEM J, V322, P815, DOI 10.1042/bj3220815; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Beroza P, 1996, J COMPUT CHEM, V17, P1229, DOI 10.1002/(SICI)1096-987X(19960730)17:10<1229::AID-JCC4>3.0.CO;2-Q; Boucher I, 1995, J BIOL CHEM, V270, P31077, DOI 10.1074/jbc.270.52.31077; BOUCHER I, 1992, APPL MICROBIOL BIOT, V38, P188, DOI 10.1007/BF00174466; Brameld KA, 1998, P NATL ACAD SCI USA, V95, P4276, DOI 10.1073/pnas.95.8.4276; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Demchuk E, 1996, J PHYS CHEM-US, V100, P17373, DOI 10.1021/jp960111d; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; Fukamizo T, 1997, BIOCHEM CELL BIOL, V75, P687, DOI 10.1139/bcb-75-6-687; HART PJ, 1995, J MOL BIOL, V248, P402, DOI 10.1006/jmbi.1995.0230; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Honda Y, 1997, FEBS LETT, V411, P346, DOI 10.1016/S0014-5793(97)00726-6; Honda Y, 1999, BBA-PROTEIN STRUCT M, V1429, P365, DOI 10.1016/S0167-4838(98)00243-X; Imoto T., 1972, ENZYMES, V7, P665; INOUE M, 1992, BIOCHEMISTRY-US, V31, P5545, DOI 10.1021/bi00139a017; Juffer AH, 1998, J COMPUT AID MOL DES, V12, P289, DOI 10.1023/A:1016089901704; Juffer AH, 1998, BIOCHEM CELL BIOL, V76, P198, DOI 10.1139/bcb-76-2-3-198; Juffer AH, 1997, J PHYS CHEM B, V101, P7664, DOI 10.1021/jp9715944; JUFFER AH, 1991, J COMPUT PHYS, V97, P144, DOI 10.1016/0021-9991(91)90043-K; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MASSON JY, 1993, CHITIN ENZYMOLOGY, P283; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; OBEROI H, 1993, BIOPHYS J, V65, P48, DOI 10.1016/S0006-3495(93)81032-4; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Saito J, 1999, J BIOL CHEM, V274, P30818, DOI 10.1074/jbc.274.43.30818; SEKI K, 1997, ADV CHITIN SCI, V2, P284; TAKAHASHI T, 1992, BIOPOLYMERS, V32, P897, DOI 10.1002/bip.360320802; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; VANDERSPOEL D, 1996, GROMACS USER MANUAL; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WATANABE T, 1993, J BIOL CHEM, V268, P18567	37	33	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25633	25640		10.1074/jbc.M002574200	http://dx.doi.org/10.1074/jbc.M002574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829022	hybrid			2022-12-27	WOS:000088849400078
J	Ishida, N; Kitagawa, M; Hatakeyama, S; Nakayama, K				Ishida, N; Kitagawa, M; Hatakeyama, S; Nakayama, K			Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; KAPPA-B-ALPHA; UBIQUITIN-MEDIATED DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL-CYCLE PROGRESSION; F-BOX PROTEIN; BREAST-CANCER; MUTATIONAL ANALYSIS; MOLECULAR ANALYSIS; BUTYROLACTONE-I	The association of the p27(Kip1) protein with cyclin and cyclin-dependent kinase complexes inhibits their kinase activities and contributes to the control of cell proliferation. The p27(Kip1) protein has now been shown to be phosphorylated in vivo, and this phosphorylation reduces the electrophoretic mobility of the protein. Substitution of Ser(10) with Ala (S10A) markedly reduced the extent of p27(Kip1) phosphorylation and prevented the shift in electrophoretic mobility. Phosphopeptide mapping and phosphoamino acid analysis revealed that phosphorylation at Ser(10) accounted for similar to 70% of the total phosphorylation of p27(Kip1), and the extent of phosphorylation at this site was similar to 25- and 75-fold greater than that at Ser(178) and Thr(187), respectively. The phosphorylation of p27(Kip1) was markedly reduced when the positions of Ser(10) and Pro(11) were reversed, suggesting that a proline-directed kinase is responsible for the phosphorylation of Ser(10) The extent of Ser(10) phosphorylation was markedly increased in cells in the G(0)-G(1) phase of the cell cycle compared with that apparent for cells in S or M phase. The p27(Kip1) protein phosphorylated at Ser(10) was significantly more stable than the unphosphorylated form. Furthermore, a mutant p27(Kip1) in which Ser(10) was replaced with glutamic acid in order to mimic the effect of Ser(10) phosphorylation exhibited a marked increase in stability both in vivo and in vitro compared with the wild-type or S10A mutant proteins. These results suggest that Ser(10) is the major site of phosphorylation of p27(Kip1) and that phosphorylation at this site, like that at Thr(187), contributes to regulation of p27(Kip1) stability.	Kyushu Univ, Dept Mol & Cell Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, K (corresponding author), Kyushu Univ, Dept Mol & Cell Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawamata N, 1996, CANCER, V77, P570; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; KITAGAWA M, 1994, ONCOGENE, V9, P2549; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Seriu T, 1996, LEUKEMIA, V10, P345; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	66	183	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25146	25154		10.1074/jbc.M001144200	http://dx.doi.org/10.1074/jbc.M001144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831586	hybrid			2022-12-27	WOS:000088849400016
J	Wada, H; Hasegawa, K; Morimoto, T; Kakita, T; Yanazume, T; Sasayama, S				Wada, H; Hasegawa, K; Morimoto, T; Kakita, T; Yanazume, T; Sasayama, S			A p300 protein as a coactivator of GATA-6 in the transcription of the smooth muscle-myosin heavy chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; CDNA CLONING; CELLS; EXPRESSION; DIFFERENTIATION; ISOFORM; IDENTIFICATION; PROLIFERATION; GATA-4/5/6; ADAPTER	The mechanisms that regulate smooth muscle development and differentiation are poorly understood. Although recent studies have suggested the possible role of a zinc finger transcription factor, GATA-6, in the differentiation of vascular smooth muscle cells (VSMCs), the downstream gene targeted by GATA-6 is unknown, The expression of smooth muscle-myosin heavy chain (Sm-MHC) provides a highly specific marker for the differentiated phenotype of VSMCs as well. as the smooth muscle cell lineage. Here, we show that GATA-6 bound to a GATA-like motif (-810/-805) within the rat Sm-MHC promoter in a sequence-specific manner and activated this promoter through this site, In addition, we show that the transcriptional coactivator p300 associated with GATA-6 during the transcription of the Sm-MHC gene. A p300/GATA-6 complex in VSMCs was up-regulated by induction of the quiescent phenotype. A wildtype E1A, which interferes with endogenous p300, but not a mutant E1A defective for p300 binding, markedly down-regulated the expression of endogenous Sm-MHC in quiescent-phenotype VSMCs, These studies provide the first identification of a functionally important GATA-6 binding site within a smooth muscle-specific promoter and suggest a role for p300 in the maintenance of the differentiated phenotype in VSMCs as a coactivator of GATA-6.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.			Wada, Hiromichi/0000-0002-8980-224X				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEY CA, 1994, CAN J PHYSIOL PHARM, V72, P1351, DOI 10.1139/y94-195; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KOCHER O, 1991, LAB INVEST, V65, P459; KUROO M, 1991, J BIOL CHEM, V266, P3768; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAGAI R, 1989, J BIOL CHEM, V264, P9734; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; OWENS GK, 1995, PHYSIOL REV, V75, P487; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; REIDY MA, 1992, ARCH PATHOL LAB MED, V116, P1276; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	34	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25330	25335		10.1074/jbc.M000828200	http://dx.doi.org/10.1074/jbc.M000828200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851229	hybrid			2022-12-27	WOS:000088849400039
J	Naik, RS; Davidson, EA; Gowda, DC				Naik, RS; Davidson, EA; Gowda, DC			Developmental stage-specific biosynthesis of glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum and its inhibition in a novel manner by mannosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDES; ERYTHROCYTIC STAGES; STRUCTURAL-ANALYSIS; MEMBRANE ANCHOR; MAMMALIAN-CELLS; GPI; PROTEINS; INTERMEDIATE; METABOLISM; PRECURSORS	Glycosylphosphatidylinositols (GPIs) are the major glycoconjugates in intraerythrocytic stage Plasmodium falciparum. Several functional proteins including merozoite surface protein 1 are anchored to the cell surface by GPI modification, and GPIs are vital to the parasite. Here, we studied the developmental stage-specific biosynthesis of GPIs by intraerythrocytic P. falciparum. Tie parasite synthesizes GPIs exclusively during the maturation of early trophozoites to late trophozoites but not during the development of rings to early trophozoites or late trophozoites to schizonts and merozoites, Mannosamine, an inhibitor of GPI biosynthesis, inhibits the growth of the parasite specifically at the trophozoite stage, preventing further development to schizonts and causing death. Mannosamine has no effect on the development of either rings to early trophozoites or late trophozoites to schizonts and merozoites. The analysis of GPIs and proteins synthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of the inhibition of GPI biosynthesis, The data also show that mannosamine inhibits GPI biosynthesis by interfering with the addition of mannose to an inositol-acylated GlcN-phosphatidylinositol (PI) intermediate, which is distinctively different from the pattern seen in other organisms. In other systems, mannosamine inhibits GPI biosynthesis by interfering with either the transfer of a mannose residue to the Man alpha 1-6Man alpha 1-4GlcN-PI intermediate or the formation of ManN-Man-GlcN-PI, an aberrant GPI intermediate, which cannot be a substrate for further addition of mannose. Thus, the parasite GPI biosynthetic pathway could be a specific target for antimalarial drug development.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041139] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1993, J BIOL CHEM, V268, P9570; Field MC, 1997, GLYCOBIOLOGY, V7, P161, DOI 10.1093/glycob/7.2.161-d; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Gowda DC, 1999, PARASITOL TODAY, V15, P147, DOI 10.1016/S0169-4758(99)01412-X; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SEVLEVER D, 1993, J BIOL CHEM, V268, P10938; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; UDEINYA IJ, 1980, B WORLD HEALTH ORGAN, V58, P445	29	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24506	24511		10.1074/jbc.M002151200	http://dx.doi.org/10.1074/jbc.M002151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833517	hybrid			2022-12-27	WOS:000088683300037
J	Sattler, M; Verma, S; Shrikhande, G; Byrne, CH; Pride, YB; Winkler, T; Greenfield, EA; Salgia, R; Griffin, JD				Sattler, M; Verma, S; Shrikhande, G; Byrne, CH; Pride, YB; Winkler, T; Greenfield, EA; Salgia, R; Griffin, JD			The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HYDROGEN-PEROXIDE; DNA-DAMAGE; GROWTH-FACTORS; CIGARETTE TAR; PHOSPHORYLATION; TRANSFORMATION; APOPTOSIS; COMPLEX; PHOSPHATASES	The BCR/ABL oncogene causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells and myeloid cells, It is shown here that transformation of the hematopoietic cell lines Ba/F3, 32Dcl3, and M07e with BCR/ABL results in an increase in reactive oxygen species (ROS) compared with quiescent, untransformed cells. The increase in ROS was directly due to BCR/ABL because it was blocked by the ABL-specific tyrosine kinase inhibitor STI571, Oxidative stress through ROS is believed to have many biochemical effects, including the potential ability to inhibit protein-tyrosine phosphatases (PTPases), To understand the significance of increased production of ROS, a model system was established in which hydrogen peroxide (H2O2) was added to untransformed cells to mimic the increase in ROS induced constitutively by BCR/ABL. H2O2 substantially reduced total cellular PTPase activity to a degree approximately equivalent to that of pervanadate, a well known PTPase inhibitor. Further, stimulation of untransformed cells with H2O2 or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Treatment of the BCR/ABL-expressing cell line MO7/p210 with the reducing agents pyrrolidine dithiocarbamate or N-acetylcysteine reduced the accumulation of ROS and also decreased tyrosine phosphorylation of cellular proteins. Further, treatment of M07e cells with H2O2 or pervanadate increased the tyrosine kinase activity of c-ABL, Drugs that alter ROS metabolism or reactivate PTPases may antagonize BCR/ABL transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sattler, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Winkler, Thomas/S-3787-2017	Winkler, Thomas/0000-0002-8072-0168; Pride, Yuri/0000-0002-5884-0964	NCI NIH HHS [CA75348-03] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CHANCE B, 1963, J BIOL CHEM, V238, P418; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Niu TQ, 1999, J CELL BIOCHEM, V72, P145, DOI 10.1002/(SICI)1097-4644(19990101)72:1<145::AID-JCB15>3.0.CO;2-G; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PEDERSEN B, 1982, BRIT J HAEMATOL, V51, P339, DOI 10.1111/j.1365-2141.1982.tb02789.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pryor WA, 1998, CHEM RES TOXICOL, V11, P441, DOI 10.1021/tx970159y; RAMBALDI A, 1989, BLOOD, V73, P1113; Rao GN, 1996, ONCOGENE, V13, P713; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; SPENCER JPE, 1995, FEBS LETT, V375, P179, DOI 10.1016/0014-5793(95)01199-O; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 1997, INT J ONCOL, V11, P471; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Yoshie Y, 1997, CARCINOGENESIS, V18, P1359, DOI 10.1093/carcin/18.7.1359; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	39	250	258	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24273	24278		10.1074/jbc.M002094200	http://dx.doi.org/10.1074/jbc.M002094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833515	hybrid			2022-12-27	WOS:000088683300007
J	Maeshima, Y; Colorado, PC; Kalluri, R				Maeshima, Y; Colorado, PC; Kalluri, R			Two RGD-independent alpha(v)beta(3) integrin binding sites on tumstatin regulate distinct anti-tumor properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IV COLLAGEN; ALPHA-3(IV) CHAIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; MOLECULAR-CLONING; LAMININ RECEPTOR; MELANOMA-CELLS; ANGIOGENESIS; PROTEIN	Vascular basement membrane is an important regulator of angiogenesis and undergoes many alterations during angiogenesis and these changes are speculated to influence neovascularization. Recently, fragments of collagen molecules have been identified to possess antiangiogenic activity. Tumstatin (alpha 3(IV)NC1 domain) is one such novel molecule with distinct anti-tumor properties and possesses an N-terminal (amino acids 54-132) anti-angiogenic and a C-terminal (amino acids 185-203) anti-tumor cell activity (Maeshima, Y., et al. 2000) J. Biol. Chem. 275, 21340-21348). Previous studies have identified the 185-203 amino acid sequence as a ligand for alpha(nu)beta(3) integrin (Shahan, T. A. et al. (1999) Cancer Res. 59, 4584-4590). In the present study, we found distinct additional RGD-independent alpha(nu)beta(3) integrin binding site within 54-132 amino acids of tumstatin. This site is not essential for inhibition of tumor cell proliferation but necessary for the anti-angiogenic activity. A fragment of tumstatin containing 54-132 amino acid (tum-2) binds both endothelial cells and melanoma cells but only inhibited proliferation of endothelial cells, with no effect on tumor cell proliferation. A similar experiment with fragment of tumstatin containing the 185-203 amino acid (tum-4) demonstrates that it binds both endothelial cells and melanoma cells but only inhibits the proliferation of melanoma cells. The presence of cyclic RGD peptides did not affect the alpha(nu)beta(3) integrin-mediated activity of tumstatin, although significant inhibition of endothelial cell binding to vitronectin was observed. The two distinct RGD-independent binding sites on tumstatin suggest unique alpha(nu)beta(3) integrin-mediated mechanisms governing the two distinct anti-tumor properties of tumstatin.	Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, RW 563A,330 Brookline Ave, Boston, MA 02215 USA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Colorado PC, 2000, CANCER RES, V60, P2520; Dhanabal M, 1999, CANCER RES, V59, P189; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERLYN D, 1990, CANCER RES, V50, P2296; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Petitclerc E, 1999, CANCER RES, V59, P2724; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahan TA, 1999, CANCER RES, V59, P4584; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	38	205	238	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23745	23750		10.1074/jbc.C000186200	http://dx.doi.org/10.1074/jbc.C000186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10837460	hybrid			2022-12-27	WOS:000088564200048
J	Krehan, A; Ansuini, H; Bocher, O; Grein, S; Wirkner, U; Pyerin, W				Krehan, A; Ansuini, H; Bocher, O; Grein, S; Wirkner, U; Pyerin, W			Transcription factors Ets1, NF-kappa B, and Sp1 are major determinants of the promoter activity of the human protein kinase CK2 alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; SUBUNIT-IV GENE; CASEIN KINASE; MEDIATED PHOSPHORYLATION; CELLULAR-REGULATION; INITIATOR ACTIVITY; ALPHA-GENE; II-ALPHA; BINDING; CK2	CK2 alpha is one of two isoforms of protein kinase CK2, a highly conserved, ubiquitous, and vital phosphotransferase whose expression is kept at constant cellular levels and whose dysregulated expression has been linked to malignant diseases. The upstream sequence of the gene coding for human CK2 alpha (CSNK1A1, chromosomal location 20p13) has been examined for promoter location and transcription factor interactions using reporter gene assays (luciferase; HeLa cells), site-directed mutagenesis, electrophoretic mobility shift assays, super-shifts, UV cross-linking, Western blotting, and DNA affinity chromatography. Highest promoter activity has been found in a region comprising positions -9 to 46, Factors Spl, Ets-1, and NF-kappa B have been identified as interaction partners and, by mutation of individual sites and simultaneous mutations of two or more sites, shown to cross-talk to each other. At least two of the factors (Spl; NF-kappa B) were susceptible to phosphorylation by CK2 holoenzyme, a tetramer: composed of two CK2 alpha and two regulatory CK2 beta proteins, but not by individual CK2 alpha, Because the phosphorylation decreases promoter binding and repeated immunoprecipitation reveals presence of "free" CK2 beta in cell extracts, it is tempting to speculate that the gene product CK2 alpha might readily form CK2 holoenzyme and feed back onto gene transcription. The data represent the first promoter control analysis of a mammalian CK2 alpha gene and provide a hypothesis of how the constant expression level of CK2 alpha may be achieved.	Deutsch Krebsforschungszentrum, Biochem Zellphysiol B0200, D-69120 Heidelberg, Germany; Univ Perugia, I-06100 Perugia, Italy	Helmholtz Association; German Cancer Research Center (DKFZ); University of Perugia	Pyerin, W (corresponding author), Deutsch Krebsforschungszentrum, Biochem Zellphysiol B0200, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	w.pyerin@dkfz-heidelberg.de						AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOHM SK, 1995, BIOCHEM J, V311, P835; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; COCHET C, 1983, J BIOL CHEM, V258, P1403; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DUAYAO MP, 1992, CURR TOP MICROBIOL I, V182, P421; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Krehan A, 1998, EUR J BIOCHEM, V251, P667, DOI 10.1046/j.1432-1327.1998.2510667.x; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Lodie TA, 1998, J IMMUNOL, V161, P268; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1995, SCIENCE, V267, P834, DOI 10.1126/science.7846527; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; Pyerin Walter, 1996, P117, DOI 10.1002/9783527615032.ch4; QUINN JP, 1991, FEBS LETT, V286, P225, DOI 10.1016/0014-5793(91)80979-D; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANDIJK MA, 1992, MOL CELL ENDOCRINOL, V88, P175, DOI 10.1016/0303-7207(92)90022-X; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wirkner U, 1999, MOL CELL BIOCHEM, V191, P59, DOI 10.1023/A:1006848814894; Wirkner U, 1998, GENOMICS, V48, P71, DOI 10.1006/geno.1997.5136; WU RL, 1994, J BIOL CHEM, V269, P28450; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	65	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18327	18336		10.1074/jbc.M909736199	http://dx.doi.org/10.1074/jbc.M909736199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849443	hybrid			2022-12-27	WOS:000087659400058
J	Lin, S; Fagan, KA; Li, KX; Shaul, PW; Cooper, DMF; Rodman, DM				Lin, S; Fagan, KA; Li, KX; Shaul, PW; Cooper, DMF; Rodman, DM			Sustained endothelial nitric-oxide synthase activation requires capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; NADPH-DIAPHORASE; ADENYLYL-CYCLASE; PLASMA-MEMBRANE; TUMOR PROMOTER; INTACT-CELLS; MICE LACKING; AEQUORIN	Endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme, is critical for vascular homeostasis. While eNOS is membrane-associated through its N-myristoylation, the significance of membrane association in locating eNOS near sources of Ca2+ entry is uncertain. To assess the Ca2+ source required for eNOS activation, chimera containing the full-length eNOS cDNA and HA-tagged aequorin sequence (EHA), and MHA (myristoylation deficient EHA) were generated and transfected into COS-7 cells. The EHA chimera was primarily targeted to the plasma membrane while MHA was located intracellularly. Both constructs retained enzymatic eNOS activity and aequorin-mediated Ca2+ sensitivity. The plasma membrane-associated EHA and intracellular MHA were compared in their ability to sense changes in local Ca2+ concentration, demonstrating preferential sensitivity to Ca2+ originating from intracellular pools (MHA) or from capacitative Ca2+ entry (EHA). Measurements of eNOS activation in intact cells revealed that the eNOS enzymatic activity of EHA was more sensitive to Ca2+ influx via capacitative Ca2+ entry than intracellular release, whereas MHA eNOS activity was more responsive to intracellular Ca2+ release. When eNOS activation by CCE was compared with that generated by an equal rise in [Ca2+](i) due to the Ca2+ ionophore ionomycin, a 10-fold greater increase in NO production was found in the former condition. These results demonstrate that EHA and MHA chimera are properly targeted and retain full functions of eNOS and aequorin, and that capacitative Ca2+ influx is the principle stimulus for sustained activation of eNOS on the plasma membrane in intact cells.	Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rodman, DM (corresponding author), Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,B133, Denver, CO 80262 USA.				NHLBI NIH HHS [HL14985, HL48038] Funding Source: Medline; NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048038, R01HL048038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CASADEI J, 1990, P NATL ACAD SCI USA, V87, P2047, DOI 10.1073/pnas.87.6.2047; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Demura Y, 1998, BRIT J PHARMACOL, V125, P1180, DOI 10.1038/sj.bjp.0702197; DOLOR RJ, 1992, AM J PHYSIOL, V262, P171; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	47	148	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17979	17985		10.1074/jbc.275.24.17979	http://dx.doi.org/10.1074/jbc.275.24.17979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849433	hybrid			2022-12-27	WOS:000087659400012
J	Zhao, L; Gregoire, F; Sul, HS				Zhao, L; Gregoire, F; Sul, HS			Transient induction of ENC-1, a Kelch-related actin-binding protein, is required for adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE CONVERSION; TRIGLYCERIDE ACCUMULATION; 3T3-L1 PREADIPOCYTES; INTERACTION MOTIF; MESSENGER-RNA; CELL-SHAPE; DOMAIN; FIBRONECTIN; COLLAGEN	In an attempt to study molecules that play a regulatory role early in adipocyte differentiation, we identified by differential display ENC-1, a Drosophila kelch-related protein. ENC-1 colocalizes with actin filaments. ENC-1 is expressed in adipose tissue, specifically in the adipose derived stroma vascular fraction. ENC-1 mRNA levels are transiently increased 8-12-fold early in in vitro adipocyte differentiation of primary cells of the adipose-derived stroma-vascular fraction and of 3T3-L1 cells. Treatment with the adipogenic inducers dexamethasone and methylisobutylxanthine causes an increase in ENC-1 mRNA levels specifically in preadipocytes, and methylisobutylxanthine is the main effector of ENC-1 expression. The induction of ENC-1 precedes expression of the transcription factors, peroxisome proliferator-activated receptor (PPAR gamma) and CCAAT/enhancer-binding protein (C/EBP alpha), and other adipocyte markers including adipocyte fatty acid-binding protein. The ENC-1 induction correlates with the subsequent differentiation of primary stroma-vascular cells into adipocytes. Furthermore, decreasing the endogenous ENC-1 levels by stable antisense transfection, thereby preventing the transient induction, effectively inhibits 3T3-L1 adipocyte differentiation. Overall, these studies indicate that ENC-1, an actin-binding protein, plays a regulatory role early in adipocyte differentiation when cytoskeletal reorganization and cell shape change from fibroblastic preadipocytes to spherical adipocytes occur.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [R01 DK 50828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANTRAS J, 1989, BIOL CELL, V66, P247, DOI 10.1016/0248-4900(89)90177-9; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BJORNTORP P, 1982, METABOLISM, V31, P366, DOI 10.1016/0026-0495(82)90112-3; CHEN W, 1995, MOL CELL BIOL, V15, P3424; DANI C, 1989, J BIOL CHEM, V264, P10119; FERNANDEZ JLR, 1989, DIFFERENTIATION, V42, P65, DOI 10.1111/j.1432-0436.1989.tb00608.x; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GREGOIRE FM, 1995, INT J OBESITY, V19, P664; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; PAIRAULT J, 1987, BIOL CELL, V61, P149, DOI 10.1111/j.1768-322X.1987.tb00581.x; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SIDHU RS, 1979, J BIOL CHEM, V254, P1111; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	30	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16845	16850		10.1074/jbc.275.22.16845	http://dx.doi.org/10.1074/jbc.275.22.16845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828068	hybrid			2022-12-27	WOS:000087392200063
J	Li, RX; Manela, J; Kong, Y; Ladisch, S				Li, RX; Manela, J; Kong, Y; Ladisch, S			Cellular gangliosides promote growth factor-induced proliferation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; GLUCOSYLCERAMIDE SYNTHASE; IMMUNOSUPPRESSIVE ACTIVITY; TYROSINE PHOSPHORYLATION; MEDIATED MODULATION; CELLS; GLYCOSPHINGOLIPIDS; INHIBITION; CERAMIDE	Cell surface gangliosides have been proposed as modulators of transmembrane signaling. In this study, we used two complementary approaches to investigate the function of cellular gangliosides in the response of mammalian fibroblasts to growth factors. First, inhibition of glucosyl ceramide synthase by a new specific inhibitor of D-1-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol-HCl (glucosylceramide synthase), which depletes cellular gangliosides at a concentration of 1 muM without causing an increase in ceramide levels, blocked epidermal growth factor-stimulated proliferation of fibroblasts. Similarly, responses to several other growth factors that activate receptor tyrosine kinases, including fibroblast growth factor, insulin-like growth factor-I, and platelet-derived growth factor, were inhibited by 50-100%. Conversely, enrichment of cellular gangliosides by preincubation of the mouse and human fibroblasts with exogenously added gangliosides enhanced growth factor-elicited cell proliferation. Novel findings of this study, distinguishing it from previous similar studies, include differential effects of preincubation versus continuous incubation of cells with gangliosides on growth factor-dependent cell proliferation and the growth factor-like action of NeuNAc alpha2-3Gal beta1-3GalNAc beta1-4(NeuNAc alpha2-3)Gal beta1-4Glc beta1-1Cer when cells are pretreated with the ganglioside.	Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; George Washington Univ, Sch Med, Dept Biochem Mol Biol, Washington, DC 20052 USA	George Washington University; George Washington University	Ladisch, S (corresponding author), Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, 111 Michigan Ave NW, Washington, DC 20010 USA.	SLadisch@cnmc.org			NCI NIH HHS [CA61010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE A, 1995, J LIPID RES, V36, P611; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505; ENDO K, 1991, CANCER RES, V51, P1613; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HYNDS DL, 1995, J NEUROCHEM, V65, P2251; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kong Y, 1998, BBA-LIPID LIPID MET, V1394, P43, DOI 10.1016/S0005-2760(98)00096-4; LADISCH S, 1994, P NATL ACAD SCI USA, V91, P1974, DOI 10.1073/pnas.91.5.1974; LADISCH S, 1995, BIOCHEMISTRY-US, V34, P1197, DOI 10.1021/bi00004a012; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LADISCH S, 1994, BIOCHEM BIOPH RES CO, V203, P1102, DOI 10.1006/bbrc.1994.2296; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meuillet EJ, 1999, CANCER RES, V59, P234; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Oderfeld-Nowak B, 1998, NEUROCHEM RES, V23, P443, DOI 10.1023/A:1022482106152; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; QUARLES RH, 1971, J NEUROCHEM, V18, P1809, DOI 10.1111/j.1471-4159.1971.tb09586.x; RADIN NS, 1993, ADV LIPID RES, V26, P183; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; SAQR HE, 1993, J NEUROCHEM, V61, P395; Slevin M, 1999, INT J CANCER, V82, P412, DOI 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J; Sorice M, 1997, J LIPID RES, V38, P969; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Yamaguchi S, 1997, GLYCOCONJUGATE J, V14, P707, DOI 10.1023/A:1018517400380; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	44	68	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34213	34223		10.1074/jbc.M906368199	http://dx.doi.org/10.1074/jbc.M906368199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10859325	hybrid			2022-12-27	WOS:000165095300031
J	Salzet, M; Chopin, V; Baert, JL; Matias, I; Malecha, J				Salzet, M; Chopin, V; Baert, JL; Matias, I; Malecha, J			Theromin, a novel leech thrombin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NITRIC-OXIDE RELEASE; HIRUDINARIA-MANILLENSIS; BIOCHEMICAL-CHARACTERIZATION; HAEMENTERIA-GHILIANII; ANTITHROMBOTIC DRUGS; RECOMBINANT HIRUDIN; BIOLOGICAL-ACTIVITY; ELASTASE INHIBITOR; TRYPSIN-INHIBITOR	We purified the most potent thrombin inhibitor described to date from the rhynchobdellid leech Theromyzon tessulatum. Designated theromin, it was purified to apparent homogeneity by gel permeation and anion exchange chromatography followed by two reverse-phase steps of high performance liquid chromatography. The primary sequence of theromin (a homodimer of 67 amino acid residues including 16 cysteine residues) was determined by a combination of reduction and s-beta-pyridylethylation, Edman degradation, trypsin enzymatic digestion, and matrix-assisted laser desorption mass spectrometry measurement. Theromin exhibits no sequence homology with any other thrombin inhibitors. Furthermore, theromin significantly diminishes, in a dose-dependent manner, the level of human granulocyte and monocyte activation induced by lipopolysaccharides. In summary, this potent thrombin inhibitor promises to have high biomedical significance.	Univ Sci & Tech Lille Flandres Artois, CNRS, Unite Propre Rech Super Associee 8017, Lab Endocrinol Annelides, F-59655 Villeneuve Dascq, France; Inst Biol Lille, Unite Mixte Rech 8526, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille		michel.salzet@univ-lille1.fr	Salzet, Michel/A-7675-2011; Matias, Ignacio R. R/D-7483-2016	Salzet, Michel/0000-0003-4318-0817; Matias, Ignacio R. R/0000-0002-2229-6178				Beijering RJR, 1996, ANN HEMATOL, V72, P177, DOI 10.1007/s002770050158; BIETH JG, 1980, CLIN RES PROC, V16, P183; BLANKENSHIP DT, 1990, BIOCHEM BIOPH RES CO, V166, P1384, DOI 10.1016/0006-291X(90)91020-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG JY, 1990, J BIOL CHEM, V265, P22159; Chopin V, 1998, EUR J BIOCHEM, V254, P565, DOI 10.1046/j.1432-1327.1998.2540565.x; Chopin V, 1998, EUR J BIOCHEM, V258, P662, DOI 10.1046/j.1432-1327.1998.2580662.x; Chopin V, 1997, EUR J BIOCHEM, V249, P733, DOI 10.1111/j.1432-1033.1997.t01-1-00733.x; CHOPIN V, 2000, IN PRESS J BIOL CHEM, V275; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V34, P9552, DOI 10.1021/bi00029a032; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; ELECTRICWALA A, 1993, J ENZYM INHIB, V6, P293, DOI 10.3109/14756369309020179; FORTKAMP E, 1986, DNA-J MOLEC CELL BIO, V5, P511, DOI 10.1089/dna.1.1986.5.511; Fritz H., 1976, Methods Enzymol, V45, P797; GASIC GJ, 1983, CANCER RES, V43, P1633; GOLDSTEIN AM, 1986, COMP BIOCHEM PHYS B, V84, P117, DOI 10.1016/0305-0491(86)90280-4; Haycraft J. B., 1884, P ROY SOC LOND B BIO, V36, P478, DOI [10.1098/rspl.1883.0135, DOI 10.1098/RSPL.1883.0135]; HEMBERGER JU, Patent No. 01404; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JUNG HI, 1995, J BIOL CHEM, V270, P13879, DOI 10.1074/jbc.270.23.13879; Kim DR, 1996, J ENZYM INHIB, V10, P81, DOI 10.3109/14756369609020161; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magazine HI, 1996, J IMMUNOL, V156, P4845; MALECHA J, 1989, CR ACAD SCI III-VIE, V309, P127; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; MARKWARDT F, 1967, PHARMAZIE, V22, P239; MARKWARDT F, 1994, PHARMAZIE, V49, P313; Nieto-Fernandez FE, 1999, COMP BIOCHEM PHYS B, V123, P295, DOI 10.1016/S0305-0491(99)00074-7; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; Prevot V, 1998, BRAIN RES, V790, P236, DOI 10.1016/S0006-8993(98)00066-3; ROSTON D, 1996, INT J CARDIOL S, V53, P11; Salzet M, 1999, IMMUNOL TODAY, V20, P541, DOI 10.1016/S0167-5699(99)01495-4; Salzet M, 1998, MOL BRAIN RES, V55, P173, DOI 10.1016/S0169-328X(97)00156-3; SALZET M, 1999, IN PRESS PRASITOL TO; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; Shionoya T, 1927, J EXP MED, V46, P19, DOI 10.1084/jem.46.1.19; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; Stefano GB, 1997, BRAIN RES, V753, P219, DOI 10.1016/S0006-8993(96)01484-9; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; STRUBE KH, 1993, J BIOL CHEM, V268, P8590; TALBOT M, 1989, SEMIN THROMB HEMOST, V15, P293, DOI 10.1055/s-2007-1002722; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; VERSTRAETE M, 1995, DRUGS, V49, P856, DOI 10.2165/00003495-199549060-00002; WALSMANN P, 1985, THROMB RES, V40, P563, DOI 10.1016/0049-3848(85)90293-2; WALSMANN P, 1981, PHARMAZIE, V36, P653	47	47	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30774	30780		10.1074/jbc.M000787200	http://dx.doi.org/10.1074/jbc.M000787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10837466	hybrid			2022-12-27	WOS:000089762700007
J	Ennion, S; Hagan, S; Evans, RJ				Ennion, S; Hagan, S; Evans, RJ			The role of positively charged amino acids in ATP recognition by human P2X(1) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-2X RECEPTOR; SENSORY NEURONS; CHANNEL; BINDING; LIGAND; DESENSITIZATION; RESIDUES; SUBUNITS; ACETYLCHOLINE; PURINOCEPTORS	P2X receptors for ATP are a family of ligand-gated cation channels. There are 11 conserved positive charges in the extracellular loop of P2X receptors. We have generated point mutants of these conserved residues (either Lys --> Arg, Lys --> Ala, Arg --> Lys, or Arg --> Ale) in the human P2X(1) receptor to determine their contribution to the binding of negatively charged ATP, ATP evoked concentration-dependent (EC50 similar to 0.8 mu M) desensitizing responses at wild-type (WT) P2X(1) receptors expressed in Xenopus oocytes, Suramin produced a parallel rightward shift in the concentration response curve with an estimated pK(B) of 6.7. Substitution of amino acids at positions Lys-53, Lys-190, Lys-215, Lys-325, Arg-202, Arg-305, and Arg-314 either had no effect or only a small change in ATP potency, time course, and/or suramin sensitivity. Modest changes in ATP potency were observed for mutants at K70R and R292K/A (20- and 100-fold decrease, respectively). Mutations at residues K68A and K309A reduced the potency of ATP by >1400-fold and prolonged the time course of the P2X(1) receptor current but had no effect on suramin antagonism. Lys-68, Lys-70, Arg-292, and Lys-309 are close to the predicted transmembrane domains of the receptor and suggest that the ATP binding pocket may form close to the channel vestibule.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.							Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; EVANS RJ, 1994, BRIT J PHARMACOL, V113, P853, DOI 10.1111/j.1476-5381.1994.tb17071.x; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; LEFF P, 1990, BRIT J PHARMACOL, V101, P645, DOI 10.1111/j.1476-5381.1990.tb14134.x; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller M, 1996, J BIOL CHEM, V271, P1877; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Valera S, 1995, RECEPTOR CHANNEL, V3, P283; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Yamamoto H, 1999, MOL CELL BIOCHEM, V190, P169, DOI 10.1023/A:1006947216144	34	151	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29361	29367		10.1074/jbc.M003637200	http://dx.doi.org/10.1074/jbc.M003637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10827197				2022-12-27	WOS:000089439800026
J	Vorachek, WR; Steppan, CM; Lima, M; Black, H; Bhattacharya, R; Wen, P; Kajiyama, Y; Locker, J				Vorachek, WR; Steppan, CM; Lima, M; Black, H; Bhattacharya, R; Wen, P; Kajiyama, Y; Locker, J			Distant enhancers stimulate the albumin promoter through complex proximal binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; GROUP PROTEIN HMG-I(Y); CBF-DNA COMPLEX; NF-KAPPA-B; TRANSCRIPTION FACTOR; IN-VIVO; ALPHA-1-FETOPROTEIN GENE; FUNCTIONAL-ANALYSIS; HMG I(Y); RAT	The albumin-alpha-fetoprotein locus epitomizes the main features of transcriptional regulation of fetal and adult hepatocyte-specific genes: developmentally regulated promoters and strong distant enhancers. Full enhancer activity required only a proximal albumin-promoter region containing the TATA box, hepatic nuclear factor 1 (HNF1), and nuclear factor Y (NF-Y) sites. Deletion of the HNF1 site abrogated enhancer and promoter activity, whereas methylation of the site reduced all activity by about 3-fold. Deletion of the NF-Y site attenuated activity by about half, but much of the activity could be replaced by juxtaposition of an upstream region (designated distal element TV). Gel shift and competition analysis demonstrated that binding of architectural factors overlapped NF-Y binding. Moreover, a mutation that eliminated NF-Y binding but only minimally perturbed the surrounding region did not affect enhancer function. In plasmids with a second promoter, the enhancers simultaneously stimulated both albumin and Lu-fetoprotein promoters with minimal competition, but surprisingly some mutations in the albumin promoter attenuated expression from both promoters, whereas another uncoupled their expression. With single promoters, the function of the proximal promoter region was controlled by three parameters in the following hierarchy: HNF1 binding > local architecture > NF-Y binding, but integrated two-promoter function had a much greater dependence on NF-Y.	Albert Einstein Coll Med, Sch Med, Dept Pathol, Bronx, NY 10461 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Locker, J (corresponding author), Albert Einstein Coll Med, Sch Med, Dept Pathol, Bronx, NY 10461 USA.				NCI NIH HHS [CA68440, CA76354] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068440, R01CA076354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1984, J MOL BIOL, V173, P159, DOI 10.1016/0022-2836(84)90187-6; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; BABISS LE, 1987, GENE DEV, V1, P256, DOI 10.1101/gad.1.3.256; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; GROUPP ER, 1994, J BIOL CHEM, V269, P22178; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; HU IM, 1992, CELL GROWTH DIFFER, V3, P577; INGRAM RS, 1981, P NATL ACAD SCI-BIOL, V78, P4694, DOI 10.1073/pnas.78.8.4694; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JIN JR, 1995, DNA CELL BIOL, V14, P267, DOI 10.1089/dna.1995.14.267; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liberati C, 1998, FEBS LETT, V433, P174, DOI 10.1016/S0014-5793(98)00905-3; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOCKER J, 1996, TRANSCRIPTION FACTOR, P12; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Maity SN, 1996, METHOD ENZYMOL, V273, P217; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; McPherson CE, 1996, NUCLEIC ACIDS RES, V24, P397, DOI 10.1093/nar/24.3.397; MILLONIG JH, 1995, MOL CELL BIOL, V15, P3848; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PEAVY DE, 1981, BIOCHEM J, V198, P289, DOI 10.1042/bj1980289; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POWER SC, 1994, BIOCHEM BIOPH RES CO, V203, P1447, DOI 10.1006/bbrc.1994.2347; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Song YH, 1998, J BIOL CHEM, V273, P28408, DOI 10.1074/jbc.273.43.28408; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TRONCHE F, 1990, MOL BIOL MED, V7, P173; URANO Y, 1986, J BIOL CHEM, V261, P3244; URANO Y, 1984, GENE, V32, P255; VACHER J, 1992, MOL CELL BIOL, V12, P856, DOI 10.1128/MCB.12.2.856; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WU KJ, 1994, J BIOL CHEM, V269, P1177; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHANG DE, 1991, J BIOL CHEM, V266, P21179	67	23	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29031	29041		10.1074/jbc.M003039200	http://dx.doi.org/10.1074/jbc.M003039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10842175	hybrid			2022-12-27	WOS:000089330700090
J	Gouedard, L; Chen, YG; Thevenet, L; Racine, C; Borie, S; Lamarre, I; Josso, N; Massague, J; di Clemente, N				Gouedard, L; Chen, YG; Thevenet, L; Racine, C; Borie, S; Lamarre, I; Josso, N; Massague, J; di Clemente, N			Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; INHIBITING SUBSTANCE; OSTEOGENIC PROTEIN-1; MOUSE EMBRYOGENESIS; LEYDIG-CELLS; KINASE; EXPRESSION; APOPTOSIS; DIFFERENTIATION; ACTIVATION	Anti-Mullerian hormone induces the regression of fetal Mullerian ducts and inhibits the transcription of gonadal steroidogenic enzymes. It belongs to the transforming growth factor-p family whose members signal through a pair of serine/threonine kinase receptors and Smad effecters. Only the anti-Mullerian hormone type II receptor has been identified. Our goal was to determine whether anti-Mullerian hormone could share a type I receptor with another family member. Co-immunoprecipitation of known type I receptors with anti-Mullerian hormone type II receptor clearly showed that the bone morphogenetic protein type LB receptor was the only cloned type I receptor interacting in a ligand-dependent manner with this type II receptor. Anti-Mullerian hormone also activates the bone morphogenetic protein-specific Smad1 pathway and the XVent2 reporter gene, an anti-Mullerian hormone type II receptor-dependent effect abrogated by a dominant negative version of bone morphogenetic protein type LB receptor. Reverse amplification experiments showed that bone morphogenetic protein type IB receptor is co-expressed with anti-Mullerian hormone type II receptor in most anti-Mullerian hormone target tissues. Our data support a model in which a ligand, anti-Mullerian hormone, gains access to a shared type I receptor and Smad1 system through a highly restricted type II receptor.	Ecole Normale Super, Dept Biol, INSERM, Unite Rech Endocrinol Dev, F-92120 Montrouge, France; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	di Clemente, N (corresponding author), Ecole Normale Super, Dept Biol, INSERM, Unite Rech Endocrinol Dev, 1 Rue Maurice Arnoux, F-92120 Montrouge, France.			Massague, Joan/0000-0001-9324-8408; di Clemente, Nathalie/0000-0001-9087-3486; Racine, Chrystele/0000-0003-0250-5355				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baur ST, 2000, DEVELOPMENT, V127, P605; Belville C, 1999, AM J MED GENET, V89, P218, DOI 10.1002/(SICI)1096-8628(19991229)89:4<218::AID-AJMG6>3.0.CO;2-E; Candia AF, 1997, DEVELOPMENT, V124, P4467; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dutertre M, 1997, MOL CELL ENDOCRINOL, V136, P57, DOI 10.1016/S0303-7207(97)00214-1; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gu ZY, 1999, DEVELOPMENT, V126, P2551; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lee MM, 1999, ENDOCRINOLOGY, V140, P2819, DOI 10.1210/en.140.6.2819; LIU F, 1995, MOL CELL BIOL, V15, P3479; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; Roberts LM, 1999, DEV BIOL, V208, P110, DOI 10.1006/dbio.1998.9190; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rouiller-Fabre V, 1998, ENDOCRINOLOGY, V139, P1213, DOI 10.1210/en.139.3.1213; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schmidt C, 1998, DEV BIOL, V202, P253, DOI 10.1006/dbio.1998.9011; Teixeira J, 1999, ENDOCRINOLOGY, V140, P4732, DOI 10.1210/en.140.10.4732; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yi SE, 2000, DEVELOPMENT, V127, P621; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	49	130	140	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27973	27978						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10854429				2022-12-27	WOS:000089197100061
J	Rumsey, SC; Daruwala, R; Al-Hasani, H; Zarnowski, MJ; Simpson, IA; Levine, M				Rumsey, SC; Daruwala, R; Al-Hasani, H; Zarnowski, MJ; Simpson, IA; Levine, M			Dehydroascorbic acid transport by GLUT4 in Xenopus oocytes and isolated rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; GROWTH-FACTOR-I; ASCORBIC-ACID; VITAMIN-C; DIABETES-MELLITUS; HUMAN NEUTROPHILS; CELL-SURFACE; SUGAR-TRANSPORT; SKELETAL-MUSCLE; INSULIN	Dehydroascorbic acid (DHA), the first stable oxidation product of vitamin C, was transported by GLUT1 and GLUT3 in Xenopus laevis oocytes with transport rates similar to that of P-deoxyglucose (2-DG), but due to inherent difficulties with GLUT4 expression in oocytes it was uncertain whether GLUT4 transported DHA (Rumsey, S, C., Kwon, O., Xu, G. W., Burant, C. F., Simpson, I., and Levine, M. (1997) J. Biol. Chem. 272, 18982-18989). We therefore studied DHA and 2-DG transport in rat adipocytes, which express GLUT4. Without insulin, rat adipocytes transported 2-DG 2-3-fold faster than DHA. Preincubation with insulin (0.67 mu M) increased transport of each substrate similarly: 7-10-fold for 2-DG and 6-8-fold for DHA, Because intracellular reduction of DHA in adipocytes was complete before and after insulin stimulation, increased transport of DHA was not explained by increased internal reduction of DHA to ascorbate, To determine apparent transport kinetics of GLUT4 for DHA, GLUT4 expression in Xenopus oocytes was reexamined. Preincubation of oocytes for >4 h with insulin (1 mu M) augmented GLUT4 transport of 2-DG and DKA by up to 5-fold. Transport of both substrates was inhibited by cytochalasin B and displayed saturable kinetics. GLUT4 had a higher apparent transport affinity (K-m of 0.98 versus 5.2 mM) and lower maximal transport rate (V-max of 66 versus 880 pmol/oocyte/10 min) for DHA compared with 2-DG. The lower transport rate for DHA could not be explained by binding differences at the outer membrane face, as shown by inhibition with ethylidene glucose, or by transporter trans-activation and therefore was probably due to substrate-specific differences in transporter/substrate translocation or release. These novel data indicate that the insulin-sensitive transporter GLUT4 transports DHA in both rat adipocytes and Xenopus oocytes, Alterations of this mechanism in diabetes could have clinical implications for ascorbate utilization.	NIDDK, Digest Dis Branch, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, Expt Diabet Metab & Nutr Sect, NIH, Bethesda, MD 20892 USA; Mead Johnson Nutr, Evansville, IN USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Levine, M (corresponding author), NIDDK, Digest Dis Branch, Mol & Clin Nutr Sect, NIH, Bldg 10 Rm 4D52 MSC 1372, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506, ZIADK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; Cunningham JJ, 1998, J AM COLL NUTR, V17, P105, DOI 10.1080/07315724.1998.10718734; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Detaille D, 1999, EUR J PHARMACOL, V377, P127, DOI 10.1016/S0014-2999(99)00413-6; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Hauner H, 1998, INT J OBESITY, V22, P448, DOI 10.1038/sj.ijo.0800606; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JANICOT M, 1989, P NATL ACAD SCI USA, V86, P2642, DOI 10.1073/pnas.86.8.2642; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KELLER K, 1990, BIOMED BIOCHIM ACTA, V49, P1201; KELLER RJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P40, DOI 10.1016/0003-9861(89)90253-1; Lindsay RM, 1998, DIABETOLOGIA, V41, P516, DOI 10.1007/s001250050940; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Miele C, 1997, DIABETOLOGIA, V40, P421, DOI 10.1007/s001250050696; MORA S, 1995, BIOCHEM J, V311, P59, DOI 10.1042/bj3110059; Mora S, 1997, BIOCHEM J, V324, P455, DOI 10.1042/bj3240455; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Nagano S, 1996, J NUTR SCI VITAMINOL, V42, P1, DOI 10.3177/jnsv.42.1; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; SINCLAIR AJ, 1994, DIABETIC MED, V11, P893, DOI 10.1111/j.1464-5491.1994.tb00375.x; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; Weber T. M., 1988, INSULIN RECEPTORS B, P171; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; Will JC, 1996, NUTR REV, V54, P193, DOI 10.1111/j.1753-4887.1996.tb03932.x; ZORZANO A, 1996, DIABETES, V45, P70	44	153	158	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28246	28253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862609				2022-12-27	WOS:000089197100095
J	Vihinen, H; Saarinen, J				Vihinen, H; Saarinen, J			Phosphorylation site analysis of Semliki Forest virus nonstructural protein 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE-II; STRAND RNA-SYNTHESIS; SINDBIS VIRUS; MASS-SPECTROMETRY; MINUS-STRAND; REPLICATION COMPLEXES; GENE-EXPRESSION; P PROTEIN; C-ZETA; CELLS	Nonstructural protein 3 (Nsp3) is an essential subunit of the alphavirus RNA replication complex, although its specific function(s) has yet to be well defined. Previously, it has been shown that Semliki Forest virus Nsp3 (482 amino acids) is a phosphoprotein, and, in the present study, we have mapped its major phosphorylation sites. Mass spectrometric methods utilized included precursor ion scanning, matrix-assisted laser desorption/ionization mass spectrometry used in conjunction with on-target alkaline phosphatase digestions, and tandem mass spectrometry, Two-dimensional peptide mapping was applied to separate tryptic P-32-labeled phosphopeptides of Nsp3, Radiolabeled peptides were then subjected to Edman sequencing, and phosphoamino acid analysis. In addition, radiolabeled Nsp3 was cleaved successively with cyanogen bromide and trypsin, and microscale iron-chelate affinity chromatography was used to enrich phosphopeptides. By combining these methods, we showed that Nsp3 is phosphorylated on serine residues 320, 327, 332, 335, 356, 359, 362, and 367, and is heavily phosphorylated on peptide Gly(338)-Lys(415), which carries 7-12 phosphates distributed over its 13 potential phosphorylation sites. These analytical findings were corroborated by constructing a Nsp3 derivative devoid of phosphorylation, The results represent the first determination of phosphorylation sites of an alphavirus nonstructural protein, but the approach can be utilized in phosphoprotein analysis in general.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Prot Chem Lab, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Vihinen, H (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Program Cellular Biotechnol, POB 56,Viikinkaari 9, FIN-00014 Helsinki, Finland.	helena.vihinen@helsinki.fi						AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARTON DJ, 1988, J VIROL, V62, P3597, DOI 10.1128/JVI.62.10.3597-3602.1988; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; Gupta AK, 2000, J VIROL, V74, P91, DOI 10.1128/JVI.74.1.91-98.2000; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; Huntley CC, 1997, J BIOL CHEM, V272, P16578, DOI 10.1074/jbc.272.26.16578; KAARIAINEN L, 1987, J CELL SCI, P231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; LASTARZA MW, 1994, J VIROL, V68, P5781, DOI 10.1128/JVI.68.9.5781-5791.1994; LASTARZA MW, 1994, VIROLOGY, V202, P224, DOI 10.1006/viro.1994.1338; LEADER DP, 1988, J GEN VIROL, V69, P1441, DOI 10.1099/0022-1317-69-7-1441; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LI GP, 1990, VIROLOGY, V179, P416, DOI 10.1016/0042-6822(90)90310-N; Liu Z, 1997, VIROLOGY, V232, P198, DOI 10.1006/viro.1997.8548; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Nyman TA, 1998, EUR J BIOCHEM, V253, P485, DOI 10.1046/j.1432-1327.1998.2530485.x; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; PERANEN J, 1991, J GEN VIROL, V72, P195, DOI 10.1099/0022-1317-72-1-195; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	34	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27775	27783						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10851234				2022-12-27	WOS:000089197100036
J	Yarmola, EG; Somasundaram, T; Boring, TA; Spector, I; Bubb, MR				Yarmola, EG; Somasundaram, T; Boring, TA; Spector, I; Bubb, MR			Actin-latrunculin A structure and function - Differential modulation of actin-binding protein function by latrunculin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOSIN BETA-4; ACANTHAMOEBA-PROFILIN; FILAMENTOUS ACTIN; MONOMERIC ACTIN; CYTOCHALASIN-D; F-ACTIN; POLYMERIZATION; SITES; INTERACTS; NUCLEOTIDES	Latrunculin A is used extensively as an agent to sequester monomeric actin in living cells. We hypothesize that additional activities of latrunculin A may be important for its biological activity. Our data are consistent with the formation of a 1:1 stoichiometric complex with an equilibrium dissociation constant of 0.2 to 0.4 mu M and provide no evidence that the actin-latrunculin A complex participates in the elongation of actin filaments. Profilin and latrunculin A bind independently to actin, whereas binding of thymosin beta(4) to actin is inhibited by latrunculin A. Potential implications of this differential effect on actin-binding proteins are discussed. From a structural perspective, if latrunculin A binds to actin at a site that sterically influences binding by thymosin beta(4), then the observation that latrunculin A inhibits nucleotide exchange on actin implies an allosteric effect on the nucleotide binding cleft. Alternatively, if, as previously postulated, latrunculin A binds in the nucleotide cleft of actin, then its ability to inhibit binding by thymosin beta(4) is a surprising result that suggests that significant allosteric changes affect the thymosin beta(4) binding site. We show that latrunculin A and actin form a crystalline structure with orthorhombic space group P2(1)2(1)2(1) and diffraction to 3.10 Angstrom. A high resolution structure with optimized crystallization conditions should provide insight regarding these remarkable allosteric properties.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Vet Affairs Med Ctr, Malcolm Randall Dept, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; State University System of Florida; Florida State University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.			Somasundaram, Thayumanasamy/0000-0002-3629-5117				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ballweber E, 1997, BIOCHEM J, V327, P787, DOI 10.1042/bj3270787; Belmont LD, 1999, J CELL SCI, V112, P1325; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Davoodian K, 1997, BIOCHEMISTRY-US, V36, P9637, DOI 10.1021/bi9711487; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KIRSCHNER MW, 1971, BIOCHEMISTRY-US, V10, P1900, DOI 10.1021/bi00786a027; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuznetsova I, 1996, FEBS LETT, V383, P105, DOI 10.1016/0014-5793(96)00238-4; LAL AA, 1985, J BIOL CHEM, V260, P132; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLZAR B, 1989, EUR J BIOCHEM, V182, P267, DOI 10.1111/j.1432-1033.1989.tb14826.x; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; Reichert A, 1996, J BIOL CHEM, V271, P1301, DOI 10.1074/jbc.271.3.1301; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Terry DR, 1997, J BIOL CHEM, V272, P7841, DOI 10.1074/jbc.272.12.7841; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WESTBROOK EM, 1985, METHOD ENZYMOL, V114, P187; Young JD, 1999, NAT MED, V5, P1424; YU FX, 1993, J BIOL CHEM, V268, P502	39	209	211	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28120	28127						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859320				2022-12-27	WOS:000089197100078
J	Inatome, R; Tsujimura, T; Hitomi, T; Mitsui, N; Hermann, P; Kuroda, S; Yamamura, H; Yanagi, S				Inatome, R; Tsujimura, T; Hitomi, T; Mitsui, N; Hermann, P; Kuroda, S; Yamamura, H; Yanagi, S			Identification of CRAM, a novel unc-33 gene family protein that associates with CRIMP3 and protein-tyrosine kinase(s) in the developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; AXON GUIDANCE; SEMAPHORIN RECEPTOR; NEUROPILIN; CELLS; OUTGROWTH; NEURONS; P72(SYK); ULIP	Four members of collapsin response mediator proteins (CRMPs) are thought to be involved in the semaphorin-induced growth cone collapse during neural development. Here we report the identification of a novel CRMPS associated protein, designated CRAM for CRMP3-associated molecule, that belongs to the unc-33 gene family. The deduced amino acid sequence reveals that the CRAM gene encodes a protein of 563 amino acids, shows 57% identity with dihydropyrimidinase, and shows 50-51% identity with CRMPs. CRAM appears to form a large complex composed of CRMPS and other unidentified proteins in vivo. Indeed, CRAM physically associates with CRMPS when co-expressed in COS-7 cells. The expression of CRAM is brain-specific, is high in fetal and neonatal rat brain, and decreases to very low levels in adult brain. Moreover, CRAM expression is up-regulated during neuronal differentiation of embryonal carcinoma P19 and PC12 cells. Finally, immunoprecipitation analysis of rat brain extracts shows that CRAM is co-immunoprecipitated with proteins that contain protein-tyrosine kinase activity, Taken together, our results suggest that CRAM, which interacts with CRMP3 and protein-tyrosine kinase(s), is a new member of an emerging family of molecules that potentially mediate signals involved in the guidance and outgrowth of axons.	Kobe Univ, Sch Med, Dept Biochem, Chuo Ku, Kobe, Hyogo 6500017, Japan; Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Ibaraki, Osaka 5670047, Japan	Kobe University; Osaka University	Yanagi, S (corresponding author), Kobe Univ, Sch Med, Dept Biochem, Chuo Ku, Kobe, Hyogo 6500017, Japan.			Yanagi, Shigeru/0000-0002-1392-8663				Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Byk T, 1996, J NEUROSCI, V16, P688; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Holder N, 1999, DEVELOPMENT, V126, P2033; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; YI F, 1991, J BIOL CHEM, V266, P3900; Yoneya H, 1998, BIOCHEM BIOPH RES CO, V245, P140, DOI 10.1006/bbrc.1998.8309	34	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27291	27302						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10851247				2022-12-27	WOS:000089144800083
J	Caterina, JJ; Yamada, S; Caterina, NCM; Longenecker, G; Holmback, K; Shi, J; Yermovsky, AE; Engler, JA; Birkedal-Hansen, H				Caterina, JJ; Yamada, S; Caterina, NCM; Longenecker, G; Holmback, K; Shi, J; Yermovsky, AE; Engler, JA; Birkedal-Hansen, H			Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; GELATINASE-A; 72-KDA GELATINASE; PROGELATINASE-A; TERMINAL DOMAIN; IV COLLAGENASE; TIMP-2; COMPLEX; FIBROBLASTS; EXPRESSION	To understand the biologic function of TIMP-2, a member of the tissue inhibitors of metalloproteinases family, an inactivating mutation was introduced in the mouse Timp-2 gene by homologous recombination, Outbred homozygous mutants developed and procreated indistinguishably from wild type littermates, suggesting that fertility, development, and growth are not critically dependent on TIMP-2, Lack of functional TIMP-2, however, dramatically altered the activation of proMMP-2 both in vivo and in vitro. Fully functional TIMP-2 is essential for efficient activation of proMMP-2 in vivo, No evidence of successful functional compensation was observed. The results illustrate the duality of TIMP-2 function, i.e. at low concentrations, TIMP-2 exerts a "catalytic" or enhancing effect on cell-mediated proMMP-2 activation, whereas at higher concentrations, TIMP-2 inhibits the activation and/or activity of MMP-2.	NIDCR, Matrix Metalloprot Unit, NIH, Bethesda, MD 20892 USA; NIDCR, Gene Targeting Res & Core Facil, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Alabama System; University of Alabama Birmingham	Caterina, JJ (corresponding author), 30 Convent Dr,MSC 4380, Bethesda, MD 20892 USA.				NCI NIH HHS [CA13148] Funding Source: Medline; NIDCR NIH HHS [DE10631, DE08228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, R01DE010631, P50DE008228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Blavier L, 1997, MOL BIOL CELL, V8, P1513, DOI 10.1091/mbc.8.8.1513; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caterina NCM, 1997, J BIOL CHEM, V272, P32141, DOI 10.1074/jbc.272.51.32141; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; *GEN COMP GROUP IN, 1999, WISC PACK VERS 9 0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Overall CM, 1999, ANN NY ACAD SCI, V878, P747, DOI 10.1111/j.1749-6632.1999.tb07780.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Sambrook J, 1989, MOL CLOINING LAB MAN; SHIMIZU S, 1992, GENE, V114, P291, DOI 10.1016/0378-1119(92)90591-C; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	30	114	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26416	26422		10.1074/jbc.M001271200	http://dx.doi.org/10.1074/jbc.M001271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827176	hybrid			2022-12-27	WOS:000088999700074
J	Crompton, AM; Foley, LH; Wood, A; Roscoe, W; Stokoe, D; McCormick, F; Symons, M; Bollag, G				Crompton, AM; Foley, LH; Wood, A; Roscoe, W; Stokoe, D; McCormick, F; Symons, M; Bollag, G			Regulation of Tiam1 nucleotide exchange activity by pleckstrin domain binding ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GLUTATHIONE-S-TRANSFERASE; DBL ONCOGENE PRODUCT; L-ASCORBIC-ACID; HOMOLOGY DOMAINS; RAS TRANSFORMATION; RECOMBINANT RAS; RHO; INVASION; KINASE	Rho family GTPases play roles in cytoskeletal organization and cellular transformation. Tiam1 is a member of the Dbl family of guanine nucleotide exchange factors that activate Rho family GTPases. These exchange factors have in common a catalytic Dbl homology and adjacent pleckstrin homology domain. Previous structural studies suggest that the pleckstrin domain, a putative phosphoinositide-binding site, may serve a regulatory function. We identified ascorbyl stearate as a compound that binds to the pleckstrin domain of p120 Ras GTPase-activating protein. Furthermore, ascorbyl stearate appears to be a general pleckstrin domain ligand, perhaps by mimicking an endogenous amphiphilic ligand. Tiam1 nucleotide exchange activity was greatly stimulated by ascorbyl stearate. Certain phosphoinositides also stimulated Tiam1 activity but were less potent than ascorbyl stearate. Tiam1 contains an additional N-terminal pleckstrin domain, but only the C-terminal pleckstrin domain was required for activation. Our results suggest that the pleckstrin domains of Dbl-type proteins may not only be involved in subcellular localization but may also directly regulate the nucleotide exchange activity of an associated Dbl homology domain. In addition, this paper introduces ascorbyl stearate as a pleckstrin domain ligand that can modulate the activity of certain pleckstrin domain-containing proteins.	Onyx Pharmaceut, Richmond, CA 94806 USA; Hoffmann La Roche Inc, Dept Oncol, Nutley, NJ 07110 USA	Roche Holding	Bollag, G (corresponding author), Onyx Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.							ANDO S, 1992, J BIOL CHEM, V267, P25709; ANDREWS GC, 1984, CARBOHYD RES, V134, P321, DOI 10.1016/0008-6215(84)85048-X; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; BOCK K, 1979, CARBOHYD RES, V68, P313, DOI 10.1016/S0008-6215(00)83780-5; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P21; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NAIDU AK, 1993, ANTICANCER RES, V13, P1469; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OHMORI M, 1983, AGR BIOL CHEM TOKYO, V47, P607, DOI 10.1080/00021369.1983.10865689; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	61	45	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25751	25759		10.1074/jbc.M002050200	http://dx.doi.org/10.1074/jbc.M002050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835422	hybrid			2022-12-27	WOS:000088849400091
J	Escolar, L; Perez-Martin, J; de Lorenzo, V				Escolar, L; Perez-Martin, J; de Lorenzo, V			Evidence of an unusually long operator for the fur repressor in the aerobactin promoter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE REGULATION PROTEIN; FERRIC UPTAKE REGULATOR; SALMONELLA-TYPHIMURIUM; VIRULENCE GENES; IRON REGULATION; BINDING; DNA; TRANSCRIPTION; EXPRESSION; SELECTION	Production of the siderophore aerobactin in Escherichia coli is transcriptionally metalloregulated through the iron-dependent binding of the Fur (ferric uptake regulator) to a large region (>100 base pairs) within the cognate promoter in the pColV-K30 plasmid. We show in this article that such an unusually long operator results from the specific addition of degenerate repeats 5'-NAT(APT)AT-3' and not from a fortuitous occupation of the DNA adjacent to the primary binding sites by an excess of the repressor. Furthermore, the protection pattern revealed by DNase I and hydroxyl radical footprinting reflected a side-by-side oligomerization of the protein along an extended DNA stretch. This type of DNA-protein interactions is more like those observed in some eukaryotic factors and nucleoid-associated proteins than typical of specific prokaryotic regulators.	CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Campus Cantoblanco, Madrid 28049, Spain.		Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; BAGG A, 1985, J BACTERIOL, V161, P450, DOI 10.1128/JB.161.1.450-453.1985; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BINDEREIF A, 1985, J BACTERIOL, V162, P109; BRICKMAN TJ, 1990, J MOL BIOL, V212, P669, DOI 10.1016/0022-2836(90)90229-F; CALDERWOOD SB, 1988, J BACTERIOL, V170, P1015, DOI 10.1128/jb.170.2.1015-1017.1988; Chai SH, 1998, J BIOL CHEM, V273, P33841, DOI 10.1074/jbc.273.50.33841; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Desai PJ, 1996, J BACTERIOL, V178, P5020, DOI 10.1128/jb.178.16.5020-5023.1996; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1997, MOL MICROBIOL, V26, P799, DOI 10.1046/j.1365-2958.1997.6211987.x; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; FRECHON D, 1994, BIOCHEM BIOPH RES CO, V201, P346, DOI 10.1006/bbrc.1994.1708; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; HANTKE K, 1984, MOL GEN GENET, V197, P337, DOI 10.1007/BF00330982; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; HUNT MD, 1994, J BACTERIOL, V176, P3944, DOI 10.1128/JB.176.13.3944-3955.1994; KARJALAINEN TK, 1991, MICROB PATHOGENESIS, V11, P317, DOI 10.1016/0882-4010(91)90017-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECAM E, 1994, P NATL ACAD SCI USA, V91, P11816, DOI 10.1073/pnas.91.25.11816; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; MAKEMSON JC, 1982, CURR MICROBIOL, V7, P181, DOI 10.1007/BF01568972; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTER L, 1989, J BACTERIOL, V171, P731, DOI 10.1128/jb.171.2.731-736.1989; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; Pizzi S, 1999, J BIOL CHEM, V274, P2539, DOI 10.1074/jbc.274.4.2539; Ptashne M., 1992, A GENETIC SWITCH; SAITO T, 1991, EUR J BIOCHEM, V197, P29, DOI 10.1111/j.1432-1033.1991.tb15878.x; Sambrook J., 2002, MOL CLONING LAB MANU; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Watnick PI, 1997, J BACTERIOL, V179, P243, DOI 10.1128/jb.179.1.243-247.1997; Watnick PI, 1998, GENE, V209, P65, DOI 10.1016/S0378-1119(98)00018-3; Wee S, 1988, Biol Met, V1, P62, DOI 10.1007/BF01128019; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zheng M, 1999, J BACTERIOL, V181, P4639, DOI 10.1128/JB.181.15.4639-4643.1999	41	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24709	24714		10.1074/jbc.M002839200	http://dx.doi.org/10.1074/jbc.M002839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833520	hybrid			2022-12-27	WOS:000088683300065
J	Poland, BW; Xu, MQ; Quiocho, FA				Poland, BW; Xu, MQ; Quiocho, FA			Structural insights into the protein splicing mechanism of PI-SceI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INTEIN; MODULATION; CLEAVAGE; LIGATION; ELEMENTS; SYSTEM	PI-SceI is a member of a class of proteins (inteins) that excise themselves from a precursor protein and in the process ligate the flanking protein sequences (exteins). We report here the 2.1-Angstrom resolution crystal structure of a PI-SceZ miniprecursor (VMA29) containing 10 N-terminal extein residues and 4 C-terminal extein residues. Mutations at the N- and C-terminal splicing junctions, blocking in vivo protein splicing, allowed the mini-precursor to be purified and crystallized. The structure reveals both the N- and C-terminal scissile peptide bonds to be in distorted trans conformations (tau approximate to 100 degrees). Modeling of the wild-type PI-SceI based on the VMA29 structure indicates a large conformational change (movement of >9 Angstrom) must occur 60 allow transesterification to be completed. A zinc atom was discovered at the C-terminal splicing junction. Residues Cys(455), His(453) and Glu(80) along with a water molecule (Wat(53)) chelate the zinc atom. The crystal structure of VMA29 has captured the intein in its pre-spliced state.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Quiocho, FA (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.		Wood, David W/B-2992-2012					Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kawasaki M, 1996, BIOCHEM BIOPH RES CO, V222, P827, DOI 10.1006/bbrc.1996.0826; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	25	123	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16408	16413		10.1074/jbc.275.22.16408	http://dx.doi.org/10.1074/jbc.275.22.16408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828056	hybrid			2022-12-27	WOS:000087392200003
J	Yue, JB; Mulder, KM				Yue, JB; Mulder, KM			Requirement of Ras/MAPK pathway activation by transforming growth factor ss for transforming growth factor ss(1) production in a Smad-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR-BETA; TGF-BETA; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; FACTOR-BETA-1 GENE; FIBROBLAST GROWTH; PROMOTER ACTIVITY; DOMAIN PROTEIN; DORSAL CLOSURE	Our previous results have shown that transforming growth factor beta (TGF beta) rapidly activates Ras, as well as both ERKs and SAPKs, In order to address the biological significance of the activation of these pathways by TGF beta, here we examined the role of the Ras/MAPK pathways and the Smads in TGF beta(3) induction of TGF beta(1) expression in untransformed lung and intestinal epithelial cells. Expression of either a dominant-negative mutant of Ras (RasN17) or a dominant-negative mutant of MKK4 (DN MKK4), or addition of the MEK1 inhibitor PD98059, inhibited the ability of TGF beta(3) to induce AP-1 complex formation at the TGF beta(1) promoter, and the subsequent induction of TGF beta(1) mRNA, The primary components present in this TGF beta(3)-inducible AP-1 complex at the TGF beta(1) promoter were JunD and Fra-2, although c-Jun and FosB were also involved. Furthermore, deletion of the AP-1 site in the TGF beta(1) promoter or addition of PD98059 inhibited the ability of TGF beta(3) to stimulate TGF beta(1) promoter activity. Collectively, our data demonstrate that TGF beta(3) induction of TGF beta(1) is mediated through a signaling cascade consisting of Ras, the MAPKKs MKK4 and MEK1, the MAPKs SAPKs and ERKs, and the specific AP-1 proteins Fra-2 and JunD. Although Smads and Smad4 were not detectable in TGF beta(3)-inducible AP-1 complexes at the TGF beta(1) promoter, stable expression of dominant-negative Smad3 could significantly inhibit the ability of TGF beta(3) to stimulate TGF beta(1) promoter activity. Transient expression of dominant-negative Smad4 also inhibited the ability of TGF beta(3) to transactivate the TGF beta(1) promoter. Thus, although the Ras/MAPK pathways are essential for TGF beta(3) induction of TGF beta(1), Smads may only contribute to this biological response in an indirect manner.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, 500 Univ Dr, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NATIONAL CANCER INSTITUTE [R01CA068444, R01CA054816] Funding Source: NIH RePORTER; NCI NIH HHS [CA68444, CA51424, CA54816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MATSUI M, 1990, ONCOGENE, V5, P249; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Yue JB, 1999, J CELL PHYSIOL, V178, P387; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	62	122	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30765	30773		10.1074/jbc.M000039200	http://dx.doi.org/10.1074/jbc.M000039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10843986	hybrid			2022-12-27	WOS:000089762700006
J	Nurcombe, V; Smart, CE; Chipperfield, H; Cool, SM; Boilly, B; Hondermarck, H				Nurcombe, V; Smart, CE; Chipperfield, H; Cool, SM; Boilly, B; Hondermarck, H			The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR RECEPTOR KINASE; TYROSINE PHOSPHORYLATION; MAP KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; MAMMARY-GLAND; HUMAN-TUMORS	To explore how heparan sulfate (HS) controls the responsiveness of the breast cancer cell lines MCF-7 and MDA-MB-231 to fibroblast growth factors (FGFs), we have exposed them to HS preparations known to have specificity for FGF-1 (HS glycosaminoglycan (HSGAG A)) or FGF-2 (HSGAGB). Proliferation assays confirmed that MCF-7 cells were highly responsive to FGF-2 complexed with GAGB, whereas migration assays indicated that FGF-1/HSGAGA combinations were stimulatory for the highly invasive MDA-MB-231 cells. Quantitative polymerase chain reaction for the levels of FGF receptor (PGFR) isoforms revealed that MCF-7 cells have greater levels of FGFR1 and that MDA-MB-231 cells have greater relative levels of FGFR2. Cross-linking demonstrated that FGF-2/HSGAGB primarily activated FGFR1, which in turn up regulated the activity of mitogen-activated protein kinase; in contrast, FGF-1/HSGAGA led to the phosphorylation of equal proportions of both FGFR1 and FGFR2, which in turn led to the up-regulation of Src and p125(FAK). MDA-MB-231 cells were particularly responsive to vitronectin substrates in the presence of FGF-1/HSGAGA, and blocking antibodies established that they used the alpha(v)beta(3) integrin to bind to it. These results suggest that the clustering of particular FGFR configurations on breast cancer cells induced by different HS chains leads to distinct phenotypic behaviors.	Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia; Univ Sci & Technol Lille, Dev Biol Lab, UPRES 1033, Grp Facteurs Croissance, F-59655 Villeneuve Dascq, France	University of Queensland; Universite de Lille - ISITE; Universite de Lille	Nurcombe, V (corresponding author), Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia.	v.nurcombe@mailbox.uq.edu.au	Cool, Simon/W-1257-2018; Smart, Chanel E/C-9583-2011; Cool, Simon McKenzie/AAG-4346-2021	Cool, Simon/0000-0001-8543-3056; 				BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; Burgess AW, 1998, PHILOS T ROY SOC B, V353, P903, DOI 10.1098/rstb.1998.0254; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Garfinkel S, 1996, BBA-MOL CELL RES, V1314, P109, DOI 10.1016/S0167-4889(96)00105-X; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONCALVES LM, 1998, REV PORT CARDIOL S2, V17, P11; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hill DJ, 1998, DIABETES CARE, V21, pB60; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; ILIE D, 1995, NATURE, V377, P539; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KE YQ, 1993, J CELL SCI, V106, P135; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin HY, 1996, J NEUROSCI, V16, P4579; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; MURGUE B, 1994, CANCER RES, V54, P5206; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Palmantier R, 1996, CANCER RES, V56, P2206; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P887, DOI 10.1177/41.6.7686196; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Szebenyi G, 1999, INT REV CYTOL, V185, P45; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Uruno T, 1998, SEIKAGAKU, V70, P446; van der Pluijm G, 1997, LAB INVEST, V77, P665; Walz A, 1997, DEVELOPMENT, V124, P2421; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	66	73	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30009	30018		10.1074/jbc.M003038200	http://dx.doi.org/10.1074/jbc.M003038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862617	hybrid			2022-12-27	WOS:000089577900014
J	Miarons, PB; Fresno, M				Miarons, PB; Fresno, M			Lectins from tropical sponges - Purification and characterization of lectins from genus Aplysina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCANASE-RELEASED OLIGOSACCHARIDES; RICINUS-COMMUNIS AGGLUTININ; GEODIA-CYDONIUM LECTIN; FUNCTIONAL-CHARACTERIZATION; ADHESION RECEPTORS; AGGREGATION FACTOR; GOLGI MEMBRANES; COMBINING SITES; ANIMAL LECTINS; CELL-ADHESION	Only a few animal phyla have been screened for the presence and distribution of lectins, Probably the most intensively studied group is the mollusk. In this investigation, 22 species from 12 families of tropical sponges collected in Los Rogues National Park (Venezuela) were screened for the presence of lectins. Nine saline extracts exhibited strong hemagglutinating activity against pronase-treated hamster red blood cells; five of these reacted against rabbit red blood cells, four with trypsin-treated bovine red blood cells, and five with human red blood cells regardless of the blood group type. Extracts from the three species studied from genus Aplysina (archeri, lawnosa, and cauliformis) were highly reactive and panagglutinating against the panel of red blood cells tested. The lectins from A. archeri and A. lawnosa were purified to homogeneity by ammonium sulfate fractionation, affinity chromatography on p-aminobenzyl-beta-1-thiogalactopyranoside-agarose, and gel filtration chromatography. Both lectins exhibited a native molecular mass of 63 kDa and by SDS-polyacrylamide gel electrophoresis under reducing conditions have an apparent molecular mass of 16 kDa, thus suggesting they occur as homotetramers. The purified lectins contain 3-4 mol of divalent cation per molecule, which are essential for their biological activity. Hapten inhibition of hemagglutination was carried out to define the sugar binding specificity of the purified A. archeri lectin. The results indicate a preference of the lectin for nonreducing beta-linked D-Gal residues being the best inhibitors of red blood cells binding methyl-beta-D-Gal and thiodigalactoside (Gal beta 1-4-thiogalactopyranoside). The behavior of several glycans on immobilized lectin affinity chromatography confirmed and extended the specificity data obtained by hapten inhibition.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Miarons, PB (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	Pbonay@cbm.uam.es		Fresno Escudero, Manuel/0000-0002-9223-5477				ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ATTA AM, 1989, BRAZ J MED BIOL RES, V22, P379; ATTA AM, 1990, BRAZ J MED BIOL RES, V23, P191; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BRETTING H, 1981, J IMMUNOL, V127, P1652; BRETTING H, 1976, BIOCHEMISTRY-US, V15, P5029, DOI 10.1021/bi00668a013; BRETTING H, 1976, BIOCHEMISTRY-US, V15, P3228, DOI 10.1021/bi00660a011; CARVER JP, 1984, BIOL CARBOHYDRATES, V2, P289; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; DEBRAY H, 1986, CARBOHYD RES, V151, P359, DOI 10.1016/S0008-6215(00)90355-0; DIEHLSEIFERT B, 1985, EUR J BIOCHEM, V147, P517; DODD RY, 1968, VOX SANG, V15, P386, DOI 10.1111/j.1423-0410.1968.tb04079.x; DRAKE DK, 1982, J CELL BIOL, V93, P383, DOI 10.1083/jcb.93.2.383; GAMULIN V, 1994, BIOL CHEM H-S, V375, P583; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN ED, 1987, J BIOL CHEM, V262, P12030; Hanisch FG, 1996, GLYCOBIOLOGY, V6, P321, DOI 10.1093/glycob/6.3.321; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1159, DOI 10.2331/suisan.56.1159; KAMIYA H, 1986, B JPN SOC SCI FISH, V52, P2205; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KAWAGISHI H, 1994, J BIOL CHEM, V269, P1375; KHUNS WJ, 1974, ANN NY ACAD SCI, V234, P58; Kruse M, 1998, J MOL EVOL, V46, P721, DOI 10.1007/PL00006353; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; Morel JL, 1997, MOL PHARMACOL, V51, P1042, DOI 10.1124/mol.51.6.1042; MULLER WEG, 1994, BRAZ J MED BIOL RES, V27, P2083; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; MULLER WEG, 1983, EUR J BIOCHEM, V133, P263, DOI 10.1111/j.1432-1033.1983.tb07457.x; MULLER WEG, 1981, EUR J CELL BIOL, V24, P28; NAMBIAR MP, 1995, EXP CELL RES, V219, P671, DOI 10.1006/excr.1995.1278; OKeefe BR, 1997, EUR J BIOCHEM, V245, P47, DOI 10.1111/j.1432-1033.1997.t01-1-00047.x; Pahler S, 1998, P ROY SOC B-BIOL SCI, V265, P421, DOI 10.1098/rspb.1998.0311; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P383, DOI 10.1590/S0100-879X1999000400002; SATO S, 1991, J BIOL CHEM, V266, P11485; Schutze J, 1999, P ROY SOC B-BIOL SCI, V266, P63, DOI 10.1098/rspb.1999.0605; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5706; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TURNER RS, 1973, NATURE, V244, P509, DOI 10.1038/244509a0; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; Wu JH, 1998, FEBS LETT, V427, P134, DOI 10.1016/S0014-5793(98)00411-6; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	52	28	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29283	29289		10.1074/jbc.M001366200	http://dx.doi.org/10.1074/jbc.M001366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10852905	hybrid			2022-12-27	WOS:000089439800016
J	Adams, A; Thorn, JM; Yamabhai, M; Kay, BK; O'Bryan, JP				Adams, A; Thorn, JM; Yamabhai, M; Kay, BK; O'Bryan, JP			Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GROWTH-FACTOR RECEPTOR; XENOPUS OOCYTES; EH-DOMAIN; MEIOTIC MATURATION; ONCOGENE PRODUCT; EPS15 HOMOLOGY; RAS PROTEINS; TRANSFORMATION; COMPONENTS	Intersectin is a member of a growing family of adaptor proteins that possess conserved Eps15 homology (EH) domains as well as additional protein recognition motifs. In general, EH domain-containing proteins play an integral role in clathrin-mediated endocytosis. Indeed, intersectin functions in the intermediate stages of clathrin-coated vesicle assembly. However, recent evidence suggests that components of the endocytic machinery also regulate mitogenic signaling pathways. In this report, we provide several lines of evidence that intersectin has the capacity to activate mitogenic signaling pathways. First, intersectin overexpression activated the Elk-l transcription factor in an MAPK-independent manner, This ability resides within the EH domains, as expression of the tandem EH domains was sufficient to activate Elk-l. Second, intersectin cooperated with epidermal growth factor to potentiate Elk-l activation; however, a similar level of Elk-l activation was obtained by expression of the tandem EH domains suggesting that the coiled-coil region and SH3 domains act to regulate the EH domains. Third, intersectin expression was sufficient to induce oncogenic transformation of rodent fibroblasts. And finally, intersectin cooperated with progesterone to accelerate maturation of Xenopus laevis oocytes. Together, these data suggest that intersectin links endocytosis with regulation of pathways important for cell growth and differentiation.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Wisconsin System; University of Wisconsin Madison	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,Bldg 101,Rm F336,MD F3-06, Res Triangle Pk, NC 27709 USA.			O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	39	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27414	27420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10851244				2022-12-27	WOS:000089144800100
J	Cabiscol, E; Piulats, E; Echave, P; Herrero, E; Ros, J				Cabiscol, E; Piulats, E; Echave, P; Herrero, E; Ros, J			Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PYRUVATE-DEHYDROGENASE; HYDROGEN-PEROXIDE; YEAST; SUPEROXIDE; RESPONSES; IDENTIFICATION; BIOCHEMISTRY; INACTIVATION	We have analyzed the proteins that are oxidatively damaged when Saccharomyces cerevisiae cells are exposed to stressing; conditions. Carbonyl groups generated by hydrogen peroxide or menadione on proteins of aerobically respiring cells were detected by Western blotting, purified, and identified. Mitochondrial proteins such as E2 subunits of both pyruvate dehydrogenase and cr-ketoglutarate dehydrogenase, aconitase, heat-shock protein 60, and the cytosolic fatty acid synthase (cu subunit) and glyceraldehyde-3-phosphate dehydrogenase were the major targets. In addition we also report the in, vivo modification of lipoamide present in the above-mentioned E2 subunits under the stressing conditions tested and that this also occurs with the homologous enzymes present in Escherichia coli cells that were used for comparative analysis. Under fermentative conditions, the main protein targets in S. cerevisiae cells treated with hydrogen peroxide or menadione were pyruvate decarboxylase, enolase, fatty acid synthase, and glyceraldehyde-3-phosphate dehydrogenase. Under the stress conditions tested, fermenting cells exhibit a lower viability than aerobically respiring cells and, consistently, increased peroxide generation as well as higher content of protein carbonyls and lipid peroxides, Our results strongly suggest that the oxidative stress in prokaryotic and eukaryotic cells shares common features.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, E-25198 Lleida, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Avinguda Rovira Roure 44, E-25198 Lleida, Spain.	joaquim.ros@cmb.udl.ed	Cabiscol, Elisa/A-4584-2009; ROS, Joaquim/ABG-7487-2020; Herrero, Enrique/B-5592-2009; Ros, Joaquim/A-7507-2010	Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648; Herrero, Enrique/0000-0002-6763-111X; 				Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brown RK, 1996, FREE RADICALS PRACTI, P119; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Demple B., 1996, REGULATION GENE EXPR, P433; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; KRESZE GB, 1981, EUR J BIOCHEM, V119, P573, DOI 10.1111/j.1432-1033.1981.tb05646.x; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MAITRA PK, 1971, J BIOL CHEM, V246, P475; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; Rivera-Nieves J, 1999, J BIOL CHEM, V274, P19525, DOI 10.1074/jbc.274.28.19525; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	48	351	360	1	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27393	27398						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852912				2022-12-27	WOS:000089144800097
J	Padre, RC; Stull, JT				Padre, RC; Stull, JT			Functional assembly of fragments from bisected smooth muscle myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RETRACTION; STRUCTURAL BASIS; PSEUDOSUBSTRATE SEQUENCE; INTRASTERIC REGULATION; CALMODULIN BINDING; NEUTRON-SCATTERING; PROTEIN-KINASES; PHOSPHORYLATION; ACTIVATION; AUTOINHIBITION	The C-terminal regulatory segment of smooth muscle myosin light chain kinase folds back on its catalytic core to inhibit kinase activity. This regulatory segment consists of autoinhibitory residues linking the catalytic core to the calmodulin-binding sequence and perhaps additional C-terminal residues including an immunoglobulin-like motif. However, mutational and biochemical analyses showed no specific involvement of residues C-terminal to the calmodulin binding sequence. To obtain additional insights on the proposed mechanisms for autoinhibition and Ca2+/calmodulin activation of the kinase, the polypeptide backbone chain of myosin light chain kinase was cleaved by genetic means to produce N- and C-terminal protein fragments. The N-terminal fragment containing the catalytic core was catalytically inactive when expressed alone. Go-expression of the N-terminal fragment with the C-terminal fragment containing the regulatory segment restored kinase activity. Deletion of the autoinhibitory linker residues without or with the calmodulin-binding sequence prevented restoration of kinase activity. In the presence or absence of Ca2+/calmodulin, regulatory segment binding occurred through the linker region connecting the catalytic core to the calmodulin-binding sequence. Collectively, these results indicate that residues C-terminal to the calmodulin-binding sequence (including the immunoglobulin-like motif) are not functional components of the regulatory segment. Furthermore, the principal autoinhibitory motif is contained in the sequence linking the catalytic core of myosin light chain kinase to the calmodulin-binding sequence.	Univ Texas, SW Med Ctr, Dept Physiol M 9040, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol M 9040, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jstull@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL29043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Barth A, 1998, J BIOL CHEM, V273, P2174, DOI 10.1074/jbc.273.4.2174; BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; Chin D, 1999, BIOCHEMISTRY-US, V38, P15061, DOI 10.1021/bi990883a; CHOI OH, 1994, J BIOL CHEM, V269, P536; CREIGHTON TE, 1983, BIOPOLYMERS, V22, P49, DOI 10.1002/bip.360220110; FAUX MC, 1993, J BIOL CHEM, V268, P12484; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1989, J BIOL CHEM, V264, P6967; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Jian XY, 1996, J NEUROBIOL, V31, P379, DOI 10.1002/(SICI)1097-4695(199611)31:3<379::AID-NEU10>3.0.CO;2-B; KAMM KE, 1989, J BIOL CHEM, V264, P21223; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Ladurner AG, 1997, J MOL BIOL, V273, P317, DOI 10.1006/jmbi.1997.1303; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; MILLER JR, 1983, MOL PHARMACOL, V24, P235; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; POTTER JD, 1975, J BIOL CHEM, V250, P4628; SANCHO J, 1992, J MOL BIOL, V224, P741, DOI 10.1016/0022-2836(92)90558-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; STULL JT, 1986, ENZYMES, P113; SWEENEY JL, 1993, AM J PHYSIOL, V264, pC1085; TANAKA M, 1995, EMBO J, V14, P2839, DOI 10.1002/j.1460-2075.1995.tb07283.x; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	61	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26665	26673						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842170				2022-12-27	WOS:000089144800002
J	Fagan, KA; Smith, KE; Cooper, DMF				Fagan, KA; Smith, KE; Cooper, DMF			Regulation of the Ca2+-inhibitable adenylyl cyclase type VI by capacitative Ca2+ entry requires localization in cholesterol-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; C6-2B GLIOMA-CELLS; RECEPTOR-LIKE PROTEIN; PLASMA-MEMBRANE; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION; CAVEOLAE MEMBRANE; POLARIZED EPITHELIA; CALCIUM; INHIBITION	The endogenous Ca2+-inhibitable adenylyl cyclase type VI of C6-2B glioma cells is regulated only by capacitative Ca2+ entry and not by a substantial elevation of [Ca2+](i) from either intracellular stores or via ionophore-mediated Ca2+ entry (Chiono, M., Mahey, R,, Tate, G,, and Cooper, D. M, F. (1995) J. Biol. Chem. 270, 1149-1155; Fagan, K, A., Mons, N., and Cooper, D, M. F, (1998) J, Biol. Chem, 273, 9297-9305), The present studies explored the role of cholesterol-rich domains in maintaining this functional association. The cholesterol-binding agent, filipin, profoundly inhibited adenylyl cyclase activity, Depletion of plasma membrane cholesterol with methyl-beta-cyclodextrin did not affect forskolin-stimulated adenylyl cyclase activity and did not affect capacitative Ca2+ entry, However, cholesterol depletion completely ablated the regulation of adenylyl cyclase by capacitative Ca2+ entry. Repletion of cholesterol restored the sensitivity of adenylyl cyclase to capacitative Ca2+ entry. Adenylyl cyclase catalytic activity and immunoreactivity were extracted into buoyant caveolar fractions with Triton X-100, The presence of adenylyl cyclase in such structures was eliminated by depletion of plasma membrane cholesterol, Altogether, these data lead us to conclude that adenylyl cyclase must occur in cholesterol-rich domains to be susceptible to regulation by capacitative Ca2+ entry. These findings are the first indication of regulatory significance for the localization of adenylyl cyclase in caveolae.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHANG YC, 1992, ANAL BIOCHEM, V205, P22, DOI 10.1016/0003-2697(92)90573-P; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1999, J BIOL CHEM, V274, P12445, DOI 10.1074/jbc.274.18.12445; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; FUJIMOTO T, 1995, J CELL SCI, V108, P7; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Haasemann M, 1998, J CELL SCI, V111, P917; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; PALADE GE, 1953, J APPL PHYS, V24, P1424; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sandhoff R, 1999, J LIPID RES, V40, P126; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557	55	111	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26530	26537		10.1074/jbc.M001369200	http://dx.doi.org/10.1074/jbc.M001369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843990	hybrid			2022-12-27	WOS:000088999700089
J	Lopez-Ongil, S; Senchak, V; Saura, M; Zaragoza, C; Ames, M; Ballermann, B; Rodriguez-Puyol, M; Rodriguez-Puyol, D; Lowenstein, CJ				Lopez-Ongil, S; Senchak, V; Saura, M; Zaragoza, C; Ames, M; Ballermann, B; Rodriguez-Puyol, M; Rodriguez-Puyol, D; Lowenstein, CJ			Superoxide regulation of endothelin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; OXYGEN RADICALS; ANGIOTENSIN-II; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; CARDIOVASCULAR-SYSTEM; LATENT COLLAGENASE; PHAGOCYTIC-CELLS; OXIDATIVE STRESS; SMOOTH-MUSCLE	Reactive oxygen species (ROS) act as signaling molecules in the cardiovascular system, regulating cellular proliferation and migration. However, an excess of ROS can damage cells and alter endothelial cell function. We hypothesized that endogenous mechanisms protect the vasculature from excess levels of ROS. We now shaw that superoxide can inhibit endothelin-converting enzyme activity (ECE) and decrease endothelin-l synthesis. Superoxide inhibits ECE but hydrogen peroxide and nitric oxide do not. Superoxide inhibits ECE by ejecting zinc from the enzyme, and the addition of exogenous zinc restores enzymatic activity. Superoxide may inhibit other zinc metalloproteinases by a similar mechanism and may thus play an important role in regulating the biology of blood vessels.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Alcala de Henares, Dept Physiol, Res Unit, Madrid 28871, Spain; IRSIN, Madrid 28871, Spain; MIT, Ctr Environm Hlth Sci, Nucl Reactor Lab, Cambridge, MA 02138 USA	Johns Hopkins University; Johns Hopkins University; Universidad de Alcala; Massachusetts Institute of Technology (MIT)	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 720 Rutland Ave, Baltimore, MD 21205 USA.	clowenst@jhmi.edu	Ballermann, Barbara J/G-5349-2016; Zaragoza, Carlos/AAH-9275-2019; Zaragoza Sanchez, Carlos/G-8718-2011; Puyol, Diego Rodriguez/AAG-9752-2020	Ballermann, Barbara J/0000-0002-8220-6381; Puyol, Diego Rodriguez/0000-0002-9125-9311; Lowenstein, Charles/0000-0003-0485-7514; Lopez-Ongil, Susana/0000-0003-0045-1680; Zaragoza, Carlos/0000-0002-1706-8592	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063706, P50HL052315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aubin P, 1997, CLIN CHEM, V43, P64; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BURKHARDT H, 1986, ENZYME, V36, P221, DOI 10.1159/000469298; BURKHARDT H, 1986, ARTHRITIS RHEUM, V29, P379, DOI 10.1002/art.1780290311; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Galis ZS, 1998, CIRCULATION, V97, P2445, DOI 10.1161/01.CIR.97.24.2445; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Griendling KK, 1997, CIRCULATION, V96, P3264; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Harrison DG, 1997, CLIN CARDIOL, V20, P11; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; KUNDU GC, 1992, LIFE SCI, V50, P965, DOI 10.1016/0024-3205(92)90175-O; KUNDU GC, 1993, INT J PEPT PROT RES, V42, P64; LopezOngil S, 1996, AM J PHYSIOL-HEART C, V271, pH1072, DOI 10.1152/ajpheart.1996.271.3.H1072; MARSDEN PA, 1990, AM J PHYSIOL, V258, pF1295, DOI 10.1152/ajprenal.1990.258.5.F1295; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Munzel T, 1999, ANN NY ACAD SCI, V874, P386, DOI 10.1111/j.1749-6632.1999.tb09253.x; OHNAKA K, 1990, BIOCHEM BIOPH RES CO, V168, P1128, DOI 10.1016/0006-291X(90)91146-J; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Owens MW, 1997, AM J PHYSIOL-LUNG C, V273, pL445, DOI 10.1152/ajplung.1997.273.2.L445; PAGANO PJ, 1993, AM J PHYSIOL, V265, pH707, DOI 10.1152/ajpheart.1993.265.2.H707; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Parks WC, 1998, BIOL EXTRAC, P263; PHAN SH, 1989, AM J PATHOL, V134, P1201; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Retsky KL, 1999, FREE RADICAL BIO MED, V26, P90, DOI 10.1016/S0891-5849(98)00151-8; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SHINGU M, 1994, RHEUMATOL INT, V14, P77, DOI 10.1007/BF00300251; SHINGU M, 1994, INFLAMMATION, V18, P613, DOI 10.1007/BF01535259; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI H, 1995, HYPERTENSION, V25, P1083, DOI 10.1161/01.HYP.25.5.1083; Suzuki YJ, 1999, J MOL CELL CARDIOL, V31, P345, DOI 10.1006/jmcc.1998.0872; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; UCHIDA K, 1993, FEBS LETT, V332, P208, DOI 10.1016/0014-5793(93)80632-5; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	54	41	42	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26423	26427		10.1074/jbc.M000767200	http://dx.doi.org/10.1074/jbc.M000767200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833511	hybrid			2022-12-27	WOS:000088999700075
J	Ragolia, L; Zuo, Q; Begum, N				Ragolia, L; Zuo, Q; Begum, N			Inhibition of myogenesis by depletion of the glycogen-associated regulatory subunit of protein phosphatase-1 in rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; INSULIN; DIFFERENTIATION; PHOSPHORYLATION; MECHANISM; MITOSIS; TYPE-1	In this study, we examined the role of the glycogen-associated regulatory subunit of protein phosphatase-l (PP-1(G)) in L6 rat skeletal muscle cell myogenesis. The level of PP-1(G) was depleted by transfection with an inducible antisense oriented PP-1(G) gene. Western blot analysis of the PP-1(G)-depleted cell line revealed a >90% depletion of PP-1(G) protein and a 45% reduction in cellular PP-1 activity and abolished the ability of L6 myoblasts to differentiate into multinucleated myotubes. PP-1(G)-depleted cells also exhibited a marked reduction in the expression of the differentiation marker myogenin as well as creatine kinase. After 7 days in culture, PP-1(G)-depleted cells sustained myoblast levels of inhibitor of differentiation-a, whereas control L6 cells had a severely lower inhibitor of differentiation-a level and progressed into myotubes. Myoblasts were unable to exit the cell cycle, as measured by the impaired induction of p27 cyclin-dependent kinase inhibitor, a >2-fold increase in DNA synthesis, and elevated levels of phosphorylated retinoblastoma protein (pRb). Replacement of the PP-1(G) gene restored PP-1(G) protein expression, PP-1 enzymatic activity, and the ability to differentiate into myotubes. We conclude that PP-1(G) plays a definite role in L6 myogenesis via its regulation of PP-1 catalytic activity.	Winthrop Univ Hosp, Diabet Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ragolia, L (corresponding author), Winthrop Univ Hosp, Diabet Res Lab, 222 Stn Plaza N,Suite 511-B, Mineola, NY 11501 USA.	lragolia@winthrop.org	Ragolia, Louis/AAW-2383-2021					Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; BEGUM N, 1998, AM J PHYSIOL, V275, pC422; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HUBBARD MJ, 1991, METHOD ENZYMOL, V201, P414; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Puntoni F, 1997, BIOCHEM BIOPH RES CO, V235, P704, DOI 10.1006/bbrc.1997.6886; Ragolia L, 1997, ENDOCRINOLOGY, V138, P2398, DOI 10.1210/en.138.6.2398; Ragolia L, 1999, MOL ENDOCRINOL, V13, P1773, DOI 10.1210/me.13.10.1773; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603	30	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26102	26108		10.1074/jbc.M001955200	http://dx.doi.org/10.1074/jbc.M001955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852907	hybrid			2022-12-27	WOS:000088999700031
J	Rosenkilde, MM; Kledal, TN; Holst, PJ; Schwartz, TW				Rosenkilde, MM; Kledal, TN; Holst, PJ; Schwartz, TW			Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; ALPHA(1B)-ADRENERGIC RECEPTOR; MURINE CYTOMEGALOVIRUS; EXTRACELLULAR DOMAIN; MCP-1 RECEPTOR; ACTIVATION; RESIDUES; IDENTIFICATION	Open reading frame 74 (ORF74) encoded by human herpesvirus 8 is a highly constitutively active seven transmembrane (7TM) receptor stimulated by angiogenic chemokines, e.g, growth-related oncogene-cv, and inhibited by angiostatic chemokines e.g, interferon-gamma-inducible protein. Transgenic mice expressing ORF74 under control of the CD2 promoter develop highly vascularized Kaposi's sarcoma-like tumors. Through targeted mutagenesis we here create three distinct phenotypes of ORF74: a receptor with normal, high constitutive signaling through the phospholipase C pathway but deprived of binding and action of chemokines obtained through deletion of 22 amino acids from the N-terminal extension; an ORF74 with high constitutive activity but with selective elimination of stimulatory regulation by angiogenic chemokines obtained through substitution of basic residues at the extracellular ends of TRI-V or TM-VI; and an ORF74 lacking constitutive activity but with preserved ability to be stimulated by agonist chemokines obtained through introduction of an Asp residue on the hydrophobic, presumed membrane-exposed face of TM-II, It is concluded that careful molecular dissection can selectively eliminate either agonist or inverse agonist modulation as well as high constitutive activity of the virally encoded oncogene ORF74 and that these mutant forms presumably can be used in transgenic animals to identify the molecular mechanism of its transforming activity.	Univ Copenhagen, Panum Inst 18 6 12, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark	University of Copenhagen	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst 18 6 12, Dept Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	schwartz@molpharm.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254; Schwartz, Thue W./0000-0002-0261-6904; Holst, Peter Johannes/0000-0002-1279-304X				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; AHUJA SK, 1999, CHEMOKINES DIS; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Dairaghi DJ, 1998, SEMIN VIROL, V8, P377, DOI 10.1006/smvy.1997.0146; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FIELD BN, 1995, FIELDS VIROLOGY; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Horuk R, 1998, NATURE, V393, P524, DOI 10.1038/31116; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; MacDonald MR, 1997, J VIROL, V71, P1671, DOI 10.1128/JVI.71.2.1671-1678.1997; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Moore BB, 1998, TRENDS CARDIOVAS MED, V8, P51, DOI 10.1016/S1050-1738(97)00128-X; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Wells TNC, 1997, CURR OPIN BIOTECH, V8, P741, DOI 10.1016/S0958-1669(97)80129-2; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	44	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26309	26315		10.1074/jbc.M003800200	http://dx.doi.org/10.1074/jbc.M003800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10842179	hybrid			2022-12-27	WOS:000088999700059
J	Yamashita, S; Mochizuki, N; Ohba, Y; Tobiume, M; Okada, Y; Sawa, H; Nagashima, K; Matsuda, M				Yamashita, S; Mochizuki, N; Ohba, Y; Tobiume, M; Okada, Y; Sawa, H; Nagashima, K; Matsuda, M			CalDAG-GEFIII activation of Ras, R-Ras, and Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; BINDING PROTEINS; CELL-ADHESION; EXPRESSION; CRK; C3G; TRANSFORMATION; KINASE	We characterized a novel guanine nucleotide exchange factor (GEF) for Ras family G proteins that is highly homologous to CalDAG-GEFI, a GEF for Rap1 and R-Ras, and to RasGRP/CalDAG-GEFII, a GEF for Res and R-Ras. This novel GEF, referred to as CalDAG-GEFIII, increased the GTP/GDP ratio of Ha-Ras, R-Ras, and Rap1 in 293T cells. CalDAG-GEFIII promoted the guanine nucleotide exchange of Ha-Ras, R-Ras, and Rap1 in vitro also, indicating that CalDAG-GEFIII exhibited the widest substrate specificity among the known GEFs for Res family G proteins. Expression of CalDAG-GEFIII was detected in the glial cells of the brain and the glomerular mesangial cells of the kidney by in. situ hybridization. CalDAG-GEFIII activated ERW MAPK most efficiently, followed by CalDAG-GEFII and CalDAG-GEFI in 293T cells. JNK activation was most prominent in cells expressing CalDAG-GEFII, followed by CalDAG-GEFIII and CaLDAG-GEFI. Expression of CalDAG-GEFIII induced neuronal differentiation of PC12 cells and anchorage-independent growth of Rat1A cells less efficiently than did CalDAG-GEFII. Thus, coactivation of Rap1 by CalDAG-GEFIII apparently attenuated Ras-MAPK-dependent neuronal differentiation and cellular transformation. Altogether, CalDAG-GEFIII activated a broad range of Res family Gr proteins and exhibited a biological activity different from that of either CalDAG-GEFI or CalDAG-GEFII.	Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, 1-12-1 Toyama, Tokyo 1628655, Japan.		Sawa, Hirofumi/AAW-8816-2021; Ohba, Yusuke/E-7944-2011; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755; Matsuda, Michiyuki/0000-0002-5876-9969				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, ONCOGENE, V9, P3281; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	42	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25488	25493		10.1074/jbc.M003414200	http://dx.doi.org/10.1074/jbc.M003414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835426	hybrid			2022-12-27	WOS:000088849400059
J	Miller, AF; Harvey, SAK; Thies, RS; Olson, MS				Miller, AF; Harvey, SAK; Thies, RS; Olson, MS			Bone morphogenetic protein-9 - An autocrine/paracrine cytokine in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; OSTEOGENIC PROTEIN-1; SIGNAL-TRANSDUCTION; RAT-KIDNEY; TGF-BETA; RECEPTOR; CELLS; INTERNALIZATION; SKELETAL	Bone morphogenetic proteins (BMPs) occupy important roles during development serving to direct cells through specific differentiation programs. While several BMPs are essential for embryonic viability, their significance in mediating intercellular communication in the context of adult organ systems remains largely unknown, In the adult rat we characterized the tissue-and cell-specific transcription and translation of BMP-9, Utilizing a ribonuclease protection assay, we determined that in the adult animal, BMP-9 expression occurs predominantly in the liver. Furthermore, we determined that the non-parenchymal cells of the liver, i.e, endothelial, Kupffer, and stellate cells, are the major sources of this message, Western analyses corroborate the ribonuclease protection assay results, confirming that LEC and KC contain an abundance of immunoreactive BMP-9, Using [I-125]BMP-9, a receptor with specific binding affinity for BRBP-9 was characterized in primary cultures of hepatic endothelial cells and Kupffer cells. BMP-9 binding to these cell types was observed to be fully reversible and highly specific for this ligand, Additionally, we demonstrate that BMPP-9 is specifically internalized upon binding to its receptor. This may represent a novel BMP receptor and is the first to be characterized in primary cultures of mature liver nonparenchymal cells. Our results depict BMP-9 as a potential autocrine/paracrine mediator in the hepatic reticuloendothelial system.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Genet Inst Inc, Cambridge, MA 02140 USA	University of Texas System; University of Texas Health San Antonio	Olson, MS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	olson@biochem.uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019473] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; Eakes AT, 1998, AM J PHYSIOL-GASTR L, V274, pG1068, DOI 10.1152/ajpgi.1998.274.6.G1068; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GANDHI CR, 1993, ARCH BIOCHEM BIOPHYS, V305, P38, DOI 10.1006/abbi.1993.1390; GANDHI CR, 1992, BIOCHEM J, V281, P485, DOI 10.1042/bj2810485; GRESSNER AM, 1994, ANN BIOL CLIN-PARIS, V52, P205; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Heck DA, 1998, LIFE SCI, V62, P1467, DOI 10.1016/S0024-3205(98)00091-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; Jortikka L, 1997, CELL SIGNAL, V9, P47, DOI 10.1016/S0898-6568(96)00094-0; KING JA, 1994, DEV BIOL, V166, P112, DOI 10.1006/dbio.1994.1300; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Knittel T, 1997, EXP CELL RES, V232, P263, DOI 10.1006/excr.1997.3504; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kossman T, 1992, GROWTH FACTORS, V7, P73, DOI 10.3109/08977199209023939; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Natsume T, 1997, J BIOL CHEM, V272, P11535; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROCKEY DC, 1994, J INVEST MED, V42, P660; ROSEN V, 1994, J BONE MINER RES, V9, P1759; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Simon N, 1999, AM J PHYSIOL-RENAL, V276, pF382, DOI 10.1152/ajprenal.1999.276.3.F382; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao GQ, 1998, DEVELOPMENT, V125, P1103	45	114	126	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17937	17945		10.1074/jbc.275.24.17937	http://dx.doi.org/10.1074/jbc.275.24.17937			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849432	hybrid			2022-12-27	WOS:000087659400006
J	Price-Schiavi, SA; Zhu, XY; Aquinin, R; Carraway, KL				Price-Schiavi, SA; Zhu, XY; Aquinin, R; Carraway, KL			Sialomucin complex (rat Muc4) is regulated by transforming growth factor beta in mammary gland by a novel post-translational mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PARTICLE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; GLYCOPROTEIN COMPLEX; EXPRESSION; PROTEIN; GROWTH-FACTOR-BETA-1; RECEPTOR	Sialomucin complex (SMC, rat Muc4) is a heterodimeric glycoprotein complex consisting of a mucin subunit ASGP-1 (for ascites sialoglycoprotein-1) and a transmembrane subunit ASGP-2, produced from a single gene and precursor. SMC expression is tightly regulated in mammary gland; the level in lactating mammary gland is about 100-fold that in virgin gland. In rat mammary epithelial cells, SMC is post-transcriptionally regulated by Matrigel by inhibition of SMC precursor synthesis. SMC is also posttranscriptionally regulated by transforming growth factor-beta (TGF beta), The repression of SMC expression by TGF beta is rapid, is independent of TGF beta-induced cell cycle arrest, and does not require new protein synthesis. Unlike Matrigel, TGF beta does not reduce SMC protein synthesis, as SMC precursor accumulation is equivalent in TGF beta-treated and untreated cells. Instead, SMC precursor in TGF beta-treated cells is more persistent and does not become processed as rapidly into mature ASGP-1 and ASGP-2, indicating that TGF beta disrupts processing of SMC precursor. These results indicate that SMC, a product of normal mammary gland and milk, is regulated by TGF beta by a novel post-translational mechanism. Thus, SMC is regulated by multiple posttranscriptional mechanisms, which serve to repress potential deleterious effects of overexpression.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; Chen TP, 1998, CANCER RES, V58, P4805; Close MJ, 1997, J CELL SCI, V110, P2861; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Juang SH, 1996, ONCOGENE, V12, P1033; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCNEER RR, 1997, FRONT BIOSCI, V2, P449; MERCIER JC, 1993, J DAIRY SCI, V76, P3079, DOI 10.3168/jds.S0022-0302(93)77647-X; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; ROBINSON SD, 1993, J CELL BIOL, V120, P245, DOI 10.1083/jcb.120.1.245; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Rydziel S, 1997, J CELL PHYSIOL, V170, P145, DOI 10.1002/(SICI)1097-4652(199702)170:2<145::AID-JCP6>3.0.CO;2-O; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; STAMPFER MR, 1993, J CELL PHYSIOL, V155, P210, DOI 10.1002/jcp.1041550127; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; SUDLOW AW, 1994, BIOCHEM J, V304, P333, DOI 10.1042/bj3040333; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WU K, 1994, J BIOL CHEM, V269, P11950; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	43	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17800	17807		10.1074/jbc.275.23.17800	http://dx.doi.org/10.1074/jbc.275.23.17800			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837499	hybrid			2022-12-27	WOS:000087485000082
J	Taylor, LM; Khachigian, LM				Taylor, LM; Khachigian, LM			Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN ATHEROSCLEROTIC LESIONS; COLLAGEN GENE-EXPRESSION; FLUID SHEAR-STRESS; TGF-BETA; FACTOR-A; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; RECEPTOR EXPRESSION; REGULATORY ELEMENTS	Transforming growth factor-beta (TGF-beta) regulates a diverse array of biological processes, such as proliferation, differentiation, extracellular matrix production, and apoptosis. In cultured vascular endothelial cells, TGF-beta induces the expression of platelet-derived growth factor (PDGF) B-chain, a mitogen and chemoattractant, at the level of transcription. The molecular mechanism(s) underlying this process are not presently understood. In this study, we performed serial 5' deletion and transient transfection analysis to define a region in the PDGF-B promoter mediating inducible responsiveness to TGF-beta. This region contains an atypical nucleotide recognition element for the Smad family of transcriptional regulators. Electrophoretic mobility shift analysis revealed that nuclear proteins bound to this site in a transient and specific manner. Supershift studies demonstrated the physical association of Smad4 with the promoter. Overexpression of Smad4 activated the PDGF-B promoter and superinduced PDGF-B promoter-dependent expression in cells exposed to TGF-beta. Moreover, simultaneous cotransfection of Smad3 and Smad4 activated the PDGF-B promoter. This effect was attenuated when Smad4 was substituted with its dominant negative counterpart. Mutation of the (-81)CAGA(-78) motif in the PDGF-B promoter abrogated Smad-inducible promoter-dependent expression. Overexpression of Smad2 and Smad3 transactivated the PDGF-B promoter in a synergistic manner. These findings demonstrate the existence of a novel, functional binding element in the proximal region of the PDGF-B promoter mediating responsiveness to TGF-beta.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BARTRAM CR, 1984, BLOOD, V63, P223; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; Evanko SP, 1998, AM J PATHOL, V152, P533; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KANZAKI T, 1995, ARTERIOSCL THROM VAS, V15, P1951, DOI 10.1161/01.ATV.15.11.1951; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LINDNER V, 1995, AM J PATHOL, V146, P1488; LINDNER V, 1995, CIRC RES, V76, P951, DOI 10.1161/01.RES.76.6.951; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nikol S, 1998, ATHEROSCLEROSIS, V139, P31, DOI 10.1016/S0021-9150(98)00050-1; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; REKHTER MD, 1994, CIRC RES, V75, P410, DOI 10.1161/01.RES.75.3.410; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; Ueda M, 1996, AM J PATHOL, V149, P831; vanEps RGS, 1997, J VASC SURG, V25, P1044, DOI 10.1016/S0741-5214(97)70128-9; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	54	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16709	16716		10.1074/jbc.275.22.16709	http://dx.doi.org/10.1074/jbc.275.22.16709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828062	hybrid			2022-12-27	WOS:000087392200045
J	Pratt, MB; Husain, SS; Miller, KW; Cohen, JB				Pratt, MB; Husain, SS; Miller, KW; Cohen, JB			Identification of sites of incorporation in the nicotinic acetylcholine receptor of a photoactivatible general anesthetic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; NONCOMPETITIVE ANTAGONIST; AMINO-ACID; GLYCINE RECEPTORS; ION-CHANNEL; M2 SEGMENT; GABA(A); ALCOHOL; MUTATIONS; ETOMIDATE	Most general anesthetics including long chain aliphatic alcohols act as noncompetitive antagonists of the nicotinic acetylcholine receptor (nAChR), To locate the sites of interaction of a long chain alcohol with the Torpedo nAChR, we have used the photoactivatible alcohol 3-[H-3]azioctanol, which inhibits the nAChR and photoincorporates into nAChR subunits. At 1 and 275 mu M, 3-[H-3]azioctanol photoincorporated into nAChR subunits with increased incorporation in the rw-subunit in the desensitized state. The incorporation into the cu-subunit was mapped to two large proteolytic fragments. One fragment of similar to 20 kDa (alpha V8-20), containing the M1, M2, and M3 transmembrane segments, showed enhanced incorporation in the presence of agonist whereas the other of similar to 10 kDa (alpha V8-10), containing the M4 transmembrane segment, did not show agonist-induced incorporation of label. Within alpha V8-20, the primary site of incorporation was alpha Glu-262 at the C-terminal end of alpha M2, labeled preferentially in the desensitized state. The incorporation at alpha Glu-262 approached saturation between 1 mu M, with similar to 6% labeled, and 215 mu M, With similar to 30% labeled. Low level incorporation was seen in residues at the agonist binding site and the protein-lipid interface at similar to 1% of the levels in alpha Glu-262. Therefore, the primary binding site of 3-azioctanol is within the ion channel with additional lower affinity interactions within the agonist binding site and at the protein-lipid interface.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; Birnir B, 1997, J MEMBRANE BIOL, V155, P157, DOI 10.1007/s002329900167; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DILGER JP, 1995, EUR J ANAESTH, V12, P31; DILGER JP, 1994, MOL PHARMACOL, V46, P169; FIRESTONE LL, 1994, MOL PHARM, V46, P449; Forman SA, 1997, BIOPHYS J, V72, P2170, DOI 10.1016/S0006-3495(97)78860-X; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; McGurk KA, 1998, BRIT J PHARMACOL, V124, P13, DOI 10.1038/sj.bjp.0701787; MEDYNSKI DC, 1983, THESIS HARVARD U; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Moody EJ, 1997, J NEUROCHEM, V69, P1310; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; Pedersen SE, 1995, J BIOL CHEM, V270, P31141, DOI 10.1074/jbc.270.52.31141; Pistis M, 1999, J PHYSIOL-LONDON, V515, P3, DOI 10.1111/j.1469-7793.1999.003ad.x; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; WOOD SC, 1995, MOL PHARMACOL, V47, P121; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	35	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29441	29451		10.1074/jbc.M004710200	http://dx.doi.org/10.1074/jbc.M004710200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10859324	hybrid			2022-12-27	WOS:000089439800037
J	Sano, M; Fukuda, K; Kodama, H; Pan, J; Saito, M; Matsuzaki, J; Takahashi, T; Makino, S; Kato, T; Ogawa, S				Sano, M; Fukuda, K; Kodama, H; Pan, J; Saito, M; Matsuzaki, J; Takahashi, T; Makino, S; Kato, T; Ogawa, S			Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; MUSCLE CELL HYPERTROPHY; MYOCYTES IN-VITRO; GENE-EXPRESSION; VENTRICULAR MYOCYTES; GROWTH-FACTOR; RAT; FIBROBLASTS; RELEASE; GP130	This study was designed to investigate whether angiotensin II induces the interleukin (IL)-6 family of cytokines in cardiac fibroblasts and, if so, whether these cytokines can augment cardiac hypertrophy. Angiotensin II increased IL-6, leukemia inhibitory factor (LIF) and cardiotrophin-1 mRNA by 6.5-, 10.2-, and 2.0-fold, respectively, but did not affect IL-11, ciliary neurotrophic factor, or oncostatin M in cardiac fibroblasts, Enzyme-linked immunosorbent assay revealed that angiotensin II-stimulated conditioned medium from cardiac fibroblasts contained 9.3 ng/ml IL-6 at 24 h, which was 24-fold higher than the control. It phosphorylated gp130 and STAT3 in cardiomyocytes, which was reduced with RX435 (anti-gp130 blocking antibody). It increased [H-3]phenylalanine uptake and cell area by 44% and 86% in cardiomyocytes compared with mock medium. RX435 suppressed these increases by 26% and 38%, while TAK044 (endothelin-A/B-R blocker) suppressed them by 52% and 52%, respectively. Antisense oligonucleotides against LIF and cardiotrophin-1 blocked their up-regulation, and attenuated the conditioned medium-induced increase in [H-3]phenylalanine uptake by 21% and 13%, respectively. The combination of antisense oligonucleotides to LIF and cardiotrophin-1 decreased their uptake by 33%, These results indicated that angiotensin II induced IL-6, LIF, and cardiotrophin-1 in cardiac fibroblasts, and that these cytokines, particularly LIF and cardiotrophin-1, activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy.	Keio Univ, Dept Internal Med, Cardiopulm Div, Shinjuku Ku, Tokyo 1608582, Japan; Chugai Pharmaceut Co Ltd, Shizuoka 4128513, Japan	Keio University; Chugai Pharmaceutical Co., Ltd.; Roche Holding	Fukuda, K (corresponding author), Keio Univ, Dept Internal Med, Cardiopulm Div, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Sano, Motoaki/L-3405-2013; Fukuda, Keiichi/L-3777-2013					BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAKER KM, 1990, AM J PHYSIOL, V259, P324; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; EID H, 1994, J CARDIOVASC PHARM, V24, P715, DOI 10.1097/00005344-199424050-00005; FISHER SA, 1995, AM J PHYSIOL-CELL PH, V268, pC910; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukuda K, 1998, J MOL CELL CARDIOL, V30, P2069, DOI 10.1006/jmcc.1998.0770; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Gray MO, 1998, CARDIOVASC RES, V40, P352, DOI 10.1016/S0008-6363(98)00121-7; Harada M, 1997, CIRCULATION, V96, P3737; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; IKEDA S, 1994, J PHARMACOL EXP THER, V270, P728; ITO H, 1993, J CLIN INVEST, V92, P395; JUDD AM, 1992, ENDOCRINOLOGY, V130, P1245, DOI 10.1210/en.130.3.1245; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; Kodama H, 1997, CIRC RES, V81, P656; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LONG CS, 1993, J MOL CELL CARDIOL, V25, P915, DOI 10.1006/jmcc.1993.1104; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MORIYAMA T, 1995, J AM SOC NEPHROL, V6, P95; NISHIDA M, 1993, J CLIN INVEST, V91, P1934, DOI 10.1172/JCI116412; Pan J, 1998, HEART VESSELS, V13, P199, DOI 10.1007/BF01745045; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	37	189	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29717	29723		10.1074/jbc.M003128200	http://dx.doi.org/10.1074/jbc.M003128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10843995	hybrid, Green Submitted			2022-12-27	WOS:000089439800072
J	Chen, J; Wang, YP; Wang, Y; Nakajima, T; Iwasawa, K; Hikiji, H; Sunamoto, M; Choi, DK; Yoshida, Y; Sakaki, Y; Toyo-oka, T				Chen, J; Wang, YP; Wang, Y; Nakajima, T; Iwasawa, K; Hikiji, H; Sunamoto, M; Choi, DK; Yoshida, Y; Sakaki, Y; Toyo-oka, T			Autocrine action and its underlying mechanism of nitric oxide on intracellular Ca2+ homeostasis in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CULTURED RAT ASTROCYTES; NA+/CA2+ EXCHANGE; HUMAN PLATELETS; RELAXING FACTOR; EXTRUSION MECHANISMS; PANCREATIC ACINAR; CALCIUM INFLUX; CYTOSOLIC CA2+	The rise in cytosolic Ca2+ concentration (Ca-i(2+)) in vascular endothelial cells (ECs) activates the production and release of nitric oxide (NO). NO modifies Ca-i(2+) homeostasis in many types of nonendothelial cells. However, its effect on endothelial Ca-i(2+) homeostasis at basal and excited states remains unclear. In the present study, to elucidate the effect of NO on basal Ca-i(2+) inositol 1,4,5-trisphosphate-induced Ca-i(2+) release (IICR) was blocked by expressing an antisense against type-1 inositol 1,1,B-trisphosphate receptors or by microinjecting heparin to individual ECs, and the effects of NO that was released by and diffused from adjacent IICR-intact ECs were recorded. After ATP or bradykinin stimulation, IICR-inhibited ECs showed a marked reduction of basal Ca-i(2+), which was abolished by NG-monomethyl-L-arginine monoacetate pretreatment. The reduction disappeared in sparsely seeded ECs. Exogenous NO gas mimicked the effect of ATP or bradykinin to reduce basal Ca-i(2+). Blocking plasma membrane Ca2+-ATPase Ca2+-ATPase (PMCA), but not Na+-Ca2+ exchange or sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase, suppressed the reduction, indicating that the reduction resulted from a NO-dependent potentiation of PMCA. To elucidate the effect of NO on elevated Ca-i(2+), ATP-, bradykinin-, or thapsigargin-evoked Ca-i(2+) response in the presence and absence of NO production was compared in adjacent BOB-intact ECs. NO was found to potentiate PMCA, which, in turn, greatly attenuated agonist-evoked Ca2+ elevation. NO also potentiated Ca2+ influx, which markedly increased the sustained phase of Ca2+, elevation and possibly NO production. NO did not affect other Ca-i(2+)-elevating and Ca-i(2+)-sequestrating components. Thus, NO-dependent potentiation of PMCA is crucial for Ca-i(2+) homeostasis over a wide Ca-i(2+) range.	Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Oral & Maxillofacial Surg, Tokyo 1130033, Japan; Univ Tokyo, Ctr Human Genome, Inst Med Sci, Tokyo 1130033, Japan; Takeda Chem Ind Ltd, Mol Chem Lab, Osaka 5320024, Japan; Niigata Univ, Dept Pharmacol, Niigata 9518122, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Takeda Chemical Industries; Niigata University	Wang, YP (corresponding author), Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.			Choi, Dong-Kug/0000-0001-7041-1524				ASANO S, 1995, J NEUROCHEM, V64, P2437; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bian XP, 1996, CELL CALCIUM, V19, P351, DOI 10.1016/S0143-4160(96)90075-5; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; Clementi E, 1997, TRENDS PHARMACOL SCI, V18, P266; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; DIPOLO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P237, DOI 10.1016/0005-2736(82)90599-5; DIPOLO R, 1978, NATURE, V274, P390, DOI 10.1038/274390a0; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1991, J BIOL CHEM, V266, P12337; Goto Y, 1996, EUR J PHARMACOL, V314, P185, DOI 10.1016/S0014-2999(96)00532-8; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HANSEN BA, 1991, ANN NY ACAD SCI, V639, P566, DOI 10.1111/j.1749-6632.1991.tb17352.x; Herscher CJ, 1997, ANN NY ACAD SCI, V834, P407, DOI 10.1111/j.1749-6632.1997.tb52284.x; HIRATA M, 1990, J BIOL CHEM, V265, P1268; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; Kawaguchi H, 1997, CIRCULATION, V95, P2441, DOI 10.1161/01.CIR.95.10.2441; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; KRATJE RB, 1985, BIOCHIM BIOPHYS ACTA, V816, P365, DOI 10.1016/0005-2736(85)90504-8; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Mountian I, 1999, CELL CALCIUM, V25, P371, DOI 10.1054/ceca.1999.0034; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; Sang KHL, 1996, BRIT J PHARMACOL, V119, P1361, DOI 10.1111/j.1476-5381.1996.tb16047.x; SARKADI B, 1978, FEBS LETT, V89, P78, DOI 10.1016/0014-5793(78)80526-2; SCHILLING WP, 1988, AM J PHYSIOL, V255, pH219, DOI 10.1152/ajpheart.1988.255.2.H219; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; SHIKANO K, 1988, J PHARMACOL EXP THER, V247, P873; Shimizu H, 1997, CELL CALCIUM, V21, P31, DOI 10.1016/S0143-4160(97)90094-4; SHIN WS, 1992, J BIOL CHEM, V267, P20377; Snitsarev VA, 1999, CELL CALCIUM, V25, P409, DOI 10.1054/ceca.1999.0041; Strobaek D, 1996, BRIT J PHARMACOL, V118, P1645, DOI 10.1111/j.1476-5381.1996.tb15587.x; Takuma K, 1996, J NEUROCHEM, V67, P1840; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; UNEYAMA H, 1994, BRIT J PHARMACOL, V111, P245, DOI 10.1111/j.1476-5381.1994.tb14051.x; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; Volk T, 1997, J CELL PHYSIOL, V172, P296, DOI 10.1002/(SICI)1097-4652(199709)172:3<296::AID-JCP3>3.0.CO;2-J; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P9121; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; WANG YP, 1996, CIRCULATION, V94, P713; XU X, 1994, J BIOL CHEM, V269, P12645; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; YUI Y, 1991, J BIOL CHEM, V266, P3369	57	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28739	28749		10.1074/jbc.M000910200	http://dx.doi.org/10.1074/jbc.M000910200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852903	hybrid			2022-12-27	WOS:000089330700055
J	Langton, KP; McKie, N; Curtis, A; Goodship, JA; Bond, PM; Barker, MD; Clarke, M				Langton, KP; McKie, N; Curtis, A; Goodship, JA; Bond, PM; Barker, MD; Clarke, M			A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in sorsby's fundus dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; PROGELATINASE-A; TERMINAL DOMAIN; IV COLLAGENASE; CELL-DEATH; TIMP-3; EXPRESSION; CLONING; GENE; ACTIVATION	Sorsby's fundus dystrophy (SFD) is a dominantly inherited degenerative disease of the retina that leads to loss of vision in middle age, It has been shown to be caused by mutations in the gene for tissue inhibitor of metalloproteinases-3 (TIMP-3). Five different mutations have previously been identified, all introducing an extra cysteine residue into exon 5 (which forms part of the C-terminal domain) of the TIMP-3 molecule; however, the significance of these mutations to the disease phenotype was unknown. In this report, we describe the expression of several of these mutated genes, together with a previously unreported novel TIMP-3 mutation from a family with SFD that results in truncation of most of the C-terminal domain of the molecule. Despite these differences, all of these molecules are expressed and exhibit characteristics of the normal protein, including inhibition of metalloproteinases and binding to the extracellular matrix. However, unlike wild-type TIMP-3, they all form dimers, These observations, together with the recent finding that expression of TIMP-3 is increased, rather than decreased, in eyes from patients with SFD, provides compelling evidence that dimerized TIMP-3 plays an active role in the disease process by accumulating in the eye. Increased expression of TIMP-3 is: also observed in other degenerative retinal diseases, including the more severe forms of age-related macular degeneration, the most common cause of blindness in the elderly in developed countries. We hypothesize that overexpression of TIMP-5 may prove to be a critical step in the progression of a variety of degenerative retinopathies.	Univ Sheffield, Sch Med, Pathol Sect, Div Oncol & Cellular Pathol, Sheffield S10 2RX, S Yorkshire, England; Univ Newcastle Upon Tyne, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; No Genet Serv, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Sheffield; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Barker, MD (corresponding author), Univ Sheffield, Sch Med, Pathol Sect, Div Oncol & Cellular Pathol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.							Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Felbor U, 1997, AM J HUM GENET, V60, P57; Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; JOMARY C, 1995, J NEUROCHEM, V64, P2370; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1994, AM J RESP CRIT CARE, V150, pS165, DOI 10.1164/ajrccm/150.6_Pt_2.S165; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267	35	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27027	27031						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854443				2022-12-27	WOS:000089144800049
J	Pan, M; Liang, J; Fisher, EA; Ginsberg, HN				Pan, M; Liang, J; Fisher, EA; Ginsberg, HN			Inhibition of translocation of nascent apolipoprotein B across the endoplasmic reticulum membrane is associated with selective inhibition of the synthesis of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; HEP G2 CELLS; UBIQUITIN-PROTEASOME PATHWAY; APO-B; INTRACELLULAR DEGRADATION; MESSENGER-RNA; SECRETION; B100; TRANSLATION	In HepG2 cells, inhibition of apolipoprotein B100 (apoB) translocation across the endoplasmic reticulum by an microsomal triglyceride transfer protein (MTP) inhibitor (CP-10447) in the presence of N-acetyl-leucinyl-norleucinal, a proteasomal inhibitor, results in accumulation of newly synthesized apoB in the translocation channel. Here we demonstrated that such accumulation led to a specific reduction of apoB synthesis. ApoB mRNA levels remained unchanged, but we observed reduced rates of elongation of nascent apoB in puromycin-synchronized cells pretreated with MTP inhibitor. This observation was consistent with a longer half-ribosome transit time for the synthesis of apoB in MTP-inhibited cells. Initiation of translation of apoB mRNA was not impaired by MTP inhibition. Overall, these findings suggest that translocation arrest of apoB in the endoplasmic reticulum channel can exert a selective and negative effect on the synthesis of apoB at the stage of elongation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA	Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168 St, New York, NY 10032 USA.			Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL58541, HL55638, T32 HL07343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, R01HL055638, R01HL058541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1990, J LIPID RES, V31, P567; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRETT DJ, 1995, BIOCHEM J, V310, P11, DOI 10.1042/bj3100011; CHEN XL, 1993, J BIOL CHEM, V268, P21007; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ESKRIDGE EM, 1983, J BIOL CHEM, V258, P1487; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Haghpassand M, 1996, J LIPID RES, V37, P1468; HALL MN, 1982, ANN INST PASTEUR MIC, VA133, P123; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; JAMIL H, 1996, P NATL ACAD SCI USA, V93, P1191; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; Jeong JK, 1997, J BIOL CHEM, V272, P7511, DOI 10.1074/jbc.272.11.7511; KIM JM, 1991, J BIOL CHEM, V266, P14931; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P53; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	41	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27399	27405						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846173				2022-12-27	WOS:000089144800098
J	Abril, AM; Salas, M; Hermoso, JM				Abril, AM; Salas, M; Hermoso, JM			Identification of residues within two regions involved in self-association of viral histone-like protein p6 from phage O29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI-29 DNA-REPLICATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; H-NS; INVITRO TRANSCRIPTION; NUCLEOPROTEIN COMPLEX; NUCLEOTIDE-SEQUENCES; HOST FACTOR; EARLY GENES; BINDING	Protein p6 of Bacillus subtilis phage phi 29 is involved in the initiation of viral DNA replication and transcription by forming a multimeric nucleoprotein complex with the phage DNA. Based on this, together with its abundance and its capacity to bind to the whole viral genome, it has been proposed to be a viral histone-like protein. Protein p6 is in a monomer-dimer-oligomer equilibrium association. we have identified protein p6 mutants deficient in self-association by testing random mutants obtained by degenerated polymerase chain reaction in an in vivo assay for dimer formation. The mutations were mainly clustered in two regions located at the N terminus, and the central part of the protein. Site-directed single mutants, corresponding to those found in vivo, have been constructed and purified. Mutant p6A44V, located at the central part of the protein, showed an impaired dimer formation ability, and a reduced capacity to bind DNA and to activate the initiation of phi 29 DNA replication. Mutant p6I8T has at least 10-fold reduced self-association capacity, does not bind DNA nor activate phi 29 DNA initiation of replication. C-terminal deletion mutants showed an enhanced dimer formation capacity. The highly acidic tail, removed in these mutants, is proposed to modulate the protein p6 self-association.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [5RO1 GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Abril AM, 1999, J MOL BIOL, V292, P581, DOI 10.1006/jmbi.1999.3078; ARCANGIOLI B, 1994, NUCLEIC ACIDS RES, V22, P2930, DOI 10.1093/nar/22.15.2930; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BAILONE A, 1978, VIROLOGY, V84, P547, DOI 10.1016/0042-6822(78)90273-8; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BARTHELEMY I, 1989, J VIROL, V63, P460, DOI 10.1128/JVI.63.1.460-462.1989; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BRAVO A, 1994, MOL GEN GENET, V245, P529, DOI 10.1007/BF00282215; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Ceschini S, 2000, J BIOL CHEM, V275, P729, DOI 10.1074/jbc.275.2.729; Claret L, 1997, J MOL BIOL, V273, P93, DOI 10.1006/jmbi.1997.1310; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KOCH C, 1988, P NATL ACAD SCI USA, V85, P4237, DOI 10.1073/pnas.85.12.4237; Leung DW, 1989, TECHNIQUE, V1, P11; MILLER HI, 1984, COLD SPRING HARB SYM, V43, P1121; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MURRAY CL, 1982, J BIOL CHEM, V257, P1053; OTERO MJ, 1989, NUCLEIC ACIDS RES, V17, P4567, DOI 10.1093/nar/17.12.4567; OTERO MJ, 1990, GENE, V95, P25, DOI 10.1016/0378-1119(90)90409-K; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROUVIEREYANIV J, 1979, FEBS LETT, V106, P297, DOI 10.1016/0014-5793(79)80518-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TALAVERA A, 1972, EUR J BIOCHEM, V31, P367, DOI 10.1111/j.1432-1033.1972.tb02542.x; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; WHITELEY HR, 1986, VIROLOGY, V155, P392, DOI 10.1016/0042-6822(86)90202-3; Williams RM, 1996, J BACTERIOL, V178, P4335, DOI 10.1128/jb.178.15.4335-4343.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26404	26410		10.1074/jbc.M002739200	http://dx.doi.org/10.1074/jbc.M002739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10829023	hybrid			2022-12-27	WOS:000088999700072
J	Vereker, E; Campbell, V; Roche, E; McEntee, E; Lynch, MA				Vereker, E; Campbell, V; Roche, E; McEntee, E; Lynch, MA			Lipopolysaccharide inhibits long term potentiation in the rat dentate gyrus by activating caspase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST; INDUCED APOPTOSIS; HIPPOCAMPAL SLICES; GLUTAMATE RELEASE; ARACHIDONIC-ACID; BRAIN-REGIONS; MESSENGER-RNA; CYTOCHROME-C; AGED RATS; PROTEIN	Lipopolysaccharide, a component of the cell wall of Gram-negative bacteria, may be responsible for at least some of the pathophysiological sequelae of bacterial infections, probably by inducing an increase in interleukin-1 beta (IL-1 beta) concentration. We report that intraperitoneal injection of lipopolysaccharide increased hippocampal caspase-1 activity and IL-1 beta concentration; these changes were associated with increased activity of the stress-activated kinase c-Jun NH2-terminal kinase, decreased glutamate release, and impaired long term potentiation. The degenerative changes in hippocampus and entorhinal cortical neurones were consistent with apoptosis because translocation of cyto chrome c and poly(ADP-ribose) polymerase cleavage were increased. Inhibition of caspase-1 blocked these changes, suggesting that IL-1 beta mediated the lipopolysaccharide-induced changes.	Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland	Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie		Lynch, Marina/0000-0002-4631-0499				Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANEVARI L, 1994, BRAIN RES, V667, P115, DOI 10.1016/0006-8993(94)91720-5; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; FARRAR WL, 1987, IMMUNOL REV, V100, P361, DOI 10.1111/j.1600-065X.1987.tb00539.x; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; HAMPTON MB, 1989, ANN NY ACAD SCI, V854, P328; IANOTTI F, 1993, J CEREB BLOOD FLOW S, V13, P125; Ilyin SE, 1998, BRAIN RES BULL, V45, P507, DOI 10.1016/S0361-9230(97)00437-1; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kong LY, 1997, NEUROCHEM INT, V30, P491, DOI 10.1016/S0197-0186(96)00086-1; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Linthorst ACE, 1998, ANN NY ACAD SCI, V840, P139, DOI 10.1111/j.1749-6632.1998.tb09558.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767; Maroney AC, 1998, J NEUROSCI, V18, P104; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; MODY I, 1989, NEUROSCI LETT, V96, P70, DOI 10.1016/0304-3940(89)90245-0; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1998, J NEUROSCI, V18, P2974; Nguyen KT, 1998, J NEUROSCI, V18, P2239; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; QUAN N, 1994, J NEUROIMMUNOL, V49, P125, DOI 10.1016/0165-5728(94)90188-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Schulz JB, 1996, J NEUROSCI, V16, P4696; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tenneti L, 1998, J NEUROCHEM, V71, P946; Tingsborg S, 1996, BRAIN RES, V712, P153, DOI 10.1016/0006-8993(95)01525-6; Van Dam AM, 1998, ANN NY ACAD SCI, V840, P128, DOI 10.1111/j.1749-6632.1998.tb09557.x; VEREKER E, 2000, IN PRESS J NEUROSCI; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	53	149	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26252	26258		10.1074/jbc.M002226200	http://dx.doi.org/10.1074/jbc.M002226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856294	hybrid			2022-12-27	WOS:000088999700052
J	Xie, ZY; Turk, E; Wright, EM				Xie, ZY; Turk, E; Wright, EM			Characterization of the Vibrio parahaemolyticus Na+/glucose cotransporter - A bacterial member of the sodium/glucose transporter (SGLT) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-GALACTOSE MALABSORPTION; POLYTOPIC MEMBRANE-PROTEINS; THYROID NA+/I SYMPORTER; ESCHERICHIA-COLI; NA+/PROLINE TRANSPORTER; SCANNING MUTAGENESIS; TRAFFICKING DEFECTS; MISSENSE MUTATIONS; CYSTEINE; PERMEASE	The Vibrio parahaemolyticus sodium/glucose transporter (vSGLT) is a bacterial member of the SGLT gene family. Wild-type and mutant vSGLT proteins were expressed in Escherichia coli, and transport activity was measured in intact cells and plasma membrane vesicles. Two cysteine less vSGLT proteins exhibited sugar transport rates comparable with that of the wild-type protein. Six residues in two regions of vSGLT known to be of functional importance in SGLT1 were replaced individually with cysteine in the cysteine-less protein. Characterization of these single cysteine-substituted vSGLTs showed that two residues (Gly-151 and Gln-428) are essential for transport function, whereas the other four residues (Leu-147, Leu-149, Ala-423, and Gln-425) are not, 2-Aminoethylmethanethiosulfonate (MTSEA) blocked Na+/glucose transport by only the transporter bearing a cysteine at position 425 (Q425C), MTSEA inhibition was reversed by dithiothreitol and blocked by the presence of both Na+ and D-glucose, indicating that conformational changes of the vSGLT protein are involved in Na+/glucose transport. A split version of vSGLT was generated by co-expression of the N-terminal (N-7) and C-terminal (C-7) halves of the transporter. The split vSGLT maintained Naf-dependent glucose transport activity. Chemical cross-linking of split vSGLT, with a cysteine in each N-7 and C-7 fragment, suggested that hydrophilic loops between helices 4 and 5 and between helices 10 and 11 are within 8 Angstrom of each other. We conclude that the mechanism of Na+/glucose transport by vSGLT is similar to mammalian SGLTs and that further studies on vSGLT will provide novel insight to the structure and function of this class of cotransporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wright, EM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	ewright@mednet.ucla.edu			NIDDK NIH HHS [DK 19567, DK 44602] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HIRAYAMA BA, 1992, BIOCHIM BIOPHYS ACTA, V1103, P37, DOI 10.1016/0005-2736(92)90054-P; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Lo B, 1998, J BIOL CHEM, V273, P903, DOI 10.1074/jbc.273.2.903; Lo B, 1998, J BIOL CHEM, V273, P29341, DOI 10.1074/jbc.273.45.29341; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; Martin MG, 1997, GASTROENTEROLOGY, V112, P1206, DOI 10.1016/S0016-5085(97)70132-X; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Sarker RI, 1997, J BACTERIOL, V179, P1805, DOI 10.1128/jb.179.5.1805-1808.1997; Sarker RI, 1996, BBA-BIOMEMBRANES, V1279, P149, DOI 10.1016/0005-2736(95)00252-9; SARKER RI, 1994, J BACTERIOL, V176, P7378, DOI 10.1128/JB.176.23.7378-7382.1994; Sarker RI, 1996, BBA-BIOMEMBRANES, V1281, P1, DOI 10.1016/0005-2736(96)00025-9; SHORT SA, 1975, J BIOL CHEM, V250, P4291; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; Turk E, 2000, J BIOL CHEM, V275, P25711, DOI 10.1074/jbc.M003127200; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	39	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25959	25964		10.1074/jbc.M002687200	http://dx.doi.org/10.1074/jbc.M002687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852908	hybrid			2022-12-27	WOS:000088999700012
J	Turk, E; Kim, O; le Coutre, J; Whitelegge, JP; Eskandari, S; Lam, JT; Kreman, M; Zampighi, G; Faull, KF; Wright, EM				Turk, E; Kim, O; le Coutre, J; Whitelegge, JP; Eskandari, S; Lam, JT; Kreman, M; Zampighi, G; Faull, KF; Wright, EM			Molecular characterization of Vibrio parahaemolyticus vSGLT - A model for sodium-coupled sugar cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-GALACTOSE MALABSORPTION; ESCHERICHIA-COLI; NA+/GLUCOSE COTRANSPORTER; NA+/PROLINE TRANSPORTER; FUNCTIONAL EXPRESSION; TRAFFICKING DEFECTS; MISSENSE MUTATIONS; MASS-SPECTROMETRY; MEMBRANE TOPOLOGY; CLONING	The Na+/galactose cotransporter (vSGLT) of Vibrio parahaemolyticus, tagged with C-terminal hexahistidine, has been purified to apparent homogeneity by Ni2+ affinity chromatography and gel filtration. Resequencing the vSGLT gene identified an important correction: the N terminus constitutes an additional 13 functionally essential residues. The mass of His-tagged vSGLT expressed under its native promoter, as determined by electrospray ionization-mass spectrometry (ESI-MS), verifies these 13 residues in wild-type vSGLT. A fusion protein of vSGLT and green fluorescent protein, comprising a mass of over 90 kDa, was also successfully analyzed by ESI-MS. Reconstitution of purified vSGLT yields proteoliposomes active in Na+-dependent galactose uptake, with sugar preferences (galactose > glucose > fucose) reflecting those of wild-type vSGLT in vivo. Substrates are transported with apparent 1:1 stoichiometry and apparent K-m values of 129 mM (Na+) and 158 mu M (galactose). Freeze-fracture electron microscopy of functional proteoliposomes shows intramembrane particles of a size consistent with vSGLT existing as a monomer. We conclude that vSGLT is a suitable model for the study of sugar cotransporter mechanisms and structure, with potential applicability to the larger SGLT family of important sodium:solute cotransporters, It is further demonstrated that ESI-MS is a powerful tool for the study of proteomics of membrane transporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Turk, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, CHS Box 951751, Los Angeles, CA 90095 USA.	eturk@mednet.ucla.edu			NIDDK NIH HHS [DK-44602, DK5-1131, DK-44582] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK051131, R01DK044582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; ASHTON DS, 1994, FEBS LETT, V342, P1, DOI 10.1016/0014-5793(94)80572-5; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DeGrip WJ, 1998, BIOCHEM J, V330, P667; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Hill RA, 1997, PROTEIN EXPRES PURIF, V10, P162, DOI 10.1006/prep.1997.0732; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Konig N, 1997, J MOL BIOL, V265, P590, DOI 10.1006/jmbi.1996.0763; KWON HM, 1992, J BIOL CHEM, V267, P6297; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; le Coutre J, 2000, BIOCHEMISTRY-US, V39, P4237, DOI 10.1021/bi000150m; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Martin MG, 1997, GASTROENTEROLOGY, V112, P1206, DOI 10.1016/S0016-5085(97)70132-X; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; Panayotova-Heiermann M, 1998, BIOCHEMISTRY-US, V37, P10522, DOI 10.1021/bi9800395; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Sarker RI, 1997, J BACTERIOL, V179, P1805, DOI 10.1128/jb.179.5.1805-1808.1997; Sarker RI, 1996, BBA-BIOMEMBRANES, V1279, P149, DOI 10.1016/0005-2736(95)00252-9; Sarker RI, 1996, BBA-BIOMEMBRANES, V1281, P1, DOI 10.1016/0005-2736(96)00025-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TURK E, 1994, J BIOL CHEM, V269, P15204; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468	44	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25711	25716		10.1074/jbc.M003127200	http://dx.doi.org/10.1074/jbc.M003127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835424	hybrid			2022-12-27	WOS:000088849400086
J	Brandt, PC; Vanaman, TC				Brandt, PC; Vanaman, TC			Elevated glucocorticoid receptor transactivation and down-regulation of alpha(1) integrin are associated with loss of plasma membrane Ca2+-ATPase isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; NEURITE OUTGROWTH; MESSENGER-RNA; PC12 CELLS; CA-2+-TRANSPORTING ATPASE; ALPHA-1-BETA-1 INTEGRIN; SKELETAL-MUSCLE; RAT-BRAIN	We have previously shown that inhibition of expression of the plasma membrane Ca2+-ATPase isoform I in PC6 cells leads to loss of nerve growth factor-mediated neurite extension (Brandt, P, C,, Sisken, J, E,, Neve, R, L,, and Vanaman, T, C, (1996) Proc. Natl, Acad, Sci, U.S.A. 93, 13843-13848). Cells lacking plasma membrane Ca2+-ATPase 1 did not attach to collagen-coated plates as tightly as controls, suggesting that a defect in adhesion might be underlying the inability to extend neurites, We report here that cell lines lacking plasma membrane Ca2+-ATPase 1 do not produce alpha(1) integrin, which is required for both collagen adherence and neurite extension. Because alpha(1) integrin gene transcription can be down-regulated by glucocorticoids, the response of cells to glucocorticoids was investigated. Cortisol-dependent transactivation from the mouse mammary tumor virus promoter in cells lacking plasma membrane Ca2+-ATPase 1 was stimulated 145-216-fold over untreated cells compared with 15-26-fold for controls. This increase was not due to increased binding affinity of the receptor for cortisol, an increased number of cortisol-binding sites, or increased translocation of the receptor to the nucleus, Expression of additional glucocorticoid receptor-dependent genes required for neurite extension must also be altered in cells missing the plasma membrane Ca2+-ATPase 1 because constitutive expression of alpha(1) integrin did not restore their nerve growth factor-mediated neurite extension capability. The impact of plasma membrane Ca2+-ATPase isoform 1 on other signaling systems and the resultant profound yet subtle effects on PC6 cells strongly suggests that it plays an important role in modulating signal transduction pathways downstream of Ca2+-mediated signals.	Texas A&M Syst Hlth Sci Ctr, Dept Med Pharmacol & Toxicol, College Stn, TX 77843 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Kentucky	Brandt, PC (corresponding author), Texas A&M Syst Hlth Sci Ctr, Dept Med Pharmacol & Toxicol, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21868] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Bach LA, 1997, J ENDOCRINOL, V155, P225, DOI 10.1677/joe.0.1550225; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; BRANDT P, 1994, J NEUROCHEM, V62, P799; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Brandt PC, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P397; Brandt PC, 1996, P NATL ACAD SCI USA, V93, P13843, DOI 10.1073/pnas.93.24.13843; BURK SE, 1992, J BIOL CHEM, V267, P19683; EAKIN TJ, 1995, MOL BRAIN RES, V29, P71, DOI 10.1016/0169-328X(94)00231-3; FREEMAN TC, 1995, AM J PHYSIOL-GASTR L, V269, pG126, DOI 10.1152/ajpgi.1995.269.1.G126; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; Grant NJ, 1996, J NEUROCHEM, V66, P1400; GREEB J, 1989, J BIOL CHEM, V264, P18569; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1994, NEUROSCI LETT, V178, P267, DOI 10.1016/0304-3940(94)90775-7; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; TURNER DC, 1989, J NEUROSCI, V9, P3287; WERB Z, 1978, J EXP MED, V147, P1684, DOI 10.1084/jem.147.6.1684; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	33	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24534	24539		10.1074/jbc.M003388200	http://dx.doi.org/10.1074/jbc.M003388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827194	hybrid			2022-12-27	WOS:000088683300041
J	Zhou, DP; Henion, TR; Jungalwala, FB; Berger, EG; Hennet, T				Zhou, DP; Henion, TR; Jungalwala, FB; Berger, EG; Hennet, T			The beta 1,3-galactosyltransferase beta 3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TERATOCARCINOMA CELLS; UDP-GALACTOSE; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; CLONING; EXPRESSION; GALACTOSYLTRANSFERASE; TUMORS; GENE	We have previously reported the molecular cloning of beta 1,3-galactosyltransferase-V (P3GalT-V), which catalyzes the transfer of Gal to GlcNAc-based accepters with a preference for the core3 O-linked glycan GlcNAc(beta 1,3)-GalNAc structure. Further characterization indicated that the recombinant beta 3GalT-V enzyme expressed in Sf9 insect cells also utilized the glycolipid Lc3Cer as an efficient acceptor. Surprisingly, we also found that beta 3GalT-V catalyzes the transfer of Gal to the terminal GalNAc unit of the globoside Gb4, thereby synthesizing the glycolipid Gb5, also known as the stage-specific embryonic antigen-3 (SSEA-3). The SSEA-3 synthase activity of beta 3GalT-V was confirmed in vivo by stable expression of the human beta 3GalT-V gene in F9 mouse teratocarcinoma cells, as detected with the monoclonal antibody MC-631 by flow cytometry analysis and immunostaining of extracted glycolipids. The biological relation between SSEA-3 formation and beta 3GalT-V was further documented by showing that F9 cells treated with the differentiation-inducing agent retinoic acid induced the expression of both the SSEA-3 epitope and the endogenous mouse beta 3GalT-V gene. This study represents the first example of a glycosyltransferase, which utilizes two kinds of sugar acceptor substrates without requiring any additional modifier molecule.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02452 USA	University of Zurich	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		zhou, dapeng/GXG-9715-2022; Zhou, Dapeng/A-6446-2019	Zhou, Dapeng/0000-0003-1347-3811	NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; Blixt O, 1999, GLYCOBIOLOGY, V9, P1061, DOI 10.1093/glycob/9.10.1061; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KOUL O, 1990, J LIPID RES, V31, P2227; KRUPNICK JG, 1994, INT J CANCER, V59, P692, DOI 10.1002/ijc.2910590518; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; WENK J, 1994, INT J CANCER, V58, P108, DOI 10.1002/ijc.2910580118; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	20	45	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22631	22634		10.1074/jbc.C000263200	http://dx.doi.org/10.1074/jbc.C000263200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837462	hybrid			2022-12-27	WOS:000088419400007
J	Mietus-Snyder, M; Gowri, MS; Pitas, RE				Mietus-Snyder, M; Gowri, MS; Pitas, RE			Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; CHOLESTEROL OXIDATION-PRODUCTS; FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PHOSPHOLIPASE A(2); GENE-EXPRESSION; SARCOPLASMIC-RETICULUM; EPITHELIAL-CELLS; LIPID PEROXIDES	Oxidative stress caused by phorbol esters or reactive oxygen up-regulates the class A scavenger receptor (SR-A) in human smooth muscle cells (SMC), which normally do not express this receptor. The increase in SR-A expression correlates with activation of the redox-sensitive transcription factors activating protein-1 c-Jun and CCAAT enhancer-binding protein beta. Here we show that coincubation of SMC with macrophages or oxidized low density lipoproteins (LDL) from macrophage-conditioned medium activates these game regulatory pathways and stimulates SR-A expression. The increased SR-A gene transcription induced by cell-oxidized LDL up-regulated SR-A mRNA and increased by 30-fold the uptake of acetyl LDL, a ligand for the SR-A. Copper-oxidized LDL also increased SR-A receptor expression. Oxidized LDL with a lipid peroxide level of 80-100 nmol/mg of LDL protein and an electrophoretic mobility similar to 1.5 times that of native LDL exhibited the greatest bioactivity. Inhibition of calcium flux suppressed SR-A induction by oxidized LDL. Conversely, calcium ionophore greatly enhanced SR-A up-regulation by oxidized LDL or other treatments that promote intracellular oxidative stress. This enhancement was dependent upon concurrent up-regulation of SMC cyclooxygenase-2 expression and activity and was blocked by the cyclooxygenase-2 inhibitors NS-398 and Resveratrol. In THP-I cells, oxidized LDL induced monocyte-to-macrophage differentiation and increased SR-A expression. These findings support a role for mildly oxidized LDL in the redox regulation of macrophage differentiation and SR-A expression and suggest that increased vascular oxidative stress may contribute to the formation of both SMC and macrophage foam cells.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pitas, RE (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Mietus-Snyder, Michele/0000-0003-2791-9896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; AZULA FJ, 1993, AM J PHYSIOL, V265, pC1681, DOI 10.1152/ajpcell.1993.265.6.C1681; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAKRABORTI S, 1989, AM J PHYSIOL, V257, P430; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DOAN TN, 1994, BIOCHEM J, V297, P209, DOI 10.1042/bj2970209; DRAKE TA, 1991, AM J PATHOL, V138, P601; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; ELSAADANI M, 1989, J LIPID RES, V30, P627; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; GROVER AK, 1988, AM J PHYSIOL, V255, pC297, DOI 10.1152/ajpcell.1988.255.3.C297; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall AJ, 1999, J BIOL CHEM, V274, P376, DOI 10.1074/jbc.274.1.376; Hamilton LC, 1999, FASEB J, V13, P245, DOI 10.1096/fasebj.13.2.245; Hong YH, 1997, J IMMUNOL, V159, P2418; INABA T, 1992, J BIOL CHEM, V267, P13107; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; MietusSnyder M, 1997, ARTERIOSCL THROM VAS, V17, P969, DOI 10.1161/01.ATV.17.5.969; MORISAKI N, 1994, BIOCHEM J, V303, P247, DOI 10.1042/bj3030247; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17, DOI 10.1152/ajpheart.1997.272.1.H17; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PITAS RE, 1992, ARTERIOSCLER THROMB, V12, P1235, DOI 10.1161/01.ATV.12.11.1235; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SEVANIAN A, 1995, J LIPID RES, V36, P1971; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; Speir E, 1998, CIRC RES, V83, P210, DOI 10.1161/01.RES.83.2.210; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; SUZUKI YJ, 1991, AM J PHYSIOL, V261, pH568, DOI 10.1152/ajpheart.1991.261.2.H568; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Verhagen JCD, 1996, J LIPID RES, V37, P1488; Vogel RA, 1997, CLIN CARDIOL, V20, P426, DOI 10.1002/clc.4960200505; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; Zhou YF, 1996, J CLIN INVEST, V98, P2129, DOI 10.1172/JCI119019	69	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17661	17670		10.1074/jbc.275.23.17661	http://dx.doi.org/10.1074/jbc.275.23.17661			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837497	hybrid			2022-12-27	WOS:000087485000065
J	Mitsuhashi, N; Miki, T; Senbongi, H; Yokoi, N; Yano, H; Miyazaki, M; Nakajima, N; Iwanaga, T; Yokoyama, Y; Shibata, T; Seino, S				Mitsuhashi, N; Miki, T; Senbongi, H; Yokoi, N; Yano, H; Miyazaki, M; Nakajima, N; Iwanaga, T; Yokoyama, Y; Shibata, T; Seino, S			MTABC3, a novel mitochondrial ATP-binding cassette protein involved in iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SIDEROBLASTIC ANEMIA; ABC TRANSPORTER; SULFONYLUREA RECEPTOR; MEMBRANE-PROTEIN; YEAST; GENE; DNA; IDENTIFICATION; ATM1P; CELLS	Atm1p, a mitochondrial half-type ATP-binding cassette (ABC) protein in Saccharomyces cerevisiae, transports a precursor of the iron-sulfur (Fe/S) cluster from mitochondria to the cytosol, We have identified a novel half-type human ABC protein, designating it MTABC3 (mammalian mitochondrial ABC protein 3). MTABC3 mRNA is ubiquitously expressed in all of the rat and human tissues examined. MTABC3 protein is shown to be present in the mitochondria, as assessed by immunoblot analysis and confocal microscopic analysis of subcellular fractions of Chinese hamster ovary cells stably expressing MTABC3. Accumulation of iron in the mitochondria, mitochondrial DNA damage, and respiratory dysfunction in the yeast ATM1 mutant strain (atm1-1 mutant cells) were almost fully reversed by expressing MTABC3 in these mutant cells. These results indicate that MTABC3 is a novel ortholog of the yeast and suggest an important role in mitochondrial function, Interestingly, the human MTABC3 gene has been mapped to chromosome 2q36, a region within the candidate locus for lethal neonatal metabolic: syndrome, a disorder of the mitochondrial function associated with iron metabolism, indicating that MTABC3 is a candidate gene for this disorder.	Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan; RIKEN, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Chiba Univ, Grad Sch Med, Dept Surg Organ Pathophysiol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Sch Med, Novo Nordisk Pharma, Dept Med Genet,Chuo Ku, Chiba 2608670, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan; Okayama Univ, Sch Med, Dept Pediat, Okayama 7008558, Japan	Chiba University; RIKEN; Chiba University; Chiba University; Novo Nordisk; Hokkaido University; Okayama University	Mitsuhashi, N (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	seino@molmed.m.chiba-u.ac.jp	MIKI, Takashi/ABD-3995-2020	MIKI, Takashi/0000-0001-5741-1626				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELMAESTRO RF, 1980, ACTA PHYSIOL SCAND, P153; Fellman V, 1998, LANCET, V351, P490, DOI 10.1016/S0140-6736(97)09272-6; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; Savary S, 1997, GENOMICS, V41, P275, DOI 10.1006/geno.1997.4658; Senbongi H, 1999, MOL GEN GENET, V262, P426; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TAKAHASHI E, 1990, HUM GENET, V86, P14; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Visapaa I, 1998, AM J HUM GENET, V63, P1396, DOI 10.1086/302123; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WENDLAND B, 1994, MOL ENDOCRINOL, V8, P1070, DOI 10.1210/me.8.8.1070	43	107	112	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17536	17540		10.1074/jbc.275.23.17536	http://dx.doi.org/10.1074/jbc.275.23.17536			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837493	hybrid			2022-12-27	WOS:000087485000046
J	Ribbe, MW; Bursey, EH; Burgess, BK				Ribbe, MW; Bursey, EH; Burgess, BK			Identification of an Fe protein residue (Glu(146)) of Azotobacter vinelandii nitrogenase that is specifically involved in FeMo cofactor insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; DEFICIENT MOFE PROTEIN; IN-VITRO BIOSYNTHESIS; KLEBSIELLA-PNEUMONIAE; DINITROGENASE REDUCTASE; SWISS-MODEL; APODINITROGENASE; PURIFICATION; MATURATION; CLUSTER	The Fe protein of nitrogenase has three separate functions. Much is known about the regions of the protein that are critical to its function as an electron donor to the MoFe protein, but almost nothing is known about the regions of the protein that are critical to its functions in either FeMo cofactor biosynthesis or FeMo cofactor insertion. Using computer modeling and information obtained from Fe protein mutants that were made decades ago by chemical mutagenesis, we targeted a surface residue GlU(146) as potentially being involved in FeMo cofactor biosynthesis and/or insertion, The Azotobacter vinelandii strain expressing an E146D Fe protein variant grows at similar to 50% of the wild type rate. The purified E146D Fe protein is fully functional as an electron donor to the MoFe protein, but the MoFe protein synthesized by that strain is partially (similar to 56%) FeMo cofactor-deficient, The E146D Fe protein is fully functional in an in vitro FeMo cofactor biosynthesis assay, and the strain expressing this protein accumulates "free" FeMo cofactor. Assays that compared the ability of wild type and E146D Fe proteins to participate in FeMo cofactor insertion demonstrate, however, that the mutant is severely altered in this last reaction. This is the first known mutation that only influences the insertion reaction.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; BAGIUNOW MC, 1993, NEW HORIZONS NITROGE, P131; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; CHANG CL, 1988, J BACTERIOL, V170, P4015, DOI 10.1128/jb.170.9.4015-4022.1988; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GREENER T, 1993, NEW HORIZONS NITROGE, P123; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER T R, 1988, Biofactors, V1, P199; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; MADDEN MS, 1991, J BACTERIOL, V173, P5403, DOI 10.1128/jb.173.17.5403-5405.1991; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Pulakat L, 1996, J BIOL CHEM, V271, P1884, DOI 10.1074/jbc.271.4.1884; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SHAH VK, 1997, BIOL NITROGEN FIXATI, P51; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; TAL S, 1991, J BIOL CHEM, V266, P10654; Thorneley RNF, 1996, J BIOL INORG CHEM, V1, P576, DOI 10.1007/s007750050095; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WHITE TC, 1992, J BIOL CHEM, V267, P24007; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	62	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17631	17638		10.1074/jbc.275.23.17631	http://dx.doi.org/10.1074/jbc.275.23.17631			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837496	hybrid			2022-12-27	WOS:000087485000061
J	Anderson, RF; Jang, MH; Hille, R				Anderson, RF; Jang, MH; Hille, R			Radiolytic studies of trimethylamine dehydrogenase - Spectral deconvolution of the neutral and anionic flavin semiquinone, and determination of rate constants for electron transfer in the one-electron reduced enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; XANTHINE-OXIDASE; SUBSTRATE; FLAVOPROTEIN; INHIBITOR; CLUSTER; BINDING	Trimethylamine dehydrogenase from the pseudomonad Methylophilus methylotrophus has been examined using the technique of pulse radiolysis to rapidly introduce a single reducing equivalent into the enzyme. Using enzyme that has had its iron-sulfur center rendered redox-inert by prior reaction with ferricenium hexafluorophosphate, we determined the spectral change associated with formation of both the anionic and neutral forms that were generated at high and low pH, respectively, of the unique 6-cysteinyl-FMN of the enzyme. With native enzyme, electron transfer was observed within the radiolytically generated one-electron reduced enzyme but only at low pH (6.0). The kinetics and thermodynamics of this electron transfer in one-electron reduced enzyme may be compared with that studied previously in the two-electron reduced enzyme. In contrast to previous studies with two-electron reduced enzyme in which a pK(a) of similar to 8 was determined for the flavin semiquinone, in the one-electron reduced enzyme the semiquinone was not substantially protonated even at pH 6.0. These results indicate that reduction of the iron-sulfur center of the enzyme significantly decreases the pK(a) of the flavin semiquinone of the active site. This provides further evidence, in conjunction with the strong magnetic interaction known to exist between the centers in the two-electron reduced enzyme, that the two redox-active centers in trimethylamine dehydrogenase are in intimate contact with one another in the active site of the enzyme.	Univ Auckland, Dept Chem, Auckland, New Zealand; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Auckland; Ohio State University	Anderson, RF (corresponding author), Univ Auckland, Dept Chem, Private Bag 92019, Auckland, New Zealand.				NIGMS NIH HHS [GM58481] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1997, FLAVINS FLAVOPROTEIN, P865; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Conrads T, 1998, BIOCHEMISTRY-US, V37, P7787, DOI 10.1021/bi972387x; Fournel A, 1998, J CHEM PHYS, V109, P10905, DOI 10.1063/1.477786; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P4559, DOI 10.1021/bi00232a028; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1991, J BIOL CHEM, V266, P5608; Huang LX, 1996, J BIOL CHEM, V271, P13401, DOI 10.1074/jbc.271.23.13401; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; Jang MH, 1999, J BIOL CHEM, V274, P13147, DOI 10.1074/jbc.274.19.13147; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM KW, 1988, J BIOL CHEM, V268, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; Roberts P, 1999, BIOCHEMISTRY-US, V38, P14927, DOI 10.1021/bi9914098; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026	31	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30781	30786		10.1074/jbc.M001256200	http://dx.doi.org/10.1074/jbc.M001256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859304	hybrid			2022-12-27	WOS:000089762700008
J	Sathyanarayanan, PV; Cremo, CR; Poovaiah, BW				Sathyanarayanan, PV; Cremo, CR; Poovaiah, BW			Plant chimeric Ca2+/calmodulin-dependent protein kinase - Role of the neural visinin-like domain in regulating autophosphorylation and calmodulin affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CALMODULIN; BINDING; HOMOLOG; GENE	Chimeric Ca2+/calmodulin-dependent protein kinase (CCaMK) is characterized by a serine-threonine kinase domain, an autoinhibitory domain, a calmodulin-binding domain and a neural visinin-like domain with three EF-hands. The neural visinin-like Ca2+-binding domain at the C-terminal end of the CaM-binding domain makes CCaMK unique among all the known calmodulin-dependent kinases. Biological functions of the plant visinin-like proteins or visinin-like domains in plant proteins are not well known. Using EF-hand deletions in the visinin-like domain, we found that the visinin-like domain regulated Ca2+-stimulated autophosphorylation of CCaMK. To investigate the effects of Ca2+-stimulated autophosphorylation on the interaction with calmodulin, the equilibrium binding constants of CCaMK were measured by fluorescence emission anisotropy using dansylated calmodulin. Binding was 8-fold tighter after Ca2+-stimulated autophosphorylation. This shift in affinity did not occur in CCaMK deletion mutants lacking Ca2+-stimulated autophosphorylation. A variable calmodulin affinity regulated by Ca2+-stimulated autophosphorylation mediated through the visinin-like domain is a new regulatory mechanism for CCaMK activation and calmodulin-dependent protein kinases. Our experiments demonstrate the existence of two functional molecular switches in a protein kinase regulating the kinase activity, namely a visinin-like domain acting as a Ca2+-triggered switch and a CaM-binding domain acting as an autophosphorylation-triggered molecular switch.	Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA; Univ Nevada, Sch Med, Dept Biochem, Reno, NV 89557 USA; Univ Nevada, Sch Agr, Reno, NV 89557 USA	Washington State University; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Poovaiah, BW (corresponding author), Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; Kobayashi M, 1998, Tanpakushitsu Kakusan Koso, V43, P1681; Lu YT, 1996, PLANTA, V199, P18; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Wang WY, 1999, J BIOL CHEM, V274, P12001, DOI 10.1074/jbc.274.17.12001; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	26	54	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30417	30422		10.1074/jbc.M000771200	http://dx.doi.org/10.1074/jbc.M000771200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10840028	hybrid			2022-12-27	WOS:000089577900068
J	Albrecht, C; von der Kammer, H; Mayhaus, M; Klaudiny, J; Schweizer, M; Nitsch, RM				Albrecht, C; von der Kammer, H; Mayhaus, M; Klaudiny, J; Schweizer, M; Nitsch, RM			Muscarinic acetylcholine receptors induce the expression of the immediate early growth regulatory gene CYR61	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-COUPLED RECEPTORS; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; CHOLINERGIC INNERVATION; EXTRACELLULAR-MATRIX; INTEGRIN ALPHA(V)BETA(3); DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; DEPENDENT ACTIVATION	In brain, muscarinic acetylcholine receptors (mAChRs) modulate neuronal functions including long term potentiation and synaptic plasticity in neuronal circuits that are involved in learning and memory formation. To identify mAChR-inducible genes, we used a differential display approach and found that mAChRs rapidly induced transcription of the immediate early gene CYR61 in HEK 293 cells with a maximum expression after 1 h of receptor stimulation. CYR61 is a member of the emerging CCN gene family that includes CYR61/CEF10, CTGF/FISP-12, and NOV; these encode secretory growth regulatory proteins with distinct functions in cell proliferation, migration, adhesion, and survival. We found that CYR61, CTGF, and NOV were expressed throughout the human central nervous system. Stimulation of mAChRs induced CYR61 expression in primary neurons and rat brain where CYR61 mRNA was detected in cortical layers V and VI and in thalamic nuclei. In contrast, CTGF and NOV expression was not altered by mAChRs neither in neuronal tissue culture nor rat brain. Receptor subtype analyses demonstrated that mi and m3 mAChR subtypes strongly induced CYR61 expression, whereas m2 and m4 mAChRs had only subtle effects. Increased CYR61 expression was coupled to mAChRs by both protein kinase C and elevations of intracellular Ca2+. Our results establish that CYR61 expression in mammalian brain is under the control of cholinergic neurotransmission; it may thus be involved in cholinergic regulation of synaptic plasticity.	Univ Zurich, Dept Psychiat Res, CH-8008 Zurich, Switzerland; Slovak Acad Sci, Inst Chem, Bratislava 84238, Slovakia; Univ Hamburg, Ctr Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Zurich; Slovak Academy of Sciences; University of Hamburg	Nitsch, RM (corresponding author), Univ Zurich, Dept Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.	nitsch@bli.unizh.ch	Klaudiny, Jaroslav/AAZ-8814-2021	Klaudiny, Jaroslav/0000-0003-0482-1212				ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRANN MR, 1993, PROG BRAIN RES, V98, P121; Brown DA, 1997, LIFE SCI, V60, P1137, DOI 10.1016/S0024-3205(97)00058-1; Chevalier G, 1998, AM J PATHOL, V152, P1563; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; Coso OA, 1996, J BIOL CHEM, V271, P3963; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; Ding WQ, 1998, J NEUROCHEM, V70, P1722; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Guillery RW, 1995, J ANAT, V187, P583; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; HUGHES P, 1994, MOL BRAIN RES, V24, P166, DOI 10.1016/0169-328X(94)90129-5; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kondo Y, 1999, BRAIN RES, V834, P146, DOI 10.1016/S0006-8993(99)01517-6; KRNJEVIC K, 1993, PROG BRAIN RES, V98, P285; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEHRACH H., 1990, GENOME ANAL, P39; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Levey AI, 1996, P NATL ACAD SCI USA, V93, P13541, DOI 10.1073/pnas.93.24.13541; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYNFORD G, 1995, NEURON, V14, P433; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OIAN Z, 1993, NATURE, V361, P453; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; Scholz G, 1996, MOL CELL BIOL, V16, P481; SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063; SEMBA K, 1989, PROG BRAIN RES, V79, P37; Staubli U, 1998, J NEUROSCI, V18, P3460; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; von der Kammer H, 1999, NUCLEIC ACIDS RES, V27, P2211, DOI 10.1093/nar/27.10.2211; von der Kammer H, 1998, J BIOL CHEM, V273, P14538, DOI 10.1074/jbc.273.23.14538; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; Xin LW, 1996, J CLIN PATHOL-CL MOL, V49, pM91; Yamagata K, 1999, J BIOL CHEM, V274, P19473, DOI 10.1074/jbc.274.27.19473; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	78	56	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28929	28936		10.1074/jbc.M003053200	http://dx.doi.org/10.1074/jbc.M003053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852911	hybrid			2022-12-27	WOS:000089330700078
J	Cheesman, EJ; Sharp, RJ; Zlot, CH; Liu, CYY; Taylor, S; Marcovina, SM; Young, SG; McCormick, SPA				Cheesman, EJ; Sharp, RJ; Zlot, CH; Liu, CYY; Taylor, S; Marcovina, SM; Young, SG; McCormick, SPA			An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); LOW-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; B GENE; BINDING; CONSERVATION; MUTAGENESIS; SEQUENCES; DOMAINS; CLONING	The assembly of lipoprotein(a) (Lp(a)) involves an initial noncovalent interaction between apolipoprotein (apo) B100 and apo(a), followed by the formation of a disulfide bond between apoB100 cysteine 4326 and apo(a) cysteine 4057, The structural features of apoB100 that are required for its noncovalent interaction with apo(a) have not been fully defined. To analyze that initial interaction, me tested whether apo(a) could bind noncovalently to two apoB proteins that lack cysteine 4326: mouse apoB100 and human apoB100-C4326G. Our experiments demonstrated that both mouse apoB and the human apoB100-C4326G bind noncovalently to apo(a), We next sought to gain insights into the apoB amino acid sequences required for the interaction between apoB100 and apo(a). Previous studies of truncated human apoB proteins indicated that the carboxyl terminus of human apoB100 (amino acids 4330-4397) is important for Lp(a) assembly. To determine whether the carboxyl terminus of mouse apoB100 can interact with apo(a), transgenic mice were produced with a mutant human apoB gene construct in which human apoB100 amino acids 4279-4536 were replaced with the corresponding mouse apoB100 sequences and tyrosine 4326 was changed to a cysteine. The mutant apoB100 bound to apo(a) and formed bona fide disulfide-linked Lp(a), but Lp(a) assembly was less efficient than with wildtype human apoB100, The fact that Lp(a) assembly was less efficient with the mouse apoB sequences provides additional support for the notion that sequences in the carboxyl terminus of apoB100 are important for Lp(a) assembly.	Univ Otago, Dept Biochem, Dunedin 9001, New Zealand; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Washington, Dept Med, NW Lipid Res Labs, Seattle, WA 98103 USA	University of Otago; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	McCormick, SPA (corresponding author), Univ Otago, Dept Biochem, POB 56, Dunedin 9001, New Zealand.	sally.mccormick@stonebow.otago.ac.nz		McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; Chauhan V, 1998, BIOCHEMISTRY-US, V37, P3735, DOI 10.1021/bi9718853; CHIESA G, 1992, J BIOL CHEM, V267, P24369; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Frank S, 1996, EUR J CLIN INVEST, V26, P109, DOI 10.1046/j.1365-2362.1996.112255.x; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1995, J BIOL CHEM, V270, P24004, DOI 10.1074/jbc.270.41.24004; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MANCINI FP, 1995, ATHEROSCLEROSIS, V10, P884; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; McCormick SPA, 1997, J BIOL CHEM, V272, P23616, DOI 10.1074/jbc.272.38.23616; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Segrest JP, 1998, J LIPID RES, V39, P85; Sharp RJ, 1999, CIRCULATION, V100, P109; TRIEU VN, 1995, BIOCHEM J, V307, P17, DOI 10.1042/bj3070017; TRIEU VN, 1995, BIOCHEM J, V309, P899, DOI 10.1042/bj3090899; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28195	28200						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837476				2022-12-27	WOS:000089197100088
J	Cho, KH; Jonas, A				Cho, KH; Jonas, A			A key point mutation (V156E) affects the structure and functions of human apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HIGH-DENSITY-LIPOPROTEIN; PHOSPHOLIPID-BINDING; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; ACTIVATION; PROTEIN; MUTANTS; DISKS; PHOSPHATIDYLCHOLINE	A naturally occurring point mutant of human apolipoprotein A-I (apoA-I), V156E, which is associated with extremely low plasma apoA-I and high density lipoprotein (HDL) levels, and coronary artery disease (Huang, W., Sasaki, J., Matsunaga, A., Nanimatsu, Il., Moriyama, K., Hen, H. Kugi, M., Koga, T., Yamaguchi, K., and Arakawa, K. (1998) Arterioscler. Throm. Vase. Biol. 18, 389-396), was produced in an Escherichia coli expression system. The purified recombinant proapoA-I V156E mutant was examined in its structural and functional properties, both, in the lipid-free and lipid-bound states. In the lipid-free form the mutant protein exhibited small changes in conformation, but was more stable, and quite resistant to self-association, compared with control apoA-I. The V156E mutant was able to interact with phospholipid (PL) at high PL:protein ratios (95:1, mol/mol), but was inefficient in forming reconstituted HDL (rHDL) complexes at lower PL:protein ratios (40:1). In the lipid-bound, rHDL state, the mutant protein was somewhat more alpha-helical and formed a larger complex (110 Angstrom) than control apoA-I (97 Angstrom). Furthermore, the rHDL particles containing the V156E mutant did not rearrange to smaller particles in the presence of low density lipoproteins, and had minimal reactivity with lecithin-cholesterol acyltransferase (LCAT), compared with rHDL particles made with control apoA-I. These results suggest a key role for Val-156, or the adjacent central region of apoA-I in the modulation of apoA-I conformation, stability, and self-association in solution, and in the formation of small HDL, the conformational adaptability of apoA-I leading to structural rearrangements of HDL, and the activation of LCAT.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Jonas, A (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 506 S Mathews Ave, Urbana, IL 61801 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939, R01HL016059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16059, HL 29939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4586, DOI 10.1021/bi00839a053; BARBEAU DL, 1979, BIOCHEMISTRY-US, V18, P362, DOI 10.1021/bi00569a021; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; BURKYBILEKOSEK A, 1999, BIOCHEM BIOPH RES CO, V258, P548; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Durbin DM, 1999, J LIPID RES, V40, P2293; FIELDING CJ, 1995, J LIPID RES, V36, P211; HEIDER JG, 1978, J LIPID RES, V19, P514; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Huang W, 1998, ARTERIOSCL THROM VAS, V18, P389, DOI 10.1161/01.ATV.18.3.389; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Jin LH, 1997, J LIPID RES, V38, P1085; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; LEROY A, 1994, BBA-LIPID LIPID MET, V1212, P285, DOI 10.1016/0005-2760(94)90202-X; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; McGuire KA, 1996, J LIPID RES, V37, P1519; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; RYE KA, 1992, J LIPID RES, V33, P215; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Xu SZ, 1997, J LIPID RES, V38, P1289; ZORICH N, 1985, J BIOL CHEM, V260, P8831	43	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26821	26827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858436				2022-12-27	WOS:000089144800023
J	Ghayor, C; Herrouin, JF; Chadjichristos, C; Ala-Kokko, L; Takigawa, M; Pujol, JP; Galera, P				Ghayor, C; Herrouin, JF; Chadjichristos, C; Ala-Kokko, L; Takigawa, M; Pujol, JP; Galera, P			Regulation of human COL2A1 gene expression in chondrocytes - Identification of C-Krox-responsive elements and modulation by phenotype alteration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(II) COLLAGEN GENE; TISSUE-SPECIFIC EXPRESSION; RABBIT ARTICULAR CHONDROCYTES; CHONDROSARCOMA CELL-LINE; TRANSCRIPTION FACTOR SP1; II COLLAGEN; TRANSGENIC MICE; ACTIVATES TRANSCRIPTION; PROCOLLAGEN GENE; MAMMALIAN-CELLS	To identify control motifs involved in human type II collagen gene transcription in both differentiated and dedifferentiated rabbit articular chondrocytes, transient transfection experiments were performed, A 715-base pair (bp) region of the first intron (+2127/+2842), including a 153-bp sequence so far uncharacterized (+2689/+2842), was found to mediate enhancer activity. In dedifferentiated chondrocytes, this enhancer activity was shown to be less effective than in primary cultures but still present. We then demonstrated that a zinc finger protein, C-Krox, activates COL2A1 gene transcription in differentiated chondrocytes through the enhancer region, whereas in subcultured cells, it inhibited the gene activity via a 266-bp promoter. Multicopies of the C-Krox binding site were found to mediate transactivation in both primary cultures and passaged cells, whereas C-Krox overexpression inhibited transcription in dedifferentiated chondrocytes. Additionally, we showed that C-Krox binds to several cis sequences that mediate its transcriptional effects. During chondrocyte dedifferentiation, the protein levels and binding activity of C-Krox were reduced, whereas those of NF-KB were increased. This was not associated with variations of mRNA levels, suggesting that post-transcriptional regulatory mechanisms could be involved in C-Krox expression. These results suggest that C-Krox plays a major role in type II collagen expression and the chondrocyte phenotype modulation.	CHU Caen, Fac Med, Lab Biochim Tissu Conjonctif, F-14032 Caen, France; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 700, Japan	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Oulu; University of Oulu; Okayama University	Galera, P (corresponding author), CHU Caen, Fac Med, Lab Biochim Tissu Conjonctif, Ave Cote Nacre, F-14032 Caen, France.		Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Ghayor, Chafik/0000-0002-3016-3412				Adolphe, 1992, BIOL REGULATION CHON, P33; ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER CW, 1990, J CELL SCI, V97, P361; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1986, DEV BIOL, V118, P296, DOI 10.1016/0012-1606(86)90096-5; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Boumediene K, 1998, EXP CELL RES, V243, P173, DOI 10.1006/excr.1998.4129; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P104; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P153; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLWASSER M, 1982, CLIN ORTHOP RELAT R, V167, P296; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; KUETTNER KE, 1982, J CELL BIOL, V93, P751, DOI 10.1083/jcb.93.3.751; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; NIMNI M, 1973, SCIENCE, V181, P751, DOI 10.1126/science.181.4101.751; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SEGHATOLESLAMI MR, 1994, MATRIX BIOL, V14, P753; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TAKIGAWA M, 1989, CANCER RES, V49, P3996; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WANG LQ, 1991, J BIOL CHEM, V266, P19878; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	59	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27421	27438						18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856292				2022-12-27	WOS:000089144800101
J	Humphreys, BD; Rice, J; Kertesy, SB; Dubyak, GR				Humphreys, BD; Rice, J; Kertesy, SB; Dubyak, GR			Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; EXTRACELLULAR ATP; MEDIATED ACTIVATION; P2X(7) RECEPTOR; CELL-DEATH; KAPPA-B; SIGNAL-TRANSDUCTION; POTASSIUM-DEPLETION; P2Z PURINORECEPTOR	In human and rodent macrophages, activation of the P2X7 nucleotide receptor stimulates interleukin-1 beta processing and release, apoptosis, and killing of intracellular Mycobacterium tuberculosis. Signaling pathways downstream of this ionotropic ATP receptor are poorly understood Here we describe the rapid activation of the stress-activated protein kinase (SAPK)/JNK pathway in BAC1 murine macrophages stimulated by extracellular ATP, Brief exposure of the cells to ATP (10-30 min) was sufficient to trigger a rapid accumulation of activated SAPK that was then sustained for >120 min. Several observations indicated that the P2X7 receptor mediated this effect. 1) ATP and 3'-O-(4-benzoyl)benzoyl-ATP were the only agonistic nucleotides, 2) The effect was inhibited by oxidized ATP and the isoquinoline KN-62, two known P2X7 receptor antagonists. 3) ATP-induced SAPK activation could be recapitulated in P2X7 receptor-transfected HEK293 cells, but not in wild-type HEK293 cells. Because P2X7 receptor stimulation can rapidly activate caspase family proteases that have been implicated in the induction of the SAPK pathway, we investigated whether ATP-dependent SAPK activation involved such proteases, Brief exposure of BAC1 macrophages to extracellular ATP induced DNA fragmentation, alpha-fodrin breakdown, and elevated levels of caspase-3-type activity. Asp-Glu-Val-Asp-cho a caspase-3 inhibitor, inhibited ATP-induced DNA fragmentation and alpha-fodrin proteolysis, but had no effect on ATP-induced SAPK activation. Tyr-Val-Ala-Asp-chloromethyl ketone, a caspase-1 inhibitor, prevented ATP-induced release of processed interleukin-1 beta, but not ATP-dependent SAPK activity. We conclude that activation of ionotropic P2X7 nucleotide receptors triggers a strong activation of SAPK via a pathway independent of caspase-1- or caspase-3-like proteases.	Case Western Reserve Univ, Sch Med E565, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Dubyak, GR (corresponding author), Case Western Reserve Univ, Sch Med E565, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.			Barclay, Janet/0000-0003-1643-6901; Dubyak, George/0000-0001-9720-4226	NIGMS NIH HHS [GM36387, GM07250-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD DK, 1995, J CELL BIOCHEM, V57, P452, DOI 10.1002/jcb.240570311; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; HKAKH BS, 1999, NAT NEUROSCI, V2, P322; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; Kuroki DW, 1996, CANCER RES, V56, P637; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC755, DOI 10.1152/ajpcell.1999.277.4.C755; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Schulze-Lohoff E, 1998, AM J PHYSIOL-RENAL, V275, pF962, DOI 10.1152/ajprenal.1998.275.6.F962; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Sikora A, 1999, J IMMUNOL, V163, P558; Solini A, 1999, J CELL SCI, V112, P297; Surprenant A, 1996, CIBA F SYMP, V198, P208; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Warny M, 1999, AM J PHYSIOL-CELL PH, V276, pC717, DOI 10.1152/ajpcell.1999.276.3.C717; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	57	181	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26792	26798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854431				2022-12-27	WOS:000089144800019
J	Allard, B; Couble, ML; Magloire, H; Bleicher, F				Allard, B; Couble, ML; Magloire, H; Bleicher, F			Characterization and gene expression of high conductance calcium-activated potassium channels displaying mechanosensitivity in human odontoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; RAT; PULP; PHARMACOLOGY; ISOFORMS; CLONING; NERVES; TEETH; GERM; CAT	Odontoblasts form a layer of cells responsible for the dentin formation and possibly mediate early stages of sensory processing in teeth. Several classes of ion channels have previously been identified in the odontoblast or pulp cell membrane, and it is suspected that these channels assist in these events. This study was carried out to characterize the K-Ca channels on odontoblasts fully differentiated in vitro using the patch clamp technique and to investigate the HSLO gene expression encoding the alpha-subunit of these channels on odontoblasts in vivo. In inside-out patches, K-Ca channels were identified on the basis of their K+ selectivity, conductance, voltage, and Ca2+ dependence. In cell-attached patches, these channels were found to be activated by application of a negative pressure as well as an osmotic shock, By reverse transcription-polymerase chain reaction, a probe complementary to K-Ca alpha-subunit mRNA was constructed and used for in situ hybridization on human dental pulp samples. Transcripts were expressed in the odontoblast layer. The use of antibodies showed that the K-Ca channels were preferentially detected at the apical pole of the odontoblasts. These channels could be involved in mineralization processes. Their mechanosensitivity suggests that the fluid displacement within dentinal tubules could be transduced into electrical cell signals.	Fac Odontol, Lab Dev Tissus Dentaires, F-69372 Lyon 08, France; Univ Lyon 1, UMR CNRS 5578, Lab Physiol Elements Excitables, F-69622 Villeurbanne, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Magloire, H (corresponding author), Fac Odontol, Lab Dev Tissus Dentaires, Rue G Paradin,EA 1892, F-69372 Lyon 08, France.	magloire@laennec.univ-lyon1.fr						ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833; DAVIDSON RM, 1994, ARCH ORAL BIOL, V39, P613, DOI 10.1016/0003-9969(94)90137-6; DAVIDSON RM, 1990, PFLUG ARCH EUR J PHY, V416, P646, DOI 10.1007/BF00370609; DONG WK, 1985, BRAIN RES, V334, P389, DOI 10.1016/0006-8993(85)90239-2; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; Guo L, 1999, J BONE MINER RES, V14, P1357, DOI 10.1359/jbmr.1999.14.8.1357; Guo L, 1998, J DENT RES, V77, P341, DOI 10.1177/00220345980770020201; HILDEBRAND C, 1995, PROG NEUROBIOL, V45, P165, DOI 10.1016/0301-0082(94)00045-J; Ibuki T, 1996, J DENT RES, V75, P1963, DOI 10.1177/00220345960750120801; JYVASJARVI E, 1989, J PHYSIOL-LONDON, V411, P663, DOI 10.1113/jphysiol.1989.sp017597; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; Mallouk N, 2000, AM J PHYSIOL-CELL PH, V278, pC473, DOI 10.1152/ajpcell.2000.278.3.C473; MARKOWITZ K, 1991, ARCH ORAL BIOL, V36, P1, DOI 10.1016/0003-9969(91)90047-X; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; Mienville JM, 1996, J MEMBRANE BIOL, V153, P211, DOI 10.1007/s002329900124; PACHA J, 1991, AM J PHYSIOL, V261, pF696, DOI 10.1152/ajprenal.1991.261.4.F696; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; SEUX D, 1994, ARCH ORAL BIOL, V39, P167, DOI 10.1016/0003-9969(94)90113-9; Shibukawa Yoshiyuki, 1997, Bulletin of Tokyo Dental College, V38, P177; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185	30	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25556	25561		10.1074/jbc.M002327200	http://dx.doi.org/10.1074/jbc.M002327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840032	hybrid			2022-12-27	WOS:000088849400068
J	Bittner, MA; Holz, RW				Bittner, MA; Holz, RW			Latrotoxin stimulates secretion in permeabilized cells by regulating an intracellular Ca2+- and ATP-dependent event - A role for protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; CALCIUM-INDEPENDENT RECEPTOR; ALPHA-LATROTOXIN; QUANTAL SECRETION; COUPLED RECEPTOR; BINDING-PROTEIN; EXOCYTOSIS; TOXIN	alpha-latrotoxin, a component of black widow spider venom, stimulates transmitter release from nerve terminals and intact chromaffin cells and enhances secretion from permeabilized chromaffin cells already maximally stimulated by Ca2+. In this study we demonstrate that chromaffin cells contain a protein antigenically similar to the cloned Ca2+-independent receptor for alpha-latrotoxin. Although this receptor has homology to the secretin family of G-protein-linked receptors, pertussis toxin has no effect on the ability of alpha-latrotoxin to enhance secretion, suggesting that neither G(i) nor G(o) is involved in the response. Furthermore, in the absence of Ca2+, alpha-latrotoxin does not stimulate polyphosphoinositide-specific phospholipase C. alpha-Latrotoxin specifically enhances ATP-dependent secretion in permeabilized cells. An in situ assay for protein kinase C reveals that alpha-latrotoxin augments the activation of protein kinase C by Ca2+, and use of protein kinase inhibitors demonstrates that this activation is important for the toxin's enhancing effect. This enhancement of secretion requires Ca2+ concentrations above 3 mu M and is not supported by Ba2+ or nonhydrolyzable guanine nucleotides, which do not stimulate protein kinase C, We conclude that cu-latrotoxin stimulates secretion in permeabilized cells by regulating a Ca2+- and ATP-dependent event involving protein kinase C.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bittner, MA (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, M 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; FESCE R, 1986, J GEN PHYSIOL, V88, P59, DOI 10.1085/jgp.88.1.59; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, J NEUROSCI, V18, P6113; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PUMPLIN DW, 1977, J PHYSIOL-LONDON, V273, P443, DOI 10.1113/jphysiol.1977.sp012103; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; SURKOVA I, 1994, ANN NY ACAD SCI, V710, P48, DOI 10.1111/j.1749-6632.1994.tb26613.x; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1992, J NEUROCHEM, V58, P680, DOI 10.1111/j.1471-4159.1992.tb09771.x; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	37	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25351	25357		10.1074/jbc.M004884200	http://dx.doi.org/10.1074/jbc.M004884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851245	hybrid			2022-12-27	WOS:000088849400042
J	Feng, LX; Ravindranath, N; Dym, M				Feng, LX; Ravindranath, N; Dym, M			Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT; PHOSPHATIDYLINOSITOL 3-KINASE; A SPERMATOGONIA; D1 EXPRESSION; GROWTH-FACTOR; GERM-CELLS; MOUSE; ACTIVATION; RECEPTOR; TESTIS	Stem cell factor (SCF)/c-kit plays an important role in the regulation of hematopoiesis, melanogenesis, and spermatogenesis, In the testis, the SCF/c-kit system is believed to regulate germ cell proliferation, meiosis, and apoptosis, Studies with type A spermatogonia in vivo and in vitro have indicated that SCF induces DNA synthesis and proliferation. However, the signaling pathway for this function of SCF/c-kit has not been elucidated. We now demonstrate that SCF activates phosphoinositide 3-kinase (P13-K) and p70 S6 kinase (p70S6K) and that rapamycin, a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K, completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia, SCF induced cyclin D3 expression and phosphorylation of the retinoblastoma protein through a pathway that is sensitive to both wortmannin and rapamycin, Furthermore, AKT, but not protein kinase C-zeta is used by SCF/c-kit/P13-K to activate p70S6K, Dominant negative AKT-K179M: completely abolished p70S6K phosphorylation induced by the constitutively active P13-K catalytic subunit p110, Constitutively active v-AKT highly phosphorylated p70S6K, which was totally inhibited by rapamycin, Thus, SCF/c-kit uses a rapamycin-sensitive P13-K/AKT/p70S6K/cyclin D3 pathway to promote spermatogonial cell proliferation.	Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University	Dym, M (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	dymm@gunet.georgetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; DIRAMI G, 1996, ERNST SCHERING RES F, P141; DYM M, 1995, BIOL REPROD, V52, P8, DOI 10.1095/biolreprod52.1.8; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; DYM M, 1983, HISTOLOGY CELL TISSU; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grewe M, 1999, CANCER RES, V59, P3581; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li H, 1997, ENDOCRINOLOGY, V138, P1289, DOI 10.1210/en.138.3.1289; Loveland KL, 1997, J ENDOCRINOL, V153, P337, DOI 10.1677/joe.0.1530337; Mauduit C, 1999, HUM REPROD UPDATE, V5, P535, DOI 10.1093/humupd/5.5.535; Orth JM, 1997, BIOL REPROD, V57, P676, DOI 10.1095/biolreprod57.3.676; PACKER AI, 1995, MOL REPROD DEV, V42, P303, DOI 10.1002/mrd.1080420307; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; TAJIMA Y, 1991, J REPROD FERTIL, V91, P441, DOI 10.1530/jrf.0.0910441; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Vincent S, 1998, DEVELOPMENT, V125, P4585; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zhang Q, 1999, ENDOCRINOLOGY, V140, P2790, DOI 10.1210/en.140.6.2790	27	189	216	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25572	25576		10.1074/jbc.M002218200	http://dx.doi.org/10.1074/jbc.M002218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10849422	hybrid			2022-12-27	WOS:000088849400070
J	Rogalski, SL; Appleyard, SM; Pattillo, A; Terman, GW; Chavkin, C				Rogalski, SL; Appleyard, SM; Pattillo, A; Terman, GW; Chavkin, C			TrkB activation by brain-derived neurotrophic factor inhibits the G protein-gated inward rectifier Kir3 by tyrosine phosphorylation of the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; POTASSIUM CHANNEL; XENOPUS OOCYTES; K+-CHANNEL; HIPPOCAMPAL-NEURONS; OPIOID RECEPTORS; KINASE; CURRENTS; SUPPRESSION; CLONING	protein-activated inwardly rectifying potassium channels (Kir3) are widely expressed throughout the brain, and regulation of their activity modifies neuronal excitability and synaptic transmission. In this study, we show that the neurotrophin brain-derived neurotrophic factor (BDNF), through activation of TrkB receptors, strongly inhibited the basal activity of Kir3, This inhibition was subunit dependent as functional homomeric channels of either Kir3.1 or Kir3.4 were significantly inhibited, whereas homomeric channels composed of Kir3.2 were insensitive. The general tyrosine kinase inhibitors genistein, GS 6976, and K252a but not the serine/threonine kinase inhibitor staurosporine blocked the BDNF-induced inhibition of the channel. BDNF was also found to directly stimulate channel phosphorylation because Kir3.1 immunoprecipitated from BDNF-stimulated cells showed enhanced labeling by anti-phosphotyrosine-specific antibodies. The BDNF effect required specific tyrosine residues in the amino terminus of Kir3.1 and Kir3.4 channels. Mutations of either Tyr-12, Tyr-67, or both in Kir3.1 or mutation of either Tyr-32, Tyr-53, or both of Kir3.4 channels to phenylalanine significantly blocked the BDNF-induced inhibition. The insensitive Kir3.2 was made sensitive to BDNF by adding a tyrosine (D41Y) and a lysine (P32R) upstream to generate a phosphorylation site motif analogous to that present in Kir3.4, These results suggest that neurotrophin activation of TrkB receptors may physiologically control neuronal excitability by direct tyrosine phosphorylation of the Kir3.1 and Kir3.4 subunits of G protein-gated inwardly rectifying potassium channels.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672, R01 DA011672, DA11672] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; Behrens MM, 1999, J NEUROCHEM, V72, P919, DOI 10.1046/j.1471-4159.1999.0720919.x; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Chauhan-Patel R, 1998, J PHYSIOL-LONDON, V512, P109, DOI 10.1111/j.1469-7793.1998.109bf.x; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Desai NS, 1999, LEARN MEMORY, V6, P284; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; Hilborn MD, 1998, J NEUROSCI, V18, P590; Holmes TC, 1996, J NEUROSCI, V16, P1581; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Iwasaki Y, 1998, J NEUROCHEM, V71, P106; Jonas EA, 1996, J NEUROSCI, V16, P1645; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kerr BJ, 1999, J NEUROSCI, V19, P5138; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; Sadick MD, 1997, EXP CELL RES, V234, P354, DOI 10.1006/excr.1997.3614; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TIMPE LC, 1994, J NEUROSCI, V14, P1195, DOI 10.1523/JNEUROSCI.14-03-01195.1994; UEDA H, 1994, NEUROREPORT, V5, P1985, DOI 10.1097/00001756-199410000-00037; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	43	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25082	25088		10.1074/jbc.M000183200	http://dx.doi.org/10.1074/jbc.M000183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833508	Green Accepted, hybrid			2022-12-27	WOS:000088849400007
J	Sohlenkamp, C; de Rudder, KEE; Rohrs, V; Lopez-Lara, IM; Geiger, O				Sohlenkamp, C; de Rudder, KEE; Rohrs, V; Lopez-Lara, IM; Geiger, O			Cloning and characterization of the gene for phosphatidylcholine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PHOSPHATIDYLSERINE SYNTHASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; RHIZOBIUM-MELILOTI; ESCHERICHIA-COLI; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; RHODOBACTER-SPHAEROIDES; SINORHIZOBIUM-MELILOTI; EXPRESSION; MUTAGENESIS	Phosphatidylcholine (PC) is the major membrane-forming phospholipid in eukaryotes and can be synthesized by either of two pathways, the CDP-choline pathway or the methylation pathway. In prokaryotes only the methylation pathway was thought to occur. Recently, however, we could demonstrate (de Rudder, K. E. E., Sohlenkamp, C., and Geiger, O. (1999) J. Biol. Chem. 274, 20011-20016) that a second pathway for phosphatidylcholine biosynthesis exists in Sinorhizobium (Rhizobium) meliloti involving a novel enzymatic activity, phosphatidylcholine synthase, that condenses choline and CDP-diacylglyceride in one step to form PC and CMP, Using a colony autoradiography method we have isolated mutants of S. meliloti deficient in phosphatidylcholine synthase and which are no longer able to incorporate radiolabeled choline into PC. Complementation of such mutants with a sinorhizobial cosmid gene bank, subcloning of the complementing fragment, and sequencing of the subclone led to the identification of a gene coding for a presumptive CDP-alcohol phosphatidyltransferase, Amplification of this gene and its expression in Escherichia coli demonstrates that it codes for phosphatidylcholine synthase, Genomes of some pathogens (Pseudomonas aeruginosa and Borrelia burgdorferi) contain genes similar to the sinorhizobial gene (pcs) for phosphatidylcholine synthase, Although pcs-deficient S. meliloti knock-out mutants show wild type-like growth and lipid composition, they are unable to perform rapid PC biosynthesis that normally is achieved via the phosphatidylcholine synthase pathway in S. meliloti wild type.	Univ Nacl Autonoma Mexico, Ctr Invest Fijac Nitrogeno, Cuernavaca 62210, Morelos, Mexico; Tech Univ Berlin, Inst Biotechnol, D-13353 Berlin, Germany	Universidad Nacional Autonoma de Mexico; Technical University of Berlin	Geiger, O (corresponding author), Univ Nacl Autonoma Mexico, Ctr Invest Fijac Nitrogeno, Apdo Postal 565-A, Cuernavaca 62210, Morelos, Mexico.		Geiger, Otto/F-6356-2019; Sohlenkamp, Christian/C-6219-2018; Lopez-Lara, Isabel/E-3153-2016	Geiger, Otto/0000-0002-7794-1568; Sohlenkamp, Christian/0000-0002-9962-2859; Lopez-Lara, Isabel/0000-0002-5066-3158				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; de Rudder KEE, 1999, J BIOL CHEM, V274, P20011, DOI 10.1074/jbc.274.28.20011; deRudder KEE, 1997, J BACTERIOL, V179, P6921, DOI 10.1128/jb.179.22.6921-6928.1997; DEWEY RE, 1994, PLANT CELL, V6, P1495, DOI 10.1105/tpc.6.10.1495; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; Dryden SC, 1996, J BACTERIOL, V178, P1030, DOI 10.1128/jb.178.4.1030-1038.1996; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FINAN TM, 1984, J BACTERIOL, V159, P120, DOI 10.1128/JB.159.1.120-124.1984; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Ge ZM, 1997, J BACTERIOL, V179, P4970, DOI 10.1128/jb.179.16.4970-4976.1997; Geiger O, 1999, MOL MICROBIOL, V32, P63, DOI 10.1046/j.1365-2958.1999.01325.x; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; Hofmann M, 1996, J BACTERIOL, V178, P6140, DOI 10.1128/jb.178.21.6140-6144.1996; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; Osteras M, 1998, P NATL ACAD SCI USA, V95, P11394, DOI 10.1073/pnas.95.19.11394; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; RUVKUN GB, 1981, NATURE, V289, P85, DOI 10.1038/289085a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; Spaink HP, 1998, MOL BIOL MODEL PLANT; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THONYMEYER L, 1999, BIOSPEKTRUM, V5, P185; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	59	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18919	18925		10.1074/jbc.M000844200	http://dx.doi.org/10.1074/jbc.M000844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858449	hybrid			2022-12-27	WOS:000087815900042
J	Illerhaus, J; Altschmied, L; Reichert, J; Zak, E; Herrmann, RG; Haehnel, W				Illerhaus, J; Altschmied, L; Reichert, J; Zak, E; Herrmann, RG; Haehnel, W			Dynamic interaction of plastocyanin with the cytochrome bf complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOTOSYSTEM-I; SPINACH PLASTOCYANIN; CRYSTAL-STRUCTURE; CROSS-LINKING; BC(1) COMPLEX; BINDING; DOMAIN; SITE; IDENTIFICATION	The interaction between plastocyanin and the intact cytochrome bf complex, both from spinach, has been studied by stopped-flow kinetics with mutant plastocyanin to elucidate the site of electron transfer and the docking regions of the molecule. Mutation of Tyr-83 to Arg or Leu provides no evidence for a second electron transfer path via Tyr-83 of plastocyanin, which has been proposed to be the site of electron transfer from cytochrome f, The data found with mutations of acidic residues indicate that both conserved negative patches are essential for the binding of plastocyanin to the intact cytochrome bf complex. Replacing Ala-90 and Gly-10 at the flat hydrophobic surface of plastocyanin by larger residues slowed down and accelerated, respectively, the rate of electron transfer as compared with wild-type plastocyanin, These opposing effects reveal that the hydrophobic region around the electron transfer site at His-87 is divided up into two regions, of which only that with Ala-90 contributes to the attachment to the cytochrome bf complex. These binding sites of plastocyanin are substantially different from those interacting with photosystem I. It appears that each of the two binding regions of plastocyanin is split into halves, which are used in different combinations in the molecular recognition at the two membrane complexes.	Univ Freiburg, Inst Biol Biochem 2, D-79104 Freiburg, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany	University of Freiburg; University of Munich	Haehnel, W (corresponding author), Univ Freiburg, Inst Biol Biochem 2, Schanzlestr 1, D-79104 Freiburg, Germany.	haehnel@uni-freiburg.de	Reichert, Jan/AAE-6609-2019	Reichert, Jan/0000-0002-6020-6049; Altschmied, Lothar/0000-0002-7692-2971				ANDERSON GP, 1987, BIOCHIM BIOPHYS ACTA, V894, P386, DOI 10.1016/0005-2728(87)90117-4; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; BENDALL DS, 1999, PHOTOTROPHIC PROKARY, P315; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BLACK MT, 1987, ARCH BIOCHEM BIOPHYS, V252, P655, DOI 10.1016/0003-9861(87)90071-3; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CHRISTENSEN HEM, 1992, BIOCHIM BIOPHYS ACTA, V1099, P35, DOI 10.1016/0304-4173(92)90005-Y; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; DUTTON PL, 1974, BIOCHIM BIOPHYS ACTA, V346, P165, DOI 10.1016/0304-4173(74)90008-1; FARVER O, 1981, P NATL ACAD SCI-BIOL, V78, P4190, DOI 10.1073/pnas.78.7.4190; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; GROSS EL, 1991, BIOCHIM BIOPHYS ACTA, V1056, P166, DOI 10.1016/S0005-2728(05)80283-X; GUSS JM, 1983, J MOL BIOL, V169, P521; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; Hibino T, 1996, J BIOCHEM-TOKYO, V120, P556; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; ILLERHAUS J, 1998, THESIS U FREIBURG FR; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; LEE BH, 1995, J BIOCHEM, V117, P1209; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Metzger SU, 1997, BBA-BIOENERGETICS, V1319, P233, DOI 10.1016/S0005-2728(96)00164-8; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1102, P85, DOI 10.1016/0005-2728(92)90068-D; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1101, P64, DOI 10.1016/0167-4838(92)90467-R; MOSS DA, 1990, EUR J BIOCHEM, V117, P591; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; PENFIELD KW, 1985, J AM CHEM SOC, V107, P4519, DOI 10.1021/ja00301a024; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RATAJCZAK R, 1988, BIOCHIM BIOPHYS ACTA, V933, P306, DOI 10.1016/0005-2728(88)90038-2; Reichert J, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P693; SANDERSON DG, 1986, BIOCHIM BIOPHYS ACTA, V852, P269, DOI 10.1016/0005-2728(86)90232-X; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; TAKENAKA K, 1984, J BIOCHEM-TOKYO, V96, P1813, DOI 10.1093/oxfordjournals.jbchem.a135015; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17590	17595		10.1074/jbc.275.23.17590	http://dx.doi.org/10.1074/jbc.275.23.17590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837495	hybrid			2022-12-27	WOS:000087485000055
J	Nevrivy, DJ; Peterson, VJ; Avram, D; Ishmael, JE; Hansen, SG; Dowell, P; Hruby, DE; Dawson, MI; Leid, M				Nevrivy, DJ; Peterson, VJ; Avram, D; Ishmael, JE; Hansen, SG; Dowell, P; Hruby, DE; Dawson, MI; Leid, M			Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ADP-RIBOSYLATION FACTOR; ACTIVATED RECEPTOR-ALPHA; GROWTH-FACTOR-BETA; MESSENGER-RNA; PLASMA-MEMBRANE; NEURONAL DIFFERENTIATION; FACTOR ARNO; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE	A novel, retinoic acid-induced gene, <(GR)under bar>P1-associated (s) under bar caffold (p) under bar rotein (GRASP), was isolated from P19 embryonal carcinoma cells using a subtractive screening strategy. GRASP was found to be highly expressed in brain and exhibited lower levels of expression in lung, heart, embryo, kidney, and ovary. The predicted amino acid sequence of GRASP is characterized by several putative protein-protein interaction motifs, suggesting that GRASP may be a component of a larger protein complex in the cell. Although GRASP does not harbor a predicted membrane spanning domain(s), the protein was observed to be associated with the plasma membrane of transiently transfected mammalian cells. Yeast two-hybrid screening revealed that GRASP interacted strongly with the (G) under bar eneral (R) under bar eceptor for (P) under bar hosphoinositides (1) under bar (GRP1), a brefeldin A-insensitive guanine nucleotide exchange factor for the ADP-ribosylation factor family of proteins, GRASP.GrRP1 interactions were also demonstrated in vitro and in mammalian cells in which GRASP was shown to enhance GRP1 association with the plasma membrane. Furthermore, GRASP colocalized with endogenous ADP-ribosylation factors at the plasma membrane in transfected cells, suggesting that GRASP may modulate signaling by this family of small GTPases.	Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Toxicol Program, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Mol Med Res Inst, Mountain View, CA 94043 USA	Oregon State University; Oregon State University; Oregon State University; Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA.	mark.leid@orst.edu			NCI NIH HHS [CA51993] Funding Source: Medline; NIEHS NIH HHS [ES002010, ES07060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; Bouillet P, 1996, MECH DEVELOP, V58, P141, DOI 10.1016/S0925-4773(96)00569-2; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Clodi M, 1998, ENDOCRINOLOGY, V139, P4984, DOI 10.1210/en.139.12.4984; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DIXON B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P321, DOI 10.1016/0167-4781(93)90165-A; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ELIAS MCQB, 1994, BRAZ J MED BIOL RES, V27, P2181; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; GAETANO C, 1994, CLIN EXP METASTAS, V12, P63, DOI 10.1007/BF01784335; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gudas L J, 1986, Prog Clin Biol Res, V226, P181; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KOBAYASHI M, 1994, FEBS LETT, V356, P60, DOI 10.1016/0014-5793(94)01238-5; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEID M, 1994, J BIOL CHEM, V269, P14175; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; LOESER RF, 1994, EXP CELL RES, V211, P17, DOI 10.1006/excr.1994.1053; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Monier S, 1998, J CELL SCI, V111, P3427; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Niethammer M, 1996, J NEUROSCI, V16, P2157; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROGUSKA MA, 1985, J BIOL CHEM, V260, P3893; ROSS SA, 1994, J CELL PHYSIOL, V159, P263, DOI 10.1002/jcp.1041590210; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; SONG S, 1989, FEBS LETT, V256, P51, DOI 10.1016/0014-5793(89)81716-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	89	69	75	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16827	16836		10.1074/jbc.275.22.16827	http://dx.doi.org/10.1074/jbc.275.22.16827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828067	hybrid			2022-12-27	WOS:000087392200061
J	Wolstein, O; Silkov, A; Revach, M; Dikstein, R				Wolstein, O; Silkov, A; Revach, M; Dikstein, R			Specific interaction of TAF(II)105 with OCA-B is involved in activation of octamer-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-SPECIFIC COACTIVATOR; TATA-BINDING PROTEIN; IN-VIVO; FUNCTIONAL-CHARACTERIZATION; PROMOTER SELECTIVITY; GENE-TRANSCRIPTION; LACKING TAF(II)S; YEAST; COMPLEX	TAF(II)105 is a TFIID-associated factor highly expressed in B lymphocytes. This subunit is found in a small portion of TFIID complexes and is homologous to human TAF(II)130 and Drosophila TAF(II)110. In the present study we show that TAF(II)105 is involved in transcription activation directed by the B cell-specific octamer element found in many B cell-specific genes. B cells overexpressing TAF(II)105 display higher octamer-dependent transcription, whereas expression of a C-terminal truncated form of TAF(II)105 inhibits octamer transcription in a dominant negative manner. In addition, antibodies directed against TAF(II)105 specifically inhibit octamer-dependent transcription. Reporter gene analysis revealed that TAF(II)105 elevates octamer transcription in the presence of OCA-B, a cofactor subunit of Oct1 and Oct2 proteins. In vitro binding assays and functional studies established that the effect of TAF(II)105 on octamer activity involves interaction of TAF(II)105 with octamer-binding complexes via the C-terminal activation domain of OCA-B. These findings link TAF(II)105 coactivator function to B cell-specific transcription.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	44	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16459	16465		10.1074/jbc.275.22.16459	http://dx.doi.org/10.1074/jbc.275.22.16459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828057	hybrid			2022-12-27	WOS:000087392200010
J	Renne, T; Dedio, J; David, G; Muller-Ester, W				Renne, T; Dedio, J; David, G; Muller-Ester, W			High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; BINDING-PROTEIN; UROKINASE RECEPTOR; GROWTH-FACTOR; LIGHT-CHAIN; PLASMA-MEMBRANE; ALPHA-SUBUNIT; HEAVY-CHAIN; SURFACE; DOMAIN	Kininogens, the high molecular weight precursor of vasoactive kinins, bind to a wide variety of cells in a specific, reversible, and saturable manner. The cell docking sites have been mapped to domains D3 and D5(H) of kininogens; however, the corresponding cellular acceptor sites are not fully established. To characterize the major cell binding sites for kininogens exposed by the endothelial cell line EA.hy926, we digested intact cells with trypsin and other proteases and found a time- and concentration-dependent loss of I-125-labeled high molecular weight kininogen (H-kininogen) binding capacity (up to 82%), indicating that proteins are crucially involved in kininogen cell attachment. Cell surface digestion with heparinases similarly reduced kininogen binding capacity (up to 78%), and the combined action of heparinases and trypsin almost eliminated kininogen binding (up to 85%), suggesting that proteoglycans of the heparan sulfate type are intimately involved. Consistently, inhibitors such as p-nitrophenyl-beta -D-xylopyranoside and chlorate interfering with heparan sulfate proteoglycan biosynthesis reduced the total number of kininogen binding sites in a time- and concentration-dependent manner (up to 67%). In vitro binding studies demonstrated that biotinylated H-kininogen binds to heparan sulfate glycosaminoglycans via domains D3 and D5(H) and that the presence of Zn2+ promotes this association. Cloning and over-expression of the major endothelial heparan sulfate-type proteoglycans syndecan-1, syndecan-2, syndecan-4, and glypican in HEK293t cells significantly increased total heparan sulfate at the cell surface and thus the number of kininogen binding sites (up to 3.3-fold). This gain in kininogen binding capacity was completely abolished by treating transfected cells with heparinases. We conclude that heparan sulfate proteoglycans on the surface of endothelial cells provide a platform for the local accumulation of kininogens on the vascular lining. This accumulation may allow the circumscribed release of short-lived kinins from their precursor molecules in close proximity to their sites of action.	Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Ctr Human Genet, B-3000 Louvain, Belgium	Goethe University Frankfurt; KU Leuven	Muller-Ester, W (corresponding author), Goethe Univ Frankfurt, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	wme@biochem2.de		Renne, Thomas/0000-0003-4594-5975				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Carey DJ, 1997, BIOCHEM J, V327, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Dedio J, 1998, J IMMUNOL, V160, P3534; DeLa Cadena RA, 1998, THROMB HAEMOSTASIS, V79, P186; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Goletz S, 1997, J CELL SCI, V110, P1585; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GREENGARD JS, 1992, METHOD ENZYMOL, V215, P369; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HOJIMA Y, 1984, BLOOD, V63, P1453; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; KITAMURA N, 1983, NATURE, V305, P545, DOI 10.1038/305545a0; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MELONI FJ, 1992, BLOOD, V79, P1233; MILTON SG, 1993, J CELL PHYSIOL, V157, P333, DOI 10.1002/jcp.1041570217; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; Moshfegh K, 1998, BIOCHEM BIOPH RES CO, V249, P903, DOI 10.1006/bbrc.1998.9125; Renne T, 1999, J BIOL CHEM, V274, P25777, DOI 10.1074/jbc.274.36.25777; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; SASTRE L, 1986, J IMMUNOL, V137, P1060; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Song Q, 1996, AM J PHYSIOL-RENAL, V270, pF919, DOI 10.1152/ajprenal.1996.270.6.F919; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; Wells MJ, 1997, J BIOL CHEM, V272, P28574, DOI 10.1074/jbc.272.45.28574; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; Zimmermann P, 1999, FASEB J, V13, pS91	53	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33688	33696		10.1074/jbc.M000313200	http://dx.doi.org/10.1074/jbc.M000313200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10843988	hybrid			2022-12-27	WOS:000090104600071
J	De Wolf, MJS				De Wolf, MJS			A dipeptide metalloendoprotease substrate completely blocks the response of cells in culture to cholera toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BREFELDIN-A; GOLGI-APPARATUS; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; MEMBRANE; PROTEIN; INHIBITION	Prior exposure (15 min at 37 degrees C) of several cell types (Vero, SH-SY5Y neuroblastoma, human intestinal epithelial T84) to 3 mM N-benzoyloxycarbonyl-Gly-Phe-amide (Cbz-Gly-Phe-NH2), a competitive substrate for metalloendoproteases, completely suppressed cholera toxin (CT)-induced intracellular cAMP accumulation. The specificity of the inhibitory effect was demonstrated by the complete lack of effect of the dipeptide Cbz-Gly-Gly-NH2, an inactive analogue of Cbz-Gly-Phe-NH2. The effect was reversible and dose- (IC50 as low as 0.2 mM depending on the cell type) and time-dependent. Adding Cbz-Gly-Phe-NH2 during the lag phase caused a diminution of its inhibitory effect similar to that observed with brefeldin A (BFA). Whereas the dipeptide completely suppressed the CT-induced adenylate cyclase (AC) activity, a direct effect on AC is unlikely since the elevation of intracellular cAMP by forskolin was only slightly reduced. The A(1) peptide of CT and NAD(+) activated the AC to the same extent in membranes from control and Cbz-Gly-Phe-NH2-treated cells or when Cbz-Gly-Phe-NH2 was added directly to the assay. The inhibitory effects of suboptimal amounts of Cbz-Gay-Phe-NH2 and BFA were not additive pointing to a similar mode of action of the two substances. However, Madin-Darby canine kidney cells of which the Golgi structure is BFA-resistant were not resistant to the inhibitory action of Cbz-Gly-Phe-NH2 on CT cytotoxicity, Several lines of evidence indicate that a perturbation of intracellular Ca2+ homeostasis by Cbz-Gly-Phe-NH2 is not responsible for the inhibitory effect of the dipeptide. The dipeptide had also no effect on the binding of I-125-CT to cells and even increased its intracellular internalization. In contrast with BFA, Cbz-Gly-Phe-NH2 did not completely suppress the formation of the catalytically active A(1) fragment from bound CT. The data are compatible with a role of metalloendoprotease activity in the intracellular trafficking and processing of CT, although other mechanisms of action of Cbz-Gly-Phe-NH2 cannot be excluded.	Univ Antwerp, RUCA, Lab Human Biochem, B-2020 Antwerp, Belgium	University of Antwerp	De Wolf, MJS (corresponding author), Univ Antwerp, RUCA, Lab Human Biochem, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.	mjdewolf@ruca.ua.ac.be						BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; BROSTROM MA, 1981, MOL PHARMACOL, V20, P59; BROSTROM MA, 1994, BIOCHEM J, V304, P499, DOI 10.1042/bj3040499; CIEPLAK W, 1995, MOL MICROBIOL, V16, P789, DOI 10.1111/j.1365-2958.1995.tb02440.x; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3547, DOI 10.1021/bi00742a031; DEWOLF M, 1985, BIOCHIM BIOPHYS ACTA, V832, P165, DOI 10.1016/0167-4838(85)90328-0; DEWOLF MJS, 1987, BIOCHEMISTRY-US, V26, P3799, DOI 10.1021/bi00387a010; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5481; FINKELSTEIN RA, 1988, HDB NATURAL TOXINS, V4, P1; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; JANICOT M, 1987, EUR J BIOCHEM, V163, P433, DOI 10.1111/j.1432-1033.1987.tb10816.x; KASSIS S, 1982, J BIOL CHEM, V257, P2148; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PITT A, 1991, EUR J CELL BIOL, V55, P328; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Sandvig K, 1996, P NATL ACAD SCI USA, V93, P12339, DOI 10.1073/pnas.93.22.12339; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30240	30247		10.1074/jbc.M004434200	http://dx.doi.org/10.1074/jbc.M004434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10831601	hybrid			2022-12-27	WOS:000089577900046
J	Heise, CE; O'Dowd, BF; Figueroa, DJ; Sawyer, N; Nguyen, T; Im, DS; Stocco, R; Bellefeuille, JN; Abramovitz, M; Cheng, R; Williams, DL; Zeng, ZZ; Liu, QY; Ma, L; Clements, MK; Coulombe, N; Liu, Y; Austin, CP; George, SR; O'Neill, GP; Metters, KM; Lynch, KR; Evans, JF				Heise, CE; O'Dowd, BF; Figueroa, DJ; Sawyer, N; Nguyen, T; Im, DS; Stocco, R; Bellefeuille, JN; Abramovitz, M; Cheng, R; Williams, DL; Zeng, ZZ; Liu, QY; Ma, L; Clements, MK; Coulombe, N; Liu, Y; Austin, CP; George, SR; O'Neill, GP; Metters, KM; Lynch, KR; Evans, JF			Characterization of the human cysteinyl leukotriene 2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOUBLE-BLIND; HUMAN LUNG; ASTHMA; ANTAGONIST; GENES; EXPRESSION; CLONING; CELLS; D4	The contractile and inflammatory actions of the cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, are thought to be mediated through at least two distinct but related CysLT G protein-coupled receptors. The human CysLT(1) receptor has been recently cloned and characterized. We describe here the cloning and characterization of the second cysteinyl leukotriene receptor, CysLT(2), a 346-amino acid protein with 38% amino acid identity to the CysLT(1) receptor. The recombinant human CysLT(2) receptor was expressed in Xenopus oocytes and HEK293T cells and shown to couple to elevation of intracellular calcium when activated by LTC4, LTD4, or LTE4. Analyses of radiolabeled LTD4 binding to the recombinant CysLT(2) receptor demonstrated high affinity binding and a rank order of potency for competition of LTC4 = LTD4 >> LTE4. In contrast to the dual CysLT(1)/ CysLT(2) antagonist, BAY u9773, the CysLT(1) receptor-selective antagonists MK-571, montelukast (Singulair(TM)), zafirlukast (Accolate(TM)), and pranlukast (Onon(TM)) exhibited low potency in competition for LTD4 binding and as antagonists of CysLT(2) receptor signaling. CysLT(2) receptor mRNA was detected in lung macrophages and airway smooth muscle, cardiac Purkinje cells, adrenal medulla cells, peripheral blood leukocytes, and brain, and the receptor gene was mapped to chromosome 13q14, a region linked to atopic asthma.	Merck & Co Inc, Dept Pharmacol, West Point, PA 19486 USA; Merck & Co Inc, Dept Bioinformat, West Point, PA 19486 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; Merck Frosst Canada & Co, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company; University of Virginia; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Merck & Company	Evans, JF (corresponding author), Merck & Co Inc, Dept Pharmacol, 770 Sumneytown Pike,POB 4, West Point, PA 19486 USA.	jilly_evans@merck.com	George, Susan R/P-9669-2018; George, Susan/W-7494-2019	IM, DONG-SOON/0000-0001-8054-8946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722, T32GM007055] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07055, R01 GM52722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN SP, 1992, BRIT J CLIN PHARMACO, V34, P409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; Folco G, 2000, AM J RESP CRIT CARE, V161, pS112, DOI 10.1164/ajrccm.161.supplement_1.ltta-22; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; HULTING AL, 1985, P NATL ACAD SCI USA, V82, P3834, DOI 10.1073/pnas.82.11.3834; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Lynch KR, 1999, NATURE, V399, P789; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; ODowd BF, 1996, FEBS LETT, V394, P325, DOI 10.1016/0014-5793(96)00901-5; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Retief JD, 1999, GENOME RES, V9, P373; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; TUDHOPE SR, 1994, EUR J PHARMACOL, V264, P317, DOI 10.1016/0014-2999(94)00485-4; Ungrin MD, 1999, ANAL BIOCHEM, V272, P34, DOI 10.1006/abio.1999.4145; Vigorito C, 1997, INT J CLIN LAB RES, V27, P178, DOI 10.1007/BF02912454; Walch L, 1999, J PHYSIOL PHARMACOL, V50, P567; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	533	564	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30531	30536		10.1074/jbc.M003490200	http://dx.doi.org/10.1074/jbc.M003490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10851239	hybrid			2022-12-27	WOS:000089577900084
J	Cai, RL; Yan-Neale, Y; Cueto, MA; Xu, H; Cohen, D				Cai, RL; Yan-Neale, Y; Cueto, MA; Xu, H; Cohen, D			HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G(2)/M checkpoint Rad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; PROMYELOCYTIC LEUKEMIA; ATAXIA-TELANGIECTASIA; HUMAN HOMOLOGS; CDNA CLONING; CONTROL GENE; FAMILY; INHIBITION	HDAC1 is a member of the histone deacetylase family, which plays an important role in modulating the eukaryotic chromatin structure. Numerous studies have demonstrated its involvement in transcription and in tumorigenesis. To better understand the functions and regulation of HDAC1, a yeast two-hybrid screening approach was chosen to identify novel interactions involving HDAC1. Human HDAC1 was found to interact specifically in yeast, mammalian cells, and irt vitro with the human Hus1 gene product, whose Schizosaccharomyces pombe homolog has been implicated in G(2)/M checkpoint control. Both HDAC1 and Hus1 proteins localize to the nuclei. Furthermore, HDAC1 and Hus1 were found to exist in a complex with Rad9, a known Hus1-interacting factor. In addition, bioinformatics analysis of the protein sequences of Hus1, Rad1, and Rad9, three checkpoint Rad proteins that form a complex, revealed that they all contain a putative proliferating cell nuclear antigen (PCNA) fold, raising the possibility that these factors may bind to DNA in a PCNA-like ring structure. The results reported in this study strongly suggest a novel pathway involving HDAC1 in G(2)/M checkpoint control through the interaction with a functional Rad complex that may utilize a PCNA-like structure. Therefore, physically and functionally similar apparatus may function during G(2)/M checkpoint and DNA replication.	Novartis Pharmaceut Corp, Funct Genom Area, Summit, NJ 07901 USA; Novartis Pharmaceut Corp, Biomol Struct & Comp, Core Technol Area, Summit, NJ 07901 USA	Novartis; Novartis	Cohen, D (corresponding author), Novartis Pharmaceut Corp, Funct Genom Area, 556 Morris Ave,LSB 1237, Summit, NJ 07901 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; DUNCAN MK, 1995, MAMM GENOME, V6, P697, DOI 10.1007/BF00354290; DUNCAN MK, 1993, J COMP PATHOL, V109, P13, DOI 10.1016/S0021-9975(08)80236-8; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENIKOFF S, 1995, GENE, V163, P17; HIGGINS DG, 1996, METHOD ENZYMOL, V266, P388; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Matsuda T, 1997, ONCOGENE, V15, P2773, DOI 10.1038/sj.onc.1201461; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; Roy WJ, 1997, ONCOGENE, V15, P2031, DOI 10.1038/sj.onc.1201372; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; WATSON TA, 1997, ONCOGENE, V17, P207; Weiss RS, 1999, GENOMICS, V59, P32, DOI 10.1006/geno.1999.5865; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	65	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27909	27916						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846170				2022-12-27	WOS:000089197100053
J	Ebnet, K; Schulz, CU; Brickwedde, MKMZ; Pendl, GG; Vestweber, D				Ebnet, K; Schulz, CU; Brickwedde, MKMZ; Pendl, GG; Vestweber, D			Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PUTATIVE RAS EFFECTOR; TIGHT-JUNCTION; ADHERENS JUNCTIONS; BINDING PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; TARGET AF-6; OCCLUDIN; IDENTIFICATION; CADHERIN	We have identified the PDZ domain protein AF-6 as an intracellular binding partner of the junctional adhesion molecule (JAM), an integral membrane protein located at cell contacts. Binding of AF-6 to JAM: required the presence of the intact C terminus of JAM, which represents a classical type II PDZ domain-binding motif. Although JAM did not interact with the single PDZ domains of ZO-1 or of CASK, we found that a ZO-1 fragment containing PDZ domains 2 and 3 bound to JAM in vitro in a PDZ domain-dependent manner. AF-6 as well as ZO-1 could be coprecipitated with JAM. from endothelial cell extracts, demonstrating the association of the endogenously expressed molecules in vivo. Targeting of JAM to sites of cell contacts could be affected by the loss of the PDZ domain-binding C terminus. Full-length mouse JAM co-distributed with endogenous AF-6 in human Caco-2 cells at sites of cell contact independent of whether adjacent cells expressed mouse JAM as an extracellular binding partner. In contrast, truncated JAM lacking the PDZ domain-binding C terminus did not co-distribute with endogenous AF-6, but was restricted to cell contacts between cells expressing mouse JAM. Our results suggest that JAM can be recruited to intercellular junctions by its interaction with the PDZ domain-containing proteins AF-6 and possibly ZO-1.	Univ Muenster, ZMBE, Inst Cell Biol, D-48149 Muenster, Germany; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany	Max Planck Society	Vestweber, D (corresponding author), Univ Muenster, ZMBE, Inst Cell Biol, Von Esmarch Str, D-48149 Muenster, Germany.		Ebnet, Klaus T/C-8314-2009	Ebnet, Klaus T/0000-0002-0417-7888; Vestweber, Dietmar/0000-0002-3517-732X				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Saito S, 1998, DNA Res, V5, P115, DOI 10.1093/dnares/5.2.115; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; VanItallie CM, 1997, J CELL SCI, V110, P1113; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watari Y, 1998, GENE, V224, P53, DOI 10.1016/S0378-1119(98)00527-7; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	51	325	334	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27979	27988						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856295				2022-12-27	WOS:000089197100062
J	Mavaddat, N; Mason, DW; Atkinson, PD; Evans, EJ; Gilbert, RJC; Stuart, DI; Fennelly, JA; Barclay, AN; Davis, SJ; Brown, MH				Mavaddat, N; Mason, DW; Atkinson, PD; Evans, EJ; Gilbert, RJC; Stuart, DI; Fennelly, JA; Barclay, AN; Davis, SJ; Brown, MH			Signaling lymphocytic activation molecule (CDw150) is homophilic but self-associates with very low affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HUMAN B-LYMPHOCYTES; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; PROTEIN INTERACTIONS; HEMOPHILIC ADHESION; LIGAND INTERACTIONS; ENCODING GENE; CD58 LFA-3; CD2	Signaling lymphocytic activating molecule ((SLAM) CDw150) is a glycoprotein that belongs to the CD2 subset of the immunoglobulin superfamily and is expressed on the surface of activated T- and B-cells, It has been proposed that SLAM is homophilic and required for bidirectional signaling during T- and B-cell activation. Previous work has suggested that the affinity of SLAM self-association might be unusually high, undermining the concept that protein interactions mediating transient cell-cell contacts, such as those involving leukocytes, have to be weak in order that such contacts are readily reversible. Using surface plasmon resonance-based methods and analytical ultracentrifugation (AUC), we confirm that SLAM is homophilic. However, we also establish a new theoretical treatment of surface plasmon resonance-derived homophilic binding data, which indicates that SLAM-SLAM interactions (solution K-d similar to 200 mu M) are in fact considerably weaker than most other well characterized protein-protein interactions at the cell surface (solution hi, similar to 0.4-20 mu M), a conclusion that is supported by the AUC analysis. Whereas further analysis of the AUC data imply that SLAM could form "head to head'' dimers spanning adjacent cells, the very low affinity raises important questions regarding the physiological role and/or properties of such interactions.	Univ Oxford, Nuffield Dept Clin Med, Mol Sci Div, Oxford OX3 9DU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England	University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Davis, SJ (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Mol Sci Div, Oxford OX3 9DU, England.			Stuart, David/0000-0002-3426-4210; Gilbert, Robert/0000-0001-9336-5604; Mavaddat, Nasim/0000-0003-0307-055X; Atkinson, Paul/0000-0001-8205-9388				ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Byron O, 1997, BIOPHYS J, V72, P408, DOI 10.1016/S0006-3495(97)78681-8; CANN JR, 1974, BIOCHEMISTRY-US, V13, P1868, DOI 10.1021/bi00706a015; Carrasco B, 1999, BIOPHYS J, V77, P2902, DOI 10.1016/S0006-3495(99)77123-7; Castro AG, 1999, J IMMUNOL, V163, P5860; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; COELFEN H, 1995, PROGR COLLOID POLYM, V99, P167; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; de la Torre JG, 1999, EUR BIOPHYS J BIOPHY, V28, P119, DOI 10.1007/s002490050191; delaFuente MA, 1997, BLOOD, V90, P2398; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; ESNOUF RM, 1997, J MOL GRAPH MODEL, V15, P112; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KRAULIS PJ, 1991, SCIENCE, V254, P581, DOI 10.1126/science.1658931; LAUE TM, 1992, 835 DS SPINC BUS UN; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Pfuhl M, 1999, J BIOMOL NMR, V14, P307, DOI 10.1023/A:1008319917267; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHACHMAN HK, 1951, J AM CHEM SOC, V73, P4808, DOI 10.1021/ja01154a099; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Sewell AK, 1999, NAT MED, V5, P399, DOI 10.1038/7398; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SIDORENKO SP, 1993, J IMMUNOL, V151, P4614; SQUIRE PG, 1979, ARCH BIOCHEM BIOPHYS, V196, P165, DOI 10.1016/0003-9861(79)90563-0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tangye SG, 1999, J IMMUNOL, V162, P6981; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9	61	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28100	28109						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10831600				2022-12-27	WOS:000089197100076
J	Sawamura, N; Morishima-Kawashima, M; Waki, H; Kobayashi, K; Kuramochi, T; Frosch, MP; Ding, K; Ito, M; Kim, TW; Tanzi, RE; Oyama, F; Tabira, T; Ando, S; Ihara, Y				Sawamura, N; Morishima-Kawashima, M; Waki, H; Kobayashi, K; Kuramochi, T; Frosch, MP; Ding, K; Ito, M; Kim, TW; Tanzi, RE; Oyama, F; Tabira, T; Ando, S; Ihara, Y			Mutant presenilin 2 transgenic mice - A large increase in the levels of A beta 42 id presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; A-BETA; IN-VIVO; MISSENSE MUTATIONS; ANCHORED PROTEINS; TRANSFECTED CELLS; PRECURSOR PROTEIN; SENILE PLAQUES; BRAIN	The N141I mutation in presenilin (PS) 2 is tightly linked with a form of autosomal dominant familial Alzheimer's disease in the Volga German families. We previously reported that mouse brains harboring mutant PS2 contained increased levels of amyloid beta protein (A beta) 42 in the Tris-saline-soluble fraction (Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., Tomita, T., Maruyama, K., Saido, T. C., Iwatsubo, T., Capell, A., Waiter, J., Grunberg, J., Ueyama, Y., Haass, C. and Ihara, Y. (1998) J. Neurochem. 71, 313-322). Here, using a new extraction protocol, we quantitated the A beta 40 and A beta 42 levels in the Tris-saline-insoluble fraction. The insoluble A beta levels were found to be higher than the soluble A beta levels, and the insoluble A beta 42 levels were markedly increased in mutant PS2 transgenic mice. To investigate the origin of the insoluble A beta 42, we prepared the detergent-insoluble, low density membrane fraction. This fraction from two independent lines of mutant PS2 transgenic mice contained remarkably increased levels of A beta 42 and significantly low levels of glycerophospholipids and sphingomyelin. This unexpected finding suggests that a large increase in the levels of A beta 42 in mutant PS2 mice is presumably induced through alterations of the lipid composition in the low density membrane domain in the brain.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Gerontol, Dept Membrane Biochem, Itabashi Ku, Tokyo 1730015, Japan; Cent Inst Expt Anim, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yihara@m.u-tokyo.ac.jp	Sawamura, Naoya/K-1663-2018; Tanzi, Rudolph/AAE-9622-2019; Frosch, Matthew P/ABD-7456-2021; Oyama, Fumitaka/P-6186-2016	Sawamura, Naoya/0000-0003-4753-1119; Tanzi, Rudolph/0000-0002-7032-1454; Frosch, Matthew P/0000-0002-3940-9861; Oyama, Fumitaka/0000-0002-1095-8306				Ando S, 1987, CHROMATOGRAPHY LIPID, P266; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLUSZTAJN JK, 1990, BRAIN RES, V536, P240, DOI 10.1016/0006-8993(90)90030-F; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hamano T, 1997, J NEUROPATH EXP NEUR, V56, P922, DOI 10.1097/00005072-199708000-00010; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; ITOH YH, 1986, ANAL BIOCHEM, V154, P200, DOI 10.1016/0003-2697(86)90515-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kang DE, 1999, J NEUROSCI, V19, P4229; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kramer EM, 1997, J BIOL CHEM, V272, P8937; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MIETTINEN T, 1959, ACTA CHEM SCAND, V13, P856, DOI 10.3891/acta.chem.scand.13-0856; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nakabayashi J, 1998, J NEUROPATH EXP NEUR, V57, P343, DOI 10.1097/00005072-199804000-00007; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Oyama F, 1998, J NEUROCHEM, V71, P313; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shinkai Y, 1997, ANN NEUROL, V42, P899, DOI 10.1002/ana.410420612; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGH H, 1971, J LIPID RES, V12, P473; SODERBERG M, 1992, J NEUROCHEM, V59, P1646; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; WAKI H, 1994, ANAL BIOCHEM, V222, P156, DOI 10.1006/abio.1994.1467; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu GY, 1996, MICROCHEM J, V53, P29, DOI 10.1006/mchj.1996.0005; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; YOO AS, 2000, IN PRESS NEURON	62	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27901	27908						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846187				2022-12-27	WOS:000089197100052
J	Koszelak, ME; Huggins, CF; Fay, PJ				Koszelak, ME; Huggins, CF; Fay, PJ			Sites in the A2 subunit involved in the interfactor VIIIa interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; CATALYZED PROTEOLYSIS; PROCOAGULANT ACTIVITY; ANTIHEMOPHILIC-FACTOR; A1/A3-C1-C2 DIMER; FACTOR-IXA; THROMBIN; INACTIVATION; A2-SUBUNIT	Factor Villa is a trimer of the Al, A2, and A3-C1-C2 subunits, Regions in the A2 subunit that interact with the A1/A3-C1-C2 dimer were localized using synthetic peptides derived from A2 sequences showing high probability of being surface exposed. Peptides were restricted to residues 373-562 of A2 based on the earlier observation that this region of A2 reacts with Al using a zero length cross-linker, Peptides were assessed for their capacity to inhibit the reconstitution of factor Villa from the isolated A1/A3-C1-C2 dimer and A2 subunit. Reconstitution was monitored using both regeneration of factor Villa activity and fluorescence quenching of an acrylodan-labeled A2 (Ac-A2) by fluorescein-labeled A1/A3-C1-C2. The activity assay identified four peptides as inhibitors, residues 373-395 (IC50 = 65 mu M), 418-428 (IC50 = 25 mu M), 482-493 (IC50 = 325 mu M), and 518-533 (IC50 = 585 mu M). The 373-395 and 518-533 peptides eliminated the fluorescence quenching of Ac-A2, whereas the 418-428 peptide reduced but did not eliminate Ac-A2 quenching, Peptide 482-493 had no effect on the fluorescence quenching of Ac-A2 suggesting that the peptide did not directly affect reassociation of the factor Villa subunits. These results identify three regions in the A2 subunit (373-395, 418-428, and 518-533) that interact with the A1/A3-C1-C2 dimer, Furthermore, comparison of results obtained using the two assays distinguish inhibition of the intersubunit interactions from intermolecular interactions.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu		Huggins, Christine/0000-0002-5873-1194	NHLBI NIH HHS [HL 30616, HL 38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; Celie PHN, 1999, BRIT J HAEMATOL, V106, P792, DOI 10.1046/j.1365-2141.1999.01590.x; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1999, J BIOL CHEM, V274, P29826, DOI 10.1074/jbc.274.42.29826; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HULTIN MB, 1981, BLOOD, V57, P476; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MANN KG, 1990, BLOOD, V76, P1; MCMULLEN BA, 1995, PROTEIN SCI, V4, P740; MIMS MP, 1993, BIOCHEMISTRY-US, V32, P9215, DOI 10.1021/bi00086a029; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1992, BLOOD, V79, P389; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27137	27144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10831590				2022-12-27	WOS:000089144800064
J	Sasaki, K; Taura, F; Shoyama, Y; Morimoto, S				Sasaki, K; Taura, F; Shoyama, Y; Morimoto, S			Molecular characterization of a novel beta-glucuronidase from Scutellaria baicalensis georgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDASE ESCHERICHIA-COLI; ACTIVE-SITE; MAMMALIAN HEPARANASE; CLONING; EXPRESSION; CDNA; GENE; MUCOPOLYSACCHARIDOSIS; PURIFICATION; DEFICIENCY	We cloned a gene encoding Scutellaria P-glucuronidase (sGUS) that is involved in the initiation of H2O2 metabolism in skullcap (Scutellaria baicalensis). This gene consists of a 1581-nucleotide open reading frame, the deduced amino acid sequence of which contains an ATP/GTP binding site and a leucine zipper motif. sGUS has apparent similarity to the heparan sulfate-metabolizing beta-glucuronidase heparanase but no homology to family 2 beta-glucuronidases. In addition, neither the family 2 glycosylhydrolase signature nor family 2 acid-base catalyst was found in this enzyme. These results suggested that sGUS does not belong to the family 2 beta-glucuronidases. We modified several residues predicted to act as the acid-base or nucleophilic residue of sGUS by site-directed mutagenesis. Mutations at Glu(212) or Glu(329) resulted in much lower k(cat)/K-m values in the mutants as compared with the wild-type enzyme, indicating that these are the acid-base and nucleophilic residues of the active site, respectively. Moreover, similar site-directed mutagenesis confirmed that Tyr(281) is also involved in the beta-glucuronidase activity. The amino acid sequences of small regions containing these active site residues were conserved in heparanases. As sGUS has various structural characteristics in common with heparanase, we concluded that sGUS and heparanase belong to the same new family.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan	Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.				NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907, R01CA056819] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-56819, CA-71907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; Fyfe JC, 1999, GENOMICS, V58, P121, DOI 10.1006/geno.1999.5825; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HODAL L, 1992, PLANT SCI, V87, P115, DOI 10.1016/0168-9452(92)90199-V; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Inoue K, 1996, FEBS LETT, V389, P273, DOI 10.1016/0014-5793(96)00601-1; Islam MR, 1999, J BIOL CHEM, V274, P23451, DOI 10.1074/jbc.274.33.23451; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LEVVY GA, 1954, BIOCHEM J, V56, P462; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; Malburg SRC, 1997, APPL ENVIRON MICROB, V63, P2449, DOI 10.1128/AEM.63.6.2449-2453.1997; Morimoto S, 1999, J BIOL CHEM, V274, P26192, DOI 10.1074/jbc.274.37.26192; Morimoto S, 1998, J BIOL CHEM, V273, P12606, DOI 10.1074/jbc.273.20.12606; MORIMOTO S, 1995, PLANTA, V195, P535, DOI 10.1007/BF00195712; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; Ray J, 1998, GENOMICS, V48, P248, DOI 10.1006/geno.1997.5189; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SCHULZ M, 1987, PHYTOCHEMISTRY, V26, P933, DOI 10.1016/S0031-9422(00)82320-1; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518	34	36	38	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27466	27472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858442				2022-12-27	WOS:000089144800105
J	Seachrist, JL; Anborgh, PH; Ferguson, SSG				Seachrist, JL; Anborgh, PH; Ferguson, SSG			beta(2)-adrenergic receptor internalization, endosomal sorting, and plasma membrane recycling are regulated by Rab GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; ENDOCYTIC PATHWAY; BETA-2-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; COATED PITS; SEQUESTRATION; RESENSITIZATION; MECHANISMS; DEPHOSPHORYLATION	Rab GTPases are recognized as critical regulatory factors involved in vesicular membrane transport and endosomal fusion. For example, Rab5 directs the transport and fusion of endocytic vesicles to and with early endosomes, whereas Rab4 is thought to control protein trafficking from early endosomes back to the plasma membrane. In the present study, we investigated the role of Rab5 and Rab4 GTPases in regulating the endocytosis, intracellular sorting, and the plasma membrane recycling of the beta(2)AR. In cells expressing the dominant-negative Rab5-S34N mutant, beta(2)AR internalization was impaired, and beta(2)AR-bearlng endocytic vesicles remained in either close juxtaposition or physically attached to the plasma membrane. In contrast, a constitutively active Rab5-Q79L mutant redirected internalized beta(2)AR to enlarged endosomes but did not prevent beta(2)AR dephosphorylation and recycling, The expression of either wild-type Rab4 or a Rab4-N121I mutant did not prevent beta(2)AR dephosphorylation. However, the dominant-negative Rab4-N121I mutant blocked beta(2)AR resensitization by blocking receptor recycling from endosomes back to the cell surface. Our data indicate that, in addition to regulating the intracellular trafficking and fusion of beta(2)AR-bearing endocytic vesicles, Rab5 also contributes to the formation and/or budding of clathrin coated vesicles. Furthermore, beta(2)AR dephosphorylation occurs as the receptor transits between Rab5- and Rab4-positive compartments.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.							BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOORE RH, 1995, J CELL SCI, V108, P2983; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	31	142	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27221	27228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854436				2022-12-27	WOS:000089144800074
J	Sessa, RA; Bennett, MH; Lewis, MJ; Mansfield, JW; Beale, MH				Sessa, RA; Bennett, MH; Lewis, MJ; Mansfield, JW; Beale, MH			Metabolite profiling of sesquiterpene lactones from Lactuca species - Major latex components are novel oxalate and sulfate conjugates of lactucin and its derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAPUS SSP OLEIFERA; MOLECULAR-BIOLOGY; BREMIA-LACTUCAE; VIROSA L; LETTUCE; CHICORY; BIOSYNTHESIS; BIOCHEMISTRY; COTYLEDONS; CULTURE	Wounding leaves or stems of Lactuca species releases a milky latex onto the lent surface. We have examined the constituents of latex from Lactuca sativa (lettuce) cv, Diana, The major components were shown to be novel 15-oxalyl and 8-sulfate conjugates of the guaianolide sesquiterpene lactones, lactucin, deoxylactucin, and lactucopicrin. The oxalates were unstable, reverting to the parent sesquiterpene lactone on hydrolysis, Oxalyl derivatives have been reported rarely from natural sources, The sulfates were stable and are the first reported sesquiterpene sulfates from plants. Unusual tannins based on 4-hydroxyphenylacetyl conjugates of glucose were also identified. Significant qualitative and quantitative variation was found in sesquiterpene lactone profiles in different lettuce varieties and in other Lactuca spp, The proportions of each conjugate in latex also changed depending on the stage of plant development. A similar profile was found in chicory, in which oxalyl conjugates were identified, but the 8-sulfate conjugates were notably absent. The presence of the constitutive sesquiterpene lactones was not correlated with resistance to pathogens but may have a significant bearing on the molecular basis of the bitter taste of lettuce and related species. The induced sesquiterpene lactone phytoalexin, lettucenin A, was found in the Lactuca spp, but not in chicory.	Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England; Univ London Wye Coll, Dept Biol Sci, Ashford TN25 5AH, Kent, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol; Imperial College London	Mansfield, JW (corresponding author), Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England.							ADEGAWA S, 1985, CHEM PHARM BULL, V33, P4906; Bell EA, 1996, PHYTOCHEMISTRY, V43, P1003, DOI 10.1016/S0031-9422(96)00425-6; BENNETT MH, 1994, PHYSIOL MOL PLANT P, V44, P321, DOI 10.1016/S0885-5765(05)80046-3; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; Bones AM, 1996, PHYSIOL PLANTARUM, V97, P194, DOI [10.1034/j.1399-3054.1996.970128.x, 10.1111/j.1399-3054.1996.tb00497.x]; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; CURTIS IS, 1994, J EXP BOT, V45, P1441, DOI 10.1093/jxb/45.10.1441; de Kraker JW, 1998, PLANT PHYSIOL, V117, P1381, DOI 10.1104/pp.117.4.1381; Esau K, 1965, PLANT ANATOMY, V2, P429; EVANS CS, 1985, PHYTOCHEMISTRY, V24, P2273, DOI 10.1016/S0031-9422(00)83025-3; FAGG J, 1991, PHYSIOL MOL PLANT P, V38, P105, DOI 10.1016/S0885-5765(05)80129-8; Fischer N, 1991, METHODS PLANT BIOCH, P187; GIAMOUSTARIS A, 1995, ANN APPL BIOL, V126, P347, DOI 10.1111/j.1744-7348.1995.tb05371.x; Giamoustaris A, 1997, PLANT PATHOL, V46, P271, DOI 10.1046/j.1365-3059.1997.d01-222.x; GORSKI PM, 1995, PHYSIOL MOL PLANT P, V47, P339, DOI 10.1006/pmpp.1995.1063; GRAYER RJ, 1994, PHYTOCHEMISTRY, V37, P19, DOI 10.1016/0031-9422(94)85005-4; GROMEK D, 1992, PHYTOTHER RES, V6, P285, DOI 10.1002/ptr.2650060514; GROMEK D, 1989, POL J CHEM, V63, P297; GROSS GG, 1999, COMPREHENSIVE NATURA, V3, P799; Hall JL, 1982, PLANT CELL STRUCTURE; HARBORNE JB, 1977, PROGR PHYTOCHEM, V4, P189; Haslam E., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P527; Kisiel W, 1997, PHYTOCHEMISTRY, V45, P365, DOI 10.1016/S0031-9422(96)00820-5; KISIEL W, 1995, PHYTOCHEMISTRY, V40, P1139, DOI 10.1016/0031-9422(95)00433-8; KUO YH, 1991, PHYTOCHEMISTRY, V30, P3241, DOI 10.1016/0031-9422(91)83184-M; MAHMOUD ZF, 1986, PHYTOCHEMISTRY, V25, P747, DOI 10.1016/0031-9422(86)88039-6; NISHIMURA K, 1986, CHEM PHARM BULL, V34, P2518; ONEILL TM, 1982, T BRIT MYCOL SOC, V79, P229, DOI 10.1016/S0007-1536(82)80108-3; Peters AM, 1998, J AM SOC HORTIC SCI, V123, P326, DOI 10.21273/JASHS.123.2.326; PICMAN AK, 1986, BIOCHEM SYST ECOL, V14, P255, DOI 10.1016/0305-1978(86)90101-8; Pink D., 1993, GENETIC IMPROVEMENT, P543; PRICE KR, 1990, J SCI FOOD AGR, V53, P185, DOI 10.1002/jsfa.2740530206; REES SB, 1985, PHYTOCHEMISTRY, V24, P2225, DOI 10.1016/S0031-9422(00)83015-0; SAVONA G, 1983, J NAT PROD, V46, P277, DOI 10.1021/np50026a025; SCHENCK G, 1939, ARCH PHARM, V277, P137; SETO M, 1988, CHEM PHARM BULL, V36, P2423, DOI 10.1248/cpb.36.2423; SKORCZYNSKI SS, 1986, BIOCHEM BIOPH RES CO, V141, P1051, DOI 10.1016/S0006-291X(86)80150-4; TAKASUGI M, 1985, J CHEM SOC CHEM COMM, P621, DOI 10.1039/c39850000621; TAMAKI H, 1995, J AGR FOOD CHEM, V43, P6, DOI 10.1021/jf00049a002; VANBEEK TA, 1990, J AGR FOOD CHEM, V38, P1035, DOI 10.1021/jf00094a026; Zidorn C, 1999, PHYTOCHEMISTRY, V51, P991, DOI 10.1016/S0031-9422(99)00163-6; [No title captured]; [No title captured]	43	125	128	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26877	26884						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858433				2022-12-27	WOS:000089144800030
J	Avvakumov, GV; Muller, YA; Hammond, GL				Avvakumov, GV; Muller, YA; Hammond, GL			Steroid-binding specificity of human sex hormone-binding globulin is influenced by occupancy of a zinc-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIZATION DOMAINS; PROLACTIN RECEPTOR; GROWTH-HORMONE; HUMAN PLASMA; PROTEIN; SERUM; TESTOSTERONE; EXPRESSION; EPITHELIUM; ESTRADIOL	One calcium-binding site (site I) and a second poorly defined metal-binding site (site II) have been observed previously within the amino-terminal laminin G-like domain (G domain) of human sex hormone-binding globulin (SHBG). By soaking crystals of this structure in 2.5 mM ZnCl2, site II and a new metal-binding site (site III) were found to bind Zn2+. Site II is located close to the steroid-binding site, and Zn2+ is coordinated by the side chains of His(83) and His(136) and the carboxylate group of Asp(65). In this site, Zn2+ prevents Asp(65) from interacting with the steroid 17 beta-hydroxy group and alters the conformations of His(83) and His(136), as well as a disordered region over the steroid-binding site. Site III. is formed by the side chains of His(101) and the carboxylate group of Asp(117) and the distance between them (2.7 Angstrom) is increased to 3.7 Angstrom in the presence of Zn2+. The affinity of SHBG for estradiol is reduced in the presence of 0.1-1 mM Zn2+, whereas its affinity for androgens is unchanged, and chemically-related metal ions (Cd2+ and Hg2+) have similar but less pronounced effects. This is not observed when Zn2+ coordination at site II is modified by substituting Gln for His(136). An alteration in the steroid-binding specificity of human SHBG by Zn2+ occupancy of site II may be relevant in male reproductive tissues where zinc concentrations are very high.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, MRC, Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Max Delbruck Ctr Mol Med, Forsch Grp Kristallog, D-13092 Berlin, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghammond@julian.uwo.ca	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertini I., 1994, BIOINORG CHEM, P37; BOCCHINFUSO WP, 1994, BIOCHEMISTRY-US, V33, P10622, DOI 10.1021/bi00201a008; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chia SE, 2000, J ANDROL, V21, P53; COWAN RA, 1976, J ENDOCRINOL, V71, P121, DOI 10.1677/joe.0.0710121; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HABIB FK, 1976, J ENDOCRINOL, V71, P133, DOI 10.1677/joe.0.0710133; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1986, J STEROID BIOCHEM, V24, P815, DOI 10.1016/0022-4731(86)90442-5; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; HARRIS WR, 1989, J NUTR, V119, P1677, DOI 10.1093/jn/119.11.1677; HILDEBRAND C, 1995, BIOCHEMISTRY-US, V34, P3231, DOI 10.1021/bi00010a012; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Janne M, 1998, MOL ENDOCRINOL, V12, P123; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH DR, 1994, VITAM HORM, V49, P197; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIEG M, 1993, J CLIN ENDOCR METAB, V77, P375, DOI 10.1210/jc.77.2.375; LAHTONEN R, 1985, PROSTATE, V6, P177, DOI 10.1002/pros.2990060208; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; NAMKUNG PC, 1990, J BIOL CHEM, V265, P18345; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSNER W, 1974, BIOCHIM BIOPHYS ACTA, V351, P92, DOI 10.1016/0005-2795(74)90068-3; ROSNER W, 1991, J STEROID BIOCHEM, V40, P813, DOI 10.1016/0960-0760(91)90307-Q; ROSS JBA, 1985, J PROTEIN CHEM, V4, P299, DOI 10.1007/BF01025495; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432	35	37	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25920	25925		10.1074/jbc.M004484200	http://dx.doi.org/10.1074/jbc.M004484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859323	hybrid			2022-12-27	WOS:000088999700007
J	Baer, M; Johnson, PF				Baer, M; Johnson, PF			Generation of truncated C/EBP beta isoforms by in vitro proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATOR PROTEIN; NF-KAPPA-B; CELL-PROLIFERATION; LEUCINE-ZIPPER; POSTTRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; MAMMARY-GLAND; DNA-BINDING	Multiple forms of the transcriptional regulator CCAAT/enhancer-binding protein beta (C/EBP beta) with molecular masses of approximately 38, 34, 20, and 14 kDa have been observed in cell extracts. It has been proposed that these proteins arise by alternative initiation at in-frame AUG codons. The truncated C/EBP beta isoforms (p14 and p20/LIP) lack transactivation domains but retain DNA-binding and dimerization sequences and are therefore assumed to function as competitive inhibitors of C/EBP-mediated transcription in vivo. By comparing various extraction procedures to analyze endogenous and overexpressed C/EBP beta proteins, we determined that p20-C/EBP beta is generated predominantly by in vitro proteolytic cleavage during isolation from cells and that p14-C/EBP beta is produced exclusively by this mechanism. In transfected cells, the full-length (p34 and p38) isoforms but not the truncated proteins were detectable in the cytoplasm, indicating that the latter are not primary translation products. In addition, the C/EBP beta leucine zipper dimerization domain was essential for the appearance of the truncated species, demonstrating that protein folding or dimerization are critical determinants of proteolytic sensitivity. Our findings suggest that the presence of truncated C/EBP beta proteins in cell extracts must be interpreted with caution and that assumptions about the in vivo relevance of these isoforms should be re-evaluated.	NCI, Frederick Canc Res & Dev Ctr, Eukaryot Transcript Regulat Sect, Adv BioSci Labs,Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Johnson, PF (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				An MR, 1996, MOL CELL BIOL, V16, P2295; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; CALKHOVEN CF, 1992, NUCLEIC ACIDS RES, V20, P4093, DOI 10.1093/nar/20.15.4093; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fattori E, 1995, ANN NY ACAD SCI, V762, P262; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lee YM, 1996, MOL CELL BIOL, V16, P4257; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Raught B, 1996, CANCER RES, V56, P4382; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Welm AL, 1999, MOL CELL BIOL, V19, P1695; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	37	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26582	26590		10.1074/jbc.M004268200	http://dx.doi.org/10.1074/jbc.M004268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856306	hybrid			2022-12-27	WOS:000088999700096
J	Elshourbagy, NA; Ames, RS; Fitzgerald, LR; Foley, JJ; Chambers, JK; Szekeres, PG; Evans, NA; Schmidt, DB; Buckley, PT; Dytko, GM; Murdock, PR; Milligan, G; Groarke, DA; Tan, KB; Shabon, U; Nuthulaganti, P; Wang, DY; Wilson, S; Bergsma, DJ; Sarau, HM				Elshourbagy, NA; Ames, RS; Fitzgerald, LR; Foley, JJ; Chambers, JK; Szekeres, PG; Evans, NA; Schmidt, DB; Buckley, PT; Dytko, GM; Murdock, PR; Milligan, G; Groarke, DA; Tan, KB; Shabon, U; Nuthulaganti, P; Wang, DY; Wilson, S; Bergsma, DJ; Sarau, HM			Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD; RAT; MORPHINE; FMRFAMIDE; PEPTIDES; BRAIN; NPFF; MEMBRANES; ANTISERUM; ANALGESIA	Opiate tolerance and dependence are major clinical and social problems. The anti-opiate neuropeptides FF and AF (NPFF and NPAF) have been implicated in pain modulation as well as in opioid tolerance and may play a critical role in this process, although their mechanism of action has remained unknown. Here we describe a cDNA encoding a novel neuropeptide Y-like human orphan G protein-coupled receptor (GPCR), referred to as HLWAR77 for which NPAF and NPFF have high affinity. Cells transiently or stably expressing HLWAR77 bind and respond in a concentration-dependent manner to NPAF and NPFF and are also weakly activated by FMRF-amide (Phe-Met-Arg-Phe-amide) and a variety of related peptides. The high affinity and potency of human NPFF and human NPAF for HLWAR77 strongly suggest that these are the cognate ligands for this receptor. Expression of HLWAR77 was demonstrated in brain regions associated with opiate activity, consistent with the pain-modulating activity of these peptides, whereas the expression in adipose tissue suggests other physiological and pathophysiological activities for FMRF-amide neuropeptides. The discovery that the anti-opiate neuropeptides are the endogenous ligands for HLWAR77 will aid in defining the physiological role(s) of these ligands and facilitate the identification of receptor agonists and antagonists.	SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Renal Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Vasc Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Glasgow	Ames, RS (corresponding author), SmithKline Beecham Pharmaceut, Dept Biol Mol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Cikos S, 1999, BIOCHEM BIOPH RES CO, V256, P352, DOI 10.1006/bbrc.1999.0332; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; DEVILLERS JP, 1994, NEUROPHARMACOLOGY, V33, P661, DOI 10.1016/0028-3908(94)90172-4; Fitzgerald LR, 1999, ANAL BIOCHEM, V275, P54, DOI 10.1006/abio.1999.4295; GOUARDERES C, 1993, EUR J PHARMACOL, V237, P73, DOI 10.1016/0014-2999(93)90095-Y; KAVALIERS M, 1991, PEPTIDES, V12, P235, DOI 10.1016/0196-9781(91)90005-A; KIVIPELTO L, 1989, J COMP NEUROL, V286, P269, DOI 10.1002/cne.902860211; KONTINEN VK, 1995, PEPTIDES, V16, P973, DOI 10.1016/0196-9781(95)00068-U; LAKE JR, 1991, NEUROSCI LETT, V132, P29, DOI 10.1016/0304-3940(91)90425-S; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MAJANE EA, 1993, ENDOCRINOLOGY, V133, P1578, DOI 10.1210/en.133.4.1578; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Sol JC, 1999, PEPTIDES, V20, P1219, DOI 10.1016/S0196-9781(99)00126-6; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STINUS L, 1995, PEPTIDES, V16, P1235, DOI 10.1016/0196-9781(95)02019-S; Vilim FS, 1999, MOL PHARMACOL, V55, P804; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	30	225	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25965	25971		10.1074/jbc.M004515200	http://dx.doi.org/10.1074/jbc.M004515200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851242	hybrid			2022-12-27	WOS:000088999700013
J	Sagami, I; Sato, Y; Daff, S; Shimizu, T				Sagami, I; Sato, Y; Daff, S; Shimizu, T			Aromatic residues and neighboring Arg(414) in the (6R)-5,6,7,8-tetrahydro-L-biopterin binding site of full-length neuronal nitric-oxide synthase are crucial in catalysis and heme reduction with NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC CYTOCHROME P-450-CAM; TETRAHYDROBIOPTERIN-BINDING; MOLECULAR-CLONING; ELECTRON-TRANSFER; NO SYNTHASE; ESCHERICHIA-COLI; PTERIN COFACTOR; LIGAND TRANS; L-ARGININE; DOMAIN	Nitric-oxide synthase (NOS) requires the cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H4B), for catalytic activity. The crystal structures of NOSs indicate that H4B is surrounded by aromatic residues. We have mutated the conserved aromatic acids, Trp(676) Trp(678), Phe(691) His(692), and Tyr(706), together with the neighboring Ar-414 residue within the H4B binding region of full-length neuronal NOS. The W676L, W678L, and F691L mutants had no NO formation activity and had very low heme reduction rates (<0.02 min(-1)) with NADPH, Thus, it appears that Trp(676), Trp(678), and Phe(691) are important to retain the appropriate active site conformation for H4B/L-Arg binding and/or electron transfer to the heme from NADPH, The mutation of Tyr(706) to Leu and Phe decreased the activity down to 13 and 29%, respectively, of that of the wild type together with a dramatically increased EC50 value for H4B (30-40-fold of wild type). The Tyr706 phenol group interacts with the heme propionate and Arg(414) amine via hydrogen bonds. The mutation of Ar-414 to Leu and Glu resulted in the total loss of NO formation activity and of the heme reduction with NADPH, Thus, hydrogen bond networks consisting of the heme carboxylate, Tyr(706), and Arg(414) are crucial in stabilizing the appropriate conformation(s) of the heme active site for H4B/L-Arg binding and/or efficient electron transfer to occur.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, I (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.							ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Feelisch M., 1996, METHODS NITRIC OXIDE; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Gorren ACF, 1998, BIOCHEM J, V331, P801, DOI 10.1042/bj3310801; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; IGNARRO L, 1996, NITRIC OXIDE BIOCH M; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Maines MD., 1996, NITRIC OXIDE SYNTHAS; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; SONO M, 1982, J BIOL CHEM, V257, P5496; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; WHITE RE, 1982, J BIOL CHEM, V257, P3073; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	52	26	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26150	26157		10.1074/jbc.M000534200	http://dx.doi.org/10.1074/jbc.M000534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846172	hybrid			2022-12-27	WOS:000088999700038
J	Liu, Z; Chen, Y; Mo, R; Hui, CC; Cheng, JF; Mohandas, N; Huang, CH				Liu, Z; Chen, Y; Mo, R; Hui, CC; Cheng, JF; Mohandas, N; Huang, CH			Characterization of human RhCG and mouse Rhcg as novel nonerythroid Rh glycoprotein homologues predominantly expressed in kidney and testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE-MEMBRANE; BLOOD-GROUP POLYPEPTIDES; GROUP ANTIGEN EXPRESSION; INSITU HYBRIDIZATION; GENE STRUCTURE; NULL DISEASE; PROTEIN; SEQUENCE; ORGANIZATION; TRANSPORT	In mammals, the Rh family includes the variable Rh polypeptides and invariant RhAG glycoprotein. These polytopic proteins are confined to the erythroid lineage and are assembled into a multisubunit complex essential for Rfi antigen expression and plasma membrane integrity. Here, we report the characterization of RhCG and Rhcg, a pair of novel Rh homologues present in human and mouse nonerythroid tissues. Despite sharing a notable similarity to the erythroid forms, including the 12-transmembrane topological fold, the RHCG/Rhcg pair is distinct in chromosome location, genomic organization, promoter structure, and tissue-specific expression. RHCG and Rhcg map at 15q25 of human chromosome 15 and the long arm of mouse chromosome 7, respectively, each having 11 exons and a CpG-rich promoter. Northern blots detected kidney and testis as the major organs of RHCG or Rhcg expression. In situ hybridization revealed strong expression of Rhcg in the kidney collecting tubules and testis seminiferous tubules. Confocal imaging of transiently expressed green fluorescence protein fusion proteins localized RhCG exclusively to the plasma membrane, a distribution confirmed by cellular fractionation and Western blot analysis. In vitro translation and ex vivo expression showed that RhCG carries a complex N-glycan, probably at the (NLS50)-N-48 sequon of exoloop 1. These results pinpoint RhCG and Rhcg as novel polytopic membrane glycoproteins that may function as epithelial transporters maintaining normal homeostatic conditions in kidney and testis.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, New York, NY 10021 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	New York Blood Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Huang, CH (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, 310 E 67th St, New York, NY 10021 USA.			Cheng, Jan-Fang/0000-0001-7315-7613	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blancher A., 1997, MOL BIOL EVOLUTION B, P147; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carritt B, 1997, HUM MOL GENET, V6, P843, DOI 10.1093/hmg/6.6.843; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; CHUMAKOV IM, 1995, NATURE, V377, P175; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; Fawcett D., 1994, TXB HISTOLOGY; FONG AD, 1990, BIOCHIM BIOPHYS ACTA, V1022, P325, DOI 10.1016/0005-2736(90)90281-R; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Huang CH, 1999, AM J HEMATOL, V62, P25, DOI 10.1002/(SICI)1096-8652(199909)62:1<25::AID-AJH5>3.0.CO;2-K; Huang CH, 1998, BLOOD, V92, P1776, DOI 10.1182/blood.V92.5.1776.417k25_1776_1784; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; Huang CH, 1998, J BIOL CHEM, V273, P2207, DOI 10.1074/jbc.273.4.2207; Huang CH, 1996, BLOOD, V88, P2326, DOI 10.1182/blood.V88.6.2326.bloodjournal8862326; Huang CH, 1997, BLOOD, V90, P391; HUANG CH, 2000, IN PRESS J MOL EVOL; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Iwamoto S, 1998, BIOCHEM BIOPH RES CO, V243, P233, DOI 10.1006/bbrc.1997.8023; Kaiser BN, 1998, SCIENCE, V281, P1202, DOI 10.1126/science.281.5380.1202; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Z, 1999, BIOCHEM GENET, V37, P119, DOI 10.1023/A:1018726303397; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Matassi G, 1998, GENOMICS, V47, P286, DOI 10.1006/geno.1997.5112; MCKUSICK VA, 1999, HUMAN GENOME DATABAS; MOLLISON PL, 1997, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROIT AJ, 1990, BIOCHEMISTRY-US, V29, P10303, DOI 10.1021/bi00497a003; Seack J, 1997, IMMUNOGENETICS, V46, P493, DOI 10.1007/s002510050310; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH RE, 1990, BLOOD, V76, P1021; TOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	47	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25641	25651		10.1074/jbc.M003353200	http://dx.doi.org/10.1074/jbc.M003353200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10852913	hybrid			2022-12-27	WOS:000088849400079
J	Schmitt, JM; Stork, PJS				Schmitt, JM; Stork, PJS			beta(2)-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein Rap1 and the serine/threonine kinase B-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; COUPLED RECEPTORS; MAP KINASE; DEPENDENT ACTIVATION; TYROSINE KINASE; CYCLIC-AMP; ADENYLYL CYCLASE; ONCOGENIC RAS; 3T3 CELLS	G protein-coupled receptors can induce cellular proliferation by stimulating the mitogen-activated protein (MAP) kinase cascade. Heterotrimeric G proteins are composed of both alpha and beta gamma subunits that can signal independently to diverse intracellular signaling pathways including those that activate MAP kinases. In this study, we examined the ability of isoproterenol, an agonist of the beta(2)-adrenergic receptor (beta(2)AR), to stimulate extracellular signal-regulated kinases (ERKs). Using HEK293 cells, which express endogenous beta(2)AR, we show that isoproterenol stimulates ERKs via beta(2)AR. This action of isoproterenol requires cAMP-dependent protein kinase and is insensitive to pertussis toxin, suggesting that G alpha(s) activation of cAMP-dependent protein kinase is required. Interestingly, beta(2)AR activates both the small G proteins Rap1 and Res, but only Rap1 is capable of coupling to Raf isoforms. beta(2)AR inhibits the Ras-dependent activation of both Raf isoforms Raf-1 and B-Raf, whereas Rap1 activation by isoproterenol recruits and activates B-Raf. beta(2)AR activation of ERKs is not blocked by expression of RasN17, an interfering mutant of Ras, but is blocked by expression of either RapN17 or Rap1GAP1, both of which interfere with Rap1 signaling. We propose that isoproterenol can activate ERKs via Rap1 and B-Raf in these cells.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	stork@ohsu.edu						Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Beavo J A, 1975, Adv Cyclic Nucleotide Res, V5, P241; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Butcher R W, 1968, Adv Enzyme Regul, V6, P357, DOI 10.1016/0065-2571(68)90023-X; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen TS, 1999, CANCER RES, V59, P213; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; IISMAA T P, 1992, Current Opinion in Cell Biology, V4, P195, DOI 10.1016/0955-0674(92)90033-9; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MOROZOV A, 1999, NEUR M OCT 23 29 MIA; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1999, MOL CELL BIOL, V19, P6057; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	76	148	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25342	25350		10.1074/jbc.M003213200	http://dx.doi.org/10.1074/jbc.M003213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840035	Green Submitted, hybrid			2022-12-27	WOS:000088849400041
J	Graff, JR; Konicek, BW; McNulty, AM; Wang, ZJ; Houck, K; Allen, S; Paul, JD; Hbaiu, A; Goode, RG; Sandusky, GE; Vessella, RL; Neubauer, BL				Graff, JR; Konicek, BW; McNulty, AM; Wang, ZJ; Houck, K; Allen, S; Paul, JD; Hbaiu, A; Goode, RG; Sandusky, GE; Vessella, RL; Neubauer, BL			Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27(Kip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; INITIATION-FACTOR 4E; INHIBITOR P27(KIP1); NEGATIVE REGULATION; ANDROGEN RECEPTOR; CELL-SURVIVAL; MESSENGER-RNA; PHOSPHORYLATION; PATHWAY	The PTEN tumor suppressor gene is frequently inactivated in human prostate cancers, particularly in more advanced cancers, suggesting that the AKT/protein kinase B (PKB) kinase, which is negatively regulated by PTEN, may be involved in human prostate cancer progression. me now show that ART activation and activity are markedly increased in androgen-independent, prostate-specific antigen-positive prostate cancer cells (LNAI cells) established from xenograft tumors of the androgen-dependent LNCaP cell line. These LNAI cells show increased expression of integrin-linked kinase, which is putatively responsible for AKT activation/Ser-473 phosphorylation, as well as for increased phosphorylation of the AKT target protein, BAD. Furthermore, expression of the p27(Kip1) cell cycle regulator was diminished in LNAI cells, consistent with the notion that AKT directly inhibits AFX/Forkhead-mediated transcription of p27(Kip1). To assess directly the impact of increased AKT activity on prostate cancer progression, an activated hAKT1 mutant was overexpressed in LNCaP cells, resulting in a B-fold increase in xenograft tumor growth. Like LNAI cells, these transfectants showed dramatically reduced p271(Kip1) expression. Together, these data implicate increased AKT activity in prostate tumor progression and androgen independence and suggest that diminished p27(Kip1) expression, which has been repeatedly associated with prostate cancer progression, may be a consequence of increased AKT activity.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Div Eli Lilly & Co, Sphinx Pharmaceut, Durham, NC 27707 USA	Eli Lilly; University of Washington; University of Washington Seattle; Eli Lilly	Graff, JR (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, DC 0546, Indianapolis, IN 46285 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249				Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; ATTIA MAM, 1966, CANCER RES, V26, P1787; Berges RR, 1995, CLIN CANCER RES, V1, P473; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Marzo AM, 1998, AM J PATHOL, V153, P911, DOI 10.1016/S0002-9440(10)65632-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Denmeade SR, 1996, PROSTATE, V28, P251; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gioeli D, 1999, CANCER RES, V59, P279; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Ittmann MM, 1998, ONCOL REP, V5, P1329; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; McConkey DJ, 1996, CANCER RES, V56, P5594; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Russell PJ, 1998, CLIN CHEM, V44, P705; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsihlias J, 1998, CANCER RES, V58, P542; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Webber MM, 1997, PROSTATE, V30, P58; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	46	328	348	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24500	24505		10.1074/jbc.M003145200	http://dx.doi.org/10.1074/jbc.M003145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827191	hybrid			2022-12-27	WOS:000088683300036
J	Saha, AK; Schwarsin, AJ; Roduit, R; Masse, F; Kaushik, V; Tornheim, K; Prentki, M; Ruderman, NB				Saha, AK; Schwarsin, AJ; Roduit, R; Masse, F; Kaushik, V; Tornheim, K; Prentki, M; Ruderman, NB			Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; SOLEUS MUSCLE; CARBOXYLASE; HEART; DIACYLGLYCEROL; PURIFICATION; CLONING; CELL; MCD	Alterations in the concentration of malonyl-CoA, an inhibitor of carnitine palmitoyltransferase I, have been linked to the regulation of fatty acid oxidation in skeletal muscle. During contraction decreases in muscle malonyl-CoA concentration have been related to activation of AMP-activated protein kinase (AMPK), which phosphorylates and inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in malonyl-CoA formation. We report here that the activity of malonyl-CoA decarboxylase (MCD) is increased in contracting muscle, Using either immunopurified enzyme or enzyme partially purified by (NH4)(2)SO4 precipitation, 2-3-fold increases in the V-max of MCD and a 40% decrease in its K-m for malonyl-CoA (190 versus 119 mu M) were observed in rat gastrocnemius muscle after 5 min of contraction, induced by electrical stimulation of the sciatic nerve. The increase in MCD activity was markedly diminished when immunopurified enzyme was treated with protein phosphatase 2A or when phosphatase inhibitors were omitted from the homogenizing solution and assay mixture. Incubation of extensor digitorum longus muscle for 1 h with 2 mM 5-aminoimidazole-4-carboxamide-1-beta-D-rib furanoside, a cell-permeable activator of AMPK, increased MCD activity g-fold, Here, too, addition of protein phosphatase 2A to the immunopellets reversed the increase of MCD activity. The results strongly suggest that activation of AMPK during muscle contraction leads to phosphorylation of MCD and an increase in its activity. They also suggest a dual control of malonyl-CoA concentration by ACC and MCD, via AMPK, during exercise.	Boston Med Ctr, Diabet Unit, Endocrinol Sect, Boston, MA 02118 USA; Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Med Ctr, Dept Physiol, Boston, MA 02118 USA; Boston Med Ctr, Dept Biochem, Boston, MA 02118 USA; Univ Montreal, Dept Nutr, Mol Nutr Unit, Montreal, PQ H2L 4M1, Canada; Univ Montreal, CR CHUM, Montreal, PQ H2L 4M1, Canada	Boston Medical Center; Boston Medical Center; Boston Medical Center; Boston Medical Center; Universite de Montreal; Universite de Montreal	Saha, AK (corresponding author), Boston Med Ctr, Diabet & Metab Unit, 650 Albany St,EBRC-827, Boston, MA 02118 USA.		Roduit, Raphael/AAC-3890-2021	Roduit, Raphael/0000-0001-7440-2799; Tornheim, Keith/0000-0002-6235-5128; Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, R01DK049147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49147, DK 19514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN KS, 1994, AM J PHYSIOL, V266, pE479, DOI 10.1152/ajpendo.1994.266.3.E479; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Dyck JRB, 1998, AM J PHYSIOL-HEART C, V275, pH2122, DOI 10.1152/ajpheart.1998.275.6.H2122; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hutber C. Adrian, 1997, American Journal of Physiology, V272, pE262; JANG SH, 1989, J BIOL CHEM, V264, P3500; KIM YS, 1979, INT J BIOCHEM, V10, P551; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P234, DOI 10.1016/0003-9861(78)90273-4; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Rasmussen BB, 1997, J APPL PHYSIOL, V83, P1104, DOI 10.1152/jappl.1997.83.4.1104; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Saha AK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1030, DOI 10.1152/ajpendo.1999.276.6.E1030; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Voilley N, 1999, BIOCHEM J, V340, P213, DOI 10.1042/0264-6021:3400213; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299	25	158	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24279	24283		10.1074/jbc.C000291200	http://dx.doi.org/10.1074/jbc.C000291200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10854420	hybrid			2022-12-27	WOS:000088683300008
J	Yang, Y; Sowden, MP; Smith, HC				Yang, Y; Sowden, MP; Smith, HC			Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOORING SEQUENCE; SECONDARY STRUCTURE; BINDING PROTEINS; IN-VITRO; COMPLEX; TISSUE; RAT; CLONING; LIVER	post-transcriptional editing of apolipoprotein B (apoB) mRNA is regulated in hepatic cells to achieve a steady state proportion of edited and unedited RNA molecules. This activity is catalyzed by APOBEC-1 apoB mRNA editing catalytic subunit 1) in what has been widely accepted as nuclear event occurring during or after mRNA splicing. Introns impair the efficiency of editing within an adjacent exon in a distance-dependent manner in reporter RNAs. We show here that this inhibition can be overcome by overexpressing APOBEC-1 and that the enhanced editing efficiency on these reporter RNAs occurred after splicing on cytoplasmic transcripts. Given the absolute requirement of auxiliary proteins in apoB mRNA editing, the data suggested that auxiliary proteins were distributed with APOBEC-1 in both the nucleus and cytoplasm of McArdle cells. In fact, immunolocalization of one such auxiliary protein, APOBEC-1 complementation factor (ACP) demonstrated a nuclear and cytoplasmic distribution. We also demonstrate that in the absence of alterations in APOBEC-1 expression, changes in edited apoB RNA induced by ethanol arise through the stimulation of nuclear editing activity. The finding that apoB mRNA editing can occur in the cytoplasm but normally does not suggests that under biological conditions, restricting editing activity to the nucleus must be an important step in regulating the proportion of the edited apoB mRNAs.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Environm Hlth Sci, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Smith, HC (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.	harold_smith@urmc.rochester.edu		Smith, Harold/0000-0001-6257-6791	NIDDK NIH HHS [DK43739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1997, NUCL ACIDS S SER, V36, P115; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; Chen L, 1996, J THEOR BIOL, V183, P391, DOI 10.1006/jtbi.1996.0230; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1993, ANN MED, V25, P539; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1995, J LIPID RES, V36, P2069; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Siddiqui JFM, 1999, EXP CELL RES, V252, P154, DOI 10.1006/excr.1999.4598; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Sowden M, 1996, RNA, V2, P274; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Steinburg MF, 1999, BIOCHEM BIOPH RES CO, V263, P81, DOI 10.1006/bbrc.1999.1329; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Van Mater D, 1998, BIOCHEM BIOPH RES CO, V252, P334, DOI 10.1006/bbrc.1998.9647; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	42	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22663	22669		10.1074/jbc.M910406199	http://dx.doi.org/10.1074/jbc.M910406199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10833526	hybrid			2022-12-27	WOS:000088419400012
J	Colucci-D'Amato, GL; D'Alessio, A; Califano, D; Cali, G; Rizzo, C; Nitsch, L; Santelli, G; de Franciscis, V				Colucci-D'Amato, GL; D'Alessio, A; Califano, D; Cali, G; Rizzo, C; Nitsch, L; Santelli, G; de Franciscis, V			Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; PROTEIN-TYROSINE-PHOSPHATASE; MEDULLARY-THYROID CARCINOMA; CELL-LINES; PC12 CELLS; SIGNALING PATHWAY; MEN 2A; PROTOONCOGENE; ACTIVATION; MUTATIONS	Oncogenic variants of the receptor tyrosine kinase, Ret, cause formation of tumors of neuroendocrine derivation in the multiple endocrine neoplasia type 2 and, thus, likely interfere with antiproliferative and/or differentiative extracellular signals. Here we took advantage of two rat pheochromocytoma-derived cell lines (PC12/MEN2A and PC12/MEN2B) to investigate whether Bet-induced nerve growth factor (NGF) unresponsiveness might involve impairment of ERK signaling. In fact, these cells, stably transfected with distinct forms of the active ret oncogene, fail to block proliferation, even upon NGF stimulation. In these cells we show the presence of both chronic ERKs activity and high expression levels of MKP-3, an ERK-specific phosphatase, Despite the presence of MKP-3, ERK activity can be further stimulated by NGF, but it fails to translocate into the nucleus and consequently to induce immediate-early gene transcription. Because of the presence of MKP-3, our results suggest the existence of a negative regulatory feedback acting on ERKs as a mechanism responsible for the abrogation of NGF-induced terminal differentiation. Indeed, MKP-3 seems to be implicated in the persistence of ERKs in cell cytoplasm, This interpretation is further supported by the observation that in ret-transfected cells, forced expression of an active form of MEK-1 may overcome this block; it restores transcription from the c-fos promoter, induces translocation of ERKs into the nucleus, and inhibits cell proliferation.	Univ Naples Federico II, CNR G Salvatore,Fac Med & Chirurg, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fdn G Pascale, Ist Nazl Tumori, I-80131 Naples, Italy	University of Naples Federico II; IRCCS Fondazione Pascale	de Franciscis, V (corresponding author), Univ Naples Federico II, CNR G Salvatore,Fac Med & Chirurg, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	defranci@unina.it	Califano, Daniela/Y-6313-2018	Califano, Daniela/0000-0001-6945-3209	Telethon [A.097] Funding Source: Medline	Telethon(Fondazione Telethon)		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1994, ONCOGENE, V9, P3379; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Missale C, 1998, P NATL ACAD SCI USA, V95, P5366, DOI 10.1073/pnas.95.9.5366; Missale C, 1996, MOL ENDOCRINOL, V10, P272, DOI 10.1210/me.10.3.272; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PONDER BAJ, 1996, GENETIC MECHANISMS M, P21; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Powers JF, 1998, ENDOCR PATHOL, V9, P325, DOI 10.1007/BF02739692; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SMITH DP, 1994, J CELL SCI, P43; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	47	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19306	19314		10.1074/jbc.275.25.19306	http://dx.doi.org/10.1074/jbc.275.25.19306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858459	hybrid			2022-12-27	WOS:000087815900090
J	Williams, DL; de la Llera-Moya, M; Thuahnai, ST; Lund-Katz, S; Connelly, MA; Azhar, S; Anantharamaiah, GM; Phillips, MC				Williams, DL; de la Llera-Moya, M; Thuahnai, ST; Lund-Katz, S; Connelly, MA; Azhar, S; Anantharamaiah, GM; Phillips, MC			Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic alpha-helix as a recognition motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; SELECTIVE UPTAKE; CHOLESTERYL ESTER; STEROIDOGENIC CELLS; TARGETED MUTATION; ADRENAL-CELLS; RAT; METABOLISM; EXPRESSION	Scavenger receptor, class B, type I (SR-BI) mediates the selective uptake of high density lipoprotein (HDL) cholesteryl ester without the uptake and degradation of the particle. In transfected cells SR-BI recognizes HDL, low density lipoprotein (LDL) and modified LDL, protein-free lipid vesicles containing anionic phospholipids, and recombinant lipoproteins containing apolipoprotein (apo) A-I, apoA-II, apoE, or apoCIII, The molecular basis for the recognition of such diverse ligands by SR-BI is unknown. We have used direct binding analysis and chemical cross-linking to examine the interaction of murine (m) SR-BI with apoA-I, the major protein of HDL. The results show that apoA-I in apoA-I/palmitoyl-oleoylphosphatidylcholine discs, HDL3, or in a lipid-free state binds to mSR-BI with high affinity (K-d congruent to 5-8 mu g/ml). ApoA-I in each of these forms was efficiently cross-linked to cell surface mSR-BI, indicating that direct protein-protein contacts are the predominant feature that drives the interaction between HDL and mSR-BI. When complexed with dimyristoylphosphatidylcholine, the N-terminal and C-terminal CNBr fragments of apoA-I each bound to SR-BI in a saturable, high affinity manner, and each cross-linked efficiently to mSR-BI. Thus, mSR-BI recognizes multiple sites in apoA-I, A model class A amphipathic alpha-helix, 37pA, also showed high affinity binding and cross-linking to mSR-BI. These studies identify the amphipathic alpha-helix as a recognition motif for SR-BI and lead to the hypothesis that mSR-BI interacts with HDL via the amphipathic cw-helical repeat units of apoA-I. This hypothesis explains the interaction of SR-BI with a wide variety of apolipoproteins via a specific secondary structure, the class A amphipathic alpha-helix, that is a common structural motif in the apolipoproteins of HDL, as well as LDL.	SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19129 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Univ Alabama, Med Ctr, Arteriosclerosis Res Unit, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Drexel University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Alabama System; University of Alabama Birmingham	Williams, DL (corresponding author), SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, P01HL022633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049705] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58012, HL 22633] Funding Source: Medline; NIDDK NIH HHS [DK 49705] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1989, J LIPID RES, V30, P1799; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1990, J BIOL CHEM, V265, P12217; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; REAVEN E, 1989, J LIPID RES, V30, P1551; Reaven E, 1999, BBA-MOL CELL BIOL L, V1436, P565, DOI 10.1016/S0005-2760(98)00169-6; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2000, J LIPID RES, V41, P343; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; VANLOO B, 1991, J LIPID RES, V32, P1253; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Xu SZ, 1997, J LIPID RES, V38, P1289	48	94	98	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18897	18904		10.1074/jbc.M002411200	http://dx.doi.org/10.1074/jbc.M002411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858447	hybrid			2022-12-27	WOS:000087815900039
J	Jensen, AA; Spalding, TA; Burstein, ES; Sheppard, PO; O'Hara, PJ; Brann, MR; Krogsgaard-Larsen, P; Brauner-Osborne, H				Jensen, AA; Spalding, TA; Burstein, ES; Sheppard, PO; O'Hara, PJ; Brann, MR; Krogsgaard-Larsen, P; Brauner-Osborne, H			Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor - Constitutive activity and inverse agonism in a family C G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; RANDOM SATURATION MUTAGENESIS; HUMAN CA2+ RECEPTOR; CA2+-SENSING RECEPTOR; MUSCARINIC RECEPTOR; EXTRACELLULAR DOMAIN; TERMINAL DOMAIN; LIGAND-BINDING; SPORADIC HYPOPARATHYROIDISM; ACTIVATING MUTATIONS	The calcium-sensing receptor (CaR) belongs to family C of the G-protein-coupled receptor superfamily. To date 14 activating mutations in Call showing increased sensitivity to Ca2+ have been identified in humans with autosomal dominant hypocalcemia. Four of these activating mutations are found in the Ala(116)-Pro(136) region of CaR, indicating that this part of the receptor is particularly sensitive to mutation-induced activation. This region was subjected to random saturation mutagenesis, and 219 mutant receptor clones were isolated and screened pharmacologically in a high throughput screening assay. Selected mutants were characterized further in an inositol phosphate assay. The vast majority of the mutants tested displayed an increased affinity for Ca2+. Furthermore, 21 of the mutants showed increased basal activity in the absence of agonist. This constitutive activity was not diminished when the mutations were transferred to a chimeric receptor Ca/la consisting of the amino-terminal domain of the CaR and the 7 transmembrane and intracellular domains of the metabotropic glutamate receptor mGluR1a. CPCCOEt, a noncompetitive antagonist acting at the 7 transmembrane domain of mGluR1a, suppressed the elevated basal response of the constitutively activated Calla mutants demonstrating inverse agonist activity of CPCCOEt Taken together, our results demonstrate that the Ala(116)-Pro(136) region is of key importance for the maintenance of the inactive conformation of CaR.	Royal Danish Sch Pharm, Dept Med Chem, NauroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; ZymoGenet Inc, Seattle, WA 98102 USA	Royal Danish School of Pharmacy; Zymogenet Inc.	Brauner-Osborne, H (corresponding author), Royal Danish Sch Pharm, Dept Med Chem, NauroSci PharmaBiotec Res Ctr, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	hbo@dfh.dk	Jensen, Anders/AAJ-3335-2020; Bräuner-Osborne, Hans/D-7260-2011	Jensen, Anders/0000-0002-7927-5052; Bräuner-Osborne, Hans/0000-0001-9495-7388				Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brauner-Osborne H, 1999, NEUROREPORT, V10, P3923; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; Chikatsu N, 1999, CLIN ENDOCRINOL, V50, P537, DOI 10.1046/j.1365-2265.1999.00729.x; Collins MT, 1998, J CLIN ENDOCR METAB, V83, P1083, DOI 10.1210/jc.83.4.1083; DeLuca F, 1997, J CLIN ENDOCR METAB, V82, P2710, DOI 10.1210/jc.82.8.2710; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kobayashi M, 1997, J CLIN ENDOCR METAB, V82, P2716, DOI 10.1210/jc.82.8.2716; Kolczewski S, 1999, BIOORG MED CHEM LETT, V9, P2173, DOI 10.1016/S0960-894X(99)00346-7; LIM K, 1989, BIOTECHNIQUES, V7, P576; Litschig S, 1999, MOL PHARMACOL, V55, P453; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Mohler H, 1999, Trends Pharmacol Sci, V20, P87, DOI 10.1016/S0165-6147(99)01323-1; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Okzaki R, 1999, J CLIN ENDOCR METAB, V84, P363; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Ward BK, 1997, HUM MUTAT, V10, P233; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Wichmann J, 1999, BIOORG MED CHEM LETT, V9, P1573, DOI 10.1016/S0960-894X(99)00227-9; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	53	55	59	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29547	29555		10.1074/jbc.M910023199	http://dx.doi.org/10.1074/jbc.M910023199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10835431	Green Submitted, hybrid			2022-12-27	WOS:000089439800050
J	Mattatall, NR; Jazairi, J; Hill, BC				Mattatall, NR; Jazairi, J; Hill, BC			Characterization of ypmQ, an accessory protein required for the expression of cytochrome c oxidase in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; COPPER TRANSPORT; SUPEROXIDE-DISMUTASE; TERMINAL OXIDASES; PLASMA-MEMBRANES; QUINOL OXIDASE; YEAST; GENE; CLONING; CHAPERONE	A search of the Bacillus subtilis genome identifies a potential homolog, ypmQ, of the inner mitochondrial membrane protein Sco1 from yeast, Sco1 has been found to aid the delivery of copper to cytochrome c oxidase, B. subtilis expresses two members of the cytochrome oxidase family, a cytochrome c oxidase that has two copper centers, Cu-A and Cu-B, and a menaquinol oxidase that has only Cu-B. Deletion of ypmQ in B. subtilis depresses expression of cytochrome c oxidase but not menaquinol oxidase, Level of cytochrome c oxidase recover when copper is added to the growth medium of the Delta ypmQ strain or when ypmQ is expressed from a plasmid, Neither treatment affects the amount or activity of menaquinol oxidase. YpmQ in which two conserved cysteines are replaced by serines and a conserved histidine is replaced by alanine do not complement the deletion of ypmQ even though these mutant forms are found in the membrane extract at a level similar to the wild type protein. Fire propose that the two cysteines and the histidine are critical for the function of YpmQ and suggest they are involved in copper exchange between YpmQ and the Cu-A site of cytochrome c oxidase.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Hill, BC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DAVID PS, 1998, THESIS QUEENS U KING; GENNIS RB, 1993, BIOCHEM SOC T, V21, P992, DOI 10.1042/bst0210992; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HENNING W, 1995, BIOCHEM J, V309, P279, DOI 10.1042/bj3090279; HILL BC, 1993, ARCH BIOCHEM BIOPHYS, V301, P129, DOI 10.1006/abbi.1993.1124; Hill BC, 1996, BIOCHEMISTRY-US, V35, P6136, DOI 10.1021/bi952486f; HILL BC, 1993, J BIOENERG BIOMEMBR, V25, P115, DOI 10.1007/BF00762853; HILL BC, 1991, J BIOL CHEM, V266, P2219; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Hunter DJB, 1997, FEBS LETT, V412, P43, DOI 10.1016/S0014-5793(97)00735-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MUELLER JP, 1989, J BACTERIOL, V171, P4967, DOI 10.1128/jb.171.9.4967-4978.1989; Papadopoulou LC, 1999, NAT GENET, V23, P333; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; SANTANA M, 1992, J BIOL CHEM, V267, P10225; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Siegal ML, 1996, BIOTECHNIQUES, V21, P614; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STEINMETZ M, 1994, GENE, V142, P79, DOI 10.1016/0378-1119(94)90358-1; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	48	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28802	28809		10.1074/jbc.M002741200	http://dx.doi.org/10.1074/jbc.M002741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10837475	hybrid			2022-12-27	WOS:000089330700062
J	Koide, T; Aso, A; Yorihuzi, T; Nagata, K				Koide, T; Aso, A; Yorihuzi, T; Nagata, K			Conformational requirements of collagenous peptides for recognition by the chaperone protein HSP47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL PEPTIDES; BINDING STRESS PROTEIN; X-Y TRIPLETS; MOLECULAR CHAPERONE; ENDOPLASMIC-RETICULUM; MODEL PEPTIDES; PROCOLLAGEN; STABILITY; RESIDUES; LIBRARY	The collagen binding chaperone HSP47 interacts with procollagen in the endoplasmic reticulum and plays a crucial role in the biosynthesis of collagen. We recently demonstrated that typical collagen model peptides, (Pro-Pro-Gly)(n), possess sufficient structural information for interaction with HSP47 (Koide, T., Asada, S., and Nagata, K. (1999) J. Biol. Chem. 274, 34523-34526). Here we show that binding of (Gly-Pro-Pro), peptides to HSP47 can be detected using the two-hybrid system in yeast if a trimerizing domain is fused to the C termini of the peptides. Some peptides interacted with HSP47 at a lowered assay temperature at 24 degrees C but not at 30 degrees C, indicating the importance of conformational change of the substrate peptides, To analyze the spectrum of HSP47 substrate sequences, we performed two-hybrid screening of collagen-like peptides in designed random peptide libraries using HSP47 as a bait. In selected peptides, the enrichment ratio calculated for each amino acid residue correlated strongly with the contribution of the residue to triple-helix stability independently determined using synthetic collagen model peptides. Taken together, our results suggest that HSP47 preferentially recognizes collagenous Gly-X-Y repeats in triple-helical conformation. We also demonstrated that screening of combinatorial peptide libraries is a powerful strategy to determine conformational requirements as web as the elucidation of binding motifs in primary structure.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan	Kyoto University	Nagata, K (corresponding author), Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto, Japan.	nagata@frontier.kyoto-u.ac.jp						Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Asada S, 1999, CELL STRUCT FUNCT, V24, P187, DOI 10.1247/csf.24.187; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Feng YB, 1997, BIOCHEMISTRY-US, V36, P8716, DOI 10.1021/bi962980z; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Hegyi H, 1997, J PROTEIN CHEM, V16, P545, DOI 10.1023/A:1026382032119; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27957	27963						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862616				2022-12-27	WOS:000089197100059
J	Evans, RL; Park, K; Turner, RJ; Watson, GE; Nguyen, HV; Dennett, MR; Hand, AR; Flagella, M; Shull, GE; Melvin, JE				Evans, RL; Park, K; Turner, RJ; Watson, GE; Nguyen, HV; Dennett, MR; Hand, AR; Flagella, M; Shull, GE; Melvin, JE			Severe impairment of salivation in Na+/K+/2Cl(-) cotransporter (NKCC1)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; NHE3 NA+/H+ EXCHANGER; NA+-K+-2CL(-) COTRANSPORTER; FLUID SECRETION; UP-REGULATION; MUSCARINIC STIMULATION; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; TARGETED DISRUPTION; CL COTRANSPORTER	The salivary fluid secretory mechanism is thought to require Na+/K+/2Cl(-) cotransporter-mediated Cl- uptake. To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na+/R+/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na+/K+/2Cl(-) cotransporter. In wildtype mice NKCC1 was localized to the basolateral membranes of parotid acinar cells, whereas expression was not detected in duct cells. The lack of functional NKCC1 resulted in a dramatic reduction (>60%) in the volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signal, Consistent with defective Cl- uptake, a loss of bumetanide-sensitive Cl- influx was observed in parotid acinar cells from mice lacking NKCC1. Cl-/HCO3- exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl- uptake. Indeed, expression of the Cl-/HCO3- exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na+/K+/2Cl(-) cotransporter. Furthermore, the ability of the parotid gland to conserve NaCl was abolished in NKCC1-deficient mice. This deficit was not associated with changes in the morphology of the ducts, but transcript levels for the alpha-, beta-, and gamma-subunits of the epithelial Na+ channel were reduced. These data directly demonstrate that NKCC1 is the major Cl- uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.	Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; NIDCR, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Dept Pediat Dent, Farmington, CT 06030 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Connecticut; University System of Ohio; University of Cincinnati	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.			Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921, Z01DE000415, ZIADE000415, P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921, DE13539] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARREOLA J, 1996, J GEN PHYSIOL, V108, P1; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; CASE RM, 1984, J PHYSIOL-LONDON, V349, P619, DOI 10.1113/jphysiol.1984.sp015177; Cook D. I., 1994, P1061; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; Field EA, 1997, BRIT J ORAL MAX SURG, V35, P96, DOI 10.1016/S0266-4356(97)90683-5; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOX PC, 1985, J AM DENT ASSOC, V110, P519, DOI 10.14219/jada.archive.1985.0384; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hayashi T, 1996, J MEMBRANE BIOL, V152, P253, DOI 10.1007/s002329900103; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Longman L P, 1995, Gerodontology, V12, P67, DOI 10.1111/j.1741-2358.1995.tb00133.x; MANDEL ID, 1989, J AM DENT ASSOC, V119, P298, DOI 10.14219/jada.archive.1989.0211; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Mount DB, 1998, J EXP BIOL, V201, P2091; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; NOVAK I, 1986, PFLUG ARCH EUR J PHY, V407, P649, DOI 10.1007/BF00582647; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; Paulais M, 1996, AM J PHYSIOL-GASTR L, V270, pG213, DOI 10.1152/ajpgi.1996.270.1.G213; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	48	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26720	26726						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10831596				2022-12-27	WOS:000089144800009
J	Barok, Z; Li, X; Fernandes, VFJ; Zhou, B; Ann, DK; Crandall, ED				Barok, Z; Li, X; Fernandes, VFJ; Zhou, B; Ann, DK; Crandall, ED			Differential regulation of rat aquaporin-5 promoter/enhancer activities in lung and salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-C; GENE-EXPRESSION; ALTERNATIVE PROMOTERS; MONOCLONAL-ANTIBODIES; WATER CHANNELS; CLONING; T1-ALPHA; CULTURE; TISSUES	Aquaporin-5 (AQP5) is a water channel protein that is selectively expressed in respiratory, salivary, and lacrimal tissues. In order to establish the tissue-specific transcriptional programs that underlie its lung and salivary-specific expression, a 4,5-kilobase pair DNA fragment encompassing the 5'-flanking region of the rat AQP5 gene has been characterized in detail. A major transcription start site utilized in lung and salivary glands has been localized downstream of a TATAA-like motif, Transient transfection assays of -4,3- and -1.7-AQP5-luciferase constructs in AQP5-expressing lung (MLE-15) and salivary (Pa-4) cells and nonexpressing fibroblast (NIH3T3) and epithelial (HeLa) cells demonstrate preferential transcriptional enhancement of reporter activities in MLE-15 and Pa-4 cells. Transient transfection assays of a series of 5' -> 3' deletion constructs of -4.3-AQP5-luciferase suggest that a common salivary and lung enhancer is located between nucleotides -274 and -139, and a lung-specific enhancer is located between nucleotides -894 and -710. There is one putative lung-specific repressor located in the region of nucleotides -1003/-894 and a common lung and salivary repressor located at nucleotides -503/-385, Moreover, 3' -> 5' deletions up to -171 and -127 base pairs almost abolish transcriptional activation in salivary and lung cells, respectively. Together, our findings indicate that the combination of enhancer/repressor elements within the proximal 5'-flankinng region of rat AQP5 gene dictates its restricted expression in both lung and salivary cells.	Univ So Calif, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Will Rogers Inst Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Barok, Z (corresponding author), Univ So Calif, Div Pulm & Crit Care Med, Dept Med, GNH 11-900,2025 Zonal Ave, Los Angeles, CA 90033 USA.	zborok@hsc.usc.edu	CRANDALL, EDWARD/AAD-8382-2020	Borok, Zea/0000-0001-8673-8177	NHLBI NIH HHS [HL38621, HL38578] Funding Source: Medline; NIDCR NIH HHS [DE 10742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038578, R01HL038621, R01HL038578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Borok Z, 1998, AM J PHYSIOL-LUNG C, V275, pL155, DOI 10.1152/ajplung.1998.275.1.L155; BOROK Z, 1994, IN VITRO CELL DEV-AN, V30A, P99; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHEEK JM, 1989, EXP CELL RES, V184, P375, DOI 10.1016/0014-4827(89)90337-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANTO SI, 1992, AM J RESP CELL MOL, V6, P296, DOI 10.1165/ajrcmb/6.3.296; DANTO SI, 1995, AM J RESP CELL MOL, V12, P497, DOI 10.1165/ajrcmb.12.5.7742013; DIGLIO CA, 1977, LAB INVEST, V37, P622; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; Dobbs LG, 1998, P NATL ACAD SCI USA, V95, P2991, DOI 10.1073/pnas.95.6.2991; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; HAMMAN S, 1998, AM J PHYSIOL, V274, pC1332; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; INASE N, 1995, J BIOL CHEM, V270, P17913, DOI 10.1074/jbc.270.30.17913; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KIKKAWA Y, 1975, LAB INVEST, V32, P295; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Koyama N, 1999, AM J RESP CRIT CARE, V159, pA293; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Lee MD, 1996, J BIOL CHEM, V271, P8599, DOI 10.1074/jbc.271.15.8599; MASON RJ, 1985, AM REV RESPIR DIS, V131, P786; MASON RJ, 1997, LUNG SCI FDN, P543; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rai T, 1997, AM J PHYSIOL-RENAL, V273, pF264, DOI 10.1152/ajprenal.1997.273.2.F264; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Ramirez MI, 1999, DEV DYNAM, V215, P319, DOI 10.1002/(SICI)1097-0177(199908)215:4<319::AID-AJA4>3.0.CO;2-B; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Schneeberger EE., 1997, LUNG SCI FDN, V2, P535; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHANNON JM, 1992, AM J PHYSIOL, V262, pL427, DOI 10.1152/ajplung.1992.262.4.L427; Smith JK, 1999, J INTERF CYTOK RES, V19, P929, DOI 10.1089/107999099313479; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 1996, AM J RESP CELL MOL, V15, P673, DOI 10.1165/ajrcmb.15.5.8918374; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Vanderbilt JN, 1998, AM J RESP CELL MOL, V19, P662, DOI 10.1165/ajrcmb.19.4.3121; Verkman AS, 1998, AM J MED SCI, V316, P310, DOI 10.1097/00000441-199811000-00004; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3	54	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26507	26514		10.1074/jbc.M910007199	http://dx.doi.org/10.1074/jbc.M910007199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849430	hybrid			2022-12-27	WOS:000088999700086
J	Rodriguez-Pascual, F; Hausding, M; Ihrig-Biedert, I; Furneaux, H; Levy, AP; Forstermann, U; Kleinert, H				Rodriguez-Pascual, F; Hausding, M; Ihrig-Biedert, I; Furneaux, H; Levy, AP; Forstermann, U; Kleinert, H			Complex contribution of the 3 '-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene - Involvement of the RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR PROMOTER; 3' UNTRANSLATED REGION; T-CELL ACTIVATION; HUMAN DLD-1 CELLS; AU-RICH ELEMENTS; MESSENGER-RNA; CYTOKINE INDUCTION; STABILITY; TRANSCRIPTION	Cytokine stimulation of human DLD-1 cells resulted in a marked expression of nitric-oxide synthase (NOS) II mRNA and protein accompanied by only a moderate increase in transcriptional activity. Also, there was a basal transcription of the NOS II gene, which did not result in measurable NOS II expression. The 3'-untranslated region (3'-UTR) of the NOS II mRNA contains four AUUUA motifs and one AUUUUA motif, known to destabilize the mRNAs of proto-oncogenes, nuclear transcription factors, and cytokines. Luciferase reporter gene constructs containing the NOS II 3'-UTR showed a significantly reduced luciferase activity. The embryonic lethal abnormal vision (ELAV)-like protein HuR was found to bind with high affinity to the adenylate/uridylate-rich elements of the NOS II 3'-UTR. Inhibition of HuR with antisense constructs reduced the cytokine-induced NOS II mRNA, whereas overexpression of HuR potentiated the cytokine-induced NOS II expression. This provides evidence that NOS II expression is regulated at the transcriptional and post-transcriptional level. Binding of HuR to the 3'-UTR of the NOS II mRNA seems to play an essential role in the stabilization of this mRNA.	Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel	Johannes Gutenberg University of Mainz; Memorial Sloan Kettering Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinert, H (corresponding author), Univ Mainz, Dept Pharmacol, Obere Zahlbacher STr 67, D-55101 Mainz, Germany.		Rodríguez-Pascual, Fernando/Q-5100-2019; Kleinert, Hartmut/M-2988-2018	Rodríguez-Pascual, Fernando/0000-0002-9765-9578; Kleinert, Hartmut/0000-0003-2202-3548; furneaux, henry/0000-0003-2212-1017				Atasoy U, 1998, J CELL SCI, V111, P3145; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Erondu NE, 1999, MOL ENDOCRINOL, V13, P495, DOI 10.1210/me.13.3.495; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; GENG Y, 1995, J CELL BIOL, V129, P1651, DOI 10.1083/jcb.129.6.1651; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1991, J IMMUNOL, V146, P1843; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; Linscheid P, 1998, BIOCHEM BIOPH RES CO, V243, P137, DOI 10.1006/bbrc.1998.8072; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nunokawa Y, 1997, BIOCHEM BIOPH RES CO, V233, P523, DOI 10.1006/bbrc.1997.6471; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; Schutte BC, 1997, BIOTECHNIQUES, V22, P40, DOI 10.2144/97221bm06; Seiler-Tuyns A, 1999, J BIOL CHEM, V274, P21714, DOI 10.1074/jbc.274.31.21714; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	152	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26040	26049		10.1074/jbc.M910460199	http://dx.doi.org/10.1074/jbc.M910460199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859327	hybrid			2022-12-27	WOS:000088999700023
J	Smolenski, A; Poller, W; Walter, U; Lohmann, SM				Smolenski, A; Poller, W; Walter, U; Lohmann, SM			Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASCULAR SMOOTH-MUSCLE; ACTIN-BASED MOTILITY; TRANSMEMBRANE CONDUCTANCE REGULATOR; LIGHT-CHAIN PHOSPHATASE; INTACT HUMAN PLATELETS; LISTERIA-MONOCYTOGENES; CYCLIC-AMP; ELEVATING VASODILATORS; MYOSIN PHOSPHATASE	cGMP-dependent protein kinase type I (cGK I), a major constituent of the atrial natriuretic peptide (ANP)/nitric oxide/cGMP signal transduction pathway, phosphorylates the vasodilator-stimulated phosphoprotein (VASP), a member of the Ena/VASP family of proteins involved in regulation of the actin cytoskeleton. Here we demonstrate that stimulation of human umbilical vein endothelial cells (HUVECs) by both ANP and 8-(4-chlorophenylthio)guanosine 3':5'-monophosphate (8-pCPT-cGMP) activates transfected cGK I and causes detachment of VASP and its known binding partner (zyxin) from focal adhesions in >60% of cells after 30 min. The ANP effects, but not the 8-pCPT-cGMP effects, reversed after 3 h of treatment. In contrast, a catalytically inactive cGK I beta mutant (cGK I beta-K405A) was incapable of mediating these effects. VASP mutated (Ser/Thr to Ala) at all three of its established phosphorylation sites (vesicular stomatitis virus-tagged VASP-AAA mutant) was not phosphorylated by cGK I and was resistant to detaching from HUVEC focal adhesions in response to 8-pCPT-cGMP. Furthermore, activation of cGK I, but not of mutant cGK I beta-K405A, caused a 1.5-2-fold inhibition of HUVEC migration, a dynamic process highly dependent on focal adhesion formation and disassembly. These results indicate that cGK I phosphorylation of VASP results in loss of VASP and zyxin from focal adhesions, a response that could contribute to cGK alteration of cytoskeleton-regulated processes such as cell migration.	Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of Wurzburg	Lohmann, SM (corresponding author), Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	slohmann@klin-biochem.uni-wuerzburg.de	Walter, ulrich/W-2478-2017; Poller, Wolfgang/AAB-2185-2021	Walter, ulrich/0000-0001-6784-2307; Poller, Wolfgang/0000-0002-2805-6634; Smolenski, Albert/0000-0001-9210-9406				Abel Kathrin, 1996, European Journal of Cell Biology, V69, P39; Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Chen LH, 1998, CIRC RES, V82, P862; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GLUCK U, 1994, J CELL SCI, V107, P1773; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IKEDA M, 1995, HYPERTENSION, V26, P401, DOI 10.1161/01.HYP.26.3.401; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; Poller W, 1996, GENE THER, V3, P521; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REINHARD M, 1999, GUIDEBOOK CYTOSKELET, P168; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TURNER CE, 1989, J BIOL CHEM, V264, P11938; Vaandrager AB, 1997, J BIOL CHEM, V272, P4195, DOI 10.1074/jbc.272.7.4195; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WALDMANN R, 1989, EUR J PHARMACOL, V159, P317, DOI 10.1016/0014-2999(89)90165-9; WALTER U, 1980, J BIOL CHEM, V255, P3757; WOLFE L, 1989, J BIOL CHEM, V264, P4157	71	110	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25723	25732		10.1074/jbc.M909632199	http://dx.doi.org/10.1074/jbc.M909632199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851246	hybrid			2022-12-27	WOS:000088849400088
J	Valentine, JE; Kalkhoven, E; White, R; Hoare, S; Parker, MG				Valentine, JE; Kalkhoven, E; White, R; Hoare, S; Parker, MG			Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID-MEDIATED REPRESSION; INTERLEUKIN-6 GENE-EXPRESSION; NEGATIVE CROSS-TALK; NUCLEAR RECEPTORS; DNA-BINDING; ANDROGEN RECEPTOR; RETINOIC ACID; AP-1 ACTIVITY; TRANSCRIPTIONAL COACTIVATORS	The estrogen receptor (ER) suppresses transcriptional activity of the Re1A subunit of nuclear factor-KB in a hormone-dependent manner by a mechanism involving both the receptor DNA binding domain and ligand binding domain (LBD). In this study we examine the role of the ER LED in mediating ligand-dependent RelA transrepression. Both ER alpha and ER beta inhibit RelA in response to 17 beta-estradiol but not in the presence of antihormones. We have identified residues within the ER alpha LED that are responsible for receptor dimerization and show that dimerization is necessary for transactivation and transrepression. Moreover we have generated mutant receptors that have lost their ability to inhibit RelA but retain their capacity to stimulate transcription and conversely mutants that are transcriptionally defective but capable of antagonizing Re1A Overexpression of p160 and cAMP-response element-binding protein-binding protein/p300 co-activators failed to relieve repression of RelA, which is consistent with the demonstration that RelA inhibition can occur independently of these co-activators. These findings suggest it is unlikely that sequestration of these cofactors required for ER transcriptional activation can account for hormone-dependent antagonism of Re1A The identification of ER mutants that discriminate between transactivation and transrepression implies that distinct surfaces within the LED are involved in mediating these two receptor functions.	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London	Parker, MG (corresponding author), Imperial Canc Res Fund, Mol Endocrinol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 2000, GENE DEV, V14, P121; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HECK S, 1997, EMBO J, V16, P4689; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ONATE SA, 1995, SCIENCE, V270, P1354; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOGEL JJ, 1996, EMBO J, V15, P101; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	74	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25322	25329		10.1074/jbc.M002497200	http://dx.doi.org/10.1074/jbc.M002497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840033	hybrid			2022-12-27	WOS:000088849400038
J	Hingorani, K; Szebeni, A; Olson, MOJ				Hingorani, K; Szebeni, A; Olson, MOJ			Mapping the functional domains of nucleolar protein B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; LOCALIZATION SIGNALS; PHOSPHOPROTEIN B23; IDENTIFICATION; NUCLEAR; OLIGOMERIZATION; TRANSLOCATION; POLYPEPTIDES; PURIFICATION; PARTICLES	Protein B23 is a multifunctional nucleolar protein whose cellular location and characteristics strongly suggest that it is a ribosome assembly factor. The protein has nucleic acid binding, ribonuclease, and molecular chaperone activities. To determine the contributions of unique polypeptide segments enriched in certain classes of amino acid residues to the respective activities, several constructs that produced N- and C-terminal deletion mutant proteins were prepared. The C-terminal quarter of the protein was shown to be necessary and sufficient for nucleic acid binding. Basic and aromatic segments at the N- and C-terminal ends, respectively, of the nucleic acid binding region were required for activity, The molecular chaperone activity was contained in the N-terminal half of the molecule, with important contributions from both nonpolar and acidic regions. The chaperone activity also correlated with the ability of the protein to form oligomers. The central portion of the molecule was required for ribonuclease activity and possibly contains the catalytic site; this region overlapped with the chaperone-containing segment of the molecule. The C-terminal, nucleic acid-binding region enhanced the ribonuclease activity but was not essential for it. These data suggest that the three activities reside in mainly separate but partially overlapping segments of the polypeptide chain.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Olson, MOJ (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J., 1998, MOL CHAPERONES LIFE, P553; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; EICHLER DC, 1982, J BIOL CHEM, V257, P4384; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; Gerlt J. A., 1993, NUCLEASES, P1; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; HADJIOLOV AA, 1985, NUCLEOLUS RIBOSOME B, P87; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nakajima H, 2000, EUR J BIOCHEM, V267, P295, DOI 10.1046/j.1432-1327.2000.00931.x; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; UMEKAWA H, 1993, CELL MOL BIOL RES, V39, P635; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WANG DR, 1994, J BIOL CHEM, V269, P30994; Warner AK, 1999, CELL MOTIL CYTOSKEL, V44, P68; Ye XJ, 1997, J BIOL CHEM, V272, P3606, DOI 10.1074/jbc.272.6.3606; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1985, BIOCHEM PHARMACOL, V34, P4059, DOI 10.1016/0006-2952(85)90387-9; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	42	204	218	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24451	24457		10.1074/jbc.M003278200	http://dx.doi.org/10.1074/jbc.M003278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829026	hybrid			2022-12-27	WOS:000088683300029
J	Kurata, S				Kurata, S			Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; BINDING; ALPHA; CELLS	Apoptosis induced by high level oxidative stress accompanies diverse cellular biochemical events including activation of the stress signal cascades of JNK and NF-kappa B, We report here selective activation of p38 MAPK cascade and mitotic arrest under a low level oxidative stress that lacks apoptosis induction. U937 human lymphoid cells treated with low dose (0.02 mM) H2O2 rapidly caused p38 MAPK cascade activation detectable by phosphorylation of MKK3/6, p38 MAPK, activating transcription factor-a, and cAMP-responsive element-binding protein, leaving the JNK and NF-KB cascades unaffected. The p38 kinase activation was sustained for 24 h under the low level stress conditions and led to formation of polyploid nuclei. N-Acetyl-L-cysteine, a precursor of anti-oxidant glutathione, canceled both p38 MAPK activation and abnormal cell cycle progression, whereas blockage of the kinase by specific inhibitor SB203580 allowed the appearance of apoptotic cells. Thus, mimicking the effects of nocodazole, the low level oxidative stimulus caused inhibition of cell division in the M phase through p38 MAPK activation. The kinase cascade may serve as a primary transducer of cytoplasmic oxidative signals to nucleus for stress-relieving gene expression and cell cycle control before apoptosis-inducing signals are transduced, This is the first report demonstrating that oxidative stress can participate in cell cycle control by induction of a signal cascade.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Kurata, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kurata SI, 1996, J BIOL CHEM, V271, P21798, DOI 10.1074/jbc.271.36.21798; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAWN MC, 1995, SCIENCE, V267, P1353; SHULL S, 1991, J BIOL CHEM, V266, P24398; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; YAN MH, 1994, NATURE, V372, P798	28	170	175	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23413	23416		10.1074/jbc.C000308200	http://dx.doi.org/10.1074/jbc.C000308200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10856288	hybrid			2022-12-27	WOS:000088564200002
J	Behncken, SN; Billestrup, N; Brown, R; Amstrup, J; Conway-Campbell, B; Waters, MJ				Behncken, SN; Billestrup, N; Brown, R; Amstrup, J; Conway-Campbell, B; Waters, MJ			Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN EPO RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; TYROSINE KINASE; COMPLEX; IDENTIFICATION; TRANSCRIPTION; ANTIBODIES; RESIDUES; AFFINITY	Growth hormone initiates signaling by inducing homodimerization of two GH receptors. Here, we have sought to determine whether constitutively active receptor can be created in the absence of the extracellular domain by substituting it with high affinity leucine zippers to create dimers of the growth hormone receptor (GHR) signaling domain. The entire extracellular domain of the GHR was replaced by the hemagglutinin-tagged zipper sequence of either the c-Fos or c-Jun transcription factor (termed Fos-GHR and Jun-GHR, respectively). Transient transfection of Fos-GHR or Jun-GHR resulted in activation of the serine protease inhibitor 2.1 promoter in Chinese hamster ovary-K1 cells to a level equal to that achieved by fully activated wild type GHR. Furthermore, stable expression of Jun-GHR alone or Fos-GHR and Jun-GHR together in the interleukin 3-dependent BaF-B03 cell line resulted in cell proliferation after interleukin 3 withdrawal at a rate equal to maximally stimulated wild type GHR-expressing cells. Activation of STAT 5b was also observed in Fos-Jun-GHR-expressing cells at a level equal to that in chronically GH-treated GHR-expressing cells. Thus, forced dimerization of the transmembrane and cytoplasmic domains of the GHR in the absence of the extracellular domain can lead to the constitutive activation of known GH signaling end points, supporting the view that proximity of Janus kinase 2 (JAK2) kinases is the essential element in signaling. Such constitutively active GH receptors may have particular utility for transgenic live-stock applications.	Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Hagedorn Res Inst, DK-2820 Gentofte, Denmark	University of Queensland; University of Queensland; Novo Nordisk; Hagedorn Research Institute	Waters, MJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia.		waters, michael j/C-9582-2014; Conway-Campbell, Becky/B-8571-2009	Billestrup, Nils/0000-0002-4968-8067				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Behncken SN, 1997, J BIOL CHEM, V272, P27077, DOI 10.1074/jbc.272.43.27077; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Chen CM, 1997, J BIOL CHEM, V272, P5133, DOI 10.1074/jbc.272.8.5133; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Mellado M, 1997, J BIOL CHEM, V272, P9189; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Patel N, 1996, J BIOL CHEM, V271, P30386, DOI 10.1074/jbc.271.48.30386; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rowlinson SW, 1998, J BIOL CHEM, V273, P5307, DOI 10.1074/jbc.273.9.5307; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Waters MJ., 1999, HDB PHYSL, P397	31	23	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17000	17007		10.1074/jbc.275.22.17000	http://dx.doi.org/10.1074/jbc.275.22.17000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828073	hybrid			2022-12-27	WOS:000087392200085
J	Ahern, GP; Hsu, SF; Klyachko, VA; Jackson, MB				Ahern, GP; Hsu, SF; Klyachko, VA; Jackson, MB			Induction of persistent sodium current by exogenous and endogenous nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY NERVE-TERMINALS; VASCULAR SMOOTH-MUSCLE; HIPPOCAMPAL-NEURONS; CELLS; CHANNELS; NA+; PROTEINS; ISCHEMIA	Most voltage-gated Na+ channels inactivate almost completely at depolarized membrane potentials, but in some cells a residual Na+ current is seen that is resistant to inactivation. This persistent Na+ current can have a profound impact on the electrical behavior of excitable cells, and the regulation of this property could have important biological consequences, However, the biological signaling mechanisms that regulate the persistence of Na+ channels are not well understood. This study showed that in nerve terminals and ventricular myocytes nitric oxide (NO) reduced the inactivation of Na+ current. This effect was independent of cGMP, was blocked by N-ethylmaleimide, and could be elicited in cell-free outside-out patches. Thus, a reactive nitrogen species acts directly on the channel or closely associated protein. Persistent Na+ current could also be induced by endogenous NO generated enzymatically by NO synthase (NOS). Application of ionomycin to raise the intracellular Ca2+ concentration in myocytes activated NOS. The NO produced in response to ionomycin was detected with an NO-sensitive fluorescent dye. Persistent Na+ current was enhanced by the same treatment, and NOS inhibitors abolished both the elevation of NO and the induction of persistent Na+ current. These experiments show that NO is a potential endogenous regulator of persistent Na+ current under physiological and pathophysiological conditions.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Biophys Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahern, GP (corresponding author), Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA.		Klyachko, Vitaly/E-9431-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30016] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern GP, 1999, J PHYSIOL-LONDON, V520, P165, DOI 10.1111/j.1469-7793.1999.00165.x; AHERN GP, 1998, SOC NEUR ABSTR, V24; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.ph.58.030196.002025; FRENCH CR, 1990, J GEN PHYSIOL, V95, P1139, DOI 10.1085/jgp.95.6.1139; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gee SH, 1998, J NEUROSCI, V18, P128; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hammarstrom AKM, 1999, J PHYSIOL-LONDON, V520, P451, DOI 10.1111/j.1469-7793.1999.t01-1-00451.x; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; Huang XP, 1997, J CELL SCI, V110, P1625; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; JACKSON MB, 1995, J PHYSIOL-LONDON, V483, P597, DOI 10.1113/jphysiol.1995.sp020609; Ju YK, 1996, J PHYSIOL-LONDON, V497, P337, DOI 10.1113/jphysiol.1996.sp021772; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Ohoi I, 1996, EUR J PHARMACOL, V306, P123, DOI 10.1016/0014-2999(96)00231-2; Raman IM, 1997, J NEUROSCI, V17, P4517, DOI 10.1523/jneurosci.17-12-04517.1997; Ravens U, 1999, PHARMACOL RES, V39, P167, DOI 10.1006/phrs.1998.0416; Segal MM, 1997, J NEUROPHYSIOL, V77, P3021, DOI 10.1152/jn.1997.77.6.3021; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Theroux P, 1999, AM J CARDIOL, V83, p3G; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	30	116	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28810	28815		10.1074/jbc.M003090200	http://dx.doi.org/10.1074/jbc.M003090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10833522	hybrid			2022-12-27	WOS:000089330700063
J	Babinski, K; Catarsi, S; Biagini, G; Seguela, P				Babinski, K; Catarsi, S; Biagini, G; Seguela, P			Mammalian ASIC2a and ASIC3 subunits co-assemble into heteromeric proton-gated channels sensitive to Gd3+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING ION CHANNELS; NA+ CHANNEL; CATION CHANNEL; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION; CAPSAICIN RECEPTOR; MOLECULAR-CLONING; DEGENERIN MDEG; SODIUM-CHANNEL; NEURONS	Proton receptors of the acid-sensing ion channel (ASIC) family are expressed in sensory neurons and thus could play a critical role in the detection of noxious acidosis. To investigate the subunit composition of native ASICs in peripheral and central neurons, we coinjected human as well as rodent ASIC2a and ASIC3 subunits in Xenopus oocytes, The amplitudes of acid-induced biphasic responses mediated by co-expressed ASIC2a and ASIC3 subunits were much larger (as much as 20-fold) than the currents mediated by the respective homomers, clearly indicating functional association. The reversal potential of the ASIC2a+3 current (greater than or equal to+20 mV) reflected a cationic current mainly selective for sodium, The sensitivity to pH or amiloride of single versus co-expressed ASIC subunits was not significantly different; however, gadolinium ions inhibited ASICS and ASIC2a+3 responses with much higher potency (IC50 similar to 40 mu M) than the ASIC2a response (IC50 greater than or equal to 1 mM). Biochemical interaction between ASIC2a and ASIC3 subunits was demonstrated by co-purification from transfected human embryonic kidney (HEK293) cells and Xenopus oocytes. Our in situ hybridization data showed that rat ASIC2a and ASIC3 transcripts are colocalized centrally, whereas reverse transcription-polymerase chain reaction data led us to detect co-expression of human ASIC2a and ASIC3 subunits in trigeminal sensory ganglia, brain, and testis where they might coassemble into a novel subtype of proton-gated channels sensitive to gadolinium.	McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Grp, Montreal, PQ H3A 2B4, Canada; Antalium Inc, Montreal, PQ H3A 1X6, Canada; Univ Modena, Dept Biomed Sci, Physiol Sect, I-41100 Modena, Italy	McGill University; Universita di Modena e Reggio Emilia	Seguela, P (corresponding author), McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Grp, 3801 Univ St,Rm 778, Montreal, PQ H3A 2B4, Canada.		Biagini, Giuseppe/F-7668-2013; Biagini, Giuseppe/I-3227-2013	Biagini, Giuseppe/0000-0002-7130-2511; Biagini, Giuseppe/0000-0002-7130-2511				Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; CUNNINGHAM JT, 1995, J NEUROPHYSIOL, V73, P2094, DOI 10.1152/jn.1995.73.5.2094; Darboux I, 1998, BIOCHEM BIOPH RES CO, V246, P210, DOI 10.1006/bbrc.1998.8183; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Hamill OP, 1996, PHARMACOL REV, V48, P231; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Marcinkiewicz M, 1997, NEUROSCIENCE, V76, P425, DOI 10.1016/S0306-4522(96)00318-1; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sakai H, 1999, J PHYSIOL-LONDON, V519, P323, DOI 10.1111/j.1469-7793.1999.0323m.x; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	31	139	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28519	28525		10.1074/jbc.M004114200	http://dx.doi.org/10.1074/jbc.M004114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10842183	hybrid			2022-12-27	WOS:000089330700026
J	Ferguson, DJ; Gorlatova, N; Grahame, DA; Krzycki, JA				Ferguson, DJ; Gorlatova, N; Grahame, DA; Krzycki, JA			Reconstitution of dimethylamine : coenzyme M methyl transfer with a discrete corrinoid protein and two methyltransferases purified from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; METHIONINE SYNTHASE; ENCODING GENES; ISOENZYME-II; METHANOL; TRIMETHYLAMINE; PURIFICATION; ISOZYMES; MONOMETHYLAMINE; METABOLISM	Methyl transfer from dimethylamine to coenzyme M was reconstituted in vitro for the first time using only highly purified proteins. These proteins isolated from Methanosarcina barkeri included the previously unidentified corrinoid protein MtbC, which copurified with MtbA, the methylcorrinoid:Coenzyme M methyltransferase specific for methanogenesis from methylamines, MtbC binds 1.0 mel of corrinoid cofactor/mol of 24-kDa polypeptide and stimulated dimethylamine:coenzyme M methyl transfer 3.4-fold in a cell extract. Purified MtbC and MtbA were used to assay and purify a dimethylamine:corrinoid methyltransferase, MtbB1. MtbB1 is a 230-kDa protein composed of 51-kDa subunits that do not possess a corrinoid prosthetic group. Purified MtbB1, MtbC, and MtbA were the sole protein requirements for in vitro dimethylamine:coenzyme M methyl transfer. An MtbB1:MtbC ratio of 1 was optimal for coenzyme M methylation with dimethylamine, MtbB1 methylated either corrinoid bound to MtbC or free co-b(I)alamin with dimethylamine, indicating MtbB1 carries an active site for dimethylamine demethylation and corrinoid methylation. Experiments in which different proteins of the resolved monomethylamine:coenzyme M methyl transfer reaction replaced proteins involved in dimethylamine:coenzyme M methyl transfer indicated high specificity of MtbB1 and MtbC in dimethylamine: coenzyme M methyl transfer activity. These results indicate MtbB1 demethylates dimethylamine and specifically methylates the corrinoid prosthetic group of MtbC, which is subsequently demethylated by MtbA to methylate coenzyme M during methanogenesis from dimethylamine.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Krzycki, JA (corresponding author), Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA.			Ferguson, Donald/0000-0002-0595-3033				Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; Daas PJH, 1996, J BIOL CHEM, V271, P22339, DOI 10.1074/jbc.271.37.22339; DANGEL W, 1987, ARCH MICROBIOL, V148, P52, DOI 10.1007/BF00429647; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; Harms U, 1996, EUR J BIOCHEM, V235, P653, DOI 10.1111/j.1432-1033.1996.00653.x; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; KING GM, 1984, APPL ENVIRON MICROB, V48, P719, DOI 10.1128/AEM.48.4.719-725.1984; KREFT JU, 1994, EUR J BIOCHEM, V226, P945, DOI 10.1111/j.1432-1033.1994.00945.x; KREMER JD, 1993, J BACTERIOL, V175, P4824, DOI 10.1128/JB.175.15.4824-4833.1993; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClerc GM, 1996, J BIOL CHEM, V271, P18725, DOI 10.1074/jbc.271.31.18725; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; Sauer K, 1997, EUR J BIOCHEM, V243, P670, DOI 10.1111/j.1432-1033.1997.t01-1-00670.x; Sauer K, 1999, EUR J BIOCHEM, V261, P674, DOI 10.1046/j.1432-1327.1999.00355.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; Vannelli T, 1999, P NATL ACAD SCI USA, V96, P4615, DOI 10.1073/pnas.96.8.4615; Wassenaar RW, 1998, EUR J BIOCHEM, V253, P692, DOI 10.1046/j.1432-1327.1998.2530692.x; Wassenaar RW, 1996, J BACTERIOL, V178, P6937, DOI 10.1128/jb.178.23.6937-6944.1996; Wassenaar RW, 1998, EUR J BIOCHEM, V258, P597, DOI 10.1046/j.1432-1327.1998.2580597.x; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031	33	68	72	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29053	29060		10.1074/jbc.M910218199	http://dx.doi.org/10.1074/jbc.M910218199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852929	hybrid			2022-12-27	WOS:000089330700092
J	Hanada, T; Lin, LH; Tibaldi, EV; Reinherz, EL; Chishti, AH				Hanada, T; Lin, LH; Tibaldi, EV; Reinherz, EL; Chishti, AH			GAKIN, a novel kinesin-like protein associates with the human homologue of the Drosophila discs large tumor suppressor in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; SYNAPTIC BOUTON STRUCTURE; KINASE-LIKE DOMAIN; POSTSYNAPTIC DENSITY; GUANYLATE KINASES; PDZ DOMAINS; GENE DLG; CHROMOSOME SEGREGATION; ORGANELLE TRANSPORT; BINDING INTERFACE	Reorganization of the cortical cytoskeleton is a hallmark of T lymphocyte activation, Upon binding to antigen presenting cells, the T cells rapidly undergo cytoskeletal re-organization thus forming a cap at the cell-cell contact site leading to receptor clustering, protein segregation, and cellular polarization. Previously, we reported cloning of the human lymphocyte homologue of the Drosophila Discs Large tumor suppressor protein (hDlg), Here we show that a novel protein termed GAKIN binds to the guanylate kinase-like domain of hDlg, Affinity protein purification, peptide sequencing, and cloning of GAKIN cDNA from Jurkat J77 lymphocytes identified GAKIN as a novel member of the kinesin superfamily of motor proteins. GAKIN mRNA is ubiquitously expressed, and the predicted amino acid sequence shares significant sequence similarity with the Drosophila kinesin-73 motor protein. GAKIN sequence contains a motor domain at the NH, terminus, a central stalk domain, and a putative microtubule-interacting sequence called the CAP-Gly domain at the COOH terminus, Among the MAGUK superfamily of proteins examined, GAKIN binds to the guanylate kinase-like domain of PSD-95 but not of p55. The hDlg and GAKIN are localized mainly in the cytoplasm of resting T lymphocytes, however, upon CD2 receptor cross-linking the hDlg can translocate to the lymphocyte cap. We propose that the GAKIN-hDlg interaction lays the foundation for a general paradigm of coupling MAGUKs to the microtubule-based cytoskeleton, and that this interaction may be functionally important for the intracellular trafficking of MAGUKs and associated protein complexes in vivo.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Med, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Anat, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Cellular Biol, Boston, MA 02135 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chishti, AH (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Med, CBR 404,736 Cambridge St, Boston, MA 02135 USA.	achishti@semc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adey NB, 2000, CANCER RES, V60, P35; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brenman JE, 1998, J NEUROSCI, V18, P8805; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Chishti A H, 1998, Curr Opin Hematol, V5, P116; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOONIN EV, 1992, NAT GENET, V2, P256, DOI 10.1038/ng1292-256; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li HP, 1997, P NATL ACAD SCI USA, V94, P1086, DOI 10.1073/pnas.94.4.1086; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Seiler S, 1997, EMBO J, V16, P3025, DOI 10.1093/emboj/16.11.3025; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	90	119	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28774	28784		10.1074/jbc.M000715200	http://dx.doi.org/10.1074/jbc.M000715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10859302	hybrid			2022-12-27	WOS:000089330700059
J	Ali, N; Pruijn, GJM; Kenan, DJ; Keene, JD; Siddiqui, A				Ali, N; Pruijn, GJM; Kenan, DJ; Keene, JD; Siddiqui, A			Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANS-ACTING FACTORS; 5' NONCODING REGION; MESSENGER-RNA; AUTOANTIGEN-LA; LEADER RNA; HEPATOCELLULAR-CARCINOMA; PROTEIN INTERACTIONS; 5'-NONCODING REGION; POLIOVIRUS RNA	The 5'-noncoding region (5'-NCR) of the hepatitis C virus (HCV) RNA genome serves as an internal ribosome entry site (IRES) and mediates translation initiation in a cap-independent manner. Previously, we reported the interaction between La antigen and the HCV IRES, which appeared to occur in the context of initiator AUG, It was further shown that HCV IRES-mediated translation was stimulated in the presence of human La antigen. In this study, we have defined the cis- and transacting elements responsible for La-5'-NCR interactions and established the dependence of the HCV IRES efficiency on cellular La antigen. During the La-IRES interaction, initiator AUG but not the neighboring codons was found to be the direct target of La binding. The C terminus effector domain-dependent modulation of La binding to the HCV IRES is demonstrated by deletion and substitution mutagenesis of the protein. An RNA systematic evolution of ligands by exponential enrichment (SELEX), generated against La protein that selectively binds La in HeLa lysates and competes for the protein binding to the 5'-NCR, was used to demonstrate the requirement of La for the HCV IRES function in the context of mono- and dicistronic mRNAs. Sequestration of La antigen by the RNA SELEX in HeLa translation lysates blocked the HCV and poliovirus IRES-mediated translation in vitro. The functional requirement of La protein for the HCV IRES activity was further established in a liver-derived cell line and in an add-back experiment in which the inhibited IRES was rescued by recombinant human La. These results strongly argue for the novel role of La protein during selection of the initiator AUG and its participation during internal initiation of translation of the HCV RNA genome.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Duke Univ, Med Ctr, Combinatorial Sci Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Radboud University Nijmegen; Duke University; Duke University	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA.	aleem.siddiqui@uchsc.edu	Pruijn, Ger/D-6664-2012	Ali, Naushad/0000-0002-0058-7396				ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; Barton DJ, 1996, METHOD ENZYMOL, V275, P35; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Collier AJ, 1998, J GEN VIROL, V79, P2359, DOI 10.1099/0022-1317-79-10-2359; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duncan RC, 1997, GENE, V201, P137, DOI 10.1016/S0378-1119(97)00438-1; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; Grolz D, 1997, J BIOL CHEM, V272, P12076, DOI 10.1074/jbc.272.18.12076; HARADA F, 1984, NUCLEIC ACIDS RES, V12, P9263, DOI 10.1093/nar/12.24.9263; Honda M, 1996, RNA, V2, P955; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Jackson RJ, 1995, RNA, V1, P985; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; KENAN DJ, 1995, THESIS DUKE U RALEIG; KURILLA MG, 1984, J VIROL, V50, P773, DOI 10.1128/JVI.50.3.773-778.1984; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; Morley SJ, 1997, RNA, V3, P1085; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; PRUIJN GJM, 1994, MANUAL BIOL MARKERS, P1; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wang C, 1995, CURR TOP MICROBIOL, V203, P99; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; XIAO QR, 1994, NUCLEIC ACIDS RES, V22, P2512	56	140	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27531	27540						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856291				2022-12-27	WOS:000089197100005
J	Stofega, MR; Argetsinger, LS; Wang, HY; Ullrich, A; Carter-Su, C				Stofega, MR; Argetsinger, LS; Wang, HY; Ullrich, A; Carter-Su, C			Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; PROMOTED TYROSYL PHOSPHORYLATION; INHIBITORY RECEPTORS; PHOSPHATASE SH-PTP2; KINASE; ACTIVATION; SHP-2; JAK2; BINDING; FAMILY	Signal regulatory proteins (SIRPs) are receptor-like transmembrane proteins, the majority of which contain a cytoplasmic proline-rich region and four cytoplasmic tyrosines that, when phosphorylated, bind SH2 domain-containing protein tyrosine phosphatases (SHP). We demonstrated previously that growth hormone (GH) induces tyrosyl phosphorylation of SIRP alpha and association of SIRP alpha with SHP-2. The GH-activated tyrosine kinase JAK2 associates with and tyrosyl-phosphorylates SIRP alpha 1. Here we show that JAK2-SIRP alpha 1 association does not require phosphotyrosines in SIRP alpha 1 or JAK2 or the proline-rich region of SIRP alpha 1. However, when the C-terminal 30 amino acids of SIRP alpha 1 containing the proline-rich region and tyrosine 495 are deleted, tyrosyl phosphorylation of SIRP alpha 1 by JAK2 and association of SHP-2 with SIRP alpha 1 are reduced. GH-dependent tyrosyl phosphorylation of JAK2 is reduced when wild-type SIRP alpha 1 compared with SIRP alpha 1 lacking the four cytoplasmic tyrosines (SIRP 4YF) is expressed in cells, suggesting that SIRP alpha 1 negatively regulates GHR/JAK2 signaling. Consistent with reduced JAK2 activity, overexpression of wild-type SIRP alpha 1 but not SIRP 4YF reduces GH-induced phosphorylation of ERKs 1 and 2, STAT3, and STAT5B. These results suggest that SIRP alpha 1 is a negative regulator of GH signaling and that the ability of SIRP alpha 1 mutants to negatively regulate GHR-JAK2 signaling correlates with their ability to bind SHP-2.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Max Planck Society	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.	cartersu@umich.edu	Wang, Hongyang/B-1340-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283, R01DK034171, P60DK020572, R37DK034171] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK034171, DK 34171, P60-DK20572, DK48283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; HARDING PA, 1994, MOL CELL ENDOCRINOL, V106, P171, DOI 10.1016/0303-7207(94)90200-3; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; SMIT LS, 1999, HDB PHYSL, V5, P445; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28222	28229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842184				2022-12-27	WOS:000089197100092
J	Akiyama, TE; Ward, JM; Gonzalez, FJ				Akiyama, TE; Ward, JM; Gonzalez, FJ			Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1 alpha (HNF1 alpha) - Alterations in fatty acid homeostasis in HNF1 alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; ACYL-COA OXIDASE; BETA-OXIDATION; RAT-LIVER; PEROXISOME PROLIFERATORS; LIPOPROTEIN-LIPASE; DIABETIC RAT; EXPRESSION; SEQUENCE; MOUSE	Hepatocyte nuclear factor 1 alpha (HNF1 alpha)-null mice have enlarged fatty livers and alterations in the expression of genes encoding enzymes involved in the synthesis, catabolism, and transport of fatty acids. Elevations in the expression of genes encoding fatty acid synthetic enzymes (fatty acid synthase and acyl-CoA carboxylase) and peroxisomal B-oxidation enzymes (CYP4A3, bifunctional enzyme, and thiolase) were observed in the livers of HNF1 alpha-null mice, whereas hepatic mitochondrial p-oxidation gene (medium and short chain acyl-CoA dehydrogenase) expression levels remain unchanged relative to HNF1 alpha-heterozygous controls. An elevation in the levels of fatty acid transporter gene expression was also observed. In contrast, there was a marked reduction of liver fatty acid-binding protein (L-FABP) gene expression in the livers of HNF1 alpha-null mice. Isolation and sequence analysis of the 5'-flanking region of the mouse L-FABP gene revealed the presence of two HNF1 alpha regulatory elements. The results of transient transfection studies indicate that HNF1 alpha is required to transactivate the expression of the L-FABP promoter. Taken together, these data define a critical role for HNF1 alpha in the pathogenesis of a phenotype marked by fatty infiltration of the liver and in the regulation of the L-FABP gene, the expression of which may have a direct impact on the maintenance of fatty acid homeostasis.	NIH, Lab Metab, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Off Lab Anim Sci, Vet & Tumor Pathol Sect,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gonzalez, FJ (corresponding author), NIH, Lab Metab, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC005561, ZIABC005561] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asayama K, 1999, MOL CELL BIOCHEM, V194, P227, DOI 10.1023/A:1006930513476; BASS NM, 1985, J BIOL CHEM, V260, P1432; BAUMHUETER S, 1989, ANN NY ACAD SCI, V557, P272; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERRY SA, 1993, J AM COLL NUTR, V12, P638; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Engels W, 1999, MOL CELL BIOCHEM, V192, P53, DOI 10.1023/A:1006855214237; Fielding BA, 1998, BRIT J NUTR, V80, P495, DOI 10.1017/S0007114598001585; GORDON JI, 1985, J BIOL CHEM, V260, P1995; GORDON JI, 1982, BIOCHEMISTRY-US, V21, P5424, DOI 10.1021/bi00265a007; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MANNAERTS GP, 1992, CELL BIOCHEM FUNCT, V10, P141, DOI 10.1002/cbf.290100303; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; MENDEL DB, 1991, J BIOL CHEM, V266, P677; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; RIFAI N, 1986, ARCH PATHOL LAB MED, V110, P694; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1993, BIOCHIM BIOPHYS ACTA, V1177, P183, DOI 10.1016/0167-4889(93)90039-R	30	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27117	27122						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852923				2022-12-27	WOS:000089144800061
J	Papanikolaou, NA; Sabban, EL				Papanikolaou, NA; Sabban, EL			Ability of Egr1 to activate tyrosine hydroxylase transcription in PC12 cells - Cross-talk with AP-1 factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; N-METHYLTRANSFERASE GENE; IMMOBILIZATION STRESS; CYCLIC-AMP; C-FOS; REGULATORY ELEMENTS; PARKINSONS-DISEASE; RESPONSE ELEMENT; EXPRESSION; COMPLEX	We have recently identified an Egr1 motif that overlaps with the Spl element in the tyrosine hydroxylase (TI-I) promoter. Here we examine whether this motif has a functional role in the regulation of TH transcription in PC12 cells. In nuclear extracts from control PC12 cells, an oligonucleotide containing the TH Sp1/Egr1 motif binds Spl-containing complexes, Treatment of PC12 cells with phorbol ester (2 mu M 12-O-tetradecanoylphorbol-13-acetate (TPA)) gives rise to a new Egr1-containing complex. TPA treatment reduces the steady-state levels of the Spl protein and leads to the appearance of immunoreactive Egr1 protein within 30-60 min, Expression of the Egr1 protein in PC12 cells stimulates the chloramphenicol acetyltransferase reporter gene placed under the control of the first 272 nucleotides of the rat TH promoter. Site-directed mutagenesis of either the Sp1/Egr1 motif or of an upstream AP-1 motif or both abolishes the Egr1 mediated induction of chloramphenicol acetyltransferase activity. An oligonucleotide encompassing the AP-1/E-box sequence of the rat TH promoter competes in electrophoretic mobility shift assays for binding of nuclear extracts from control and TPA-treated cells to an oligonucleotide containing the Sp1/Egr1 element, indicating that; these two enhancers may interact. The results show that Egr1 can activate TH transcription and reveals cross-talk between Sp1/Egr1 and AP-1 factors.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Sabban, EL (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	sabban@nymc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAO XM, 1993, J BIOL CHEM, V268, P16949; Corti O, 1999, P NATL ACAD SCI USA, V96, P12120, DOI 10.1073/pnas.96.21.12120; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; EBERT SN, 1994, J BIOL CHEM, V269, P20885; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; FAUCONBIGUET N, 1986, EMBO J, V5, P287; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; Imaoka T, 1998, HUM GENE THER, V9, P1093, DOI 10.1089/hum.1998.9.7-1093; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumer SC, 1996, J NEUROCHEM, V67, P443; Kvetnansky R, 1998, ANN NY ACAD SCI, V851, P342, DOI 10.1111/j.1749-6632.1998.tb09008.x; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Mallet J, 1996, TRENDS NEUROSCI, V19, P191, DOI 10.1016/S0166-2236(96)10029-1; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; Menezes A, 1996, J NEUROCHEM, V67, P2316; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN DG, 1988, ANN NY ACAD SCI, V515, P145, DOI 10.1111/j.1749-6632.1988.tb32978.x; MORITA K, 1995, J BIOL CHEM, V270, P11161, DOI 10.1074/jbc.270.19.11161; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NANKOVA B, 1993, J NEUROCHEM, V61, P776; NANKOVA B, 1994, P NATL ACAD SCI USA, V91, P5937, DOI 10.1073/pnas.91.13.5937; Noti JD, 1996, MOL CELL BIOL, V16, P2940; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Osaka H, 1997, MOL BRAIN RES, V49, P222, DOI 10.1016/S0169-328X(97)00148-4; OSAKA H, 1994, SOC NEUROSCI, V20, P125; Papanikolaou NA, 1999, J NEUROCHEM, V73, P433, DOI 10.1046/j.1471-4159.1999.0730433.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Sabban EL, 1997, SEMIN CELL DEV BIOL, V8, P101, DOI 10.1006/scdb.1996.0129; Sharma P, 1998, HYPERTENSION, V32, P676, DOI 10.1161/01.HYP.32.4.676; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; Wei J, 1997, LIFE SCI, V61, P1341, DOI 10.1016/S0024-3205(97)00679-6; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WONG DL, 1999, FUND CLIN PHARMACOL, V13; Yang CY, 1998, J NEUROCHEM, V71, P1358; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	47	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26683	26689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842166				2022-12-27	WOS:000089144800004
J	Kessler, SP; Rowe, TM; Gomos, JB; Kessler, PM; Sen, GC				Kessler, SP; Rowe, TM; Gomos, JB; Kessler, PM; Sen, GC			Physiological non-equivalence of the two isoforms of angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR ISOZYME; BLOOD-PRESSURE; MESSENGER-RNAS; MALE-FERTILITY; CELL-SURFACE; SOMATIC ACE; GENE; MICE; TRANSCRIPTION; EXPRESSION	The structurally related somatic and germinal isoforms of angiotensin-converting enzyme (ACE) contain the same catalytic active center and are encoded by the same gene, whose disruption causes renal atrophy, hypotension, and male sterility. The reason for the evolutionary conservation of both isozymes is an enigma, because, in vitro, they have very similar enzymatic properties. Despite the common enzymatic properties, discrete expression of both isoforms is maintained in alternate cell types. We have previously shown that sperm-specific expression of transgenic germinal ACE in Ace -/- male mice restores fertility without curing their other abnormalities (Ramaraj, P., Kessler, S. P., Colmenares, C. & Sen, G. C. (1998) J. Clin. Invest. 102, 371-378). In this report we tested the biological equivalence of somatic ACE and germinal ACE utilizing an in vivo isozymic substitution approach. Here we report that restoration of male fertility was not achieved by the transgenic expression of enzymatically active, somatic ACE in the sperm of Ace -/- mice. Therefore, the requisite physiological functions of the two tissue-specific isozymes of ACE are not interchangeable.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org			NHLBI NIH HHS [HL 48258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; Ertoy D, 2000, V CH MO CAR, V1, P205; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Isaac RE, 1999, ANN NY ACAD SCI, V897, P342, DOI 10.1111/j.1749-6632.1999.tb07904.x; Isaac RE, 1997, BIOCHEM J, V328, P587, DOI 10.1042/bj3280587; Kessler SP, 1996, GENE EXPRESSION, V6, P73; Kessler SP, 1998, J BIOL CHEM, V273, P9971, DOI 10.1074/jbc.273.16.9971; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Krebs LT, 2000, J PHARMACOL EXP THER, V293, P260; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PERICH RB, 1992, MOL PHARMACOL, V42, P286; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SEN I, 1991, J BIOL CHEM, V266, P21985; Strawn WB, 1999, HYPERTENSION, V33, P207, DOI 10.1161/01.HYP.33.1.207; STRITTMATTER SM, 1987, NEUROSCIENCE, V21, P407, DOI 10.1016/0306-4522(87)90131-X; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875	30	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26259	26264		10.1074/jbc.M004006200	http://dx.doi.org/10.1074/jbc.M004006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10831599	hybrid			2022-12-27	WOS:000088999700053
J	Doostzadeh-Cizeron, J; Yin, S; Goodrich, DW				Doostzadeh-Cizeron, J; Yin, S; Goodrich, DW			Apoptosis induced by the nuclear death domain protein p84N5 is associated with caspase-6 and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; CELL-DEATH; RECOMBINANT ADENOVIRUS; CYTOCHROME-C; P53; GENE; EXPRESSION; FAMILY; PHOSPHORYLATION; LYMPHOCYTES	Although the mechanisms involved in responses to extracellular or mitochondrial apoptotic signals have received considerable attention, the mechanisms utilized within the nucleus to transduce apoptotic signals are not well understood. We have characterized apoptosis induced by the nuclear death domain-containing protein p84N5, Adenovirus-mediated N5 gene transfer or transfection of p84N5 expression vectors induces apoptosis in tumor cell lines with nearly 10096 efficiency as indicated by cellular morphology, DNA fragmentation, and annexin V staining, Using peptide substrates and Western blotting, we have determined that NB-induced apoptosis is initially accompanied by activation of caspase-6. Activation of caspases-3 and -9 does not peak until 3 days after the peak of caspase-8 activity. Expression of p84N5 also leads to activation of NF-KB as indicated by nuclear translocation of p65RelA and transcriptional activation of a NF-kappa B-dependent reporter promoter. Changes in the relative expression level of Bcl-2 family proteins, including Bak and Bcl-Xs, are also observed during p84N5-induced apoptosis, Finally, we demonstrate that p84N5-induced apoptosis does not require p53 and is not inhibited by p53 coexpression. We propose that p84N5 is involved in an apoptotic pathway distinct from those triggered by death domain-containing receptors or by p53.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.	goodrich@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA070292] Funding Source: NIH RePORTER; NCI NIH HHS [CA-70292, CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cregan SP, 1999, J NEUROSCI, V19, P7860; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; MIYASHITA T, 1995, CELL, V80, P293; Orth R, 1997, J BIOL CHEM, V272, P8841; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YIN S, 2000, IN PRESS CANC GENE T, P32; Yu YJ, 1998, CANCER RES, V58, P4277; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25336	25341		10.1074/jbc.M000793200	http://dx.doi.org/10.1074/jbc.M000793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840029	hybrid			2022-12-27	WOS:000088849400040
J	Skalski, V; Brown, KR; Choi, BY; Lin, ZY; Chen, S				Skalski, V; Brown, KR; Choi, BY; Lin, ZY; Chen, S			A 3 '-5 ' exonuclease in human leukemia cellsn - Implications for resistance to 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5 '-monophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; CYTOSINE-ARABINOSIDE; SYNDROME PROTEIN; DNA-POLYMERASES; CELLULAR DNA; FLUDARABINE; 3'->5'-EXONUCLEASE; IDENTIFICATION; TRIPHOSPHATE	A 3'-5' exonuclease that excises the nucleotide analogs 1-beta-D-arabinofuranosylcytosine monophosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate incorporated at 3' ends of DNA was purified from the nuclei of: 1) primary human chronic lymphocytic leukemia cells, 2) primary and established human acute myeloblastic leukemia cells, and 3) lymphocytes obtained from healthy individuals. The activity of this nuclear exonuclease (exoN) is elevated approximately 6-fold in 1-beta-D-arabinofuranosylcytosine-resistant leukemia cells as compared with drug-sensitive cells, and it differs between two healthy individuals and among three leukemia patients. exoN is a 46-kDa monomer, requires 50 mM KCl and 1 mM magnesium for optimal activity, and shows a preference for single-stranded over duplex DNA. Its physical and enzymatic properties indicate that exoN is a previously uncharacterized enzyme whose activity may confer resistance to clinical nucleoside analogs in leukemia cells.	Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Skalski, V (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, 620 Univ Ave, Toronto, ON M5G 2M9, Canada.			Brown, Kevin/0000-0002-5514-2538				BELYAKOVA NV, 1993, EUR J BIOCHEM, V217, P493, DOI 10.1111/j.1432-1033.1993.tb18269.x; Bennett JM, 1997, CANCER, V80, P2205; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; FREI E, 1969, CANCER RES, V29, P1325; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P18; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; HU ZB, 1995, LEUKEMIA, V9, P789; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; HUANG P, 1990, J BIOL CHEM, V265, P16617; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KEATING MJ, 1989, BLOOD, V74, P19; KOISTINEN P, 1991, LEUKEMIA, V5, P704; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICKEL W, 1992, J BIOL CHEM, V267, P848; PANASCI L, 1988, CANCER RES, V48, P1972; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; RICHEL DJ, 1990, CANCER RES, V50, P6515; RUSTUM YM, 1979, CANCER RES, V39, P42; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; SPRIGGS D, 1986, BIOCHEM PHARMACOL, V35, P247, DOI 10.1016/0006-2952(86)90521-6; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P318; STEUART CD, 1971, NATURE-NEW BIOL, V233, P109, DOI 10.1038/newbio233109a0; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; Vincent B R, 1979, Somatic Cell Genet, V5, P67; WILEY JS, 1982, J CLIN INVEST, V69, P479, DOI 10.1172/JCI110472; Zhu L, 1999, BIOCHEM BIOPH RES CO, V259, P262, DOI 10.1006/bbrc.1999.0774	34	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25814	25819		10.1074/jbc.M001460200	http://dx.doi.org/10.1074/jbc.M001460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833512	hybrid			2022-12-27	WOS:000088849400099
J	Yengo, CM; Chrin, LR; Rovner, AS; Berger, CL				Yengo, CM; Chrin, LR; Rovner, AS; Berger, CL			Tryptophan 512 is sensitive to conformational changes in the rigid relay loop of smooth muscle myosin during the MgATPase cycles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; X-RAY STRUCTURE; MOTOR DOMAIN; LIGHT-CHAIN; CRYSTAL-STRUCTURE; ADP RELEASE; ACTIVE-SITE; LEVER ARM; HEAD; FLUORESCENCE	To examine the structural basis of the intrinsic fluorescence changes that occur during the MgATPase cycle of myosin, we generated three mutants of smooth muscle myosin motor domain essential light chain (MDE) containing a single conserved tryptophan residue located at Trp-441 (W441-MDE), Trp-512 (W512-MDE), or Trp-597 (W597-MDE), Although W441- and W597-MDE were insensitive to nucleotide binding, the fluorescence intensity of W512-MDE increased in the presence of MgADP-berellium fluoride (BeFX) (31%), MgADP-AIF(4)(-) (31%), MgATP (36%), and MgADP (30%) compared with the nucleotide-free environment (rigor), which was similar to the results of wild type-RIDE. Thus, Trp-512 may be the sole ATP-sensitive tryptophan residue in myosin, In addition, acrylamide quenching indicated that Trp-512 was more protected from solvent in the presence of MgATP or MgADP-AIF(4)(-) than in the presence of MgADP-BeFX MgADP, or in rigor. Furthermore, the degree of energy transfer from Trp-512 to 2'(3')-O-(N-methylanthraniloyl)-labeled nucleotides was greater in the presence of MgADP-BeFX MgATP, or MgADP-AIF(4)(-) than MgADP, We conclude that the conformation of the rigid relay loop containing Trp-512 is altered upon MgATP hydrolysis and during the transition from weak to strong actin binding, establishing a communication pathway from the active site to the actin-binding and converter/lever arm regions of myosin during muscle contraction.	Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Berger, CL (corresponding author), Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL38113, HL63798] Funding Source: Medline; NIAMS NIH HHS [AR44219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063798, R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044219] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fairclough R H, 1978, Methods Enzymol, V48, P347; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Franks-Skiba K., 1995, Biophysical Journal, V68, P142; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Highsmith S, 1999, BIOCHEMISTRY-US, V38, P9791, DOI 10.1021/bi9907633; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; JOHNSON WC, 1991, P NATL ACAD SCI USA, V88, P9748, DOI 10.1073/pnas.88.21.9748; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P305; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Park S, 1996, BBA-PROTEIN STRUCT M, V1296, P1, DOI 10.1016/0167-4838(96)00086-6; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RICHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLEDGE R, 1985, ENERGETIC ASPECTS MU, P155; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; Xiao M, 1998, P NATL ACAD SCI USA, V95, P15309, DOI 10.1073/pnas.95.26.15309; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944	44	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25481	25487		10.1074/jbc.M002910200	http://dx.doi.org/10.1074/jbc.M002910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827189	hybrid			2022-12-27	WOS:000088849400058
J	Cabral, CM; Choudhury, P; Liu, Y; Sifers, RN				Cabral, CM; Choudhury, P; Liu, Y; Sifers, RN			Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT ALPHA-MANNOSIDASE; QUALITY-CONTROL; INTRACELLULAR DEGRADATION; LINKED OLIGOSACCHARIDES; HUMAN ALPHA(1)-ANTITRYPSIN; APOLIPOPROTEIN-B; HUMAN-DISEASE; PROTEIN; PROTEASOME; CALNEXIN	In the early secretory pathway, a distinct set of processing enzymes and family of lectins facilitate the folding and quality control of newly synthesized glycoproteins, In this regard, we recently identified a mechanism in which processing by endoplasmic reticulum mannosidase I, which attenuates the removal of glucose from asparagine-linked oligosaccharides, sorts terminally misfolded alpha(1)-antitrypsin for proteasome-mediated degradation in response to its abrogated physical dissociation from calnexin (Liu, Y,, Choudhury, P., Cabral, C,, and Sifers, R, N. (1999) J. Biol, Chem. 274, 5861-5867), In the present study, we examined the quality control of genetic variant PI Z, which undergoes inappropriate polymerization following biosynthesis. Here we show that in stably transfected hepatoma cells the additional processing of asparagine-linked oligosaccharides by endoplasmic reticulum mannosidase II partitions variant PI Z away from the conventional disposal mechanism in response to an arrested posttranslational interaction with calnexin. Intracellular disposal is accomplished by a nonproteasomal system that functions independently of cytosolic components but is sensitive to tyrosine phosphatase inhibition. The functional role of ER mannosidase II in glycoprotein quality control is discussed.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Grad Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Sifers, RN (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	rsifers@bcm.tmc.edu	Sifers, Richard Norman/AGQ-7262-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062553] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/DK62553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRANTLY M, 1988, AM J MED, V84, P13; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Choudhury P, 1997, NEWS PHYSIOL SCI, V12, P162; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; Liao W, 2000, J BIOL CHEM, V275, P3950, DOI 10.1074/jbc.275.6.3950; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; McCracken AA, 1996, GENETICS, V144, P1355; Miller SC, 1998, J BIOL CHEM, V273, P32618, DOI 10.1074/jbc.273.49.32618; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Novoradovskaya N, 1998, J CLIN INVEST, V101, P2693, DOI 10.1172/JCI549; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SIFERS RN, 1992, SEMIN LIVER DIS, V12, P301, DOI 10.1055/s-2008-1040399; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	55	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25015	25022		10.1074/jbc.M910172199	http://dx.doi.org/10.1074/jbc.M910172199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827201	hybrid			2022-12-27	WOS:000088683300104
J	Ishijima, J; Nakai, T; Kawaguchi, S; Hirotsu, K; Kuramitsu, S				Ishijima, J; Nakai, T; Kawaguchi, S; Hirotsu, K; Kuramitsu, S			Free energy requirement for domain movement of an enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES; ESCHERICHIA-COLI; ACTIVE-SITE; TYROSINE AMINOTRANSFERASE; CONFORMATIONAL-CHANGES; SUBSTRATE RECOGNITION; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; SPECIFICITY	Domain movement is sometimes essential for substrate recognition by an enzyme. X-ray crystallography of aminotransferase with a series of aliphatic substrates showed that the domain movement of aspartate aminotransferase was changed dramatically from an open to a closed form by the addition of only one CH2 to the side chain of the C4 substrate CH3(CH2)C(alpha)H(NH3+)COO-. These crystallographic results and reaction kinetics (Kawaguchi, S., Nobe, Y., Yasuoka, J., Wakamiya, T., Kusumoto, S., and Kuramitsu, S. (1997) J. Biochem. (Tokyo) 122, 55-63; Kawaguchi, S, and Kuramitsu, S, (1998) J. Biol. Chem. 273, 18353-18364) enabled us to estimate the free energy required for the domain movement.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Osaka City Univ, Grad Sch Sci, Dept Chem, Sumiyoshi Ku, Osaka 5588585, Japan; RIKEN, Genom Sci Ctr, Wako, Saitama 3510198, Japan	Osaka University; Osaka Metropolitan University; RIKEN	Kuramitsu, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, 1-1 Machikaneyama Cho, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp	Nakai, Tadashi/F-8047-2010	Nakai, Tadashi/0000-0001-9770-8168				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BIRCHMEIER W, 1973, J BIOL CHEM, V248, P1751; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CHRISTEN P, 1985, TRANSAMINASE; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KARPLUS M, 1983, ANNU REV BIOCHEM, V52, P263, DOI 10.1146/annurev.bi.52.070183.001403; Kasper P, 1996, EUR J BIOCHEM, V240, P751, DOI 10.1111/j.1432-1033.1996.0751h.x; Kawaguchi S, 1998, J BIOL CHEM, V273, P18353, DOI 10.1074/jbc.273.29.18353; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; Ko TP, 1999, ACTA CRYSTALLOGR D, V55, P1474, DOI 10.1107/S0907444999006630; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; Okamoto A, 1999, BIOCHEMISTRY-US, V38, P1176, DOI 10.1021/bi981921d; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; PFISTER K, 1985, J BIOL CHEM, V260, P1414; Pugmire WJ, 1998, J MOL BIOL, V281, P285, DOI 10.1006/jmbi.1998.1941; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; RYU K, 1992, BIOCHEMISTRY-US, V31, P2588, DOI 10.1021/bi00124a020; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; Takezawa Y, 1999, BIOPHYS J, V76, P1770, DOI 10.1016/S0006-3495(99)77338-8; WANGIKAR PP, 1995, BIOCHEMISTRY-US, V34, P12302, DOI 10.1021/bi00038a026; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	39	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18939	18945		10.1074/jbc.275.25.18939	http://dx.doi.org/10.1074/jbc.275.25.18939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858450	hybrid			2022-12-27	WOS:000087815900045
J	Bellmann, K; Burkart, V; Bruckhoff, J; Kolb, H; Landry, J				Bellmann, K; Burkart, V; Bruckhoff, J; Kolb, H; Landry, J			p38-dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; P38 MAP KINASE; STRESS-INDUCED APOPTOSIS; NONOBESE DIABETIC MICE; SIGNALING PATHWAY; IN-VITRO; SERINE PHOSPHORYLATION; MOLECULAR CHAPERONES; EPITHELIAL-CELLS; CARDIAC MYOCYTES	Heat shock protein (hsp) 70 protects cells against stress by means of its ability to chaperone denatured proteins and to modulate stress-activated signaling pathways. Because inflammatory processes are often accompanied by hsp expression and because stress and cytokines share several signaling pathways, we investigated the possibility that hsp70 might modulate the cellular response to cytokines. We found that stable cell clones overexpressing hsp70, or cells shortly after transfection with hsp70, produced 2 times more nitric oxide and inducible nitric-oxide synthase (iNOS) protein and mRNA in response to cytokines than control cells expressing undetectable amounts of hsp70. Since mitogen-activated protein kinases participate in the activation of iNOS by cytokines, we investigated whether hsp70 affected the activation of these signaling pathways. hsp70 overexpression led to a specific enhancement of the activation of the p38 pathway by cytokines, producing little or no effect on the activation of extracellular signal-regulated kinase or Jun N-terminal kinase. Blocking p38 activity with SB203580 totally abolished the enhancing effect of hsp70 on cytokine-induced endogenous iNOS mRNA accumulation or transcription of an iNOS promoter-driven luciferase gene, while having little effect on the cytokine response observed in control cells. We conclude that the p38 pathway acts as an enhancing factor in the activation of iNOS by cytokines and that, hsp70 can modulate the cellular response to cytokines by acting on signaling elements upstream of p38.	Univ Laval, Ctr Rech Cancerol, Hotel Dieun Quebec, Quebec City, PQ G1R 2J6, Canada; German Diabet Res Inst, Immunobiol Sect, D-40225 Dusseldorf, Germany	Laval University; Deutsches Diabetes-Zentrum (DDZ)	Bellmann, K (corresponding author), Univ Laval, Ctr Rech Cancerol, Hotel Dieun Quebec, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.							BELLMANN K, 1995, J CLIN INVEST, V95, P2840, DOI 10.1172/JCI117989; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BERNARD C, 1994, EUR J PHARM-ENVIRON, V270, P115, DOI 10.1016/0926-6917(94)90087-6; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, ESSAYS BIOCHEM, V29, P125; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chan ED, 1999, J IMMUNOL, V162, P415; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; deVera ME, 1996, HEPATOLOGY, V24, P1238; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; ENSOR JE, 1994, AM J PHYSIOL, V266, pC967, DOI 10.1152/ajpcell.1994.266.4.C967; Faure V, 1999, J BIOL CHEM, V274, P4794, DOI 10.1074/jbc.274.8.4794; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FINCATO G, 1991, BLOOD, V77, P579; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1998, AM J PHYSIOL-RENAL, V274, pF673, DOI 10.1152/ajprenal.1998.274.4.F673; HALL TJ, 1994, EXPERIENTIA, V50, P1048, DOI 10.1007/BF01923460; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kluger MJ, 1997, AM J PHYSIOL-REG I, V273, pR858, DOI 10.1152/ajpregu.1997.273.3.R858; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Liu H, 1999, ONCOGENE, V18, P3461, DOI 10.1038/sj.onc.1202699; LOWFRIEDRICH I, 1992, BASIC RES CARDIOL, V87, P12, DOI 10.1007/BF00795385; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Ozawa Y, 1996, J AUTOIMMUN, V9, P517, DOI 10.1006/jaut.1996.0069; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rothe H, 1996, DIABETOLOGIA, V39, P119; ROTHE H, 1994, DIABETOLOGIA, V37, P1154, DOI 10.1007/BF00418380; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Stewart S, 1999, MOL CELL BIOL, V19, P5523; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; Tishler M, 1996, SEMIN ARTHRITIS RHEU, V26, P558, DOI 10.1016/S0049-0172(96)80043-6; Todryk S, 1999, J IMMUNOL, V163, P1398; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763	77	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18172	18179		10.1074/jbc.M000340200	http://dx.doi.org/10.1074/jbc.M000340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849439	hybrid			2022-12-27	WOS:000087659400037
J	Rao, GN				Rao, GN			Oxidant stress stimulates phosphorylation of eIF4E without an effect on global protein synthesis in smooth muscle cells - Lack of evidence for a role of H2O2 in angiotensin II-induced hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; RECEPTOR TYROSINE KINASE; CAP-BINDING PROTEIN; C-JUN EXPRESSION; HYDROGEN-PEROXIDE; TRANSLATION INITIATION; MESSENGER-RNA; FACTOR EIF-4E; MAP KINASE; PHAS-I	Reactive oxygen species (ROS) are implicated in the pathogenesis of several proliferative diseases, including atherosclerosis and cancer. Eukaryotic translation initiation factor 4E (eIF4E) plays an important role in cell proliferation and differentiation. To gain insight into molecular mechanisms by which ROS influence the pathogenesis of these diseases, I have studied the effect of H2O2, a ROS, on eIF4E phosphorylation. H2O2 induced eIF4E phosphorylation in a dose- and time-dependent manner in growth-arrested smooth muscle cells (SMC). H2O2-induced eIF4E phosphorylation occurred on serine residues. PD098059, a specific inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase inhibited ERK activities but had no significant effect on eIF4E phosphorylation induced by H2O2. Similarly, SB203580, a specific inhibitor of p38 MAPK, although inhibiting H2O2-induced p38 MAPK activity, had no effect on H2O2-induced eIF4E phosphorylation. Calphostin C, a specific inhibitor of protein kinase C, also had no effect on H2O2-induced eIF4E phosphorylation. In contrast, trifluoperazine, an antagonist of calcium/calmodulin kinases, completely blocked H2O2-induced eIF4E phosphorylation. In addition, intracellular and extracellular Ca2+ chelators significantly inhibited H2O2-induced eIF4E phosphorylation. Despite its ability to induce eIF4E phosphorylation, H2O2 had no significant effect on protein levels and new protein synthesis as compared with control. In contrast, it induced the expression of c-Fos, c-Jun, and HSP70 in a time-dependent manner in SMC. Together, these results suggest that H2O2, a ROS and a cellular oxidant, induces eIF4E phosphorylation in a manner that is dependent on Ca2+' and Ca2+/calmodulin kinases and independent of ERKs, p38 MAPK, and protein kinase C. These results also suggest that enhanced eIF4E phosphorylation by H2O2 appears to be an important event in SMC in response to oxidant stress and that eIF4E phosphorylation may be associated with the translation of a small subset of mRNAs such as c-fos, c-jun, and HSP70 gene mRNAs, whose products may have a critical role in cell survival.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Rao, GN (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 10-138 Med Res Bldg,301 Univ Blvd,Rt 1043, Galveston, TX 77555 USA.	grao@utmb.edu						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CRAWFORD D, 1988, ONCOGENE, V3, P27; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIGUERE R, 1980, CLIN BIOCHEM, V13, P103, DOI 10.1016/S0009-9120(80)90723-7; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; RAO GN, 1994, J BIOL CHEM, V269, P7180; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Rousseau D, 1996, ONCOGENE, V13, P2415; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	71	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16993	16999		10.1074/jbc.275.22.16993	http://dx.doi.org/10.1074/jbc.275.22.16993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828072	hybrid			2022-12-27	WOS:000087392200084
J	Blanchard, F; Duplomb, L; Wang, YP; Robledo, O; Kinzie, E; Pitard, V; Godard, A; Jacques, Y; Baumann, H				Blanchard, F; Duplomb, L; Wang, YP; Robledo, O; Kinzie, E; Pitard, V; Godard, A; Jacques, Y; Baumann, H			Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-II RECEPTOR; MOUSE ONCOSTATIN-M; PHASE PLASMA-PROTEINS; DI-LEUCINE MOTIF; GROWTH-FACTOR; HEPATIC CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; DOWN-REGULATION	Leukemia inhibitory factor (LIF) signals via the heterodimeric receptor complex comprising the LIF receptor alpha subunit (LIFR alpha) and the common signal transducing subunit for interleukin-6 cytokine receptors, gp130. This study demonstrates that in different cell types, the level of LIFR alpha decreases during treatment with LIF or the closely related cytokine oncostatin M (OSM). Moreover, insulin and epidermal growth factor induce a similar LIFR alpha down-regulation. The regulated loss of LIFR alpha is specific since neither gp130 nor OSM receptor beta shows a comparable change in turnover. LIFR alpha downregulation correlates with reduced cell responsiveness to LIF. Using protein kinase inhibitors and point mutations in LIFR alpha, we demonstrate that LIFR alpha downregulation depends on activation of extracellular signal-regulated kinase 1/2 and phosphorylation of the cytoplasmic domain of LIFR alpha at serine 185. This modification. appears to promote the endosomal/lysosomal pathway of the LIFR alpha. These results suggest that extracellular signal-regulated kinase-activating factors like OSM and growth factors have the potential to lower specifically LIF responsiveness in vivo by regulating LIFR alpha half-life.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Inst Biol, INSERM U463, F-44035 Nantes 01, France; Univ Bordeaux 2, CNRS UMR 5540, F-33076 Bordeaux, France	Roswell Park Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Blanchard, F (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	frederic.blanchard@roswellpark.org	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NCI NIH HHS [CA16056, CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; BOWER J, 1995, J CELL PHYSIOL, V164, P93, DOI 10.1002/jcp.1041640112; BROWN MA, 1994, CYTOKINE, V6, P300, DOI 10.1016/1043-4666(94)90027-2; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLOWES GHA, 1988, TRAUMA SEPSIS SHOCK, P1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; FRAYN KN, 1976, BRIT J EXP PATHOL, V57, P316; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAEMURA JR, 1993, LYMPHOKINE CYTOK RES, V12, P187; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; Richards CD, 1997, J IMMUNOL, V159, P2431; Sasaoka T, 1999, ENDOCRINOLOGY, V140, P3826, DOI 10.1210/en.140.8.3826; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Strous GJ, 1999, J CELL SCI, V112, P1417; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; WANG Y, 2000, IN PRESS J BIOL CHEM, V275; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318	53	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28793	28801		10.1074/jbc.M003986200	http://dx.doi.org/10.1074/jbc.M003986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10858440	hybrid			2022-12-27	WOS:000089330700061
J	Pollevick, GD; Di Noia, JM; Salto, ML; Lima, C; Leguizamon, MS; de Lederkremer, RM; Frasch, ACC				Pollevick, GD; Di Noia, JM; Salto, ML; Lima, C; Leguizamon, MS; de Lederkremer, RM; Frasch, ACC			Trypanosoma cruzi surface mucins with exposed variant epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE SUBMAXILLARY MUCIN; O-LINKED GLYCOPROTEINS; MAMMALIAN-CELLS; METACYCLIC TRYPOMASTIGOTES; PLASMODIUM-FALCIPARUM; CHAGAS-DISEASE; SIALIC-ACID; GLYCOSYLATION; ANTIGENS; GENES	The protozoan parasite Trypanosoma cruzi, the agent of Chagas disease, has a large number of mucin molecules on its surface, whose expression is regulated during the life cycle, These mucins are the main accepters of sialic acid, a monosaccharide that is required by the parasite to infect and survive in the mammalian host. A large mucin-like gene family named TcMUC containing about 500 members has been identified previously in T. cruzi, TcMUC can be divided into two subfamilies according to the presence or absence of tandem repeats in the central region of the genes. In this work, T. cruzi parasites were transfected with one tagged member of each subfamily. Only the product from the gene with repeats was highly O-glycosylated in vivo, The O-linked oligosaccharides consisted mainly of beta-D-Galp(1-->4)GlcNAc and beta-D-Galp(1-->4)[beta-D-Galp(1-->6)]-D-GlcNAc. The same glycosyl moieties were found in endogenous mucins, The mature product was anchored by glycosylphosphatidylinositol to the plasma membrane and exposed to the medium. Sera from infected mice recognized the recombinant product of one repeats-containing gene thus showing that they are expressed during the infection, TcMUC genes encode a hypervariable region at the N terminus. We now show that the hypervariable region is indeed present in the exposed mature N termini of the mucins because sera from infected hosts recognized peptides having sequences from this region. The results are discussed in comparison with the mucins from the insect stages of the parasite (Di Noia, J. M,, D'Orso, I., Sanchez, D. O., and Frasch, A. C. C. (2000) J, Biol. Chem. 275, 10218-10227) which do not have variable regions.	Univ Nacl Gen San Martin, CONICET, Inst Tecnol Chascomus, Inst Invest Biotecnol, RA-1650 San Martin, Buenos Aires, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, CONICET,CIHIDECAR, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Microbiol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Frasch, ACC (corresponding author), Univ Nacl Gen San Martin, CONICET, Inst Tecnol Chascomus, Inst Invest Biotecnol, Av Gral Paz S-N,INTI,Edificio 24, RA-1650 San Martin, Buenos Aires, Argentina.	cfrasch@iib.unsam.edu.ar	Di Noia, Javier Marcelo/D-2285-2012	Di Noia, Javier Marcelo/0000-0003-2896-0321; Frasch, Alberto Carlos/0000-0001-7532-653X				ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; ALVES MJM, 1975, FEBS LETT, V52, P188, DOI 10.1016/0014-5793(75)80803-9; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; CAMPETELLA O, 1992, PARASITOL TODAY, V8, P378, DOI 10.1016/0169-4758(92)90175-2; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P119; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DEARRUDA MV, 1989, EUR J BIOCHEM, V182, P413, DOI 10.1111/j.1432-1033.1989.tb14847.x; DELEDERKREMER RM, 1976, BIOCHIM BIOPHYS ACTA, V444, P85, DOI 10.1016/0304-4165(76)90226-9; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Fernandez V, 1999, J EXP MED, V190, P1393, DOI 10.1084/jem.190.10.1393; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; FUKUDA M, 1993, GLYCOBIOLOGY PRACTIC, P15; Gallo-Rodriguez C, 1997, CARBOHYD RES, V305, P163, DOI 10.1016/S0008-6215(97)00256-5; Gallo-Rodriguez C, 1999, ORG LETT, V1, P245, DOI 10.1021/ol9905811; GalloRodriguez C, 1996, J ORG CHEM, V61, P1886, DOI 10.1021/jo951934m; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; Harlow E., 1988, ANTIBODIES LAB MANUA; ISHIDA C, 1993, J CLIN MICROBIOL, V31, P936, DOI 10.1128/JCM.31.4.936-940.1993; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kahn SJ, 1997, J IMMUNOL, V159, P4444; Labriola Carlos, 1993, Biological Research, V26, P101; MartinezCalvillo S, 1997, GENE, V199, P71, DOI 10.1016/S0378-1119(97)00348-X; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; Millar AE, 1999, J IMMUNOL, V162, P6092; MORTARA RA, 1992, INFECT IMMUN, V60, P4673, DOI 10.1128/IAI.60.11.4673-4678.1992; PASTINI AC, 1994, CLIN CHEM, V40, P1893; Pereira-Chioccola VL, 2000, J CELL SCI, V113, P1299; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; REYES MB, 1994, GENE, V140, P139, DOI 10.1016/0378-1119(94)90745-5; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; Salto ML, 2000, ANAL BIOCHEM, V279, P79, DOI 10.1006/abio.1999.4466; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENKEIN H A, 1991, Critical Reviews in Oral Biology and Medicine, V2, P65; SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Van Klinken BJW, 1998, ANAL BIOCHEM, V265, P103; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Wahlgren M, 1999, CELL, V96, P603, DOI 10.1016/S0092-8674(00)80569-3; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; ZINGALES B, 1982, FEBS LETT, V142, P238, DOI 10.1016/0014-5793(82)80143-9; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0	60	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27671	27680						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10843987				2022-12-27	WOS:000089197100021
J	Robyr, D; Gegonne, A; Wolffe, AP; Wahli, W				Robyr, D; Gegonne, A; Wolffe, AP; Wahli, W			Determinants of vitellogenin B1 promoter architecture - HNF3 and estrogen responsive transcription within chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; XENOPUS-LAEVIS; CRYSTAL-STRUCTURE; IN-VIVO; HISTONE ACETYLTRANSFERASE; INDEPENDENT ACTIVATION; INVITRO TRANSCRIPTION; GLOBULAR DOMAIN; DISTAL PROMOTER; LINKER HISTONES	The liver-specific vitellogenin B1 promoter is efficiently activated by estrogen within a nucleosomal environment after microinjection into Xenopus laevis oocytes, consistent with the hypothesis that significant nucleosome remodeling over this promoter is not a prerequisite for the activation by the estrogen receptor (ER alpha). This observation lead us to investigate determinants other than ER alpha of chromatin structure and transcriptional activation of the vitellogenin B1 promoter in this system and in vitro. We find that the liver-enriched transcription factor HNF3 has an important organizational role for chromatin structure as demonstrated by DNase I-hypersensitive site mapping. Both HNF3 and the estrogen receptor activate transcription synergistically and are able to interact with chromatin reconstituted in vitro with three positioned nucleosomes. We propose that HNF3 is the cellular determinant which establishes a promoter environment favorable to a rapid transcriptional activation by the estrogen receptor.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	University of Lausanne; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, Batiment Biol, CH-1015 Lausanne, Switzerland.		Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Wahli, Walter/0000-0002-5966-9089				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BATES AD, 1993, FOCUS; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; BURCH JBE, 1986, MOL CELL BIOL, V6, P1886, DOI 10.1128/MCB.6.6.1886; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG TC, 1990, J BIOL CHEM, V265, P8176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORTHESY B, 1990, MOL CELL BIOL, V10, P3926, DOI 10.1128/MCB.10.8.3926; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; FORTUNE JE, 1983, DEV BIOL, V99, P502, DOI 10.1016/0012-1606(83)90299-3; GERBERHUBER S, 1981, NUCLEIC ACIDS RES, V9, P2475, DOI 10.1093/nar/9.11.2475; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marilley D, 1998, MOL CELL ENDOCRINOL, V141, P79, DOI 10.1016/S0303-7207(98)00090-2; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MCKENZIE EA, 1990, MOL CELL BIOL, V10, P6674, DOI 10.1128/MCB.10.12.6674; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; TATA JR, 1979, RECENT PROG HORMONE, V35, P95; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tsai-Pflugfelder M, 1998, MOL ENDOCRINOL, V12, P1525, DOI 10.1210/me.12.10.1525; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; WAHLI W, 1979, CELL, V16, P535, DOI 10.1016/0092-8674(79)90028-X; Wahli W, 1985, Oxf Surv Eukaryot Genes, V2, P96; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; WATSON CS, 1991, J STEROID BIOCHEM, V38, P423, DOI 10.1016/0960-0760(91)90330-8; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WILLIAMS JL, 1983, NUCLEIC ACIDS RES, V11, P1151, DOI 10.1093/nar/11.4.1151; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zaret K, 1998, CURR OPIN GENET DEV, V8, P526, DOI 10.1016/S0959-437X(98)80006-3; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	69	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28291	28300						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10854430				2022-12-27	WOS:000089197100101
J	Barbosa-Tessmann, IP; Chen, C; Zhong, C; Siu, F; Schuster, SM; Nick, HS; Kilberg, MS				Barbosa-Tessmann, IP; Chen, C; Zhong, C; Siu, F; Schuster, SM; Nick, HS; Kilberg, MS			Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; LIGATION-MEDIATED PCR; TRANSCRIPTIONAL REGULATION; EXPRESSION; CELLS; CHOP; IDENTIFICATION; DEPRIVATION; INDUCTION; BINDING	The human asparagine synthetase (AS) gene is transcriptionally regulated by amino acid deprivation (amino acid response, AAR) and the endoplasmic reticulum stress response (ERSR), also known as the unfolded protein response pathway. The results reported here document the novel observation that induction of the AS gene by the AAR and ERSR pathways occurs via the same set of genomic elements. Data supporting this conclusion include transient transfection of AS promoter/reporter gene constructs that illustrate that the transcriptional control elements used by both pathways are contained with nucleotides -111 to -34 of the AS pro meter. In vivo footprinting analysis of this region identified six specific protein-binding sites. Within two of these sites, altered footprinting was observed following amino acid or glucose deprivation, but the patterns were identical for both the AAR and the ERSR pathway. Site-directed mutation of individual nucleotides within these two binding sites confirmed their importance for regulated transcription, and none of the mutations resulted in loss of response of only one pathway, Neither of these two sites corresponds to a recently identified ERSR cis-element, nor do they contain consensus sequences for known transcription factors, Collectively, the data document that there are at least two independent transcriptional mechanisms for gene activation by the ERSR pathway, one of which terminates at the same genomic elements used by the AAR pathway.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.		Barbosa-Tessmann, Ione Parra/H-3856-2012	Barbosa-Tessmann, Ione Parra/0000-0001-9860-378X	NIDDK NIH HHS [DK-51064] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; Heal R, 1998, BIOCHEM J, V329, P389, DOI 10.1042/bj3290389; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERRIGAN LA, 1994, CURRENT PROTOCOLS MO; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1981, P NATL ACAD SCI-BIOL, V78, P4922, DOI 10.1073/pnas.78.8.4922; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZHANG YP, 1989, GENOMICS, V4, P259, DOI 10.1016/0888-7543(89)90329-7; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	43	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26976	26985						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856289				2022-12-27	WOS:000089144800042
J	Carew, MA; Yang, XN; Schultz, C; Shears, SB				Carew, MA; Yang, XN; Schultz, C; Shears, SB			myo-inositol 3,4,5,6-tetrakisphosphate inhibits an apical calcium-activated chloride conductance in polarized monolayers of a cystic fibrosis cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; ACINAR-CELLS; SECRETION; AGONIST; PHOSPHATES; CHANNELS; TRANSPORT; EPITHELIA; MEMBRANE	Does inositol 3,4,5,6 tetrakisphosphate (Ins(3,4,5,6)P-4) inhibit apical Ca2+-activated Cl- conductance (CaCC)? We studied this question using human CFPAC-1 pancreatoma cells grown in polarized monolayers. Cellular Ins(3,4,5,6)P-4 levels were acutely sensitive to purinergic receptor activation, rising 3-fold within 1 min of agonist addition. Intracellular Ins(3,4,5,6)P-4, levels were therefore specifically elevated, independently of receptor activation, by incubating cells with a cell-permeant bioactivable analogue, 1,2-di-O-butyl-myo-inositol 3,4,5,6-tetrakisphosphate octakis(acetoxymethyl)ester (Bt(2)Ins (3,4,5,6)P-4/AM). The latter inhibited Ca2+-activated Cl- secretion by 60%. We next used nystatin to selectively permeabilize the basolateral membrane to monovalent anions and cations, thereby preventing this membrane from electrochemically dominating ion movements through the apical membrane. Thus, we studied autonomous regulation of apical Cl- channels in situ. The properties of Cl- flux across the apical membrane were those expected of CaCC: niflumic acid sensitivity, outward rectification, and 2-fold greater permeability of I- over Cl-. Following nystatin-treatment, we elevated intracellular levels of Ins(3,4,5,6)P-4, with either purinergic agonists or with Bt(2)Ins(3,4,5,6)P-4/AM. Both protocols inhibited Ca2+-activated Cl- secretion (up to 70%). These studies provide the first demonstration that, in a physiologically relevant context of a polarized monolayer, there is an apical, Ins(3,4,5,6)P-4-inhibited CaCC.	NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Bremen, Inst Organ Chem, UFT, D-28359 Bremen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bremen	Carew, MA (corresponding author), NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		; shears, stephen/C-6335-2019	Schultz, Carsten/0000-0002-5824-2171; shears, stephen/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACRA SA, 1991, JPEN-PARENTER ENTER, V15, pS93, DOI 10.1177/014860719101500393S; AlNakkash L, 1997, AM J PHYSIOL-GASTR L, V273, pG204, DOI 10.1152/ajpgi.1997.273.1.G204; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Andersson L1992A, SCRIPTA BOT BELG, V1, P1; BALLA T, 1989, J BIOL CHEM, V264, P13605; BARKER CJ, 1992, BIOCHEM J, V286, P469, DOI 10.1042/bj2860469; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; DEVOR DC, 1992, AM J PHYSIOL, V263, pC780, DOI 10.1152/ajpcell.1992.263.4.C780; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; GALIETTA LJV, 1994, PFLUG ARCH EUR J PHY, V426, P534, DOI 10.1007/BF00378531; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Greger R, 2000, ANNU REV PHYSIOL, V62, P467, DOI 10.1146/annurev.physiol.62.1.467; Grubb BR, 1997, AM J PHYSIOL-GASTR L, V273, pG258, DOI 10.1152/ajpgi.1997.273.2.G258; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KNOWLES MR, 1995, CHEST, V107, pS71, DOI 10.1378/chest.107.2_Supplement.71S; MCCONNELL FM, 1992, BIOCHEM J, V284, P447, DOI 10.1042/bj2840447; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; O'Reilly CM, 1998, BRIT J PHARMACOL, V124, P1597, DOI 10.1038/sj.bjp.0701990; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Rudolf MT, 1998, J MED CHEM, V41, P3635, DOI 10.1021/jm970781n; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHEARS SB, 1997, SIGNALLING INOSITIDE, P33; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; Tan Z, 1997, J BIOL CHEM, V272, P2285; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973	47	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26906	26913						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842174				2022-12-27	WOS:000089144800034
J	Kamino, K; Inoue, K; Maruyama, T; Takamatsu, N; Harayama, S; Shizuri, Y				Kamino, K; Inoue, K; Maruyama, T; Takamatsu, N; Harayama, S; Shizuri, Y			Barnacle cement proteins - Importance of disulfide bonds in their insolubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEGABALANUS-ROSA; ACORN BARNACLE	Barnacles produce a cement that is a proteinaceous underwater adhesive for their secure attachment to the substratum, The biochemical properties of the cement have not previously been elucidated, because the insolubility of the cement proteins hampers their purification and characterization. We developed a non-hydrolytic method to render soluble most of the cement components, thereby allowing the proteins to be analyzed. Megabalanus rosa cement could be almost completely rendered soluble by its reduction with 0.5 M dithiothreitol at 60 degrees C in a 7 M guanidine hydrochloride solution, the high concentration of dithiothreitol being indispensable to achieve this. The effectiveness of this reduction treatment was confirmed by the detachment of the barnacle from the substratum. Three proteins comprising up to 94% of the whole cement were identified as the major cement components. The cDNA clone of one of these major proteins was isolated, and the site-specific expression of the gene in the basal portion of the adult barnacle, where the cement glands are located, was demonstrated. A sequence analysis revealed this cement component to be a novel protein of 993 amino acid residues, including a signal peptide. This is the first report of the major component of the barnacle cement protein complex.	Marine Biotechnol Inst, Shimizu Labs, Shizuoka 4240037, Japan; Marine Biotechnol Inst, Kamaishi Labs, Kamaishi, Iwate 0260001, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Sagamihara, Kanagawa 228, Japan	Kitasato University	Kamino, K (corresponding author), Marine Biotechnol Inst, Shimizu Labs, 1900 Sodeshi, Shizuoka 4240037, Japan.			Harayama, Shigeaki/0000-0003-2103-7796				Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DOUGHERTY WJ, 1990, J CRUSTACEAN BIOL, V10, P469, DOI 10.2307/1548336; FYHN UEH, 1976, BIOL BULL, V150, P47, DOI 10.2307/1540588; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; Kamino K, 1996, BIOL BULL, V190, P403, DOI 10.2307/1543033; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOMBE D, 1970, BIOL BULL, V139, P164, DOI 10.2307/1540134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURSEN RA, 1992, BIOPOLYMERS, P55; Naldrett MJ, 1997, MAR BIOL, V127, P629, DOI 10.1007/s002270050053; Rzepecki LM, 1995, MOL MAR BIOL BIOTECH, V4, P313; SAROYAN JR, 1970, BIOL BULL, V139, P333, DOI 10.2307/1540088; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKOOG B, 1986, TRENDS ANALC HEM, V5; TAKAMATSU N, 1993, GENE, V128, P251; WAITE JH, 1987, INT J ADHES ADHES, V7, P9, DOI 10.1016/0143-7496(87)90048-0; WALKER G, 1972, J MAR BIOL ASSOC UK, V52, P429, DOI 10.1017/S0025315400018786; WALKER G, 1970, MAR BIOL, V7, P239, DOI 10.1007/BF00367494; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211	20	153	158	2	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27360	27365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840046				2022-12-27	WOS:000089144800093
J	Vispe, S; Satoh, MS				Vispe, S; Satoh, MS			DNA repair patch-mediated double strand DNA break formation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; PURIFIED HUMAN PROTEINS; LIGASE-I; MAMMALIAN-CELLS; IONIZING-RADIATION; POLYMERASE-EPSILON; DEPENDENT REPAIR; URACIL RESIDUES; RAD51 PROTEIN; DAMAGED DNA	To investigate the mechanism of double strand DNA break formation in mammalian cells, an in vitro assay was established using closed circular DNA containing two uracils on opposite DNA strands (18 and 30 base pairs apart) and extracts prepared from human cells. In this assay, formation of double strand breaks was detected by the conversion of circular DNA to linear DNA. Approximately 4-fold more double strand DNA breaks were produced by extracts from cells deficient in DNA ligase I (46BR) relative to those produced by extracts from control cells (MRC5, derived from a clinically normal individual). In parallel with the amount of double strand DNA breaks, extracts from 46BR cells produced longer repair patches (up to 24 bases in length) than those from MRC5 cells (typically <5 bases long). When purified DNA ligase I was added to 46BR extracts to complement the DNA ligase deficiency, only a negligible difference was found between the amount of double strand DNA breaks or the repair patch size generated in the assay relative to MRC5 extracts. Together, our data demonstrate that double strand DNA breaks are produced through formation of DNA repair patches. We refer to this process of double strand break formation as the "DNA repair patch-mediated pathway."	Univ Laval, Fac Med, CHUQ, Med Res Ctr,Hlth & Environm Unit,DNA Repair Grp, Quebec City, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), Univ Laval, Fac Med, CHUQ, Med Res Ctr,Hlth & Environm Unit,DNA Repair Grp, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Masahiko.Sato@crchul.ulaval.ca						AHNSTROM G, 1982, INT J RADIAT BIOL, V41, P671, DOI 10.1080/09553008214550761; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRADLEY MO, 1987, MUTAT RES, V189, P69, DOI 10.1016/0165-1218(87)90034-6; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; CLEAVER JE, 1985, CANCER RES, V45, P1163; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; DUGLE DL, 1976, P NATL ACAD SCI USA, V73, P809, DOI 10.1073/pnas.73.3.809; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; NOCENTINI S, 1995, RADIAT RES, V144, P170, DOI 10.2307/3579256; Nocentini S, 1999, RADIAT RES, V151, P423, DOI 10.2307/3579829; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; Vispe S, 1997, BIOCHIMIE, V79, P587, DOI 10.1016/S0300-9084(97)82007-X; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALKER IG, 1984, CAN J BIOCHEM CELL B, V62, P329, DOI 10.1139/o84-046; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Ward JF, 1998, CONT CANC RES, P65; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X	44	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27386	27392						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827190				2022-12-27	WOS:000089144800096
J	Chen, H; Deere, M; Hecht, JT; Lawler, J				Chen, H; Deere, M; Hecht, JT; Lawler, J			Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; COMP GENE; PLATELET THROMBOSPONDIN; ENDOPLASMIC-RETICULUM; PSEUDOACHONDROPLASIA; TENDON; CELLS	Mutations in residues in the type 3 calcium-binding repeats and COOH-terminal globular region of cartilage oligomeric matrix protein (COMP) lead to two skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia, It has been hypothesized that these mutations cause COMP to misfold and to be retained in the endoplasmic reticulum, However, this hypothesis is not supported by previous reports that COMP, when purified in the presence of EDTA, shows no obvious difference in electron microscopic appearance in the presence or absence of calcium ions. Since this discrepancy may be due to the removal of calcium during purification, we have expressed wild-type COMP and the most common mutant form found in pseudoachondroplasia, MUT3, using a mammalian expression system and have purified both proteins in the presence of calcium. Both proteins are expressed as pentamers, Direct calcium binding experiments demonstrate that wild-type COMP, when purified in the presence of calcium, is a calcium-binding protein, Rotary shadowing electron microscopy and Limited trypsin digestion at various calcium concentrations show that there are conformational changes associated with calcium binding to COMP, Whereas COMB exists in a more compact conformation in the presence of calcium, it shows a more extended conformation when calcium is removed. MUT3, with a single aspartic acid deletion in the type 3 repeats, binds less calcium and presents an intermediate conformation between the calcium-replete and calcium depleted forms of COMP, In conclusion, we show that a single mutation in the type 3 repeats of COMP causes the mutant protein to misfold, Our data demonstrate the importance of calcium binding to the structure of COMP and provide a plausible explanation for the observation that mutations in the type 3 repeats and COOH-terminal globular region lead to pseudoachondroplasia.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor BIol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Texas System	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor BIol & Angiogenesis, Res N,Rm 270C,99 Brookline Ave, Boston, MA 02215 USA.		Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049081] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49081] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; COOPER RR, 1973, J BONE JOINT SURG AM, VA 55, P475, DOI 10.2106/00004623-197355030-00003; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1999, HUM MOL GENET, V8, P123, DOI 10.1093/hmg/8.1.123; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Horton William A., 1993, P641; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PEDRINIMILLE A, 1984, J BONE JOINT SURG AM, V66A, P1408, DOI 10.2106/00004623-198466090-00014; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Zaia J, 1997, J BIOL CHEM, V272, P14120, DOI 10.1074/jbc.272.22.14120	39	88	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26538	26544		10.1074/jbc.M909780199	http://dx.doi.org/10.1074/jbc.M909780199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852928	hybrid, Green Published			2022-12-27	WOS:000088999700090
J	Chen, L; Trujillo, K; Sung, P; Tomkinson, AE				Chen, L; Trujillo, K; Sung, P; Tomkinson, AE			Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; XRCC4 PROTEIN; GENE-PRODUCT; I GENE; KU; IDENTIFICATION	The DNA-dependent protein kinase (DNA-PK), consisting of Ku and the DNA-PK catalytic subunit (DNA-PKcs), and the DNA ligase IV-XRCC4 complex function together in the repair of DNA double-strand breaks by non-homologous end joining. These protein complexes are also required for the completion of V(D)J recombination events in immune cells, Here we demonstrate that the DNA ligase IV-XRCC4 complex binds specifically to the ends of duplex DNA molecules and can act as a bridging factor, linking together duplex DNA molecules with complementary but non-ligatable ends. Although the DNA end-binding protein Ku inhibited DNA joining by DNA ligase IV-XRCC4, it did not prevent this complex from binding to DNA, Instead, DNA ligase TVXRCC4 and Ku bound simultaneously to the ends of duplex DNA molecules. DNA ligase TV-XRCC4 and DNA-PKcs also formed complexes at the ends of DNA molecules, but DNA-PKcs did not inhibit ligation, Interestingly, DNA-PKcs stimulated intermolecular ligation by DNA ligase TV-XRCC4, In the presence of DNA-PK, the majority of the joining events catalyzed by DNA ligase IV-XRCC4 were intermolecular because Ku inhibited intramolecular ligation, but DNA-PKcs still stimulated intramolecular ligation, We suggest that DNA-PKcs-containing complexes formed at DNA ends enhance the association of DNA ends via protein-protein interactions, thereby stimulating intermolecular ligation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047251, R01GM047251] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM47251] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; GOTTESMA.ME, 1966, J BIOL CHEM, V241, P4339; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SODERHALL S, 1973, BIOCHEM BIOPH RES CO, V53, P910, DOI 10.1016/0006-291X(73)90178-2; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEBSTER ADB, 1992, LANCET, V339, P1508, DOI 10.1016/0140-6736(92)91266-B; WEI YF, 1995, MOL CELL BIOL, V15, P3206; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034	45	174	182	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26196	26205		10.1074/jbc.M000491200	http://dx.doi.org/10.1074/jbc.M000491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854421	hybrid			2022-12-27	WOS:000088999700044
J	Cozzi, A; Corsi, B; Levi, S; Santambrogio, P; Albertini, A; Arosio, P				Cozzi, A; Corsi, B; Levi, S; Santambrogio, P; Albertini, A; Arosio, P			Overexpression of wild type and mutated human ferritin H-chain in HeLa cells - In vivo role of ferritin ferroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERFERRITINEMIA-CATARACT SYNDROME; IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; OXIDATIVE STRESS; GENE-EXPRESSION; MAMMALIAN-CELLS; MECHANISM; HETEROPOLYMERS; PROTEIN; SUBUNIT	Transfectant HeLa cells were generated that expressed human ferritin H-chain wild type and an H-chain mutant with inactivated ferroxidase activity under the control of the tetracycline-responsive promoter (Tet-off), The clones accumulated exogenous ferritins up to levels 14-16-fold over background, half of which were as H-chain homopolymers. This had no evident effect in the mutant ferritin clone, whereas it induced an iron-deficient phenotype in the H-ferritin wild type clone, manifested by similar to 5-fold increase of IRPs activity, similar to 2.5-fold increase of transferrin receptor, similar to 1.8-fold increase in iron-transferrin iron uptake, and similar to 50% reduction of labile iron pool. Overexpression of the H-ferritin, but not of the mutant ferritin, strongly reduced cell growth and increased resistance to H2O2 toxicity, effects that were reverted by prolonged incubation in iron-supplemented medium. The results show that in HeLa cells H-ferritin regulates the metabolic iron pool with a mechanism dependent on the functionality of the ferroxidase centers, and this affects, in opposite directions, cellular growth and resistance to oxidative damage. This, and the finding that also in vivo H-chain homopolymers are much less efficient than the H/L heteropolymers in taking up iron, indicate that functional activity of H-ferritin in HeLa cells is that predicted from the in vitro data.	IRCCS H San Raffaele, Dibit, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Brescia, Dept MI & Biomed Technol, I-25100 Brescia, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia	Arosio, P (corresponding author), Via Olgettina 58, I-20132 Milan, Italy.		levi, sonia/A-3161-2015; arosio, paolo/E-6817-2010; Santambrogio, Paolo/AAN-3837-2020; Cozzi, Anna/AAN-3821-2020; arosio, paolo/S-3272-2019	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992; albertini, alberto/0000-0002-7989-649X				BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; Cazzola M, 1997, BLOOD, V90, P814, DOI 10.1182/blood.V90.2.814.814_814_821; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Fan HZ, 1996, FEBS LETT, V382, P145, DOI 10.1016/0014-5793(96)00143-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARRISON PM, 1994, ADV EXP MED BIOL, V356, P1; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hwang J, 2000, SCIENCE, V287, P122, DOI 10.1126/science.287.5450.122; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Juan SH, 1998, ARCH BIOCHEM BIOPHYS, V355, P56, DOI 10.1006/abbi.1998.0722; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1994, J BIOL CHEM, V269, P30334; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; Levi S, 1996, BIOCHEM J, V317, P467, DOI 10.1042/bj3170467; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LOUACHE F, 1985, FEBS LETT, V183, P223, DOI 10.1016/0014-5793(85)80781-X; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; ROBERTS S, 1988, J BIOL CHEM, V263, P19181; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; Santambrogio P, 1996, BIOCHEM J, V314, P139, DOI 10.1042/bj3140139; Yang XK, 1999, BIOCHEM J, V338, P615, DOI 10.1042/0264-6021:3380615; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	35	199	214	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25122	25129		10.1074/jbc.M003797200	http://dx.doi.org/10.1074/jbc.M003797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833524	hybrid			2022-12-27	WOS:000088849400013
J	Katsumi, A; Tuley, EA; Bodo, I; Sadler, JE				Katsumi, A; Tuley, EA; Bodo, I; Sadler, JE			Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; HUMAN VONWILLEBRAND-FACTOR; NORRIE DISEASE; SELECTIVE REDUCTION; DIMERIZATION; SEQUENCE; MUTATION; LINKAGE; CHAIN; CELLS	von Willebrand factor (VWF) is a multimeric glycoprotein that is required for normal hemostasis. After translocation into the endoplasmic reticulum, proVWF subunits dimerize through disulfide bonds between their C-terminal cystine knot-like (CK) domains. CK domains are characterized by six conserved cysteines, Disulfide bonds between cysteines 2 and 5 and between cysteines 3 and 6 define a ring that is penetrated by a disulfide bond between cysteines 1 and 4. Dimerization often is mediated by additional cysteines that differ among CK domain subfamilies. When expressed in a baculovirus system, recombinant VWF CK domains (residues 1957-2050) were secreted as dimers that were converted to monomers by selective reduction and alkylation of three unconserved cysteine residues: Cys(2008), CyS2010 and Cys(2048). BY partial reduction and alkylation, chemical and proteolytic digestion, mass spectrometry, and amino acid sequencing, the remaining intrachain disulfide bonds were characterized: Cys(1961)-Cys(2011) (1-4), Cys(1987)-Cys(2041) (2-5), Cys(1991)-Cys(2045) (3-6), and Cys(1976)- Cys(2025). The mutation C2008A or C2010A prevented dimerization, whereas the mutation C2048A did not. Symmetry considerations and molecular modeling based on the structure of transforming growth factor-beta suggest that one or three of residues Cys(2008), Cys(2010), and Cys(2048) in each subunit mediate the covalent dimerization of proVWF.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X				Bures EJ, 1998, BIOCHEMISTRY-US, V37, P12172, DOI 10.1021/bi981082v; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; CORMACK B, 1997, CURRENT PROTOCOLS MO; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ENAYAT MS, 1997, THROMB HAEMOST S, V82, P655; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Haniu M, 1996, BIOCHEMISTRY-US, V35, P16799, DOI 10.1021/bi9605550; Haniu M., 1997, CURRENT TOPICS PEPTI, V2, P115; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Katsumi A, 1996, BLOOD, V87, P4164, DOI 10.1182/blood.V87.10.4164.bloodjournal87104164; Katsumi A, 2000, THROMB HAEMOSTASIS, V83, P239; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Montgomery RR, 1999, BLOOD, V94, p443A; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; RANDI AM, 1992, J BIOL CHEM, V267, P21187; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; Schneppenheim R, 1999, BLOOD, V94, p453A; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195	32	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25585	25594		10.1074/jbc.M002654200	http://dx.doi.org/10.1074/jbc.M002654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831592	hybrid			2022-12-27	WOS:000088849400072
J	Stockinger, W; Brandes, C; Fasching, D; Hermann, M; Gotthardt, M; Herz, J; Schneider, WJ; Nimpf, J				Stockinger, W; Brandes, C; Fasching, D; Hermann, M; Gotthardt, M; Herz, J; Schneider, WJ; Nimpf, J			The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; HUMAN ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; TERMINAL KINASE JNK; LIPOPROTEIN RECEPTOR; C-JUN; SIGNAL-TRANSDUCTION; BRAIN-DEVELOPMENT; ADAPTER PROTEINS; VLDL RECEPTOR	Correct positioning of neurons during embryonic development of the brain depends, among other processes, on the proper transmission of the reelin signal into the migrating cells via the interplay of its receptors with cytoplasmic signal transducers. Cellular components of this signaling pathway characterized to date are cell surface receptors for reelin like apolipoprotein E receptor 2 (ApoER2), very low density lipoprotein receptor (VLDLR), and cadherin-related neuronal receptors, and intracellular components like Disabled-1 and the nonreceptor tyrosine kinase Fyn, which bind to the intracellular domains of the ApoER2 and VLDL receptor or of cadherin-related neuronal receptors, respectively. Here we show that ApoER2, but not VLDLR, also binds the family of JNK-interacting proteins (JIPs), which act as molecular scaffolds for the JNK-signaling pathway. The ApoER2 binding domain on JIP-2 does not overlap with the binding sites for MLK3, MKK7, and JNK. These results suggest that ApoER2 is able to assemble a multiprotein complex containing Disabled-1 and JIPs, together with their binding partners, to the cell surface of neurons. This complex might participate in ApoER2-specific reelin signaling and thus would explain the different phenotype of mice lacking the ApoER2 from that of VLDLR-deficient mice.	Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nimpf, J (corresponding author), Bioctr, Dept Mol Genet, Inst Med Biochem, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.		Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492; Hermann, Marcela/0000-0003-2298-4269	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gliemann J, 1998, BIOL CHEM, V379, P951; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Riddell DR, 1999, ATHEROSCLEROSIS, V144, P83, DOI 10.1016/S0021-9150(99)80317-7; Riddell DR, 1997, J BIOL CHEM, V272, P89; Robaire B., 1988, P999; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wang NP, 1999, ARTERIOSCL THROM VAS, V19, P2078, DOI 10.1161/01.ATV.19.9.2078; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zerbinatti CV, 1999, BIOL REPROD, V61, P665, DOI 10.1095/biolreprod61.3.665; Zhu Y, 1999, BBA-MOL CELL BIOL L, V1436, P557, DOI 10.1016/S0005-2760(98)00167-2; Zhu Y, 1998, ARTERIOSCL THROM VAS, V18, P473, DOI 10.1161/01.ATV.18.3.473	49	190	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25625	25632		10.1074/jbc.M004119200	http://dx.doi.org/10.1074/jbc.M004119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827199	hybrid			2022-12-27	WOS:000088849400077
J	Tan, Y; Demeter, MR; Ruan, H; Comb, MJ				Tan, Y; Demeter, MR; Ruan, H; Comb, MJ			BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; DEATH AGONIST; MAP KINASE; BH3 DOMAIN; PATHWAY; PROTEIN; AKT; ACTIVATION; APOPTOSIS	The BH3 domain of BAD mediates its death-promoting activities via heterodimerization to the Bcl-XL family of death regulators. Growth and survival factors inhibit the death-promoting activity of BAD by stimulating phosphorylation at multiple sites including Ser-112 and Ser-136, Phosphorylation at these sites promotes binding of BAD to 14-3-3 proteins, sequestering BAD away from the mitochondrial membrane where it dimerizes with Bcl-XL to exert its killing effects. We report here that the phosphorylation of BAD at Ser-155 within the BH3 domain is a second phosphorylation-dependent mechanism that inhibits the death-promoting activity of BAD, Protein kinase A, RSK1, and survival factor signaling stimulate phosphorylation of BAD at Ser-155, blocking the binding of BAD to Bcl-XL, RSK1 phosphorylates BAD at both Ser-112 and Ser-155 and rescues BAD-mediated cell death in a manner dependent upon phosphorylation at both sites.	Cell Signaling Technol, Cummings Ctr 166B, Beverly, MA 01915 USA		Comb, MJ (corresponding author), Cell Signaling Technol, Cummings Ctr 166B, Beverly, MA 01915 USA.	combm@cellsignal.com			NIDA NIH HHS [DA05706] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	35	266	271	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25865	25869		10.1074/jbc.M004199200	http://dx.doi.org/10.1074/jbc.M004199200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837486	hybrid			2022-12-27	WOS:000088849400105
J	Uittenbogaard, A; Smart, EJ				Uittenbogaard, A; Smart, EJ			Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CAVEOLAE; NITRIC-OXIDE SYNTHASE; ONCOGENICALLY TRANSFORMED-CELLS; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; RECEPTOR; PROTEIN; LOCALIZATION; TRAFFICKING; EXPRESSION	We previously demonstrated that a caveolin-chaperone complex transports newly synthesized cholesterol from the endoplasmic reticulum through the cytoplasm to caveolae, Caveolin-1 has a 33-amino acid hydrophobic domain and three sites of palmitoylation in proximity to the hydrophobic domain. in the present study, we hypothesized that palmitoylation of caveolin-1 is necessary for binding of cholesterol, formation of a caveolin-chaperone transport complex, and rapid, direct transport of cholesterol to caveolae. To test this hypothesis, four caveolin-1 constructs were generated that substituted an alanine for a cysteine at position 133, 143, or 156 or all three sites (triple mutant). These mutated caveolins and wild type caveolin-1 were stably expressed in the lymphoid cell line, L1210-JF, which does not express caveolin-1, does not form a caveolin-chaperone complex, and does not transport newly synthesized cholesterol to caveolae. All of the caveolins were expressed and the proteins localized to plasma membrane caveolae, Wild type caveolin-1 and mutant 133 assembled into complete transport complexes and rapidly (10-20 min) transported cholesterol to caveolae, Caveolin mutants 143 and 156 did not assemble into complete transport complexes, weakly associated with cholesterol, and transported small amounts of cholesterol to caveolae, The triple mutant did not assemble into complete transport complexes and did not associate with cholesterol, We conclude that palmitoylation of caveolin-1 at positions 143 and 156 is required for cholesterol binding and transport complex formation.	Univ Kentucky, Sch Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Sch Med, Dept Physiol, MS 508 C,800 Rose St, Lexington, KY 40536 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058475, R01HL058475] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58475] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Field FJ, 1998, J LIPID RES, V39, P1938; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISCUM L, 1992, J LIPID RES, V33, P1239; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525	30	149	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25595	25599		10.1074/jbc.M003401200	http://dx.doi.org/10.1074/jbc.M003401200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833523	hybrid, Green Published			2022-12-27	WOS:000088849400073
J	Wang, HCR; Fecteau, KA				Wang, HCR; Fecteau, KA			Detection of a novel quiescence-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOBACTERIUM-VIOLACEUM NO-968; ARREST-SPECIFIC GENE; IRRADIATION-INDUCED APOPTOSIS; CASPASE-MEDIATED ACTIVATION; GROWTH ARREST; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION SITES; CELLS; DEPSIPEPTIDE	We have identified a cell quiescence-specific 33-kDa cytoplasmic protein kinase (p33(QIK), Quiescence-Induced Kinase) based on induction of p33(QIK)-specific kinase activity of cells growth-arrested in the quiescent phase and deactivation upon entry into the cell cycle. Blockage of macromolecular synthesis prevents p33(QIK) from deactivation, indicating a requirement of newly synthesized regulators for deactivation of p33(QIK) during G(0)/G(1) transition. Stress shock induces additional increases of p33(QIK) activity in a quiescence-dependent manner that correlates with induction of apoptosis, Using a specific antibody to Krs1/Mst2 protein, we found that p33(QIK) is related to p63(Krs1) and is distinguishable from a 36-kDa protein kinase, which is induced through proteolytic modification of activated p63(Krs1) in proliferating cells undergoing apoptosis, p33(QIK) is constantly expressed in quiescent, proliferating, and apoptotic quiescent cells, Regulation of p33(QIK) activity involves protein phosphorylation/dephosphorylation in a proteolysis-independent manner. Regulation of p33(QIK) and related p63(Krs1) and p36 appears to involve distinct pathways in quiescent and proliferating cells, respectively. Our results illustrate the relevance of p33(QIK) activity for cell quiescence that may provide a new insight into signaling pathways regulated in cells during quiescence and quiescence-related apoptosis.	Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Wang, HCR (corresponding author), Univ Tennessee, Coll Vet Med, Dept Comparat Med, 2407 River Dr, Knoxville, TN 37996 USA.	hcrwang@utk.edu	Wang, Hwa-Chain/L-5646-2015	Wang, Hwa-Chain/0000-0001-5836-4120	NATIONAL CANCER INSTITUTE [R29CA069530] Funding Source: NIH RePORTER; NCI NIH HHS [1R29CA69530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI GE, 1988, FASEB J, V2, P3010, DOI 10.1096/fasebj.2.14.2846396; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Chan WH, 1999, J CELL PHYSIOL, V178, P397, DOI 10.1002/(SICI)1097-4652(199903)178:3<397::AID-JCP14>3.3.CO;2-U; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL FLO; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Kakeya H, 1998, CANCER RES, V58, P4888; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIM YH, 1993, J BIOL CHEM, V268, P18513; LARSSON O, 1985, J CELL SCI, V75, P259; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; Rajgolikar G, 1998, BREAST CANCER RES TR, V51, P29, DOI 10.1023/A:1006091014092; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Scholz G, 1996, MOL CELL BIOL, V16, P481; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	50	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25850	25857		10.1074/jbc.M000818200	http://dx.doi.org/10.1074/jbc.M000818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840030	hybrid			2022-12-27	WOS:000088849400103
J	Liu, CY; Schroder, M; Kaufman, RJ				Liu, CY; Schroder, M; Kaufman, RJ			Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; KAR2 BIP GENE; TRANSCRIPTIONAL INDUCTION; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; RESIDENT PROTEINS; MAMMALIAN-CELLS	IRE1 and PERK are type I transmembrane serine/threonine protein kinases that are activated by unfolded proteins in the endoplasmic reticulum (ER) to signal adaptive responses. IRE1 is present in all eukaryotic cells and signals the unfolded protein response through its kinase and endoribonuclease activities. PERK signals phosphorylation of a translation initiation factor to inhibit protein synthesis in higher eukaryotic cells but is absent in the Saccharomyces cerevisiae genome. The amino acid sequences of the amino-terminal ER luminal domains (NLDs) from IRE1 and PERK display limited homology and have diverged among species. In this study, we have demonstrated that the NLD of yeast Ire1p is required for signaling. However, the NLDs from human IRE1 alpha and murine IRE1 beta and the Caenorhabditis elegans IRE1 and PERK function as replacements for the S. cerevisiae Ire1p-NLD to signal the unfolded protein response. Replacement of the Ire1p-NLD with a functional leucine zipper dimerization motif yielded a constitutively active kinase that surprisingly was further activated by ER stress. These results demonstrate that ER stress-induced dimerization of the NLD is sufficient for IRE1 and PERK activation and is conserved through evolution. We propose that ligand-independent activation of IRE1 and PERK permits homodimerization upon accumulation of unfolded proteins in the lumen of the ER.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, 4570 MSRB II,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010; Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900				Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; BEH CT, 1995, P NATL ACAD SCI USA, V92, P9820, DOI 10.1073/pnas.92.21.9820; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FARRELL RE, 1993, RNA METHODOLOGIES LA, P47; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vidan S, 1997, MOL CELL BIOL, V17, P2688, DOI 10.1128/MCB.17.5.2688; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	41	301	319	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24881	24885		10.1074/jbc.M004454200	http://dx.doi.org/10.1074/jbc.M004454200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835430	hybrid			2022-12-27	WOS:000088683300086
J	Romero, MF; Henry, D; Nelson, S; Harte, PJ; Dillon, AK; Sciortino, CM				Romero, MF; Henry, D; Nelson, S; Harte, PJ; Dillon, AK; Sciortino, CM			Cloning and characterization of a Na+-driven anion exchanger (NDAE1) - A new bicarbonate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BASE TRANSPORT; INTRACELLULAR PH; DROSOPHILA-MELANOGASTER; CHLORIDE TRANSPORT; COTRANSPORTER; SODIUM; MOSQUITO; MIDGUT; CELLS; FIBROBLASTS	Regulation of intra- and extracellular ion activities (e,g. H+, Cl-, Na+) is key to normal function of the central nervous system, digestive tract, respiratory tract, and urinary system. With our cloning of an electrogenic Na+/HCO3- cotransporter (NBC), we found that NBC and the anion exchangers form a bicarbonate transporter superfamily, Functionally three other HCO3- transporters are known: a neutral Na+/HCO3- cotransporter, a K+/HCO3- cotransporter, and a Na+-dependent Cl--HCO3- exchanger. We report the cloning and characterization of a Na+-coupled Cl--HCO3- exchanger and a physiologically unique bicarbonate transporter superfamily member. This Drosophila cDNA encodes a 1030-amino acid membrane protein with both sequence homology and predicted topology similar to the anion exchangers and NBCs, The mRNA is expressed throughout Drosophila development and is prominent in the central nervous system. When expressed in Xenopus oocytes, this membrane protein mediates the transport of Cl-, Na+, H+, and HCO3- but does not require HCO3-. Transport is blocked by the stilbene 4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonates and may not be strictly electroneutral. Our functional data suggest this Na+ driven anion exchanger (NDAE1) is responsible for the Nai-dependent Cl--HCO3- exchange activity characterized in neurons, kidney, and fibroblasts. NDAE1 may be generally important for fly development, because disruption of this gene is apparently lethal to the Drosophila larva.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Romero, MF (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, E-545,2119 Abington Rd, Cleveland, OH 44106 USA.	mfr2@po.cwru.edu			NIDDK NIH HHS [DK07678] Funding Source: Medline; NIGMS NIH HHS [GM39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; Butcher GA, 1996, EXP PARASITOL, V84, P371, DOI 10.1006/expr.1996.0125; BUTLER GAD, 1994, EXP EYE RES, V59, P343, DOI 10.1006/exer.1994.1116; CASSEL D, 1988, J BIOL CHEM, V263, P6122; Choi I, 1999, FASEB J, V13, pA400; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DADD RH, 1975, J INSECT PHYSIOL, V21, P1847, DOI 10.1016/0022-1910(75)90252-8; DOW JAT, 1992, J EXP BIOL, V172, P355; DUNCAN G, 1992, EXP EYE RES, V54, P941, DOI 10.1016/0014-4835(92)90158-O; Ganz MB, 1998, AM J PHYSIOL-RENAL, V274, pF550, DOI 10.1152/ajprenal.1998.274.3.F550; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GUGGINO WB, 1983, J MEMBRANE BIOL, V71, P227, DOI 10.1007/BF01875464; Hacker JK, 1997, VIROLOGY, V235, P40, DOI 10.1006/viro.1997.8675; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; Lee AH, 1998, CANCER RES, V58, P1901; MOFFETT DF, 1994, PHYSIOL ZOOL, V67, P68, DOI 10.1086/physzool.67.1.30163835; PARDUE ML, 1994, METHOD CELL BIOL, V44, P333, DOI 10.1016/S0091-679X(08)60922-X; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; Roch F, 1998, MOL GEN GENET, V257, P103, DOI 10.1007/PL00008620; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, CANCER RES, V49, P205; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; TOROK T, 1993, GENETICS, V135, P71; Zhuang ZP, 1999, J EXP BIOL, V202, P2449	39	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24552	24559		10.1074/jbc.M003476200	http://dx.doi.org/10.1074/jbc.M003476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827195	hybrid			2022-12-27	WOS:000088683300044
J	Spelbrink, JN; Toivonen, JM; Hakkaart, GAJ; Kurkela, JM; Cooper, HM; Lehtinen, SK; Lecrenier, N; Back, JW; Speijer, D; Foury, F; Jacobs, HT				Spelbrink, JN; Toivonen, JM; Hakkaart, GAJ; Kurkela, JM; Cooper, HM; Lehtinen, SK; Lecrenier, N; Back, JW; Speijer, D; Foury, F; Jacobs, HT			In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; BINDING PROTEIN; ACCESSORY SUBUNIT; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MUTATIONAL SPECTRUM; POLYACRYLAMIDE GELS; GAMMA; IDENTIFICATION	The human gene POLG encodes the catalytic subunit of mitochondrial DNA polymerase, but its precise roles in mtDNA metabolism in Dice have not hitherto been documented. By expressing POLG fusion proteins in cultured human cells, we show that the enzyme is targeted to mitochondria, where the Myc epitope-tagged POLG is catalytically active as a DNA polymerase. Long-term culture of cells expressing wild-type POLG-myc revealed no alterations in mitochondrial function. Expression of POLG-myc mutants created dominant phenotypes demonstrating important roles for the protein in mtDNA maintenance and integrity. The D198A amino acid replacement abolished detectable 3'-5' (proofreading) exonuclease activity and led to the accumulation of a significant load (1:1700) of mtDNA point mutations during 3 months of continuous culture. Further culture resulted in the selection of cells with an inactivated mutator polymerase, and a reduced mutation load in mtDNA Transient expression of POLG-myc variants D890N or D1135A inhibited endogenous mitochondrial DNA polymerase activity and caused mtDNA depletion. Deletion of the POLG CAG repeat did not affect enzymatic properties, but modestly up-regulated expression. These findings demonstrate that POLG exonuclease and polymerase functions are essential for faithful mtDNA maintenance in vivo, and indicate the importance of key residues for these activities.	Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain La Neuve, Belgium; Univ Amsterdam, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; Universite Catholique Louvain; University of Amsterdam; University of Glasgow	Jacobs, HT (corresponding author), Tampere Univ, Inst Med Technol, POB 607, FIN-33101 Tampere, Finland.		Toivonen, Janne M./E-5691-2011; B, Jw/N-7879-2019; Speijer, Dave/AAE-4613-2019; Jacobs, Howard T/G-2434-2011; Back, JW/B-3641-2009; Spelbrink, Johannes N/L-4661-2015	Toivonen, Janne M./0000-0002-7243-1737; B, Jw/0000-0002-1310-4373; Speijer, Dave/0000-0002-2340-2753; Back, JW/0000-0002-1310-4373; Spelbrink, Johannes N/0000-0002-9756-2602; Jacobs, Howard/0000-0003-1895-6003				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andre P, 1997, GENOME RES, V7, P843, DOI 10.1101/gr.7.8.843; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, NUCLEIC ACIDS RES, V19, P955, DOI 10.1093/nar/19.4.955; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; El Meziane A, 1998, NAT GENET, V18, P350; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; Fuenmayor J, 1998, J EUKARYOT MICROBIOL, V45, P404, DOI 10.1111/j.1550-7408.1998.tb05091.x; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY H, 1992, J BIOL CHEM, V267, P5835; HAUSWIRTH WW, 1987, MITOCHONDRIA PRACTIC, P176; HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7; HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1997, HUM MOL GENET, V6, P185, DOI 10.1093/hmg/6.2.185; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Lehtinen SK, 2000, GENETICS, V154, P363; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Marcelino LA, 1998, CANCER RES, V58, P2857; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; Mikhailov VS, 1996, J BIOL CHEM, V271, P30774, DOI 10.1074/jbc.271.48.30774; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nielsen-Preiss SM, 2000, ARCH BIOCHEM BIOPHYS, V374, P229, DOI 10.1006/abbi.1999.1590; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOUBRIDGE EA, 1995, BIOCHEM BIOPH RES CO, V213, P189, DOI 10.1006/bbrc.1995.2115; SPELBRINK JN, 1994, HUM MOL GENET, V3, P1989, DOI 10.1093/hmg/3.11.1989; Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; VANDENBOGERT C, 1991, BIOCHIM BIOPHYS ACTA, V1097, P87, DOI 10.1016/0925-4439(91)90090-V; Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690; Walker RL, 1997, GENOMICS, V40, P376, DOI 10.1006/geno.1996.4580; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; ZEVIANI M, 1995, BBA-MOL BASIS DIS, V1271, P153, DOI 10.1016/0925-4439(95)00022-V	57	156	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24818	24828		10.1074/jbc.M000559200	http://dx.doi.org/10.1074/jbc.M000559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827171	hybrid			2022-12-27	WOS:000088683300079
J	Cismowski, MJ; Ma, CL; Ribas, C; Xie, XB; Spruyt, M; Lizano, JS; Lanier, SM; Duzic, E				Cismowski, MJ; Ma, CL; Ribas, C; Xie, XB; Spruyt, M; Lizano, JS; Lanier, SM; Duzic, E			Activation of heterotrimeric G-protein signaling by a Ras-related protein - Implications for signal integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; SACCHAROMYCES-CEREVISIAE; TRANSDUCTION; YEAST; PATHWAYS; CELLS; IDENTIFICATION; SPECIFICITY; MECHANISM	Utilizing a functional screen in the yeast Saccharomyces cerevisiae we identified mammalian proteins that activate heterotrimeric G-protein signaling pathways in a receptor-independent fashion. One of the identified activators, termed AGS1 (for activator of G-protein signaling), is a human Res-related G-protein that defines a distinct subgroup of the Res superfamily. Expression of AGS1 in yeast and in mammalian cells results in specific activation of G alpha(i)/G alpha(o) heterotrimeric signaling pathways. In addition, the in vivo and in vitro properties of AGS1 are consistent with it functioning as a direct guanine nucleotide exchange factor for G alpha(i)/G alpha(o). AGS1 thus presents a unique mechanism for signal integration via heterotrimeric G-protein signaling pathways.	OSI Pharmaceut, Tarrytown, NY 10591 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA	Astellas Pharmaceuticals; OSI Pharmaceuticals; Medical University of South Carolina	Cismowski, MJ (corresponding author), Neurocrine Biosci Inc, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.	mcismowski@neurocrine.com	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bevan N, 1998, NEUROREPORT, V9, P2703, DOI 10.1097/00001756-199808240-00003; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DUZIC E, 1992, J BIOL CHEM, V267, P24045; Falk JD, 1999, J NEUROSCI RES, V57, P782, DOI 10.1002/(SICI)1097-4547(19990915)57:6<782::AID-JNR3>3.0.CO;2-9; Foster R, 1996, MOL CELL BIOL, V16, P2689; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; KUROSE H, 1983, J BIOL CHEM, V258, P4870; Lee NH, 1996, MOL PHARMACOL, V50, P140; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; NANOFF C, 1995, MOL PHARMACOL, V48, P806; NEAL SE, 1988, J BIOL CHEM, V263, P19718; Odagaki Y, 1998, LIFE SCI, V62, P1537, DOI 10.1016/S0024-3205(98)00103-9; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Pausch MH, 1997, TRENDS BIOTECHNOL, V15, P487, DOI 10.1016/S0167-7799(97)01119-0; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WARNER JR, 1991, METHOD ENZYMOL, V194, P423	30	121	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23421	23424		10.1074/jbc.C000322200	http://dx.doi.org/10.1074/jbc.C000322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10840027	hybrid			2022-12-27	WOS:000088564200004
J	Lee, DS; Tomita, S; Kirino, Y; Suzuki, T				Lee, DS; Tomita, S; Kirino, Y; Suzuki, T			Regulation of X11L-dependent amyloid precursor protein metabolism by XB51, a novel X11L-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; CYTOPLASMIC DOMAIN; ALZHEIMERS; IDENTIFICATION; CLEAVAGE; COMPLEX; BRAIN; CELLS; APP	We isolated a cDNA encoding a novel protein, XB51, that interacts with the amino-terminal domain of the neuron-specific X11-like protein (X11L). The protein XB51 inhibited the association of X11L with amyloid precursor protein through a non-competitive mechanism and abolished the suppression of beta-amyloid production by X11L. The majority of XB51 is localized around the nucleus and recovered in 3-[(3-cholamidopropy1)dimethylammonio]-1-propanesulfonic acid (CHAPS) buffer-insoluble fraction when XB51 is expressed in cells. Association of XB51 with X11L changed the intracellular distribution of XB51 and resulted in redistribution of XB51 into the CHAPS buffer-soluble fraction. These observations suggest that XB51, together with X11L, plays an important role in the regulatory system of amyloid precursor protein metabolism and beta-amyloid generation.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Suzuki, Toshiharu/B-5342-2013					Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	12	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23134	23138		10.1074/jbc.C000302200	http://dx.doi.org/10.1074/jbc.C000302200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10833507	hybrid			2022-12-27	WOS:000088419400072
J	Kato, Y; Zhao, M; Morikawa, A; Sugiyama, T; Chakravortty, D; Koide, N; Yoshida, T; Tapping, RI; Yang, Y; Yokochi, T; Lee, JD				Kato, Y; Zhao, M; Morikawa, A; Sugiyama, T; Chakravortty, D; Koide, N; Yoshida, T; Tapping, RI; Yang, Y; Yokochi, T; Lee, JD			Big mitogen-activated kinase regulates multiple members of the MEF2 protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN PROMOTER; TRANSCRIPTION FACTOR MEF2C; SIGNAL-TRANSDUCTION PATHWAY; MAP-KINASE; PROTEIN-KINASE-1 BMK1; COUPLED RECEPTORS; P38; INDUCTION; GENE; PHOSPHORYLATION	Big mitogen-activated protein (MAP) kinase (BMK1), a member of the mammalian MAP kinase family, is activated by growth factors. The activation of BMK1 is required for growth factor-induced cell proliferation and cell cycle progression. me have previously shown that BMK1 regulates c-jun gene expression through direct phosphorylation and activation of transcription factor MEF2C. MEF2C belongs to the myocyte enhancer factor 2 (MEF2) protein family, a four-membered family of transcription factors denoted MEF2A, -2B, -2C, and -2D. Here, we demonstrate that, in addition to MEF2C, BMK1 phosphorylates and activates MEF2A and MEF2D but not MEF2B. The blocking of BMK1 signaling inhibits the epidermal growth factor-dependent activation of these three MEF2 transcription factors. The sites phosphorylated by activated BMK1 were mapped to Ser-355, Thr-312, and Thr-319 of MEF2A and Ser-179 of MEF2D both in vitro and in vivo. Site-directed mutagenesis reveals that the phosphorylation of these sites in MEF2A and MEF2D are necessary for the induction of MEF2A and 2D transactivating activity by either BMK1 or by epidermal growth factor. Taken together, these data demonstrate that, upon growth factor induction, BMK1 directly phosphorylates and activates three members of the MEF2 family of transcription factors thereby inducing MEF2-dependent gene expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Aichi Med Univ, Dept Microbiol & Immunol, Nagakute, Aichi 4801195, Japan; Linking Univ, Dept Pathol 2, SE-58185 Linkoping, Sweden	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Aichi Medical University	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		chakravortty, dipshikha/A-9492-2009; Chakravortty, Dipshikha/AAI-4448-2020		NIGMS NIH HHS [GM53214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Coso OA, 1996, J BIOL CHEM, V271, P3963; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lin Q, 1998, DEVELOPMENT, V125, P4565; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang SH, 1999, MOL CELL BIOL, V19, P4028; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	37	124	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18534	18540		10.1074/jbc.M001573200	http://dx.doi.org/10.1074/jbc.M001573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849446	hybrid			2022-12-27	WOS:000087659400085
J	Lionberger, JM; Wilson, MB; Smithgall, TE				Lionberger, JM; Wilson, MB; Smithgall, TE			Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; POSITIVE HUMAN LEUKEMIAS; DNA-BINDING ACTIVITY; FES TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; C-ABL; FIBROBLAST TRANSFORMATION; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; ACTIVATION	Bcr-Abl is the constitutively active protein-tyrosine kinase expressed as a result of the Philadelphia translocation in chronic myelogenous leukemia. Bcr-Abl is coupled to many of the same signaling pathways normally regulated by hematopoietic cytokines. Recent work shows that Hck, a member of the Src tyrosine kinase family with myeloid-restricted expression, associates with and is activated by Bcr-Abl. Here we investigated the mechanism of Hck interaction with Bcr-Abl and the requirement for Hck activation in Bcr-Abl transformation signaling. Binding studies demonstrated that the Hck SH3 and SH2 domains are sufficient for interaction with Bcr-Abl in vitro. Hck binding localizes to the Abl SH2, SH3, and kinase domains as well as the distal portion of the C-terminal tail. To address the requirement for endogenous Src family kinase activation in Bcr-Abl signaling a kinase defective mutant of Hck was stably expressed in the cytokine-dependent myeloid leukemia cell line DAGM. Kinase-defective Hck dramatically suppressed Bcr-Abl-induced outgrowth of these cells in the absence of cytokine compared with a control cell line expressing beta-galactosidase. In contrast, kinase-defective Hck did not affect cell proliferation in response to interleukin-3, suggesting that the effect is specific for Bcr-Abl, These data show that Hck interacts with Bcr-Abl through a complex mechanism involving kinase-dependent and -independent components and that interaction with Hck or other Src family members is essential for transformation signaling by Bcr-Abl.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA81398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Lionberger JM, 2000, CANCER RES, V60, P1097; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Shuai K, 1996, ONCOGENE, V13, P247; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	42	104	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18581	18585		10.1074/jbc.C000126200	http://dx.doi.org/10.1074/jbc.C000126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849448	hybrid			2022-12-27	WOS:000087659400091
J	Moe, PC; Levin, G; Blount, P				Moe, PC; Levin, G; Blount, P			Correlating a protein structure with function of a bacterial mechanosensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ION-CHANNEL; SINGLE RESIDUE; PATCH-CLAMP; MSCL; PRESSURE; MEMBRANE; RECONSTITUTION; ACTIVATION; STRESS	MscL, a mechanosensitive channel found in many bacteria, protects cells from hypotonic shock by reducing intracellular pressure through release of cytoplasmic osmolytes. First isolated from Escherichia coli, this protein has served as a model for how a protein senses and responds to membrane tension. Recently the structure of a functionally uncharacterized MscL homologue from Mycobacterium tuberculosis was solved by x-ray diffraction to a resolution of 3.5 Angstrom Here we demonstrate that the protein forms a functional MscL-like mechanosensitive channel in E, coli membranes and azolectin proteoliposomes Furthermore, we show that M. tuberculosis MscL crystals, when re-solubilized and reconstituted, yield wild-type channel currents in patch damp, demonstrating that the protein does not irreversibly change conformation upon crystallization. Finally, we apply functional clues acquired from the E, coli MscL to the M. tuberculosis channel and show a mechanistic correlation between these channels. However, the inability of the M. tuberculosis channel to gate at physiological membrane tensions, demonstrated by in vivo E. coli expression and in vitro reconstitution, suggests that the membrane environment or other additional factors influence the gating of this channel.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	pbloun@mednet.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barik S, 1997, Methods Mol Biol, V67, P173; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; Ghazi A, 1998, BIOCHIMIE, V80, P357; GUHARAY F, 1985, J PHYSIOL-LONDON, V363, P119, DOI 10.1113/jphysiol.1985.sp015699; HAMILL O, 1993, BIOPHYS J, V65, P17, DOI 10.1016/S0006-3495(93)81028-2; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Nakamaru Y, 1999, FEBS LETT, V444, P170, DOI 10.1016/S0014-5793(99)00054-X; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; Spencer RH, 1999, CURR OPIN STRUC BIOL, V9, P448, DOI 10.1016/S0959-440X(99)80063-3; Sukharev S, 1999, FASEB J, V13, pS55; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2	37	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31121	31127		10.1074/jbc.M002971200	http://dx.doi.org/10.1074/jbc.M002971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10846181	hybrid			2022-12-27	WOS:000089762700054
J	Merkel, JS; Regan, L				Merkel, JS; Regan, L			Modulating protein folding rates in vivo and in vitro by side-chain interactions between the parallel beta strands of green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE DISULFIDE BONDS; PHAGE-T4 LYSOZYME; PAIR CORRELATIONS; MUTATIONS; SHEETS; STABILITY; MUTANTS; THERMOSENSITIVITY; STABILIZATION; CHROMOPHORE	We have identified pairs of residues across the two parallel beta strands of green fluorescent protein that facilitate native strand register of the surface-exposed beta barrel. After constructing a suitable host environment around two guest residues, minimizing interactions of the guest residues with surrounding side-chains yet maintaining the wild-type protein structure and the chromophore environment, we introduced a library of cross-strand pairings by cassette mutagenesis. Colonies of Escherichia coli transformed with the library differ in intracellular fluorescence. Most of the fluorescent pairs have predominantly charged and polar guest site residues. The magnitude and the rate of fluorescence acquisition in vivo from transformed E. coli cells varies among the mutants despite comparable levels of protein expression. Spectroscopic measurements of purified mutants show that the native protein structure is maintained. Kinetic studies using purified protein with fully matured chromophores demonstrate that the mutants span a 10-fold range in folding rates with undetectable differences in unfolding rates. Thus, green fluorescent protein provides an ideal system for monitoring determinants of in vivo protein folding. Cross-strand pairings affect both protein stability and folding kinetics by favoring the formation of native strand register preferentially to non-native strand alignments.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Regan, L (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	lynne@csb.yale.edu						Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Blasie CA, 1997, BIOCHEMISTRY-US, V36, P6218, DOI 10.1021/bi962805i; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cootes AP, 1998, PROTEINS, V32, P175, DOI 10.1002/(SICI)1097-0134(19980801)32:2<175::AID-PROT4>3.0.CO;2-K; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hutchinson EG, 1998, PROTEIN SCI, V7, P2287, DOI 10.1002/pro.5560071106; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Merkel JS, 1999, STRUCT FOLD DES, V7, P1333, DOI 10.1016/S0969-2126(00)80023-4; Merkel JS, 1998, FOLD DES, V3, P449, DOI 10.1016/S1359-0278(98)00062-5; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; NICHOLSON H, 1992, BIOPOLYMERS, V32, P1431, DOI 10.1002/bip.360321103; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; Smith CK, 1996, PROTEIN SCI, V5, P2009, DOI 10.1002/pro.5560051007; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Thor JJ, 1998, BIOCHEMISTRY-US, V37, P16915, DOI 10.1021/bi981170f; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	36	23	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29200	29206		10.1074/jbc.M004734200	http://dx.doi.org/10.1074/jbc.M004734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10844000	hybrid			2022-12-27	WOS:000089439800005
J	Lenferink, AEG; van Zoelen, EJJ; van Vugt, MJH; Grothe, S; van Rotterdam, W; van de Poll, MLM; O'Connor-McCourt, MD				Lenferink, AEG; van Zoelen, EJJ; van Vugt, MJH; Grothe, S; van Rotterdam, W; van de Poll, MLM; O'Connor-McCourt, MD			Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; MITOGENIC ACTIVITY; TYROSINE KINASES; ALPHA CHIMERAS; HIGH-AFFINITY; BINDING-SITE; LIGAND; INTERNALIZATION	Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF alpha) are mitogenic hormones that exert their activity primarily by binding to the EGF receptor, also known as ErbB-1, We have recently characterized a set of EGF/TGF alpha chimeric molecules with similar high affinity for ErbB-1 as EGF and TGF alpha and shown that three of these chimeras induce mitogenic cell stimulation at already a 10-fold lower concentration than their wild-type counterparts (Lenferink, A. E,, Kramer, R, H,, van Vugt, M. J., Konigswieser, M., DiFiore, P, P,, van Zoelen, E, J,, and van de Poll, M. L. (1997) Biochem. J, 327, 859-865), In the present study we show that these so-called superagonistic chimeras do not differ from EGF and TGF alpha in their ability to induce ErbB-1 tyrosine phosphorylation but are considerably more potent in activation of mitogen-activated protein kinase phosphorylation. Direct cell binding studies and analysis of ligand-receptor interaction by surface plasmon resonance measurements revealed that both the association rate constant (k(on)) and the dissociation rate constant (k(off)) of these superagonists is 3-5-fold higher in comparison with the wild-type ligands and nonsuperagonistic chimeras. These data indicate that the dynamic on and off rate constants for receptor binding may be more specific parameters for determining the mitogenic activity of peptide hormones than their constants for equilibrium receptor binding.	Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Radboud University Nijmegen; National Research Council Canada	van Zoelen, EJJ (corresponding author), Catholic Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		van Zoelen, Everardus J./D-9192-2012					Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Debanne M T, 1995, Methods Mol Biol, V39, P349; GRIMAUX M, 1989, TUMOR BIOL, V10, P215, DOI 10.1159/000217618; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Puddicombe SM, 1996, J BIOL CHEM, V271, P30392, DOI 10.1074/jbc.271.48.30392; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; van de Poll MLM, 1998, J BIOL CHEM, V273, P16075, DOI 10.1074/jbc.273.26.16075; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26748	26753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840042				2022-12-27	WOS:000089144800013
J	DeCamp, DL; Thompson, TM; de Sauvage, FJ; Lerner, MR				DeCamp, DL; Thompson, TM; de Sauvage, FJ; Lerner, MR			Smoothened activates G alpha(i)-mediated signaling in frog melanophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; SONIC HEDGEHOG; RECEPTOR COMPLEX; HUMAN HOMOLOG; G-PROTEINS; GENE; DROSOPHILA; ENCODES; MUTATIONS; CULTURE	The 7-pass transmembrane protein Smoothened was investigated for its ability to act as a G-protein-coupled receptor in Xenopus laevis melanophores. A plasmid containing the human Smoothened cDNA insert was transfected into immortalized frog pigment cells. Cells expressing the protein showed a phenotype of persistent pigment aggregation, a hallmark of constitutive G(alpha i) activation. Smoothened-mediated pigment aggregation was reversed by treatment with pertussis toxin or by co-expression with dominant negative G(alpha i). The ability of melanophores to express functional Smoothened was also determined by its co-expression with the twelve-pass transmembrane protein, Patched. Patched blocked Smoothened-mediated melanosome aggregation in a dose-dependent manner, consistent with its physiological role as an inhibitor of Smoothened. That the reconstituted Patched-Smoothened receptor complex functions normally in pigment cells was demonstrated by co-transfection with the activating ligand, Sonic hedgehog, as well as by direct application of the recombinant Sonic hedgehog protein. Sonic hedgehog reversed Patched-mediated inhibition of Smoothened and induced pigment aggregation. The findings demonstrate that the human Sonic hedgehog receptor complex can be functionally reconstituted in melanophores and that it is capable of transmembrane signaling by utilizing endogenous G(alpha i).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Roche Holding; Genentech; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lerner, MR (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd,F4-100, Dallas, TX 75390 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30 AR41940] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcedo J, 1997, BIOL CHEM, V378, P583; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Chen Y, 1998, DEVELOPMENT, V125, P4943; DANIOLOS A, 1990, PIGM CELL RES, V3, P38, DOI 10.1111/j.1600-0749.1990.tb00260.x; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hammerschmidt M, 1998, DEV BIOL, V194, P166, DOI 10.1006/dbio.1997.8796; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LIM K, 1989, BIOTECHNIQUES, V7, P576; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Sehgal A, 1998, J SURG ONCOL, V69, P239, DOI 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	28	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26322	26327		10.1074/jbc.M004055200	http://dx.doi.org/10.1074/jbc.M004055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835429	hybrid			2022-12-27	WOS:000088999700061
J	Wooten, DK; Xie, XL; Bartos, D; Busche, RA; Longmore, GD; Watowich, SS				Wooten, DK; Xie, XL; Bartos, D; Busche, RA; Longmore, GD; Watowich, SS			Cytokine signaling through Stat3 activates integrins, promotes adhesion, and induces growth arrest in the myeloid cell line 32D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; DEPENDENT KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TARGETED DISRUPTION; T-CELLS; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS	Hematopoietic cell development and function is dependent on cytokines and on intercellular interactions with the microenvironment. Although the intracellular signaling pathways stimulated by cytokine receptors are well described, little is known about the mechanisms through which these pathways modulate hematopoietic cell adhesion events in the microenvironment. Here we show that cytokine-activated Stats stimulates the expression and function of cell surface adhesion molecules in the myeloid progenitor cell line 32D. We generated an erythropoietin receptor (EpoR) isoform (ER343/401-S3) that activates Stats rather than Stat5 by substituting the Stats binding/activation sequence motif from gp130 for the sequences surrounding tyrosines 343 and 401 in the receptor cytoplasmic region, Activation of Stats leads to homotypic cell aggregation, increased expression of intercellular adhesion molecule 1 (ICAM-1), CD18, and CD11b, and activation of signaling through CD18-containing integrins. Unlike the wild type EpoR, ER343/401-S3 is unable to support long term Epo-dependent proliferation in 32D cells. Instead, Epo-treated ER343/401-S3 cells undergo G(1) arrest and express elevated levels of the cyclin-dependent kinase inhibitor p27(Kip1). Sustained activation of Stats in these cells is required for their altered morphology and growth properties since constitutive SOCS3 expression abrogates homotypic cell aggregation, signaling through CD18-containing integrins, G(1) arrest, and accumulation of p27(Kip1). Collectively, our results demonstrate that cytokine-activated Stats stimulates the expression and function of cell surface adhesion molecules, indicating that a role for Stats is to regulate intercellular contacts in myeloid cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Watowich, SS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 178,1515 Holcombe Blvd, Houston, TX 77030 USA.			Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [R01 CA077447-03, CA 77447, R01 CA077447-02, CA 75315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447, R01CA075315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan ASH, 1997, J IMMUNOL, V159, P934; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENBERGER JS, 1980, VIROLOGY, V105, P425, DOI 10.1016/0042-6822(80)90043-4; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nielsen M, 1996, J IMMUNOL, V157, P5350; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; StCroix B, 1996, NAT MED, V2, P1204; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zamorano J, 1998, J IMMUNOL, V160, P3502	65	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26566	26575		10.1074/jbc.M003495200	http://dx.doi.org/10.1074/jbc.M003495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858439	hybrid, Green Accepted			2022-12-27	WOS:000088999700094
J	Sato, K; Ebihara, T; Adachi, E; Kawashima, S; Hattori, S; Irie, S				Sato, K; Ebihara, T; Adachi, E; Kawashima, S; Hattori, S; Irie, S			Possible involvement of aminotelopeptide in self-assembly and thermal stability of collagen I as revealed by its removal with proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; CROSS-LINKING; INVITRO; MATRIX; EXPRESSION; SITES	The functions of aminotelopeptide and N-terminal cross-linking of collagen I were examined. Acetic acid-soluble collagen I (ASC) was purified from neonatal bovine skin and treated with three kinds of proteases, The amino acid sequencing analysis of the N terminus showed that ASC contained a full-length aminotelopeptide. Pepsin and papain cleaved the aminotelopeptide of the alpha 1 chain at the same site and the aminotelopeptide of the alpha 2 chain at different sites. Proctase-treated ASC lost the whole aminotelopeptide, and the N-terminal sequence began from the tenth residue inside the triple helical region. The rates of fibril formation of pepsin-treated ASC and proctase-treated ASC were the same and were slower than that of ASC. The denaturation temperatures, monitored by CD ellipticity at 221 nm, of ASC, pepsin-treated, or papain-treated collagens were the same at 41.8 degrees C, Proctase-treated ASC showed a lower denaturation temperature of 39.9 degrees C. We also observed the morphology of the collagen fibrils under an electron microscope. The ASC fibrils were straight and thin, whereas the fibrils of pepsin-treated ASC were slightly twisted, and the fibrils from papain- and proctase-treated ASC were highly twisted and thick. When the collagen gel strength was examined by a modified method of viscosity-measurement, ASC was the strongest, followed by pepsin-treated ASC, and papain- and proctase-treated ASCs were the weakest. These results suggest that the aminotelopeptide plays important roles in fibril formation and thermal stability. In addition, the functions of intermolecular cross-linking in aminotelopeptides may contribute to the formation of fibrils in the correct staggered pattern and to strengthening the collagen gel.	Nippi Res Inst Biomatrix, Adachi Ku, Tokyo 1208601, Japan; Japan Inst Leather Res, Dept Biomatrix Engn, Adachi Ku, Tokyo 1208601, Japan; Kitasato Univ, Grad Sch Med, Dept Mol Morphol, Sagamihara, Kanagawa 2288555, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Biol, Bunkyo Ku, Tokyo 1138613, Japan	Kitasato University; Tokyo Metropolitan Institute of Medical Science	Sato, K (corresponding author), Nippi Res Inst Biomatrix, Adachi Ku, Tokyo 1208601, Japan.							ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Adachi E, 1997, INT REV CYTOL, V173, P73; BORNSTEIN P, 1966, BIOCHEMISTRY-US, V5, P3803, DOI 10.1021/bi00876a010; Ebihara T, 1999, CONNECT TISSUE, V31, P17; Freemont AJ, 1999, ANN RHEUM DIS, V58, P357, DOI 10.1136/ard.58.6.357; GELMAN RA, 1979, J BIOL CHEM, V254, P180; HAYASHI T, 1974, J BIOCHEM-TOKYO, V75, P651, DOI 10.1093/oxfordjournals.jbchem.a130433; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; Muraoka M, 1996, J BIOCHEM-TOKYO, V119, P167; NAGAN N, 1994, J BIOL CHEM, V269, P22366; PIEZ KA, 1968, ANNU REV BIOCHEM, V37, P547, DOI 10.1146/annurev.bi.37.070168.002555; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; SATO K, 2000, CONNECT TISSUE, V32, P1; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Stimler NP., 1976, BIOCH COLLAGEN, P137; Suzuki Y, 1999, J BIOCHEM, V126, P54, DOI 10.1093/oxfordjournals.jbchem.a022436; Uitto VJ, 1998, AM J PATHOL, V152, P1489; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; YAMAUCHI M, 1987, J BIOL CHEM, V262, P11428	22	106	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25870	25875		10.1074/jbc.M003700200	http://dx.doi.org/10.1074/jbc.M003700200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851240	hybrid			2022-12-27	WOS:000088849400106
J	Zimmer, S; Stocker, A; Sarbolouki, MN; Spycher, SE; Sassoon, J; Azzi, A				Zimmer, S; Stocker, A; Sarbolouki, MN; Spycher, SE; Sassoon, J; Azzi, A			A novel human tocopherol-associated protein - Cloning, in vitro expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RAT OLFACTORY EPITHELIUM; ALPHA-TOCOPHEROL; BINDING-PROTEIN; IN-VIVO; CELL; SUPPLEMENTATION; IDENTIFICATION; PURIFICATION	Vitamin E (alpha-tocopherol) is an essential dietary nutrient for humans and animals. The mechanisms involved in cellular regulation as well as in the preferential cellular and tissue accumulation of alpha-tocopherol are not yet well established. We previously reported (Stocker, A., Zimmer, S., Spycher, S. E., and Azzi, A. (1999) IUBMB Life 48, 49-55) the identification of a novel 46-kDa tocopherol-associated protein (TAP) in the cytosol of bovine liver. Here, we describe the identification, the molecular cloning into Escherichia coli, and the in vitro expression of the human homologue of bovine TAP, hTAP. This protein appears to belong to a family of hydrophobic ligand binding proteins, which have the CRAL (cis-retinal binding motif) sequence in common. By using a biotinylated alpha-tocopherol derivative and the IASys resonant mirror biosensor, the purified recombinant protein was shown to bind tocopherol at a specific binding site with K-d 4.6 x 10(-7) M. Northern analyses showed that hTAP mRNA has a size of approximately 2800 base pairs and is ubiquitously expressed. The highest amounts of hTAP message are found in liver, brain, and prostate. In conclusion, hTAP has sequence homology to proteins containing the CRAL_TRIO structural motif. TAP binds to alpha-tocopherol and biotinylated tocopherol, suggesting the existence of a hydrophobic pocket, possibly analogous to that of SEC14.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Tehran, Inst Biochem & Biophys, Tehran, Iran; Univ Bern, Inst Gen Microbiol, CH-3012 Bern, Switzerland	University of Bern; University of Tehran; University of Bern	Stocker, A (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	achim.stocker@mci.unibe.ch	Stocker, Achim/O-5217-2017	Stocker, Achim/0000-0001-6862-7887				Aratri E, 1999, FEBS LETT, V447, P91, DOI 10.1016/S0014-5793(99)00277-X; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; Azzi A, 1999, DIABETES RES CLIN PR, V45, P191, DOI 10.1016/S0168-8227(99)00049-2; Azzi A, 1998, Z ERNAHRUNGSWISS, V37, P21; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURTON GW, 1982, LANCET, V2, P327; Cavalier L, 1998, AM J HUM GENET, V62, P301, DOI 10.1086/301699; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; DuttaRoy AK, 1997, METHOD ENZYMOL, V282, P278; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Karasu C, 1997, METABOLISM, V46, P872, DOI 10.1016/S0026-0495(97)90072-X; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; KUHLENKAMP J, 1993, PROTEIN EXPRES PURIF, V4, P382, DOI 10.1006/prep.1993.1050; Labauge P, 1998, REV NEUROL-FRANCE, V154, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merkulova MI, 1999, FEBS LETT, V450, P126, DOI 10.1016/S0014-5793(99)00470-6; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; NOVOSELOV VI, 1994, FEBS LETT, V353, P286, DOI 10.1016/0014-5793(94)01051-X; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Ozer NK, 1998, FREE RADICAL BIO MED, V24, P226, DOI 10.1016/S0891-5849(97)00136-6; Pastori M, 1998, BIOCHEM BIOPH RES CO, V250, P582, DOI 10.1006/bbrc.1998.9351; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Poynter ME, 1999, CELL IMMUNOL, V195, P127, DOI 10.1006/cimm.1999.1525; Ricciarelli R, 1999, FREE RADICAL BIO MED, V27, P729, DOI 10.1016/S0891-5849(99)00007-6; Rubio I, 1997, BIOTECHNIQUES, V22, P269, DOI 10.2144/97222bm15; SAXENA P, 1992, J BACTERIOL, V174, P1956, DOI 10.1128/jb.174.6.1956-1964.1992; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Stocker A, 1999, IUBMB LIFE, V48, P49, DOI 10.1080/152165499307413; STRAFACE E, 1995, INT J RADIAT BIOL, V68, P579, DOI 10.1080/09553009514551571; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Vatassery GT, 1998, J NUTR, V128, P152, DOI 10.1093/jn/128.2.152; Wu DY, 1999, ATHEROSCLEROSIS, V147, P297, DOI 10.1016/S0021-9150(99)00199-9; YOSHIDA H, 1992, J LIPID RES, V33, P343	39	168	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25672	25680		10.1074/jbc.M000851200	http://dx.doi.org/10.1074/jbc.M000851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829015	hybrid, Green Published			2022-12-27	WOS:000088849400082
J	Zhou, XM; Liu, YM; Payne, G; Lutz, RJ; Chittenden, T				Zhou, XM; Liu, YM; Payne, G; Lutz, RJ; Chittenden, T			Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser(155)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SIGNALING PATHWAY; APOPTOSIS; SURVIVAL; MITOCHONDRIA; BINDING; BCL-2; TRANSCRIPTION; RECOGNITION; BCL-X(L)	The Bcl-2 family protein BAD promotes apoptosis by binding through its BH3 domain to Bcl-x(L) and related cell death suppressors. When BAD is phosphorylated on either Ser(12) or Ser(136), it forms a complex with 14-3-3 in the cytosol and no longer interacts with Bcl-x(L) at the mitodhondria. Here we show that phosphorylation of a distinct site Ser(155), which is at the center of the BAD BH3 domain, directly suppressed the pro-apoptotic function of BAD by eliminating its affinity for Bcl-x(L) Protein kinase A functioned as a BAD Ser(155) kinase bath fn vitro and in cells. BAD Ser(155) was found to be a major site of phosphorylation induced following stimulation by growth factors and prevented by protein kinase A inhibitors but not by inhibitors of the phosphatidylinosital 3-kinase/Akt pathway, Growth factors inhibited BAD-induced apoptosis in both a Ser(112)/Ser(136)- and a Ser(155)-dependent fashion. Thus, growth factors engage an anti-apoptotic signaling pathway that inactivates BAD by direct modification of its BH3 cell death effector domain.	Apoptosis Technol Inc, Cambridge, MA 02139 USA		Zhou, XM (corresponding author), Apoptosis Technol Inc, 128 Sidney St, Cambridge, MA 02139 USA.							BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Burtscher I, 1999, CANCER RES, V59, P3923; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAY RN, 1989, J BIOL CHEM, V264, P431; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LINDER ME, 1992, SCI AM, V267, P56; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; PESO LD, 1997, SCIENCE, V278, P687; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; TORTORA G, 1994, INT J CANCER, V59, P712, DOI 10.1002/ijc.2910590521; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	26	196	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25046	25051		10.1074/jbc.M002526200	http://dx.doi.org/10.1074/jbc.M002526200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10837473	hybrid			2022-12-27	WOS:000088683300108
J	Yang, PF; Sale, WS				Yang, PF; Sale, WS			Casein kinase I is anchored on axonemal doublet microtubules and regulates flagellar dynein phosphorylation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLAMYDOMONAS-REINHARDTII IDENTIFY; CENTRAL-PAIR MICROTUBULES; INNER ARM DYNEIN; RADIAL SPOKES; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; INTERMEDIATE CHAIN; BENDING PATTERNS; SPERM FLAGELLA	Flagellar dynein activity is regulated by phosphorylation, One critical phosphoprotein substrate in Chlamydomonas is the 138-kDa intermediate chain (IC138) of the inner arm dyneins (Habermacher, G., and Sale, W. S. (1997) J. Cell Biol. 136, 167-176). In this study, several approaches were used to determine that casein kinase I (CKI) is physically anchored in the flagellar axoneme and regulates IC138 phosphorylation and dynein activity. First, using a videomicroscopic motility assay, selective Chi inhibitors rescued dynein-driven microtubule sliding in axonemes isolated from paralyzed flagellar mutants lacking radial spokes. Rescue of dynein activity failed in axonemes isolated from these mutant cells lacking IC138, Second, CKI was unequivocally identified in salt extracts from isolated axonemes, whereas casein kinase II was excluded from the flagellar compartment, Third, Western blots indicate that within flagella, CKI is anchored exclusively to the axoneme, Analysis of multi pie Chlamydomonas motility mutants suggests that the axonemal CKI is located on the outer doublet microtubules. Finally, CKI inhibitors that rescued dynein activity blocked phosphorylation of IC138, We propose that CKI is anchored on the outer doublet microtubules in position to regulate flagellar dynein.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Sale, WS (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 1648 Pierce Dr, Atlanta, GA 30322 USA.	win@cellbio.emory.edu			NIGMS NIH HHS [GM51173, GM17666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051173, R37GM051173] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROKAW CJ, 1985, CELL MOTIL CYTOSKEL, V5, P195, DOI 10.1002/cm.970050303; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; CHAUDHRY PS, 1995, CELL MOTIL CYTOSKEL, V32, P65, DOI 10.1002/cm.970320108; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P221, DOI 10.1016/0167-4838(91)90005-K; DUTCHER SK, 1995, TRENDS GENET, V11, P398, DOI 10.1016/S0168-9525(00)89123-4; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fu Z, 1999, J NEUROCHEM, V73, P830, DOI 10.1046/j.1471-4159.1999.0730830.x; GARDNER LC, 1994, J CELL BIOL, V127, P1311, DOI 10.1083/jcb.127.5.1311; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Habermacher G, 1996, J CELL SCI, V109, P1899; HAMASAKI T, 1989, CELL MOTIL CYTOSKEL, V12, P1, DOI 10.1002/cm.970120102; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HASEGAWA E, 1987, CELL MOTIL CYTOSKEL, V8, P302, DOI 10.1002/cm.970080403; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P308, DOI 10.1016/0076-6879(83)99066-3; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HOSOKAWA Y, 1987, J CELL BIOL, V105, P1297, DOI 10.1083/jcb.105.3.1297; HOWARD DR, 1994, J CELL BIOL, V127, P1683, DOI 10.1083/jcb.127.6.1683; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SJ, 1997, J CELL BIOL, V136, P177, DOI 10.1083/jcb.136.1.177; KING SM, 1994, J BIOL CHEM, V269, P5452; Kuret J, 1997, J NEUROCHEM, V69, P2506; Mitchell DR, 2000, J PHYCOL, V36, P261, DOI 10.1046/j.1529-8817.2000.99218.x; Mitchell DR, 1999, J CELL BIOL, V144, P293, DOI 10.1083/jcb.144.2.293; Myster SH, 1999, J CELL BIOL, V146, P801, DOI 10.1083/jcb.146.4.801; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; Omoto CK, 1999, MOL BIOL CELL, V10, P1; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1994, J CELL BIOL, V125, P1109, DOI 10.1083/jcb.125.5.1109; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PORTER ME, 1992, J CELL BIOL, V118, P1163, DOI 10.1083/jcb.118.5.1163; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Roush AM, 1999, MOL BIOL CELL, V10, p388A; San Agustin JT, 1998, J BIOL CHEM, V273, P24874, DOI 10.1074/jbc.273.38.24874; SANAGUSTIN JT, 1994, CELL MOTIL CYTOSKEL, V27, P206, DOI 10.1002/cm.970270303; SHUGAR D, 1994, CELL MOL BIOL RES, V40, P411; SMITH EF, 1992, J CELL BIOL, V117, P573, DOI 10.1083/jcb.117.3.573; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; Smith EF, 1997, CELL MOTIL CYTOSKEL, V38, P1; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALCZAK CE, 1993, BIOCHEM J, V296, P729, DOI 10.1042/bj2960729; WALCZAK CE, 1994, CELL MOTIL CYTOSKEL, V27, P101, DOI 10.1002/cm.970270202; WARNER FD, 1974, J CELL BIOL, V63, P35, DOI 10.1083/jcb.63.1.35; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; Yang PF, 1998, MOL BIOL CELL, V9, P3335, DOI 10.1091/mbc.9.12.3335; Yang PF, 2000, J CELL SCI, V113, P91; Yoshimura M, 1999, CELL STRUCT FUNCT, V24, P43, DOI 10.1247/csf.24.43	63	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18905	18912		10.1074/jbc.M002134200	http://dx.doi.org/10.1074/jbc.M002134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858448	hybrid			2022-12-27	WOS:000087815900040
J	Hartenstine, MJ; Goodman, MF; Petruska, J				Hartenstine, MJ; Goodman, MF; Petruska, J			Base stacking and even/odd behavior of hairpin loops in DNA triplet repeat slippage and expansion with DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEAT; RAT-BRAIN; TRANSGLUTAMINASE; DISEASE; THERMODYNAMICS; TRANSCRIPTION; INSTABILITY; ATAXIN-1	Repetitions of CAG or CTG triplets in DNA can form intrastrand hairpin loops with combinations of normal and mismatched base pairs that easily rearrange. Such loops may promote primer-template slippage in DNA replication or repair to give triplet-repeat expansions like those associated with neurodegenerative diseases. Using self-priming sequences (e.g (CAG)(16)(CTG)(4)), we resolve all hairpin loops formed and measure their slippage and expansion rates with DNA polymerase at 37 degrees C. Comparing CAG/CTG loop structures with GAC/GTC structures, having similar hydrogen bonding but different base stacking, we find that GAG, CTG, and GTC triplets predominantly form even-membered loops that slip in steps of two triplets, whereas GAC triplets favor odd-numbered loops Slippage rates decline as hairpin stability increases, supporting the idea that slippage initiates more easily in less stable regions. Loop stabilities (in low salt) increase in the order GTC < CAG < GAC < CTG, while slippage rates decrease in the order GTC > CAG approximate to GAC > CTG. Loops of GTC compared with CTG melt 9 degrees C lower and slip g-fold faster. We interpret results in terms of base stacking, by relating melting temperature to standard enthalpy changes for doublets of base pairs and mispairs, considering enthalpy-entropy compensation.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, SHS Rm,172 Univ Pk, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398, P01AG017179] Funding Source: NIH RePORTER; NIA NIH HHS [AG17179, AG11398] Funding Source: Medline; NIGMS NIH HHS [GM 21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GAEY AM, 1995, CELL, V81, P533; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; OHASHI H, 1995, J BIOCHEM-TOKYO, V118, P1271, DOI 10.1093/oxfordjournals.jbchem.a125018; PEARSON CE, 1996, AM J HUM GENET, V59, P244; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; PETRUSKA J, 1995, J BIOL CHEM, V270, P746, DOI 10.1074/jbc.270.2.746; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875	29	61	63	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18382	18390		10.1074/jbc.275.24.18382	http://dx.doi.org/10.1074/jbc.275.24.18382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849445	hybrid			2022-12-27	WOS:000087659400065
J	Zhong, LW; Holmgren, A				Zhong, LW; Holmgren, A			Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG ADENOCARCINOMA CELLS; ESCHERICHIA-COLI; HELA-CELLS; GLUTATHIONE-REDUCTASE; GLUTAREDOXIN SYSTEMS; REDOX REGULATION; HUMAN PLACENTA; RAT-LIVER; PURIFICATION; NADPH	Mammalian thioredoxin reductases (TrxR) are dimers homologous to glutathione reductase with a selenocysteine (SeCys) residue in the conserved C-terminal sequence -GIy-Cys-SeCys-Gly. We removed the selenocysteine insertion sequence in the rat gene, and we changed the SeCys(498) encoded by TGA to Cys or Ser by mutagenesis. The truncated protein having the C-terminal SeCys-Gly dipeptide deleted, expected in selenium deficiency, was also engineered. All three mutant enzymes were overexpressed in Escherichia coli and purified to homogeneity with 1 mol of FAD per monomeric subunit, Anaerobic titrations with NADPH rapidly generated the A(540nm) absorbance resulting from the thiolate-flavin charge transfer complex characteristic of mammalian TrxR. However, only the SeCys(498) --> Cys enzyme showed catalytic activity in reduction of thioredoxin, with a 100-fold lower k(cat) and a 10-fold lower K-m compared with the wild type rat enzyme. The pH optimum of the SeCys(498) --> Cys mutant enzyme was 9 as opposed to 7 for the wild type TrxR, strongly suggesting involvement of the low pK(a) SeCys selenol in the enzyme mechanism. Whereas H2O2 was a substrate for the wild type enzyme, all mutant enzymes lacked hydroperoxidase activity. Thus selenium is required for the catalytic activities of TrxR explaining the essential role of this trace element in cell growth.	Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.							Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CLARKE LC, 1997, JAMA-J AM MED ASSOC, V276, P1957; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Gallegos A, 1997, CANCER RES, V57, P4965; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gorlatov SN, 1999, ARCH BIOCHEM BIOPHYS, V369, P133, DOI 10.1006/abbi.1999.1356; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; GUILBERT LJ, 1976, NATURE, V263, P594, DOI 10.1038/263594a0; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Smith AD, 1999, J NUTR, V129, P194, DOI 10.1093/jn/129.1.194; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZHONG L, 1997, PROTEIN SCI, V6, P84	48	325	342	3	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18121	18128		10.1074/jbc.M000690200	http://dx.doi.org/10.1074/jbc.M000690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849437	hybrid			2022-12-27	WOS:000087659400031
J	Stevens, J; Jones, RC; Bordoli, RS; Trowsdale, J; Gaskell, SJ; Butcher, GW; Joly, E				Stevens, J; Jones, RC; Bordoli, RS; Trowsdale, J; Gaskell, SJ; Butcher, GW; Joly, E			Peptide specificity of RT1-A1(c), an inhibitory rat major histocompatibility complex class I natural killer cell ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; SEQUENCE-DERIVED PEPTIDES; HLA-E BINDS; NK CELLS; MASS-SPECTROMETRY; LEADER PEPTIDE; RECOGNITION; IDENTIFICATION; MOLECULES; ANTIGEN	The rat major histocompatibility complex class Ia allelomorph RT1-A1(c) is a potent ligand for the recently identified inhibitory rLy-49 receptor, STOK-2. With the ultimate objective of studying the interactions of these molecules using structural and functional methods, we undertook a detailed study of its peptide specificity. The study revealed that designing an "ideal peptide" by choosing the most abundant residues in the "binding motif" obtained by pool sequencing does not necessarily yield an optimal binding peptide. For RT1-A1(c), as many as four positions, P2, P4, P5, and P9, were detected as putative anchors. Since this molecule displays a preference for highly hydrophobic peptides, we tested binding of peptides derived from the known leader peptide sequences of other rat histocompatibility complex class I molecules. One such peptide, found to bind well, requiring 1.6 mu M peptide to achieve 50% stabilization, was searched for in vivo. Natural RT1-A1(c) binding peptides were purified from rat splenocytes and characterized by mass spectrometry using a combined matrix-assisted laser desorption ionization/time-of-flight and quadrupole time-of-flight approach. Results showed that the signal sequence-derived peptide was not detectable in the purified peptide pool, which was composed of a complex spectrum of peptides. Seven of these self-peptides were successfully sequenced.	Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Univ Manchester, Inst Sci & Technol, Dept Chem, Manchester M60 1QD, Lancs, England; Micromass UK Ltd, Manchester M23 9LE, Lancs, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Manchester	Stevens, J (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC206,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Backman-Petersson E, 2000, INT IMMUNOL, V12, P843, DOI 10.1093/intimm/12.6.843; Bhuyan PK, 1997, J IMMUNOL, V158, P3753; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brooks AG, 1999, J IMMUNOL, V162, P305; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DeCloux A, 1997, J IMMUNOL, V158, P2183; Dohring C, 1997, CRIT REV IMMUNOL, V17, P285, DOI 10.1615/CritRevImmunol.v17.i3-4.20; Engh E, 1998, TRANSPLANTATION, V65, P319, DOI 10.1097/00007890-199802150-00005; Fogli A, 1999, CYTOGENET CELL GENET, V86, P225, DOI 10.1159/000015344; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; Joly E, 1996, J IMMUNOL, V157, P1551; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kraus E, 1996, EUR J IMMUNOL, V26, P2582, DOI 10.1002/eji.1830261107; Lanier LL, 1998, CELL, V92, P705, DOI 10.1016/S0092-8674(00)81398-7; Lau P, 2000, IMMUNOGENETICS, V51, P148, DOI 10.1007/s002510050023; Llano M, 1998, EUR J IMMUNOL, V28, P2854, DOI 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; Manilay JO, 1998, CURR OPIN IMMUNOL, V10, P532, DOI 10.1016/S0952-7915(98)80219-7; Murphy WJ, 1997, IMMUNOL REV, V157, P167, DOI 10.1111/j.1600-065X.1997.tb00981.x; Naper C, 1996, INT IMMUNOL, V8, P1779, DOI 10.1093/intimm/8.11.1779; Naper C, 1999, EUR J IMMUNOL, V29, P2046, DOI 10.1002/(SICI)1521-4141(199906)29:06&lt;2046::AID-IMMU2046&gt;3.0.CO;2-Z; Naper C, 1998, J IMMUNOL, V160, P219; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Ozaki T, 1997, DNA CELL BIOL, V16, P985, DOI 10.1089/dna.1997.16.985; PARKER KE, 1991, IMMUNOGENETICS, V34, P211, DOI 10.1007/BF00205827; Peruzzi M, 1996, J EXP MED, V184, P1585, DOI 10.1084/jem.184.4.1585; Peruzzi M, 1996, J IMMUNOL, V157, P3350; POWIS SJ, 1993, TRANSPLANT P, V25, P2752; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rolstad B, 1997, IMMUNOL REV, V155, P91, DOI 10.1111/j.1600-065X.1997.tb00942.x; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; Stevens J, 1998, EUR J IMMUNOL, V28, P1272, DOI 10.1002/(SICI)1521-4141(199804)28:04<1272::AID-IMMU1272>3.0.CO;2-E; Stevens J, 1998, J BIOL CHEM, V273, P2874, DOI 10.1074/jbc.273.5.2874; VAAGE JT, 2000, IN PRES SJ IMMUNOL; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	45	15	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29217	29224		10.1074/jbc.M002565200	http://dx.doi.org/10.1074/jbc.M002565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10856297	hybrid			2022-12-27	WOS:000089439800007
J	Groth, A; Weber, JD; Willumsen, BM; Sherr, CJ; Roussel, MF				Groth, A; Weber, JD; Willumsen, BM; Sherr, CJ; Roussel, MF			Oncogenic Ras induces p19(ARF) and growth arrest in mouse embryo fibroblasts lacking p21(Cip1) and p27(Kip1) without activating cyclin D-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; S-PHASE; P53-DEPENDENT APOPTOSIS; COOPERATING ONCOGENES; INHIBITOR P27(KIP1); PROTEASOME PATHWAY; GENE-EXPRESSION	Oncogenic Res induces two products of the INK4a/ARF tumor suppressor locus (p16(INK4a) and p19(ARF)) in primary human and rodent fibroblasts, ultimately leading to a permanent state of cell cycle arrest resembling replicative senescence. Whereas p16(INK4a) antagonizes the activities of cyclin D-dependent kinases, p19(ARF) activates the p53 transcription factor. Immortalized rodent fibroblast cell lines that lack INK4a/ARP function, ARF alone, or p53 are resistant to the growth inhibitory effects of oncogenic Res and instead continue to proliferate and undergo morphological transformation. Primary mouse embryo fibroblasts lacking Cip1 and Kip1 genes encoding inhibitors of cyclin-dependent kinase-2 were used to further explore the effects of oncogenic Res on arrest of the cell division cycle. Although early passage primery fibroblast strains that lack both p21(Cip1) and p27(Kip1) fail to assemble cyclin Ii-dependent kinases, oncogenic has retained its ability to induce p19(ARF), but not p16(INK4a), protecting Cip/Kip-null cells from proliferating and undergoing transformation. Under these conditions, Res did not induce G(1) phase arrest but instead triggered DNA synthesis, abnormal nuclear divisions, failure of cytokinesis, and emergence of polyploid cells. Therefore, in the absence of p16(INK4a), p21(Cip1), and p27(Kip1), oncogenic Res affects the functions of genes required for completion of the cell cycle.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark	St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Copenhagen	Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38101 USA.	sherr@stjude.org	Sherr, Charles J/N-8074-2018; Willumsen, Berthe M/H-1903-2012; Groth, Anja/AAH-5386-2019; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Willumsen, Berthe M/0000-0002-2277-6999; Groth, Anja/0000-0003-0577-1771; Roussel, Martine F/0000-0002-1740-8139; Weber, Jason/0000-0002-1069-6983	NCI NIH HHS [CA-21765, CA-71907, CA-56819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056819, P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	93	76	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27473	27480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842176				2022-12-27	WOS:000089144800106
J	Inagaki, N; Nishizawa, M; Arimura, N; Yamamoto, H; Takeuchi, Y; Miyamoto, E; Kaibuchi, K; Inagaki, M				Inagaki, N; Nishizawa, M; Arimura, N; Yamamoto, H; Takeuchi, Y; Miyamoto, E; Kaibuchi, K; Inagaki, M			Activation of Ca2+/calmodulin-dependent protein kinase II within post-synaptic dendritic spines of cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; INTERMEDIATE FILAMENTS; POSTSYNAPTIC DENSITY; NUCLEAR-LOCALIZATION; CAM KINASE; PHOSPHORYLATION; CALMODULIN; EXPRESSION; RECEPTORS; CELLS	To understand the cell signaling of protein kinases, it is essential to monitor their activity in each of the subcellular compartments. Here we developed a method to visualize the activities of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the cytoplasm, plasma membrane, and nucleus, separately, by utilizing targeted phosphorylation motifs and phosphorylation-specific antibodies. This approach was used to monitor the activities of post-synaptic CaMKII in cultured hippocampal neurons. Strong stimulation of the neurons by N-methyl-D-aspartate led to global activations of CaMKII in the cell bodies and dendrites, On the other hand, weak stimulation by removal of Mg2+ block of N-methyl-D-aspartate receptors induced CaMKII signaling localized within single dendritic spines. Post-synaptic CaMKII is thought to modify synaptic efficiency. The present data for the first time demonstrate the activation of CaMKII localized within single dendritic spines and are consistent with the notion that synaptic efficiency is modified by CaMKII in single or multiple spine level depending on the strength of receptor activation.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Aichi Canc Ctr, Inst Res, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Nara Institute of Science & Technology; Aichi Cancer Center; Kumamoto University	Inagaki, N (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		Inagaki, Masaki/B-9920-2016	Inagaki, Naoyuki/0000-0002-2664-9196				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; Craig A. M, 1998, CULTURING NERVE CELL, P79; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mochly-Rosen D, 1998, FASEB J, V12, P35; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Ouyang Y, 1997, J NEUROSCI, V17, P5416; Peters A., 1991, FINE STRUCTURE NERVO; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Takeuchi Y, 1999, J NEUROCHEM, V72, P815, DOI 10.1046/j.1471-4159.1999.0720815.x; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	38	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27165	27171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852918				2022-12-27	WOS:000089144800067
J	Perdiz, D; Grof, P; Mezzina, M; Nikaido, O; Moustacchi, E; Sage, E				Perdiz, D; Grof, P; Mezzina, M; Nikaido, O; Moustacchi, E; Sage, E			Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells - Possible role of Dewar photoproducts in solar mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; ULTRAVIOLET-B RADIATION; HUMAN-SKIN FIBROBLASTS; INDUCED DNA-DAMAGE; TRANS-SYN-I; XERODERMA-PIGMENTOSUM; CIS-SYN; WAVELENGTH DEPENDENCE; SIMULATED SUNLIGHT; 6-4 PHOTOPRODUCTS	In order to better understand the relative contribution of the different UV components of sunlight to solar mutagenesis, the distribution of the bipyrimidine photolesions, cyclobutane pyrimidine dimers (CPD), (6-4) photoproducts ((6-4)PP), and their Dewar valence photoisomers (DewarPP) was examined in Chinese hamster ovary cells irradiated with WC, UVB, or UVA radiation or simulated sunlight. The absolute amount of each type of photoproduct was measured by using a calibrated and sensitive immune-dot-blot assay. As already established for UVC and UVB, we report the production of CPD by UVA radiation, at a yield in accordance with the DNA absorption spectrum. At biologically relevant doses, DewarPP were more efficiently produced by simulated solar light than by WE (ratios of DewarPP to (6-4)PP of 1:3 and 1:8, respectively), but were detected neither after UVA nor after UVC radiation, The comparative rates of formation for CPD, (6-4)PP and DewarPP are 1:0.25 for UVC, 1:0.12:0.014 for UVB, and 1:0.18:0.06 for simulated sunlight. The repair rates of these photoproducts were also studied in nucleotide excision re pair-proficient cells irradiated with UVB, UVA radiation, or simulated sunlight. Interestingly, DewarPP were eliminated slowly, inefficiently, and at the same rate as CPD, In contrast, removal of (6-4) photoproducts was rapid and completed 24 h after exposure, Altogether, our results indicate that, in addition to CPD and (6-4)PP, DewarPP may play a role in solar cytotoxicity and mutagenesis.	Inst Curie Rech, CNRS UMR 218, LRC 1, Commissariat Energie Atom, F-75248 Paris 05, France; Semmelweis Univ, Inst Biophys & Radiat Biol, H-1444 Budapest, Hungary; CNRS, Genethon 3, CNRS URA 1923, F-91002 Evry, France; Kanazawa Univ, Fac Pharmaceut Sci, Div Radiat Biol, Kanazawa, Ishikawa 9200934, Japan	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Semmelweis University; Centre National de la Recherche Scientifique (CNRS); Kanazawa University	Sage, E (corresponding author), Inst Curie Rech, CNRS UMR 218, LRC 1, Commissariat Energie Atom, F-75248 Paris 05, France.	Evelyne.Sage@curie.u-psud.fr	Perdiz, Daniel/R-4471-2018; Grof, Pal/C-5107-2013	Grof, Pal/0000-0002-6488-893X; Perdiz, Daniel/0000-0002-6804-5980				Alapetite C, 1996, INT J RADIAT BIOL, V69, P359, DOI 10.1080/095530096145922; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; CHADWICK CA, 1995, J PHOTOCH PHOTOBIO B, V28, P163, DOI 10.1016/1011-1344(94)07096-7; CLINGEN PH, 1995, CANCER RES, V55, P2245; CLINGEN PH, 1995, PHOTOCHEM PHOTOBIOL, V61, P163, DOI 10.1111/j.1751-1097.1995.tb03955.x; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; Douki T, 1999, PHOTOCHEM PHOTOBIOL, V70, P184, DOI 10.1111/j.1751-1097.1999.tb07988.x; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Douki T, 1997, PHOTOCHEM PHOTOBIOL, V66, P171, DOI 10.1111/j.1751-1097.1997.tb08639.x; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DROBETSKY EA, 1994, CARCINOGENESIS, V15, P1577, DOI 10.1093/carcin/15.8.1577; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; EVENO E, 1995, CANCER RES, V55, P4325; Fekete A, 1998, PHOTOCHEM PHOTOBIOL, V68, P527, DOI 10.1562/0031-8655(1998)068<0527:AOTEOV>2.3.CO;2; FREEMAN SE, 1989, P NATL ACAD SCI USA, V86, P5605, DOI 10.1073/pnas.86.14.5605; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HASELTINE WA, 1983, CELL, V33, P13, DOI 10.1016/0092-8674(83)90329-X; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Hwang GS, 1996, EUR J BIOCHEM, V235, P359, DOI 10.1111/j.1432-1033.1996.00359.x; IARC (International Agency for Research on Cancer), 1992, MON EV CARC RISKS HU, V55; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; KOCHEVAR IE, 1990, BIOORGANIC PHOTOCHEM, P273; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; Mitchell DL, 1999, CANCER RES, V59, P2875; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1993, INT CONGR SER, V1021, P337; MITCHELL DL, 1987, PHOTOCHEM PHOTOBIOL, V45, P781, DOI 10.1111/j.1751-1097.1987.tb07882.x; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; MULLAART E, 1988, J INVEST DERMATOL, V90, P346, DOI 10.1111/1523-1747.ep12456316; Nakagawa A, 1998, J INVEST DERMATOL, V110, P143, DOI 10.1046/j.1523-1747.1998.00100.x; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; REARDON JT, 1993, J BIOL CHEM, V268, P21301; REGAN JD, 1990, MUTAT RES, V235, P157, DOI 10.1016/0921-8777(90)90069-H; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; ROSENSTEIN BS, 1991, RADIAT RES, V126, P338, DOI 10.2307/3577923; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; ROZA L, 1988, PHOTOCHEM PHOTOBIOL, V48, P627, DOI 10.1111/j.1751-1097.1988.tb02873.x; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sage E, 1999, NATO ASI 2, V55, P115; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; SUTHERLAND JC, 1981, RADIAT RES, V86, P399, DOI 10.2307/3575456; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Tung BS, 1996, MUTAT RES-DNA REPAIR, V362, P65, DOI 10.1016/0921-8777(95)00034-8; TYRRELL RM, 1973, PHOTOCHEM PHOTOBIOL, V17, P69, DOI 10.1111/j.1751-1097.1973.tb06334.x; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; VINK AA, 1994, J PHOTOCH PHOTOBIO B, V24, P25, DOI 10.1016/1011-1344(94)07005-9; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; WEISS RB, 1993, PHOTOCHEM PHOTOBIOL, V58, P219, DOI 10.1111/j.1751-1097.1993.tb09552.x; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Zhang XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119, DOI 10.1111/j.1751-1097.1997.tb01886.x	67	213	217	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26732	26742						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827179				2022-12-27	WOS:000089144800011
J	Piserchio, A; Usdin, T; Mierke, DF				Piserchio, A; Usdin, T; Mierke, DF			Structure of tuberoinfundibular peptide of 39 residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PARATHYROID-HORMONE; PTH-RELATED PEPTIDE; NMR-SPECTROSCOPY; RECEPTOR INTERACTIONS; COUPLING-CONSTANTS; AMINO-TERMINUS; CROSS-LINKING; PROTEIN; LIGAND; AGONIST	The recently identified natural peptide ligand, tuberoinfundibular peptide of 39 residues (TIP39) for the parathyroid hormone-2 (PTHS) receptor has been structurally characterized by high resolution NMR, circular dichroism, and computer simulations. The structural features of TIP39, determined in the presence of a zwitterionic lipid to mimic the membrane environment of the G-protein-coupled PTH2 receptor, consist of two a-helices, Ala(5)-Arg(21) and Leu(26)-Val(35). Although TIP39 shares limited sequence homology with parathyroid hormone (PTH), a comparison of the structural features of TIP39 and PTH illustrates a similar topological display of residues of the N-terminal helix important for PTH2 receptor activation. The C-terminal helix of TIP39 differs from that of PTH with respect to size and amphipathicity, suggesting an altered mode of binding for TIP39, consistent with the receptor chimera and ligand truncation studies presented in the accompanying paper (Hoare, S. R. J., Clark, J, A, and Usdin, T. B. (2000) J. Biol. Chen. 275, 27274-27283). The structural characterization of TIP39 also provides some insight into the lack of affinity of this novel ligand for the PTH1 receptor.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Div Biol & Med, Providence, RI 02912 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA; NIMH, Genet Lab, Cell Biol Unit, Bethesda, MD 20892 USA	Brown University; Brown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Mierke, DF (corresponding author), Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Box G-B4, Providence, RI 02912 USA.	dale_mierke@brown.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054082, R01GM054082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002685, ZIAMH002685] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00995] Funding Source: Medline; NIGMS NIH HHS [GM54082] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BROWN LR, 1981, BIOCHIM BIOPHYS ACTA, V642, P296, DOI 10.1016/0005-2736(81)90447-8; CARTER PH, 1998, ASBMR IBMS 2 JOINT M, pSA178; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Crippen GM, 1988, DISTANCE GEOMETRY MO; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fasman G.D., 1996, CIRCULAR DICHROISM C; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; Hoare SRJ, 2000, J BIOL CHEM, V275, P27274; Hoare SRJ, 1999, ENDOCRINOLOGY, V140, P4419, DOI 10.1210/en.140.10.4419; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; Hull KL, 1998, COMP BIOCHEM PHYS C, V119, P389, DOI 10.1016/S0742-8413(98)00010-3; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; MIERKE DF, 1994, INT J PEPT PROT RES, V44, P325, DOI 10.1111/j.1399-3011.1994.tb01016.x; MIERKE DF, 1994, BIOPOLYMERS, V34, P559, DOI 10.1002/bip.360340411; MORODER L, 1993, BIOCHEMISTRY-US, V32, P13551, DOI 10.1021/bi00212a022; Moroder L, 1997, J PEPT SCI, V3, P1; MULLER L, 1979, J AM CHEM SOC, V101, P4481; PAPAVOINE CHM, 1994, BIOCHEMISTRY-US, V33, P12990, DOI 10.1021/bi00248a007; Peggion E, 1999, BIOPOLYMERS, V50, P525; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Pellegrini M, 1999, BIOPOLYMERS, V51, P208, DOI 10.1002/(SICI)1097-0282(1999)51:3<208::AID-BIP4>3.0.CO;2-U; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SCHWYZER R, 1991, BIOPOLYMERS, V31, P785, DOI 10.1002/bip.360310624; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Usdin TB, 2000, TRENDS PHARMACOL SCI, V21, P128, DOI 10.1016/S0165-6147(00)01455-3; Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724; Usdin TB, 1999, ENDOCRINOLOGY, V140, P3363, DOI 10.1210/en.140.7.3363; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	54	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27284	27290						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856302				2022-12-27	WOS:000089144800082
J	Nguyen, LH; Erzberger, JP; Root, J; Wilson, DM				Nguyen, LH; Erzberger, JP; Root, J; Wilson, DM			The human homolog of Escherichia coli orn degrades small single-stranded RNA and DNA oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; ACTIVE-SITE; AMINO-ACID; EXONUCLEASE; PROTEIN; OLIGORIBONUCLEASE; NUCLEUS; MOTIFS; DECAY; GENE	We report here the identification of human homologues to the essential Escherichia coli Orn protein and the related yeast mitochondrial DNA-escape pathway regulatory factor Ynt20, The human proteins appear to arise from alternatively spliced transcripts, and are thus identical, except the human Ynt20 equivalent contains an NH2-terminal extension that possesses a predicted mitochondrial protease cleavage signal. In vitro analysis revealed that the smaller human protein exhibits a 3' to 5' exonuclease activity for small (primarily less than or equal to 5 nucleotides in length) single-stranded RNA and DNA oligomers, We have named this human protein Sfn for Small fragment nuclease to reflect its broad substrate range, and have termed the longer protein hSfn alpha. Sfn prefers Mn2+ as a metal cofactor and displays a temperature-resistant (to 50 degrees C) nuclease activity. Kinetic analysis indicates that Sfn exhibits a similar affinity for small RNAs and DNAs (K-m of similar to 1.5 mu M), but degrades small RNAs similar to 4-fold more efficiently than DNA, Mutation of a conserved aspartate (Asp(136)) to alanine abolishes both nuclease activities of Sfn, Northern blot analysis revealed that a l-kilobase transcript corresponding to SFN and/or SFN alpha (these mRNAs differ by only two nucleotides) is expressed at varying levels in all fetal and adult human tissues examined. Expressed tag sequence clone analysis found that the two splice variants, SFN to SFN alpha, are present at a ratio of roughly 4 to 1, respectively. The results presented within suggest a role for human Sfn in cellular nucleotide recycling.	Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Wilson, DM (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, Livermore, CA 94551 USA.		Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395	NCI NIH HHS [CA79056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLUTHNER M, 1992, J EXP MED, V176, P973, DOI 10.1084/jem.176.4.973; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DATTA AK, 1975, J BIOL CHEM, V250, P7313; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P4372, DOI 10.1073/pnas.96.8.4372; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; KOONIN EV, 1997, CURR BIOL, V7, P604; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; NIYOGI SK, 1975, J BIOL CHEM, V250, P7307; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Sambrook J., 2002, MOL CLONING LAB MANU; Shafer KS, 1999, CURR GENET, V36, P183, DOI 10.1007/s002940050489; SHAFER KS, 1999, CURR GENET, V34, P438; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Zhang XL, 1998, J BACTERIOL, V180, P2779, DOI 10.1128/JB.180.10.2779-2781.1998; ZIEMIN L, P NATL ACAD SCI US, V88, P10735	27	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25900	25906		10.1074/jbc.M002672200	http://dx.doi.org/10.1074/jbc.M002672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851236	hybrid			2022-12-27	WOS:000088999700004
J	Crosas, B; Allali-Hassani, A; Martinez, SE; Martras, S; Persson, B; Jornvall, H; Pares, X; Farres, J				Crosas, B; Allali-Hassani, A; Martinez, SE; Martras, S; Persson, B; Jornvall, H; Pares, X; Farres, J			Molecular basis for differential substrate specificity in class IV alcohol dehydrogenases - A conserved function in retinoid metabolism but not in ethanol oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYFATTY ACIDS; HUMAN STOMACH; EXPRESSION PATTERNS; MUTANT MICE; SEQUENCE; CDNA; ADH; AMPLIFICATION; PURIFICATION; ISOENZYMES	Mammalian class IV alcohol dehydrogenase enzymes are characteristic of epithelial tissues, exhibit moderate to high K-m values for ethanol, and are very active in retinol oxidation, The human enzyme shows a K-m value for ethanol which is 2 orders of magnitude lower than that of rat class IV. The uniquely significant difference in the substrate-binding pocket between the two enzymes appears to be at position 294, Val in the human enzyme and Ala in the rat enzyme. Moreover, a deletion at position 117 (Gly in class I) has been pointed out as probably responsible for class IV specificity toward retinoids, With the aim of establishing the role of these residues, we have studied the kinetics of the recombinant human and rat wild-type enzymes, the human G117ins and V294A mutants, and the rat A294V mutant toward aliphatic alcohols and retinoids, 9-cis-Retinol was the best retinoid substrate for both human and rat class IV, strongly supporting a role of class IV in the generation of 9-cis-retinoic acid. In contrast, 13-cis retinoids were not substrates, The G117ins mutant showed a decreased catalytic efficiency toward retinoids and toward three-carbon and longer primary aliphatic alcohols, a behavior that resembles that of the human class I enzyme, which has Gly(117). Th, K-m values for ethanol dramatically changed in the 294 mutants, where the human V294A mutant showed a 280-fold increase, and the rat A294V mutant a 50-fold decrease, compared with those of the respective wild-type enzymes. This demonstrates that the Val/Ala exchange at position 294 is mostly responsible for the kinetic differences with ethanol between the human and rat class IV. In contrast, the kinetics toward retinoids was only slightly affected by the mutations at position 294, compatible with a more conserved function of mammalian class IV alcohol dehydrogenase in retinoid metabolism.	Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Autonomous University of Barcelona; Karolinska Institutet	Pares, X (corresponding author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain.		Farrés, Jaume/F-8648-2016; Pares, Xavier/K-8228-2017	Farrés, Jaume/0000-0001-9069-3987; Pares, Xavier/0000-0002-5071-9465				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BENSON S A, 1984, Biotechniques, V2, P126; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Cleland W W, 1979, Methods Enzymol, V63, P103; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; DOWNES JE, 1995, ADV EXP MED BIOL, V372, P349; EKLUND H, 1990, EUR J BIOCHEM, V193, P303, DOI 10.1111/j.1432-1033.1990.tb19337.x; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Foglio MH, 1999, BBA-PROTEIN STRUCT M, V1432, P239, DOI 10.1016/S0167-4838(99)00104-1; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; HELLER J, 1973, J BIOL CHEM, V248, P6308; HURLEY TD, 1995, ADV EXP MED BIOL, V372, P321; JORNVALL H, 1995, ALCOHOL ALCOHOLISM, V30, P153; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kitson KE, 1996, ALCOHOL CLIN EXP RES, V20, pA82, DOI 10.1111/j.1530-0277.1996.tb01752.x; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; MORENO A, 1991, J BIOL CHEM, V266, P1128; PARES X, 1990, METHOD ENZYMOL, V189, P436; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; PARK DH, 1992, J BIOL CHEM, V267, P5527; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; Xie PGT, 1999, PROTEIN SCI, V8, P2639; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZgombicKnight M, 1997, GENOMICS, V41, P105, DOI 10.1006/geno.1997.4637; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P4305, DOI 10.1074/jbc.270.9.4305; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	41	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25180	25187		10.1074/jbc.M910040199	http://dx.doi.org/10.1074/jbc.M910040199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829036	hybrid			2022-12-27	WOS:000088849400020
J	Tanaka, N; Yonekura, H; Yamagishi, S; Fujimori, H; Yamamoto, Y; Yamamoto, H				Tanaka, N; Yonekura, H; Yamagishi, S; Fujimori, H; Yamamoto, Y; Yamamoto, H			The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear Factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; GROWTH-FACTOR; DIABETIC-RETINOPATHY; ESTROGEN-RECEPTOR; BINDING-PROTEINS; GENE-EXPRESSION; OXIDANT STRESS; TRANSCRIPTIONAL ACTIVATION; POSSIBLE MECHANISM; SURFACE RECEPTOR	The binding of advanced glycation end products (AGE) to the receptor for AGE (RAGE) is known to deteriorate various cell functions and is implicated in the pathogenesis of diabetic vascular complications. Here we show that AGE, tumor necrosis factor-alpha (TNF-alpha), and 17 beta-estradiol (E-2) up-regulated RAGE mRNA and protein levels in human microvascular endothelial cells and ECV304 cells, with the mRNA stability being essentially invariant. Transient transfection experiments with human RAGE promoter-luciferase chimeras revealed that the region from nucleotide number -751 to -629 and the region from -239 to -89 in the RAGE 5'-flanking sequence exhibited the AGE/TNF-alpha and E-2 responsiveness, respectively. Site-directed mutation of an nuclear factor-kappa B (NF-kappa B) site at -671 or of Sp-1 sites at -189 and -172 residing in those regions resulted in an abrogation of the AGE/TNF-alpha- or E-2-mediated transcriptional activation. Electrophoretic mobility shift assays revealed that ECV304 cell nuclear extracts contained factors which retarded the NF-kappa B and Sp-1 elements, and that the DNA-protein complexes were supershifted by anti-p65/p50 NF-kappa B and anti-Sp-1/estrogen receptor or antibodies, respectively. These results suggest that AGE, TNF-alpha, and E-2 can activate the RAGE gene through NF-kappa B and Sp-1, causing enhanced AGE-RAGE interactions, which would lead to an exacerbation of diabetic microvasculopathy.	Kanazawa Univ, Sch Med, Dept Biochem, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Sch Med, Dept Ophthalmol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University	Yamamoto, H (corresponding author), Kanazawa Univ, Sch Med, Dept Biochem, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.							Algarte M, 1999, MOL CELL BIOL, V19, P6140; AxerSiegel R, 1996, OPHTHALMOLOGY, V103, P1815, DOI 10.1016/S0161-6420(96)30421-1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRADFORD MM, 1972, ANAL BIOCHEM, V71, P248; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kaji M, 1996, CANCER GENE THER, V3, P393; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOLONEY JBM, 1982, AM J OPHTHALMOL, V93, P745, DOI 10.1016/0002-9394(82)90471-8; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schocket LS, 1999, AM J OPHTHALMOL, V128, P477, DOI 10.1016/S0002-9394(99)00234-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Suzuma I, 1999, INVEST OPHTH VIS SCI, V40, P2122; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172	55	367	406	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25781	25790		10.1074/jbc.M001235200	http://dx.doi.org/10.1074/jbc.M001235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829018	hybrid			2022-12-27	WOS:000088849400095
J	Martin, DW; Sachs, JR				Martin, DW; Sachs, JR			Ligands presumed to label high affinity and low affinity ATP binding sites do not interact in an (alpha beta)(2) diprotomer in duck nasal gland Na+,K+-ATPase, nor do the sites coexist in native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; ACTIVE-SITE; SODIUM; NA,K-ATPASE; MECHANISM; PUMP	The inter-action of ligands deemed to be ATP analogues with renal Na+,K+-ATPase suggests that two ATP binding sites coexist on each functional unit. Previous studies in which fluorescein B-isothiocyanate (FITC) was used to label the high affinity ATP site and 2'(3')O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-ADP) was used to probe the low affinity site suggested that the two sites coexist on the same alpha beta protomer, Other studies in which FITC labeled the high affinity site and erythrosin-5-isothiocyanate (ErITC) labeled the low affinity site led to the conclusion that the high and low affinity sites exist on separate interacting protomers in a functional diprotomer, We report here that at 100% inhibition of ATPase activity by FITC, each cup protomer of duck nasal gland enzyme has a single bound FITC, Both TNP-ADP and ErITC interact with FITC-bound protomers, which unambiguously demonstrates that putative high and low affinity ATP sites coexist on the same protomer, In unlabeled nasal gland enzyme, TNP-ADP and ErITC inhibit both ATPase activity and p-nitrophenyl phosphatase activity, functions attributed to the putative high and low affinity ATP site, respectively, by interacting with a single site with characteristics of the high affinity ATP binding site. In FITC-labeled enzyme, TNP-ADP and ErITC inhibit p-nitrophenyl phosphatase activity but at much higher concentrations than with the unmodified enzyme. Low affinity sites do not exist on the unmodified enzyme but can be detected only after the high affinity site is modified by FITC.	SUNY Stony Brook, Div Hematol, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Martin, DW (corresponding author), SUNY Stony Brook, Div Hematol, Dept Med, HSC T15-040, Stony Brook, NY 11794 USA.	dwight.martin@sunysb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19185] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BUXBAUM E, 1991, SODIUM PUMP RECENT D, P405; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CZERWINSKI A, 1967, AM J PHYSIOL, V213, P786, DOI 10.1152/ajplegacy.1967.213.3.786; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; Faller LD, 2000, BIOPHYS J, V78, p77A; GLYNN IM, 1982, MEMBRANES TRANSPORT, V1, P529; HELLEN EH, 1997, BIOPHYS CHEM, V69, P197; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHONER W, 1994, SODIUM PUMP, P332; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	24	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24512	24517		10.1074/jbc.M003179200	http://dx.doi.org/10.1074/jbc.M003179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831595	hybrid			2022-12-27	WOS:000088683300038
J	Chomyn, A; Enriquez, JA; Micol, V; Fernandez-Silva, P; Attardi, G				Chomyn, A; Enriquez, JA; Micol, V; Fernandez-Silva, P; Attardi, G			The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNA(Leu(UUR)) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-SYNTHESIS; POINT MUTATION; NADH DEHYDROGENASE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; TERTIARY STRUCTURE; MELAS SUBGROUP; AMINO-ACIDS; HUMAN-CELLS	The pathogenetic mechanism of the mitochondrial tRNA(Leu(UUR)) A3243G transition associated with the mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome has been investigated in transmitochondrial cell lines constructed by transfer of mutant mitochondrial DNA (mtDNA)-carrying mitochondria from three genetically unrelated MELAS patients or of isogenic wild-type mtDNA-carrying organelles into human mtDNA-less cells. An in vivo footprinting. analysis of the mtDNA segment within the tRNA(Leu(UUR)) gene that binds the transcription termination factor failed to reveal any difference in occupancy of sites or qualitative interaction with the protein between mutant and wild-type mtDNAs, Cell lines nearly homoplasmic for the mutation exhibited a strong (70-75%) reduction in the level of aminoacylated tRNA(Leu(UUR)) and a decrease in mitochondrial protein synthesis rate. The latter, however, did not show any significant correlation between synthesis defect of the individual polypeptides and number or proportion of UUR codons in their mRNAs, suggesting that another step, other than elongation, may be affected. Sedimentation analysis in sucrose gradient showed a reduction in size of the mitochondrial polysomes, while the distribution of the two rRNA components and of the mRNAs revealed decreased association of mRNA with ribosomes and, in the most affected cell line, pronounced degradation of the mRNA associated with slowly sedimenting structures. Therefore, several lines of evidence indicate that the protein synthesis defect in A3243G MELAS mutation-carrying cells is mainly due to a reduced association of mRNA with ribosomes, possibly as a consequence of the tRNA(Leu(UUR)) amino-acylation defect.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Chomyn, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Silva, Patricio Fernandez/U-2256-2017; Micol, Vicente/K-6841-2014; Enríquez, J.A./M-8468-2016	Silva, Patricio Fernandez/0000-0001-8971-7355; Enríquez, J.A./0000-0002-3671-2961; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P427; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; El Meziane A, 1998, NAT GENET, V18, P350; Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHELGHODSIAN N, 1995, AM J OTOLARYNG, V16, P403, DOI 10.1016/0196-0709(95)90078-0; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233; GOLDMAN E, 1982, J MOL BIOL, V158, P619, DOI 10.1016/0022-2836(82)90252-2; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; ICHIKI T, 1988, ANN NEUROL, V23, P287, DOI 10.1002/ana.410230312; Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744; JOHNS DR, 1991, LANCET, V337, P927, DOI 10.1016/0140-6736(91)90272-Q; KING MP, 1993, J BIOL CHEM, V268, P10228; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI M, 1987, J PEDIATR-US, V110, P223, DOI 10.1016/S0022-3476(87)80158-0; KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; Maxam A M, 1980, Methods Enzymol, V65, P499; Micol V, 1997, J BIOL CHEM, V272, P18896, DOI 10.1074/jbc.272.30.18896; Micol V, 1996, Methods Enzymol, V264, P3, DOI 10.1016/S0076-6879(96)64003-8; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; OJALA D, 1972, J MOL BIOL, V65, P273, DOI 10.1016/0022-2836(72)90282-3; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PUGLISI JD, 1993, NUCLEIC ACIDS RES, V21, P41, DOI 10.1093/nar/21.1.41; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Senger B, 1996, BIOCHIMIE, V78, P597, DOI 10.1016/S0300-9084(96)80006-X; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Soll D., 1993, RNA WORLD, P157; TANAKA M, 1986, BIOCHEM BIOPH RES CO, V140, P88, DOI 10.1016/0006-291X(86)91061-2; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANVENRO.WJ, 1972, BIOCHIM BIOPHYS ACTA, V259, P127, DOI 10.1016/0005-2787(72)90480-7; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	58	159	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19198	19209		10.1074/jbc.M908734199	http://dx.doi.org/10.1074/jbc.M908734199			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858457	Green Accepted, hybrid			2022-12-27	WOS:000087815900077
J	Ogawa, H; Muramatsu, H; Kobayashi, T; Morozumi, K; Yokoyama, I; Kurosawa, N; Nakao, A; Muramatsu, T				Ogawa, H; Muramatsu, H; Kobayashi, T; Morozumi, K; Yokoyama, I; Kurosawa, N; Nakao, A; Muramatsu, T			Molecular cloning of endo-beta-galactosidase C and its application in removing alpha-galactosyl xenoantigen from blood vessels in the pig kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE ENDOTHELIAL-CELLS; MAJOR SWINE XENOANTIGEN; HYPERACUTE REJECTION; EXPRESSION; EPITOPES; GENE; ANTIBODIES; XENOTRANSPLANTATION; GAL-ALPHA-1->3GAL; TRANSFECTION	Gal alpha 1-3Gal is the major xenoantigenic epitope responsible for hyperacute rejection upon pig to human xenotransplantation. Endo-beta-galactosidase C from Clostridium perfringens destroys the antigenic epitope by cleaving the beta-galactosidic linkage in the Gal alpha 1-3Gal beta 1-4GlcNAc structure. Based on partial peptide sequences of the enzyme, we molecularly cloned the enzyme gene, which encodes a protein with a predicted molecular mass of about 93 kDa, The deduced protein sequence of the enzyme has limited homology in the C-terminal half with endo-beta-galactosidase from Flavobacterium keratolyticus and beta-1,3-glucanases, The enzyme expressed in Escherichia coli removed the alpha-galactosyl epitope nearly completely from pig erythrocytes and from pig aortic endothelial cells. The enzyme-treated endothelial cells in culture were greatly reduced in cell surface antigens, which were recognized by IgM, IgG, or IgA in human sera, and became much less susceptible to complement-mediated cytotoxicity caused by human sera. When the pig kidney was perfused with the enzyme, the vascular endothelial cells became virtually devoid of the alpha-galactosyl epitope, with concomitant decrease in binding to IgM in human plasma. These results demonstrated that the recombinant endo-beta-galactosidase C is a valuable aid in xenotransplantation.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya City Univ, Dept Internal Med 3, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya University; Nagoya University; Nagoya City University	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			Ogawa, Haruko/0000-0001-5889-499X; Kurosawa, Nobuyuki/0000-0002-1548-4541				ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; BACH FH, 1991, TRANSPL P, V23, P205; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; FUSHUKU N, 1987, J BIOL CHEM, V262, P10086; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GOOD AH, 1992, TRANSPL P, V24, P559; KAMADA Y, 1988, J BIOCHEM-TOKYO, V104, P738, DOI 10.1093/oxfordjournals.jbchem.a122543; KAMADA Y, 1988, CARBOHYD RES, V176, P237, DOI 10.1016/0008-6215(88)80135-6; Kobayashi T, 1999, Subcell Biochem, V32, P229; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVECCHIO JA, 1995, TRANSPLANTATION, V60, P841, DOI 10.1097/00007890-199510270-00014; Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; Luo Y, 1999, XENOTRANSPLANTATION, V6, P238, DOI 10.1034/j.1399-3089.1999.00035.x; Nagasaka T, 1997, BIOCHEM BIOPH RES CO, V232, P731, DOI 10.1006/bbrc.1997.6360; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SHIMIZU T, 1991, INFECT IMMUN, V59, P137, DOI 10.1128/IAI.59.1.137-142.1991; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPILLIAERT R, 1994, EUR J BIOCHEM, V224, P923, DOI 10.1111/j.1432-1033.1994.00923.x; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; Tanemura M, 1998, J BIOL CHEM, V273, P16421, DOI 10.1074/jbc.273.26.16421; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; Watier H, 1996, TRANSPLANTATION, V62, P105, DOI 10.1097/00007890-199607150-00020; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8	35	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19368	19374		10.1074/jbc.M001888200	http://dx.doi.org/10.1074/jbc.M001888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858461	hybrid			2022-12-27	WOS:000087815900097
J	Kimura, K; Tsuji, T; Takada, Y; Miki, T; Narumiya, S				Kimura, K; Tsuji, T; Takada, Y; Miki, T; Narumiya, S			Accumulation of GTP-bound RhoA during cytokinesis and a critical role of ECT2 in this accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; CELL-ADHESION; PROTEIN-RHO; GTPASES; KINASE; CDC42; TARGET; CYCLE; G(1)	We developed a new pull-down assay for GTP-Rho and examined its level during cell cycle. HeLa cells were arrested in the S phase by thymidine and were enriched in the prometaphase, metaphase, telophase, and G(1) phase by collecting at 0, 45, 90, and 180 min after the release from the nocodazole arrest, respectively. The level of GTP-Rho did not change significantly from the S phase to the prometaphase, but increased thereafter, peaking in the telophase, and returned to the original level in the G(1) phase. The GDP-GTP exchange activity for Rho measured in cell lysates in parallel increased also during the mitosis with a peak in the metaphase. Using this system, we examined a role of ECT2, an exchanger for Rho GTPases, suggested to be involved in cytokinesis (Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I., and Miki., T. (1999) J. Cell. Biol, 147, 921-928). Expression of the dominant negative form of ECT2 completely suppressed both the rise of GTP-Rho in the telophase and the increased GDP-GTP exchange activity in the mitotic cell extracts. These results suggest a critical role of ECT2 in Rho activation during cytokinesis.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.							Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nishimura Y, 1998, FEBS LETT, V441, P121, DOI 10.1016/S0014-5793(98)01531-2; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	23	134	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17233	17236		10.1074/jbc.C000212200	http://dx.doi.org/10.1074/jbc.C000212200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837491	hybrid			2022-12-27	WOS:000087485000004
J	Simpson, CS; Morris, BJ				Simpson, CS; Morris, BJ			Regulation of neuronal cell adhesion molecule expression by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-II; POSTSYNAPTIC DENSITY PROTEIN; SYNAPTIC PLASTICITY; GENE-EXPRESSION; ALZHEIMERS-DISEASE; STRIATAL NEURONS; MEMORY FORMATION; RAT HIPPOCAMPUS	The neuronal cell adhesion molecule (NCAM) is a key mediator of structural plasticity in the central nervous system, but the mechanisms that control its expression are unknown. Equally, although the transcription factor NF-kappa B is present in the brain, few NF-kappa B-regulated genes relevant for central nervous system function have been identified. We have previously demonstrated that NF-kappa KB is activated in neuronal cultures treated with kainic acid or nitric oxide. We show here that kainic acid or nitric oxide also increase the levels of NCAM mRNA and protein in neurons and that this induction of NCAM expression is sensitive to dexamethasone and to antisense, but not missense, oligonucleotides designed to suppress NF-kappa B synthesis. Nitric oxide also stimulates protein binding to an NF-kappa B site in the promoter of the NCAM gene. This indicates that NF-kappa B, which has recently been implicated in synaptic plasticity and also in the etiology of neurodegenerative disease, plays a crucial role in the activity-dependent regulation of NCAM gene expression, In addition, since both NCAM and NF-kappa B are present in the post-synaptic density, this represents a route allowing direct communication between the synapse and the nucleus.	Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Morris, BJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.							Arami S, 1996, BEHAV BRAIN RES, V81, P81, DOI 10.1016/S0166-4328(96)00046-0; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 1998, P NATL ACAD SCI USA, V95, P13242, DOI 10.1073/pnas.95.22.13242; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DESMOND NL, 1986, J COMP NEUROL, V253, P476, DOI 10.1002/cne.902530405; DIFIGLIA M, 1989, J NEUROSCI, V9, P4158; Doyle C, 1996, J NEUROSCI, V16, P418; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; GEDDES JW, 1985, SCIENCE, V230, P1179, DOI 10.1126/science.4071042; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GERTZ HJ, 1987, NEUROSCI LETT, V76, P228, DOI 10.1016/0304-3940(87)90720-8; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GREENSTREET EH, 1994, NEUROREPORT, V6, P109, DOI 10.1097/00001756-199412300-00029; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Guerrini L, 1997, J NEUROSCI, V17, P6057; Holst BD, 1998, P NATL ACAD SCI USA, V95, P2597, DOI 10.1073/pnas.95.5.2597; HOLST BD, 1995, MOL BIOL CELL, V6, P573; Inglis FM, 1998, J NEUROSCI, V18, P10493; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; KHACHIGIAN LM, 1995, BIOCHEM BIOPH RES CO, V206, P462, DOI 10.1006/bbrc.1995.1065; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krushel LA, 1999, J BIOL CHEM, V274, P2432, DOI 10.1074/jbc.274.4.2432; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mikkonen M, 1999, EUR J NEUROSCI, V11, P1754, DOI 10.1046/j.1460-9568.1999.00593.x; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Morris BJ, 1997, EUR J NEUROSCI, V9, P2334, DOI 10.1111/j.1460-9568.1997.tb01650.x; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberts LA, 1998, MOL BRAIN RES, V56, P38, DOI 10.1016/S0169-328X(98)00026-6; Roberts LA, 1996, MOL BRAIN RES, V42, P123, DOI 10.1016/S0169-328X(96)00148-9; Rodriguez JJ, 1998, EUR J NEUROSCI, V10, P2994, DOI 10.1046/j.1460-9568.1998.00316.x; ROSE SPR, 1995, BEHAV BRAIN RES, V66, P73, DOI 10.1016/0166-4328(94)00127-2; Rusakov DA, 1997, NEUROSCIENCE, V80, P69, DOI 10.1016/S0306-4522(97)00125-5; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster T, 1998, J NEUROBIOL, V37, P359, DOI 10.1002/(SICI)1097-4695(19981115)37:3<359::AID-NEU2>3.0.CO;2-4; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Simpson CS, 1999, J NEUROCHEM, V73, P353, DOI 10.1046/j.1471-4159.1999.0730353.x; Skibo GG, 1998, NEUROSCIENCE, V82, P1; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; THOMAS KL, 1994, NEURON, V13, P737, DOI 10.1016/0896-6273(94)90040-X; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; XIE QW, 1994, J BIOL CHEM, V269, P4705	73	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16879	16884		10.1074/jbc.275.22.16879	http://dx.doi.org/10.1074/jbc.275.22.16879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828070	hybrid			2022-12-27	WOS:000087392200068
